CN101065502A

CN101065502A - Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection

Info

Publication number: CN101065502A
Application number: CNA2005800323153A
Authority: CN
Inventors: R·B·布兰登; M·R·托马斯
Original assignee: Immunexpress Pty Ltd
Current assignee: Immunexpress Pty Ltd
Priority date: 2004-08-13
Filing date: 2005-08-15
Publication date: 2007-10-31
Anticipated expiration: 2025-08-15
Also published as: CN101065502B

Abstract

The present invention discloses molecule and test about diseases can be used for diagnosing and evaluating the animals infected by herpes virus, and for testing the animals in herpes virus infection or in sequela. The invention allows early diagnosis and monitoring of an infected animal's immune response and thus enables better treatment and management decisions to be made in clinical and sub-clinically affected animals.

Description

Carry out microarray-mediated herpesvirus infection diagnosis by detecting the distinctiveness genetic expression of infecting the back host

Invention field

Present invention relates in general to diagnosis, detect host response, the method and system of herpesvirus infection in monitoring, treatment and the processing Mammals.The present invention can be applied to early diagnosis and infect, detects the specific immune response (having or do not have clinical symptom) to herpesvirus infection, can be to being subjected to the clinical and subclinical Mammals that influences to make better treatment and handling decision.The present invention also can be applied to monitor the Mammals of the clinical sign recurrence that the relevant sequela risk of bleb takes place or cause because of latent virus.This Mammals includes but not limited to: because of suffer from other disease or give due to the medicine, suffer from chronic fatigue syndrome, meet with stress or the animal that weakens of training immunity.

Background of invention

Simplexvirus has been represented and has extensively caused people and the domestic and viral extended familys wildlife various diseases.Known herpes virus type surpasses 80 kinds, but has only 8 kinds knownly can cause the human disease.These 8 kinds are divided into three subfamilies shown in the following table.

1. α herpetoviridae
1. α herpetoviridae	Human herpesvirus 1 (HHV-1) human herpesvirus 2 (HHV-2) herpes virus hominis 3 (HHV-3)	Human herpes simplex vicus 1 (HSV-1) human herpes simplex vicus's 2 (HSV-2) varicella zoster virus (VZV)
2. β herpetoviridae
2. β herpetoviridae	Human herpesvirus 5 (HHV-5) herpes virus hominis 6 (HHV-6) herpes virus hominis 7 (HHV-7)	Cytomegalovirus (CMV) Roseolovirus

3. gamma herpes viruses section
3. gamma herpes viruses section		Human herpesvirus 4 (HHV-4) human herpes virus 8 (HHV-8)	The Lymphocryptovirus Rhadinovirus

Herpesvirus infection is widely distributed, and the disease that causes has serious Economic Importance.In fact, the Mammals of most of kinds is in the early stage at least a virus strain infection that once was subjected to simplexvirus of life.Infection is persistent, and does not have known methods of treatment.Can use antiviral to treat, but after symptom takes place, use and/or take (when they have the time spent at least) often, because side effect and expense and can not be as the prevention administration.Therefore, their application is generally limited to the mankind.

At present can only detect clinical sign and the antibody that back and patient produce behind other zoogenetic infection occur based on the diagnostic method of antibody test.Other detection method comprises polymerase chain reaction (PCR) amplification virus transcription thing or viral DNA, tissue culture isolated viral and/or virus neutralization tests.

All herpesvirus infections are persistent.After the primary infection, virus enters latent period.When patient's immunizing power weaken or be subjected to stress or strong movements when training, disease can activate again.Again the activation of virus can cause symptomatic recurrence, or general malaise, or the tolerance or the performance of taking exercise reduced, perhaps can be asymptomatic.

The mensuration of antiviral antibody, antigen or transcript (value) not necessarily is associated with disease or clinical sign.

The available effective vaccine does not almost have.

Available medicine is treated, but their costlinesses need give before main clinical sign occurs for obtaining greatest treatment efficacy.

Epidemiology and clinical manifestation

Simplexvirus can cause several clinical manifestations in the host that normal and immunizing power weaken.Asymptomatic during most of herpesvirus infection, most of cases that bleb is propagated are people that outburst fashion is not recognized or still do not diagnosed out.

The adult of 50-90% has the antibody to HHV-1 or 1 type human herpes simplex vicus (HSV-1); The 20-30% adult has the antibody to HHV-2 or 2 type human herpes simplex vicuses (HSV-2).(virus) propagation in the low colony of socio-economic status chooses friends indiscriminately individuality with property is more general.HSV-1 is usually relevant with actinal surface portion (orofacial) regional primary infection, the latent infection gasserian ganglion, and HSV-2 is common relevant with genital infection, latent infection rumpbone neuroganglion.Though initial and recurrent infection is (self-limited) of self-limit normally, HSV can cause serious disease, newborn infant's dissemination bleb for example, viral encephalitis and blinding keratitis (blinding keratitis).

During acute primary infection, HSV hide lastingly with skin that enters or the corresponding nerve root ganglion of mucosal sites (nerve root ganglia) in.In lip (orolabial) infected, HSV hid in gasserian ganglion, and hides in the rumpbone neuroganglion when sexual organ or anorectal infection.Various stimulations, for example the damage of UV-light and sensory nerve can activate the HSV that hides again.The recurrence venereal disease is decreased and to be occurred in or near the primary infection position.Recurrence as if with some mode reduce individual relevant to the factor of disease resistance, for example flu or upper respiratory tract infection, the high strength physical sport, Exposure to Sunlight, stress, woman month is through triggering because of food with some individualities, particularly a large amount of chocolates or peanut.

During reactivation, HSV duplicates in neuroganglion, and the progeny virus particle moves to the mucous membrane or the epithelial surface of its reactivation neuroganglion domination to outer planet along sensory nerve.Virus is in the active typical clinical sign and sick the damage (situation that recurs flu as the people who infected by HSV) that has produced the HSV infection and recurrence of duplicating of skin surface then.

" Epstein-Barr virus " (EBV) or HHV-4 and be also referred to as the infectious mononucleosis of " glandular fever " and tumour to form (for example, Burkitt lymphoma and nasopharyngeal carcinoma (nasopharyngeocarcinoma)) relevant.In addition, in the patient of immunosuppression and trouble Hodgkin, find to have EBV.EBV has in the whole world, and most of people were infected by it once in life at it.In the U.S., nearly 95% adult is infected in 35-40 when year.In case maternal antibody provide protection (existing during birth) disappears, the baby is promptly to the EBV susceptible.

The EBV symptom of infectious mononucleosis comprises heating, throat pain, lymph gland swelling.Spleen or liver swelling can take place sometimes.Rare cardiac problems or relate to central nervous system, infectious mononucleosis is fatal scarcely ever.The most of individualities that contact with the people who suffers from infectious mononucleosis were infected by EBV in the past, did not have the risk of suffering from infectious mononucleosis.In addition, EBV propagates and need contact closely with sufferer's saliva (finding virus in mouth).This virus is not generally by air or blood propagation.Latent period, or from infect to the time that symptom occurs be 4-6 week.The infectious mononucleosis patient propagates this infectious diseases to other people in can be in several weeks.Yet, do not recommend special preventive measures or partition method, because in healthy people's saliva, often can find this virus yet.In fact, many healthy persons can carry and intermittently propagate this virus all the life.These people are the main source (primary reservoir) of person to person's propagation normally.In view of this, may prevent this virus disseminating hardly.

Though the symptom of infectious mononucleosis can disappear 1 or 2 middle of the month usually, Epstein-Barr virus can be kept in a few cell that lies dormant or latent in throat and blood in all the other times in this person's all one's life.This virus can periodically activate again, is common in sufferer's the saliva.This reactivation does not often have obvious disease symptoms when taking place, but nonspecific symptom can be arranged, and for example discomfort or athletic performance are not good.EBV also can set up lifelong dormancy and infect in some cells of body immune system.Two kinds of rare cancers of seldom finding in the U.S. Burkitt lymphoma and nasopharyngeal carcinoma can appear, in this virus few carrier afterwards.As if EBV plays an important role in these malignant tumours take place, but may not be the sole cause of these diseases.

Cytomegalovirus (CMV) or HHV-5 generally see in all geographic areas and the colony of social economy, and in the U.S., 40 years old adult of 50%-85% is infected.CMV can cause immunosuppression person's pulmonary infection.In addition, it is believed that CMV is relevant with EBV and chronic fatigue syndrome, per 100,000 philtrums have 6 people influenced by this disease.Can discharge infectious CMV in the infected's the body fluid before any, thereby can in urine, saliva, blood, tears, seminal fluid and breast milk, find.The discharge of virus can intermittently take place, and does not have detectable sign, does not also cause symptom.CMC is in interpersonal propagation.CMV can also can propagate through breast milk, transplanted organ through spreading through sex intercourse, and seldom propagates through blood transfusion.Though should virus not be hyperinfection, its demonstration can be propagated within the family with among the young children.Often can stop the propagation of this virus,, should virus be absorbed then by susceptible person's nose or mouth because its modal circulation way is to contact with hand by infected body fluid.Therefore, should the heart when the article of handling children such as diaper.With soap and water simply wash one's hands can be effectively with should virus from removing on hand.

The symptom that CMV causes is less than EBV, and long-term unconspicuous infection often takes place, and virus resides in the cell and do not cause detectable damage or clinical disease during this period.Because of taking medicine or disease causes body immune system to be badly damaged making often this virus from hiding or dormant state activates again.Cmv infection is common but do not have symptom in baby and child; Therefore, known infected children are dropped out of school or drop out of school unreasonable also unnecessary.Similarly, inpatient does not need independent or meticulous isolation preventive measures.The value of children or patient being carried out the CMV screening is suspicious.The cost of this method is unrealistic with operation.The known children that infected CMV should not got rid of separately, isolate or treat especially.On the contrary, suggestion is educated the personnel that take care of children and is set up effective hygiene measure.It is gestation that CMV may cause the situation of problem, the people of baby and child care work and the people that immunizing power weakens.

Varicella zoster virus (VZV) or HHV-3 cause children varicella usually, and its (infection) needs suction the infected's nose or throat to drain into the small droplets that contains virion of air.This virus enters human body by the cell that infects respiratory tract, thereby diffuses to other position of great majority of health, comprises skin and causes the characteristic fash.Each sick decrease (spot) has experienced the series of features sexual stage in an about week.Papule and vesicle develop into warts, incrustation then, healing.The notable feature of varicella is to grow several consecutive spots, reaches the peak period (occur first fash 3-4 days after) of disease, develops into all ill damage of all stages of incrustation from new bubble.

The ability that VZV propagates in this way shows that varicella has infectivity.Virus is discharged from air flue and is started from the later stage of hiding, and continues to institute's spottiness incrustation.Though skin blister contains virion, they are not main contagium.Scar does not have infectivity.The interference method that is of long duration is to reduce heating and uncomfortable (that is, antipyretic, cooling bath and comfort washing lotion (soothing lotion)) as far as possible.

Varicella is the clinical manifestation of VZV primary infection.After the primary infection recovery, VZV does not disappear in body, but sensorineural root is in dormant state (but common many decades) in spinal cord.After infecting activation again, cause infected sensory nerve institute's distributed areas pain and fash.Latent infection can cause the zoster outbreak.This takes place in the elderly usually, may be that immunity system can not be controlled this virus because with age.The fash of zoster contains the VZV particle, as the fash of varicella.Therefore, zoster infects varicella to the people's who does not suffer from the past varicella risk little.The baby usually can be by catching varicella with grand parents's intimate contact of suffering from zoster, but this propagation risk is low, because VZV does not discharge by throat during the zoster.

Roseola virus or HHV-6 infect relevant with " roserash " and " baby's rash (infantum) " that children and immunizing power weaken the patient.For example, AIDS patient shows HHV-6 and infects, though the meaning that HHV-6 infects it be unclear that.HHV-6 enantiopathy cytotoxic drug sensitivity.Yet how antiviral is resisted HHV-6 or should virus how the resistance of this medicine to be produced it be unclear that.The meaningful aspect of HHV-6 is that it infers that it is relevant with multiple sclerosis and chronic fatigue syndrome respectively.

HHV-7 and HHV-8 (elongated virus) are understood still less.The clear and definite evidence that HHV-7 participates in any human diseases directly yet there are no report.Yet, studies show that HHV-7 may be relevant with the HHV-6 infections relating.One relevant viewpoint is that it is relevant with Kaposi sarcoma to it is believed that HHV-8 infects.

In addition, think that simplexvirus is the reason of the motor capacity of the major reason of horse keeping industry loss and grievous injury horse.Animal doctor, trainer and horse owner people tend to only rely on the horse that experiential therapy is suffered from respiratory tract disease, in default of clinical guidelines and laboratory method, also because do not understand virus and Secondary cases infectation of bacteria and the relation of disease between the time length.Other diagnosis or appraisal procedure complexity, invasive, inconvenience, costliness, consuming time, animal often may and often need animal is transported to diagnositc center because of injured dangerous of this method.

In the research that carry out the West Australia, have the blood of the horse that respiratory problems or (motion) perform poor from 48% and to be separated to simplexvirus.Yet can be separated to simplexvirus from 54% Malaysia and China that do not have clinical sign yet, thereby reach a conclusion: having this virus in the hemocyte is not the determinative of disease.Isolated viral more can show respiratory tract infection from the nose swab, but only is separated in 50% clinical case.According to reports Britain nearly 75% horse carry this virus.

Equine rhinopneumonia is generally acknowledged equine disease different by two kinds but that antigenicity associated virus (being called 4 type EHVs (EHV-4) and 1 type EHV (EHV-1)) causes with equine abortion.EHV-1 is the cause of disease of the popular miscarriage of horse, perinatal death, respiratory tract disease and neurosigns (once in a while).Miscarriage is the surprising and the most fearful result that EHV infects, and it is raiser's economic woes, causes customer churn and a large amount of insurance benefits.The respiratory tract disease that EHV-1 or extremely relevant EHV-4 cause can poorly influence the sports performance of horse.

Studies show that what Australian Hunter Valley carried out the EHV-1 infection is popular in the horse keeping industry, young coltfoal is infected by EHV-1 often before these place 60 ages in days.The independent studies of carrying out in the U.S. shows young coltfoal 6-8 month seropositive conversion after wean of 85%.It is believed that young coltfoal is to contact by the respiratory droplets with mare or the young coltfoal of same group to infect.

EHV-1 is a kind of DNA α simplexvirus of having a preference for airway epithelial cell.This virus is transmitted to other organ by immune system cell at whole body.Because these two kinds of viruses are relevant on antigenicity, can't determine whether horse is subjected among EHV-4 or the EHV-1 one or both infection by serologic test (blood test) at present.For example, if infected by EHV-4 as the horse of young coltfoal, the antibody that produces in its serum can not only also can react with EHV-1 with EHV-4, therefore, can't know whether this young coltfoal infected by EHV-4.EHV-4 only confirms to cause respiratory tract disease, and EHV-1 can also cause neural and reproductive disease (Wilcox and Raidal, 2000, " effect of virus in respiratory tract disease " (Role of viruses inrespiratory disease), RIRDC publication number 00/146, RIRDC item number UMU-22A; Dunowska etc., 2002, New Zealand Veterinary Journal 50 (4): 132-139; Dunowska etc., 2002, New Zealand Veterinary Journal 50 (4): 140-147).

Proved that EHV-1 is lasting, lifelong latent infection, it activates again and causes the horse respiratory tract disease to be shown effect once more.Yet when other horses that infect when contacting with first dry goods (index case (index case)) were pregnant mares in the pasture, this virus activated again and it is propagated to other pregnant mare that contacts with it, and its consequence is more serious to raising the farm.One or many abortion of mares that contact with it may be miscarried or cause to index case mare oneself.Fetus, fetal membrane and the liquid of miscarriage are subjected to the EHV-1 severe infections, have polluted the place that miscarriage takes place.Born other curious mare comes the miscarriage place in this pasture, smells this fetus and peptide film.Like this, in this pasture almost 100% mare infected, miscarriage in 10 or 20 days, thus cause " the miscarriage storm " that be commonly referred to.This outburst of EHV-1 miscarriage is to global horse keeping industry, and particularly thoroughbred (Thoroughbred) and standard-bred (Standardbred) have Economic Importance.

Immunizing power and diagnosis

Simplexvirus can be induced strong humoral antibody reaction, though this reaction protection host's validity is doubtful.Finally be by cell-mediated mechanism, for example cytotoxic lymphocyte or natural killer cell are given provide protection.One of key feature of herpesvirus infection is lifelong long-lasting infection and hides.This virus maintains in the nucleus, for a long time still can be separated to from many organs after clinical symptom disappears.Therefore, when patient (horse) has the clinical sign that is difficult to describe, for example (motion) perform poor or be uncomfortable, can be from the separate tissue to virus, it be unclear that but whether the activation of virus is the reason of these symptoms.Stress or other factors can cause dormancy activated viral and the clinical sign followed (Walker etc., 1999, Veterinary Microbiology, 68:3-13).

HSV-1 or HSV-2 infect the immunizing power of energy inducing cell mediation, produce the antibody of general type and particular type.Do not influence generation or the recurrence frequency that HSV hides though these immune mechanisms be it seems, activate again in case (virus) takes place, they can be regulated the seriousness of clinical recurrence and reduce HSV and duplicate.

HSV-1 or HSV-2 infect the host immune response that causes and show to provide and resist the part provide protection that HSV subsequently infects because in the individuality that HSV infects common resistibility to self infection.In addition, with the physiognomy ratio that did not infect in the past HSV, when the patient who infected HSV was infected by another HSV type, clinical sign often more relaxed.

HSV is the most frequent detected virus in the diagnostic test chamber.Can be by virus separation, polymerase chain reaction (PCR) (Espy etc., 2000, J Clin Microbiol., 38 (2): 795-799) make diagnosis with histopathology (method).These methods all can not be used for control and monitoring of diseases.Other laboratory inspection that can be used for diagnosing comprises scrapes bits (scrapings) and blood antibody test with the microscopy special disposal.Some detect only effective in early days, may need multiple these checks for confirming that bleb exists.Genital herpes may mistaken diagnosis be other disease, comprises syphilis.Serum antibody level height also is the index of recent infection.If someone has visible symptom really, cultivate check in preceding 48 hours after being recommended in symptom and occurring.After 48 hours, the risk that obtains the false negative assay is arranged because symptom may begin to fully recover and skin on do not have enough virus to cultivate.

When someone does not have visible symptom, but when worrying herpes infection is arranged, can adopt blood test.In fact blood test is not to detect virus; But look for antibody (immune response of body), but the human blood of 50-90% has positive antibody.Available twice blood test at present obtains the precise results of bleb.The same with any blood test, it is oral cavity or reproductive tract that these checks can not be measured infection site.Yet because the most of cases of genital herpes are that HSV-2 causes, 2 type antibody results are positive, and most probable shows it is genital herpes.With regard to the most accurate result, recommend from possible last duration of contact waiting until that 12-16 has the enough time to produce antibody after week at least with bleb (virus).

According to the clinical diagnosis of generating heat, having sore throat, lymph gland swelling symptom and patient's age proposing EBV and infectious mononucleosis.Usually need laboratory inspection to confirm.Infectious mononucleosis patient's serology result comprises that white blood cell count(WBC) raises, some atypia white corpuscle per-cent raises and " single spot " check is positive.

By enzyme-linked immunosorbent assay (or ELISA), a kind of serologic test that detects antibody carries out the CMV clinical diagnosis.Can utilize its result to determine whether the baby has the maternal antibody of acute infection, infection in the past or passive acquisition.Other check comprises various fluorescent tests, IHAT and milk agglutination test.

According to respiratory symptom, promptly cough or nasal mucus carry out the EHV diagnosis.Yet, distinguish respiratory bacillary infection or viral infection, exercise inductive lung is hemorrhage with irritated most important.The cost of mistaken diagnosis is very big.The cost of horse owner's diagnose medical conditions comprises transportation, animal doctor's expense and pathological examination.Respiratory tract disease can kill (horses) fast, produces lifelong deformity, hinders (motion) performance or need long-term rest.Be in the horses that challenge virus carries situation and can infect other animal again.

With horse keeping already is example, need whether have that EHV-4 and/or EHV-1 antibody carry out accurately to horses, the monitoring of the serology of type specific helps the epidemiology (characteristics) that we understand these virus, particularly EHV-1.EHV-1 infects and is difficult to diagnosis and treatment, any useful information how the sector welcome treats ill horses.Yet, can not distinguish EHV-1 or EHV-4 antibody in the polyclonal serum at present, because between these two kinds of viruses antigenicity cross reaction is widely arranged.Adopt this specific serum to learn check control (perhaps eradicating) EHV-1 is also had far reaching significance with the candidate horses of selecting vaccine inoculation.Be subjected to short duration protection opposing EHV-1 though infect the back horses, do not have enough high-caliber permanent immunity power to resist the EHV-1 disease consistently usually.Therefore, but horses its in life repeated infection for several times, and simplexvirus can be set up lifelong latent infection and made the vaccine inoculation scheme complicated in host animal.

Still there is not to prevent the vaccine of HSV disease generation.Though and then the back clinical trial phase based on the some protein subunit vaccine of HSV-2 envelope glycoprotein.Select these antigens to be because they are the target and the energy trigger cell immunizing power of neutralizing antibody reaction.

Developed oral antiviral, for example acyclovir, Famciclovir (famcyclovir) or valacyclovir (valacyclovir) are effectively treated bleb (virus) infection.These medicines can be used for treating the bleb outburst or can be used for suppressing the bleb recurrence.Lower dosage helps to reduce the number of times of bleb outbreak among the frequent outburst crowd.Ganciclovir, Penciclovir (penciclovir) and acyclovir are effective inhibitor of 1 type (HSV-1) and 2 types (HSV-2) hsv.This antiviral therapy costliness need give when clinical sign outbreak the earliest.These antiviral therapies are based on the employing suicide gene, for example the thymidine kinase gene.Having compared ganciclovir, Penciclovir and acyclovir induces hsv thymidine kinase (HSVTK) system to cause effect (Shaw etc., 2001, Antivir Chem Chemother., 12 (3): 175-86) of necrocytosis.All compound retards the HSVTK transformant growth or reduced its survival.

Except treating these symptoms, EBV and infectious mononucleosis there is not special methods of treatment.There are not antiviral or vaccine to use.Some physicians have opened 5 days steroid and have controlled throat and tonsilla swelling the course of treatment.Have report to say that the use sterol can reduce the total time and the seriousness of disease, but these reports are not delivered.At last, even detect EBV antibody, when for example early antigen test prompting existed reactivation to infect, this result showed that not necessarily the present medical conditions of patient is due to EBV infects.Many healthy persons that do not have a symptom can have the EBV early antigen for many years after infecting EBV first antibody.

At present, the cmv infection that exists in the healthy individual needn't be treated.Now just in the baby, assessing the antiviral therapy.Ganciclovir is used for the treatment of immunosuppression and the patient who suffers from visual correlation or life-threatening disease.Vaccine still is in the research and development stage.

Usually antiviral compound treatment varicella that need not be special is because its time length is short and common gentle character is uncomplicated.Some doctors believe that antiviral is suitable for the elderly that disease may be more serious.Chickenpox vaccine (varicella virus (varicella) vaccine) was brought into use from nineteen ninety-five.Studies show that the prophylactic validity of Varivax is 85%.This vaccine is of value to the grownup of no immunizing power, particularly is in high risk grownup, for example child care and health worker.Because most of grownups have immunizing power, be recommended in the preceding serology state of checking of vaccine inoculation.

The main difficult point of treatment zoster is a fast pain relief.Four kinds of factors have increased the risk of lasting pain independently: age growth, the pain (being called forerunner's pain) when fash occurs before serious or medium serious pain (being called acute pain), the fash appearance occur failing to obtain enough antiviral therapies in 3 days with fash.Think pain, due to the infected nerve injury that particularly lasting pain is virus induction to a great extent.The principle of using antiviral is very simple: reduce nerve injury as far as possible by the fast as far as possible virus replication that stops.Zoster is to oral antiviral, and promptly acyclovir, Famciclovir and valacyclovir truly have reaction.

The early stage EHV-1 of evaluation infects, and particularly virus abortion is most important for the treatment horses, thereby makes the susceptible horses can generating period repeated infection and recurrence.Because cause training fate forfeiture, repeated infection and palindromia, miscarriage and (motion) to perform poor, the cost that the EHV infection already causes horse keeping is very big.Treatment mainly depends on accurate diagnosis.Can utilize vaccine to cause strong humoral immune reaction, but these vaccines complete protection of tool not.Sudden infection (breakthrough infection) betides the vaccine inoculation animal usually.Though can adopt vaccine, generally know that the provide protection that they provide is very few, and sudden infection often takes place in the vaccine inoculation animal.Antybody therapy can only prevent the Secondary cases infectation of bacteria.

At present, the simplexvirus in the diagnosis blood and the method for relative disease are according to antibody-antigen quantitative assay or detect viral genetic information (for example, passing through the polymerase chain reaction).For example, United States Patent (USP) 6,506,553 have described the test of diagnosing EBV and relative disease by the antigen-antibody in the detection blood sample.This test detects in the blood, more particularly the IgG and the IgM antibody of the dispersivity of EBV early antigen (EA-D) and restricted (EA-R) component in the serum.Can adopt this to test and diagnose the EBV-relative disease, for example infectious mononucleosis (IM); Also can be used for distinguishing the acute phase and the convalescent individuality of this disease.Yet the method that this patent is described is to detect EA-Ab, rather than detects virus or to this viral immune response.

United States Patent (USP) 6,537,555 have described the composition and the method for diagnosing and treating the HSV infection according to HSV detection of antigens (result).Yet this patent is not described and is detected virus or to the immunoreactive method of this virus.

Genetic expression that international publication WO 99/45155 describes and molecular diagnosis method are used for amplification and detect EBV nucleic acid, particularly RNA specific sequence.This method is specially adapted to detect in the circulation peripheral blood cells, (utilizing " in the solution " amplification or " original position " amplification technique) in people's (tumour) tissue sample and the thin section thereof, with other biological sample that may contain the EBV cells infected in late period of EBV genetic expression infect.Yet this method only detects the virus transcription thing, is suitable for the terminal illness diagnosis most.This method does not detect causing the immune responses of the virus infection of symptom the earliest such as discomfort, heating and swollen lymph node yet.

U.S. Patent Application Publication 20040072147 discloses utilizes probe oligonucleotides and at least two kinds of primer tasteless nucleotides to come the target area section of following particular type simplexvirus of selective amplification or strain to comprise: HSV-1, resistance HSV-1, HSV-2, resistance HSV-2, VZV, EBV (HHV-4a and HHV-4b), CMV, lymph cryptovirus (HHV-6a, HHV-6b), HHV-7 and elongated virus (HHV-8).Yet this method can not provide when infected whether disease stage or animal or disease be any information of active.

United States Patent (USP) 6,193,983 have described the method that detects EVH-4 and EVH-1 type specificity glycoprotein is used for relevant with the feature of this glycoprotein clinically field.This method detects anti-EHV-1 and EHV-4 specific antibody, but it is contacted in childhood and these virus to know most of horses, the sustainable certain hour of antibody titers.So this method can not provide when infected whether disease stage or animal or disease be any information of active.

In a word, the various virus strain infections of simplexvirus are general phenomenon in the community, cause having the disease of serious economic impact.Most of people and domestic animal are in the infection that all is subjected at least a strain of simplexvirus in petticoats, and this infection is lifelong.Simplexvirus enters latent period, can activate again and causes symptomatic recurrence.The reactivation frequentation of virus is toward asymptomatic, but can show as discomfort or nonspecific symptom, for example low fever, drowsiness, confirmed fatigue, exercise tolerance is not good or athletic performance is not good.Physiological stress (for example, heavy exercise, concurrent disease, stress), or immunity system weakens (for example HIV infect, immunosuppressant therapy) and can cause the simplexvirus reactivation and produce the chronic infection symptom.In view of these reasons, the monitoring herpesvirus infection is often important, particularly the patient that weakens of immunizing power or outstanding sportsmen.Present antibody diagnosis method itself is not monitored herpesvirus infection because the serum antibody that these methods detect 7-14 talent after infection raises and due to illness poison hide and continue and raise.Other present diagnostic method, for example virus is separated and PCR itself does not monitor (virus infection), because these method efforts or viral genome are not constantly to be present in the blood cell.The result that the current diagnosis method obtains does not join with the time correlation that clinical sign shows effect.For example, but at first can detect antibody and long-term existence in 10-14 days in the initial back of infecting.Depend merely on antibody test and can not show time or the disease activity level that takes place that infect, detect virus transcription thing or viral protein and also do not show the disease activity level.Host's immunity system finally is responsible for the provide protection that opposing virus is invaded.Be immune response, but rather than the viral clinical sign that causes this disease itself.The monitoring method that more is appropriate to herpesvirus infection is to detect the specific immune response of host to infecting.

Equally, need more efficient methods to diagnose herpesvirus infection at present, be fit to use the animal of antiviral treatment or preventive therapy by host immune response mensuration activity herpesvirus infection and evaluation.In all cases, primary infection causes latent infection, and the patient that immunizing power weakens also often has risk of relapse.In this case, symptom may be obvious or not obvious, can detect maybe and can propagate.Therefore, need better method and reagent to assess and monitor the Mammals that is in herpesvirus infection and/or the risk of relapse at present.

The invention summary

The invention discloses the detection herpesvirus infection, particularly the method and system of reactivity herpesvirus infection.Identify and the gene of having described one group of predictability of the immune system cell that is used for (detection) herpesvirus infection.These genes and product thereof can be used for gene expression test, protein expression test, full test cell line and design and preparation therapeutical agent.They also can be used for measuring the animal that has or do not have the disease clinical sign.Someone proposes, and is frequent when opposing viral active indicator reaction when these tests, can obtain better that reply determines and treatment plan, comprises that outstanding sportsmen or immunizing power weaken the used scheme of patient.

The present invention has represented the marked improvement of present processing infected animals treatment technology.In some preferred embodiment, depend on the level that detects some mark, particularly circulating leukocyte in the host cell, rather than detect viral product or antiviral antibody.Equally, these methods are applicable to that extensive screening has symptom and asymptomatic animal.In some embodiment that with the circulating leukocyte is analytic target, can before detecting serum simplexvirus specific antibody, should detect the host at the very commitment of this virus progress, the particularly reaction of EHV infection to herpesvirus infection.

Therefore, the present invention is by detecting the host solves the diagnosis herpesvirus infection to the reaction of simplexvirus problem.Embodiment preferred comprises some expression of gene in the immune peripheral leukocytes of monitoring, and described genetic expression is reflected in the change that exists relevant rna level of herpesvirus infection or protein to produce pattern.

Therefore, on the one hand, the invention provides the diagnostic test object, particularly have herpesvirus infection in the horses tested object, particularly the method for movable herpesvirus infection.These methods generally comprise and detect at least a unconventionality expression that is selected from following gene (this paper is also referred to as " herpesvirus infection marker gene " or " HVI marker gene ") in this tested object: (a) a kind of gene, its polynucleotide expression product contains and following arbitrary sequence have at least 50% (and at least 51%-at least 99% and between all integer per-cents) nucleotide sequence of sequence homogeny: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113 (referring to table 1), or its complementary sequence; (b) a kind of gene, its polynucleotide expression product contain the nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114 (referring to table 1); (c) a kind of gene, its polynucleotide expression product contains coding and at least a portion of following arbitrary sequence at least 50% (and at least 51%-at least 99% and between all integer per-cents) nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) a kind of gene, its polynucleotide expression product contain at least can be under low preciseness, middle preciseness or high preciseness condition and the sequence of (a) and (b), (c) or the nucleotide sequence of its complementary sequence hybridization.These HVI marker gene of the present invention are at herpesvirus infection or suffer from abnormal expression in the animal of herpesvirus infection associated conditions, the exemplary example of described illness comprise immunosuppression, stress, high-intensity athletic training, an accompanying infection and a special venereal disease disease.

This paper is called the polynucleotide expression product of used HVI marker gene " herpesvirus infection mark polynucleotide " or " HVI mark polynucleotide ".This paper is called the expression of polypeptides of HVI marker gene " herpesvirus infection mark " or " HVI labeling polypeptide ".

Therefore, in some embodiments, described method comprises and detects the unconventionality expression be selected from following HVI mark polynucleotide: (a) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of sequence homogeny nucleotide sequence: SEQ IDNO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (c) contain coding and at least a portion of following arbitrary sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In other embodiments, described method comprises and detects the unconventionality expression that is selected from following HVI labeling polypeptide: (i) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polypeptide of aminoacid sequence of sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; The polypeptide that (ii) contains a following arbitrary sequence part: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 5 contiguous amino acid residues of this sequence; At least 15 contiguous amino acid residues of (iii) amino acid contained sequence and following arbitrary sequence have the polypeptide of 30% similarity at least: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; The polypeptide that (iv) contains the part of following arbitrary sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 5 contiguous amino acid residues of this sequence, and with can and (i), (ii) or (iii) described certain sequence immune interactional antigen binding molecules takes place immunity takes place interacts.

This unconventionality expression generally detects by following steps: (1) detects the level or the functionally active of at least a HVI marker gene expression product in the biological sample that derives from tested object, (2) with the level or the functionally active of detected each expression product and derive from one or more normal subjects or one or morely (for example do not suffer from this disease, the level or the functionally active of corresponding expression product are made comparisons in the reference sample of object no activity infection), wherein compare with the level or the functionally active of corresponding expression product in the reference sample, the level of this expression product or functionally active are variant in this biological sample, show to have herpesvirus infection or associated conditions in this tested object.In some embodiments, when this expression product or the detected level of each expression product or functionally active and corresponding this expression product or the detected level of each expression product or functionally active not simultaneously, described method also comprises existence, stage or degree or the associated conditions of herpesvirus infection in this tested object of diagnosis.In these embodiments, compare with the level or the functionally active of each corresponding expression product, it is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% that the level of described each expression product of difference ordinary representation or functionally active improve at least, perhaps even at least improves about 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% or 1000%; Perhaps reduce at least about 10%, 20%, 30% 40%, 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 97%, 98% or 99%, perhaps even at least reduce about 99.5%, 99.9%, 99.95%, 99.99%, 99.995% or 99.999%, promptly hereinafter alleged " unconventionality expression ".In the exemplary example of this type, reduce existence or the associated conditions of measuring herpesvirus infection by detecting at least a level or the functionally active that is selected from following HVI mark polynucleotide: (a) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQID NO:6,10,19,24,25,29,33,34,35,37,38,41,53,57,61,63,65,66,73,77,83,89,93,94,96,100,101,102,104,106,107 or 108, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:11,20,30,36,42,54,58,62,64,74,78,90,95,97,103 or 105; (c) contain coding and at least a portion of following sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:11,20,30,36,42,54,58,62,64,74,78,90,95,97,103 or 105, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In other exemplary example, determine the existence or the associated conditions of herpesvirus infection by the raising that detects at least a level that is selected from following HVI mark polynucleotide or functionally active: (a) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQ ID NO:1,2,4,8,12,13,15,17,21,23,26,27,31,39,43,45,47,49,51,55,59,67,69,71,75,76,79,81,85,87,91,98,99109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,14,16,18,22,28,32,40,44,46,48,50,52,56,60,68,70,72,80,82,86,88,92,110,112 or 114; (c) contain coding and following arbitrary sequence at least a portion and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:3,5,9,14,16,18,22,28,32,40,44,46,48,50,52,56,60,68,70,72,80,82,86,88,92,110,112 or 114, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In some embodiments, when institute's detection level of this expression product or the detected level of each expression product or functionally active and corresponding this expression product or each expression product or functionally active were same or similar, described method comprised that also diagnosis does not exist herpesvirus infection or associated conditions.In these embodiments, the difference of detected level of the corresponding expression product with each of detected level of each expression product or functionally active or functionally active is no more than about 20%, 18%, 16%, 14%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or at 0.1% o'clock, hereinafter referred to as " normal expression ".

In some embodiments, described method comprises that detection is at least about 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77 or the level or the functionally active of 78 kind of each expression product of HVI mark polynucleotide.For example, described method can comprise independent detection a kind of HVI mark polynucleotide or joint-detection as many as 77,76,75,74,73,72,71,70,69,68,67,66,65,64,63,62,61,60,59,58,57,56,55,54,53,52,51,50,49,48,47,46,45,44,43,42,41,40,39,38,37,36,35,34,33,32,31,30,29,28,27,26,25,24,23,22,21,20,19,18,17,16,15,14,13,12,11,10,9,8,7,6,5,4,3,2 or the level or the functionally active of a kind of other HVI mark polynucleotide.In another embodiment, described method can comprise a kind of HVI labeling polypeptide of independent detection or joint-detection as many as 77,76,75,74,73,72,71,70,69,68,67,66,65,64,63,62,61,60,59,58,57,56,55,54,53,52,51,50,49,48,47,46,45,44,43,42,41,40,39,38,37,36,35,34,33,32,31,30,29,28,27,26,25,24,23,22,21,20,19,18,17,16,15,14,13,12,11,10,9,8,7,6,5,4,3,2 or the level or the functionally active of a kind of other HVI labeling polypeptide.In the exemplary example of this type, described method comprises detection and has at least 1 of herpesvirus infection or associated conditions or its risk height correlation (p＜0.00001), 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16 or the level or the functionally active of each expression product of 17 kind of HVI marker gene (hereinafter referred to as " one-level be correlated with HVI marker gene "), its representative example includes but not limited to: (a) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25 or 26, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20 or 22; (c) contain coding and at least a portion of following sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20 or 22, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In other exemplary example, described method comprises detection and has at least 1 of herpesvirus infection or associated conditions or its risk height correlation (p＜0.0001), 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20 or the level or the functionally active of each expression product of 21 kind of HVI marker gene (hereinafter referred to as " secondary be correlated with HVI marker gene "), its representative example includes but not limited to: (a) contain and following arbitrary sequence have at least 50% (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQID NO:27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61 or 63, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:28,30,32,36,40,42,44,46,48,50,52,56,58,60,62 or 64; (c) contain coding and at least a portion of following arbitrary sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:28,30,32,36,40,42,44,46,48,50,52,56,58,60,62 or 64, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In other exemplary example, described method comprises detection and has at least 1 of herpesvirus infection or associated conditions or its risk medium relevant (p＜0.0003), 2,3,4,5,6,7,8,9,10,11,12,13,14 or the level or the functionally active of each expression product of 15 kind of HVI marker gene (hereinafter referred to as " three grades of relevant HVI marker gene "), its representative example includes but not limited to: (a) contain and following arbitrary sequence have at least 50% (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQ ID NO:65,66,67,69,71,73,75,76,77,79,81,83,84,85 or 87, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:68,70,72,74,78,80,82,86 or 88; (c) contain coding and at least a portion of following arbitrary sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:68,70,72,74,78,80,82,86 or 88, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In other exemplary example, described method comprises detection and has at least 1 of herpesvirus infection or associated conditions or its risk appropriateness relevant (p＜0.06), 2,3,4,5,6,7,8,9,10,11,12,13,14,16 or the level or the functionally active of each expression product of 17 kind of HVI marker gene (hereinafter referred to as " level Four be correlated with HVI marker gene "), its representative example includes but not limited to: (a) contain and following arbitrary sequence have at least 50% (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQ ID NO:89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:90,92,95,97,103,105,110,112 or 114; (c) contain coding and at least a portion of following arbitrary sequence and have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of polypeptide of sequence similarity: SEQ ID NO:90,92,95,97,103,105,110,112 or 114, wherein said part contains 15 contiguous amino acid residues of this sequence at least; (d) containing at least can be under low preciseness, middle preciseness or high preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

In some embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least a kind of one-level of detection.In other embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 2 kinds of one-levels of detection.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of secondary expression product.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of one-levels of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of secondary expression product.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 2 kinds of relevant HVI marker gene of secondary expression products.

In some embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least a kind three grades relevant HVI marker gene expression products.In other embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of one-levels of detection or the level or the functionally active of functionally active and at least a kind three grades relevant HVI marker gene expression products.In also having other embodiment, these methods comprise the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 2 kinds three grades relevant HVI marker gene expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 3 kinds three grades relevant HVI marker gene expression products.

In some embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In other embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of one-levels of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 2 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 3 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of one-level of detection or the level or the functionally active of functionally active and at least 4 kinds of relevant HVI marker gene of level Four expression products.

In some embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least a kind of secondary of detection.In other embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 2 kinds of secondarys of detection.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least a kind three grades relevant HVI marker gene expression products.In other embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of secondarys of detection or the level or the functionally active of functionally active and at least a kind three grades relevant HVI marker gene expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 2 kinds three grades relevant HVI marker gene expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 3 kinds three grades relevant HVI marker gene expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 4 kinds three grades relevant HVI marker gene expression products.

In some embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In other embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of secondarys of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 2 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 3 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 4 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 5 kinds of relevant HVI marker gene of level Four expression products.

In some embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least a kind of secondary of detection.In other embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 2 kinds of secondarys of detection.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of Pyatyi expression product.In other embodiments, described method comprises the level of the relevant HVI marker gene expression product of at least 2 kinds of secondarys of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of Pyatyi expression product.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 2 kinds of relevant HVI marker gene of Pyatyi expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 3 kinds of relevant HVI marker gene of Pyatyi expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 4 kinds of relevant HVI marker gene of Pyatyi expression products.In also having other embodiment, described method comprises the level of the relevant HVI marker gene expression product of at least a kind of secondary of detection or the level or the functionally active of functionally active and at least 5 kinds of relevant HVI marker gene of Pyatyi expression products.

In some embodiments, described method comprises the level or the functionally active of at least a kind three grades relevant HVI marker gene expression products of detection.In other embodiments, described method comprises the level or the functionally active of at least 2 kinds three grades relevant HVI marker gene expression products of detection.In also having other embodiment, described method comprises the level of at least a kind three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In other embodiments, described method comprises the level of at least 2 kinds three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least a kind of relevant HVI marker gene of level Four expression product.In also having other embodiment, described method comprises the level of at least a kind three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least 2 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of at least a kind three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least 3 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of at least a kind three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least 4 kinds of relevant HVI marker gene of level Four expression products.In also having other embodiment, described method comprises the level of at least a kind three grades relevant HVI marker gene expression products of detection or the level or the functionally active of functionally active and at least 5 kinds of relevant HVI marker gene of level Four expression products.

In some embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least a kind of level Four of detection.In other embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 2 kinds of level Four of detection.In other embodiments, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 3 kinds of level Four of detection.In also having other embodiment, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 3 kinds of level Four of detection.In also having other embodiment, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 4 kinds of level Four of detection.In also having other embodiment, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 5 kinds of level Four of detection.In also having other embodiment, described method comprises the level or the functionally active of the relevant HVI marker gene expression product of at least 6 kinds of level Four of detection.

Biological sample preferably includes and should contain leukocytic blood, particularly peripheral blood.Described expression product should be selected from RNA molecule or polypeptide.In some embodiments, described expression product is identical with corresponding expression product.In other embodiments, the described expression product variant (for example, allele variant) that is corresponding expression product.

In certain embodiments, described expression product or corresponding expression product be target RNA (for example, mRNA) or the DNA of this target RNA copy, its horizontal available energy copies at least a nucleic acid probe of hybridizing with this target RNA or this DNA and detects under low preciseness condition, this nucleic acid probe contains 15 contiguous nucleotides of certain HVI mark polynucleotide at least.In these embodiments, this target RNA or its DNA are copied level or the abundance stdn of detected level or abundance by the DNA copy of the reference RNA that exists in the same sample or this reference RNA.Nucleic acid probe should be fixed on solid or the semi-solid upholder.In the exemplary example of this type, this nucleic acid probe forms the part of nucleic acid probe space array.In some embodiments, detect the level that copies the bonded nucleic acid probe with this target RNA or this DNA by hybridization (for example adopting nucleic acid array).In other embodiments, detect the level that copies the bonded nucleic acid probe with this target RNA or this DNA by nucleic acid amplification (for example, adopting polymerase chain reaction (PCR)).In also having other embodiment, detect the level that copies the bonded nucleic acid probe with this target RNA or this DNA by the nuclease protection test.

In other embodiments, described expression product or corresponding expression product are the target polypeptide, and its horizontal available energy and this target polypeptide the interactional at least a antigen binding molecules of immunity take place detect.In these embodiments, with the detected level of this target polypeptide or abundance by the reference polypeptide level standardization that exists in the same sample.Antigen binding molecules should be fixed on solid or the semi-solid upholder.In the exemplary example of this type, this antigen binding molecules forms the part of antigen binding molecules space array.In some embodiments, with the level of immunoassay (for example utilizing ELISA) detection with this target polypeptide bonded antigen binding molecules.

In also having other embodiment, described expression product or corresponding expression product are the target polypeptide, and at least a substrate that its horizontal available energy and the reaction of this target polypeptide form reaction product detects.In these embodiments, with of the functionally active stdn of the detected functionally active of this target polypeptide by the reference polypeptide that exists in the same sample.

In some embodiments, available suitably comprise at least one with base station (base station) mutually a kind of system in the terminal station (end station) of coupling connection carry out this diagnostic method.This base station should (a) be accepted data by network of communication from the terminal station, wherein said data represented parameter value is detected or level of standardization or functionally active corresponding at least a expression product in the biological sample, (b) with described data with represent the detected or standardization of at least a corresponding expression product in the reference sample or the tentation data of functionally active to make comparisons, thereby measure with the reference sample in the flat or functionally active of corresponding expression product water compare any difference of the level of this expression product or functionally active in this biological sample.The base station preferably can also diagnose whether have herpesvirus infection associated conditions or its degree.In these embodiments, the base station also can will diagnose indication to be passed to the terminal station by network of communication.

On the other hand, the present invention has considered to adopt above broadly described method to monitor, treat and control to have the animal that possibility causes the patient's condition of herpesvirus infection, and the exemplary example of the described patient's condition comprises: immunosuppression, new birth, stress or high-intensity training scheme.In these embodiments, use diagnostic method of the present invention often can effectively monitor the early stage generation or the associated conditions of herpesvirus infection, thus can early treatment intervention and this illness of treatment.

On the other hand, the invention provides treatment, prevention or suppress herpesvirus infection in the object or the method for associated conditions.These methods generally comprise the unconventionality expression of at least a HVI marker gene in the detected object, and the medicine that gives this object significant quantity is with treatment or relief of symptoms, perhaps reverse or suppress this object generation herpesvirus infection or associated conditions.The representative example of this treatment or medicine includes but not limited to: the palliative supportive treatment of microbiotic, steroid and anti-inflammatory drug, intravenously (injection) liquid, vasoactive (medicine), damage or damage organ (for example, the oxygen supply of respiratory distress, the hypovolemia transfusion) and monitor vital organ closely.

On the other hand, the invention provides the isolating polynucleotide that this paper is called " HVI mark polynucleotide ", described polynucleotide are selected from: (a) contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polynucleotide of nucleotide sequence of sequence homogeny: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence; (b) contain the polynucleotide that comprise a following arbitrary sequence part: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence, wherein said part contains 15 contiguous nucleotides of this sequence or complementary sequence at least; (c) at least can be under low preciseness, middle preciseness or high preciseness condition and (a) or (b) polynucleotide of described sequence or its complementary sequence hybridization; (d) contain the polynucleotide of the part of following arbitrary sequence: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence, wherein said part contains 15 contiguous nucleotides of this sequence or complementary sequence and at least can be under low preciseness, middle preciseness or high preciseness condition and (a) and (b) or (c) described sequence or its complementary sequence hybridization at least.

Also having on the other hand, the invention provides and contain the nucleic acid construct thing that operability is connected in the above broadly described polynucleotide of regulatory element, this construction can be operated in host cell.In certain embodiments, described construction is a carrier format, particularly expression vector.

Also having on the other hand, the invention provides the isolating host cell that contains above broadly described nucleic acid construct thing or carrier.In some preferred embodiment, described host cell is selected from bacterial cell, yeast cell and insect cell.

Also having on the other hand, the invention provides and be used for detecting the probe whether nucleic acid exists above broadly described polynucleotide.These probes generally comprise at least can be under low preciseness condition and the nucleotide sequence of above broadly described multi-nucleotide hybrid.In some embodiments, described probe is basically by constituting corresponding to nucleotide sequence at least a portion of the following arbitrary aminoacid sequence of coding or with its complementary nucleotide sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part is to 15 Nucleotide of the youthful and the elderly.In other embodiments, described probe contains the nucleotide sequence that can hybridize with nucleotide sequence at least a portion of arbitrary aminoacid sequence below the coding at least under low preciseness condition: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part is to 15 Nucleotide of the youthful and the elderly.In also having other embodiment, described probe contains the nucleotide sequence that can hybridize with at least a portion of following sequence at least under low preciseness condition: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, wherein said part is to 15 Nucleotide of the youthful and the elderly.Be used to detect the representative probe of HVI mark polynucleotide of the present invention shown in SEQID NO:145-2150 (seeing Table 2).

In related fields, the invention provides solid or the semi-solid upholder of having fixed at least a above broadly described nucleic acid probe thereon.In some embodiments, this solid or semi-solid upholder comprise the nucleic acid probe space array that is fixed thereon.

In others, the invention provides the isolated polypeptide that this paper is called " HVI labeling polypeptide ", described polypeptide generally is selected from: (i) contain and the expression of polypeptides product of above broadly described HVI marker gene have 50% at least (and at least 51%-at least 99% and between all integer per-cents) polypeptide of aminoacid sequence of sequence similarity, for example, particularly contain and following arbitrary sequence have 50% at least (and at least 51%-at least 99% and between all integer per-cents) the HVI marker gene of nucleotide sequence of sequence homogeny: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113; (ii) as the part of polypeptide as described in (i), wherein this part contains 5 contiguous amino acid residues of this polypeptide at least; (iii) contain and (i) at least 15 contiguous amino acid residues of described polypeptide have at least 30% similarity (and at least 31%-at least 99% and between all integer per-cents) the polypeptide of aminoacid sequence; (iv) contain can with (i), (ii) or (iii) described sequence the polypeptide that immune interactional aminoacid sequence takes place immune interactional antigen binding molecules takes place.

A further aspect of the present invention provides and can immune interactional antigen binding molecules take place with above broadly described HVI labeling polypeptide.

In related fields, the invention provides solid or the semi-solid upholder of having fixed at least a above-mentioned antigen binding molecules thereon.In some embodiments, this solid or semi-solid upholder comprise the antigen binding molecules space array that is fixed thereon.

The present invention provides the application in the test kit that preparation diagnosis object herpesvirus infection associated conditions exists of one or more above broadly described HVI mark polynucleotide, one or more above broadly described probes, one or more above broadly described HVI labeling polypeptides or one or more above broadly described antigen binding molecules in addition on the other hand.

Each side of the present invention relates to above broadly described diagnostic method, broadly described HVI mark polynucleotide, one or more above broadly described probes, one or more above broadly described HVI labeling polypeptides or one or more above broadly described antigen binding molecules are used for diagnosis trouble herpesvirus infection associated conditions more than one or more.Animal (vertebrates), Mammals, non-human mammal for example relate to the horse and the pet (for example, dog and cat) that bear a heavy burden or move (for example sports).

Each side of the present invention relates to animal (vertebrates), Mammals, non-human mammal, for example relates to the horse and the pet (for example, dog and cat) that bear a heavy burden or move (for example sports).

The accompanying drawing summary

Fig. 1 is the receptor operating curve (Receiver Operator Curve) of group 1 virus inoculation animal, has compared the genetic expression with other fate in the 2nd, 4 and 6 day.Utilize this check sensitivity and the specificity of genetic expression mark (signature) outstanding, area under curve surpasses 0.9.

Fig. 2 is when utilizing the selection gene of clinical infection animal, the diagram of receptor operating curve.Utilize the check sensitivity and the specificity of genetic expression mark outstanding.

Fig. 3 utilizes when regarding the selection gene of the animal with reactivity virus infection as the diagram of receptor operating curve.Utilize this check sensitivity and the specificity of genetic expression mark outstanding.

Fig. 4 is when utilizing all genes of clinical infection animal, the diagram of receptor operating curve.Utilize this check sensitivity and the specificity of allelic expression good.

Fig. 5 utilizes when regarding the selection gene with challenge virus infected animals as the diagram of receptor operating curve.Utilize this check sensitivity and the specificity of allelic expression good.

Fig. 6 shows that EHV-1 organizes the synoptic diagram of gene expression index (Log volume unit), serum EHVAb level (450nm absorbancy), date, fate (D=days) and the clinical sign of 1 young coltfoal.The children coltfoal is in inoculation on March 18th, 2003 (virus).The variation of gene expression index is corresponding to the clinical sign that exists, before 10-14 days of anti--EHV-1 antibody generation that this variation occurs in specific serum.

Fig. 7 is that the main ingredient of group 1 young coltfoal is analyzed synoptic diagram.These components are according to the fate mapping of inoculation after (virus).

Detailed Description Of The Invention

1. definition

Unless otherwise defined, all technology used herein are identical with the meaning that one skilled in the art of the present invention understand usually with scientific terminology. Although can utilize to any method similar or of equal value described herein and material and implement or check the present invention, preferred method as herein described and material. For purpose of the present invention has defined following term.

Article used herein " one " and " one " refer to that one or more (being at least one) this article is at phraseological object. For example, " element " refers to an element or a plurality of element.

This paper is used for describing the term " unconventionality expression " that the HVI marker gene is expressed, refer to and take from health objects or be not subjected to certain HVI marker gene in the cell of herpesvirus infection object or the expression of its variant, and/or with take from health objects do not have the tissue sample of object of herpesviral or body fluid in certain HVI marker gene product (for example, transcript or polypeptide) higher or reduced levels compare this HVI marker gene overexpression or express not enough. Specifically, if with take from health objects or do not have the cell of the object of herpesviral, the expression of certain HVI marker gene is compared in tissue or the humoral sample, this HVI marker gene is at least high by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, or even at least high by about 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% or 1000%, perhaps low at least about 10%, 20%, 30%40%, 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 97%, 98% or 99%, or even at least low by about 99.5%, 99.9%, 99.95%, 99.99%, 99.995% or 99.999%, this HVI marker gene unconventionality expression then.

This paper is used for describing the term " unconventionality expression " that HVI mark polynucleotides are expressed, refer to and take from health objects or (for example do not have the herpesvirus infection relevant disease, the expression of certain HVI mark polynucleotides or its variant in the cell of object no activity herpesvirus infection), and/or take from health objects or do not have the tissue sample of object of herpesvirus infection disease or body fluid in certain HVI mark polynucleotide products (for example, transcript or polypeptide) higher or lower level compare this HVI mark polynucleotides overexpression or express not enough. Specifically, if with take from health objects or do not have the cell of the object of herpesviral disease, the expression of certain HVI marker gene in tissue or the humoral sample, and/or with take from health objects do not have the tissue sample of object of herpesviral disease or body fluid in the expression of certain HVI mark polynucleotides compare, the expression of these HVI mark polynucleotides is at least high by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, or even at least high by about 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% or 1000%, perhaps hang down about 10% at least, 20%, 30%40%, 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 97%, 98% or 99%, or even at least low by about 99.5%, 99.9%, 99.95%, 99.99%, 99.995% or 99.999%, this HVI mark polynucleotides unconventionality expression then. Abnormal gene expression in the immune system cell of the present invention, particularly circulating leukocyte can be derived from following two consecutive steps: (1) notes abnormalities, and the gene of expressing is diagnosed, prognosis is assessed with illness; (2) gene of clinical affirmation unconventionality expression.

(for example often organizing the cell or tissue sample according to following steps, immune cell, such as but not limited to leucocyte) in be subjected to significantly raising or those genes of downward modulation (p＜0.06) and determine the gene expression that notes abnormalities: (a) keep constant constant gene according to expression under normal and disease state and come standardization, (b) employing (for example can prevent false-positive statistical method, Holm and FDR judge) explain multivariate data, for example the intrinsic false positive of microarray data is found. The technical staff in Gene Expression Data Analysis field know admissible data normalization other form and can material change's character of the present invention (for example MAS5, stable multi-chip equalization (Robust multi chip averaging), multi-chip equalization (GC Robust multi chip averaging) or Li Wong algorithm that GC is stable). With regard to diagnosis, the cell or tissue sample usually derives from one group and represents the true negative cell or tissue sample of illness interested and the true positives cell or tissue sample that a group represents this illness. All other parameters or variable usually need to suitably utilize identical animal and induce this animal that illness interested takes place and control in these groups, and for example age, geographical position, sex, sport health and other normal biology change. The technical staff in experimental design field knows and can adopt other method to control other parameter and variable and can material alterations character of the present invention. This method includes but not limited to: the co-variation amount (covariates) that randomization, blocking-up (blocking) and utilization are analyzed. With regard to prognosis, the cell or tissue sample usually derives from one group and represents same group of true positives cell or tissue sample that the true negative cell or tissue sample of illness interested and subsequently (behind the certain hour) represent this illness. All other parameters or variable need to utilize identical animal usually in these groups, induce those animals that illness interested and temporal evolution take place and take from the sample of same animal and control, for example age, geographical position, sex, sport health and other normal biology change. With regard to assessment, the cell or tissue sample usually derive from one group of an end of the detected clinical parameter collection of illustrative plates relevant with representing illness interested with represent along the array that can detect clinical parameter collection of illustrative plates each point. Similarly, all other parameters or variable usually need to suitably utilize identical animal and induce this animal that illness interested takes place and control in these groups, and for example age, geographical position, sex, sport health and other normal biology change.

In finding inventory according to the constant gene standardization in the cell or tissue after; those genes that proof significantly raises or reduces; and analyze that interested situation is to make the gene of unconventionality expression at those genes of the correct diagnosis of at least 75% time or assessment illness in the clinical cell or tissue sample used in discover method, thereby determine the abnormal gene expression of clinical affirmation. Receiver operating curve (ROC) generally is the useful testing tool of carrying out this diagnosis. The technical staff in Gene Expression Data Analysis field knows that available other standardized method (for example MAS5, the multi-chip equalization that stable multi-chip equalization, GC is stable or Li Wong algorithm) replaces constant gene standardized method and can material alterations character of the present invention. In addition, the technical staff in Gene Expression Data Analysis field knows that can adopt many methods to measure those genes is subjected to " significantly raising or downward modulation ".

" pact " refers to compare with amount, level, numerical value, numeral, frequency, percentage, dimension, size, consumption, weight or the length of reference product, and 30,25,20,25,10,9,8,7,6,5,4,3,2 or 1% different amount, level, numerical value, numeral, frequency, percentage, dimension, size, consumption, weight or length variations arranged at most.

Term " Active infection " uses with wide significance at this paper, comprise virus to host's intrusion, live away from home and/or breed, usually clinically may be obviously with one or more or may unconspicuous pathology symptom. Active infection comprises part, subclinical or temporary infection. Local infection can exist lastingly and expand to acute, subacute or chronic clinical infection or morbid state by propagation. When cell entry lymph or vascular system, local infection also can become general. " Active infection " is often referred to the Infection Status of host's the infected factor activator of immune system.

Term " amplicon " refers to the amplified production of the target sequence of the target sequence that increases and/or amplification. In some other embodiment, " amplicon " can comprise probe or the primer sequence for amplification.

" antigen binding molecules " refers to target antigen is had the molecule of binding affinity. Will be appreciated that this term can extend to the protein framework that shows that immunoglobulin (Ig), immunoglobulin fragment and NIg with antigen-binding activity derived.

When term used herein " specific binding ", " specific immunity interaction " etc. referred to certain antigen binding molecules, this term referred to can determine to exist the association reaction of this antigen in the heterogeneous population of protein and other biological products. Therefore, under specified immunoassays condition, described antigen binding molecules can combine with its specific antigen and not combine with other oroteins or the antigen that exists in obvious amount and the sample. Specific binding with certain antigen under this condition may need to select that this specific antigen is had specific antigen binding molecules. For example, can prepare the antigen binding molecules for selected proteantigen, this molecular energy with this antigen but not in the sample other oroteins antigen combine. Can adopt various forms of immunoassays select can with the interactional antigen binding molecules of certain specified protein generation specific immunity. For example, conventional adopt solid phase ELISA immunoassays select can with the interactional monoclonal antibody of certain protein generation specific immunity. The immunoassays mode and the condition that can be used for measuring specific immune response can be referring to Harlow and Lane, (1988), " antibody, laboratory manual " (Antibodies, A Laboratory Manual), cold spring port publication, New York.

" BA part " referred to keep the total length parental generation peptide of parental generation molecular activity or the part of polypeptide. Term used herein " BA part " comprises deletion mutant with parental generation molecular activity and for example has peptide at least about 8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,30,40,50,60,70,80,90,100,120,150,300,400,500,600,700,800,900,1000 continuous amino acid residues. The recombinant nucleic acid technology of available standards obtains or adopts conventional liquid phase or solid phase synthesis technique to synthesize this type of part. For example, can be with reference to publishing such as Blackwell Scientific Publications, in the publication of " synthetic vaccine " (Synthetic Vaccines) by name that Nicholson compiles Atherton and Shephard institute famous for the liquid phase described in " peptide is synthetic " (Peptide Synthesis) the 9th chapter synthetic or solid phase synthesize. Perhaps, available protease, for example endoLys-C, endoArg-C, endoGlu-C and staphylococcus V8-protease digestion peptide of the present invention or polypeptide prepare this class peptide. The fragment that can digest by for example high performance liquid chroma-tography (HPLC) technology purifying. Also can adopt the recombinant nucleic acid technology to prepare this protein.

Term used herein " biological sample " refers to from the sample animal extraction, that be untreated, process, dilute or concentrate. Biological sample can comprise biological fluid, such as whole blood, serum, blood plasma, saliva, urine, sweat, ascites, peritoneal fluid, synovial fluid, amniotic fluid, cerebrospinal fluid, biopsy (sample) etc. In certain embodiments, biological sample is blood, particularly peripheral blood.

Should understand term used herein " cis acting sequence ", " cis-acting elements ", " cis regulatory region " or " regulatory region " or similarly term refer to when the appropriate location that places certain can express genetic sequence, can regulate any nucleotide sequence of this genetic sequence expression of at least part of adjusting. Those skilled in the art will know that the cis regulatory region can be after transcribing or translating level activation, reticent, the expression and/or cell type specificity and/or the development-specific that strengthen, suppress or change gene order. In certain embodiments of the invention, cis acting sequence is to strengthen or to stimulate certain can express the activation sequence that genetic sequence is expressed.

Unless needs are arranged in the literary composition in addition, the word in this specification " comprises " and " containing " is interpreted as referring to comprise certain described step or element or one group of step or element, but does not get rid of any other step or element or one group of step or element.

" correspondence " or " corresponding to " refer to following polynucleotides: (a) all or part of of its nucleotide sequence that contains and certain reference polynucleotide sequence is substantially the same or complementary, or (b) amino acid sequence of its coding is identical with the amino acid sequence of certain peptide or protein. The scope of this phrase also comprises amino acid sequence peptide or the polypeptide substantially the same with the amino acid sequence of reference peptide or protein that contains.

In this paper treatment or prevent in the chapters and sections of certain disease, " effective dose " refers to need the individuality of this treatment or prevention, this consumption can prevent effectively that the symptom of this illness from this symptom and/or the existing symptom for the treatment of taking place, suppressing with the part of single dose or successive doses the activity of this consumption (compound). Effective dose according to the assessment of the formulation of the taxology group of the health of individuality to be treated and health, individuality to be treated, composition, medical condition with other correlative factor and different. Wish that this consumption can determine to have relative broad range with routine test.

Term " expression " or " gene expression " refer to produce RNA information or are protein or polypeptide with the RNA information translation. Adopting methods described herein to detect all types of gene expressions is parts of the present invention.

" expression vector " refers to instruct the contained polynucleotides of this carrier to transcribe and suitably synthesizes the coded peptide of these polynucleotides or any autonomous genetic elements of polypeptide. Those skilled in the art will know that this expression vector.

Genomic any with all discontinuous code areas of term used herein " gene " phalangeal cell and relevant non-coding and regulatory region thereof. 5 ' and 3 ' the non-coding nucleotide sequence that adjoins of regulating is expressed in gene also refer to encode ORF, introne, the participation of concrete polypeptide. In this, gene also can contain and the natural relevant adjustment signal of certain given gene, for example promoter, enhancer, termination and/or polyadenylation signal, or allos adjustment signal. Dna sequence dna can be cDNA or genomic DNA or its fragment. Gene can be introduced in the suitable carrier and be maintained at outside the chromosome or be integrated into the host.

Every cm such as " high density polynucleotides array " finger²At least those arrays that contain 400 different elements (feature).

Phrase " height distinctive hybridization conditions " refers to determine the hybridization conditions of a base mispairing.

This paper produces hybrid dna-DNA or hybrid dna-RNA with the pairing of " hybridization " expression complementary nucleotide sequence. Complementary base sequence is by basepairing rule those sequences that are mutually related. In DNA, A and T pairing, C and G pairing. In RNA, U and A pairing, C and G pairing. In this, term used herein " coupling " and " mispairing " refer to the hybridization possibility of pairing nucleotides in the complementary nucleic acid chain. The nucleotides of coupling can effectively be hybridized for example above-mentioned typical A-T and C-G base pairing. Mispairing is other combination that can not effectively hybridize nucleotides.

Phrases " specific hybrid " etc. refer to that under the preciseness condition when certain specific nucleotide sequence was present in complicated DNA or the RNA mixture (for example, total cell), double helix or hybridization are combined, are formed to certain molecule only with this sequence.

This paper mentions that " immunity interacts " comprises any interaction, reaction or other combining form of (particularly when one of described molecule is or simulates the immune system component) between the molecule.

" immunologic function " or " immunoreactivity " refers to detect immune system to the respond of exotic antigen by code test well known in the art.

The described material of " separation " expression in fact or be substantially free of its under native state normally with component. For example, " polynucleotides of separation " used herein have referred to remove the polynucleotides of its side joint sequence under the native state, have for example removed the dna fragmentation that normally adjoins sequence with it. Perhaps, " peptide of separation " used herein or fingers such as " polypeptide of separation " are separated peptide or peptide molecule and its n cell environment and other cellular component of being combined with it and/or purifying external. Polynucleotides, peptide or the polypeptide that separates can refer to (being not limited to) by separating the native sequences of purifying or the sequence that produces by restructuring or synthetic method.

" marker gene " thus expression can be given the cell of expressing this marker gene that unique phenotype makes this transformant and other gene of cell phase region that does not contain this mark. But selectable marker gene is given and is equaled the characteristic energy according to the resistance of selectivity factor (for example, the processing method of herbicide, antibiotic, radiation, heat or other destruction no transformed cells) is selected. The proterties that screenable marker gene (or reporter) is given can by observing or check, namely be identified (for example, non-existent beta-Glucuronidase, luciferase or other enzymatic activity in the non-transformed cell) by " screening ".

" natural generation " used herein nucleic acid molecules refers to have RNA or the dna molecular of the nucleotide sequence of natural generation. For example, the naturally occurring nucleic acid molecules protein of natural generation of encoding.

" available from " represent certain sample, for example cell extract or nucleic acid or polypeptide extract be separate from or derived from particular source. For example, can be directly from the biological fluid of object or tissue, separate and obtain extract.

Term used herein " oligonucleotides " refers to through phosphodiester bond continuous a plurality of nucleotide residues (deoxyribonucleotide or ribonucleotide, or its relevant structural variant or synthetic analogues, comprise and contain the nucleotides of modifying or replacing glycosyl group etc.) polymer that consists of (or its relevant structural variant or synthetic congener). Therefore, although nucleotide residue and the connecting key between residue that term " oligonucleotides " is often referred to wherein are naturally occurring nucleotide polymers, but the scope that should know this term also comprises various congeners, includes but not limited to: peptide nucleic acid (PNA), thiophosphate, phosphorodithioate, seleno phosphate (phosphoroselenoate), two seleno phosphates (phosphorodiselenoate), phosphoroanilothioate, phosphoraniladate, phosphoramidite, methyl-phosphonate, 2-O-methylribose nucleic acid etc. The definite size of this molecule is looked concrete application and difference. Oligonucleotides is the polynucleotides subgroup of 200 of length or following base. Oligonucleotides is a long 10-60 base preferably, and most preferably long 12,13,14,15,16,17,18,19 or 20-40 base. Although oligonucleotides can be double-stranded, for example be used for making up variant nucleic acid sequences, oligonucleotides is strand normally, for example probe. Oligonucleotides of the present invention can be the sense or antisense oligonucleotides.

Term " oligonucleotide arrays " refers to contain the substrate of oligonucleotide probe, has deposited different known arrays in the known discontinuous position of this substrate surface. For example, this substrate can be such as U.S. Patent number 5,424,186 described bidimensional substrate forms. This substrate can be used for oligonucleotides (matrix) array of synthetic two-dimensional space addressing. Perhaps, this substrate is characterised in that being rolled into three-dimensional tube shape configuration by the thin slice with two-dimensional plane forms tube array. This substrate also can be taked the microballoon or the pearl form that link to each other with optical fiber surface, such as Chee etc. described in the WO 00/39587 like that. These oligonucleotide arrays have two kinds of different elements at least, and its density is every cm²At least 400 elements. In certain embodiments, the density of these arrays can be every cm²About 500, at least one thousand, at least one ten thousand, at least ten ten thousand, at least one 1,000,000 or at least one ten million elements. For example, this substrate can be silicon or glass, has the thickness of slide or cover glass, perhaps can be made of other synthetic polymer. When the method for testing at this substrate comprises that light detects, the substrate of available printing opacity. This term also refers to the substrate of probe array and a coupled formation wafer part.

Term used herein " operability connection " or " operability links to each other " expression place structural gene under the regulation and control of promoter, thereby can control transcribing and optional translation of this gene. When making up allogeneic promoter/structural gene combination, usually preferably genetic sequence or promoter are placed in arrange with the distance of genetic transcription initiation site is natural with it in this genetic sequence or promoter and its gene of regulating and control, the distance cardinal principle of the gene of namely derive this genetic sequence or promoter is identical. The known in the art permission this not loss of function apart from doing some changes. Similarly, the regulating and controlling sequence element can utilize this element in its natural setting with placing the preferred orientation of heterologous gene under its control, and the location in its gene of namely deriving is determined.

Term " pathogen " this paper with its most widely implication use, but refer to biology or the infectant of the diseases induced reaction of the living tissue cell of infection animal.

Term used herein " polynucleotides " or " nucleic acid " refer to mRNA, RNA, cRNA, cDNA or DNA. This term is often referred to the polymerized form of the nucleotides of 10 bases of the youthful and the elderly, no matter is the modified forms of ribonucleotide or deoxyribonucleotide or this two classes nucleotides. This term comprises strand or the double chain form of DNA.

Term " polynucleotides variant " and " variant " refer to show the polynucleotides that have the basic sequence homogeny with the reference polynucleotide sequence, or the polynucleotides that can hybridize with reference sequence under following preciseness condition. These terms also comprise wherein has one or more nucleotides to add or deletion, or with the polynucleotides of different nucleotides replacements. In this, well knownly can make some change to described polynucleotides according to the reference polynucleotides, comprise sudden change, interpolation, disappearance and replace, thereby make the polynucleotides of change still keep biological function or the activity of these reference polynucleotides. Term " polynucleotides variant " and " variant " also comprise the allele variant of natural generation.

" polypeptide ", " peptide " and " protein " are used interchangeably at this paper, refer to the polymer of amino acid residue and variant thereof and synthetic congener. Therefore, these terms are applicable to that wherein one or more amino acid residues are the amino acid polymer of the alpha-non-natural amino acid that synthesizes (for example, the chemical analog of corresponding natural amino acid) and the amino acid polymer of natural generation.

Term " polypeptide variants " refer to by at least one amino acid residue interpolation, disappearance or replacement and with other polypeptide of reference polypeptide phase region. In certain embodiments, one or more amino acid residues of reference polypeptide can replace with different amino acid. As described below, more well known amino acid can be replaced with other amino acid with similar quality roughly and the activity (the conservative replacement) that can not change polypeptide.

" primer " expression can start the synthetic oligonucleotides of primer extension product in the presence of suitable polymerization agent when a chain with DNA matches. For making the amplification efficiency maximum, the preferred strand of primer, but or can be double-stranded. Thereby primer answers long enough can cause synthetic extension products when polymerization agent exists. The length of primer depends on many factors, comprising: the temperature that use, adopts, template reaction condition, other reagent and primer source. For example, the complexity that depends on target sequence, 3 ' terminal comparable template sequence length weak point of primer can extend nucleic acid chains at least about 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,35,40,50,75,100,150,200,300,400,500 to 1 base, although the extensible 3 ' end that exceeds template sequence of primer 5 ' tip length. In certain embodiments, primer can be big polynucleotides, and for example about 35 nucleotides are to more than thousands of bases. Can select the primer with template sequence " basically complementary ", these primers of design can be with template hybridization and as synthetic starting point. " basically complementary " represents the complementary enough and target polynucleotide hybridization of this primer. Primer and the design with it template of hybridization preferably do not contain mispairing, but this is optional. For example, the incomplementarity nucleotide residue can be connected 5 ' end of primer, and the remainder of this primer sequence and template complementation. Perhaps, can will be between the extension of incomplementarity nucleotide residue or incomplementarity nucleotide residue insert in the primer, prerequisite be this primer sequence with and the template sequence of its hybridization complementary enough and form the required template of the extension products of synthetic this primer.

" probe " refer to can with particular sequence or the subsequence or the other parts bonded molecule of another molecule.Except as otherwise noted, term " probe " is often referred to and can matches and another polynucleotide (often being called " target polynucleotide ") bonded polynucleotide probes by complementary base.The preciseness that depends on hybridization conditions, probe can in conjunction with the target polynucleotide of this probe shortage sufficient sequence complementarity.Probe is mark directly or indirectly, and its scope comprises primer.

Term used herein " recombination of polynucleotide " refers to make it become that occurring in nature is not normally found form and at the polynucleotide of external formation by operation nucleic acid.For example, recombination of polynucleotide can be taked the expression vector form.This expression vector generally comprises operability and is connected in transcribing of this nucleotide sequence and translates adjusting nucleic acid.

Recombinant technology is adopted in " recombinant polypeptide " expression, promptly expresses the polypeptide for preparing by recon or synthetic polynucleotide.

" regulatory element " or " adjusting sequence " is illustrated in and expresses the required nucleotide sequence of the continuous encoding sequence of operability in the concrete host cell (for example, DNA).For example, be applicable to that the adjusting sequence of prokaryotic cell prokaryocyte comprises promotor and optional cis acting sequence, as operon sequence and ribosome bind site.Be applicable to that eukaryotic regulating and controlling sequence comprises the leading and tailer sequence of promotor, polyadenylation signal, transcriptional enhancer, translational enhancer, regulating mRNA stability, and the targeting sequencing that makes interior compartment of the polynucleotide encoding product targeted cells of transcribing or target born of the same parents external environment.

Term used herein " sequence homogeny " refer to two sequences on comparison window nucleotide pair Nucleotide or amino acid to amino acid whose homogeny degree.Therefore, " sequence homogeny per-cent " can calculate by following steps: the sequences that compare two best comparisons on comparison window, (for example measure nucleotide base identical in the two sequences, A, T, C, G, I) or identical amino-acid residue (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) the position number produces the position number of coupling, with the matched position number (promptly divided by total positional number of comparison window, window size), again the result be multiply by 100 and obtain sequence homogeny per-cent.Be purpose of the present invention, " sequence homogeny " should be interpreted as with DNASIS computer program (2.5 editions of existing windows; Available from Hitachi Software engineering Co., Ltd., South San Francisco, California, the U.S.), adopt the standard of using in the appended reference manual of this software to give tacit consent to " match-percentage " that (parameter) calculated.

Such as following table 3 definition, " similarity " refers to identical or constitutes the conservative amino acid percentage ratio that replaces.Can utilize sequence comparison program, for example GAP (Deveraux etc., 1984, Nucleic Acids Research, 12,387-395) mensuration similarity.Length and sequence similarity described herein or different basically sequences can be inserted the room in this way and come comparison in arrangement, this room can be determined by the used comparison algorithm of for example GAP.

The term that is used to describe the serial correlation between two or above polynucleotide or the polypeptide comprises " reference sequence ", " comparison window ", " sequence homogeny ", " sequence homogeny per-cent " and " substantially the same ".At least 12 of the length of " reference sequence ", but more common 15-18, often at least 25 monomeric units comprise Nucleotide and amino-acid residue.Because two polynucleotide respectively contain similar between (1) two a polynucleotide sequence (promptly, be the part of whole polynucleotide sequence), article (2) two, a differentiated sequence between the polynucleotide sequence, then general by in " comparison window " thus go up that the sequence of these two polynucleotide is relatively identified and relatively regional area sequence similarity two (more than) carry out sequence between the polynucleotide and compare." comparison window " is to contain at least 6, usually about 50-is about 100, notional fragment of about 150 continuous positions of more common about 100-, wherein after the best comparison of certain sequence and reference sequence, this sequence is made comparisons with the reference sequence that contains the similar number continuous position.Be the best comparison of (carrying out) two sequences, compare that comparison window can comprise about 20% or following interpolation or disappearance (that is room) with reference sequence (do not comprise and add or disappearance).Be the comparison comparison window, can pass through computer execution algorithm (GAP, BESTFIT, FASTA and TFASTA, Wisconsin Genetics Software Package Release 7.0, GeneticsComputer Group, 575 Science Drive Madison, WI, the U.S.), or come that by the best comparison (promptly causing highest homology per-cent on the comparison window) that one of range estimation and selected the whole bag of tricks produce all sequences are carried out the best and compare.Also can be as Altschul etc., 1997, Nucl.Acids Res., 25:3389 is described, compares by BLAST family program.Visible Ausubel etc. is described in sequential analysis in detail, the 15th chapter of " up-to-date molecular biology method " (Current Protocols in Molecular Biology), Unit the 19.3rd, John Wiley ﹠amp; Sons Inc, 1994-1998.

The term " object ", " individuality " or " patient " that are used interchangeably at this paper refer to any object, particularly vertebrate subject of needs treatment or prevention, even more refer in particular to mammalian object.Suitable vertebrates includes but not limited in the scope of the invention: primate, birds, domestic animal are (for example, sheep, cow, horse, donkey, pig), the laboratory inspection animal (for example, rabbit, mouse, rat, cavy, hamster), companion animals (for example, cat, dog) and the wildlife (for example, fox, deer, wild dog) that catches.Preferably to as if need the related indication animal of treatment or prophylaxis of herpes viral infections or its, particularly horse class animal.However, it should be understood that above term has not hinted that symptom exists.

The phrase of this paper " similar basically avidity " refer to target sequence under selected one group of preciseness condition to the complementary of them or complementary oligonucleotide probe hybridization intensity is similar and can detect basically.

Term used herein " template " refers to be used for producing and the nucleic acid that is somebody's turn to do " template " chain complementary nucleic acid chains.Template can be RNA and/or DNA, and its complementary strand also can be RNA and/or DNA.In certain embodiments, complementary strand can comprise all or part of complementary sequence of this " template ", and/or can comprise sudden change, thereby it is not the complete complementary strand of this " template ".In detection as herein described test and other test known in the art, not with the complete complementary chain of template strand also can with the template strand specific hybrid, this complementary strand that can be used for detecting test is a part of the present invention.

Term " conversion " expression changes certain organism by introducing external source or endogenous nucleic acid, for example the genotype of bacterium, yeast, Mammals, birds, Reptilia, fish or plant.

Term " treatment " expression therapeutic and prophylactic treatment.

The polynucleotide molecule of certain polynucleotide can be inserted or be cloned into to " carrier " expression therein, and suitable carriers can be derived from, the dna molecular of plasmid, bacteriophage, yeast, virus, Mammals, birds, Reptilia or fish for example.Carrier preferably contains the restriction site of one or more uniquenesses and can comprise self-replicating in target cell or tissue or its daughter cell or the tissue at the host cell of determining, thereby or can integrate reproducible sequence of cloning with the host cell gene group of determining.Therefore, carrier can be the carrier of self-replicating, i.e. the carrier that exists with the outer entity of karyomit(e), and it duplicates and is independent of THE REPLICATION OF CHROMOSOME, for example linear or closed loop plasmid, extra-chromosomal element, minichromosomes or artificial chromosome.Carrier can contain the element of guaranteeing self-replication.Perhaps, it can be integrated in the genome and duplicates with the karyomit(e) that is integrated into after carrier is introduced host cell.Carrier system can comprise a kind of carrier or plasmid, contains two or more carriers or the plasmid of the total DNA that introduces the host cell gene group together, or transposon.The selection carrier generally depends on this carrier and waits to introduce the consistency of the host cell of this carrier.Carrier also can comprise selective marker, for example can be used for selecting the antibiotics resistance gene of suitable transformant.The example of the known this resistant gene of those skilled in the art.

Term " wild-type " and " normally " are used interchangeably, and refer to the characteristic phenotype of the species of most of natural generations, and its opposite example is a mutation type surface.

2. abbreviation

Use following abbreviation in the specification sheets:

Nt=Nucleotide

Many Nucleotide of nts=

Aa=amino acid

Kb=kilobase or kilobase are right

The kDa=kilodalton

D=day

H=hour

S=second

3. the mark of herpesvirus infection and application thereof

The present invention relates to herpesvirus infection, particularly early detection, diagnosis, monitoring or the prognosis of EHV infection or its associated conditions.The invention discloses the cell of the object that has infected simplexvirus, hemocyte particularly, more specifically be alternative (surrogate) mark of herpesvirus infection in the peripheral blood cells, the form of described mark is the RNA molecule of particular sequence or the polypeptide of these RNA developed by molecule.These marks are indexs of herpesvirus infection, with compare in normal subjects or the expression do not had in the herpesvirus infection object, diagnosable this tested object generation herpesvirus infection, particularly reactivity herpesvirus infection when their differential expressions, or have risk.The prior art in field is compared therewith, thisly is marked with many advantages.Utilize in the preferred embodiment that peripheral blood analyzes at some, may before detecting serum antibody, promptly diagnose herpesvirus infection.

It seems that nucleotide sequence as herein described can be used for the various Application Areass of simplexvirus detection, diagnosis, prognosis and treatment.In this paper scope these examples of applications comprise utilize primer amplified HVI mark, by with oligonucleotide probe hybridization, isolating nucleic acid is mixed carrier, makes the expression of nucleic acid that mixes carrier for RNA and protein and make the immunology reagent colour development corresponding to the coded product of this mark detect the HVI mark.

The HVI mark of being identified and then can be used for designing specific oligonucleotide probe and primer.This probe and primer can be can with any length of the marker gene sequence-specific identified hybridization, it is about 10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,35,40,50,75,100,150,200,300,400,500 Nucleotide at least, and probe is the total length of the marker gene sequence that this paper identifies.Thereby also can comprising other sequence at its 5 ' and/or 3 ' end, probe can extend beyond target sequence with its hybridization.

When the coupling nucleic acid amplification method, the transcript of these probes and primer energy real-time analysis biological sample (for example, peripheral blood sample) certification mark gene or detection or quantitative assay marker gene.This method comprises any method or the technology that is used to duplicate or increase the copy number or the content of target nucleic acid or its complementary sequence known in the art or described herein.

The mark of being identified also can be used for identifying the full-length gene order with the isolation of genomic DNA library, comprises the regulatory element of genetic expression, is preferably the element in (but being not limited to) source, Malaysia.The cDNA sequence that this paper identifies can be used as hybridization probe and comes the screening genome dna library with routine techniques.In case identify portion gene group clone, can be by " karyomit(e) walking " (being also referred to as " overlapping hybridization "), employing, for example Chinault and Carbon (1979, Gene, 5:111-126) described method is separated full-length gene.Obtain portion gene group clone in case utilize the cDNA hybridization probe to separate, being positioned near this portion gene group clone two non-replicating sections terminal or it can be used as hybridization probe and does further genomic library screening, the final whole gene order that obtains HVI mark interested of separating.Should know available total length as herein described or Partial cDNA Sequence or short expressed sequence tag (ETS), adopt for example Sambrook etc., (" molecular cloning. laboratory manual " (MOLECULAR CLONING.A LABORATORY MANUAL), (cold spring port press, 1989) and Ausubel etc., (" up-to-date molecular biology method " (CURRENTPROTOCOLS IN MOLECULAR BIOLOGY), John Wiley ﹠amp; Sons, Inc., 1994) described standard technique acquisition full-length gene.In addition, can adopt disclosedly, for example above, utilize described sequence to identify and obtain full length cDNA sequence with separating with reference to the standard technique described in the teaching material.Can utilize these technical evaluation and isolating sequence, adopt detection method described herein to detect the HVI marker gene, these sequences are parts of the present invention.

Those of ordinary skills can select some sections to be used for various detections, diagnosis or method of prognosis as a part of the present invention from the marker gene of being identified, vector construct, preparation antigen binding molecules, test kit and/or any embodiment described herein.The marker gene sequence that the present invention preferably uses is SEQID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109, sequence shown in 111 or 113.

3.1 nucleic acid molecule of the present invention

As described in embodiment and table 1, this paper provides and has passed through GeneChip ^TM63 kinds of simplexvirus marks (that is 63 kinds of simplexvirus marker gene) that analysis identifies from the blood of normal horses and the horses with EHV clinical evidence.In these 63 kinds of marker gene, 44 kinds have the total length or the encoding sequence of total length basically, and all the other 21 kinds have partial sequence information in their 5 ' and 3 ' terminal one or both ends.The HVI marker gene of being identified comprises 21 kinds of former not horse genes of characterized.

According to the present invention, find that isolated nucleic acid sequences described herein itself can be used as hybridization probe or amplimer.These nucleic acid can be used for, and for example diagnostic is assessed biological sample or is used to clone full-length cDNA or its corresponding genomic clone.In certain embodiments, these probes and primer provide length to be enough to and to mention from the RNA of biological sample or the oligonucleotide of DNA sample specific hybrid.About usually 10-20 the Nucleotide of these sequences is long, but can be longer.Some embodiments needs long sequence, for example about 30,40,50,100,500 Nucleotide and even total length nearly.

The present invention has considered to have following SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109, about 10 of arbitrary sequence shown in 111 or 113,15,17,20,30,40,50,60, the nucleic acid molecule that adjoins the extension of 75 or 100 or 500 Nucleotide.The present invention also considered and above-mentioned sequence complementation, can be under high preciseness condition bonded molecule with it.These probes can be used for various hybridization embodiments, for example Southern and Northern trace.In some instances, the present invention considers to use the probe that can not damage their efficient diagnosis herpesvirus infection abilities with multiple target sequence hybridization.In a word, it is considered herein that the expression that reagent that hybridization probe described herein both can be used as solution hybridization (in PCR) detects corresponding gene also can be used in the solid phase embodiment.

Various probes and primer have been designed around described nucleotide sequence.For example, in certain embodiments, the sequence that is used for designing probe and primer can comprise the repetition extension (poly-A tail) of the adenine nucleotide of RNA two ends that are connected in institute's identifying mark gene usually.In other embodiments, those of ordinary skills may think that some section more is applicable to described detection method, so probe and primer can be specifically designed as these or other section that does not comprise institute's identifying mark gene.In any situation, those of ordinary skill all can be selected primer or probe sequence for selected Application Areas.The exemplary probe sequence that is used to detect the HVI marker gene sees Table 2.

Primer can be two strands or single stranded form, though single stranded form is more desirable.Probe design can be need not to be used for amplification method for combining (although may cause) with target DNA or RNA.In certain embodiments, available radioactive substance ( ³²P, ¹⁴C, ³⁵S, ³H or other marker), fluorophore (for example rhodamine, fluorescein) or chemiluminescent labels (for example, luciferase) these probes of mark or primer.

The invention provides cDNA sequence and the EST or the Partial cDNA Sequence of the total length basically that can be used as the EHV mark.However, it should be understood that this paper content is not limited to these disclosed sequences, particularly to comprise at least can with the isolating nucleic acid of the variant of the nucleic acid that contains disclosed sequence or these nucleic acid hybridization.For example, the partial sequence of available nucleic acid is identified gene or its deutero-full-length gene group or the cDNA clone of structurally associated.The cDNA of the target sequence that can be used as above-mentioned probe known in the art and the preparation method of genomic library (referring to, Sambrook etc. for example, 1989, the same and Ausubel etc., 1994, the same).All this nucleic acid and specific nucleic acid molecule as herein described are referred to as " simplexvirus mark polynucleotide " or " HVI mark polynucleotide ".In addition, scope of the present invention comprises the expression product (that is, rna transcription thing and polypeptide) of the isolated or purified of HVI mark polynucleotide.

Therefore, the present invention includes nucleic acid isolating or purifying basically or protein composition." isolating " or " purifying " nucleic acid molecule or protein, or its biologic activity partly is not contain the natural together normal or interactional component with it found in the environment that exists of this nucleic acid molecule or protein basically or in itself.Therefore, it is substantially free of other cellular material or medium component when the polynucleotide of isolated or purified or polypeptide produce by recombinant technology, perhaps when they are substantially free of precursor or other chemical substance during with chemosynthesis." isolating " polynucleotide should not contain the sequence (that is, being positioned at 5 ' and 3 ' terminal sequence of these polynucleotide) of natural these polynucleotide of side joint in the genomic dna of the organism that produces these polynucleotide, particularly proteinic encoding sequence.For example, in various embodiments, isolating HVI mark polynucleotide can contain the nucleotide sequence of natural these polynucleotide of side joint in the genomic dna of cell of these polynucleotide of generation that are less than about 5kb, 4kb, 3kb, 2kb, 1kb, 0.5kb or 0.1kb.The polypeptide that is substantially free of cellular material comprises the protein articles that contains the contaminating protein matter that is less than about 30%, 20%, 10%, 5% (with dry weight basis).When protein of the present invention or its biologic activity were partly used recombinant methods, substratum should contain precursor or the non-proteins of interest materialization material that is less than about 30%, 20%, 10% or 5% (with dry weight basis).

The present invention also comprises the total length of HVI mark polynucleotide or the each several part of full length nucleotide sequence basically, perhaps the DNA of their transcript or these transcripts copy.The each several part codified polypeptide portion of HVI labeled nucleotide sequence or keep the section of this natural polypeptides biologic activity.Perhaps, the each several part that can be used as the HVI labeled nucleotide sequence of hybridization probe is not encoded usually and is kept the aminoacid sequence of this biologic activity.Therefore, the each several part of HVI labeled nucleotide sequence contains about 15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,40,50,60,80,90,100 Nucleotide of the nucleotide sequence of code book invention HVI labeling polypeptide at least, perhaps almost reaches its total length.

The part of the HVI labeled nucleotide sequence of the biologic activity part of code book invention HVI labeling polypeptide is about 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,30,40,50,60,70,80,90,100,120,150,300,400,500,600,700,800,900 in the codified total length HVI labeling polypeptide or 1000 or even at least about 2000,3000,4000 or 5000 continuous amino acid residues, perhaps almost up to its amino acid sum at least.The each several part that can be used as the HVI labeled nucleotide sequence of hybridization probe or PCR primer generally need not the to encode biologic activity part of HVI labeling polypeptide.

Therefore, the biologic activity part of a part of codified HVI labeling polypeptide of HVI labeled nucleotide sequence, perhaps it can be the fragment that is used as hybridization probe or PCR primer in standard method known in the art.Can be by separating the part of a HVI labeled nucleotide sequence of the present invention, the part (activity) expressing the part (for example passing through in-vitro recombination expression) of its coded HVI labeling polypeptide and assess this coded HVI labeling polypeptide prepares the biologic activity part of this HVI labeling polypeptide.At least contain about 15,16,17,18,19,20,25,30,50,75,100,150,200,250,300,350,400,450,500,550,600 or 650 Nucleotide in the total length HVI labeled nucleotide sequence as the nucleic acid molecule of HVI labeled nucleotide sequence each several part, perhaps almost up to its Nucleotide sum.

The present invention has also considered the variant of HVI labeled nucleotide sequence.The nucleic acid variant can be natural generation, for example allele variant (same locus), homologue (different genes seat) with directly to homologue (different organism) or can be that non-natural produces.Can adopt the Protocols in Molecular Biology of knowing, polymerase chain reaction for example known in the art (PCR) and hybridization technique are identified the variant of natural generation, for example described these variants.Can pass through induced-mutation technique, comprise that the technology that is applicable to polynucleotide, cell or organism prepares the variant that non-natural produces.These variants can contain Nucleotide replacement, disappearance, inversion and insertion.Coding can morph with non-coding region.Variation both can cause conservative property also can cause non-conservation aminoacid replacement (comparing with coded product).With regard to nucleotide sequence, examples of conservative variations comprise because of the genetic codon degeneracy still can code book those (nucleic acid) sequences of aminoacid sequence of one of invention HVI labeling polypeptide.The variant nucleotide sequence also comprises synthetic the generation but still the nucleotide sequence of energy code book invention HVI labeling polypeptide, for example those sequences that produce by site-directed mutagenesis.Generally, the variant and this specific nucleotide sequence that utilize default parameters to be measured to the present invention's specific nucleotide sequence by sequence alignment program as herein described have about 30%, 40%, 50%, 55%, 60%, 65%, 70% at least, generally at least about 75%, 80%, 85%, more than preferred about 90%-95%, the sequence homogeny more than 98% more preferably from about.

HVI labeled nucleotide sequence of the present invention can be used for separating other organism, particularly corresponding sequence of the horse of other Mammals, especially other kind and allelic variant sequence.The hybridizing method of nucleotide sequence is not difficult in this area to obtain.Can separate the encoding sequence that obtains other organism according to it with the sequence homogeny of encoding sequence described herein by knowing technology.In these technology, the known coded sequence of all or part can be used as probe, with cloned genes group dna fragmentation or middle other HVI marker coding sequence selective cross that exists of cDNA segment group (that is, genome or cDNA library) of selected organism.Therefore, the present invention also consider under following preciseness condition can with the polynucleotide of described HVI marker gene nucleotide sequence or its complementary sequence hybridization.The condition of having described hybridization and washing " hybridized " in term used herein under low preciseness, medium preciseness, high preciseness or high preciseness condition.Carry out (1998, the same) such as the visible Ausubel of guide of hybridization, the 6.3.1-6.3.6 part.Described water-based and non-aqueous method in this reference, the two is all available.The low preciseness condition that this paper mentions comprises at least about 1%-at least about the methane amide of 15%v/v with at least about the salt of 1-at least about 2M, 42 ℃ of hybridization, and at least about the salt of 1-at least about 2M, and 42 ℃ of washings.Low preciseness condition also can comprise 1% bovine serum albumin (BSA), 1mM EDTA, 0.5M NaHPO ₄(pH 7.2), 7%SDS, 65 ℃ of hybridization, with (i) with 2 * SSC, 0.1%SDS; Or (ii) use 0.5%BSA, 1mM EDTA, 40mM NaHPO ₄(pH 7.2), 5%SDS, room temperature washing.An embodiment of low preciseness condition comprises about 45 ℃ of hybridization in 6 * sodium chloride/sodium citrate (SSC), then at least 50 ℃ (wash temperature of hanging down the preciseness condition can be increased to 55 ℃) with 0.2 * SSC, 0.1%SDS washed twice.Medium preciseness condition comprises at least about 16-at least about the methane amide of 30%v/v with at least about the salt of 0.5-at least about 0.9M, 42 ℃ of hybridization, and at least about the salt of 0.1-at least about 0.2M, and 55 ℃ of washings.Medium preciseness condition also can comprise 1% bovine serum albumin (BSA), 1mM EDTA, 0.5M NaHPO ₄(pH7.2), 7%SDS, 65 ℃ of hybridization, with (i) with 2 * SSC, 0.1%SDS; Or (ii) use 0.5%BSA, 1mM EDTA, 40mM NaHPO ₄(pH 7.2), 5%SDS, 60-65 ℃ of washing.An embodiment of medium preciseness condition comprises that about 45 ℃ hybridize in 6 * SSC, 60 ℃ with 0.2 * SSC, more than the 0.1%SDS washing once then.High preciseness condition comprises that at least about 31-at least about the methane amide of 50%v/v and the salt of the about 0.15M of about 0.01-, 42 ℃ of hybridization are with the salt of the about 0.02M of the about 0.01-of usefulness, 55 ℃ of washings.High preciseness condition also can comprise 1%BSA, 1mM EDTA, 0.5M NaHPO ₄(pH 7.2), 7%SDS, 65 ℃ of hybridization, with (i) with 0.2 * SSC, 0.1%SDS; Or (ii) use 0.5%BSA, 1mM EDTA, 40mM NaHPO ₄(pH 7.2), 1%SDS, temperature washing more than 65 ℃.An embodiment of high preciseness condition comprises that about 45 ℃ hybridize in 6 * SSC, 65 ℃ with 0.2 * SSC, more than the 0.1%SDS washing once then.

In certain embodiments, the HVI labeling polypeptide is by can be under high preciseness condition and the polynucleotide encoding of described nucleotide sequence hybridization.An embodiment of high preciseness condition comprises that 65 ℃ hybridize in 0.5M sodium phosphate, 7%SDS, 65 ℃ with 0.2 * SSC, more than the 1%SDS washing once then.

Well known other preciseness condition, the technician knows can control the specificity that various factors is optimized hybridization.The preciseness that can optimize final washing step is to guarantee highly hybridization.Specific example can be referring to Ausubel etc., and is the same, 2.10.1-2.10.16 page or leaf and Sambrook etc., (1989, the same), 1.101-1.104 part.

Though generally under about 42 ℃-68 ℃ temperature, carry out the preciseness washing, those skilled in the art will know that other temperature also is suitable for the preciseness condition.For forming DNA-DNA hybridization, maximum hybrid rate generally occurs in and compares T _mLow about 20 ℃-25 ℃ temperature.Well known T _mBe melting temperature(Tm), or two dissociated temperature of complementary polynucleotide sequence.Well known estimation T _mMethod (referring to Ausubel etc., the same, 2.10.8 page or leaf).Generally, can utilize the double-helical T of optimum matching of following formula prediction DNA _mApproximation:

T _m=81.5+16.6 (log ₁₀M)+0.41 (%G+C)-0.63 (% methane amide)-(600/ length)

Wherein: M is Na ⁺Concentration, preferred 0.01-0.4 mole; %G+C is the per-cent that guanosine and cytidine base sum account for the base sum, its scope 30% and 75%G+C between; The % methane amide is the methane amide percentage of by volume; Length is the number of base pair in the dna double spiral.Mismatched bases is to the every rising 1% of number, the T of duplex DNA at random _mReduce about 1 ℃.High preciseness washing is usually at T _mCarry out in the time of-15 ℃, perhaps medium preciseness is at T _m-30 ℃ are carried out.

In an example of hybridizing method, the film (for example, nitrocellulose filter or nylon membrane) that will contain fixed dna is hybridized in containing the hybridization buffer of label probe (50% deionized formamide, 5 * SSC, 5 * Denhardt solution (0.1%ficoll, 0.1% polyvinylpyrrolidone and 0.1% bovine serum albumin), 0.1%SDS and 200mg/mL denatured salmon sperm dna) for 42 ℃ and is spent the night.Then (promptly with twice of medium this film of preciseness continuous washing, 45 ℃ with 2 * SSC, 0.1%SDS the washing 15 minutes, then 50 ℃ with 2 * SSC, 0.1%SDS the washing 15 minutes), again (promptly with twice of higher preciseness continuous washing, 55 ℃ with 0.2 * SSC, 0.1%SDS washing 12 minutes, and 65-68 ℃ with 0.2 * SSC, 0.1%SDS solution washing 12 minutes then).

3.2 polypeptide of the present invention

The present invention has also considered the full-length polypeptide of HVI marker gene coding of the present invention and the biologic activity part of those polypeptides, is referred to as " herpesvirus infection mark polynucleotide " or " HVI labeling polypeptide " at this paper.The biologic activity of total length HVI labeling polypeptide partly comprise be about 6,8,10,12,14,16,18,20,25,30,40,50,60 amino-acid residues at least have an immunity active part that interacts.For example, the immunity interaction fragment that the present invention considered is to 6 of the youthful and the elderlys, preferred at least 8 amino-acid residues, thus they can cause immune response and produce and can immune interactional antigen binding molecules take place with HVI labeling polypeptide of the present invention in animal.The relevant HVI labeling polypeptide of structure and/or function in available this other Mammals of antigen binding molecules screening, particularly horse class Mammals.The each several part of total length HVI labeling polypeptide generally may participate in certain interaction, for example intramolecularly or molecular interaction.Molecular interaction can be specificity binding interactions or enzymatic interaction (for example described interaction can be an instantaneity, can form or interrupt certain covalent linkage).The biologic activity of total length HVI labeling polypeptide partly comprises the aminoacid sequence that contains with certain (supposition) total length HVI labeling polypeptide, aminoacid sequence for example shown below is enough similar or derived from the peptide of the aminoacid sequence of this aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, these sequences contain the amino acid that is less than total length HVI labeling polypeptide and show a kind of activity of this polypeptide at least.Biologic activity part comprises usually and has total length HVI labeling polypeptide a kind of active structures territory or motif at least.The biologic activity part of total length HVI labeling polypeptide can be long, for example 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,30,40,50,60,70,80,90,100,120,150,300,400,500,600,700,800,900 or 1000, perhaps even at least about the polypeptide of 2000,3000,4000 or 5000 above amino-acid residues.Described part should be to contain to be not less than its about 1%, 10%, 25%, 50% active " the biologic activity part " of full-length polypeptide of deriving.

The present invention has also considered variant HVI labeling polypeptide." variant " polypeptide comprises in the following manner from natural protein deutero-protein: delete (being called brachymemma) or add one or more amino acid at the N-of this natural protein end and/or C-end; In the one or more site deletion of this natural protein or add one or more amino acid; Perhaps the one or more site at this natural protein replace one or more amino acid.Variant proteins of the present invention has biologic activity, and promptly they still have the required biologic activity of this natural protein.For example, genetic polymorphism or manual operation can form this variant.Utilize default parameters to be measured to the biologic activity variant of natural HVI labelled protein of the present invention and the aminoacid sequence of this natural protein can have at least 40%, 50%, 60%, 70% by sequence alignment program as herein described, generally at least 75%, 80%, 85%, more than preferred about 90%-95%, the sequence similarity more than 98% more preferably from about.The proteinic biologic activity variant of the present invention and this protein generally can have nearly 1000,500,400,300,200,100,50 or 20 amino-acid residues, perhaps should lack to 1-15 amino-acid residue, few to 1-10 (for example 6-10 is individual), lack to 5, lack to 4,3,2 or even 1 amino-acid residue difference.

HVI labeling polypeptide of the present invention be can change in every way, aminoacid replacement, disappearance, brachymemma and insertion comprised.This area generally knows that this working method.The aminoacid sequence variant that for example, can prepare the HVI labelled protein by dna mutation.The method that well known mutagenesis and nucleotide sequence change.Referring to, for example Kunkel (1985, Proc.Natl.Acad.Sci.USA, 82:488-492), Kunkel etc., (1987, Methods in Enzymol., 154:367-382), U.S. Patent number 4,873,192; Watson, J.D. etc., the reference that quote (" molecular biology of gene " (Molecular Biology of the Gene), the 4th edition, Benjamin/Cummings, Menlo Park, Calif., 1987) and they.The guide that suitably carries out aminoacid replacement and do not influence the biologic activity of proteins of interest matter is seen Dayhoff etc., (1978), " protein sequence and structure iron " (Atlas of Protein Sequenceand Structure), (Natl.Biomed.Res.Found., Washington, model D.C.).Screening known in the art contains the combinatorial library gene product of passing through point mutation or brachymemma (method) preparation of selected characteristics and the method for screening cDNA library gene product.This method is applicable to the gene library of rapid screening by the HVI labeling polypeptide of combinatorial mutagenesis generation.But coupling can improve the technology-recursion group mutagenesis (REM) of functional mutation frequency in this library identifies HVI labeling polypeptide variant (Arkin and Yourvan, (1992), Proc.Natl.Acad.Sci.USA, 89:7811-7815 with shaker test; Delgrave etc., (1993), Protein Engineering, 6:327-331).The ideal conservative property hereinafter has been described in detail in detail has replaced, for example replaced certain monoamino-acid with another amino acid with similar characteristics.

Compare with parental generation HVI marker amino acid sequence, variant HVI labeling polypeptide can contain conservative amino acid at the different positions along their sequences and replace." conservative amino acid replacement " is to replace certain amino-acid residue with the amino-acid residue with similar side chain.This area has defined the amino-acid residue family with similar side chain, and they generally can be further divided into:

Acid: this residue is electronegative because of lose the H ion under physiological pH, and this residue is attracted by the aqueous solution, and therefore when the peptide that comprises it was in the physiological pH aqueous medium, this residue was in the surface location of this peptide configuration.The amino acid that contains acid side-chain comprises L-glutamic acid and aspartic acid.

Alkalescence: this residue is because of under physiological pH or positively charged (for example in conjunction with the H ion in its one or two pH unit, Histidine), this residue is attracted by the aqueous solution, and therefore when the peptide that comprises it was in the physiological pH aqueous medium, this residue was in the surface location of this peptide configuration.The amino acid that contains basic side chain comprises arginine, Methionin and Histidine.

Charged: these residues are electrically charged when physiological pH, therefore comprise the amino acid (that is, L-glutamic acid, aspartic acid, arginine, Methionin and Histidine) that contains acidity or basic side chain.

Hydrophobicity: these residues neutral and repelled by the aqueous solution under physiological pH, therefore when the peptide that comprises it was in the aqueous medium, this residue was in the interior location of this peptide configuration.The amino acid that contains hydrophobic side chain comprises tyrosine, Xie Ansuan, Isoleucine, leucine, methionine(Met), phenylalanine and tryptophane.

Neutrality/polarity: these residues are neutral under physiological pH, but the aqueous solution is not enough to repel them, and therefore when the peptide that comprises this residue was in the aqueous medium, this residue was adsorbed in the interior location of this peptide configuration.The amino acid that contains neutrality/polar side chain comprises l-asparagine, glutamine, halfcystine, Histidine, Serine and Threonine.

This specification sheets also is accredited as some amino acid characteristics " little " amino acid, because their side chain big inadequately (even lacking polar group) thereby can not hydrophobic property.Except that proline(Pro), " little " amino acid is those amino acid that have 4 following carbon and have 3 following carbon when at least one polar group is arranged on the side chain when not having polar group on the side chain.Amino acid with little side chain comprises glycine, Serine, L-Ala and Threonine.The secondary amino acid of genes encoding--proline(Pro) is because of the influential special case that becomes of known its secondary configuration to peptide chain.The structure of proline(Pro) combines the amino acid that is different from all other natural generations because of its side chain with alpha-amino nitrogen-atoms and alpha-carbon atom.For example Dayhoff etc. ((1978), " model that protein evolution changes " (A model of evolutionary change in proteins)) discloses several amino acid similarity matrixes (for example, PAM120 matrix and PAM250 matrix).Yet, publish in " protein sequence and structure iron " (Atlas of Protein Sequence andStructure) that M.O.Dayhoff compiles, the 5th volume, the 345-358 page or leaf, national biomedical research foundation (NationalBiomedical Research Foundation), Washington DC; With Gonnet etc., 1992, Science, 256 (5062): the matrix that is used for measuring long-range relation in 144301445 is included in proline(Pro) glycine, Serine, L-Ala and Threonine same group.Therefore, proline(Pro) is classified as " little " amino acid for purpose of the present invention.

(amino acid) is divided into polarity or required attraction or the repulsion degree of nonpolar classification is random, so the special amino acid of considering of the present invention can be divided into a class or another kind of.Can classify according to the amino acid that known performance is not named specially to great majority.

Amino-acid residue also can be further divided into ring-type or non-annularity, aromatic series or non-aromatic, according to the classification of can justifying oneself of the side chain substituents of residue, be divided into little or big.If certain residue contains 4 following carbon atoms (comprising carboxyl carbon) altogether, think that it is a p1 amino acid, prerequisite is to have other polar substituent; If there is no other polar substituent, the residue that contains 3 following carbon atoms altogether can be thought p1 amino acid.Little residue is non-aromatic residue always certainly.Can it be divided into two or more kinds according to the structure properties of amino-acid residue.With regard to the gal4 amino acid of natural generation, see Table 3 according to the subclassification of this scheme.

The conservative amino acid replacement also comprises according to side chain classifies.For example, the one group of amino acid that contains aliphatic lateral chain is glycine, L-Ala, Xie Ansuan, leucine and Isoleucine; The one group of amino acid that contains aliphatic series-hydroxyl side chain is Serine and Threonine; One group of amino acid with amide containing side chain is l-asparagine and glutamine; The one group of amino acid that contains the aromatic series side chain is phenylalanine, tyrosine and tryptophane; The one group of amino acid that contains basic side chain is Methionin, arginine and Histidine; With one group of amino acid with sulfur-containing side chain be halfcystine and methionine(Met).For example, can reasonably expect to replace with Isoleucine or Xie Ansuan that leucine, glutamine replace l-asparagine, Serine replaces Threonine, can not have a strong impact on the performance of the variant polypeptide that is produced during perhaps with certain seed amino acid of amino acid similarity ground replacement of structurally associated.Whether amino acid change can produce functional HVI labeling polypeptide is not difficult by checking its activity to measure.Conservative property replaces the title see Table 4 exemplary replacement.Preferred replacement title is seen in preferred replacement.Aminoacid replacement in the scope of the invention generally by selected substituting group to keeping: (a) replace regional peptide backbone structure, (b) electric charge of this molecule target site or hydrophobicity, or (c) volume of side chain not have the obvious not replacement of same-action to realize.After introducing replacement, the variant that screening has biologic activity.

Perhaps, can will prepare the similar amino acid that conservative property replaces according to the homogeny of side chain is divided three classes.As Zubay, G., " biological chemistry " (Biochemistry), the third edition, Wm.C.Brown Publishers, (1993) are described, first group comprises L-glutamic acid, aspartic acid, arginine, Methionin, the Histidine that all contains electrically charged side chain; Second group comprises glycine, Serine, Threonine, halfcystine, tyrosine, glutamine, l-asparagine; The 3rd group comprises leucine, Isoleucine, Xie Ansuan, L-Ala, proline(Pro), phenylalanine, tryptophane, methionine(Met).

Therefore, replace the non-essential amino acid residue of estimating in the HVI labeling polypeptide with another amino-acid residue in the identical side chain family usually.Perhaps, can introduce sudden change at random along HVI marker gene encoding sequence all or part of, for example by saturation mutagenesis, the mutant that obtains of screening has or not the activity of parental generation polypeptide to identify and has kept this active mutant then.Behind the mutagenesis encoding sequence, can recombinant expressed coded peptide, measure the activity of this peptide.

Therefore, the present invention also considers the variant of HVI labeling polypeptide sequence of natural generation or their biological active fragment, and wherein said variant can be by adding, lack or replacing one or more amino-acid residues and distinguish mutually with the sequence of natural generation.Generally, variant can show and parental generation HVI labeling polypeptide sequence that arbitrary sequence has the similarity at least about 30,40,50,55,60,65,70,75,80,85,90,91,92,93,94,95,96,97,98,99% shown in for example following SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114.Variant preferably with parental generation HVI labeling polypeptide sequence, arbitrary sequence has the sequence homogeny at least about 30,40,50,55,60,65,70,75,80,85,90,91,92,93,94,95,96,97,98,99% shown in for example following SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114.In addition, the present invention consider by add, lack or replace 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,30,40,50,60,70,80,90,100,150,200,300,500 with upper amino acid with natural or the parental generation sequence is different but still kept the sequence of this parental generation HVI labeling polypeptide characteristic.The HVI labeling polypeptide also comprises can be under rigorous condition defined herein, the polypeptide of the polynucleotide encoding of hybridizing with the invention described above HVI mark polynucleotide sequence or its noncoding strand under the particularly high rigorous condition.

In one embodiment, variant polypeptide has at least one with the HVI flag sequence but to be less than 50,40,30,20,15,10,8,6,5,4,3 or 2 amino-acid residues different.In another embodiment, variant polypeptide and the corresponding sequence shown in the following SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114 have at least 1% but to be lower than 20%, 15%, 10% or 5% residue different.If (this compares (method) and needs comparison, then should compare the maximum comparability of these sequences.Because of disappearance or " ring " outer sequence that insertion or mispairing produced can think that difference is arranged).These difference preferably are positioned at the difference or the change of nonessential residue, or conservative property replaces.

" nonessential " amino-acid residue is can change from the wild-type sequence of certain concrete polypeptide and do not destroy or do not change its residue a kind of or various active basically.Described change does not preferably change one of these activity basically, and for example 20% of wild-type activity, 40%, 60%, 70% or 80%." essential " thus amino-acid residue is the activity that can destroy this parental generation molecule when changing this residue of HVI labeling polypeptide wild-type sequence of the present invention is lower than the activity 20% of wild type peptide.

In other embodiments, variant polypeptide comprises the corresponding sequence with the HVI labeling polypeptide, for example following SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110, arbitrary sequence has at least about 50% shown in 112 or 114,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%95%, 96%, 97%, 98% or above similarity and have the active aminoacid sequence of this HVI labeling polypeptide.

Can prepare HVI labeling polypeptide of the present invention by any appropriate method well known by persons skilled in the art.For example, can prepare these polypeptide by the method that may further comprise the steps: (a) preparation contains the mosaic type construction of the nucleotide sequence of encoding certain HVI mark polynucleotide at least a portion and linking to each other with the regulatory element operability; (b) this mosaic type construction is introduced in the host cell; (c) cultivate this HVI labeling polypeptide of this host cell expression; (d) from host cell, separate this HVI labeling polypeptide.In exemplary example, sequence shown in the described nucleotide sequence coded following SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, or at least a portion of its variant.

The mosaic type construction is taked the form of expression vector usually, should be selected from the outer carrier (for example plasmid) of karyomit(e) of self-replication and can be integrated into carrier in the host genome.

Regulatory element generally should be suitable for expressing the used host cell of this HVI labeling polypeptide.The expression vector of many types of various host cells known in the art and regulatory element.The demonstrative component of this type includes but not limited to: promoter sequence (for example can be the composing type or the inducible promoters of natural generation or the composition element with multiple promotor), leading or signal sequence, ribosome bind site, transcription initiation and terminator sequence, translation initiation and terminator sequence and enhanser or activation sequence.

In some embodiments, expression vector comprises selectable marker gene to select transformed host cells.But selectable marker gene is well known in the art and different with used host cell.

Described expression vector fusion partner (being provided by this expression vector usually) also can be provided thereby the HVI labeling polypeptide can be prepared as the fusion polypeptide that contains fusion partner.The major advantage of fusion partner is that they help to identify and/or this fusion polypeptide of purifying.Be the preparation fusion polypeptide, HVI mark polynucleotide need be connected into fusion partner is overlapped with the translation frame of HVI mark polynucleotide.The well-known examples of fusion partner includes but not limited to: Fc part, maltose binding protein (MBP) and six Histidines (hexahistidine) (HIS of glutathione-S-transferase (GST), human IgG ₆), these companions are particularly useful for separating fusion polypeptide by affinity chromatography.In some embodiments, can utilize with fusion partner bonded matrix (such as but not limited to: gsh-, amylose starch-and nickel-or cobalt-coupling resin) by these fusion polypeptide of affinitive layer purification.Many this matrix can " test kit " form be buied, and for example utilize (HIS ₆) companion's QIAexpress ^TMSystem (Qiagen) and Pharmacia GST purification system.Other fusion partner known in the art is a photoprotein, for example can be used as fluorescence " label " identified and/or separated fusion polypeptide by fluorescent microscopy or flow cytometry green fluorescent protein (GFP) and luciferase.The flow cytometry method, for example fluorescence-activated cell sorting (FACS) method is particularly useful in use this back one.

Fusion partner also preferably contains proteolytic enzyme cutting site, for example factor X _aOr the cleavage site of zymoplasm, thereby make the associated protein enzyme partly digest this fusion polypeptide and from fusion construct, discharge the HVI labeling polypeptide.Can separate polypeptide and the fusion partner that is discharged by chromatographic separating process subsequently.

The scope of fusion partner also comprises " epi-position label ", and these labels normally can be buied the short peptide sequence of its specific antibody.The well-known examples that is easy to buy the epi-position label of monoclonal antibody specific comprises c-Myc, influenza virus hemagglutinin and FLAG label.

Can mosaic type construction of the present invention be introduced among the host by comprising " transduction " and proper methods such as " transfections ", this means the transgenosis that mediates by nucleic acid technically with nucleic acid, and for example expression vector is introduced in the donee's cells.Yet the genotype that " conversion " refers to the host is taken in the process that exogenous DNA or RNA change because of cell, and for example transformant contains expression system of the present invention.The mosaic type construction is introduced cell many methods are arranged.Used method generally depends on the selection of host cell.Those skilled in the art know the technology of the mosaic type construction being introduced host cell.Described four classes nucleic acid molecule has been sent method into cell: (1) chemical process, for example precipitation and the lipofection of calcium phosphate precipitation, polyoxyethylene glycol (PEG)-mediation; (2) physical method, for example microinjection, electroporation, accelerated method and vacuum are infiltrated; (3) carrier method, for example conversion of bacterium and virus vector mediation; (4) receptor-mediated conversion.Those skilled in the art know the transformation technology of these and other type, and new technology also continues to bring out.Concrete efficient and the concrete method of selecting of employing of selecting transformation technology to depend on this technical transform particular host cell implemented the present invention's people's experience and preference.The concrete selection that the technician obviously introduces the mosaic type construction conversion system in the cell as can be known is not substantial or limitation of the present invention, as long as this system can realize acceptable nucleic acid transfer level.

Can prepare reorganization HVI labeling polypeptide by cultivating through mosaic type construction transformed host cells.With host cell and different, the technician is by normal experiment definite these conditions of being not difficult with selected expression vector for condition that be fit to express the HVI labeling polypeptide.The host cell that is fit to express can be protokaryon or eukaryotic cell.The exemplary host cell of expressing polypeptide of the present invention is a bacterium.Used bacterium can be intestinal bacteria (Escherichia coli).Perhaps, host cell can be yeast cell or insect cell, for example utilizes the SF9 cell of baculovirus expression system.

Can adopt as Sambrook etc., (1989, the same), particularly the 16th and 17 parts; Ausubel etc., (1994, the same), particularly the 10th and 16 chapters; With Coligan etc., " fresh approach of protein science " (CURRENT PROTOCOLS IN PROTEIN SCIENCE), (John Wiley﹠amp; Sons, Inc., 1995-1997), particularly the standard method described in the 1st, 5 and 6 chapters is not difficult to prepare reorganization HVI labeling polypeptide.Perhaps, can be by chemosynthesis, for example adopt as Atherton and Shephard, (the same) the 9th Zhanghe Roberge etc., (1995, Science, 269:202) liquid phase described in is synthesized or solid-phase synthesis comes chemosynthesis HVI labeling polypeptide.

4. antigen binding molecules

The present invention also provide can with the interactional antigen binding molecules of HVI labeling polypeptide generation specific immunity of the present invention.In one embodiment, this antigen binding molecules comprises the polyclone whole antibody.Can pass through, for example HVI labeling polypeptide of the present invention is injected into the animal (comprising mouse and rabbit) that can produce (antibody) and prepare this antibody to obtain polyclonal antiserum.Those skilled in the art know the method for preparing polyclonal antibody.Adoptable exemplary method sees, Coligan etc. for example, " immunology fresh approach " (CURRENTPROTOCOLS IN IMMUNOLOGY), (John Wiley ﹠amp; Sons, Inc, 1991) and Ausubel etc., the III part of (1994-1998, the same), particularly Chapter 11.

Can adopt, for example K_hler and Milstein (1975, Nature, 256,495-497) described standard method or employing, for example Coligan etc., (1991, the same) described up-to-date improving one's methods, prepare monoclonal antibody with the infinite multiplication splenocyte or other antibody produced cell that derive from generation (antibody) animal that has inoculated one or more HVI labeling polypeptides of the present invention, substitute from producing the polyclonal antiserum that (antibody) animal obtains.

The present invention also considers with Fv, Fab, Fab ' and F (ab ') ₂Immunoglobulin fragment is as antigen binding molecules.Perhaps, antigen binding molecules can comprise the Fv fragment that synthetic is stable.The exemplary fragment of this type comprises with peptide linker difference bridging V _HThe N-terminal of structural domain or C-terminal and V _LThe strand Fv fragment (sFv is commonly referred to scFv) of the C-terminal of structural domain or N-end.ScFv lacks all constant regions of complete antibody, thereby can not activating complement.Can basis, for example Kreber etc. (Kreber etc., 1997, J.Immunol.Methods, 201 (1): 35-55) method of being summarized prepares ScFv.Perhaps, can pass through U.S. Patent number 5,091,513; European patent number 239,400 or the article (1991 of Winter and Milstein, Nature, 349:293) and Pl ü ckthun etc. (1996, publish in " antibody engineering: a kind of practical approach " (Antibodyengineering:A practical approach), 203-252) described method prepares them.In another embodiment, the stable Fv fragment of synthetic comprises the stable Fv of disulfide linkage (dsFv), in this fragment two cysteine residues is introduced V _HAnd V _LThereby in the structural domain in folding fully molecule this two residue form disulfide linkage to each other.The appropriate method that produces dsFv is described in, for example (Glockscuther etc., Biochem., 29:1363-1367; Reiter etc., 1994, J.Biol.Chem., 269:18327-18331; Reiter etc., 1994, Biochem., 33:5451-5459; Reiter etc., 1994, Cancer Res., 54:2714-2718; Webber etc., 1995, Mol.Immunol., 32:249-258).

Preparation known in the art is anti--and the phage display of the antigen binding molecules of HVI labeling polypeptide and combined method be (for example, described in the following document: Ladner etc., U.S. Patent number 5,223,409; Kang etc., international publication number WO 92/18619; Dower etc., international publication number WO 91/17271; Winter etc., international publication WO 92/20791; Markland etc., international publication number WO 92/15679; Breitling etc., international publication WO 93/01288; McCafferty etc., international publication number WO 92/01047; Garrard etc., international publication number WO 92/09690; Ladner etc., international publication number WO 90/02809; Fuchs etc., (1991), Bio/Technology, 9: 1370-1372; Hay etc., (1992), Hum Antibod Hybridomas, 3: 81-85; Huse etc., (1989), Science, 246: 1275-1281; Griffths etc., (1993), EMBOJ, 12: 725-734; Hawkins etc., (1992), J Mol Biol, 226: 889-896; Clackson etc., (1991), Nature, 352: 624-628; Gram etc., (1992), PNAS, 89: 3576-3580; Garrad etc., (1991), Bio/Technology, 9: 1373-1377; Hoogenboom etc., (1991), Nuc AcidRes, 19: 4133-4137; With Barbas etc., (1991), PNAS, 88: 7978-7982).These antigen binding molecules can be used for screening the variant HVI labeling polypeptide in the expression library.They also can be used for detecting and/or separating HVI labeling polypeptide of the present invention.Therefore, the present invention also considers to utilize these antigen binding molecules, adopts for example any suitable immune affine method (including but not limited to immunochromatography and immunoprecipitation) to separate the HVI labeling polypeptide.Suitable method is utilized solid phase adsorption, wherein will resist-antigen binding molecules of HVI labeling polypeptide links to each other with appropriate resin, and this resin is contacted with suspecting the sample that contains the HVI labeling polypeptide, then wash-out HVI labeling polypeptide (if present) from the resin.Exemplary resin comprises: Sepharose ^TM(Pharmacia), Poros ^TMResin (Roche Molecular Biochemicals, Indianapolis), ActigelSuperflow ^TMResin (Sterogene Bioseparations Inc., Carlsbad Calif.) and Dynabeads ^TM(Dynal Inc., Lake Success, N.Y.).

Can be with antigen binding molecules and compound, marker for example, as radionuclide, or imaging agents, as radioactivity, enzymic activity (reagent) or other imaging agents, as the coupling of NMR contrast agent phase.The preferred marker that can produce detectable radioactive ray or fluorescence.Be abundance and pattern that evaluating protein matter is expressed, can utilize the antigen binding molecules (for example, monoclonal antibody) of anti--HVI labeling polypeptide to detect HVI labeling polypeptide (for example, in cell lysate or cell conditioned medium liquid).In some advantageous applications of the present invention, available this antigen binding molecules comes the HVI labeling polypeptide level in the monitoring biological sample (containing complete cell and liquid) and diagnoses the risk that whether has herpesvirus infection and degree or herpesvirus infection associated diseases.Antibody and detectable substance (that is antibody labeling) phase coupling (that is physical connection) are helped to detect.The example of detectable substance comprises various enzymes, prothetic group, fluorescent material, luminescent material, bioluminescent material and radio active material.The example of suitable enzyme comprises horseradish peroxidase, alkaline phosphatase, beta-galactosidase enzymes or acetylcholinesterase; The example of suitable prothetic group mixture comprises Streptavidin/vitamin H and avidin/biotin; The example of suitable fluorescent material comprises Umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichloro three azine amine fluoresceins (dichlorotriazinylamine fluorescein), dansyl chloride or phycoerythrin; The example of luminescent material comprises luminol,3-aminophthalic acid cyclic hydrazide; The example of bioluminescent material comprises luciferase, fluorescein and aequorin; The example of suitable radio active material comprises ¹²⁵I, ¹³¹I, ³⁵S or ³H.Marker can be selected from chromogen, catalyzer, enzyme, fluorophor, chemiluminescent molecule, lanthanide ion, as europium (Eu ³⁴But), the marker of radio isotope and direct viewing.But with regard to the direct viewing marker, available colloidal metal particle or non-metallic particle, dye granule, enzyme or substrate, organic polymer, latex particle, liposome or contain the preparation marks such as other carrier that signal produces material.

US Patent specification U.S.4,366,241; U.S.4,843,000 and U.S.4,849,338 disclose the enzyme that can be used as marker in a large number.Available enzyme labelling thing of the present invention comprises alkaline phosphatase, horseradish peroxidase, luciferase, beta-galactosidase enzymes, glucose oxidase, N,O-Diacetylmuramidase, malate dehydrogenase (malic acid dehydrogenase) etc.Can use separately enzyme labelling thing solution or with second kind of enzyme coupling.

5. detecting unusual HVI marker gene expresses or allelic method

The present invention is partly based on following discovery: compare with the horses that are not subjected to herpesvirus infection, be subjected to some gene of horses, particularly those horses of reactivity herpesvirus infection that simplexvirus (particularly EHV) infects or some allelotrope (this paper is called the HVI marker gene) abnormal expression of these genes.This paper proposes to find these genes or their homologue or straight abnormal expression to homologue in being subjected to other animal of herpesvirus infection.Therefore, the invention is characterized in that the unconventionality expression of taking from certain HVI marker gene in the biological sample of object by detection assesses herpesvirus infection or the diagnosis herpesvirus infection, the particularly method of reactivity herpesvirus infection of this object (preferred mammal).Herpesvirus infection should comprise that one of simplexvirus subfamily member of being selected from α herpetoviridae, β herpetoviridae and gamma herpes viruses section infects.The exemplary example of the simplexvirus of α herpetoviridae subfamily comprises: HHV-1 (HSV-1), HHV-2 (HSV-2), HHV-3 (VZV) and EHV (as, EHV-1 and EHV-4).The non-limitative example of the simplexvirus of β herpetoviridae subfamily comprises: HHV-5 (CMV), HHV-6 (roseola virus) and HHV-7.The representative example of the simplexvirus of gamma herpes viruses section subfamily includes but not limited to: and HHV-4 (the lymph cryptovirus, EBV) and HHV-8 (elongated virus).In specific embodiment, described simplexvirus is EHV, particularly EHV-1, more especially reactivity EHV-1.

For making assessment or diagnosis, need qualitatively or quantitatively determine the level of HVI marker gene transcript, the specific allelic existence of certain HVI marker gene or the level or the functionally active of level or HVI labeling polypeptide.In some embodiments, certain the HVI marker gene product detection level that exists in biological sample is lower than to be taken from normal subjects or not to be subjected to herpesvirus infection, when particularly not being subjected to the simplexvirus reactivity to infect the level of this gene in the reference sample of object, diagnosable herpesvirus infection state, degree or stage, perhaps the existence generation simplexvirus sequela risk of existing.In other embodiments, but the detection level of certain HVI marker gene product is higher than and takes from normal subjects or be not subjected to herpesvirus infection in biological sample, when particularly not being subjected to the simplexvirus reactivity to infect the level of this gene of reference sample of object, then diagnosable herpesvirus infection state, degree or stage, perhaps the existence generation simplexvirus sequela risk of existing.In a word, the level of corresponding HVI marker gene product or functionally active are compared and are had 10% at least in the level of certain the HVI marker gene product in the biological sample or functionally active and reference sample, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 97%, 98% or 99%, or even at least about 99.5%, 99.9%, 99.95%, 99.99%, 99.995% or 99.999%, or even at least about 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, during 900% or 1000% difference, can make this diagnosis.The exemplary rising or the reduction of representative HVI marker gene expression level see Table 5-7.

Corresponding gene product is selected from the same gene product that exists in the biological sample, variant gene (for example, homology or orthologous gene) expressed genes product or their protein that contains allele variant or splice variant usually.In some embodiments, this method comprises that detection is at least about 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29 or the level or the functionally active of 30 kind of each expression product of HVI marker gene.

Biological sample generally comprises blood, peripheral blood particularly, or its component or extract.Biological sample contains hemocyte usually, for example ripe, immature and grow white corpuscle, comprise lymphocyte, polymorphonuclear leukocyte, neutrophil, monocyte, reticulocyte, basophilic granulocyte, chamber born of the same parents, hemocyte, eosinophilic granulocyte, megalokaryocyte, scavenger cell, dendritic cell, natural killer cell, or the component of these cells (for example, nucleic acid or protein portion).In specific embodiment, biological sample contains white corpuscle, comprises peripheral blood lymphocytes (PBMC).

5.1 diagnostic nucleic acid

Can according to standard method (Sambrook etc., 1989, the same; Ausubel etc., 1994, the same) isolating nucleic acid is used for the polynucleotide test from the contained cell of biological sample.Described nucleic acid generally is fractionated (for example, poly A ⁺RNA) or whole-cell rna.When during as detected object, RNA being changed RNA into complementary DNA.In some embodiments, adopt template dependency nucleic acid amplification technologies this nucleic acid that increases.Existing many template dependency methods increase, and certain gives the HVI flag sequence that exists in the solid plate sample.Exemplary nucleic acid amplification technologies is specified in U.S. Patent number 4,683,195; 4,683,202 and 4,800,159; Ausubel etc. (the same) and Innis etc., the polymerase chain reaction (being called PCR) in (" PCR method " (PCRProtocols), Academic Press, Inc., San Diego Calif., 1990).In brief, in PCR, two primer sequences of regional complementarity on preparation and the relative complementary strand of this flag sequence.In reaction mixture, add excessive deoxynucleoside triphosphate and archaeal dna polymerase, for example Taq polysaccharase.If there is homology HVI flag sequence in certain sample, these primers will combine with this mark (sequence), and polysaccharase can make this primer extend along flag sequence by adding Nucleotide.By raising and reduce the temperature of reaction mixture, the primer of extension can with mark (sequence) the formation reaction product of dissociating, excessive primer can combine with mark (sequence) and reaction product, and carries out this process repeatedly.MRNA content for quantitative assay is increased can adopt the reverse transcriptase PCR amplification method.With the RNA reverse transcription is that the method for cDNA is known, and it is described in Sambrook etc., 1989, and the same.Other reverse transcription method is utilized heat-staple RNA dependent dna-polymerases.WO90/07641 has described these methods.Well known polymerase chain reaction method.

In some preferred embodiment, the template dependent amplification comprises real-time quantitative mensuration transcript.For example, can adopt real time pcr (Higuchi etc., 1992, Biotechnology, 10:413-417) quantitative assay RNA or DNA.By measuring the concentration of finishing similar number amplification round in the PCR reaction and being in the target DNA amplified production in the linearity range, can determine the relative concentration of specific target sequence in the original DNA mixture.If the DNA mixture is the relative abundance from the specific mrna that separates from the RNA of different tissues or cell synthetic cDNA, then can measure each tissue that produces this target sequence or cell.This direct proportional relationship between the concentration of PCR product and the mRNA relative abundance is only just correct in the linearity range of PCR reaction.Can measure the final concentration of this curve terrace part target DNA by the utilization ratio of reagent in the reaction mixture, this final concentration does not rely on the starting point concentration of this target DNA.

Another amplification method is EPO No.320 308 disclosed ligase chain reaction (LCR)s (" LCR ").In LCR, prepare two pairs of complementary probe, thereby the opposed complementary chain combination of the every pair of probe and target sequence is adjoined them in the presence of target sequence.In the presence of ligase enzyme, these two pairs of probes can link to each other and form a unit.With the same among the PCR, by temperature cycle, make bonded connect unit and dissociate, then with connecting excess probe right " target sequence " from target sequence.U.S. Patent number 4,883,750 described similar to LCR, make probe to target sequence bonded method.

Also can use the described Q β of PCT application number PCT/US87/00880 replicative enzyme.In this method, in the presence of RNA polymerase, will have with the rna replicon sequence of the regional complementary region mutually of target sequence and add in the sample.Polysaccharase can copy this replication sequence, detects then.

Utilize the amplification of restriction endonuclease and ligase enzyme also to can be used for the nucleic acid of the present invention that increases in the constant-temperature amplification method that the restriction site of a chain contains the target molecule of Nucleotide 5 ' α-sulfo--triphosphoric acid, Walker etc., (1992, Proc.Natl.Acad.Sci.U.S.A, 89:392-396).

Strand displacement amplification (SDA) is the another kind of method of carrying out nucleic acid constant-temperature amplification, and this method comprises many wheel strand displacements with synthetic, i.e. nick translation.The similarity method that is called reparation chain reaction (RCR) comprises anneals several probes on the entire target zone of amplification, only repair reaction to two kinds in four kinds of bases then.For ease of detecting other two kinds of bases are added as the biotinylation derivative.Adopted similar method among the SDA.Also can adopt circle probe reaction (CPR) detection specificity target sequence.In CPR, has the DNA hybridization that exists in the probe of 3 ' and the 5 ' sequence of non-specific DNA and specific RNA stage casing sequence and the sample.After the hybridization, with RNA enzyme H processing reaction (mixture), the product of probe is accredited as the different products that the digestion back discharges.Make the annealing of primary template and another circle probe, repeat this reaction.

Also can adopt the described another kind of amplification method of GB Patent Application No. 2 202 328 and PCT application number PCT/US89/01025.In last application, the template and the enzyme dependency that " modification " primer are used for the PCR-sample are synthetic.Available part (for example, vitamin H) and/or test section (for example, the enzyme) mark of catching modified these primers.In one application of back, excessive label probe is added sample.In the presence of target sequence, probe in conjunction with and cut by enzyme catalysis.After the cutting, the complete release of target sequence and then combine with excess probe.The cutting of label probe is the signal that target sequence exists.

Other nucleic acid amplification method comprises transcription amplification system (TAS), comprises amplification of nucleic acid sequences (NASBA) and 3SR (Kwoh etc., 1989, Proc.Natl.Acad.Sci.U.S.A., 86:1173; Gingeras etc., PCT applies for WO 88/10315).In NASBA, can the extraction of standard phenol/chloroform, thermally denature, lysis buffer by clinical sample handle and microcentrifugation (minispin) post DNA isolation and RNA or extract RNA by the chlorination guanidine and prepare the nucleic acid that is used to increase.These amplification techniques comprise makes the primer annealing with target-specific sequence.After the polymerization, the DNA/RNA crossbred with RNA enzyme H digestion hybridization carries out thermally denature again to double chain DNA molecule.In two kinds of situations, thus by add second target-specific primer then polymerization single stranded DNA is made complete two strands.Use RNA polymerase then, for example T7 or SP6 transcribe this double chain DNA molecule for many times.In the constant temperature circulating reaction, be single stranded DNA with the RNA reverse transcription, change double-stranded DNA then into, then use RNA polymerase, for example T7 or SP6 transcribe again.No matter the product that obtains is brachymemma or the complete target-specific sequence that all is shown as.

Davey etc., EPO No.329 822 discloses a kind of nucleic acid amplification method, comprises can be used for circulation synthetic single stranded RNA of the present invention (" ssRNA "), ssDNA and double-stranded DNA (dsDNA).SsRNA is the template of first primer tasteless nucleotide of reversed transcriptive enzyme (RNA dependent dna-polymerases) extension.Utilize the effect of ribonuclease H (RNA enzyme H has specific RNA enzyme to RNA in the duplex that contains DNA or RNA) to remove RNA in the DNA:RNA duplex that obtains then.The ssDNA that produces is the template of second primer, and this primer also contains promoter sequence with this template homologous RNA polymerase (for example T7 RNA polymerase) at 5 ' (end).Use archaeal dna polymerase (for example big " Klenow " fragment of e. coli dna polymerase I) to extend this primer then, obtain double-stranded DNA (" dsDNA ") molecule, its sequence is identical with original RNA between the primer, also contains promoter sequence at an end.Suitable R NA polysaccharase can utilize this primer sequence to prepare the many parts of RNA copies of this DNA.Thereby these copies can enter the circulation rapid amplifying more then.Suitably select enzyme, but constant temperature carries out this amplification (method) and need not at every adding enzyme of taking turns.Owing to the recursive nature of this method, can select the homing sequence of DNA or rna form.

Disclosed amplification of nucleic acid sequences scheme in PCT application WO 89/06700 such as Miller is transcribed many parts of RNA copies of this sequence then according to promotor/primer sequence and strand target DNA (" ssDNA ") hybridization.This scheme is not circulative, and the rna transcription thing that promptly obtains does not produce new template.Other amplification method comprises " RACE " and " monolateral (one-sided) PCR " (Frohman, M.A., publish in " PCR method: method and application guide " (PCR Protocols:A Guide to Methods andApplications), Science Press, N.Y., 1990; Ohara etc., 1989, Proc.Natl Acad.Sci.U.S.A., 86:5673-567).

Also can adopt the nucleic acid that contains to some extent " two-oligonucleotide " sequence that produces connect down two (or many) thereby oligonucleotide increases the method for this " two-oligonucleotide " come amplifying target nucleic acid sequence.Wu etc., (1989, Genomics, 4:560).

Depend on used mode, can adopt for example above-mentioned template dependent amplification or after amplification, directly identify interested HVI labeling nucleic acid in the sample with second kind of known nucleic acid.Detect the product of being identified then.In some applications, can detect (for example, gel ethidium bromide staining) by visual method.Perhaps, detection can comprise by chemoluminescence, radiolabeled radioactivity scintiphotography or fluorescent marker or even identify product (Affymax Technology indirectly by the system that utilizes electricity or thermal pulse signal; Bellus, 1994, J Macromol.Sci.Pure, Appl.Chem., A31 (1): 1355-1376).

In some embodiments, can observe amplified production or " amplicon " to confirm the amplification of HVI flag sequence.A kind of typical visual method comprises uses the ethidium bromide staining gel, observes under UV light.Perhaps, if amplified production has been integrated mark radioactivity or fluorescently-labeled Nucleotide can make these amplified productions exposure x-radiographic films or observe under suitable excitation spectrum after the separation.In some embodiments, can observe indirectly.Amplified production makes the nucleic acid probe of mark contact with the HVI flag sequence of amplification after separating.Probe preferably with chromophore's coupling, but but also radio-labeling.Perhaps, with probe and binding partners, for example antigen binding molecules or vitamin H coupling, but and carry test section or report molecule in conjunction with another right member.Related technology is well known to those skilled in the art, can find in the standard textbook of many molecular methods (for example, referring to Sambrook etc., 1989, the same and Ausubel etc., 1994, the same).For example, can be during increasing or thereafter with chromophore or radiolabeled probe or primer evaluation target (sequence).

In certain embodiments, adopt engram technology quantitative assay target nucleic acid well known to those skilled in the art.The Sourthern trace utilizes DNA as target, and the Northern trace utilizes RNA as target.Each method can provide different kinds of information, though the cDNA trace is similar to above-mentioned trace or RNA in many aspects.In brief, probe is used for target and is fixed in suitable matrix, normally DNA on the nitrocellulose filter or RNA.Different sorts nucleic acid spatially should separate so that analyze.Often by the nucleic acid gel electrophoresis, " trace " realized to film then for this.Subsequently, common trace target (sequence) and the probe (the normally probe of mark) cultivated under the condition that promotes sex change and hybridization (rehybridisation) again.Because probe design is and target (sequence) base pairing that probe can combine with the part of target sequence under the renaturation condition.Remove unconjugated probe then, detect as mentioned above.

After detected/quantified is measured, can or not have herpesvirus infection, particularly do not have the reference group that statistical significance is arranged of reactivity herpesvirus infection object and make comparisons finding result and the control reaction (result) or the normal subjects of certain given object.Detected HVI labeling nucleic acid content is associated with the process or the seriousness of disease.

The present invention also considers as Kristensen etc., (Biotechniques, 30 (2): 318-322) described methods of genotyping and allelotrope discrimination method and technology, these methods and technology comprise the single nucleotide polymorphisms analysis of employing, high performance liquid chromatography, TaqMan ^TM, liquid chromatography (LC) and mass spectrum.

The present invention also considers biochip technology, for example Hacia etc. (1996, Nature Genetics, 14:441-447) and Shoemaker etc. (1996, Nature Genetics, 14:450-456) described technology.In brief, these technology comprise the method for quantitatively determining of the many genes of quick Accurate Analysis.By tagging to gene with oligonucleotide or utilizing fixed probe array, available biochip technology that target molecule is separated into high density arrays and according to these molecules of screening by hybridization.Also referring to Pease etc. (1994, Proc.Natl.Acad.Sci.U.S.A., 91:5022-5026); Fodor etc. (1991, Science, 251:767-773).In brief, summarize as this paper, the nucleic acid probe of preparation HVI mark polynucleotide links to each other it with being used to screen with the biochip of diagnostic method.The nucleic acid probe that connects biochip can be designed to basically and specific expressed HVI labeling nucleic acid, be no matter target sequence (is target sequence or other probe sequence of sample, the sequence in the sandwich assay for example) complementation, thus target sequence and probe hybridization of the present invention made.This complementarity need not perfection; The base-pair mismatch that can have the interference hybridization of some amount between target sequence and the nucleic acid probe of the present invention.Yet if do not hybridize under minimum preciseness hybridization conditions even the quantity of mispairing is too big, this sequence is not the complementary sequence of target sequence yet.In certain embodiments, every sequence can be utilized multiple probe, can utilize the eclipsed probe or at the probe of target sequence different piece.That is, available two kinds, three kinds, the probe more than four kinds (preferred three kinds) make up concrete target (sequence) and have Feng Yudu.These probes can be eclipsed (being that some sequence is identical) or isolating.

Those of ordinary skills should be understood that and can in every way nucleic acid be connected in or be fixed in solid support." fixed " of this paper or its grammer vocabulary of equal value shows being connected or being combined under following combination, washing, analysis and the removal condition enough stable between nucleic acid probe and the solid support.In conjunction with can being covalently or non-covalently." the non-covalent combination " of this paper and its grammer vocabulary of equal value shows one or more of static, wetting ability and hydrophobic interaction.Non-covalent combination comprises molecule, and for example Streptavidin combines with the non-covalent of Streptavidin with the covalently bound and biotinylated probe of upholder." covalent attachment " of this paper and grammer thereof vocabulary of equal value shows two portions, and promptly solid support and probe by a key, comprise that σ key, π key link to each other with coordinate bond at least.Can be formed directly in covalent linkage between probe and the solid support, perhaps can form covalent linkage by cross linker or by solid support or probe the two or the contained specific reaction active group of these two kinds of molecules.Immobilization also can comprise unites with covalency and noncovalent interaction.

In a word, those skilled in the art will know that linking probe and biochip in every way.As described herein, can first nucleic acid, link to each other with biochip then, perhaps direct nucleic acid on biochip.

Biochip comprises suitable solid or semi-solid substrate or solid support." substrate " or " solid support " expression is modified and contain and be fit to link to each other with nucleic acid probe or discontinuous a plurality of sites of bonded and be applicable to any material of at least a detection method.Those skilled in the art will know that the available substrate is a lot, include but not limited to: glass and modification or functional glass, plastics (multipolymer of vinylformic acid, polystyrene and vinylbenzene and other material, polypropylene, polyethylene, polybutene, urethane, Teflon ^TMDeng), polysaccharide, nylon or nitrocellulose, resin, silicon-dioxide or material (silicon that comprises modification), carbon, metal, unorganic glass, plastics etc.In a word, these substrates can detect and not be with fluorescence with optical means.

Described substrate generally is flat, though those skilled in the art will know that the substrate that also can utilize other configuration.For example, reduce sample volume as far as possible, probe can be placed the internal surface of test tube for the sample that flows through is analyzed.Similarly, described substrate can be flexible, and for example the bendable foam plastics comprise the porous plastics that the sealing cell is arranged that particular plastic is made.

In certain embodiments, known in the art can be on substrate synthetic oligonucleotide probe.For example, utilize the photoactivation technology of photopolymerization compounds and technology.In an exemplary example, adopt the light version printing technology of knowing, for example WO 95/25116; WO 95/35505; U.S. Patent number 5,700,637 and 5,445,934 and the reference quoted described in technology original position nucleic acid; These methods of attachment constitute Affymetrix GeneChip ^TMThe basis of technology.

In the example of an exemplary analyzing biochips, the oligonucleotide probe on the biochip is contacted at the nucleic acid samples that helps under the condition of specific hybrid to contain one or more simplexvirus polynucleotide with suspection.Can from the suspension of biomaterial, prepare the DNA of sample or RNA extract (no matter strand or two strands), perhaps grind biomaterial, perhaps according to the preparation of lysis step, described step includes but not limited to: handle with SDS (or other washing composition), osmotic pressure impact, guanidinium isothiocyanate and N,O-Diacetylmuramidase and carry out cracking.The suitable DNA that can be used for the inventive method comprises cDNA.Can adopt this DNA of one of multiple common method preparation, for example see Ausubel etc., 1994, the same; With Sambrook etc., 1989, same as above.

The suitable RNA that can be used for the inventive method comprises complementary RNA (cRNA) or geneome RNA or the subgenomic RNA that messenger RNA(mRNA), DNA transcribe.Can adopt standard method to prepare this RNA, Ausubel etc. for example, 1994, the same; With Sambrook etc., 1989, same as above.

Can pass through, for example ultrasonication or handle with restriction endonuclease and to make the cDNA fragmentation.Thereby it is preferably make the cDNA fragmentation make the dna fragmentation of generation be longer than the fixed oligonucleotide probe, but enough little and can under suitable hybridization conditions, contact the fixed probe fast.Perhaps, can adopt for example above-mentioned suitable amplification oligonucleotide technology cDNA fragment of selecting and increase, this relate to utilize suitable at random or Auele Specific Primer.

Usually thereby detectability labels targets HVI mark polynucleotide can be measured the hybridization of they and each probe.Usually with report molecule detectability labels targets polynucleotide, the exemplary example of described report molecule comprises chromogen, catalyzer, enzyme, fluorescence dye, chemiluminescent molecule, bioluminescent molecules, lanthanide ion (for example, Eu ³⁴But), the marker of radio isotope and direct viewing.But, can utilize colloidal metal particle or non-metallic particle, dye granule, enzyme or substrate, organic polymer, latex particle, liposome or contain other carrier etc. that signal produces material for the marker of direct viewing.This type of exemplary marker comprises big colloid, and metallic colloid for example is as gold, selenium, silver, tin and titanium oxide colloid.At some but enzyme is used as in the embodiment of direct viewing marker, biotinylated base is mixed in the target polynucleotide.Detect hybridization by cultivating with Streptavidin-report molecule.

Suitable fluorescence dye includes but not limited to: fluorescein isothiocyanate (FITC), isothiocyanic acid tetramethyl-rhodamine (TRITC), R-phycoerythrin (RPE) and Texas red (Texas Red).Other exemplary fluorescence dye comprises described in (international publication WO 93/06121) such as Dower.Fluorescence dye also can be with reference to United States Patent (USP) 5,573,909 (Singer etc.); 5,326,692 (Brinkley etc.).Perhaps, fluorescence dye can be with reference to U.S. Patent number 5,227,487; 5,274,113; 5,405,975; 5,433,896; 5,442,045; 5,451,663; 5,453,517; 5,459,276; 5,516,864; 5,648,270 and 5,723, described in 218.The fluorescent marker that can buy comprises, fluorescein phosphoramidite for example is as Fluoreprime ^TM(Pharmacia), Fluoredite ^TM(Millipore) and FAM (Applied Biosystems International).

Radioactivity report molecule comprises, for example can pass through the 32P of X-ray or phosphoric acid imaging (phosphoimager) technology for detection.

Can under the condition that is suitable for oligonucleotide probe and test nucleic acid (comprising DNA or RNA) hybridization, hybridize the formation step.Thus, but reference example as " nucleic acid hybridization, a kind of practical approach " (NUCLEICACID HYBRIDIZATION, A PRACTICAL APPROACH), (Homes compile with Higgins), (IRL press, Washington D.C., 1985).In a word, hybridization whether be subjected to concentration, the hybridization formation of length, pH, temperature, monovalence and the divalent cation of oligonucleotide probe and the polynucleotide sequence of test distinguish in ratio, the dielectric viscosity of G and C Nucleotide and the influence of the denaturing agent that may exist.These variable factors also influence the hybridization required time.Therefore, preferred condition depends on concrete application.Yet available ordinary method is determined these empirical conditions and be need not too much experiment.

Some preferred embodiment adopts height distinctive hybridization conditions.For example, can be with reference to Wallace etc. (1979, Nucl.Acids Res., 6:3543), he has described with the similar oligonucleotide probe that contains an inner base-pair mismatch and has compared, and can distinguish and the hybridization conditions of target sequence Perfect Matchings with the oligonucleotide probe of complete homologous 11-17 base length.Also can be with reference to Wood etc. (1985, Proc.Natl.Acid.Sci.USA, 82:1585), he has described the condition of utilizing the 3M tetramethylammonium chloride to make the long oligonucleotide hybridization of 11-20 base, wherein the melting temperature(Tm) of crossbred only depends on the length of oligonucleotide probe, and its GC content no matter.In addition, Drmanac etc. (the same) have described the rigorous hybridization conditions of the long oligomer of 6-10 Nucleotide, utilize nucleotide analog, for example " locked nucleic acid " be not difficult to obtain simulated condition (Christensen etc., 2001, Biochem J, 354:481-4).

Hybridization generally can carry out in the presence of hybridization buffer, optional hybridization optimization reagent, for example stablizer (isostabilising agent), denaturing agent and/or the renaturation accelerator of containing of described damping fluid.The example of stablizer includes but not limited to: trimethyl-glycine and rudimentary tetraalkylammonium salt.Denaturing agent is the composition that reduces the double chain acid molecule melting temperature(Tm) by the hydration of hydrogen bond between the interference double-strandednucleic acid base or nucleic acid molecule.Denaturing agent includes but not limited to: methane amide, formaldehyde, dimethyl sulfoxide (DMSO), tetraethyl-acetic ester (tetraethylacetate), urea, guanidinium isothiocyanate (guanidium isothiocyanate), glycerine and chaotropic salt.The hybridization accelerator comprises heterogeneous nuclear ribonucleoprotein (hnRP) A1 and cationic detergent in the nuclear, as cetyl trimethylammonium bromide (CTAB) and Trimethyllaurylammonium bromide (DTAB), polylysine, spermine, spermidine, single strand binding protein (SSB), phage T4 gene 32 albumen and ammonium acetate and alcoholic acid mixture.Hybridization buffer can contain concentration and be the about 50nM of about 0.005-, preferably about 0.5-5nM, the target polynucleotide of 1-2nM more preferably from about.

The hybridization mixture that contains target HVI mark polynucleotide is contacted with probe array and cultivate appropriate time so that the target sequence in the target polynucleotide is hybridized with any complementary probe in room temperature.Can in any suitable containers, contact, for example be designed for the dish or the cell that hold the solid support that is connected with probe on it.Cultivate temperature and be generally the used temperature of nucleic acid hybridization, for example about 20 ℃-Yue 75 ℃, 25 ℃ according to appointment, about 30 ℃, about 35 ℃, about 40 ℃, about 45 ℃, about 50 ℃, about 55 ℃, about 60 ℃, or about 65 ℃.Length surpasses the preferred 20-50 of probe ℃ of 14 Nucleotide.For short probe, preferred lesser temps.Target polynucleotide sample and probe cultivated when enough reach required hybridization level between the target sequence in the chien shih target polynucleotide and any complementary probe.For example, can in methane amide, hybridize 1-2 days at about 45 ℃+/-10 ℃.

After hybrid forms step, optimize the hybridization buffer washing probe of agent to remove any unconjugated nucleic acid with containing with the hybridization of the used same concentrations of hybridization step.This washing step only stays the bonded target polynucleotide.But detection probes is to identify the hybridization of which kind of probe and target polynucleotide then.

Can detect hybridization then to determine which kind of probe and corresponding target sequence hybridization.The character that depends on the report molecule that is connected with target polynucleotide can be used the instrument detecting signal: use the rayed fluorescent marker, detect fluorescence with photofluorometer in the following manner; Provide enzyme system to produce the color that available spectrophotometer detects; Perhaps detect dye granule or colored colloidal metal particle or non-metallic particle with the light reflectometer; Adopt radiation counter or radioautography during with radioactively labelled substance or chemiluminescent molecule.Therefore, proofing unit should be applicable to detection or the relevant light of passing marker thing, and described light can comprise fluorescence, cold light, focused beam or laser.At this moment, charge available coupled apparatus (CCD) or photocell scan each position probe in the microarray: the light of target polynucleotide hybrid emission is also directly at the digital machine identifying recording layer.In some cases, need not the detected electronically signal.For example, producing the color spot relevant with the nucleic acid array pattern with enzymatic is example, estimates this array with regard to the pattern on the soluble array.In the nucleic acid array situation, proofing unit preferably links to each other with mode identificating software and the signal mode of array is converted into ordinary language heredity distribution pattern.In certain embodiments, the specific oligonucleotide probe that different HVI stress the marker gene product is taked the nucleic acid array form, with the report signal that molecule produced on " chip-reader " detection arrays.(U.S. Patent number 5,143,854) such as detection system that " chip-reader " adopts such as Pirrung are described.Chip-reader comprises also that usually some signal courses of processing determine that the signal at certain concrete array position or element place is true positives or may is spurious response.Exemplary chip-reader for example Fodor etc. (U.S. Patent number 5,925,525) is described.Perhaps, when array is when being made by the microballon mixture of various addressable phenotypic markers, can adopt this reaction of Flow cytometry.

5.2 protein diagnostic

Consistent with the present invention is, exists the HVI labelled protein of abnormal concentrations to show herpesvirus infection, the particularly existence of reactivity herpesvirus infection, degree or stage, or the risk of herpesvirus infection sequela takes place.Can adopt the imitate level of HVI labelled protein in the product of any appropriate method detection of biological known in the art.For example, when the HVI labelled protein is enzyme, can come this protein of quantitative assay according to its catalytic activity or contained per sample this protein molecule number.Can adopt antibody technique, for example immunohistology and immunohistochemical method come the level of proteins of interest matter in the test set tissue samples.For example, provide specific recognition, detect anti-existing (or combination) with second detection system with one anti-(polyclone or mono-clonal).Can be with detectable, but for example fluorescent marker, radioactively labelled substance maybe can produce quantitative assay (as colored) product enzyme (as, alkaline phosphatase, horseradish peroxidase) with two anti-couplings mutually.In another suitable method, detectability ground mark one is anti-own.Therefore can make the immunohistology mark to tissue slice.In some embodiments, preparation is analyzed and is used protein extract from biological sample (for example, tissue, cell).Can adopt routine immunization trace method (Jalkanen etc., 1985, J.Cell.Biol., 101:976-985; Jalkanen etc., 1987, J.Cell.Biol., 105:3087-3096) level of proteins of interest matter in western-trace or spot/narrow line experiment (analysis) this extract (for example, washing composition extract).

Other useful antibody method comprises immunoassay, for example enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA).For example, the protein specific monoclonal antibody can be used as immunosorbent and enzyme labelled probe detects and the interested HVI labelled protein of quantitative assay.Can adopt the linear regression computerized algorithm (referring to, Lacobilli etc., 1988, Breast Cancer Research and Treatment, 11:19-30), the content in the reference standard goods comes this Protein content in the calculation sample.Other embodiment can be with two kinds of different monoclonal antibodies of proteins of interest matter, and a kind of as immunosorbent, another kind is as enzyme labelled probe.

In addition, the latest developments in protein capture array field make and can detect simultaneously and/or a large amount of protein of quantitative assay.For example, low density protein array on the filter membrane is as general protein array system (Ge, 2000, Nucleic Acids Res., 28 (2): e3) adopt standard ELISA technology and scanning electric charge coupling device spare (CCD) detector to take the AM picture of forming array.Also developed the immunosensor array that can detect clinical (multiple) analyte simultaneously.Can come in the analysing body fluid with protein array at present, for example the protein expression distribution pattern in the object serum before and after health or ill object and the pharmacological agent.

The protein capture array generally comprises the multiple proteins trapping agent, and they have formed the different element in this array manifold position separately.The protein capture agent can be energy conjugated protein and any molecule or the molecular complex that is fixed in the protein capture agent site on the array.The protein capture agent can be a kind of protein, its natural function in cell be specificity in conjunction with another kind of protein, for example antibody or acceptor.Perhaps, the protein capture agent can be that the energy specificity is in conjunction with certain proteinic partial synthesis or protein complete synthesis or reorganization.Perhaps, the protein capture agent can be external basis to the binding affinity of specific target protein matter or peptide from mutagenesis, at random or the protein of selecting completely randomization and the synthetic library.It is methods of exhibiting known in the art that used system of selection can be chosen wantonly, for example ribosomal display or phage display method.Perhaps, the protein capture agent that obtains through external selection can be can specificity in conjunction with the DNA of target protein or RNA fit (referring to, Potyrailo etc. for example, 1998, Anal.Chem., 70:3419-3425; Cohen etc., 1998, Proc.Natl.Acad.Sci.USA, 95:14272-14277; Fukuda etc., 1997, Nucleic Acids Symp.Ser., 37:237-238; Derive from SomaLogic).For example, from oligonucleotide library, selects fitly with the SelexTM method, can pass through covalently boundly, for example mix bromination deoxyuridine and UV-activated crosslinked (light is fit) and improve they and protein interactions.Fit advantage be to be easy to by automatic oligonucleotide synthesize prepare and DNA stable and firmly; Can adopt general fluorescence protein staining technique to detect in conjunction with situation.Perhaps, the protein capture agent of external selection can be polypeptide (for example, antigen) (referring to, for example Roberts and Szostak, 1997, Proc.Natl.Acad.Sci.USA, 94:12297-12302).

The another kind of array of capture molecules is the array of making by " molecule printing " technology, peptide wherein (for example proteinic C-stub area) produces complementary structure as template in polymerizable matrix sequence-specific space; These spaces energy specificitys are caught (sex change) protein with corresponding one-level aminoacid sequence and (for example, are derived from ProteinPrint then ^TMWith Aspira Biosystems).

The exemplary proteins capture array comprises that being commonly referred to has living space containing of antibody array and goes up the array of addressable antigen binding molecules, and this array helps on a large scale the numerous protein of parallel analysis to determine protein group or protein subgroup.Antibody array shows to have required specificity character and acceptable background, and some arrays can be buied (for example, BD Biosciences, Clontech, BioRad and Sigma).The existing report of the whole bag of tricks of preparation antibody array (referring to, Lopez etc. for example, 2003, J.Chromatogr.B, 787:19-27; Cahill, 2000, Trends in Biotechnology, 7:47-51; U.S. Patent Application Publication 2002/0055186; U.S. Patent Application Publication 2003/0003599; PCT announces WO03/062444; PCT announces WO 03/077851; PCT announces WO 02/59601; PCT announces WO02/39120; PCT announces WO 01/79849; PCT announces WO 99/39210).The antigen binding molecules of these arrays can be discerned the expressed protein subgroup of certain cell or cell mass at least, and its exemplary example comprises growth factor receptors, hormone receptor, neurotransmitter receptor, the catecholamine acceptor, the amino acid derivative acceptor, cytokine receptor, the extracellular matrix acceptor, antibody, lectin, cytokine, silk presses down albumen, proteolytic enzyme, kinases, Phosphoric acid esterase, ras-sample GTP enzyme, lytic enzyme, steroid hormone receptor, transcription factor, thermal excited transcryption factor, DNA-is conjugated protein, zinc finger protein, leucine zipper protein, homeodomain protein, intracellular signal transduction conditioning agent and effector, the apoptosis correlation factor, the DNA composition-factor, the DNA reparative factor, the DNA recombinant factor, cell-surface antigens, hepatitis C virus (HCV) proteolytic enzyme and hiv protease.

In phage display or ribosomal display library (for example, derive from Cambridge AntibodyTechnology, BioInvent, Affitech and Biosite) in can be (for example after selecting by the routine immunization method, polyclonal serum and hybridoma), or as the antigen binding molecules for preparing antibody array usually at the recombinant fragment of expression in escherichia coli.Perhaps, " combinatorial antibody (combibody) " form that contains non-covalent associating VH and VL structural domain of preparation makes up formed matrix for producing double antibody bacterial clone (for example, deriving from Domantis).Exemplary antigen binding molecules as the protein capture agent comprises monoclonal antibody, polyclonal antibody, Fv, Fab, Fab ' and F (ab ') ₂Immunoglobulin fragment, synthetic are stablized Fv fragment (as strand Fv fragment (scFv), by the stable Fv fragment (dsFv) of disulfide linkage), the little antibody of single variable region structural domain (dAbs) (minibody), combinatorial antibody and multivalent antibody (as double antibody and many-scFv), the single structure territory of camel (camelids) or engineered people's equivalence antibody.

Each different protein capture agent of locus is connected in usually generally to be flat or the support surface of fluctuating is arranged.Physical support thing commonly used comprises slide glass, silicon, micropore, nitrocellulose or pvdf membrane and magnetic micro-beads and other microballon.

Though extensively adopt the protein droplet is delivered on the plane, but also can adopt other relevant structure, the CD centrifugal device that comprises the progress exploitation of instrument Microfluidics (for example, available from Gyros) and specialized chip design, engineered microchannel (for example, The Living Chip in the plane for example ^TM, available from Biotrove) and the small 3D post (for example, deriving from Zyomyx) of silicon face.

Also the basis of the particle in the suspension as array can be needed only the identity coding to them; These systems comprise with color-coded microballon (for example, available from Luminex, Bio-Rad and NanomicsBiosystems), semiconductor nanocrystal (for example, Qdots ^TM, available from Quantum Dots), clavate encoded beads (UltraPlex ^TM, available from Smartbeads) and many metals microbot (Nanobarcodes ^TMParticle is available from Surromed).Also these pearls can be assembled into planar array (for example, available from LEAPS technology and BioArray Solutions) on semi-conductor chip.When using particle, each protein capture agent is connected in each particle usually and determines position or the array that separates so that the space to be provided.Distinguish (but parallel) then with isolation method, for example detect these particles in the hole of titer plate or in the different test tube.

In operation, with the optional fragmentation of protein example with form peptide fragment (referring to, for example U.S. Patent Application Publication 2002/0055186), be suitable for being delivered to the protein capture array under protein or the peptide bonded condition; Wash this array with in the sample not in conjunction with or the component of non-specific binding flush away from the array.Then, utilize the protein of each combination of elements on suitable detection system detection and the array or the existence or the content of peptide.To make comparisons with the protein determination amount of certain combination of elements on the array and second Protein content of this array second combination of elements.In certain embodiments, second Protein content is known or known constant in the sample.

For analyzing the difference of protein expression between two kinds of cells or the cell mass, the protein example of first kind of cell or cell mass is being suitable for being delivered to this array under the condition of protein bound.The protein example of second kind of cell or cell mass is delivered to second array identical with first array in a similar manner.Wash then two arrays with in the sample not in conjunction with or the component of non-specific binding flush away from the array.At last, will keep with the first array element bonded protein content and keep with the respective element bonded protein content of second array and make comparisons.For measuring the difference of protein expression mode between two kinds of cells or the cell mass, will with the protein content of first each combination of elements of array from the respective element bonded protein content of second array deduct.

In an exemplary example, can utilize fluorescent mark to detect and array bonded protein.Will with understand the used identical instrument application of dna microarray in the protein capture array.For showing difference, the available fluorescent mark protein detection capture array that derives from two kinds of different states cells (for example, antibody array), the cell lysate of two states with different fluorophores (for example, Cy-3 and Cy-5) mark and mixing, thus the reading that color can be changed as target (molecule) abundance.The sensitivity of fluorescence reading can be improved 10-100 doubly by junket acid amides amplification of signal (TSA) (for example, available from PerkinElmer Lifesciences).Slab guide technology (for example, available from Zeptosens) can be carried out overdelicate fluoroscopic examination, and its another advantage is to need not washing.Utilize mark thing (for example, available from Luminex) or utilize the suspended beads and the particle of semiconductor nanocrystal (for example, available from Quantum Dot) performance also can realize highly sensitive of phycoerythrin.Adopted the combination (for example, available from Affibody) that FRET (fluorescence resonance energy transfer) detects the unmarked part that can be used for array.Several other reading devices have been developed, the modifying device that comprises following method: surperficial plasmon resonance (for example, available from HTS Biosystems and Intrinsic Bioprobes), rolling circulation DNA cloning (for example, available from Molecular Staging), mass spectrum (for example, available from Sense Proteomic, Ciphergen, Intrinsic and Bioprobes), resonant light scattering (for example, available from Genicon Sciences) and atomic force microscope (for example, available from BioForce Laboratories).NextGen and PerkinElmer Life Sciences have developed jointly and have been used for sample and the automatic microfluid system of cultivating and washing of slide glass array.

In certain embodiments, the technology that is used to detect HVI marker expression product comprises with inside or external perimysium reference product comes quantitative or those products of semiquantitative determination, thus the level or the functionally active of corresponding expression product in these expression products and the reference sample in the comparative biology sample effectively.The technician adopts standard method can determine this standard substance.The level of each expression product or the absolute value of functionally active have been measured in the specific embodiment.

In specific embodiment, can utilize as awaiting the reply described in the PCT application number PCT/AU03/01517 of submitting in international publication number WO 02/090579 and on November 14th, 2003, comprise with the base station mutually the system at least one terminal station of coupling connection carry out this diagnostic method.The base station usually with one or more databases mutually coupling join, these databases contain the representative HVI marker expression product level of a large amount of individualities or the tentation data of functionally active, and when collecting these tentation datas these individual virtual conditions indication (for example, the existence of herpesvirus infection, do not exist, degree, stage or the risk of simplexvirus sequela takes place).In operation, the base station is data by station, network of communication receiving terminal and described data and the tentation data that is stored in the database made comparisons generally, and described data represented at least a expression product detects or level of standardization or functionally active in the tested object biological sample corresponding to taking from.The data of this object and tentation data made comparisons make the base station can determine the state of this object according to comparative result.Therefore, the individuality that has the similarity parameter value with tested object is attempted to identify in the base station, in case determined state according to this evaluation (result), the terminal station can be delivered to the diagnosis that shows in the base station.

5.3 test kit

Can be assembled in the test kit with required all necessary materials and the reagent of quantitative assay HVI marker gene expression product detecting.These test kits are also optional to be equipped with suitable agent, the positive and negative control, washing soln, blotting membrane, the titer plate dilution buffer liquid etc. of certification mark thing.For example, kit for detecting nucleic acid can be equipped with (i) HVI mark polynucleotide (can be used as positive control), (ii) can with the primer or the probe of certain HVI mark polynucleotide specific hybrid.Also the enzyme that is applicable to amplification of nucleic acid can be housed, comprise various polysaccharases (reversed transcriptive enzyme, Taq, Sequenase ^TMDna ligases etc. depend on the nucleic acid amplification technologies that is adopted), deoxynucleotide and damping fluid are to provide amplification required reaction mixture.This test kit generally is equipped with the different vessels of all ingredients and enzyme and various primer or probe with suitable method.Perhaps, protein detection reagent kit can be equipped with: immune interactional antigen binding molecules, (ii) can take place with certain HVI mark polynucleotide in (i) HVI labeling polypeptide (can be used as positive control).The feature of this test kit also is to be equipped with various devices and the reagent that carries out test described herein; And/or the working instructions of the printing of expressing with this test kit quantitative assay HVI marker gene.

These test kits are optional to be equipped with suitable agent, the positive and negative control, washing soln, blotting membrane, the titer plate dilution buffer liquid etc. of certification mark thing.For example, kit for detecting nucleic acid can be equipped with (i) HVI mark polynucleotide (can be used as positive control), (ii) can with the primer or the probe of certain HVI mark polynucleotide specific hybrid.Also the enzyme that is applicable to amplification of nucleic acid can be housed, comprise various polysaccharases (reversed transcriptive enzyme, Taq, Sequenase ^TMDna ligases etc. depend on the nucleic acid amplification technologies that is adopted), deoxynucleotide and damping fluid are to provide amplification required reaction mixture.This test kit generally is equipped with the different vessels of all ingredients and enzyme and various primer or probe with suitable method.Perhaps, protein detection reagent kit can be equipped with: immune interactional antigen binding molecules, (ii) can take place with certain HVI mark polynucleotide in (i) HVI labeling polypeptide (can be used as positive control).The feature of this test kit also is to be equipped with various devices and the reagent that carries out test described herein; And/or the working instructions of the printing of expressing with this test kit quantitative assay HVI mark polynucleotide.

6. treat or prevention method

Make object have herpesvirus infection sequela risk positive diagnosis takes place after, the present invention is also extensible to be used for the treatment of or the herpesvirus infection, particularly reactivity herpesvirus infection of object of prevention.Generally, described treatment comprises the medicine of diagnosing male object significant quantity or treatment improving symptom or to reverse the generation of herpesvirus infection, or reduces the possibility of object generation herpesvirus infection sequela.The medicine that is applicable to the treatment herpesvirus infection at present includes but not limited to: for example U.S. Patent Application Publication No. 20020147210 described acyclovirs, Famciclovir, valacyclovir, ganciclovir, Penciclovir, Zidovodine, cytidine arabinose glycosides, ribavirin, amantadine, iododeoxyuridine, poscarnet, trifluoridine, Metisazone (methizazone), vidarabine, levanisole 4-amino-α, alpha-alpha-dimethyl-2-ethoxyl methyl-1H-imidazoles (imidazo) [4,5-c] quinoline-1-ethanol; U.S. Patent Application Publication No. 20020103262 described hydroxylation tolane; U.S. Patent number 5,840,728 described cyclopropylization (cyclopropanated) carbocyclic rings 2 '-deoxynucleoside; U.S. Patent number 6,048,843 described thymus pyrimidines-analogue herpes medicine; (PFA originates from Astra to U.S. Patent Application Publication No. 20040053891 described phosphine formic acid, Sodertlje, the Foscavir of Sweden ^TM), 5-(E)-bromo vinyl uracil analogues and relevant pyrimidine nucleoside; U.S. Patent Application Publication No. 20040024209 described 1-aryl-4-oxygen-1,4-dihydro-3-quinolinecarboxamideas; With Raymond etc., (1984, Biochem.Bioph.Res.Comm., 121 (3): 848-854) described spermidine catechol acid amides iron chelating agent.

Perhaps, can utilize as U.S. Patent Application Publication No. 20020099426 described device treatment targets, described device is delivered to infected skin of patient or mucous membrane with electricity irritation.Apply electricity irritation with a series of electricimpulses with different electrical features.

However, it should be understood that the present invention includes to can be used for treating or any medicine or the method for prophylaxis of herpes viral infections, be not limited to above-mentioned exemplary compound and preparation.

The simplexvirus cushion generally becomes medicine (or veterinary science) composition with pharmaceutically acceptable vehicle group, realizes the purpose that they are required with significant quantity.The dosage that gives the active compound of object should be enough to cause useful reaction in for some time in object, for example reduces or alleviate herpesvirus infection, particularly the symptom of reactivity herpesvirus infection.The consumption of the pharmaceutically active compound that gives depends on object to be treated, comprises its age, sex, body weight and whole body health situation.Thus, the accurate consumption of the active compound that is given depends on the doctor's that obtains employment judgement.Determining to treat or during the significant quantity of the active compound of prophylaxis of herpes viral infections, doctor or animal doctor should assess with herpesvirus infection and have related indication seriousness, comprise above-mentioned herpesvirus infection sequela related symptoms.In any situation, those skilled in the art are not difficult to determine the suitable dose of herpesvirus infection cushion and suitable treatment plan and need not too much experiment.

In specific embodiment, there is EHV or after its stage at the positive object of diagnosis, the extensible EHV of being used for the treatment of of the present invention infects, treatment EHV infection and recurrence or object of prevention are further infected by EHV.Generally, treatment comprises to be isolated in case further infect, and the palliative treatment damages avoiding over a long time with having a rest.The present invention can make more effective isolation and control decision when animal is infectivity, thereby the animal doctor, horse owner people and the trainer that know this information just can stop protecting from infection other horses, particularly other pregnant mare until the virus diffusion with these animals isolation.On the contrary, existing method can only could be diagnosed EHV later at infection stage warp, therefore can not be used for isolating decision.

For ease of understanding and implementing the present invention, particularly preferred embodiment has been described by following non-limiting example.

Embodiment

Embodiment 1

Identify the specific diagnosis gene of herpesvirus infection

Experimental disease test design

At different time, in two groups of 13 young coltfoals, induce equid herpesvirus 1 (EHV-1) to infect.6 young coltfoal tracing observations 20 days (group 1) infected at the 0th day (experimental inoculation).7 young coltfoal tracing observations 42 days (group 2) infected at the 21st day (experimental inoculation).All young coltfoals of EHV-1 nasopharynx aerosol infection with vitro culture.Group 1 blood sample was 8 time point collections of the 0th, 1,2,4,6,10,13 and 20 day.Group 2 blood sample was 16 time point collections of the 0th, 1,2,4,6,10,13,20,21,22,23,25,27,31,34 and 41 day.The 0th day sample is as the contrast of each dry goods.

The animal of discovery group then 2 has been subjected to natural and nonsynchronous infection of EHV.All animal serums sun of group 2 changes, and utilizes the time (before seropositive conversion 10-14 days) of seropositive conversion time estimation natural infection.Because group 2 infection time is asynchronous, the diagnostic characteristic that utilizes the gene expression datas of these animals to check utilization group 1 to obtain.

Carry out following check and observation at all time points:

● health check-up comprises body temperature, pulse and respiration measurement

● hematology and biological chemistry (check)

● nose swab is carried out PCR

● serum EHV-1 antibody (Ab) titre

● leukocyte specific gene array is carried out gene expression analysis.

Utilization contains the GeneChips of thousands of kinds of expressed genes of horse white corpuscle ^TM(using method is specified in hereinafter " generation gene expression data ") analyzes the blood sample of taking from infected animals.Analyze these data (" identifying response gene and proof diagnosis potentiality " vide infra) disclose infect before and after the EHV and back first day of infection between many genetic expressions of animal variant.Can design in a kind of test test sample at least a, the rna level of preferred at least two kinds of HVI marker gene, the representative transcription sequence of described gene is as follows: 1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113.The specificity and the level of sensitivity of this method are 94%.Perhaps, any combination of one of at least two kinds of polynucleotide and listed other the 61 kinds of HVI mark polynucleotide of table 1 all has strong diagnosis capability.

Materials and methods

Blood sampling

Extract high-quality RNA or protein from horses (non-affective state) blood sampling.The suitable blood sampling test tube of collection, preservation, transhipment and isolation of RNA comprises PAXgene ^TMTest tube (PreAnalytix Inc., Valencia, CA, the U.S.).Perhaps, blood collecting can be gone into contain to be designed in the test tube of solution (available from Roche, Ambion, Invitrogen and ABI) of preservation nucleic acid.Be to measure protein level, the 50ml blood collecting is gone into to contain in the test tube of 4ml 4% Trisodium Citrate in case condense.Separate white corpuscle and blood plasma, freezing is used for subsequent analysis and detection specificity protein.The PAXgene test tube is remained in room temperature, extract RNA then.With standard format record clinical sign.

The test kit of Qiagen Inc (Valencia, CA, the U.S.) be equipped with the 2.5mL blood of collection PAXgene blood rna test tube (PAXgene Blood RNA Tube) with reagent that separates total RNA and working instructions.Separation begins to precipitate nucleic acid the PAXgene blood rna test tube from centrifugation step.Washing precipitate, resuspended, cultivate with digesting protein with the optimization damping fluid that contains Proteinase K.Recentrifuge is removed residual cell debris, and supernatant liquor is transferred in the fresh micro-centrifuge tube.Add ethanol and regulate, lysate is put on PAXgene RNA spin (spin) post in conjunction with condition.During simple centrifugal, RNA optionally combines with pellosil, and pollutent flows out.Remove residual pollutent through three effective washing steps, use buffer B R5 eluted rna then.

Need before the test with absorbancy 260/280 ratio quantitatively and qualitative test RNA with Agilent biological analyser and spectrophotometer.

DNA extraction

(Valencia, CA, test kit USA) are equipped with the PAXgene blood DNA test tube (PAXgene Blood DNA Tube) and reagent that separates total DNA and working instructions of the 8.5ml blood of collection to Qiagen Inc.It is centrifugal then that separation begins to add extra cracked solution.Washing precipitate, resuspended is cultivated with digesting protein with the optimization damping fluid that contains Proteinase K.Ethanol sedimentation DNA, centrifugal again primary sedimentation nucleic acid.Residual contaminants is removed in washing, then DNA is resuspended among the buffer B G4.

Need before the test quantitatively and qualitative test DNA with spectrophotometer or agarose gel electrophoresis.

Serum antibody is measured

Basically as Foote etc., (Equine Vet J., 36 (4): 341-345,2004) are described, measure the serum antibody level of EHV-1 by ELISA with reorganization EHV-1 glycoprotein G.Total RNA extracts.

Produce gene expression data

Method is selected

Can adopt the specific RNA level in the various technology for detection tissue samples.Two kinds of routines well known in the art and wieldy technology are:

Adopt the Affymetrix technology to make GeneChip ^TMAnalyze;

Real-time polymerase chain reaction (for example, the TaqMan of Applied Biosystems ^TM).

GeneChips ^TMCome quantitative assay RNA by detecting with the mark cRNA that is structured in the short oligonucleotide hybridization on the silicon substrate.This technology and method see www.affymetrix.com for details.

Real-time polymerase chain reaction (RT-PCR) utilizes the probe of two kinds of PCR primers, mark and heat-stable DNA polymerase to come quantitative assay RNA.The color that the PCR product produces is released into solution, detects this color.Internal contrast commonly used, for example original level of total RNA in the 18S rna probe working sample.Measure each gene and internal contrast respectively.This technology and method see www.appliedbiosytems.com or www.qiagen.com or www.biorad..com for details.AppliedBiosystems provides following service: promptly the client provides dna sequence dna information and negative expense, provides as feedback the said firm each gene is carried out the required whole reagent of RT-PCR.

GeneChip ^TMThe advantage of analyzing is once can analyze thousands of genes.Yet this analysis is expensive and carry out a test and take more than 3 days.RT-PCR generally once can only analyze a kind of gene, but cheap and can finish in one day.

If concrete number gene to be analyzed is less than 20, then RT-PCR is optional gene expression analysis method.When needs are analyzed many genes simultaneously, GeneChip ^TMOr other gene expression analysis technology (for example Illumina pearl array) is optional method.

Be used for producing and analyzing GeneChip ^TMThe method and the PCR in real time of data are summarized in hereinafter.

Produce GeneChip ^TMData

Preparation cDNA and cRNA

Prepare the method that the following method of cDNA and cRNA adopts Affymetrix (www.affymetrix.com) to provide and recommend from total RNA.

Step is:

● total RNA of 3 μ g is as the double-stranded cDNA of template for preparing altogether.

● preparation cRNA also marks with biotinylation uridylic (dUTP).

● the cRNA that purifying (clean) vitamin H is marked, utilize spectrophotometer and the quantitative assay of MOPS gel analysis.

● the cRNA fragment of marking is turned to about 300bp size.

● utilize Agilent " Lab-on-a-Chip " system (Agilent Technologies) to measure rna content.

Hybridization, washing and dyeing

Step is:

● preparation contains 0.05 μ g/ μ L marks and the cRNA of fragmentation, the hybridization mixture that doping (spike-in) positive is hybridized contrast and Affymetrix oligonucleotide B2, bioB, bioC, bioD and cre.

● the hybridization mixture of final volume (80 μ L) is added GeneChip ^TMIn the medicine box.

● this medicine box is placed the hybrid heater of constant rotational speed, 16 hours.

● remove GeneChip ^TMIn liquid and preserve.

● with GeneChip ^TMPlace the fluid station.

● with each GeneChip ^TMExperiment condition be recorded as the .EXP file.

● after the helpmate added suitable solution, all washings and dyeing course were carried out in Affymetrix fluid station.

● washing GeneChip ^TM,, wash once more with low salts solution then with Streptavidin-phycoerythrin dyeing.

● after washing is finished, " excite " dyestuff on the probe array, pass through CCD camera image with Affymetrix scanner (Agilent manufacturing) with laser.

Scanning and generation data file

Scanner and MAS 5 softwares produce a GeneChip ^TMImage file, be called .DAT file (referring to the figure at the back side).

Carry out statistical analysis behind the pre-treatment .DAT file.

The pre-treatment step of data (before any statistical analysis) comprising:

● the quality control of .DAT file (QC).

● produce the .CEL file.

● demarcate (scaling) and stdn.

.DAT the quality control of file

.DAT file is a kind of image.The manual human factor (artifact) (for example, high/low intensity spot, cut, high local background or total background) of checking these images.(by changing intensity mode that produces the border and the cross performance that the array title is not difficult to identify the B2 oligonucleotide arrays).Thereby MAS 5 softwares utilize B2 oligonucleotide border to come grid on the comparison chart picture can concentrate and identify the oligonucleotide of each grid.

Utilize other doping (spiked) hybridization contrast (bioB, bioC, bioD and cre) by reading the hybridization efficiency of assessing sample with " basis " gene test introducing sub-routine of their relative concentrations of increase reflection of signal value.(if the .DAT file has suitable quality, is translated into intensity data file (.CEL file) with Affymetrix MAS 5 softwares).

Produce the .CEL file

The .CEL file that produces from the .DAT file with MAS 5 softwares comprises the green strength that this probe groups is calculated.The background value that deduction calculates from each cell (mensuration) value obtains gene expression data.For removing negative intensity level, used noise compensation fraction based on the local noise value of the standard deviation of minimum 2% background value.

With GeneChip ^TMAll .CEL file applications that produce are in specific quality metric canonical parameter.

Some modules are recommended by Affymetrix is conventional, can be used as GeneChip ^TMA part and the Affymetrix internal contrast that provides is measured.Other module rule of thumb with many GeneChip ^TMProcessing and decide.

Analyze GeneChip ^TMData

Three kinds of exemplary method that can be used for data normalization are:

● Affymetrix MAS 5 algorithms.

● the reliable multicore sheet of Irizarry is analyzed (Robust Multi-chip Analysis) (RMA) algorithm (Irizarray etc., 2002, Biostatistics (in the printing)).

● reliable multicore sheet is analyzed reserving model (Robust Multi-chip Analysis Saved model) (RMAS)

Those skilled in the art should know and can adopt many other methods and can materially affect not arranged to the present invention.

Affymetrix MAS 5 algorithms

Affymetrix MAS 5 softwares utilize the .CEL file to come stdn or nominal data.The nominal data of chip piece is made comparisons to the similar nominal data of another chip.

Acquiescence " whole world calibration (Global Scaling) " option to .CEL file applications MAS 5 algorithms is realized Affymetrix MAS 5 stdn.This method has been deducted the reliable estimated value of probe value distribution center, again divided by the variable reliable estimated value of probe.This has produced a core assembly sheet that has common location and demarcation in the probe level.

By all probes reliable equalization method is obtained gene expression index to certain given gene.The result is forced to non-feminine gender.

In view of being demarcates in the probe level rather than at gene level, so even overall gene expression dose also may there are differences between chip after the stdn.After standard MAS 5 stdn, make each genic value go trend (de-trend) according to chip intensity intermediate value.That is, each genic value returns according to chip intensity intermediate value, calculates residual error.Get these residual errors and go the estimated value of trend as each genetic expression.

With Affymetrix MAS5 arithmetic calculation chip median intensity, but calibration factor fixedly is one.

RMA analyzes

Except setting up probe weight and target fractile (quantile) with the long-term library of chip.cel file and not to these specificity chips again outside the double counting, this method is identical with the RMA method.The probe level is carried out stdn once more.

Produce the PCR in real time data

(2000, J Mol Endocrinol can obtain to carry out the background information of PCR in real time in 25:169-193) in the summary of for example http://dorakmt.tripod.com/genetics/realtime.html and Bustin SA.

TaqMan ^TMPrimer and probe design guide:

1.Primer Express ^TM(ABI) software design melting temperature(Tm) (Tm) be probe more than 10 ℃ for 58-60 ℃ primer and Tm value.The Tm of two kinds of primers should be identical;

2. primer should a long 15-30 base;

3.G+C the preferred 30-80% of content.Can't avoid if G+C content is higher, then need to adopt high annealing and melting temperature(Tm), use cosolvent, for example glycerine, DMSO or 7-denitrogenation are mixed-dGTP;

4. should avoid the identical Nucleotide of bunchiness.This is even more important for G, and the G string more than 4 cannot be arranged;

5. the sum of G and C should be no more than 2 (this software of more recent version has the option that automatically performs this function) in last 5 Nucleotide of primer 3 ' end.Thereby this helps to reduce non-specific sensitization in 3 ' the terminal relative instability of introducing of primer.The primer condition is identical with SYBR Green test;

6. the length of maximum amplicon should not surpass 400 bp (preferred 50-150 base).Less amplicon can obtain more consistent result because PCR is more effective and reaction conditions more tolerated require the short function of length irrelevant with 5 ' nuclease);

7. this probe should not contain the identical Nucleotide (the particularly continuous G more than 4) of bunchiness, and G+C content should be 30-80%, and C should be more than G, and 5 ' end should not be G.The quantity of C is many more, and the Δ Rn of generation is high more.Should select probe earlier;

8. be the false positive due to the contaminative genomic dna in the cDNA preparation of having avoided gene-amplification, primer should be crossed over exon-exon joining region.So can amplifying genom DNA (the PDAR test kit that is used for people GAPDH amplification is equipped with this primer);

9. if design TaqMan ^TMProbe is distinguished allelotrope, and the Nucleotide of mispairing (pleomorphism site) should be at probe centre rather than two ends;

10. can utilize near the primer that contains dA Nucleotide the 3 ' end to pass through AmpErase ^TMDegrade effectively (see EZ RT-PCR test kit handbook the 9th page of any primer dimer of being produced of UNG; P/N 402877).If can not be chosen near the primer that contains dA Nucleotide two ends, then should consider to utilize primer with 3 ' terminal dU-Nucleotide.

(also can referring to the general principle of " PCR design of primers " (PCR Primer Design) of Invitrogen).

Universal method:

1. (not containing oligomerization-dT) is cDNA with total RNA reverse transcription with random hexamer.With oligomerization-dT, then should avoid the upstream that two kilobase above long mRNA transcript or amplicon are arranged if having to, 18S RNA can not be used as standard substance;

2. multiplex PCR only has in limited time at the contrast primer and can correctly carry out (primer that the ABI contrast agents does not limit them);

3. target cDNA amount ranges is 10ng-1g.If with DNA (being mainly used in the allelotrope Study on Identification), optimum amount is 100ng-1g;

4. the most handy DNA enzyme that does not contain the RNA enzyme is handled each RNA goods and is polluted to avoid genomic dna.Even best RNA extracting method also can produce some genomic dnas.Certainly the not primer of amplifying genom DNA is preferably arranged, but this does not accomplish sometimes;

5. for obtaining optimum, reagent (before preparation PCR mixture) and PCR mixture itself (before the application of sample) should fully vibrate (vortex) with mix.Otherwise the Rn value may have drift in the early stage round (0-5) of PCR.Earlier probe is added the damping fluid component make its at room temperature balance the reagent preparation mixture is also very important again.

TaqMan ^TMPrimer and probe:

Order TaqMan from ABI medium-scale (midi-scale) ^TMIt when probe is received the suspension of 100 μ M.If prepare 1/20 diluent, then obtain 5 μ M solution.This stock solution should be divided into equal portions, freezing, black out preservation.Its consumption is the 100nM final concentration that 1 μ L obtains recommending in 50 μ L reaction volumes.

Be freeze dried when primer is received, content is marked on (for example 150.000pmol equals 150nmol) on the test tube with pmol.If the primer of X nmol is resuspended in the X μ L water, the solution that obtains is 1mM.It is freezing preferably this storing solution to be divided into equal portions.When the 1mM storing solution was diluted 100 times, the working solution that obtains was 10 μ M.For making the 50-900nM of final primer concentration for recommending in the 50 μ L reaction volumes, 0.25-4.50 μ L (500nM final concentration with 2.5 μ L) is used in each reaction.

PDAR primer and probe provide to be stored in a mixture in the test tube.Their consumptions in 50 μ L reaction volumes are 2.5 μ L.

One step TaqMan is set ^TMReaction:

One step PCR in real time is used as template with RNA (opposite with cDNA).Preferred this method if the RNA strength of solution is low, but only when carrying out the substance reaction.Shortcoming is that the RNA hangover makes enzyme AmpErase can not be used for single step reaction.In this method, reverse transcription and PCR in real time occur in the same test tube.The downstream PCR primer also is used as the primer (random hexamer or oligomerization-dT can not be used for the reverse transcription of an one step RT-PCR) of reversed transcriptive enzyme.Single step reaction needs higher dNTP concentration (more than or equal to 300mM and 200mM), because this reaction has merged a kind of of two kinds of reactions needing dNTP.It is as follows that one of Gold RT-PCR test kit goes on foot the used type reaction mixture of PCR:

Reagent	Volume
Reagent	Volume	H ₂O+RNA:10X TaqMan damping fluid: MgCl ₂(25mM): dATP (10mM): dCTP (10mM): dGTP (10mM): dUTP (20mM): primers F (10 μ M) ^: primer R (10 μ M) ^: the TaqMan probe ^*: AmpliTaq Gold: reversed transcriptive enzyme: RNA enzyme inhibitors:	20.5 μ L[24 μ L is if use PDAR] 5.0 μ L, 11.0 μ L, 1.5 μ L[final concentrations are 300 μ M] 1.5 μ L[final concentrations are 300 μ M] 1.5 μ L[final concentrations are 300 μ M] 1.5 μ L[final concentrations are 600 μ M] 2.5 μ L[final concentrations are 500nM] 2.5 μ L[final concentrations are 500nM] 1.0 μ L[final concentrations are 100nM] 0.25 μ L[can increase to obtain higher efficient] 0.25 μ L, 1.00 μ L

If use PDAR, then use primer+probe mixture of 2.5 μ L.

10pg-100ng RNA is preferably used in this reaction.Attention is reduced to 50ng with the template consumption from 100ng will make the CT value increase by 1.For making the CT value reduce by 3, initial template consumption should increase by 8 times.ABI declares that this system can detect the RNA of 2 piks, and the maximum consumption of RNA can be 1 microgram.For carrying out routine analysis, the RNA of available 10pg-100ng and 100pg-1 μ g genomic dna.

The loop parameter of one step PCR:

Reverse transcription (MuLV), 48 ℃ 30 minutes.

AmpliTaq activation, 95 ℃ 10 minutes.

PCR:95 ℃ of sex change 15 seconds, 1 minute (repeating 40 times) (on ABI 7700, the minimal maintenance time is 15 seconds) of 60 ℃ of annealing/extensions.

The EZ one-step of up-to-date introduction ^TMThe RT-PCR test kit can utilize UNG, because utilized the thermostability reversed transcriptive enzyme to make that the cultivation time of reverse transcription is 60 ℃.This temperature also is the better selection of avoiding in 48 ℃ of formation primer dimers and non-specific binding.

Operation A BI 7700:

Should confirm following item before bringing into operation:

1. Yun Hang loop parameter is correct;

2. the selection of spectrally compensating correct (off is selected in the substance reaction, and multiple reaction selects on);

3.Analysis " Number of PCR Stages (the PCR stage numbers) " among the Options box (analysis option frame) (Analysis (analysis)/Options (option)) selects correct.If do not have data among the amplification figure, but in orthographic plan as seen, and the X-axle indication range 0-1 wheel of amplification (figure), then manually setting this (parameter) after operation once.

4. template contrasts (Template Control) mark (being accurate calculation Δ Rn) like this;

5. should correctly select dye component before the data analysis;

6. you must entitle (can not keep unnamed) before the operation beginning and preserve;

7. when end of run, preserve data earlier and begin again to analyze;

It is extremely careful that (use) ABI software needs.Press down do not attempt behind Run (operation) button out of service.You have problem and if desired during the switch machine, must grade just can restart operation at least 1 hour.

When analytical data, remember that the baseline setting of giving tacit consent to is 3-15.If any CT value＜15 should change baseline (baseline stop to be worth should than the little 1-2 of CT value of minimum) thereupon." ABI baseline and threshold value are provided with guide " (ABI Tutorial on Setting Baselines andThresholds) seen in the useful discussion of this problem.(interesting is that TaqMan is seen in the best discussion of this problem ^TMIn the handbook of human endogenous control board (Human Endogenous Control Plate)).

If the result is nonsensical, check that original spectrum sees that run duration CDC photographic camera (whether) may be saturated.Utilize optical cover (optical cap) rather than optics viscosity cover (optical adhesive cover) can prevent that the CDC photographic camera is saturated.When utilizing SYBR Green I, multiple (reaction) and higher concentration probes, (the CDC photographic camera is saturated) more may take place.

The result resolves:

When each reaction finished, the fluorescence intensity that is write down was used for following calculating:

Rn ⁺It is the Rn value of reacting when containing all components; Rn-is the Rn value (value that detects among baseline value or the NTC) of unreacted sample.Δ Rn is Rn ⁺And the difference between the Rn-.It is the number of signals magnitude index that PCR produces.

Quantitative assay template content has three kinds of exemplary method:

1. absolute standard method: in this method, with the known standard substance of content, for example in vitro translated RNA (cRNA).

2. relative standard's method: the target nucleic acid that comprises known quantity in the test design of each run;

3. comparative CT method: this method is without the known standard substance of content, but the relative quantity of target sequence and any reference value of selection are made comparisons, the amount that the result provides with respect to reference value (for example expression level of tranquillization lymphocyte or standard cell lines system).

The comparative CT method (Δ Δ CT) that the genetic expression relative quantification is measured:

This method need not production standard curve quantitative assay template relatively and improves quantity of sample handling when the expression level of observing with respect to active reference contrast (standard substance).Be successful implementation this method, should make the dynamicrange of target and reference substance similar.The sensitive method of controlling this (dynamicrange) is to observe Δ C _THow (same starting template consumption is made the difference between two CT values of twice PCR gained) change with the extent of dilution of template.If the efficient of two kinds of amplicons about equally, with the logarithm and the Δ C of input _TMapping obtains the line (slope＜0.10) near level.It is identical that this is illustrated in the twice PCR efficient of carrying out in the starting template amount ranges.If this figure display efficiency is unequal, should adopt the typical curve method to come quantitative measurement of gene expression.Should measure the accurate minimum of (1) target result's accurate minimum and maximum concentration and (2) two kinds of gene content results and the dynamicrange of the two the most at high proportion.In conventional competitive RT-PCR, this dynamicrange is limited in target-competition thing ratio and is about 10: 1-1: 10 (1: 1 ratio can obtain best accuracy).PCR in real time can realize dynamicrange widely.

Amplification target and endogenous contrast in different test tubes adopt the typical curve method to need hardly to optimize and checking.Adopt the advantage of comparative CT method to be need not production standard curve (sample can utilize more hole).The negative impact of issuable any dilution error when this method has also been eliminated production standard curve sample.

As long as target has similar dynamicrange with standard substance, comparative CT method (Δ Δ CT method) is the most practical method.Estimate the expression level height (therefore, CT value lower) of standard substance than target.Begin quantitative Analysis from the difference (Δ CT) between the CT value that obtains target and standard substance:

Δ CT=CT (target)-CT (standard substance)

This value of quantitative each sample is treated in calculating, and (unless the expression level of target is higher than standard substance, this value should positive value.If feminine gender is also harmless).Relatively should select one of these samples as reference product (baseline) at every turn.Comparative Δ Δ CT calculates and comprises the difference that finds between each sample Δ CT and the baseline Δ CT.If baseline value is represented minimum expression level, estimate that then Δ Δ CT value is negative (because the Δ CT of baseline sample has maximum CT value but maximum because of it).Increase if express in some samples, and reduce in other, Δ Δ CT value will be the mixed number of negative and positive numerical value.The final step of quantitative assay is that these numerical value are converted into absolute value.This calculation formula is:

Comparative expression level=2-Δ Δ CT

With regard to expression, compare with baseline values, (sample) increases about 23=8 doubly, and reduces the 2-3=1/8 that is about the reference product level.By import simply the CT value with the Excel of Microsoft carry out these calculating (ABI at http://www.appliedbiosystems.com/support/tutorials/7700amp/ relevant for utilizing extension layer program (spread sheet program) to produce the online guide of amplification figure; TaqMan ^TMHuman endogenous control board (Human Endogenous Control Plate) method also comprises the relevant detailed description of carrying out the PCR in real time data analysis with MSExcel).

Is other (definitely) quantivative approach summarized in ABI user's bulletin (http://docs.appliedbiosystems.com/search.taf? _ UserReference=A8658327189850A13A0C598E).Bulletin #2 and #5 are to complete understanding PCR in real time and quantitatively the most useful.

Recommend method:

1. utilize normotopia displacement liquid pipe (positive-displacement pipette) to avoid moving the liquid out of true;

2. the sensitivity of PCR in real time can detect the target among the total RNA of 2pg.The copy number that reacts used total RNA preferably should promptly be enough to produce signal (preferably being lower than 100ng) by the 25-30 wheel.For realizing that this purpose should reduce or increase consumption;

3. the optimum concn of each reagent is as follows;

I. the concentration of magnesium chloride should be 4-7mM.For the primer/probe the best with Primer Express software (primer expression software) design is 5.5mM;

Ii. except that dUTP (if you are using), the concentration of each dNTP is answered balance.Replace the dTTP twice that to control the residual dUTP of the needs concentration of PCR product be other dNTP with dUTP.Though the optimum range of dNTP concentration is 500 μ M-1mM (one step RT-PCRs), the various dNTP of typical TaqMan reaction (just PCR) adopt 200 μ M (dUTP of 400 μ M);

Iii. in per 50 μ L reactants, add 0.25 μ L (1.25 U) AmpliTaq archaeal dna polymerase (5.0U/ μ L) usually.This is minimum requirements.If desired, this amount can be increased 0.25U and reach optimum;

Iv. best concentration and probe concentration is 50-200nM, and primer concentration is 100-900nM, tackle three kinds of differing tempss (TaqMan primer 58,60 and 62 ℃) and three kinds of concentration (50,300,900nM) various Combinatorial Optimizations each to primer.This means to be provided with different three groups (three kinds of temperature), every group is utilized the target template of fixed amount that nine kinds of reactions (50/50mM, 50/300mM, 50/900,300/50,300/300,300/900,900/50,900/300,900/900mM) are arranged.If desired, can (carry out) second takes turns to optimize and improves the result.Selection can provide the primer concentration of minimum CT and the highest Δ Rn to realize optimum performance.Similarly, concentration and probe concentration should be optimized for 25-225nM;

4. if with AmpliTaq Gold archaeal dna polymerase, need be for realizing this purpose in 92-95 ℃ of heating 9-12 minute before PCR.If with AmpliTaq Gold archaeal dna polymerase, need be in reaction on ice.Typical TaqMan reaction comprises that 50 ℃ of UNG (vide infra) cultivated 2 minutes; 95 ℃ of activated polymerization enzymes 10 minutes; Take turns and 60 ℃ 1 minute (annealing and extension) with 95 ℃ of (sex change) 40 in 15 seconds.If parent material is total RNA, before the TaqMan reaction, should carry out the reverse transcription circulation usually, this circulation (cDNA synthetic) is by 25 ℃ 10 minutes (primer cultivations), 48 ℃ 30 minutes (carrying out reverse transcription with conventional reversed transcriptive enzyme) and 95 ℃ 5 minutes (deactivation reversed transcriptive enzyme);

5. in this reaction, add AmpErase uridylic-N-glycosylase (UNG) and remove any uridylic of mixing in the amplicon in case residual PCR product increases again.This is a reason of using dUTP rather than dTTP in the PCR reaction why.UNG does not cut the single stranded DNA that contains terminal dU Nucleotide inoperative more than 55 ℃.Unless reverse transcription and PCR adopt the rTth archaeal dna polymerase, an one step RT-PCR should not use the main mixture (TaqMan EZ RT-PCR test kit) that contains UNG;

6. must comprise in every deblocking reaction flat board at least three parts of non-amplifications contrasts (NAC) and three parts of non-template contrasts (NTC) (for the target amplification of determining+/-reach 99.7% confidence level in the threshold value, must carry out sextuplicate NTC).The NAC model contains sample, does not contain enzyme.Need to get rid of in the sample or the existing of fluorescence pollutent (these pollutents can cause false positive) in the heat block (heating block) of thermal cycler.If may there be the fluorescence pollutent greater than NTC in the absolute fluorescence of NAC in the sample or in the heat block of thermal cycler behind the PCR.

7. if Δ Δ CT method is used for relative quantification measures, should verify the dynamicrange of primer/probe system and standard substance thereof.Realize this verification by carry out (in triplicate) reaction with 5 kinds of RNA concentration (for example, 0.80pg/ μ L, 400pg/ μ L, 2ng/ μ L and 50ng/ μ L).For identical total rna concentration scope, logarithm and the CT value mapping (typical curve) of carrying out the initial content that the real-time RT-PCR of target and standard substance obtains should be (approaching) straight lines;

8. passive reference substance is the dyestuff (ROX) (being present in the TaqMan universal PC R master mixture) that adds in the reaction.It does not participate in the reaction of 5 ' nuclease.It provides the inside reference substance of background emission fluorescence.Available its comes stdn acceptor-dye signal.To (concentration or volume difference) between the Kong Yukong or the non-PCR fluorescence associated fluctuation that change to take place in time carry out this stdn, be different from the stdn that cDNA consumption or PCR efficient are carried out.The emitted luminescence intensity of report dyestuff is carried out stdn divided by the emitted luminescence intensity of passive reference substance.The ratio that obtains is defined as Rn;

9. if carry out multiple (reaction), abundanter target will exhaust all reacted constituents before other target is increased.For avoiding this kind situation, should limit the concentration of its primer to abundanter target material;

10.TaqMan universal PC R master mixture should be stored in 2-8 ℃ (not being-20 ℃);

11., use VIC mark Pre-Developed TaqMan with the GAPDH probe that JOE report dye marker TaqMan Gold RT-PCR test kit provides ^TMThe same probe that Assay Reagents (PDAR) test kit provides.The primer of these people GAPDH test of design can amplifying genom DNA;

12. residual for preventing enzyme, need an one step RT-PCR method of 48 ℃ of cultivations can not utilize AmpErase UNG, but available in the EZ RT-PCR test kit;

13. substance reaction can only be with an one step RT-PCR method, it (is not random hexamer or oligomerization-dT) that the reverse transcription method can only be selected downstream primer;

Control and move the liquid error 14. preferably carry out duplicate (reaction), but this unavoidably can increase cost;

15. if, before operation, should verify spectrally compensating option (in AdvancedOptions (Advanced Options)) carry out multiple (reaction);

16. utilizing the passive reference substance (ROX) in the reaction is diverse ways with fluorescence fluctuation (value) stdn with endogenous contrast (for example GAPDH, active reference substance) with the efficiency standardization of cDNA/PCR consumption;

7700 also can be used for terminal point PCR 17.ABI not only can be used for quantitative RT-PCR.The latter comprises existence/do not exist test or allelotrope telling test (for example SNP somatotype);

18.PCR former wheel the (0-5 wheel) in the Rn value drift to represent to react all components uneven at first, but do not influence net result, as long as reset the lower value of baseline scope;

19. if notice amplification figure unusual (CT value＜15 detect the round of amplified signal in former the wheel), should reduce the higher limit of baseline scope, answer dilute sample to improve CT value (pollution also may improve the CT value);

20. Δ Rn value low the CT value of expectation (or be higher than) shows that PCR efficient copy number not good or target is low;

21.CT showing, the standard deviation of value＞0.16 moves the liquid out of true;

22. the color green clauses and subclauses of SYBR (SYBR Greenentry) that are provided with in (Pure Dye Setup) of pure color are abbreviated as " SYBR " with capitalization.Any other abbreviation or lowercase can have problems;

23.ABI having with 8.1 editions Macintosh operating system, 7700 SDS software conflicts.Should be on this computer analytical data.

24.ABI 7700 do not answer Long-time Shut-down.If it is closed, before operation, answer preheating at least 1 hour.Recommendation is being driven instrument at any time, and this is useful to laser.If just start shooting before the operation, the frame of makeing mistakes of display operation system version conflict may appear.If this situation takes place, select " AutoDownload (downloading automatically) " option.

25.ABI a kind of in 7700 real-time PCR systems that just can buy, other comprises the system of BioRad, Cepheid, Corbett Research, Roche and Stratagene.

Gene type assay

Many methods can be used for the genotype of analyzing DNA.The summary of allelotrope discrimination method is seen (Biotechniques, 30 (2): 318-322, (2001)) such as Kristensen.This paper has only described a kind of method, allele-specific PCR method.

Design of primers

Can utilize the computer program that arbitrarily obtains, for example Primer3 (http://frodo.wi.mit.edu/primer3/primer3_code.html) designs concrete allelic specificity upstream and downstream PCR primer.Perhaps, can utilize such as ClustalW (http://www.ebi.ac.uk/clustalw/) program with at there being dna sequence dna difference but keep enough specificitys and the Auele Specific Primer of the zone design of the correct amplicon of guaranteeing to increase is compared each allelic dna sequence dna.Pcr amplification of preferred design has restriction enzyme site in an allelotrope, and does not have in other allelotrope.Long usually 18-25 the base pair of primer has similar melting temperature(Tm).

Pcr amplification

The description that PCR reaction is formed be seen everywhere (" clinical application of PCR " (ClinicalApplications of PCR), Dennis Lo (volume), Blackwell Publishing, 1998).In brief, this reaction contains primer, DNA, damping fluid and thermostability polysaccharase.Be reflected at thermal cycler, for example on the PTC-96V type MJ Research thermal cycler, the temperature step of extending by sex change, hybridization and DNA circulate (maximum 50 times).

DNA analysis

Can in all sorts of ways, comprise that carrying out molecular size with mass spectrum, capillary gel electrophoresis and agarose gel electrophoresis differentiates and analyze the PCR product.If pcr amplification of design contains different restriction enzyme sites, the DNA in available DNA-column or the deposition and purification PCR reaction, water is resuspended, carries out restricted cutting with suitable Restriction Enzyme then.DNA with restricted cutting makes agarose gel electrophoresis then, utilizes electric current that DNA is carried out size separation.Whether the various allelotrope bases of certain gene contain restriction site has different sizes.

Embodiment 2

The priority ordering of identification diagnosis marker gene and these genes

Just organize with regard to 1, according to the empirical Bayes method of Lonnstedt and Speed (Lonnstedt and Speed, 2002, Statistica Sinica, 12:31-46) analyzing animal is in the difference that infects genetic expression before and after the EHV.Time point is analyzed before relatively infecting each time point of back and infecting.Utilize the multiple term of each animal effect, clinical state (infecting before and after the EHV) term fits to general linear model according to each gene.Back time property difference (posterior odds) according to all genes differential expression between each clinical state group sorts to them.Only write down those genes that statistics significantly changes (rule of thumb property Bayes dwindle standard deviation (shrunken standard deviation) add up with t assess).Utilize the Holm of p value to proofread and correct (Holm, S., 1979, Scandinavian Journal of Statistics 6:65-70) keeps the strong control of 1 type specific inaccuracy.Before and after metainfective every day EHV being infected, show that the statistics gene that there were significant differences is tabulating.

In addition, clinical affected animal (clinical sign that confirmation has EHV to infect) is made comparisons with healthy animal; To regard animal with " reactivity virus infection " and healthy animal (animal of " reactivity virus infection " be usually included in known EHV metainfective about 7 day period) as makes comparisons and analyzes.

Table 5 has shown at these analyzes the gene of back according to p value ordering significant difference.This analyzes once more and compares according to proofreaied and correct the p value through the Holm method two groups." effect size (effectsize) " in these forms (M) represents logarithmic value, shows the multiple that genetic expression compared with the control changes.The negative value representative is reduced and is raised on the occasion of representative.The t statistics is a meaningful value as herein described with the p value.B statistics is a time property logarithm difference (Bayesian posterior log odds of differentialexpression) behind the differentially expressed Bayesian.

Table 6 has shown at these analyzes the gene of back according to T value ordering significant difference.Mark shows which kind of gene raises and which kind of gene downward modulation (negative or positive " difference " and t value), and " difference " shows the amplitude of reaction.This analyzes once more and compares according to proofread and correct the p value through the Holm method two groups.

Embodiment 3

Proof has the diagnosis potentiality to measuring herpesvirus infection

Main ingredient scoring (Jolliffe according to genetic expression calculating, I.T., " main ingredient analysis " (Principal components analysis), Springer-Verlag, 1986) adopt discrimination analysis (Venables and Ripley, 2002, " modern Application of statistics in S " (Modern AppliedStatistics in S) Springer) assessed the diagnosis potentiality of whole group of gene of each time point after the infection.Entire method is through cross validation.Each removal (drop) animal carries out cross validation (rather than once observing).Sensitivity and specificity are priority (uniform prior) as calculated.This may be interpreted as a kind of adjusting of dwindling of form, and these estimated values are narrowed down in the scope (reduced space) that reduces.

Utilize the other function score of debating of cross validation (discriminant function scores) to estimate the receptor operating curve.Crucial threshold value moved along the axle of discriminant function scoring calculate the receptor operating curve.Calculate two kinds of original inspectability ROC, and the method smoothing ROC of employing Lloyd (Lloyd C.J., 1998, Journal of the American Statistical Association, 93:1356-1364).The curve that calculates is used for the comparison of clinical feminine gender and clinical positive animal.Different curves were calculated in the genetic expression of every day after utilization was infected.Adopt trapezoidal rule, calculate area under the receptor operating curve, be applied to the ROC of empirical ROC and smoothing.

Available ROC sums up the diagnosis potentiality of certain test.Perfectly the ROC of diagnostic test is a sea line that is equal to 1 point by sensitivity and specificity.Area is 1 under the ROC of this perfect diagnosis (test).The ROC of useless diagnostic test is 45 degree lines by initial point.The area of this no information diagnosis (test) is 0.5.

Table 8 has shown area under sensitivity, selectivity and the ROC that organizes the sample of obtaining in the 2nd, 4,13 and 20 day 1 each young coltfoal infection back.As can be known from these results, evidence suggests that to infect the 2nd and 4 day the diagnosis potentiality in back strong, and evidence suggests that seldom the diagnosis potentiality were arranged at the 13rd or the 20th day.

In addition, after having symptom and asymptomatic time point corresponding infection the 0th, 13 and 20 day period of back and infect, group 1 young coltfoal makes comparisons between the 2nd, 4 and 6 day.Fig. 1 shows the ROC that is used for comparison.ROC sensitivity and specificity relatively is respectively 1 and 0.867.Experience is respectively 0.892 and 0.952 with the area of smoothing under the ROC.These (results) are for providing strong evidence corresponding to the otherness genetic expression that has symptom EHV to infect.

In addition, utilize the selected gene of clinical infection animal to obtain ROC curve (Fig. 2).Utilize this check sensitivity and the specificity of genetic expression mark all outstanding.

In addition, utilization has the selected gene of reactivity virus infection animal to obtain ROC curve (Fig. 3).Utilize the sensitivity and the specificity of this check of genetic expression mark all outstanding.

In addition, utilize all genes of clinical infection animal to obtain ROC curve (Fig. 4).Utilize the sensitivity and the specificity of this check of genetic expression mark all good.

In addition, utilization has all genes of reactivity virus infection animal to obtain ROC curve (Fig. 5).Utilize the sensitivity and the specificity of check of genetic expression mark all good.

According to the estimated value of dwindling of whole group gene on the chip, the receptor operating curve of Ji Suaning is guarded in this way, that is, they tend to underestimate the diagnosis potentiality.In the operability diagnosis, should be able to obtain better diagnosis performance according to selected gene subgroup.

Table 7 provided organize 1 young coltfoal the 2nd, 4,6,13 with the hematology and the biological chemistry result that compared with the 0th day in 20 days, the significance,statistical of clinical parameter (heart rate (HR) and respiration rate (RR)) and these parameters.All detected values except PCV (hematocrit cell volume) all have significance,statistical, and these detected value most probables have reflected the associated change of herpesvirus infection.Yet these variations are nonspecific, also may be relevant with many other illnesss.These parameters of organizing 2 young coltfoals do not provide analog result, and they do not have significant difference, though these young coltfoals are subjected to subclinical infection through managing in fact.

Fig. 6 is gene expression index (Log volume unit), serum EHV Ab level (450nm absorbancy), date, the fate (D=days) of group 1 young coltfoal, the figure of clinical sign.Organize 1 young coltfoal in inoculation on March 18th, 2003 (experimental infection).The variation of gene expression index is corresponding with existing of clinical sign, than serum anti--the Zao 10-14 of appearance days of EHV-1 antibody.This may be of practical significance to treatment and control than the Zao 10-14 of antibody test days diagnosis herpesvirus infections during clinical sign occurring especially.For example, present medicine is exactly the most effective during this period, and for many herpesvirus infections, the also during this period tool infectivity of animal.

Fig. 7 comprises that utilization organizes the figure of preceding 4 kinds of main ingredient genetic expressions of 1 young all genes of coltfoal.Each component is mapped according to postvaccinal fate.From these figure obviously as can be known the main variation of genetic expression occur in during behind the inoculation simplexvirus 10 days.During this also corresponding with existing of clinical sign (referring to Fig. 2).

Because group 2 young coltfoals experience uncontrolled natural infection in different time points, be the EHV Infection Status that prediction group 2 young coltfoals are trained to the genetic expression classification (classifier) of each sample in the basis with the data of organizing 1 young coltfoal.This prediction comprises the maximum back time property probability (posterior probability) of prediction and the Discrimination Functions scoring (it is the linear combination of each gene of sample) of prediction.Table 9 has shown the type (EHV infects positive and negative) of prediction and has differentiated scoring.

Utilize serum EHV-1Ab result, determine that 4 young coltfoals (360,364,368 and 369: see Table 9) all may be subjected to natural infection (i.e. preceding 4 days of experiment beginning (the 0th day)) at-4 days.In these animals, clinical sign appearred respectively in young coltfoal 364 and 368 at the 0th and the 2nd day and the 2nd day.Divide time-like when we utilize this genetic method, it should be noted that some day or all 4 days these the young coltfoals between the 0th and the 4th day are determined infected by EHV-1 separately.This shows the diagnosis (index) that this EHV-1 gene expression characteristics can be EHV-1, no matter and whether animal shows clinical sign.Utilize serum EHV-1Ab result, determine that young coltfoal 362 was subjected to natural infection at-1 day, this means should be able to be between the-1 day and the 6th day any moment detect feature.Utilize this gene sorting method, all observed positive findings (meaning " infected ") at the 0th, 2 and 6 day in this young coltfoal.But clinical sign does not appear in this animal.According to serum EHV-1Ab result, young coltfoal 375 is diagnosed infected about the 6th day.Observe positive classification results at the 2nd, 4 and 6 day, but also clinical sign do not occur.Utilize serum EHV-1Ab result, can not determine still that until the 14th day young coltfoal 366 is subjected to natural infection, this means that seropositive conversion will occur in the 27th or 28 day.Should note testing 2 animal at the 21st day all under fire (challenged).Therefore, this young coltfoal was a seronegativity at the 21st day.Except having the slight clinical sign at the 23rd day, young coltfoal 366 does not produce any clinical sign.These results show serum Ab level (humoral immunity) experiment attack in (the 21st day) almost be enough to watch for animals and can not produce the obvious sign of clinical disease.Therefore, when we do not observe any positive findings when using this genetic expression sorting technique experimental postvaccinal period.

Therefore, even be with or without in the presence of the clinical sign (or hematology and biochemical any remarkable change) and all can identifying the early stage natural infection of EHV-1 when group 2 young coltfoals demonstrate the preliminary classification indication that obtains of group 1 young coltfoal.

Embodiment 4

What have estimated performance respectively organizes gene

Though identify about 63 kinds of genes with diagnosis potentiality, common acceptable diagnosis performance only needs the seldom gene of number.

Table 10 shows cross validation classification results, sensitivity and the specificity that obtains according to the linear discriminant analysis that is selected from two kinds of genes in the group with diagnosis potentiality gene.The all of proposition is to produce the gene that maximum prefetch is surveyed the result to gene, and many other gene pairss produce acceptable classification results.Those skilled in the art are not difficult to identify other gene pairs.The right technology of identified gene includes, but is not limited to the forward mutability and selects (Venables W.N. and Ripley B.D., " modern Application of statistics in S " (ModernApplied Statistics in S), the 4th edition, 2002., Springer), best subgroup is selected, oppositely (backward) eliminates (Venables W.N. and Ripley B.D., 2002, the same), progressively (stepwise) selects (Venables W.N. and Ripley B.D., 2002, the same) and variable at random elimination (FigueradoM.A., " adaptability of supervised learning is sparse " (Adaptive Sparseness for SupervisedLearning)).

Table 11 shows that basis is selected from three kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of three kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to three kinds of HVI marker gene selects.

Table 12 shows that basis is selected from four kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of four kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to three kinds of HVI marker gene selects.

Table 13 shows that basis is selected from five kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of five kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to five kinds of HVI marker gene selects.

Table 14 shows that basis is selected from six kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of six kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to six kinds of HVI marker gene selects.

Table 15 shows that basis is selected from seven kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of seven kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to seven kinds of HVI marker gene selects.

Table 16 shows that basis is selected from eight kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of eight kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to eight kinds of HVI marker gene selects.

Table 17 shows that basis is selected from nine kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of nine kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to eight kinds of HVI marker gene selects.

Table 18 shows that basis is selected from ten kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of ten kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to ten kinds of HVI marker gene selects.

Table 19 shows that basis is selected from 20 kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of 20 kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to 20 kinds of HVI marker gene selects.

Table 20 shows that basis is selected from 30 kinds of genes of diagnostic bank and carries out the cross validation classification results that linear discriminant analysis obtains.20 groups of 20 kinds of genes only are provided.Those skilled in the art are not difficult to understand that can make other suitable diagnosis according to 20 kinds of HVI marker gene selects.

Other gene may be introduced noise (decreasing the sensitivity and the specificity of cross validation) by overfitting (over-fitting).

Embodiment 5

Specific confirmation

By only training classification and to surpassing 850 GeneChip according to testing data ^TMThis classification of big gene expression data transporting something containerized row, checked the specificity of described simplexvirus mark.Gene expression results in this database derives from the horse sample of suffering from various diseases and illness, and described disease and illness comprise: the acute and chronic EPM of clinical inductive, herpesvirus infection, degenerative osteoarthritis, stress, the animal and the clinical normal animal of rhodococcus infection, endotoxemia (endotoxaemia), laminitis, stomach ulcer syndrome, training.

Two kinds of classification results have been obtained.The two is according to the reactivity virus infection and comparisons clinical normal horses.The former has utilized GeneChip ^TMOn all genes.The latter has only utilized those listed genes of table 1.The latter's mark can be identified all known EHV-infected animals.Also identify other horses of 25 unknown EHV states, comprise as another clinical trial part be in stress under animal, have the rhodococcus horse and infect sick 5 the young coltfoals that decrease of relevant known lung.

Utilize the genetic marker of this method and 63 kinds of genes, the specificity that detects herpesvirus infection from a group sample more than 850 is 95%, and sensitivity is 100%.

Embodiment 7

Gene ontology

For gene being divided into groups, adopt BLAST algorithm (Altschul, S.F. according to function, metabolic process or cellular component, Gish, W., Miller, W., Myers, E.W. and Lipman, D.J., (1990), " the basic gopher of local sequence alignment " (Basic local alignment search tool), J.Mol.Biol., 215:403-410) gene order and GeneBank database are made comparisons, carry out the retrieval of dna homolog and gene ontology.According to these standards, table 21 has been listed the grouping of these genes.Some situation does not have available information (NA).Also referring to the table 1 of the sequence information that contains each gene.

The content of every piece of patent, patent application and publication that this paper quotes is included this paper in as a reference in full.

Any reference that this paper quoted should not be construed as admits that this reference is that the application can profit " prior art ".

The purpose of entire description is the particular combinations of describing the preferred embodiments of the invention rather than the present invention being limited to a certain embodiment or feature.Those skilled in the art should know in view of this paper content and can make various improvement and change and do not depart from the scope of the present invention the specific embodiments of demonstration.All this improvement will be included in the scope of additional claims with change.

Table 1

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
B1961481.V1.3_AT	No homology	1 ACTGACAGTTGAAACGATCAATGGAATGATCAGCACAAACAGAAAATATTACTGTTACTG 61 TAATATTATGTGATATCCTCTATATCTAAGATATATATTATATATATGATGTAAGATAAG 121 ATATATATTAAATATATAATGTAATATATATTATATAACATGTACTCTCTCTATATATAC 181 ATATGTATCACGTAATGTATATATATAATGTAATATAATATTGCTGTTACTGGAAAGATG 241 ACCGCAAGAAGTTGATTTTTTATCTACCAGAAGTTTTCTTCGCTGTGTTTTAAGTCGGCG 301 ATCTGCTTTGATCGTTTTGTTCGCTTCTGCTGTTTGAGAAGAACGATTGAAAGGAGCCA	SEQ?ID?NO：a)
B1961481.V1.3_AT	No homology		SEQ?ID?NO：a)	WBC026C03_V1.3_AT	Homo sapiens (Homo sapiens) Interferon, rabbit, γ-inducible protein matter 16, mRNA.	1 GCAGAATAGGAGCAAGCCAGCACTAGTCAGCTAACTAAGTGACTCAACCAAGGCCTTTTT 61 TCCTTGTTATCTTTGCAGATACTTCATTTTCTTAGCGTTTCTGGAGATTACAACATCCTG 121 CGGTTCCGTTTCTGGGAACTTTACTGATTTATCTCCCCCCTCACACAAATAAGCATTGAT 181 TCCTGCATTTCTGAAGATCTCAAGATCTGGACTACTGTTGAAAAAATTTCCAGTGAGGCT 241 CACTTATGTCTGTAAAGATGGGAAAAAAATACAAGAACATTGTTCTACTAAAAGGATTAG 301 AGGTCATCAATGATTATCATTTTAGAATGGTTAAGTCCTTACTGAGCAACGATTTAAAAC 361 TTAATTTAAAAATGAGAGAAGAGTATGACAAAATTCAGATTGCTGACTTGATGGAAGAAA 421 AGTTCCGAGGTGATGCTGGTTTGGGCAAACTAATAAAAATTTTCGAAGATATACCAACGC 481 TTGAAGACCTGGCTGAAACTCTTAAAAAAGAAAAGTTAAAAGTAAAAGGACCAGCCCTAT 541 CAAGAAAGAGGAAGAAGGAAGTGGATGCTACTTCACCTGCACCCTCCACAAGCAGCACTG 601 TCAAAACTGAAGGAGCAGAGGCAACTCCTGGAGCTCAGAAAAGAAAAAAATCAACCAAAG 661 AAAAGGCTGGACCCAAAGGGAGTAAGGTGTCCGAGGAACAGACTCAGCCTCCCTCTCCTG 721 CAGGAGCCGGCATGTCCACAGCCATGGGCCGTTCCCCATCTCCCAAGACCTCATTGTCAG 781 CTCCACCCAACACTTCTTCAACTGAGAACCCGAAAACAGTGGCCAAATGTCAGGTAACTC 841 CCAGAAGAAATGTTCTCCAAAAACGCCCAGTGATAGTGAAGGTACTGAGTACAACAAAGC 901 CATTTGAATATGAGACCCCAGAAATGGAGAAAAAAATAATGTTTCATGCTACAGTGGCTA 961 CACAGACACAGTTCTTCCATGTGAAGGTTTTAAACACCAGCTTGAAGGAGAAATTCAATG 1021?GAAAGAAAATCATCATCATATCAGATTATTTGGAATATGATAGTCTCCTAGAGGTCAATG 1081?AAGAATCTACTGTATCTGAAGCTGGTCCTAACCAAACGTTTGAGGTTCCAAATAAAATCA 1141?TCAACAGAGCAAAGGAAACTCTGAAGATTGATATTCTTCACAAACAAGCTTCAGGAAATA 1201?TTGTATATGGGGTATTTATGCTACATAAGAAA?CAGTAAATCAGAAGACCACAATCTACG 1261?AAATTCAGGATGATAGAGGAAAAATGGATGTAGTGGGGACAGGACAATGTCACAATATCC 1321?CCTGTGAAGAAGGAGATAAGCTCCAACTTTTCTGCTTTCGACTTAGAAAAAAGAACCAGA 1381?TGTCAAAACTGATTTCAGAAATGCATAGTTTTATCCAGATAAAGAAAAAAACAAACCCGA 1441?GAAACAATGACCCCAAGAGCATGAAGCTACCCCAGGAACAGAGTCAGCTTCCAAATCCTT 1501?CAGAGGCCAGCACAACCTTCCCTGAGAGCCATCTTCGGACTCCTCAGATGCCACCAACAA 1561?CTCCATCCAGCAGTTTCTTCACCAAGAAAAGTGAAGACACAATCTCCAAAATGAATGACT 1621?TCATGAGGATGCAGATACTGAAGGAAGGGAGTCATTTTCCAGGACCGTTCATGACCAGCA 1681?TAGGCCCAGCTGAGAGCCATCCCCACACTCCTCAGGTGCCACCACCAACCCCATCCAGCA 1741?GTTCCTTAATCAAGAAGAAACCAAGATTGAAGGCTGTACCTAAAGAAGCTTCCAAAGAAG 1801?AGGGTCTACAGACGGACCCCAAAGAAGTGATGGTACTGAAGGCAACAGAACCATTTGCAT 1861?ATGAGCCCAAAGAGCAGAAGAAAATGTTCCATGCCACAGTGGCTACTGAGAGCCAGTTCT 1921?TCCGAGTGAAGGTTTTTGATGTCAGTCTGAAGCAGAAGTTCATCCCAAAGAAAATCATTG 1981?CCATATCAGATTATATTGGCCGCAATGGGTTCCTGGAGGTGTACAGTGCCTCATCTGTGT	SEQ?ID?NO：b)

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2041?CTGATGTTAATGCTGACCGAAAGATGGAGGTCTCAAAAAGACTGATTGCAAATGCAAATG 2101?CAACTCCTAAAATCAATCATCTGTGCTCACAAGCTCCAGGAACATTTGTGAATGGGGTGT 2161?ATGAGGTGCATAAGAAAATAGTGTGGAATGATTTCATATATTATGAAATACAAGATGATA 2221?CAGGGAAGATGGAAGTCATGGTGTATGGACGACTGACCAAAATCAACTGCGAGGAAAGAG 2281?ATAAACTTCAACTCATCTGCTTTGAATTGGCACCGAAAAGTGGGAATACCGGGGAGTTGA 2341?GATCTGTAATTCACAGTTTCATCAAGGTCATCAAGGCCAGGTAAAGCAAGAAAGACATAC 2401?TCAATCCTGATTCAAGTATGGAAACTTCACCAGACTTTTTCTTCTAAAATCTGGATGTCA 2461?TTGACGATAATGTTTATGGAGATAAGGTCTAAGTGCCTAAAAAAATGTACATATACCTGG 2521?TTGAAATACAACACTATACATACACACCACCATATATACTAGCTGTTAATCCTATGGAAT 2581?GGGGTATTGGGAGTGCTTTTTTAATTTTTCATAGTTTTTTTTTAATAAAATGGCATATTT 2641?TGCATCTACAACTTCTATAATTTGAAAAAATAAATAAACATTATCTTTTTTGTGAAAAAA 2701?AAAAAAAAA 1 M G K K Y K N I V L L K G L E V I N D Y 1 ATGGGAAAAAAATACAAGAACATTGTTCTACTAAAAGGATTAGAGGTCATCAATGATTAT 21 H F R M V K S L L S N D L K L N L K M R 61 CATTTTAGAATGGTTAAGTCCTTACTGAGCAACGATTTAAAACTTAATTTAAAAATGAGA 41 E E Y D K I Q I A D L M E E K F R G D A 121 GAAGAGTATGACAAAATTCAGATTGCTGACTTGATGGAAGAAAAGTTCCGAGGTGATGCT 61 G L G K L I K I F E D I P T L E D L A E 181 GGTTTGGGCAAACTAATAAAAATTTTCGAAGATATACCAACGCTTGAAGACCTGGCTGAA 81 T L K K E K L K V K G P A L S R K R K K 241 ACTCTTAAAAAAGAAAAGTTAAAAGTAAAAGGACCAGCCCTATCAAGAAAGAGGAAGAAG 101 E V D A T S P A P S T S S T V K T E G A 301 GAAGTGGATGCTACTTCACCTGCACCCTCCACAAGCAGCACTGTCAAAACTGAAGGAGCA 121 E A T P G A Q K R K K S T K E K A G P K 361 GAGGCAACTCCTGGAGCTCAGAAAAGAAAAAAATCAACCAAAGAAAAGGCTGGACCCAAA 141 G S K V S E E Q T Q P P S P A G A G M S 421 GGGAGTAAGGTGTCCGAGGAACAGACTCAGCCTCCCTCTCCTGCAGGAGCCGGCATGTCC 161 T A M G R S P S P K T S L S A P P N T S 481 ACAGCCATGGGCCGTTCCCCATCTCCCAAGACCTCATTGTCAGCTCCACCCAACACTTCT 181 S T E N P K T V A K C Q V T P R R N V L 541 TCAACTGAGAACCCGAAAACAGTGGCCAAATGTCAGGTAACTCCCAGAAGAAATGTTCTC 201 Q K R P V I V K V L S T T K P F E Y E T 601 CAAAAACGCCCAGTGATAGTGAAGGTACTGAGTACAACAAAGCCATTTGAATATGAGACC 221 P E M E K K I M F H A T V A T Q T Q F F 661 CCAGAAATGGAGAAAAAAATAATGTTTCATGCTACAGTGGCTACACAGACACAGTTCTTC	SEQ?ID?NO：c)

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			241 H V K V L N T S L K E K F N G K K I I I 721 CATGTGAAGGTTTTAAACACCAGCTTGAAGGAGAAATTCAATGGAAAGAAAATCATCATC 261 I S D Y L E Y D S L L E V N E E S T V S 781 ATATCAGATTATTTGGAATATGATAGTCTCCTAGAGGTCAATGAAGAATCTACTGTATCT 281 E A G P N Q T F E V P N K I I N R A K E 841 GAAGCTGGTCCTAACCAAACGTTTGAGGTTCCAAATAAAATCATCAACAGAGCAAAGGAA 301 T L K I D I L H K Q A S G N I V Y G V F 901 ACTCTGAAGATTGATATTCTTCACAAACAAGCTTCAGGAAATATTGTATATGGGGTATTT 321 M L H K K T V N Q K T T I Y E I Q D D R 961 ATGCTACATAAGAAAACAGTAAATCAGAAGACCACAATCTACGAAATTCAGGATGATAGA 341 G K M D V V G T G Q C H N I P C E E G D 1021?GGAAAAATGGATGTAGTGGGGACAGGACAATGTCACAATATCCCCTGTGAAGAAGGAGAT 361 K L Q L F C F R L R K K N Q M S K L I S 1081?AAGCTCCAACTTTTCTGCTTTCGACTTAGAAAAAAGAACCAGATGTCAAAACTGATTTCA 381 E M H S F I Q I K K K T N P R N N D P K 1141?GAAATGCATAGTTTTATCCAGATAAAGAAAAAAACAAACCCGAGAAACAATGACCCCAAG 401 S M K L P Q E Q S Q L P N P S E A S T T 1201?AGCATGAAGCTACCCCAGGAACAGAGTCAGCTTCCAAATCCTTCAGAGGCCAGCACAACC 421 F P E S H L R T P Q M P P T T P S S S F 1261?TTCCCTGAGAGCCATCTTCGGACTCCTCAGATGCCACCAACAACTCCATCCAGCAGTTTC 441 F T K K S E D T I S K M N D F M R M Q I 1321?TTCACCAAGAAAAGTGAAGACACAATCTCCAAAATGAATGACTTCATGAGGATGCAGATA 461 L K E G S H F P G P F M T S I G P A E S 1381?CTGAAGGAAGGGAGTCATTTTCCAGGACCGTTCATGACCAGCATAGGCCCAGCTGAGAGC 481 H P H T P Q V P P P T P S S S S L I K K 1441?CATCCCCACACTCCTCAGGTGCCACCACCAACCCCATCCAGCAGTTCCTTAATCAAGAAG 501 K P R L K A V P K E A S K E E G L Q T D 1501?AAACCAAGATTGAAGGCTGTACCTAAAGAAGCTTCCAAAGAAGAGGGTCTACAGACGGAC 521 P K E V M V L K A T E P F A Y E P K E Q 1561?CCCAAAGAAGTGATGGTACTGAAGGCAACAGAACCATTTGCATATGAGCCCAAAGAGCAG 541 K K M F H A T V A T E S Q F F R V K V F 1621?AAGAAAATGTTCCATGCCACAGTGGCTACTGAGAGCCAGTTCTTCCGAGTGAAGGTTTTT

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	561 D V S L K Q K F I P K K I I A I S D Y I 1681?GATGTCAGTCTGAAGCAGAAGTTCATCCCAAAGAAAATCATTGCCATATCAGATTATATT 581 G R N G F L E V Y S A S S V S D V N A D 1741?GGCCGCAATGGGTTCCTGGAGGTGTACAGTGCCTCATCTGTGTCTGATGTTAATGCTGAC 601 R K M E V S K R L I A N A N A T P K I N 1801?CGAAAGATGGAGGTCTCAAAAAGACTGATTGCAAATGCAAATGCAACTCCTAAAATCAAT 621 H L C S Q A P G T F V N G V Y E V H K K 1861?CATCTGTGCTCACAAGCTCCAGGAACATTTGTGAATGGGGTGTATGAGGTGCATAAGAAA 641 I V W N D F I Y Y E I Q D D T G K M E V 1921?ATAGTGTGGAATGATTTCATATATTATGAAATACAAGATGATACAGGGAAGATGGAAGTC 661 M V Y G R L T K I N C E E R D K L Q L I 1981?ATGGTGTATGGACGACTGACCAAAATCAACTGCGAGGAAAGAGATAAACTTCAACTCATC 681 C F E L A P K S G N T G E L R S V I H S 2041?TGCTTTGAATTGGCACCGAAAAGTGGGAATACCGGGGAGTTGAGATCTGTAATTCACAGT 701 F I K V I K A R - 2101?TTCATCAAGGTCATCAAGGCCAGGTAA
WBC005G04_V1.3_AT	Homo sapiens's myelocyte nuclear differentiation antigen mRNA, code sequence stream fully.	1 ATTGAGAGTGGCTCTAACAAGTGCCATTTTTCCTTGTTAGCTTTCATTTCTCAGCCCTTT 61 ACAAGATTAAAATAGTCTGCAGTTTAATCTCTCCAAAGCTTTACGGACAGTGATTCTGTC 121 CTAAACAAGACAGTGACTCCAGGATTTCTGAAGACTATTGTGGAAGAAGCATCCATTAAG 181 GCCAAGCTATAACATCAGAAATGGTGAATGAATACAAGAAAATTCTTTTGCTGAAAGGAT 241 TTGAGCTCATGGATGATTATCATTTTACATCAATTAAGTCCTTACTGGCCTATGATTTAG 301 GACTAACTACAAAAATGCAAGAGGAATACAACAGAATTAAGATTACAGATTTGATGGAAA 361 AAAAGTTCCAAGGCGTTGCCTGTCTAGACAAACTAATAGAACTTGCCAAAGATATGCCAT 421 CACTTAAAAACCTTGTTAACAATCTTCGAAAAGAGAAGTCAAAAGTTGCTAAGAAAATTA 481 AAACACAAGAAAAAGCTCCAGTGAAAAAAATAAACCAGGAAGAAGTGGGTCTTGCGGCAC 541 CTGCACCCACCGCAAGAAACAAACTGACATCGGAAGCAAGAGGGAGGATTCCTGTAGCTC 601 AGAAAAGAAAAACTCCAAACAAAGAAAAGACTGAAGCCAAAAGGAATAAGGTGTCCCAAG 661 AGCAGAGTAAGCCCCCAGGTCCCTCAGGAGCCAGCACATCTGCAGCTGTGGATCATCCCC 721 CACTACCCCAGACCTCATCATCAACTCCATCCAACACTTCGTTTACTCCGAATCAGGAAA 781 CCCAGGCCCAACGGCAGGTGGATGCAAGAAGAAATGTTCCCCAAAACGACCCAGTGACAG 841 TGGTGGTACTGAAAGCAACAGCGCCATTTAAATACGAGTCCCCAGAAAATGGGAAAAGCA 901 CAATGTTTCATGCTACAGTGGCCAGTAAGACTCAATATTTCCATGTGAAAGTCTTCGACA 961 TCAACTTGAAAGAGAAATTTGTAAGGAAGAAGGTCATTACTATATCAGATTACTTTGAAT 1021?GTAAAGGAATCCTGGAGGTAAATGAAGCATCATCTGTATCTGAAGCTGGTATTGATCCAA 1081?AGATTGAGGTCCCTACCAGAATTATCAAAAGAGCAAATCAAACTCCCAAGATTGATAATC 1141?TTCACAAACAAGCATCGGGAACATTTGTTTATGGGTTGTTTGTGTTACATCAGAAAAAAG 1201?TGAATAACAAGAACACGATCTATGAAATAGAGGATAAAACAGGAAAGATGGATGTAGTGG 1261?GGAATGGAAAATGGCACAATATCAAGTGTGAGGAAGGAGATAAACTTCGACTCTTCTGCT 1321?TTCAATTGAGAACACTTGACAAGAGGCTGAAACTGACATGTGGAAATCACAGTTTCATTC 1381?AGGTCATCAAGGCTAAGAAAAACAAGGAAGGACCAATGAATGTTAATTGAAATATGAAAG	SEQ?ID?NO：d)

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1441?CTGAAATGCAACAAACAACTTCCGCTTAAAACAATTAAGTTGTTAATAACTGTGATTTTG 1501?TAAATTTCAGTAATTCATTTAAATGATGTTTCAGTAGATATATTCTAGCATATTAAGAGC 1561?TTTTATAACTGAGTTATAGATTAGTTTGCTTTCTGGAATAAAATTTTCTTCTTATACTCT 1621?TCCTTTTTTTTAGATATTACATTTTGCTTTTATGACATTCACGAGGCAAAAAACCG 1 M V N E Y K K I L L L K G F E L M D D Y 1 ATGGTGAATGAATACAAGAAAATTCTTTTGCTGAAAGGATTTGAGCTCATGGATGATTAT 21 H F T S I K S L L A Y D L G L T T K M Q 61 CATTTTACATCAATTAAGTCCTTACTGGCCTATGATTTAGGACTAACTACAAAAATGCAA 41 E E Y N R I K I T D L M E K K F Q G V A 121 GAGGAATACAACAGAATTAAGATTACAGATTTGATGGAAAAAAAGTTCCAAGGCGTTGCC 61 C L D K L I E L A K D M P S L K N L V N 181 TGTCTAGACAAACTAATAGAACTTGCCAAAGATATGCCATCACTTAAAAACCTTGTTAAC 81 N L R K E K S K V A K K I K T Q E K A P 241 AATCTTCGAAAAGAGAAGTCAAAAGTTGCTAAGAAAATTAAAACACAAGAAAAAGCTCCA 101 V K K I N Q E E V G L A A P A P T A R N 301 GTGAAAAAAATAAACCAGGAAGAAGTGGGTCTTGCGGCACCTGCACCCACCGCAAGAAAC 121 K L T S E A R G R I P V A Q K R K T P N 361 AAACTGACATCGGAAGCAAGAGGGAGGATTCCTGTAGCTCAGAAAAGAAAAACTCCAAAC 141 K E K T E A K R N K V S Q E Q S K P P G 421 AAAGAAAAGACTGAAGCCAAAAGGAATAAGGTGTCCCAAGAGCAGAGTAAGCCCCCAGGT 161 P S G A S T S A A V D H P P L P Q T S S 481 CCCTCAGGAGCCAGCACATCTGCAGCTGTGGATCATCCCCCACTACCCCAGACCTCATCA 181 S T P S N T S F T P N Q E T Q A Q R Q V 541 TCAACTCCATCCAACACTTCGTTTACTCCGAATCAGGAAACCCAGGCCCAACGGCAGGTG 201 D A R R N V P Q N D P V T V V V L K A T 601 GATGCAAGAAGAAATGTTCCCCAAAACGACCCAGTGACAGTGGTGGTACTGAAAGCAACA 221 A P F K Y E S P E N G K S T M F H A T V 661 GCGCCATTTAAATACGAGTCCCCAGAAAATGGGAAAAGCACAATGTTTCATGCTACAGTG 241 A S K T Q Y F H V K V F D I N L K E K F 721 GCCAGTAAGACTCAATATTTCCATGTGAAAGTCTTCGACATCAACTTGAAAGAGAAATTT 261 V R K K V I T I S D Y F E C K G I L E V 781 GTAAGGAAGAAGGTCATTACTATATCAGATTACTTTGAATGTAAAGGAATCCTGGAGGTA 281 N E A S S V S E A G I D P K I E V P T R	SEQ?ID?NO：e)

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			841 AATGAAGCATCATCTGTATCTGAAGCTGGTATTGATCCAAAGATTGAGGTCCCTACCAGA 301 I I K R A N Q T P K I D N L H K Q A S G 901 ATTATCAAAAGAGCAAATCAAACTCCCAAGATTGATAATCTTCACAAACAAGCATCGGGA 321 T F V Y G L F V L H Q K K V N N K N T I 961 ACATTTGTTTATGGGTTGTTTGTGTTACATCAGAAAAAAGTGAATAACAAGAACACGATC 341 Y E I E D K T G K M D V V G N G K W H N 1021?TATGAAATAGAGGATAAAACAGGAAAGATGGATGTAGTGGGGAATGGAAAATGGCACAAT 361 I K C E E G D K L R L F C F Q L R T L D 1081?ATCAAGTGTGAGGAAGGAGATAAACTTCGACTCTTCTGCTTTCAATTGAGAACACTTGAC 381 K R L K L T C G N H S F I Q V I K A K K 1141?AAGAGGCTGAAACTGACATGTGGAAATCACAGTTTCATTCAGGTCATCAAGGCTAAGAAA 401 N K E G P M N V N - 1201?AACAAGGAAGGACCAATGAATGTTAATTGA
WBC020C09_V1.3_AT	No homology	1 TCATGATCCTGGGACAATGAGGAGCTGGGAACAGTGGTAGGAACCACGGCAGTGTACCGG 61 TAGGCCTGACTCAGTCACTGGTCCTCAACCTTTAGTGCCTATGAAATGAGCCTCTGGTGA 121 GCCCTGCTTTGCCTGACTCAAGGTAGCACTGAGGATCACAGAGGTAATCTTCATAAAGGT 181 CTCGTCAGGCTTCCTTCAGAGCTTCACCATGAGGCAGGTTAGGAGCAGGCTCCTGCTGGC 241 CCAGAGGAGACCTAGAGTCACAACCCAGGCCCCACACTCCCTCACCCACTTGCTTGCTCT 301 CTGAGCAGGGCAGCTACCACCACCCCTCTCAACCTGGGTTCTGCCTTAGAGGGCAGAGTT 361 TGCTTCACTCATCTGGTTTCCACAAGGCCTGCAAGATAGGAGTTGTAGTCTTTGCTGTAA 421 AAAACTGAGGCTCAAAGAGGTGAAGCGACTTGCCCAAGGGCACACAGCTGGTAAGTAGCA 481 TACCTGAGGTGTATCTAACTCCAAAGCCTACATTGTTTAATGACTATGGAGATGCTTCCT 541 AGAACCATGGTCCAGATTCTACCTCAAATTCTGCTGCTGCCTTCTCCCTGATGGTTTAAA 601 ATGACTGATTAGTGCTACTGAGTCCCCATTTAGGAAGAAAACCTTAAGCTAATATGGTGC 661 TTTGAATGGTGGAATCCAAGCAATATGGAAAATATGGGGGCCTTTTCTGGCACCTCTGAA 721 GTCACTCCACAAAAGTGGCCACCTCCTGTCAAGCTTGGACCTATCACAGCCCAAACCTAG 781 ACTCAAATGTGGGGAGTCTCCCCTGGCACAGGAGAGGTGCCTGACACACCGTTGTTGGCT 841 GATGGTAGGCAACAGGAAGCAAATGTGGTCTGCACAGGCCCAGCTGGGCCTAGAGGCAGG 901 GACTCCCACAGGCCACGGTG 1 GCACAGACAAGGGACTTAAGGCTGGCGAGGGAGAAACCAAAGCCATTCCAGCATGTGTGT 61 CCTTTGTGCTGCCTCTAATCTAAGCTGGGTGAGTTTGTGGGAAGCGACCCTCGAGATTCT 121 GATGACAGTTTTGCCACTGAGCCGTGTGAGGCCTGGGACAAGTATTTTCTTCTCTGCTTC 181 AGTTTTCCTGAGTACAGTGTCACCATATCACACTAGAGACAGCCCCTTGTAAAGATCGTG 241 TGTTATGAGAAATCAGCAGAGCTGGGGACCCTCAGGCTACACAGCACTGCCCCGTGCTAT 301 CACAGTGGGAGCACAGAGGCTCTGAACCCTCAGGGACCCGGCCATGCCCACAAAGCCAGG 361 ACAGGGACCCAAGTCCTTGGCTACTTGGGCCCTGCCCTTCCCTCTGCTCCACAGAAGGGC 421 TACATGATGCTCCTCTGCCTCCCACACACACTCTCCTGGGTGTAGCTGGAGGACAGGAAA 481 TAAATCTTTATTGCGTCAGTTTAAAAAAAAAAAAAAAAAAAAA	SEQ?ID?NO：f) SEQ?ID?NO：g)
WBC020C09_V1.3_AT	No homology		SEQ?ID?NO：f) SEQ?ID?NO：g)	WBC007A05_V1.3_AT	Homo sapiens G albumen-link coupled acceptor

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:		65，mRNA	1 TTCTTGACTTGATGCAGGCACAGATTTATCAAGCTCCTCAGTCAACAAACACATCACCGG 61 AAGAAACATGGAAGGAAAGGAATTTTAAAAAGAGATGTCAATCTCTGTAAAAATAAAGCC 121 TTATGTATTCATGTTTGCACTAATCTACTGTGAGATTTATGAAGAAAAACAAATTGCGGA 181 CAACTCTCTATGTACACTTACAAATGCCTCAGTTGATGCTTGTGGGCTGTTTGTCAGCAT 241 TCTGTGACAATGAGCGCATGGACTTCAGCTCATTAAAATCGACTGACCACTTTAGCTAAC 301 AGCCAGGAGCCTGGATTCTGACTTCCAACCATCGATATCTGTGTGAAAATTGATCTACAC 361 CCACCCTTTAAAAGCATTGATGAATTAATAAGAACTTTTGAAAACAAAGAAAAATGGAAT 421 AAATCTTAGTAAAAGAGAATTGAATGTTGAAAACAAACTACAACGAGGCAAGACTTACTT 481 TGCTATTTATCCTCTAAGAACAGATGTAATTGCTACCTTAAAAAGAAAAGATGAACAGCA 541 CATGTATTGAAGAACAGCATGACCTGGATCACTATTTGTTTCCGATTGTCTACGTCATTG 601 TGGTCATAGTCAGCATTCCAGCCAATATTGGATCTCTCTGTGTGTCTTTTCTGCAAGTAA 661 AAAAGGAAAATGAATTGGGAATTTACCTCTTCAGTTTATCACTGTCAGATCTGCTGTATA 721 CATTAACTCTCCCTCTATGGATTGATTATACTTGGAATAAAGACAACTGGACTTTCTCTC 781 CTGCCTTGTGCAAAGGGAGTGCTTTTCTCATGTACATGAATTTTTACAGCAGCACAGCAT 841 TCCTCACCTGCATTGCCGTTGATCGGTATTTGGCTGTTGTCTACCCTTTGAAGTTTTTTT 901 TCCTAAGGACAAGAAGATTTGCACTCATGGTCAGCCTGTCCATCTGGATATTGGAAACCA 961 TCTTCAATGCTGTCATGTTGTGGGAAGATGAAACAGTTGTTGAATATTGCGATGCCGAAA 1021?AGTCTAATTTTACTTTATGCTATGACAAATACCCTTTAGAGAAATGGCAAATCAACCTCA 1081?ACTTGTTTAGAACGTGTGCATGCTATGCCATACCTCTGGTCATCATAATGGTTTGCAACC 1141?TGAAGGTCTACCAAGCTGTGCAGCATAATCGAGCCACGGAAGACAGTGAAAAGAAGAGAA 1201?TCATAAAACTACTTGTTAGTATCACATTGACTTTTATCTTGTGTTTTACTCCCTTTCATG 1261?TGATGTTGCTGATTCGCTGCATTCTAGAGCATGCTGTGAACTTCGAAGACCACAGCAATT 1321?CTGGGAAGCGAACTTACACAATGTATAGAATCACGGTTGCTTTAACAAGCTTAAATTGTG 1381?TTGCGGATCCAATTCTGTACTGTTTTGTGACTGAAACAGGAAGATCTGATATGTGGAATG 1441?TACTAAAATTCTGTACTGGGAGGCTCAACACATCACAAAGACAAAGAAAACGCATACCGT 1501?CTATGTCTACAAAAGATACTGTAGAATTAGAGGTCCTTGAGTAGAACCAAGGATGTTTTG 1561?AAGGGAAGGGAAGTTTAAGTTATGCATTATTATATCACCAAGATTGCGTTTTGAAAAGGA 1621?AATCTAGCATGTGAGGGGACTAAGTGTTCTCAGAGTGATGTTTTAATCCAGTCCAATAAA 1681?AATATCTTAAAACTGCATTGTACAGCTCCCTCCCTGCGTTTTATTAAATGATGTATATTA 1741?AACAAAGATCAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 M N S T C I E E Q H D L D H Y L F P I V 1 ATGAACAGCACATGTATTGAAGAACAGCATGACCTGGATCACTATTTGTTTCCGATTGTC 21 Y V I V V I V S I P A N I G S L C V S F 61 TACGTCATTGTGGTCATAGTCAGCATTCCAGCCAATATTGGATCTCTCTGTGTGTCTTTT 41 L Q V K K E N E L G I Y L F S L S L S D 121 CTGCAAGTAAAAAAGGAAAATGAATTGGGAATTTACCTCTTCAGTTTATCACTGTCAGAT 61 L L Y T L T L P L W I D Y T W N K D N W 181 CTGCTGTATACATTAACTCTCCCTCTATGGATTGATTATACTTGGAATAAAGACAACTGG 81 T F S P A L C K G S A F L M Y M N F Y S 241 ACTTTCTCTCCTGCCTTGTGCAAAGGGAGTGCTTTTCTCATGTACATGAATTTTTACAGC 101 S T A F L T C I A V D R Y L A V V Y P L 301 AGCACAGCATTCCTCACCTGCATTGCCGTTGATCGGTATTTGGCTGTTGTCTACCCTTTG	SEQ?ID?NO：h) SEQ?ID?NO：i)

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	121 K F F F L R T R R F A L M V S L S I W I 361 AAGTTTTTTTTCCTAAGGACAAGAAGATTTGCACTCATGGTCAGCCTGTCCATCTGGATA 141 L E T I F N A V M L W E D E T V V E Y C 421 TTGGAAACCATCTTCAATGCTGTCATGTTGTGGGAAGATGAAACAGTTGTTGAATATTGC 161 D A E K S N F T L C Y D K Y P L E K W Q 481 GATGCCGAAAAGTCTAATTTTACTTTATGCTATGACAAATACCCTTTAGAGAAATGGCAA 181 I N L N L F R T C A C Y A I P L V I I M 541 ATCAACCTCAACTTGTTTAGAACGTGTGCATGCTATGCCATACCTCTGGTCATCATAATG 201 V C N L K V Y Q A V Q H N R A T E D S E 601 GTTTGCAACCTGAAGGTCTACCAAGCTGTGCAGCATAATCGAGCCACGGAAGACAGTGAA 221 K K R I I K L L V S I T L T F I L C F T 661 AAGAAGAGAATCATAAAACTACTTGTTAGTATCACATTGACTTTTATCTTGTGTTTTACT 241 P F H V M L L I R C I L E H A V N F E D 721 CCCTTTCATGTGATGTTGCTGATTCGCTGCATTCTAGAGCATGCTGTGAACTTCGAAGAC 261 H S N S G K R T Y T M Y R I T V A L T S 781 CACAGCAATTCTGGGAAGCGAACTTACACAATGTATAGAATCACGGTTGCTTTAACAAGC 281 L N C V A D P I L Y C F V T E T G R S D 841 TTAAATTGTGTTGCGGATCCAATTCTGTACTGTTTTGTGACTGAAACAGGAAGATCTGAT 301 M W N V L K F C T G R L N T S Q R Q R K 901 ATGTGGAATGTACTAAAATTCTGTACTGGGAGGCTCAACACATCACAAAGACAAAGAAAA 321 R I P S M S T K D T V E L E V L E - 961 CGCATACCGTCTATGTCTACAAAAGATACTGTAGAATTAGAGGTCCTTGAGTAG
B1961581	Homo sapiens NAD kinases accession number BC001709	1 GTAGACGTGGCGGGCGGACCCGGGGGCGCCCTCCGGACGCGGCAGGCATCAGTGTTTTTC 61 TGACCGAAGTTCTCATTTCCTGACAATGGAAATGGAACAAGAAAAAATGACCATGAATAA 121 GGAATTGAGTCCAGACGCGGCTGCTTACTGCTGCTCGGCCTGCCACGGCGATGAGACCTG 181 GAGTTACAACCACCCCATCCGGGGCCGGGCCAAGTCTCGCAGCCTGTCTGCCTCGCCCGC 241 CCTGGGGAGCACCAAGGAGTTCAGGAGGACACGCTCTCTTCATGGGCCATGCCCGGTGAC 301 CACTTTTGGACCAAAGGCCTGTGTGCTGCAGAACCCCCAGACCATCATGCACATTCAGGA 361 CCCCGCGAGCCAGCGGCTGACGTGGAACAAGTCCCCAAAGAGCGTCCTTGTCATCAAGAA 421 GATGAGAGATGCCAGCCTACTGCAGCCGTTCAAGGAGCTCTGCACGCACCTCATGGAGGA 481 GAACATGATCGTGTATGTGGAAAAGAAAGTGCTAGAAGACCCTGCCATCGCCAGCGATGA 541 AAGCTTTGGGGCAGTGAAGAAGAAATTCTGTACCTTTCGAGAAGATTATGATGACATTTC 601 CAATCAGATAGACTTCATCATCTGCCTGGGGGGAGACGGGACGCTGCTGTACGCTTCCTC 661 GCTTTTCCAGGGCAGCGTCCCTCCGGTCATGGCCTTCCACCTGGGCTCCCTGGGCTTCCT 721 GACCCCATTCAGCTTTGAGAACTTTCAGTCCCAAGTTACTCAGGTGATAGAGGGGAACGC 781 AGCTGTTGTTCTCCGGAGTCGGCTGAAGGTCAGGGTGGTGAAGGAGCTCCGGGGGAAGAA	SEQ?ID?NO：10

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			841 GACGGCCGTGCACAATGGGCTGGGTGAGAAAGGCTCGCAGGCTGCAGGCCTGGACATGGA 901 TGTCGGGAAGCAGGCCATGCAGTACCAGGTCCTGAATGAGGTGGTGATTGACAGAGGCCC 961 CTCCTCCTACCTGTCCAATGTGGATGTCTACCTGGACGGACACCTCATCACCACGGTGCA 1021?GGGCGACGGAGTGATCGTGTCCACCCCGACGGGCAGCACGGCGTATGCGGCCGCGGCCGG 1081?GGCCTCCATGATCCACCCCAACGTGCCGGCCATCATGATCACGCCCATCTGCCCCCACTC 1141?GCTGTCCTTCCGGCCCATCGTGGTCCCCGCAGGGGTCGAGCTGAAGATCATGCTGTCACC 1201?TGAAGCAAGGAACACAGCATGGGTGTCCTTTGATGGACGGAAGAGACAAGAGATCCGCCA 1261?TGGAGACAGCATCAGCATCACTACCTCATGCTACCCGCTCCCCTCCATCTGTGTGCGGGA 1321?CCCCGTGAGCGACTGGTTTGAGAGCCTCGCCCAGTGCCTGCATTGGAACGTCCGGAAGAA 1381?GCAAGCCCACTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGGCTAGGTCAAGCCCCTATC 1441?CAGGCCCGAATCCTTCCGCTGCCCTCCAAGCGCCCTCTGGGGACAGACCAATCTGCGTGT 1501?GTCTGTGACCGCCTGTCTCAGTGGCACGGCCACTTCCTTTCTGTAGCTGGGTTAGAGCCT 1561?GGGTCTGCCTTTTGTCCAGATCAGCTGTTTTTTTAAAATGTCTGACTTTTTTTGCATTTC 1621?TAAAGAAGCGTGAGAAATGGGCTGGGAGTGCTTCTGTCCTGCTGACACCCCGCGGTGGGT 1681?CCCTGGAGCGCGGCCTCCAGCTGCCGCAATTTCCATGCCAGGATATTTTTCCGCAAATCA 1741?GTCGGTTGAAATTCAGAGGAGTCAGAATGACTCGACCTGTCCTTCAATGTTGATAATAAA 1801?TGTCTCAGCCAAAAACCTTCCTTGAGCTGCCATGCTTTTCCCCTTGACCTGCACCTCTTC 1861?CCCTAAAACTTCTGCAGGGAAGCCCCTGGCGGAGGCGCCATTGAAAGCATGGTCTTGCCA 1921?GTGGCTGGCAAGGCGGTTTTGTTCTGCTCAGTTTCTGGAGAGGGTTGGATGCGTCCCCTG 1981?CCATCCAGCCCTCCCCGCTTGAGGCCAGCACTGAGTCTGGGACACTCAGCGGGAAGGGGG 2041?CTGGCATCGCCAGCGACCCACACATTCCTCACGTAGCTTCTGCTCCCAGGAAGGTAGTTT 2101?AAATCCTGTATATACTTTTTAGAGACTCTTTTAAACTTTCTGAAGTGCTGATGTACATAC 2161?TTTCTCGTACACACTTTTGTGAAGATTTCAAGGGGAAGGGAGTTGTCTGCCATTCAATGT 2221?TTACATTTATGTTCTGCAAGACGCTGTCCTCAGGGACCATTAGGGGACCATTCTGTTCAG 2281?TGCGACCCTGATGGTCCGGGAGATGAGGGTTTCCGGGGCTAGTGATCGTGATCCCTTTTA 2341?TTTGCAACTGTAATGAGAATTTTTCACACTAACACAGCGAGGGACTCAACACGCTGATTC 2401?TCCTCCTGCCTCTCCCGTGAGTCTCCAGCCTGCCCAGCACCAGCAGCTGTGGAGCACGTG 2461?GATGCTGCCTACCCCGGCGCCCGCGTCTTCCACGGGCACAGGTGTGTGGAGGCCGTGGTC 2521?GGACCCTGGTGTCCTGGTTACTGCTGCCCGGGTGTCTTTTTTTTGAGTAACTGCTCTCTG 2581?AGTTTTGCACACGAAGTTGCCCTCATCTGCTGGAGATCGATAAGGAAGGCACAAGACGTT 2641?CTCCTCTGCCCGTGAGGAGCTTCCCGCAGCCGCCTGGCCCAGCCTGGGCACGTTCTCCGA 2701?GGCATGTGTCTCCCTGCTCACCCTCGTCTGGGCACCTCAGCATCTGTGGACTTGAGCGTC 2761?CAAAAACCCTGAGTGTGATTCTGGGCAGCCGGCCTGGCTTGAAGTCCGCCATGACCCTGG 2821?GCACAGGGGAAGCCCAGCCGTGGGCTTAGGAGAGAGGGACCAGCGCCCAGCGTTAGGGCT 2881?GGAAGACGGCAGTGTTCAGAATTCCAGCCGCTCATCTGAACACAGAAGGTGTGAACTGAC 2941?CTCTAAAGCAGCGTGAGATGGGAATGATCTAGAAAACTTTGGATTTTTGAAGTAAATTTT 3001?AATGTTTCATATTAATTTCTTGAAAATGTATTAAATGTCATTGAAAGCCTTATTACGCTT 3061?TTCAGATCCTTTCAATAAACAAGACTTGTAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 3121?AAAAAAAAAAAAAAAAAAAA 1 MEMEQEKMTMNKELSPDAAAYCCSACHGDETWSYNHPIRGRAKSRSLSASPALGSTKEFR 61 RTRSLHGPCPVTTFGPKACVLQNPQTIMHIQDPASQRLTWNKSPKSVLVIKKMRDASLLQ 121 PFKELCTHLMEENMIVYVEKKVLEDPAIASDESFGAVKKKFCTFREDYDDISNQIDFIIC 181 LGGDGTLLYASSLFQGSVPPVMAFHLGSLGFLTPFSFENFQSQVTQVIEGNAAVVLRSRL 241 KVRVVKELRGKKTAVHNGLGEKGSQAAGLDMDVGKQAMQYQVLNEVVIDRGPSSYLSNVD	SEQ?ID?NO：11

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			301 VYLDGHLITTVQGDGVIVSTPTGSTAYAAAAGASMIHPNVPAIMITPICPHSLSFRPIVV 361 PAGVELKIMLSPEARNTAWVSFDGRKRQEIRHGDSISITTSCYPLPSICVRDPVSDWFES 421 LAQCLHWNVRKKQAHFEEEEEEEEEG-
BM735170.V1.3_AT	No homology	1 TCGTCCTCACTGTTTTTACCTTGACTTCAACTGCCCACCCATTCAGCTGAGCAGCTGGGG 61 ATGACTGGTTTTTTTCTGTCATTATTTACATATATTTGCTGGAGCTGATTACTGAACTCG 121 TATTTAATCTCTATTGCCAGTGAAATGTTACATTATTTTTCTGATTGGTTTCCCCTCTTA 181 TTGGAAGTATAATTCCAGCAATGTTAGTAGGATAGAAAAGGAGGGAATCATTTGAGGCTT 241 TCAGGTTAGCAAGAGCTATGGGCGTTACATGCTTGTTTTTTCCAAGCAGCTAATTTTTAT 301 CTACTTCTCAGATTAGGTTTGGGGGAGCTTTGGCATCTTTTTAGATTTTAATCTCTATTT 361 TCTTAATCCAGGGTACAAATGTGAGCAAAAGAAAAAAAGAAATCTTTTATACTTTTTTAA 421 ATAAATTTATAAATAAATTTTGAGCTGCTTCGGT	SEQ?ID?NO：12
BM735170.V1.3_AT	No homology		SEQ?ID?NO：12	WBC010C05	The ox analogue (LOC529385) of putative protein matter	＜1 ATTTCTGCTCCTAATGAATTTGATCTTATGTTCACACTGGAGGTTCCCCGAATTCAGCTG 61 GAAGAATATTGCCACAATACTGATGTCATTATGGAGAGGAAGAAAAGAGGGAGCCCTGCT 121 GTAACACTTCTGATTAGAAAACCTAGAGAAATATCTGTGGATATAATCCTGGCTTTGGAG 181 TCAAAAAGCAGCTGGCCTGCTAGCACCCAGAAAGGCCTGCCCATCAGTAACTGGCTTGGA 241 ACAAAAGTTAAGGACAATCTAAAACGACAGCCATTTTACCTGGTACCCAAGCACGCAAAG 301 GAAGGAAGTCTTTTCCAAGAAGAAACATGGCGGCTGTCCTTCTCTCACATTGAAAAGGCC 361 ATTTTGACAAATCATGGACAAACTAAAACATGCTGTGAAACTGAAGGAGTAAAATGTTGC 421 AGGAAAGAGTGTTTAAAGCTGATGAAATACCTTTTAGAACAACTGAAAAAAAAGTTTGGA 481 AAGCAAAGGGGACTGGATAAGTTCTGTTCTTATCATGTGAAGACTGCCTTCCTTCATGTC 541 TGTACCCAGAACCCGCATGACAGTTGGTGGCTCTACAAAGACCTGGAGCTCTGCTTTGAT 601 AACTGTGTGACATACTTTCTTCAGTGTCTCAAGACAGAACACCTTGAGCACTATTTCATT 661 CCTGATGTCAATCTCTTCTCTCGAGACGAAATTGGCAAGCCAAGTAAAGAATTTCTGTCA 721 AAGCAAATTGAATATGAGCAAAACAATGGATTTCCGGTTTTTGATGAGTTTTGA ＜1 I S A P N E F D L M F T L E V P R I Q L 1 ATTTCTGCTCCTAATGAATTTGATCTTATGTTCACACTGGAGGTTCCCCGAATTCAGCTG 21 E E Y C H N T D V I M E R K K R G S P A 61 GAAGAATATTGCCACAATACTGATGTCATTATGGAGAGGAAGAAAAGAGGGAGCCCTGCT 41 V T L L I R K P R E I S V D I I L A L E 121 GTAACACTTCTGATTAGAAAACCTAGAGAAATATCTGTGGATATAATCCTGGCTTTGGAG 61 S K S S W P A S T Q K G L P I S N W L G 181 TCAAAAAGCAGCTGGCCTGCTAGCACCCAGAAAGGCCTGCCCATCAGTAACTGGCTTGGA 81 T K V K D N L K R Q P F Y L V P K H A K 241 ACAAAAGTTAAGGACAATCTAAAACGACAGCCATTTTACCTGGTACCCAAGCACGCAAAG 101 E G S L F Q E E T W R L S F S H I E K A 301 GAAGGAAGTCTTTTCCAAGAAGAAACATGGCGGCTGTCCTTCTCTCACATTGAAAAGGCC	SEQ?ID?NO：13 SEQ?ID?NO：14

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	121 I L T N H G Q T K T C C E T E G V K C C 361 ATTTTGACAAATCATGGACAAACTAAAACATGCTGTGAAACTGAAGGAGTAAAATGTTGC 141 R K E C L K L M K Y L L E Q L K K K F G 421 AGGAAAGAGTGTTTAAAGCTGATGAAATACCTTTTAGAACAACTGAAAAAAAAGTTTGGA 161 K Q R G L D K F C S Y H V K T A F L H V 481 AAGCAAAGGGGACTGGATAAGTTCTGTTCTTATCATGTGAAGACTGCCTTCCTTCATGTC 181 C T Q N P H D S W W L Y K D L E L C F D 541 TGTACCCAGAACCCGCATGACAGTTGGTGGCTCTACAAAGACCTGGAGCTCTGCTTTGAT 201 N C V T Y F L Q C L K T E H L E H Y F I 601 AACTGTGTGACATACTTTCTTCAGTGTCTCAAGACAGAACACCTTGAGCACTATTTCATT 221 P D V N L F S R D E I G K P S K E F L S 661 CCTGATGTCAATCTCTTCTCTCGAGACGAAATTGGCAAGCCAAGTAAAGAATTTCTGTCA 241 K Q I E Y E Q N N G F P V F D E F - 721 AAGCAAATTGAATATGAGCAAAACAATGGATTTCCGGTTTTTGATGAGTTTTGA
WBC009D04_V1.3_AT	Be positioned at the people mRNA of the X-CGD gene that relates to the granuloma disease on the chromosome x	1 CTTCCTCTGCCACCATCGGGGAACTGGGCTGTGAATGAGGGGCTCTCCATTTTTGCTATT 61 CTGGTTTGGCTGGGGTTGAACGTCTTCCTCTTTGTCTGGTATTACCGGGTTTATGATATT 121 CCACCTAAGTTCTTTTACACAAGAAAACTTCTTGGGTCAGCACTGGCACTGGCCAGGGCC 181 CCTGCAGCCTGCCTGAATTTCAACTGCATGCTGATTCTCTTGCCAGTCTGTCGAAATCTG 241 CTGTCCTTCCTCAGGGGTTCCAGTGCGTGCTGCTCAACAAGAGTTCGAAGACAACTGGAC 301 AGGAATCTCACCTTTCATAAAATGGTGGCATGGATGATTGCACTTCACTCTGCGATTCAC 361 ACCATTGCACATCTATTTAATGTGGAATGGTGTGTGAATGCCCGAGTCAATAATTCTGAT 421 CCTTATTCAGTAGCACTCTCTGAACTTGGAGACAGGCAAAATGAAAGTTATCTCAATTTT 481 GCTCGAAAGAGAATAAAGAACCCTGAAGGAGGCCTGTACCTGGCTGTGACCCTGTTGGCA 541 GGCATCACTGGAGTTGTCATCACGCTGTGCCTCATATTAATTATCACTTCCTCCACCAAA 601 ACCATCCGGAGGTCTTACTTTGAAGTCTTTTGGTACACACATCATCTCTTTGTGATCTTC 661 TTCATTGGCCTTGCCATCCATGGAGCTGAACGAATTGTACGTGGGCAGACCGCAGAGAGT 721 TTGGCTGTGCATAATATAACAGTTTGTGAACAAAAAATCTCAGAATGGGGAAAAATAAAG 781 GAATGCCCAATCCCTCAGTTTGCTGGAAACCCTCCTATGACTTGGAAATGGATAGTGGGT 841 CCCATGTTTCTGTATCTCTGTGAGAGGTTGGTGCGGTTTTGGCGATCTCAACAGAAGGTG 901 GTCATCACCAAGGTGGTCACTCACCCTTTCAAAACCATCGAGCTACAGATGAAGAAGAAG 961 GGGTTCAAAATGGAAGTGGGACAATACATTTTTGTCAAGTGCCCAAAGGTGTCCAAGCTG 1021?GAGTGGCACCCTTTTACACTGACATCCGCCCCTGAGGAAGACTTCTTTAGTATCCATATC 1081?CGCATCGTTGGGGACTGGACAGAGGGGCTGTTCAATGCTTGTGGCTGTGATAAGCAGGAG 1141?TTTCAAGATGCGTGGAAACTACCTAAGATAGCGGTTGATGGGCCCTTTGGCACTGCCAGT 1201?GAAGATGTGTTCAGCTATGAGGTGGTGATGTTAGTGGGAGCAGGGATTGGGGTCACACCC 1261?TTCGCATCCATTCTCAAGTCAGTCTGGTACAAATATTGCAATAACGCCACCAATCTGAAG 1321?CTCAAAAAGATCTACTTCTACTGGCTGTGCCGGGACACACATGCCTTTGAGTGGTTTGCA 1381?GATCTGCTGCAACTGCTGGAGAGCCAGATGCAGGAAAGGAACAATGCCGGCTTCCTCAGC 1441?TACAACATCTACCTCACTGGCTGGGATGAGTCTCAGGCCAATCACTTTGCTGTGCACCAT 1501?GATGAGGAGAAAGATGTGATCACAGGCCTGAAACAAAAGACTTTGTATGGACGGCCCAAC	SEQ?ID?NO：15

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1561?TGGGATAATGAATTCAAGACAATTGCAAGTCAACACCCTAATACCAGAATAGGAGTTTTC 1621?CTCTGTGGACCTGAAGCCTTGGCTGAAACCCTGAGTAAACAAAGCATCTCCAACTCTGAG 1681?TCTGGCCCTCGGGGAGTGCATTTCATTTTCAACAAGGAAAACTTCTAACTTGTCTCTTCC 1741?ATGAGGAAATAAATGTGGGTTGTGCTGCCAAATGCTCAAATAATGCTAATTGATAATATA 1801?AATACCCCCTGCTTAAAAATGGACAAAAAGAAACTATAATGTAATGGTTTTCCCTTAAAG 1861?GAATGTCAAAGATTGTTTGATAGTGATAAGTTACATTTATGTGGAGCTCTATGGTTTTGA 1921?GAGCACTTTTACAAACATTATTTCATTTTTTTCCTCTCAGTAATGTCAGTGGAAGTTAGG 1981?GAAAAGATTCTTGGACTCAATTTTAGAATCAAAAGGGAAAGGATCAAAAGGTTCAGTAAC 2041?TTCCCTAAGATTATGAAACTGTGACCAGATCTAGCCCATCTTACTCCAGGTTTGATACTC 2101?TTTCCACAATACTGAGCTGCCTCAGAATCCTCAAAATCAGTTTTTATATTCCCCAAAAGA 2161?AGAAGGAAACCAAGGAGTAGCTATATATTTCTACTTTGTGTCATTTTTGCCATCATTATT 2221?ATCATACTGAAGGAAATTTTCCAGATCATTAGGACATAATACATGTTGAGAGTGTCTCAA 2281?CACTTATTAGTGACAGTATTGACATCTGAGCATACTCCAGTTTACTAATACAGCAGGGTA 2341?ACTGGGCCAGATGTTCTTTCTACAGAAGAATATTGGATTGATTGGAGTTAATGTAATACT 2401?CATCATTTACCACTGTGCTTGGCAGAGAGCGGATACTCAAGTAAGTTTTGTTAAATGAAT 2461?GAATGAATTTAGAACCATGCAATGCCAGGGTAGAATTAATTTAAGGCCTTAAAGAGAAAT 2521?ATCTAAGGAAATAACTTCTGTTACTCTTACAGACCAAAGGAACCCGATTCTTCTGACAGT 2581?AGAGAACAGGCTAAAGATAGTAACCAATAGGATGTCCTGGAGGTTCCCTCACATTCTTGT 2641?TTGAAGCATGGAGGAAAGGGAGATGGAGGCAGAGAATGGACCTCCTACCATAACTGGCTG 2701?GCTCCTCTAGTCCTGCTCCCCGTGCCATGAAAGAAATGCAAACTGATTTACTGCCTGAAA 2761?GGGTCTCCTCCAGCCAGCACTTGTGAATTTGAAATTAAGAATTGTGACAAATATGTGTCT 2821?GATATGCCCATCTGCTTTAAATAGCATCCACCCCTTGTTTTACTTAAATACACACACAAA 2881?ATGGATCGCATCTGTGTGACTAATGGTTTATTTGTATTATATCATCATCATCATCCTAAA 2941?ATTAACAACCCAGAAACAAAAATCTCTATACAGAGATCAAATTCACACTCAATAGTATGT 3001?TCTGAATATATGTTCAAGAGAGAGTCTCTAAATCACTGTTAGTGTGGCCAAGAGCAGGGT 3061?TTTCTTTTTGTTCTTAGAACTGCTCTTATTTCTGGGAACTATAAACAGATTTGTTGGCCC 3121?CACCCTCTGGAACCACAGATATTTAGAGCTATTTAAATTTGGTAATGCGGAAGAAGGAGA 3181?AAGAGCTGGGGGAAGGGCAGAAGACTGGTTTAGGAGGAAAAGGAAATAAGGAGAAAAGAG 3241?AATGGGAGAGTGAGAGAAAATAAAAAAGGCAAAAGGGAGAGAGAGGGGAAGGGGGTCTCA 3301?TATTGGTCATTCCCTGCCCCAGATTTCTTAAAGTTTGATATGTATAGAATATAATTGAAG 3361?GAGGTATACACATACTGATGTTGTTTTGATTATCTATGGTATTGAATCTTTTAAAATCTG 3421?GTCACAAATTTTGATGCTGAGGGGGATTATTCAAGGGACTAGGATGAACTAAATAAGAAC 3481?TCAGTTGTTCTTTGTCATACTACTATTCCTTTCGTCTCCCAGAATCCTCAGGGCACTGAG 3541?GGTAGGTCTGACAAATAAGGCCTGCTGTGCGAATATAGCCTTTCTGAAATGTACCAGGAT 3601?GGTTTCTGCTTATAGACACTTAGGTCCAGCCTGTTCACACTGCACCTCGAGTATCAGTTC 3661?ATTCATTCAACAAATTTTTATTGTGCTGTTACCATGACTCACGCTCTGTTTATTGTTTCA 3721?ATTCTTTACACCAAAGTATGAACTGGAGAGGGTACCTCAGTTATAAGGAGCCTGAGAATC 3781?TTGGTCCCTCCAACCTATGTGGCCCAAGTAAAACCAACTCCATTTGTTGCTCTGAAAATG 3841?TTTCTCCAGGGTTTTCTATCTTCAAAACCAACTAAGTTATGAAAGTAGAGAGATCTGCCC 3901?TGTGTTATCCAGTTATGAGATAAAAAATGAGTATAAAAGTGCTTGTCATTATAAAAGTTT 3961?CCTTTTTATCTCTCAAGCCACCAGCTGCCAGCCACCACGAGCCAGCTGCCAGCCTAGCTT 4021?TTTTTTTTTTTTTTTTTTTAGCACTTAGCATTTAGCATTTAGTAACAGGTACTGAGAGAA 4081?CGATTAAGCATTGTTTTTAATCTCAAGGCTATGAAGGCTTTTTTTAGTTCTCCTGCTTTT 4141?GCAATATTGCGTTTATGAAATTTGAATGCTTGTAGGTGTTGTGTGTGAATAATTTTGGGG 4201?GGCCTGGGAGATATTCCTAGGAAGAACTATTAAAATTGTGCTCAACTATTAAAATGAATG 4261?AGCTTTC 1 M L I L L P V C R N L L S F L R G S S A	SEQ?ID?NO：16

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1 ATGCTGATTCTCTTGCCAGTCTGTCGAAATCTGCTGTCCTTCCTCAGGGGTTCCAGTGCG 21 C C S T R V R R Q L D R N L T F H K M V 61 TGCTGCTCAACAAGAGTTCGAAGACAACTGGACAGGAATCTCACCTTTCATAAAATGGTG 41 A W M I A L H S A I H T I A H L F N V E 121 GCATGGATGATTGCACTTCACTCTGCGATTCACACCATTGCACATCTATTTAATGTGGAA 61 W C V N A R V N N S D P Y S V A L S E L 181 TGGTGTGTGAATGCCCGAGTCAATAATTCTGATCCTTATTCAGTAGCACTCTCTGAACTT 81 G D R Q N E S Y L N F A R K R I K N P E 241 GGAGACAGGCAAAATGAAAGTTATCTCAATTTTGCTCGAAAGAGAATAAAGAACCCTGAA 101 G G L Y L A V T L L A G I T G V V I T L 301 GGAGGCCTGTACCTGGCTGTGACCCTGTTGGCAGGCATCACTGGAGTTGTCATCACGCTG 121 C L I L I I T S S T K T I R R S Y F E V 361 TGCCTCATATTAATTATCACTTCCTCCACCAAAACCATCCGGAGGTCTTACTTTGAAGTC 141 F W Y T H H L F V I F F I G L A I H G A 421 TTTTGGTACACACATCATCTCTTTGTGATCTTCTTCATTGGCCTTGCCATCCATGGAGCT 161 E R I V R G Q T A E S L A V H N I T V C 481 GAACGAATTGTACGTGGGCAGACCGCAGAGAGTTTGGCTGTGCATAATATAACAGTTTGT 181 E Q K I S E W G K I K E C P I P Q F A G 541 GAACAAAAAATCTCAGAATGGGGAAAAATAAAGGAATGCCCAATCCCTCAGTTTGCTGGA 201 N P P M T W K W I V G P M F L Y L C E R 601 AACCCTCCTATGACTTGGAAATGGATAGTGGGTCCCATGTTTCTGTATCTCTGTGAGAGG 221 L V R F W R S Q Q K V V I T K V V T H P 661 TTGGTGCGGTTTTGGCGATCTCAACAGAAGGTGGTCATCACCAAGGTGGTCACTCACCCT 241 F K T I E L Q M K K K G F K M E V G Q Y 721 TTCAAAACCATCGAGCTACAGATGAAGAAGAAGGGGTTCAAAATGGAAGTGGGACAATAC 261 I F V K C P K V S K L E W H P F T L T S 781 ATTTTTGTCAAGTGCCCAAAGGTGTCCAAGCTGGAGTGGCACCCTTTTACACTGACATCC 281 A P E E D F F S I H I R I V G D W T E G 841 GCCCCTGAGGAAGACTTCTTTAGTATCCATATCCGCATCGTTGGGGACTGGACAGAGGGG 301 L F N A C G C D K Q E F Q D A W K L P K 901 CTGTTCAATGCTTGTGGCTGTGATAAGCAGGAGTTTCAAGATGCGTGGAAACTACCTAAG 321 I A V D G P F G T A S E D V F S Y E V V 961 ATAGCGGTTGATGGGCCCTTTGGCACTGCCAGTGAAGATGTGTTCAGCTATGAGGTGGTG

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	341 M L V G A G I G V T P F A S I L K S V W 1021?ATGTTAGTGGGAGCAGGGATTGGGGTCACACCCTTCGCATCCATTCTCAAGTCAGTCTGG 361 Y K Y C N N A T N L K L K K I Y F Y W L 1081?TACAAATATTGCAATAACGCCACCAATCTGAAGCTCAAAAAGATCTACTTCTACTGGCTG 381 C R D T H A F E W F A D L L Q L L E S Q 1141?TGCCGGGACACACATGCCTTTGAGTGGTTTGCAGATCTGCTGCAACTGCTGGAGAGCCAG 401 M Q E R N N A G F L S Y N I Y L T G W D 1201?ATGCAGGAAAGGAACAATGCCGGCTTCCTCAGCTACAACATCTACCTCACTGGCTGGGAT 421 E S Q A N H F A V H H D E E K D V I T G 1261?GAGTCTCAGGCCAATCACTTTGCTGTGCACCATGATGAGGAGAAAGATGTGATCACAGGC 441 L K Q K T L Y G R P N W D N E F K T I A 1321?CTGAAACAAAAGACTTTGTATGGACGGCCCAACTGGGATAATGAATTCAAGACAATTGCA 461 S Q H P N T R I G V F L C G P E A L A E 1381?AGTCAACACCCTAATACCAGAATAGGAGTTTTCCTCTGTGGACCTGAAGCCTTGGCTGAA 481 T L S K Q S I S N S E S G P R G V H F I 1441?ACCCTGAGTAAACAAAGCATCTCCAACTCTGAGTCTGGCCCTCGGGGAGTGCATTTCATT 501 F N K E N F - 1501?TTCAACAAGGAAAACTTCTAA
B1961434.V1.3_AT/ B1961054.V1.3_AT B1961434.V1.3_S_AT	But the IP-10mRNA of interferon--induced protein-10	61 AGCACCATGAACACAAGTGGTTTTCTTATTTTCTGCCTTATCCTTCTGACTCTGAGTCAA 121 GGCATACCTCTCTCTAGGAATACACGCTGTACCTGCATCGAGATCAGTAATGGATCTGTT 181 AATCCAAGGTCCTTAGAAAAACTTGAACTGATTCCTGCAAGTCAATCCTGCCCACGTGTT 241 GAGATCATTGCCACAATGAAAAAGAATGGGGAGAAAAGATGTCTGAATCCAGAGTCCAAG 301 ACCGTCAAGAATTTACTGAAAGCAATTAGCAAGCAAAGGTCTAAAAGATCTCCTCGAACA 361 CTGAGAGAAGTATAATTACGGTACTACTGATAGGATGGCCCAGAGAGAGGCCGCCTCTGC 421 CATCATTTCCCTGCATACAGTATATGTCAAGCCCTAATTGTCCCCGGATTGCAGTTCTCC 481 TAAAAGATGACCAAGCCAGTCACCTAATTAGCTGCTACTACTCCTGCAGGGGGTGGATGG 541 TTCATCATCCTGAGCTGTTCAGTAGTAACTCTGCCTTGGCACTATGACTATAAACTATGC 601 TGAGGTGCTACATTCTTAGTAAATGTGCCAAGACCTAGTCCTGCTACTGACACTTTCCTC 661 GCCTTGCCATACTCTAAAGGTTCTCAACGGATCTTTCCACCTCTGGGCTTATCAGAGTTC 721 TCAGGATCTCAAATAACTAAAAGGTAATCAAAGCAATAATACAATCTGCTTTTTTAAGAA 781 AGATCTTCACTCCATGGACTTCACTGCCATCCCCCCAAGGAGCCCATATTCTTCCAGGTT 841 ATATACACAAAATTCCAAATACATAGAAGAAGCTAGAAATGTCTGGAAATGTACGTGAAA 901 ACAGTATTATTTAATGGAAAGCTATACAAAATAGAAGTCTTAGATGTACATATTTCTTAC 961 ATTGTTTTCAGTGTTTATGGAATAACTTACGTGATTAAGTACTACACATGAATGACCAAT 1021?AGGAGAAAATTTTTGAAATCTAGATATATGTTCTGCATGATATGTAAGACAAAATATGCT 1081?GGATGTTTTTCAAAATAGAAATAATGTGCTCTCCCAGAAATATTAAGA	SEQ?ID?NO：17

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	1 M N T S G F L I F C L I L L T L S Q G I 1 ATGAACACAAGTGGTTTTCTTATTTTCTGCCTTATCCTTCTGACTCTGAGTCAAGGCATA 21 P L S R N T R C T C I E I S N G S V N P 61 CCTCTCTCTAGGAATACACGCTGTACCTGCATCGAGATCAGTAATGGATCTGTTAATCCA 41 R S L E K L E L I P A S Q S C P R V E I 121 AGGTCCTTAGAAAAACTTGAACTGATTCCTGCAAGTCAATCCTGCCCACGTGTTGAGATC 61 I A T M K K N G E K R C L N P E S K T V 181 ATTGCCACAATGAAAAAGAATGGGGAGAAAAGATGTCTGAATCCAGAGTCCAAGACCGTC 81 K N L L K A I S K Q R S K R S P R T L R 241 AAGAATTTACTGAAAGCAATTAGCAAGCAAAGGTCTAAAAGATCTCCTCGAACACTGAGA 101 E V - 301 GAAGTATAA	SEQ?ID?NO：18
BM780886.V1.3_AT	Homo sapiens 6-phosphogluconolactonase, mRNA (cDNA clone MGC:20013 IMAGE:4053022)	1 CTCCTCCCCGCCGCCGCCCTCGCCATGGCCGCGCCGGCCCCGGGCCTCATCTCGGTGTTC 61 TCGAGTTCCCAGGAGCTGGGTGCGGCGCTAGCGCAGCTGGTGGCCCAGCGCGCAGCATGC 121 TGCCTGGCAGGGGCCCGCGCCCGTTTCGCGCTCGGCTTGTCGGGCGGGAGCCTCGTCTCG 181 ATGCTAGCCCGCGAGCTACCCGCCGCCGTCGCCCCTGCCGGGCCAGCTAGCTTAGCGCGC 241 TGGACGCTGGGCTTCTGCGACGAGCGCCTCGTGCCCTTCGATCACGCCGAGAGCACGTAC 301 GGCCTCTACCGGACGCATCTTCTCTCCAGACTGCCGATCCCAGAAAGCCAGGTGATCACC 361 ATTAACCCCGAGCTGCCTGTGGAGGAGGCGGCTGAGGACTACGCCAAGAAGCTGAGACAG 421 GCATTCCAAGGGGACTCCATCCCGGTTTTCGACCTGCTGATCCTGGGGGTGGGCCCCGAT 481 GGTCACACCTGCTCACTCTTCCCAGACCACCCCCTCCTACAGGAGCGGGAGAAGATTGTG 541 GCTCCCATCAGTGACTCCCCGAAGCCACCGCCACAGCGTGTGACCCTCACGCTACCTGTC 601 CTGAATGCAGCACGAACTGTCATCTTTGTGGCAACTGGAGAAGGCAAGGCAGCTGTTCTG 661 AAGCGCATTTTGGAGGACAAGGAGGAAAACCCGCTCCCCGCCGCCCTGGTCCAGCCCCAC 721 ACTGGGAAACTCTGCTGGTTCCTGGACGAGGCAGCGGCCCGACTCCTGACCGTGCCCTTC 781 GAGAAGCATTCCACTTTGTAGCTGGCCAGAGGGACGCCGCAGCTGGGACCAGGCACGCGG 841 CCCATGGGGCTGGGCCCCTGCTGGCCGCCACTCTCCGGGCTCTCCTTTCAAAAAGCCACG 901 TCGTGCTGCTGCTGGAAGCCAACAGCCTCCGGCCAGCAGCCCTACCCGGGGCTCAACACA 961 CAGGCTGTGGCTCTGGACATCCGGATATTAAAAGGAGCGTTGCTGGAAAAAAAAAAAAAA 1021?AAAAAAAAAAAAAA 1 M A A P A P G L I S V F S S S Q E L G A 1 ATGGCCGCGCCGGCCCCGGGCCTCATCTCGGTGTTCTCGAGTTCCCAGGAGCTGGGTGCG 21 A L A Q L V A Q R A A C C L A G A R A R 61 GCGCTAGCGCAGCTGGTGGCCCAGCGCGCAGCATGCTGCCTGGCAGGGGCCCGCGCCCGT 41 F A L G L S G G S L V S M L A R E L P A 121 TTCGCGCTCGGCTTGTCGGGCGGGAGCCTCGTCTCGATGCTAGCCCGCGAGCTACCCGCC 61 A V A P A G P A S L A R W T L G F C D E	SEQ?ID?NO：19 SEQ?ID?NO：20		SEQ?ID?NO：18

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 GCCGTCGCCCCTGCCGGGCCAGCTAGCTTAGCGCGCTGGACGCTGGGCTTCTGCGACGAG 81 R L V P F D H A E S T Y G L Y R T H L L 241 CGCCTCGTGCCCTTCGATCACGCCGAGAGCACGTACGGCCTCTACCGGACGCATCTTCTC 101 S R L P I P E S Q V I T I N P E L P V E 301 TCCAGACTGCCGATCCCAGAAAGCCAGGTGATCACCATTAACCCCGAGCTGCCTGTGGAG 121 E A A E D Y A K K L R Q A F Q G D S I P 361 GAGGCGGCTGAGGACTACGCCAAGAAGCTGAGACAGGCATTCCAAGGGGACTCCATCCCG 141 V F D L L I L G V G P D G H T C S L F P 421 GTTTTCGACCTGCTGATCCTGGGGGTGGGCCCCGATGGTCACACCTGCTCACTCTTCCCA 161 D H P L L Q E R E K I V A P I S D S P K 481 GACCACCCCCTCCTACAGGAGCGGGAGAAGATTGTGGCTCCCATCAGTGACTCCCCGAAG 181 P P P Q R V T L T L P V L N A A R T V I 541 CCACCGCCACAGCGTGTGACCCTCACGCTACCTGTCCTGAATGCAGCACGAACTGTCATC 201 F V A T G E G K A A V L K R I L E D K E 601 TTTGTGGCAACTGGAGAAGGCAAGGCAGCTGTTCTGAAGCGCATTTTGGAGGACAAGGAG 221 E N P L P A A L V Q P H T G K L C W F L 661 GAAAACCCGCTCCCCGCCGCCCTGGTCCAGCCCCACACTGGGAAACTCTGCTGGTTCCTG 241 D E A A A R L L T V P F E K H S T L - 721 GACGAGGCAGCGGCCCGACTCCTGACCGTGCCCTTCGAGAAGCATTCCACTTTGTAG
WBC004E01_V1.3_AT	Homo sapiens Apo-2 ligand mRNA, encoding sequence completely	1 TTTCCTCACTGACTATAAAAGAATAGAGAAGGAAGGGCTTCAGTGACCGGCTGCCTGGCT 61 GACTTACAGCAGTCAGACTCTGACAGGATCATGGCTATGATGGAGGTCCAGGGGGGACCC 121 AGCCTGGGACAGACCTGCGTGCTGATCGTGATCTTCACAGTGCTCCTGCAGTCTCTCTGT 181 GTGGCTGTAACTTACGTGTACTTTACCAACGAGCTGAAGCAGATGCAGATCAAATACTCC 241 AAAAGTGGCATTGCCTGTTTCTTAAAGGAAGATGACAGCGATTGGGACCCAAATGACGAA 301 GAGAGTATGAACAGCCCCTGCTGGCAAGTCAAGTGGCAGCTGCGTCAGTTTGTTAGAAAG 361 ATGATTTTGAGAACCTATGAGGAATCCATTCCTACAACTTCAGAAAAGCGACAAAATATT 421 CCTCCCTTAGTAAGAGAAAGAGGTCTTCAGAGAGTAGCAGCTCACATAACTGGGACCAGT 481 CGGAGAAGAAGCACAGTCTCAATTCCACGCTCCAAGAATGAAAAAGCACTGGGCCAGAAA 541 ATAAACGCCTGGGAGACATCAAGAAAAGGACATTCGTTCTTGAATAATTTACACTTGAGG 601 AATGGAGAGCTGGTTATCCATCAAACAGGGTTTTATTACATCTATTCCCAAACATACTTT 661 CGATTTCAGGAGGAAATAAAAGAAAACACAAAGAACGACAAACAAATGGTACAATATATT 721 TACAAAAGCACAGACTATCCTGACCCTATACTGCTGATGAAAAGTGCTAGAAATAGTTGT 781 TGGTCTAAAGATTCAGAATATGGACTCTATTCCATCTATCAAGGTGGAATATTTGAGCTT 841 AAGGAAAATGACAGAATTTTTGTCTCTGTAACTAATGAGCAATTGATTGACATGGACCAA 901 GAAGCCAGTTTCTTCGGGGCCTTTTTAGTTGGCTAACTGACCTGGAAAGAAAAAGCAATA 961 ACCTCAAAGTGACTATTCAGTTTTCAGGATGATACACTATGAAGATGTTTCAAAAAATCT 1021?GACCAAAACAAACAAACAGAAA	SEQ?ID?NO：21

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	1 M A M M E V Q G G P S L G Q T C V L I V 1 ATGGCTATGATGGAGGTCCAGGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTG 21 I F T V L L Q S L C V A V T Y V Y F T N 61 ATCTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAAC 41 E L K Q M Q I K Y S K S G I A C F L K E 121 GAGCTGAAGCAGATGCAGATCAAATACTCCAAAAGTGGCATTGCCTGTTTCTTAAAGGAA 61 D D S D W D P N D E E S M N S P C W Q V 181 GATGACAGCGATTGGGACCCAAATGACGAAGAGAGTATGAACAGCCCCTGCTGGCAAGTC 81 K W Q L R Q F V R K M I L R T Y E E S I 241 AAGTGGCAGCTGCGTCAGTTTGTTAGAAAGATGATTTGAGAACCTATGAGGAATCCATT 101 P T T S E K R Q N I P P L V R E R G L Q 301 CCTACAACTTCAGAAAAGCGACAAAATATTCCTCCCTTAGTAAGAGAAAGAGGTCTTCAG 121 R V A A H I T G T S R R R S T V S I P R 361 AGAGTAGCAGCTCACATAACTGGGACCAGTCGGAGAAGAAGCACAGTCTCAATTCCACGC 141 S K N E K A L G Q K I N A W E T S R K G 421 TCCAAGAATGAAAAAGCACTGGGCCAGAAAATAAACGCCTGGGAGACATCAAGAAAAGGA 161 H S F L N N L H L R N G E L V I H Q T G 481 CATTCGTTCTTGAATAATTTACACTTGAGGAATGGAGAGCTGGTTATCCATCAAACAGGG 181 F Y Y I Y S Q T Y F R F Q E E I K E N T 541 TTTTATTACATCTATTCCCAAACATACTTTCGATTTCAGGAGGAAATAAAAGAAAACACA 201 K N D K Q M V Q Y I Y K S T D Y P D P I 601 AAGAACGACAAACAAATGGTACAATATATTTACAAAAGCACAGACTATCCTGACCCTATA 221 L L M K S A R N S C W S K D S E Y G L Y 661 CTGCTGATGAAAAGTGCTAGAAATAGTTGTTGGTCTAAAGATTCAGAATATGGACTCTAT 241 S I Y Q G G I F E L K E N D R I F V S V 721 TCCATCTATCAAGGTGGAATATTTGAGCTTAAGGAAAATGACAGAATTTTTGTCTCTGTA 261 T N E Q L I D M D Q E A S F F G A F L V 781 ACTAATGAGCAATTGATTGACATGGACCAAGAAGCCAGTTTCTTCGGGGCCTTTTTAGTT 281 G - 841 GGCTAA	SEQ?ID?NO：22
B1961659.V1.3_AT	No homology	1 GCACGAGGACCATCCATATCAAATATGCCCATTCAAACATTACCCAGCATCATGGCTTAT 61 GATCAGGAACTCCGGTCCTTATGTCTAGTAGCATTTTGAATCCTTTATGCCATGATAGTG	SEQ?ID?NO：23		SEQ?ID?NO：22

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			121 CCGCAGTATCGAGAGGATTTTATGGAGAATTGGAATAGTCTCCATGACCACAGCTAAATA 181 AAGGACAAGCAGCCTGTCTTGGGGTTTTGAAAAGGTTATTCTTAACAATCTTTTTTTTTT 241 CCTACCCAGGGACTTTCTGACAGTATGACTGTTACCTTACTTGAAAAGCAGTACCCAATT 301 GCTTTATTATTTTAAATAGATTCACATTAACCAACATAATTTTTTAGATTGTTTAGGATT 361 AGCCTGAGTTTCTAAGTCAGCTTCCAGCTGTGTTTCATCTCCTTCACCTGCATTTTATTT 421 GGTGTTTGTCTGAAGGAAAGAGGAAAGCAAATGTGAATTGTACTATTTGTACTAATCTTT 481 GGAATTTATTGGTAAATTTATTTCAGGATAGGGTATCAGAAAAAG?AAAACTTTGTTTCT 541 TAGACTGAAGGTCTAACTGATTAATAATTTGACTTATAAGCATGGTTTGTTCACTCCTTC 601 AAATGAATTTACTTTG?AAACAAATGAAGAGCTGCTCTCCTTCTTTCCTCCACTAAGCAG 661 ATGATCCTGCTGGATTCCCGCTGGAGCAGTGCTACCCTCTGTTCCGGTGATTGGTTTGTT 721 CCTTTCTTGTATCCCCCAAAGTGGACACAAACAACTACACGATCCCAGAGACATATCTAG 781 TTAATTCCAGCTGACGAGAGACCAGAAAATTGTAAATGGATGGTTTGATATTACTGCA
WBC008B04	No homology	1 GACAATAGCAGTTATTAAATTGGGTCTCTCATCTGTATGTTTTTGTTACACTGAGGTTAA 61 GAGGCCGGATTCTTGGCAGCCAGGTCCCTCTTCAGGATCACGTTGGCTGCAACGTGAGTT 121 ATATTGGAGCACTTTAATCTGAAGGATGATACTGTAACTTGATTTATCTAATTAGCTTTT 181 AATTATCTATAGCGATTTTATTTAATCCTCTCCTACAGTCCTGGGGACCTCTGTAAACTT 241 CTCAGATGACTCGTATTTTTGTAGTGCTACGAAATTTATTTACAGACCTATAAAGAAAGC 301 TGTTTATTCACTTGAAGTCTGAAAATGTACACAGATATGTTTATTCTGCAATCTGTTTTG 361 TACTTGATAGAAATATATTTTGACTGTGATAACCCAAGTGCCCTGGGGCAGGGGTACTCG 421 GCATGGTTCCTCCTCTGAAGAGCGGGTGTGGAAACCTCAACTGCTCACGAGAAGTGCTTG 481 GTTTGGGGACAGCTGCTGCTAGGACGTGGGGGATGTGACTTGGTCAGGGTGTGAGAGGGG 541 CGTCTGGCTGGAGGAGAGTTCCTGTGCTCTGAAATGCCACTTGGGAACTCTGGAGATTGA 601 AGGACAATTTACTTCAAGGGTGTCTGGTTTCTACCACTGCTGGAAAAAAATTCGGTTTGT 661 AGCATTCCTGCACCTCACAAGTAGATCGCCTGGAGGTCATTAGTTAATAGCTGTCTGTGA 721 GGACTCTGCTTTCAGGGAGAATTTATCT Non?contiguous 1 AAAATGTCAGTCCTTTGCCTGGTTGTTCCATCTCATCTCATTCCTTGGACTTTGACAGAT 61 ATCCTGCCCTGTGTTTTATTCCTGTGTGTTAACCTCATCAGGGAAGCAGAATGGAGGAGC 121 AAGAAAGTCTGCCCTTTGCCATGCCAAACAGCTCTCAGCCCTGTGTGGTGAGGCGTGTGC 181 GCACGTACATGCATGAGTGGGGTGCATGGGTGTGGTTTCCAGCTTTGCTGACAGTGGGAG 241 CTCAGCAGAGCGTAGAGGCAGGAAGGTCCATGGCACTCAGCCACACACTATTGAAGGCTA 301 GAGGCGGTTTAGTGTTAGATTATGCGGGATCTTCCCTCCCTGGGTCACTTCTCCCAATCA 361 ACCTTTTTTTCTTTTTTAGAACTACTAATTAATGATTCCTCAAGGCCGAAAGGTTAATTT 421 CCTTGGGAGGAGAACTTAGCCTCCTAGTATCCACACCAGTCTCAACTCTGGTTTCTCAAG 481 ATCTGTCACGTTGGCCTACTAACTTGACGTCTTCCCCCCTCCCACTGAAGGATCGCCCAG 541 CGTTTTTAGATTGTAGAATTATCTCTTGCTTTGTTACTTTGGGAATTTTGAATTTCTTTG 601 GTTTTGTTTTTAAGAAGTAACCTAAAATTTCCTACAACACTAAATAAAATGGTACTACCT 661 TTCAAAAAAAAAAAAAAAAAAA	SEQ?ID?NO：24 SEQ?ID?NO：25
WBC008B04	No homology		SEQ?ID?NO：24 SEQ?ID?NO：25	BM735449.V1.3_AT	No homology	1 AATNTCAGTTACTTCAGAAAGTTTTAATTTAGAGTAATTCCAATTCATGCATATAAGCAT 61 GAATTGAAAAGATAACTATGATTGTTCTTATATAAAAATATGATTGCCATAGAAGTTAAT 121 GAATACACTTATAAGAATGTAATATGATTTCCCTTTACTTCCTACCCTTCTGTTAAACTG 181 CTGCTACTGGAGTTCGCCTTTAAAAAATACTTGTTCTTAGCTTTACAGAAGTTGAGATTT 241 GAAGTCCTTGGCATCCTGAAGTATGTTATATGCCATGTGCTTGTTATGAAGATTATGGTA 301 TGCCAGGAGACATTCTCCTGATTTTCATTATATAGAGAATCATATTTGAGAATGCTGTTC 361 TTCTTATCTTTTATAACATCAATTTCCGTTGTTTCGCTTGTCTTTTTTTAAATGTCGTCG	SEQ?ID?NO：26

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	421 GTTTAAAGAGTTTACTTCATTAAACACTTTACTTCAGCAGTTTGAATAGTAGATGGAAAA 481 ATAGGCCCCGGTCTACATTAATTTTCCCCAGTCTGCATTAGAATATTTTTGAAGATTATA 541 CTTTTCCAAACAAAGAAAATAATTTGTATTTGTGTCTAAAATTAAACTTTGTTTAAAAC 601 TCTG
WBC029A01	Homo sapiens's apoptosis 10 (PDCD10) is transcribed variant 3	1 TGCAAGGTGGGAAGTGAAGTCAGTGCCTCAGTTGCTGATCAGTGTGTTTTTTGTGTCCAA 61 TTCTTTTATCACCAAAAAAGAGAAGAAATATTGCAGTGAATGAAGATTCCTCTGCATTTT 121 AGCACTGCTTTTTCAACTGTAGTTGGCTTTTGAATGAGGATGACAATGGAAGAGATGAAG 181 AATGAAGCTGAGACCACATCCATGGTTTCTATGCCCCTCTATGCAGTCATGTATCCTGTG 241 TTTAATGAGCTAGAACGAGTAAATCTGTCTGCAGCCCAGACACTGAGAGCCGCTTTCATC 301 AAGGCTGAAAAAGAAAATCCAGGTCTCACACAAGACATCATTATGAAAATTTTAGAGAAA 361 AAAAGCGTGGAAGTTAACTTCACGGAGTCCCTTCTTCGTATGGCAGCTGATGATGTAGAA 421 GAGTATATGATTGAACGACCAGAGCCAGAATTCCAAGACCTAAACGAAAAGGCACGAGCA 481 CTTAAACAAATTCTCAGTAAGATCCCAGATGAGATCAATGACAGAGTGAGGTTTCTGCAG 541 ACAATCAAGGATATAGCTAGTGCAATAAAAGAACTTCTTGATACAGTGAATAATGTCTTC 601 AAGAAATATCAATACCAGAACCGCAGGGCACTTGAACACCAAAAGAAAGAATTTGTAAAG 661 TACTCCAAAAGTTTCAGTGATACTCTGAAAACGTATTTTAAAGATGGCAAGGCAATAAAT 721 GTGTTCGTAAGTGCCAACCGACTAATTCATCAAACCAACTTAATACTTCAGACCTTCAAA 781 ACTGTGGCCTGAAAGTTGTATATGTTAAGAGATGTACTTCTCAGTGGCAGTATTGAACTG 841 CCTTTATCTGTAAATTTTAAAGTTTGACTGTATAAATTATCAGTCCCTCCTGAAGGGATC 901 TAATCCAGGATGTTGAATGGGATTATTGCCATCTTACACCATATTTTTGTAAAATGTAGC 961 TTAATCATAATCTCACACTGAAGATTTTGCATCACTTTTGCTATTATCATTCTTTTAAGA 1021?ATTATAAGCCAAAAGAATTTACGCCTTAATGTGTCATTATATAACATTCCTTAAAAGAAT 1081?TGTAAATATTGGTGTTTGTTTCTGACATTTTAACTTGAAAGCGATATGCTGCAAGATAAT 1141?GTATTTAACAATATTTGGTGGCAAATATTCAATAAATAGTTTACATCTGTTAAAAAAAAA 1201?AAAAAAAAAAAA 1 M R M T M E E M K N E A E T T S M V S M 1 ATGAGGATGACAATGGAAGAGATGAAGAATGAAGCTGAGACCACATCCATGGTTTCTATG 21 P L Y A V M Y P V F N E L E R V N L S A 61 CCCCTCTATGCAGTCATGTATCCTGTGTTTAATGAGCTAGAACGAGTAAATCTGTCTGCA 41 A Q T L R A A F I K A E K E N P G L T Q 121 GCCCAGACACTGAGAGCCGCTTTCATCAAGGCTGAAAAAGAAAATCCAGGTCTCACACAA 61 D I I M K I L E K K S V E V N F T E S L 181 GACATCATTATGAAAATTTTAGAGAAAAAAAGCGTGGAAGTTAACTTCACGGAGTCCCTT 81 L R M A A D D V E E Y M I E R P E P E F 241 CTTCGTATGGCAGCTGATGATGTAGAAGAGTATATGATTGAACGACCAGAGCCAGAATTC 101 Q D L N E K A R A L K Q I L S K I P D E 301 CAAGACCTAAACGAAAAGGCACGAGCACTTAAACAAATTCTCAGTAAGATCCCAGATGAG 121 I N D R V R F L Q T I K D I A S A I K E 361 ATCAATGACAGAGTGAGGTTTCTGCAGACAATCAAGGATATAGCTAGTGCAATAAAAGAA	SEQ?ID?NO：27 SEQ?ID?NO：28

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			141 L L D T V N N V F K K Y Q Y Q N R R A L 421 CTTCTTGATACAGTGAATAATGTCTTCAAGAAATATCAATACCAGAACCGCAGGGCACTT 161 E H Q K K E F V K Y S K S F S D T L K T 481 GAACACCAAAAGAAAGAATTTGTAAAGTACTCCAAAAGTTTCAGTGATACTCTGAAAACG 181 Y F K D G K A I N V F V S A N R L I H Q 541 TATTTTAAAGATGGCAAGGCAATAAATGTGTTCGTAAGTGCCAACCGACTAATTCATCAA 201 T N L I L Q T F K T V A - 601 ACCAACTTAATACTTCAGACCTTCAAAACTGTGGCCTGA
BM781436.V1.3_AT	Homo sapiens SH3 structural domain associativity is rich in the albumen sample 3 of L-glutamic acid, mRNA	1 GGGAAGGGGCCTCTGGCGTGCGGGGCGGTGTCGCGCAGGTCCCACCCCGCCTGCCCGCGC 61 CGCCCATTGGTCCCGAGCGCGATGACTTGGCGGGCGGAGCAGGAAGGAAACCGCTCCCGA 121 GCACGGCGGCGGCGTCGTCTCCCGGCAGTGCAGCTGCCGCTACCGCCGCCCTCTGCCCGC 181 CGGCCCGTCTGTCTACCCCCAGCATGAGCGGCCTGCGCGTCTACAGCACGTCGGTCACCG 241 GCTCCCGCGAAATCAAGTCCCAGCAGAGCGAGGTGACCCGAATCCTGGATGGGAAGCGCA 301 TCCAGTACCAGCTAGTGGACATCTCTCAGGACAACGCCCTGCGGGATGAGATGCGAGCCT 361 TGGCAGGCAACCCTAAGGCCACCCCACCCCAGATTGTCAACGGGGACCAGTACTGTGGGG 421 ACTATGAGCTCTTCGTGGAGGCTGTGGAGCAAAACACGCTGCAGGAGTTCCTGAAACTGG 481 CTTGAGTCAAGCCTGTCCAGAGTTCCCCTGCTGGACTCCATCACCACATTCCCCCCAGCC 541 TTCACCTGGCCATGAAGGACCTTTTGACCAACTCCCTGTCATTCCTAACCTAACCTTAGA 601 GTCCCTCCCCCAATGCAGGCCACTTCTCCTCCCTCCTCTCTAAATGTAGTCCCCTCTCCT 661 CCATCTAAAGGCCACATTCCTTACCCACTAGTCTCAGAAATTGTCTTAAGCAACAGCCCA 721 AGTGCTGGCTGTCCTCAGCCAGGCCCTGGGGCTGCCACCCTGCCTGACACTGGCTGATGG 781 GCACCTATGTTGGTTCCATTAGCCAGGGCTCTGCCAAAGGCCCCGCAATCCCTCTCCCAG 841 GAGGACCCTAGAGGCAATTAAATGATGTCCTGTTCCATTGGCAAAAAAAAAAAAAAAA 1 M S G L R V Y S T S V T G S R E I K S Q 1 ATGAGCGGCCTGCGCGTCTACAGCACGTCGGTCACCGGCTCCCGCGAAATCAAGTCCCAG 21 Q S E V T R I L D G K R I Q Y Q L V D I 61 CAGAGCGAGGTGACCCGAATCCTGGATGGGAAGCGCATCCAGTACCAGCTAGTGGACATC 41 S Q D N A L R D E M R A L A G N P K A T 121 TCTCAGGACAACGCCCTGCGGGATGAGATGCGAGCCTTGGCAGGCAACCCTAAGGCCACC 61 P P Q I V N G D Q Y C G D Y E L F V E A 181 CCACCCCAGATTGTCAACGGGGACCAGTACTGTGGGGACTATGAGCTCTTCGTGGAGGCT 81 V E Q N T L Q E F L K L A - 241 GTGGAGCAAAACACGCTGCAGGAGTTCCTGAAACTGGCTTGA	SEQ?ID?NO：29 SEQ?ID?NO：30
BM781436.V1.3_AT			SEQ?ID?NO：29 SEQ?ID?NO：30	BM735054.V1.3_AT	Homo sapiens family with sequence similarity 14, member A, mRNA	1 CCGGACGGCCTCACCATGATGAAACGGGCAGCTGCTGCTGCAGTGGGAGGAGCCCTGACC 61 GTGGGGGCTGTCCCCGTGGTGCTCGGCGCCATGGGCTTCACTGGGGCAGGAATCACCGCC	SEQ?ID?NO：31

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	(cDNA clone MGC:44913 IMAGE:5229498).	121 TCGTCCTTAGCGGCCAAGATGATGTCCACGGCCGCCATTGCCAACGGGGGTGGAGTTGCG 181 GCCGGCAGCCTGGTGGCCACTCTACAGTCCGTGGGAGCGGCTGGACTCTCCACATCATCC 241 AACATCCTCCTGGCCTCTGTTGGGTCAGTGTTGGGGGCCTGCTTGGGGAATTCACCTTCT 301 TCTTCTCTCCCAGCTGAACCCGAGGCTAAAGAAGATGAGGCAAGAGAAAATGTACCCCAA 361 GGTGAACCTCCAAAACCCCCACTCAAGTCAGAGAAACATGAGGAATAAAGGTCACATGCA 421 GATGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 481 AAAAAAAAAAAAAAA 1 M M K R A A A A A V G G A L T V G A V P 1 ATGATGAAACGGGCAGCTGCTGCTGCAGTGGGAGGAGCCCTGACCGTGGGGGCTGTCCCC 21 V V L G A M G F T G A G I T A S S L A A 61 GTGGTGCTCGGCGCCATGGGCTTCACTGGGGCAGGAATCACCGCCTCGTCCTTAGCGGCC 41 K M M S T A A I A N G G G V A A G S L V 121 AAGATGATGTCCACGGCCGCCATTGCCAACGGGGGTGGAGTTGCGGCCGGCAGCCTGGTG 61 A T L Q S V G A A G L S T S S N I L L A 181 GCCACTCTACAGTCCGTGGGAGCGGCTGGACTCTCCACATCATCCAACATCCTCCTGGCC 81 S V G S V L G A C L G N S P S S S L P A 241 TCTGTTGGGTCAGTGTTGGGGGCCTGCTTGGGGAATTCACCTTCTTCTTCTCTCCCAGCT 101 E P E A K E D E A R E N V P Q G E P P K 301 GAACCCGAGGCTAAAGAAGATGAGGCAAGAGAAAATGTACCCCAAGGTGAACCTCCAAAA 121 P P L K S E K H E E - 361 CCCCCACTCAAGTCAGAGAAACATGAGGAATAA	SEQ?ID?NO：32
WBC31	No homology	1 GGCTTTTGAAGAGGTTTGGAGACAAGTTTTGTTTGTCGCGAGGACTTGGGGCTCCTACTG 61 GCGTGTAGCGGGCAGGGACTAGGGGTTCTAAACAGCCTGCCATGCGTCTGTGCAATGAAG 121 AGTTGGCCCACCCCCTGGATCCCCCTTGAGAGACTCTGGCAGCTGATGTGGCTCCTTGTG 181 GAAACAAGAGGAACAGGGAATAAGGATTCCCACCTCTCCTGTCAGGAAAGCGTTGACACT 241 GACCTACTCTGGGAATGGACGGGGAAAGATTCTGGGAGCTGGGAGTCACTGCTGAAACTG 301 GCAAACAATTACTAGGCATTAAGTCTGCGGAGGGCCATTTGCTGTGCAGAACCAAGGAAC 361 ACAAACAATAAGAAGACCGTCCGTACCCGTCCTGAAGGAGTTCACGGTCAGGCTGGGAGA 421 AATAATAGCAATAATAATAACGCATTAAGTTTCTGCTGAATACCGGATGTGTTTACATCC 481 ATCTTTTCACTTGATGCAGTCCTGAATCTGGTTCTATGATCAGCCCCCAGGTACAGAGGA 541 GGACACTGAGGCTCAGCGGTTACATGACATACGTCATGTAACCCCTCATGTATGTGATGT 601 AACACAGAAGTATGGGACCGAGCTGGGATTTGAACCCAGGTCTCACACCAAGGCCCGTGA 661 TTTTTCTACCAGACCTCACTGCCTCTGTGCTTAGGGAAGAGATCATATCTGCCCCAGCTG 721 GATGTTTCGAGGATCCTCCTCCCTCTAGACATTGGGAGAAAGATTCTTTGGAACCCCCCC 781 CAAACACACACACACACCAAGTTGAGTGACCTAAAGAAAAGGGGACAAGGTGGCCAATGC 841 AAATTGAGAGCTCCCTGTCCTCAGCCCTGAACTGGGAATTGCTGAATGGGAGCAATAAAA 901 TGGAAAAAGGCCAAGTGGCTGCTTGGAAAGGTGG NON?CONTIGUOUS 1 TCTAGACATTGGGAGAAAGATTCTTTGGAACCCCCCCCACACACACACACACACCAAGTT	SEQ?ID?NO：33 SEQ?ID?NO：34	(cDNA clone MGC:44913 IMAGE:5229498).		SEQ?ID?NO：32

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	61 GAGTGACCTAAAGAAAAGGGGACAAGGTGGCCAATGCAGATTGAGAGCTCCCTGTCCTCA 121 GCCCTGAACTGGGAATTGCTGAATGGGAGCAATAAGATGGAGAGAGGCCAAGTGGCTGCT 181 TGGAGAGGTGGTCACAGGGGTAGGAGACTTAGCTCTACACGCTCAAACTCCCAGGGTCCT 241 GGGCTTCCCAAGGGCCACAGTCTCTAGCCAACCAAACTCACAAGAGCCTGATGTATAAGC 301 CAGAGGCCCAGTGTTTCCACCAGGCGTGGAGTAAGCAGATAAGAGCTCAGCTCTGGAGCT 361 GTTAGTGCCTGGTGTAACTCTTGCCTCCACCAATCACTAGCCCTGTGATTCTGTGCAAGT 421 TATTGATTGATCTCTCTAAGCCTCAATTTCCTCATCTGTGAAATGGCAATAAAATGTTCA 481 ATACAAAAAAAAAAAAAAAAA
BM734900	Homo sapiens's matrix metalloproteinase 9 (gelatinase B, the 92kDa gelatinase, 92kDa IV Collagen Type VI enzyme), mRNA (cDNA clone MGC:12688 IMAGE:4054882)	1 TCACCATGAGCCTCTGGCAGCCCCTGGTCCTGGTGCTCCTGGTGCTGGGCTGCTGCTTTG 61 CTGCCCCCAGACAGCGCCAGTCCACCCTTGTGCTCTTCCCTGGAGACCTGAGAACCAATC 121 TCACCGACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTGGCAG 181 AGATGCGTGGAGAGTCGAAATCTCTGGGGCCTGCGCTGCTGCTTCTCCAGAAGCAACTGT 241 CCCTGCCCGAGACCGGTGAGCTGGATAGCGCCACGCTGAAGGCCATGCGAACCCCACGGT 301 GCGGGGTCCCAGACCTGGGCAGATTCCAAACCTTTGAGGGCGACCTCAAGTGGCACCACC 361 ACAACATCACCTATTGGATCCAAAACTACTCGGAAGACTTGCCGCGGGCGGTGATTGACG 421 ACGCCTTTGCCCGCGCCTTCGCACTGTGGAGCGCGGTGACGCCGCTCACCTTCACTCGCG 481 TGTACAGCCGGGACGCAGACATCGTCATCCAGTTTGGTGTCGCGGAGCACGGAGACGGGT 541 ATCCCTTCGACGGGAAGGACGGGCTCCTGGCACACGCCTTTCCTCCTGGCCCCGGCATTC 601 AGGGAGACGCCCATTTCGACGATGACGAGTTGTGGTCCCTGGGCAAGGGCGTCGTGGTTC 661 CAACTCGGTTTGGAAACGCAGATGGCGCGGCCTGCCACTTCCCCTTCATCTTCGAGGGCC 721 GCTCCTACTCTGCCTGCACCACCGACGGTCGCTCCGACGGCTTGCCCTGGTGCAGTACCA 781 CGGCCAACTACGACACCGACGACCGGTTTGGCTTCTGCCCCAGCGAGAGACTCTACACCC 841 GGGACGGCAATGCTGATGGGAAACCCTGCCAGTTTCCATTCATCTTCCAAGGCCAATCCT 901 ACTCCGCCTGCACCACGGACGGTCGCTCCGACGGCTACCGCTGGTGCGCCACCACCGCCA 961 ACTACGACCGGGACAAGCTCTTCGGCTTCTGCCCGACCCGAGCTGACTCGACGGTGATGG 1021?GGGGCAACTCGGCGGGGGAGCTGTGCGTCTTCCCCTTCACTTTCCTGGGTAAGGAGTACT 1081?CGACCTGTACCAGCGAGGGCCGCGGAGATGGGCGCCTCTGGTGCGCTACCACCTCGAACT 1141?TTGACAGCGACAAGAAGTGGGGCTTCTGCCCGGACCAAGGATACAGTTTGTTCCTCGTGG 1201?CGGCGCATGAGTTCGGCCACGCGCTGGGCTTAGATCATTCCTCAGTGCCGGAGGCGCTCA 1261?TGTACCCTATGTACCGCTTCACTGAGGGGCCCCCCTTGCATAAGGACGACGTGAATGGCA 1321?TCCGGCACCTCTATGGTCCTCGCCCTGAACCTGAGCCACGGCCTCCAACCACCACCACAC 1381?CGCAGCCCACGGCTCCCCCGACGGTCTGCCCCACCGGACCCCCCACTGTCCACCCCTCAG 1441?AGCGCCCCACAGCTGGCCCCACAGGTCCCCCCTCAGCTGGCCCCACAGGTCCCCCCACTG 1501?CTGGCCCTTCTACGGCCACTACTGTGCCTTTGAGTCCGGTGGACGATGCCTGCAACGTGA 1561?ACATCTTCGACGCCATCGCGGAGATTGGGAACCAGCTGTATTTGTTCAAGGATGGGAAGT 1621?ACTGGCGATTCTCTGAGGGCAGGGGGAGCCGGCCGCAGGGCCCCTTCCTTATCGCCGACA 1681?AGTGGCCCGCGCTGCCCCGCAAGCTGGACTCGGTCTTTGAGGAGCCGCTCTCCAAGAAGC 1741?TTTTCTTCTTCTCTGGGCGCCAGGTGTGGGTGTACACAGGCGCGTCGGTGCTGGGCCCGA 1801?GGCGTCTGGACAAGCTGGGCCTGGGAGCCGACGTGGCCCAGGTGACCGGGGCCCTCCGGA 1861?GTGGCAGGGGGAAGATGCTGCTGTTCAGCGGGCGGCGCCTCTGGAGGTTCGACGTGAAGG 1921?CGCAGATGGTGGATCCCCGGAGCGCCAGCGAGGTGGACCGGATGTTCCCCGGGGTGCCTT 1981?TGGACACGCACGACGTCTTCCAGTACCGAGAGAAAGCCTATTTCTGCCAGGACCGCTTCT 2041?ACTGGCGCGTGAGTTCCCGGAGTGAGTTGAACCAGGTGGACCAAGTGGGCTACGTGACCT 2101?ATGACATCCTGCAGTGCCCTGAGGACTAGGGCTCCCGTCCTGCTTTGGCAGTGCCATGTA 2161?AATCCCCACTGGGACCAACCCTGGGGAAGGAGCCAGTTTGCCGGATACAAACTGGTATTC 2221?TGTTCTGGAGGAAAGGGAGGAGTGGAGGTGGGCTGGGCCCTCTCTTCTCACCTTTGTTTT 2281?TTGTTGGAGTGTTTCTAATAAACTTGGATTCTCTAACCTTTAAAAAAAAAAAAAAAAAAA	SEQ?ID?NO：35

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2341?AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 M S L W Q P L V L V L L V L G C C F A A 1 ATGAGCCTCTGGCAGCCCCTGGTCCTGGTGCTCCTGGTGCTGGGCTGCTGCTTTGCTGCC 21 P R Q R Q S T L V L F P G D L R T N L T 61 CCCAGACAGCGCCAGTCCACCCTTGTGCTCTTCCCTGGAGACCTGAGAACCAATCTCACC 41 D R Q L A E E Y L Y R Y G Y T R V A E M 121 GACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTGGCAGAGATG 61 R G E S K S L G P A L L L L Q K Q L S L 181 CGTGGAGAGTCGAAATCTCTGGGGCCTGCGCTGCTGCTTCTCCAGAAGCAACTGTCCCTG 81 P E T G E L D S A T L K A M R T P R C G 241 CCCGAGACCGGTGAGCTGGATAGCGCCACGCTGAAGGCCATGCGAACCCCACGGTGCGGG 101 V P D L G R F Q T F E G D L K W H H H N 301 GTCCCAGACCTGGGCAGATTCCAAACCTTTGAGGGCGACCTCAAGTGGCACCACCACAAC 121 I T Y W I Q N Y S E D L P R A V I D D A 361 ATCACCTATTGGATCCAAAACTACTCGGAAGACTTGCCGCGGGCGGTGATTGACGACGCC 141 F A R A F A L W S A V T P L T F T R V Y 421 TTTGCCCGCGCCTTCGCACTGTGGAGCGCGGTGACGCCGCTCACCTTCACTCGCGTGTAC 161 S R D A D I V I Q F G V A E H G D G Y P 481 AGCCGGGACGCAGACATCGTCATCCAGTTTGGTGTCGCGGAGCACGGAGACGGGTATCCC 181 F D G K D G L L A H A F P P G P G I Q G 541 TTCGACGGGAAGGACGGGCTCCTGGCACACGCCTTTCCTCCTGGCCCCGGCATTCAGGGA 201 D A H F D D D E L W S L G K G V V V P T 601 GACGCCCATTTCGACGATGACGAGTTGTGGTCCCTGGGCAAGGGCGTCGTGGTTCCAACT 221 R F G N A D G A A C H F P F I F E G R S 661 CGGTTTGGAAACGCAGATGGCGCGGCCTGCCACTTCCCCTTCATCTTCGAGGGCCGCTCC 241 Y S A C T T D G R S D G L P W C S T T A 721 TACTCTGCCTGCACCACCGACGGTCGCTCCGACGGCTTGCCCTGGTGCAGTACCACGGCC 261 N Y D T D D R F G F C P S E R L Y T R D 781 AACTACGACACCGACGACCGGTTTGGCTTCTGCCCCAGCGAGAGACTCTACACCCGGGAC 281 G N A D G K P C Q F P F I F Q G Q S Y S 841 GGCAATGCTGATGGGAAACCCTGCCAGTTTCCATTCATCTTCCAAGGCCAATCCTACTCC 301 A C T T D G R S D G Y R W C A T T A N Y 901 GCCTGCACCACGGACGGTCGCTCCGACGGCTACCGCTGGTGCGCCACCACCGCCAACTAC	SEQ?ID?NO：36

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			321 D R D K L F G F C P T R A D S T V M G G 961 GACCGGGACAAGCTCTTCGGCTTCTGCCCGACCCGAGCTGACTCGACGGTGATGGGGGGC 341 N S A G E L C V F P F T F L G K E Y S T 1021?AACTCGGCGGGGGAGCTGTGCGTCTTCCCCTTCACTTTCCTGGGTAAGGAGTACTCGACC 361 C T S E G R G D G R L W C A T T S N F D 1081?TGTACCAGCGAGGGCCGCGGAGATGGGCGCCTCTGGTGCGCTACCACCTCGAACTTTGAC 381 S D K K W G F C P D Q G Y S L F L V A A 1141?AGCGACAAGAAGTGGGGCTTCTGCCCGGACCAAGGATACAGTTTGTTCCTCGTGGCGGCG 401 H E F G H A L G L D H S S V P E A L M Y 1201?CATGAGTTCGGCCACGCGCTGGGCTTAGATCATTCCTCAGTGCCGGAGGCGCTCATGTAC 421 P M Y R F T E G P P L H K D D V N G I R 1261?CCTATGTACCGCTTCACTGAGGGGCCCCCCTTGCATAAGGACGACGTGAATGGCATCCGG 441 H L Y G P R P E P E P R P P T T T T P Q 1321?CACCTCTATGGTCCTCGCCCTGAACCTGAGCCACGGCCTCCAACCACCACCACACCGCAG 461 P T A P P T V C P T G P P T V H P S E R 1381?CCCACGGCTCCCCCGACGGTCTGCCCCACCGGACCCCCCACTGTCCACCCCTCAGAGCGC 481 P T A G P T G P P S A G P T G P P T A G 1441?CCCACAGCTGGCCCCACAGGTCCCCCCTCAGCTGGCCCCACAGGTCCCCCCACTGCTGGC 501 P S T A T T V P L S P V D D A C N V N I 1501?CCTTCTACGGCCACTACTGTGCCTTTGAGTCCGGTGGACGATGCCTGCAACGTGAACATC 521 F D A I A E I G N Q L Y L F K D G K Y W 1561?TTCGACGCCATCGCGGAGATTGGGAACCAGCTGTATTTGTTCAAGGATGGGAAGTACTGG 541 R F S E G R G S R P Q G P F L I A D K W 1621?CGATTCTCTGAGGGCAGGGGGAGCCGGCCGCAGGGCCCCTTCCTTATCGCCGACAAGTGG 561 P A L P R K L D S V F E E P L S K K L F 1681?CCCGCGCTGCCCCGCAAGCTGGACTCGGTCTTTGAGGAGCCGCTCTCCAAGAAGCTTTTC 581 F F S G R Q V W V Y T G A S V L G P R R 1741?TTCTTCTCTGGGCGCCAGGTGTGGGTGTACACAGGCGCGTCGGTGCTGGGCCCGAGGCGT 601 L D K L G L G A D V A Q V T G A L R S G 1801?CTGGACAAGCTGGGCCTGGGAGCCGACGTGGCCCAGGTGACCGGGGCCCTCCGGAGTGGC 621 R G K M L L F S G R R L W R F D V K A Q 1861?AGGGGGAAGATGCTGCTGTTCAGCGGGCGGCGCCTCTGGAGGTTCGACGTGAAGGCGCAG

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			641 M V D P R S A S E V D R M F P G V P L D 1921?ATGGTGGATCCCCGGAGCGCCAGCGAGGTGGACCGGATGTTCCCCGGGGTGCCTTTGGAC 661 T H D V F Q Y R E K A Y F C Q D R F Y W 1981?ACGCACGACGTCTTCCAGTACCGAGAGAAAGCCTATTTCTGCCAGGACCGCTTCTACTGG 681 R V S S R S E L N Q V D Q V G Y V T Y D 2041?CGCGTGAGTTCCCGGAGTGAGTTGAACCAGGTGGACCAAGTGGGCTACGTGACCTATGAC 701 I L Q C P E D - 2101?ATCCTGCAGTGCCCTGAGGACTAG
B1961438	No homology	1 GCACGAGGCAGCCAGCAGCTTTGGAGCCCCCACAACCTGGACACTCACATCGAAGTCTCT 61 GCCTAGCCACCCTCTCCCTGAGCCCATCTCAGATGCCCCTCCCCCCCAGGCTGCCAGGTG 121 GCTGGGGTGAGGTCAGGTGGCAGGCCCAGAATAGGCCCAGTCATCCACTCCCCTCCCTCT 181 CAGGATTGCAGGAGTCTGAGCTATTCCCGGCCACCTCTATCTCCCACCCCACCTTCTCCA 241 CCATAGCCAGGGGCTGGGCCCCGTAGGTGAAACAAGCGGGTGAAACCCCTCTGGGGCCCA 301 GACATGCAAACCTCTGGCACCACTGGGTCCTGGCTGAACCCCTGGGTGGTGTGCAGCTTC 361 CCCTCTGGTCTCAGTTTCCTTTCCTGAAAAGCGAGGAGTTGGAGGCAACGTTCTCCTCCT 421 GGCCTGTGGCCCTCAGAGGAGAAGGACTGGAAGGAACTTCAGAGAATCCTCACTCCCCTC 481 ATTTTACAGATGAGGAAACT Non?contiguous 1 CCTTTCCTGAAAAGCGAGGAGTTGGAGGCAACGTTCTCCTCCTGGCCTGTGGCCCTCAGA 61 GGAGAAGGACTGGAAGGAACTTCAGAGAATCCTCACTCCCCTCATTTTACAGATGAGGAA 121 ACTGAGGCCCAGAGTGGGCAGAGACTTGGCATCATTGTCATCCAGCAAATAACAGAAGGG 181 AAGTTCCTTGGGGAAGAACCAGGAGCAGAGGTCTGGGGAGAGGTGGGCAAGGAGGGGGTC 241 AGTCTCCCCTAGTCCAGAAAAGGGCCTCACCTGCCAGGGGCCTCCAGTCTCTGGCCCTCT 301 GTCCTGCGCATTGCTTTCCAAGGAGCCTTCTTGAGGTCACTGCATTTGATCTTCATGGCG 361 GCACCTGGAAGAGAGACATGAGCGTTTGTGTTTGCTTTAAAAAAAGCATTTTTCATTTTA 421 AAAAATCAAGGTGTGCTTTGTAGACACTTTGGAAAGTTCAGGAGAGTAATCCAGGGTGGA 481 GTCTATGCAGAAATGACCCATAATCCAGCAACGCCAGGCCCCTGAGTGGTGGCTTCTATG 541 TAGCTGTAATCGTACTATACAT	SEQ?ID?NO：37 SEQ?ID?NO：38
B1961438	No homology		SEQ?ID?NO：37 SEQ?ID?NO：38	B1961550.V1.3_AT	Homo sapiens cDNA FLJ40597 fis, clone THYMU2011118	1 ATTGTTATCAACTCTTTGATATCTGATGATCAATGCTCCAAAGAATTGGATTAATATTTT 61 TACACAATATTGTTGTAGTCAGTAACTGTTTCTATTTCCAGGCATTTTTAGATGAATTCA 121 CTAACTGGTCAAGAATAAATCCCAACAAGGCCAGGATTCCCATGGCAGGAGATACCCAAG 181 GTGTGGTCGGGACTGTCTCTAAGCCTTGTTTCACAGCATATGAAATGAAAATCGGTGCAA 241 TTACTTTTCAGGTTGCTACTGGAGATATAGCCACTGAACAGGTAGATGTTATTGTAAACT 301 CAACAGCAAGGACATTTAATCGGAAATCAGGTGTGTCAAGAGCTATTTTAGAAGGTGCTG 361 GACAAGCTGTGGAAAGTGAATGTGCTGTACTAGCTGCACAGCCTCACAGAGATTTTATAA 421 TTACACCAGGTGGATGCTTAAAGTGCAAAATAATAATTCATGTTCCTGGGGGAAAAGATG 481 TCAGGAAAACGGTCACCAGTGTTCTAGAAGAGTGTGAACAGAGGAAGTACACATCGGTTT 541 CCCTTCCAGCCATTGGAACAGGAAATGCCGGAAAAAACCCTATCACAGTTGCTGATAACA 601 TAATCGATGCTATTGTAGACTTCTCATCACAACATTCCACCCCATCATTAAAAACAGTTA 661 AAGTTGTCATTTTTCAACCTGAGCTGCTAAATATATTCTACGACAGCATGAAAAAAAGAG 721 ACCTCTCTGCATCACTGAACTTTCAGTCCACATTCTCCATGACTACATGTAATCTTCCTG 781 AACACTGGACTGACATGAATCATCAGCTGTTTTGCATGGTCCAGCTAGAGCCAGGACAAT	SEQ?ID?NO：39

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			841 CAGAATATAATACCATAAAGGACAAGTTCACCCGAACTTGTTCTTCCCACGAAATAGAGA 901 AGATTGAGAGGATACAGAATGTATTTCTCTGGGAGAGCTACCAGGTAAAGAAAAACCACA 961 TGGACACCAAGAATGGCCATACCAATAACGAGAGACAACTCTTCCACGGCACAGATGCAG 1021?ACACAGTGCCGTACATCAATCAGCACGGCTTTAATCGCAGTTATGCTGGGAAGAACGCTA 1081?CAGTCTTTGGAAAAGGAACGTATTTCGCTGTTGATGCCAGTTATTCTGCTAACGATGCAT 1141?ACTCCAGAGCAGACAGCAGTGGGAGAAAGCATATTTACGTTGTGCGAGTACTTACAGGAG 1201?TCTACACAGTTGGACACGCAGCAATAAAAAGCCCTCCACCAAAGAACCCTGACAACCCTA 1261?CGGATCTGTTTGACTCTGTCACAGATGATACACGGCATCCAAAGCTATTTGTGGTATTCT 1321?CTGATCATCAAGCTTACCCAGAATATCTCATAACTTTCACGGCTTAAAAATATTTTTATC 1381?ATCAAAGAGATGATTTAAGTCATCTGTAAGAACAACATGCAATCTTTGTCTTTGCTTCTG 1441?GCCTGTGTAAGCAGATGAAAGTTTCCCTTTTAGGTGCCAAAATGCTGAAAATTACCTTTT 1501?TAAAGTGCTCTATTGCTGCGATTTGTAGCATACCTTTTTTTCTCAGCAAATTGATGGGTG 1561?GAAGCTGAGAAATGTATGGTAAATGTCACAGAGCTACAACCATTCACAGACACCAAATCT 1621?CTAGGAGAATAAAAAGCACATTATTCTTTTTCTATCAGAAAAAAACAAGATGCATCACCT 1681?TAAAACCAAGATGACATTGTTCTTCTTGGAACATGTTAAGACATCGAATGGTGGCGGGTT 1741?AAACTGTACTGCTTAAGTGGAGCGGCTACCGTTATGCATCTATCACAGTTGGGGATTTTG 1801?CCTTATTAAGGAAAACTTGTCAATAGTTCAGCTGAAATGACTGAATCACAGAATATTAAC 1861?TCTGTTATGGAACAAATCATAACAGATTTTACCTGTTTACATTTCAGGTAAAAATGTATC 1921?GCATTGTTATCTAATATTAAAAAATTACCCCCAATT 1 M L Q R I G L I F L H N I V V V S N C F 1 ATGCTCCAAAGAATTGGATTAATATTTTTACACAATATTGTTGTAGTCAGTAACTGTTTC 21 Y F Q A F L D E F T N W S R I N P N K A 61 TATTTCCAGGCATTTTTAGATGAATTCACTAACTGGTCAAGAATAAATCCCAACAAGGCC 41 R I P M A G D T Q G V V G T V S K P C F 121 AGGATTCCCATGGCAGGAGATACCCAAGGTGTGGTCGGGACTGTCTCTAAGCCTTGTTTC 61 T A Y E M K I G A I T F Q V A T G D I A 181 ACAGCATATGAAATGAAAATCGGTGCAATTACTTTTCAGGTTGCTACTGGAGATATAGCC 81 T E Q V D V I V N S T A R T F N R K S G 241 ACTGAACAGGTAGATGTTATTGTAAACTCAACAGCAAGGACATTTAATCGGAAATCAGGT 101 V S R A I L E G A G Q A V E S E C A V L 301 GTGTCAAGAGCTATTTTAGAAGGTGCTGGACAAGCTGTGGAAAGTGAATGTGCTGTACTA 121 A A Q P H R D F I I T P G G C L K C K I 361 GCTGCACAGCCTCACAGAGATTTTATAATTACACCAGGTGGATGCTTAAAGTGCAAAATA 141 I I H V P G G K D V R K T V T S V L E E 421 ATAATTCATGTTCCTGGGGGAAAAGATGTCAGGAAAACGGTCACCAGTGTTCTAGAAGAG 161 C E Q R K Y T S V S L P A I G T G N A G 481 TGTGAACAGAGGAAGTACACATCGGTTTCCCTTCCAGCCATTGGAACAGGAAATGCCGGA 181 K N P I T V A D N I I D A I V D F S S Q	SEQ?ID?NO：40

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	541 AAAAACCCTATCACAGTTGCTGATAACATAATCGATGCTATTGTAGACTTCTCATCACAA 201 H S T P S L K T V K V V I F Q P E L L N 601 CATTCCACCCCATCATTAAAAACAGTTAAAGTTGTCATTTTTCAACCTGAGCTGCTAAAT 221 I F Y D S M K K R D L S A S L N F Q S T 661 ATATTCTACGACAGCATGAAAAAAAGAGACCTCTCTGCATCACTGAACTTTCAGTCCACA 241 F S M T T C N L P E H W T D M N H Q L F 721 TTCTCCATGACTACATGTAATCTTCCTGAACACTGGACTGACATGAATCATCAGCTGTTT 261 C M V Q L E P G Q S E Y N T I K D K F T 781 TGCATGGTCCAGCTAGAGCCAGGACAATCAGAATATAATACCATAAAGGACAAGTTCACC 281 R T C S S H E I E K I E R I Q N V F L W 841 CGAACTTGTTCTTCCCACGAAATAGAGAAGATTGAGAGGATACAGAATGTATTTCTCTGG 301 E S Y Q V K K N H M D T K N G H T N N E 901 GAGAGCTACCAGGTAAAGAAAAACCACATGGACACCAAGAATGGCCATACCAATAACGAG 321 R Q L F H G T D A D T V P Y I N Q H G F 961 AGACAACTCTTCCACGGCACAGATGCAGACACAGTGCCGTACATCAATCAGCACGGCTTT 341 N R S Y A G K N A T V F G K G T Y F A V 1021?AATCGCAGTTATGCTGGGAAGAACGCTACAGTCTTTGGAAAAGGAACGTATTTCGCTGTT 361 D A S Y S A N D A Y S R A D S S G R K H 1081?GATGCCAGTTATTCTGCTAACGATGCATACTCCAGAGCAGACAGCAGTGGGAGAAAGCAT 381 I Y V V R V L T G V Y T V G H A A I K S 1141?ATTTACGTTGTGCGAGTACTTACAGGAGTCTACACAGTTGGACACGCAGCAATAAAAAGC 401 P P P K N P D N P T D L F D S V T D D T 1201?CCTCCACCAAAGAACCCTGACAACCCTACGGATCTGTTTGACTCTGTCACAGATGATACA 421 R H P K L F V V F S D H Q A Y P E Y L I 1261?CGGCATCCAAAGCTATTTGTGGTATTCTCTGATCATCAAGCTTACCCAGAATATCTCATA 441 T F T A - 1321?ACTTTCACGGCTTAA
BM734862.V1.3_AT	The homo sapiens who is expressed on the myelocyte 1 triggers acceptor, mRNA	1 GTCCCGGGAGCCCTCAGCAGCAGTTGGAGCTGGTGCACAGGAAGGATGAGGAAGACCAGG 61 CTCTGGGGGCTGCTGTGGATGCTCTTTGTCTCAGAACTCCGAGCTGCAACTAAATTAACT 121 GAGGAAAAGTATGAACTGAAAGAGGGGCAGACCCTGGATGTGAAATGTGACTACACGCTA 181 GAGAAGTTTGCCAGCAGCCAGAAAGCTTGGCAGATAATAAGGGACGGAGAGATGCCCAAG 241 ACCCTGGCATGCACAGAGAGGCCTTCAAAGAATTCCCATCCAGTCCAAGTGGGGAGGATC 301 ATACTAGAAGACTACCATGATCATGGTTTACTGCGCGTCCGAATGGTCAACCTTCAAGTG 361 GAAGATTCTGGACTGTATCAGTGTGTGATCTACCAGCCTCCCAAGGAGCCTCACATGCTG	SEQ?ID?NO：41

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	421 TTCGATCGCATCCGCTTGGTGGTGACCAAGGGTTTTTCAGGGACCCCTGGCTCCAATGAG 481 AATTCTACCCAGAATGTGTATAAGATTCCTCCTACCACCACTAAGGCCTTGTGCCCACTC 541 TATACCAGCCCCAGAACTGTGACCCAACCCCCACCCAAGTCAACTGCCGGTGTCTCCCGC 601 CCTGGACTTGAAGTCAACCCCACACATGTGACAGACGTCACCAGGATCTCTGTGTTCAGC 661 ATTGTCATTCCTGTGGCGTGCGCACTCGTGACTAAGAGCCTGGTCCTTACTGTCCTGTTT 721 GCTGTCACACAGAAGTCATTTGGATCCTAGGCCCATGGACCCATGAGGATGACCTCTGAT 781 CTCCATCTACATCCATCTGGCAGTTGTGCCAAGGGAGGAGGGAGGAGGTAAAAGGCAGGG 841 AGTTAATAACATGAATTAAATCTGTAATCACCGCCAAAAAAAAAAAAAAAAAAAAAAAAA 901 AAAAA 1 M R K T R L W G L L W M L F V S E L R A 1 ATGAGGAAGACCAGGCTCTGGGGGCTGCTGTGGATGCTCTTTGTCTCAGAACTCCGAGCT 21 A T K L T E E K Y E L K E G Q T L D V K 61 GCAACTAAATTAACTGAGGAAAAGTATGAACTGAAAGAGGGGCAGACCCTGGATGTGAAA 41 C D Y T L E K F A S S Q K A W Q I I R D 121 TGTGACTACACGCTAGAGAAGTTTGCCAGCAGCCAGAAAGCTTGGCAGATAATAAGGGAC 61 G E M P K T L A C T E R P S K N S H P V 181 GGAGAGATGCCCAAGACCCTGGCATGCACAGAGAGGCCTTCAAAGAATTCCCATCCAGTC 81 Q V G R I I L E D Y H D H G L L R V R M 241 CAAGTGGGGAGGATCATACTAGAAGACTACCATGATCATGGTTTACTGCGCGTCCGAATG 101 V N L Q V E D S G L Y Q C V I Y Q P P K 301 GTCAACCTTCAAGTGGAAGATTCTGGACTGTATCAGTGTGTGATCTACCAGCCTCCCAAG 121 E P H M L F D R I R L V V T K G F S G T 361 GAGCCTCACATGCTGTTCGATCGCATCCGCTTGGTGGTGACCAAGGGTTTTTCAGGGACC 141 P G S N E N S T Q N V Y K I P P T T T K 421 CCTGGCTCCAATGAGAATTCTACCCAGAATGTGTATAAGATTCCTCCTACCACCACTAAG 161 A L C P L Y T S P R T V T Q P P P K S T 481 GCCTTGTGCCCACTCTATACCAGCCCCAGAACTGTGACCCAACCCCCACCCAAGTCAACT 181 A G V S R P G L E V N P T H V T D V T R 541 GCCGGTGTCTCCCGCCCTGGACTTGAAGTCAACCCCACACATGTGACAGACGTCACCAGG 201 I S V F S I V I P V A C A L V T K S L V 601 ATCTCTGTGTTCAGCATTGTCATTCCTGTGGCGTGCGCACTCGTGACTAAGAGCCTGGTC 221 L T V L F A V T Q K S F G S - 661 CTTACTGTCCTGTTTGCTGTCACACAGAAGTCATTTGGATCCTAG	SEQ?ID?NO：42
WBC041B04_V1.3_AT	The proteinic people mRNA of interferon-induced 56Kda	1 CCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCTGCAGAACGGCTGCCTAATTTACAGC	SEQ?ID?NO：43		SEQ?ID?NO：42

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			61 AACCATGAGTACAAATGGTGATGATCATCAGGTCAAGGATAGTCTGGAGCAATTGAGATG 121 TCACTTTACATGGGAGTTATCCATTGATGACGATGAAATGCCTGATTTAGAAAACAGAGT 181 CTTGGATCAGATTGAATTCCTAGACACCAAATACAGTGTGGGAATACACAACCTACTAGC 241 CTATGTGAAACACCTGAAAGGCCAGAATGAGGAAGCCCTGAAGAGCTTAAAAGAAGCTGA 301 AAACTTAATGCAGGAAGAACATGACAACCAAGCAAATGTGAGGAGTCTGGTGACCTGGGG 361 CAACTTTGCCTGGATGTATTACCACATGGGCAGACTGGCAGAAGCTCAGACTTACCTGGA 421 CAAGGTGGAGAACACTTGCAAGAAGTTTGCAAATCCCTCCAGCTATAGAATCGACTGTCC 481 TCAGATGGACTGTGAGGAAGGATGGGCCTTGCTGAAATGTGGAGGAAAGAATTATAAACG 541 GGCCAAGGCCTGCTTTGAAAAGGCTCTGGAAGTGGACCCAGAAAACCCTGAATTCAGCAC 601 TGGGTATGCAATCACCGCCTATCGCCTGGACGGCTTTAAATTAGCCACAAAAAATCACAA 661 GCCATTTTCTTTGCTTCCCCTAAGGCAGGCTGTCCGCTTAAATCCAGACAATGGATATAT 721 TAAGGTTCTCCTTGCCCTGAAGCTTCAGGATGTAGGACAAGAAGCTGAAGGAGAAAAGTA 781 CATTGAAGAAGCGCTGACCAACACGTCCTCGCAGACCTATGTCCTTCGATATGCGGCCAA 841 GTTTTACAGAAAAAAAGGCTCTCTGGATAAAGCTCTTCAGCTCTTTAAAAAGGCCTTGAA 901 AGCAACACCCTCCTCTGCCTTCGTGCATCACCAGATAGGGCTTTGCTACAGAGGACAAGT 961 GATTCAAATGAAGAAAGCTGCAAACTGGCAGCCTAGAGGACAGGATAGAAAAAATGTTGA 1021?GAGAATTGCAAGATTAGCCATATCTCATTTGGAATTTGCTCTGGAAGAAAAACCCACACT 1081?TGATATTGCTTATGTAGACCTGGCAGAAATGTATATAGAAGCAGGTGACCACAGAAAAGC 1141?TGAAGACACTTATCAAAAAGTGTTAACCATGAAAGTACTCGAAGAAGAAAAGCTGCAAAG 1201?GGTACATTTCTCCTATGGCCGATTTCAGGAATTTCAAAATAAATCTGAAGACCATGCAAT 1261?TATCCATTATTTAAAAGCAGCAGAAATAGAAAACGCATCTTTTCTAAGAGATAAAAGTAT 1321?CAGGTCTTTGGAGAAATTGGCTTTAAAGAAACTTCAGAGAAACCAGTGGTAGAAGAAACA 1381?ATGCAAGACATACATTTCTACTATGGTCGGTTTCAGGAATTTCAAAAGAAATCTGACGTC 1441?AATGCAATTATCCATTATTTAAAAGCTATAAAAATAGAACAGGCATCATTAACAAGGGAT 1501?AAAAGTATCAATTCTTTGAAGAAATTGGTTTTAAGGAAACTTCGGAGAAAGGCATTAGAT 1561?CTGGAAAGCTTGAGCCTCCTTGGGTTCGTCTACAAATTGGAAGGAAATATGAATGAAGCC 1621?CTGGAGTACTATGAGCGGGCCCTGAGACTGGCTGCTGACTTTGAGAACTCTGTGAGACAA 1681?GGTCCTTAGGCACCCAGATATCAGCCACTTTCACATTTTATGTTAACACATACTAATCAT 1741?CTTACCTGCTTGCTGCTTTCAGAACATGTTATGTAATTTACTGTAATGATGCAATTTTTG 1801?AATAATAAATCTGACAAAATATT 1 M S T N G D D H Q V K D S L E Q L R C H 1 ATGAGTACAAATGGTGATGATCATCAGGTCAAGGATAGTCTGGAGCAATTGAGATGTCAC 21 F T W E L S I D D D E M P D L E N R V L 61 TTTACATGGGAGTTATCCATTGATGACGATGAAATGCCTGATTTAGAAAACAGAGTCTTG 41 D Q I E F L D T K Y S V G I H N L L A Y 121 GATCAGATTGAATTCCTAGACACCAAATACAGTGTGGGAATACACAACCTACTAGCCTAT 61 V K H L K G Q N E E A L K S L K E A E N 181 GTGAAACACCTGAAAGGCCAGAATGAGGAAGCCCTGAAGAGCTTAAAAGAAGCTGAAAAC 81 L M Q E E H D N Q A N V R S L V T W G N 241 TTAATGCAGGAAGAACATGACAACCAAGCAAATGTGAGGAGTCTGGTGACCTGGGGCAAC 101 F A W M Y Y H M G R L A E A Q T Y L D K 301 TTTGCCTGGATGTATTACCACATGGGCAGACTGGCAGAAGCTCAGACTTACCTGGACAAG	SEQ?ID?NO：44

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			121 V E N T C K K F A N P S S Y R I D C P Q 361 GTGGAGAACACTTGCAAGAAGTTTGCAAATCCCTCCAGCTATAGAATCGACTGTCCTCAG 141 M D C E E G W A L L K C G G K N Y K R A 421 ATGGACTGTGAGGAAGGATGGGCCTTGCTGAAATGTGGAGGAAAGAATTATAAACGGGCC 161 K A C F E K A L E V D P E N P E F S T G 481 AAGGCCTGCTTTGAAAAGGCTCTGGAAGTGGACCCAGAAAACCCTGAATTCAGCACTGGG 181 Y A I T A Y R L D G F K L A T K N H K P 541 TATGCAATCACCGCCTATCGCCTGGACGGCTTTAAATTAGCCACAAAAAATCACAAGCCA 201 F S L L P L R Q A V R L N P D N G Y I K 601 TTTTCTTTGCTTCCCCTAAGGCAGGCTGTCCGCTTAAATCCAGACAATGGATATATTAAG 221 V L L A L K L Q D V G Q E A E G E K Y I 661 GTTCTCCTTGCCCTGAAGCTTCAGGATGTAGGACAAGAAGCTGAAGGAGAAAAGTACATT 241 E E A L T N T S S Q T Y V L R Y A A K F 721 GAAGAAGCGCTGACCAACACGTCCTCGCAGACCTATGTCCTTCGATATGCGGCCAAGTTT 261 Y R K K G S L D K A L Q L F K K A L K A 781 TACAGAAAAAAAGGCTCTCTGGATAAAGCTCTTCAGCTCTTTAAAAAGGCCTTGAAAGCA 281 T P S S A F V H H Q I G L C Y R G Q V I 841 ACACCCTCCTCTGCCTTCGTGCATCACCAGATAGGGCTTTGCTACAGAGGACAAGTGATT 301 Q M K K A A N W Q P R G Q D R K N V E R 901 CAAATGAAGAAAGCTGCAAACTGGCAGCCTAGAGGACAGGATAGAAAAAATGTTGAGAGA 321 I A R L A I S H L E F A L E E K P T L D 961 ATTGCAAGATTAGCCATATCTCATTTGGAATTTGCTCTGGAAGAAAAACCCACACTTGAT 341 I A Y V D L A E M Y I E A G D H R K A E 1021?ATTGCTTATGTAGACCTGGCAGAAATGTATATAGAAGCAGGTGACCACAGAAAAGCTGAA 361 D T Y Q K V L T M K V L E E E K L Q R V 1081?GACACTTATCAAAAAGTGTTAACCATGAAAGTACTCGAAGAAGAAAAGCTGCAAAGGGTA 381 H F S Y G R F Q E F Q N K S E D H A I I 1141?CATTTCTCCTATGGCCGATTTCAGGAATTTCAAAATAAATCTGAAGACCATGCAATTATC 401 H Y L K A A E I E N A S F L R D K S I R 1201?CATTATTTAAAAGCAGCAGAAATAGAAAACGCATCTTTTCTAAGAGATAAAAGTATCAGG 421 S L E K L A L K K L Q R N Q W - 1261?TCTTTGGAGAAATTGGCTTTAAAGAAACTTCAGAGAAACCAGTGGTAG

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	WBC422.GRSP.V1.3_AT	Homo sapiens's guanine nucleotide binding protein 5, mRNA.	1 CTCCAGGCTGTGGAACCTTTGTTCTTTCACTCTTTGCAATAAATCTTGCTGCTGCTCACT 61 CTTTGGGTCCACACTGCCTTTATGAGCTGTAACACTCACTGGGAATGTCTGCAGCTTCAC 121 TCCTGAAGCCAGCGAGACCACGAACCCACCAGGAGGAACAAACAACTCCAGACGCGCAGC 181 CTTAAGAGCTGTAACACTCACCGCGAAGGTCTGCAGCTTCACTCCTGAGCCAGCCAGACC 241 ACGAACCCACCAGAAGGAAGAAACTCCAAACACATCCGAACATCAGAAGGAGCAAACTCC 301 TGACACGCCACCTTTAAGAACCGTGACACTCAACGCTAGGGTCCGCGGCTTCATTCTTGA 361 AGTCAGTGAGACCAAGAACCCACCAATTCCGGACACGCTAATTGTTGTAGATCATCACTT 421 CAAGGTGCCCATATCTTTCTAGTGGAAAAATTATTCTGGCCTCCGCTGCATACAAATCAG 481 GCAACCAGAATTCTACATATATAAGGCAAAGTAACATCCTAGACATGGCTTTAGAGATCC 541 ACATGTCAGACCCCATGTGCCTCATCGAGAACTTTAATGAGCAGCTGAAGGTTAATCAGG 601 AAGCTTTGGAGATCCTGTCTGCCATTACGCAACCTGTAGTTGTGGTAGCGATTGTGGGCC 661 TCTATCGCACTGGCAAATCCTACCTGATGAACAAGCTGGCTGGGAAGAACAAGGGCTTCT 721 CTGTTGCATCTACGGTGCAGTCTCACACCAAGGGAATTTGGATATGGTGTGTGCCTCATC 781 CCAACTGGCCAAATCACACATTAGTTCTGCTTGACACCGAGGGCCTGGGAGATGTAGAGA 841 AGGCTGACAACAAGAATGATATCCAGATCTTTGCACTGGCACTCTTACTGAGCAGCACCT 901 TTGTGTACAATACTGTGAACAAAATTGATCAGGGTGCTATCGACCTACTGCACAATGTGA 961 CAGAACTGACAGATCTGCTCAAGGCAAGAAACTCACCCGACCTTGACAGGGTTGAAGATC 1021?CTGCTGACTCTGCGAGCTTCTTCCCAGACTTAGTGTGGACTCTGAGAGATTTCTACCTAG 1081?CCCTGGAAGCAGATGGGCAACTCGTCACAGCCGATGAATACCTGGAGAATTCGCTGAGGC 1141?AAAAGCAAGGCACCGATCGAAGTCTCCAAAATTTCAATTTGCCCCGTCTGTGTATACAGA 1201?AATTCTTTCCAAGAAAGAAATGCTTTATTTTTGACTTGCCCACTCACCGGAAGAAGCTTG 1261?CCCACCTCGAGACACTGCATAATGATGAGCTGGATTCTGACTTTGTGCAACAAGTGGCAG 1321?AATTCTGTTCATACGTCTTCAAGCATTCCAAGACTAAAACCCTTTCAGGAGGCATTAAAG 1381?TCAATGGACCTCAATTAGAGAGCCTGGTGCTGACCTATGTCAACGCCATCAGCCGTGGGT 1441?ATCTGCCCTGCATGGAGAACTCAGTCTTGGCCTTGGCTCAGATCAAGAACTCAGCAGCAG 1501?TGCAAAAGGCCATTGCTCACTATGACCAGCAGATGGGCCGGAAGCTGCAGCTGCCCACGG 1561?AAACCCTCCAGGAGCTGCTAGACCTGCACAGGGCCAGTGAGAAAGAAGCCATTGCCGTCT 1621?TCATGAAGAACTCTTTCAAGGATGTGAACCAAAGTTTCCAGAAAAAATTACGGACCCAGC 1681?TAGAAGCAAAACAGGATGACTTTTATCAACAGAACTTGGAGGCATCACTGGATCGTTGCT 1741?CAGCTTTACTTCAGGATCTTTTTGGTCCTCTAGAAGAAGCAGTGAAGCAGGGAATTTATT 1801?CTAAGCCAGGAGGCCATAATCTCTTCATTCAGAAAACAGAAGAACTGAAGGCAAAGTACT 1861?ATCGGGAGCCTCGGAAAGGAATACAGGCTGAAGAAGTTCTGCAGAAATATTTAAAGTCCA 1921?AGGAGTCTGTGAGTCATGCAATATTACAGACTGACCAGGCTCTCACAGAGACGGAAAAAA 1981?AGAAGAAAGAGGCACAAGTGAAAGCAGAAGCTGAAAAGGCTGAAGCGCAAAGGTTGGCGG 2041?CGATTCAAAGGCAGAACGAGCAAATGATGCAGGAGAGGGAGAGACTCCATCAGGAACAAG 2101?TGAGACAAATGGAGATAGCCAAACAAAATTGGCTGGCAGAGCAACAGAAAATGCAGGAAC 2161?AACAGATGCAGGAACAGGCTGCACAGCTCAGCACAACATTCCAAGCTCAAAATAGAAGCC 2221?TTCTCAGTGAGCTCCAGCACGCCCAGAGGACTGTTAATAACGATGATCCATGTGTTTTAC 2281?TCTAAAGTGCTAAATATGGGAGTTTCCTTTTTTTACTCTTTGTCACTGATGACACAACAG 2341?AAAAGAAACTGTAGACCTTGGGACAATCAACATTTAAATAAACTTTATAATTATTTTTTC 2401?AAACTTTAAAAAAAAAAAAAAAAAAAAAAAA 1 M A L E I H M S D P M C L I E N F N E Q 1 ATGGCTTTAGAGATCCACATGTCAGACCCCATGTGCCTCATCGAGAACTTTAATGAGCAG 21 L K V N Q E A L E I L S A I T Q P V V V 61 CTGAAGGTTAATCAGGAAGCTTTGGAGATCCTGTCTGCCATTACGCAACCTGTAGTTGTG	SEQ?ID?NO：45 SEQ?ID?NO：46

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			41 V A I V G L Y R T G K S Y L M N K L A G 121 GTAGCGATTGTGGGCCTCTATCGCACTGGCAAATCCTACCTGATGAACAAGCTGGCTGGG 61 K N K G F S V A S T V Q S H T K G I W I 181 AAGAACAAGGGCTTCTCTGTTGCATCTACGGTGCAGTCTCACACCAAGGGAATTTGGATA 81 W C V P H P N W P N H T L V L L D T E G 241 TGGTGTGTGCCTCATCCCAACTGGCCAAATCACACATTAGTTCTGCTTGACACCGAGGGC 101 L G D V E K A D N K N D I Q I F A L A L 301 CTGGGAGATGTAGAGAAGGCTGACAACAAGAATGATATCCAGATCTTTGCACTGGCACTC 121 L L S S T F V Y N T V N K I D Q G A I D 361 TTACTGAGCAGCACCTTTGTGTACAATACTGTGAACAAAATTGATCAGGGTGCTATCGAC 141 L L H N V T E L T D L L K A R N S P D L 421 CTACTGCACAATGTGACAGAACTGACAGATCTGCTCAAGGCAAGAAACTCACCCGACCTT 161 D R V E D P A D S A S F F P D L V W T L 481 GACAGGGTTGAAGATCCTGCTGACTCTGCGAGCTTCTTCCCAGACTTAGTGTGGACTCTG 181 R D F Y L A L E A D G Q L V T A D E Y L 541 AGAGATTTCTACCTAGCCCTGGAAGCAGATGGGCAACTCGTCACAGCCGATGAATACCTG 201 E N S L R Q K Q G T D R S L Q N F N L P 601 GAGAATTCGCTGAGGCAAAAGCAAGGCACCGATCGAAGTCTCCAAAATTTCAATTTGCCC 221 R L C I Q K F F P R K K C F I F D L P T 661 CGTCTGTGTATACAGAAATTCTTTCCAAGAAAGAAATGCTTTATTTTTGACTTGCCCACT 241 H R K K L A H L E T L H N D E L D S D F 721 CACCGGAAGAAGCTTGCCCACCTCGAGACACTGCATAATGATGAGCTGGATTCTGACTTT 261 V Q Q V A E F C S Y V F K H S K T K T L 781 GTGCAACAAGTGGCAGAATTCTGTTCATACGTCTTCAAGCATTCCAAGACTAAAACCCTT 281 S G G I K V N G P Q L E S L V L T Y V N 841 TCAGGAGGCATTAAAGTCAATGGACCTCAATTAGAGAGCCTGGTGCTGACCTATGTCAAC 301 A I S R G Y L P C M E N S V L A L A Q I 901 GCCATCAGCCGTGGGTATCTGCCCTGCATGGAGAACTCAGTCTTGGCCTTGGCTCAGATC 321 K N S A A V Q K A I A H Y D Q Q M G R K 961 AAGAACTCAGCAGCAGTGCAAAAGGCCATTGCTCACTATGACCAGCAGATGGGCCGGAAG 341 L Q L P T E T L Q E L L D L H R A S E K 1021?CTGCAGCTGCCCACGGAAACCCTCCAGGAGCTGCTAGACCTGCACAGGGCCAGTGAGAAA

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	361 E A I A V F M K N S F K D V N Q S F Q K 1081?GAAGCCATTGCCGTCTTCATGAAGAACTCTTTCAAGGATGTGAACCAAAGTTTCCAGAAA 381 K L R T Q L E A K Q D D F Y Q Q N L E A 1141?AAATTACGGACCCAGCTAGAAGCAAAACAGGATGACTTTTATCAACAGAACTTGGAGGCA 401 S L D R C S A L L Q D L F G P L E E A V 1201?TCACTGGATCGTTGCTCAGCTTTACTTCAGGATCTTTTTGGTCCTCTAGAAGAAGCAGTG 421 K Q G I Y S K P G G H N L F I Q K T E E 1261?AAGCAGGGAATTTATTCTAAGCCAGGAGGCCATAATCTCTTCATTCAGAAAACAGAAGAA 441 L K A K Y Y R E P R K G I Q A E E V L Q 1321?CTGAAGGCAAAGTACTATCGGGAGCCTCGGAAAGGAATACAGGCTGAAGAAGTTCTGCAG 461 K Y L K S K E S V S H A I L Q T D Q A L 1381?AAATATTTAAAGTCCAAGGAGTCTGTGAGTCATGCAATATTACAGACTGACCAGGCTCTC 481 T E T E K K K K E A Q V K A E A E K A E 1441?ACAGAGACGGAAAAAAAGAAGAAAGAGGCACAAGTGAAAGCAGAAGCTGAAAAGGCTGAA 501 A Q R L A A I Q R Q N E Q M M Q E R E R 1501?GCGCAAAGGTTGGCGGCGATTCAAAGGCAGAACGAGCAAATGATGCAGGAGAGGGAGAGA 521 L H Q E Q V R Q M E I A K Q N W L A E Q 1561?CTCCATCAGGAACAAGTGAGACAAATGGAGATAGCCAAACAAAATTGGCTGGCAGAGCAA 541 Q K M Q E Q Q M Q E Q A A Q L S T T F Q 1621?CAGAAAATGCAGGAACAACAGATGCAGGAACAGGCTGCACAGCTCAGCACAACATTCCAA 561 A Q N R S L L S E L Q H A Q R T V N N D 1681?GCTCAAAATAGAAGCCTTCTCAGTGAGCTCCAGCACGCCCAGAGGACTGTTAATAACGAT 581 D P C V L L - 1741?GATCCATGTGTTTTACTCTAA
WBC007E09	Homo sapiens's sterol-C5-desaturase (ERG3 delta-5-desaturase homologue, fungi)-and sample, transcript variant 2	1 AGAGACTTCAGCGCCTGGGACTCGGGTGGGCGAGGCGGAAGGTGTCCTCGCAGCACGGCT 61 TTTCTCCGCGCCGCGGTTGGTTAGCGAGTGCCCTCTGGGTGCTAGGCGTTGGGCGGATGG 121 TAGGATCGCGGTAGCATACGGATCCGAGTCCTGCGCCGAGTGAGAGGAGAGGCTGGCAGG 181 GGCTAAGTGATGGATCTTGTACTCCGTGTTGCAGATTACTATTTTTTTACACCATACGTG 241 TATCCAGCCACATGGCCAGAAGATGACATCTTCCGACAAGCTATTAGTCTTCTGATTGTA 301 ACAAATGTTGGTGCTTACATCCTTTATTTCTTCTGTGCAACACTGAGCTATTATTTTGTC 361 TTCGATCATGCATTAATGAAACATCCACAATTTTTAAAGAATCAAGTCCGTCGAGAGATT 421 AAGTTTACTGTCCAGGCATTGCCATGGATAAGTATTCTTACTGTTGCACTGTTCTTGCTG 481 GAGATAAGAGGTTACAGCAAATTACATGATGACCTAGGAGAGTTTCCATATGGATTGTTT 541 GAACTTGTCGTTAGTATAATATCTTTCCTCTTTTTCACTGACATGTTCATCTACTGGATT 601 CACAGAGGCCTTCATCATAGACTGGTATATAAGCGCCTACATAAACCTCACCATATTTGG 661 AAGATTCCTACTCCATTTGCAAGTCATGCTTTTCACCCTATTGATGGCTTTCTTCAGAGT	SEQ?ID?NO：47

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	721 CTACCTTACCATATATACCCTTTTATCTTTCCATTACACAAGGTGGTTTATTTAAGTCTG 781 TACATCTTGGTTAATATCTGGACAATTTCCATTCATGACGGTGATTTTCGTGTCCCCCAA 841 ATCTTACAGCCATTTATTAATGGCTCAGCTCATCATACAGACCACCATATGTTCTTTGAC 901 TATAATTATGGACAATATTTCACTTTGTGGGATAGGATTGGCGGCTCATTCAAAAATCCT 961 TCATCCTTTGAGGGGAAGGGACCGCTCAGTTATGTGAAGGAGATGACAGAGGGAAAGCGC 1021?AGCAGCCATTCAGGAAATGGCTGTAAGAATGAAAAATTATTCAATGGAGAGTTTACAAAG 1081?ACTGAATAGATTATTGCCCAGTTATTCTTAAGTAAGGACAAAGAAGGAAATATCATCGTA 1141?TTTCTTTTTTTTAATAAGGAAAAAATAATATCCATACAGTCAAGATACATAGTAAATGGT 1201?ATCATTTGGAAATCAGCATCGTGGGCACTGCTGAGGAATGATCCTAGTGGTAGGTCAGAA 1261?GAAGATGCTGTGAACACCAGGACTTTAATCTTATGCTTAAAATGCCAGATGTTGTTCGGG 1321?GGACAACTTGTATCTTTCTAGCAGCAGATCTGTAGTTTGTATAGCCTCAACAACAATTTT 1381?AAATAAGATGGAGAATAAATTATTGAGGGGACTAGGCTATATGCATTTGCCTTCATCCAC 1441?CCATGTTTATTAAGAATCATTGTGCTTAATAATACCAAGACTAAGCACCATAACCAAGAA 1501?ATACTAATGTAAAGATTGTTTCTTGTTTCAGGAATGGTTAATTCTTCAACGTTGGTATGA 1561?TAATGATAACTTGTTTTGACTTGAATAAAGTACTACATCAGTGTGGAAAAAAATTCTGAT 1621?ACATTAGCAGCTATGTAAATGACCTAATTGATAGCAGGTGTAATAAGACTATCGTCTTCC 1681?TACACATAGGAGGCTCATTCTCTGGACACACTATCACCTATTACATTTTACTGATTAACA 1741?AATAAATTGGAATTTAAAAATATCGATATCACCATGATTTAATCCAGATCTGGGATTATG 1801?TAGCTAAACATTGTGATGATTATTATTTAAAACCATTATTTAATAAGAGTAAAAATATGT 1861?GAATCTGGATATATTTAAAAAAAGAAATTTGATGCCCAGATAATATATTAGGCACTACTG 1921?ATTTTTTAGTTAAATTGATGCACTACACTTTTGATGTTTGAAGTTACAAACCTGTAATTT 1981?TTTTGTAAAGGAAATAATTGCCAAATACCTAGGCCCATTGCTGACGATTAGTTCTAAAAT 2041?CTTATTCCTCCTCTTCTCCCCTCACTTTTCCCTACTTCCTCTGCAAAAAGATTTAACAAA 2101?TACATTCATAAGGAAATGTGTGTTGTAACAAATATATTGCAAAAACATAGTTTGTAAAGG 2161?CATTCTATAAGCTATTTATGTAAAATCAATAAAAGTTGATCATAATTAAAAAAAAAAAAA 2221?AAAAAAAA 1 MDLVLRVADYYFFTPYVYPATWPEDDIFRQAISLLIVTNVGAYILYFFCATLSYYFVFDH 61 ALMKHPQFLKNQVRREIKFTVQALPWISILTVALFLLEIRGYSKLHDDLGEFPYGLFELV 121 VSIISFLFFTDMFIYWIHRGLHHRLVYKRLHKPHHIWKIPTPFASHAFHPIDGFLQSLPY 181 HIYPFIFPLHKVVYLSLYILVNIWTISIHDGDFRVPQILQPFINGSAHHTDHHMFFDYNY 241 GQYFTLWDRIGGSFKNPSSFEGKGPLSYVKEMTEGKRSSHSGNGCKNEKLFNGEFTKTE-	SEQ?ID?NO：48
BM735031.V1.3_AT	Homo sapiens N-myc (and STAT) interactant (interactor), mRNA (cDNA clone MGC:5050 IMAGE:3452659).	1 GGCGCGCTGGGCCTTGGGGAGCTGCGCTCGGCGGGCGGACGCGGGGGATCATGGAAGCTG 61 ATAAAGATGACACACAACAAATTCTTAAGGAGCATTCGCCAGATGAATTTATAAAAGATG 121 AACAAAATAAGGGACTAATTGATGAAATTACAAAGAAAAATATTCAACTAAAGAAGGAGA 181 TCCAAAAGCTTGAAACGGAGTTACAAGAGGCTACCAAAGAATTCCAGATTAAAGAGGATA 241 TTCCTGAAACAAAGATGAAATTCTTATCAGTTGAAACTCCTGAGAATGACAGCCAGTTGT 301 CAAATATCTCCTGTTCATTTCAAGTGAGCTCGAAAGTTCCTTATGAGATACAAAAAGGAC 361 AAGCACTTATCACCTTTGAAAAAGAAGAAGTTGCTCAAAATGTGGTAAGCATGAGTAAAC 421 ATCATGTACAGATAAAAGATGTAAATCTGGAGGTTACGGCCAAGCCAGTTCCATTAAATT 481 CAGGAGTCAGATTCCAGGTTTATGTAGAAGTTTCTAAAATGAAAATCAATGTTACTGAAA 541 TTCCTGACACATTGCGTGAAGATCAAATGAGAGACAAGCTAGAACTGAGCTTTTGTAAGT 601 CCCGACACGGAGGAGGAGAGGTGGAATGCGTGAAGTACGATAAGCGGTCTGGAAGTGCTG	SEQ?ID?NO：49		SEQ?ID?NO：48

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			661 TCATCACGTTTGTGGAAACTGGAGTTGCTGACGAGATTTTGAAGAAGAAAGACTATCCTC 721 TTTATACAGATCATAGCTGCCATAGAGTTACTGTTTCTCCGTACATAGAAAAACACTTGA 781 AAAAGTTTCAGGTATTTTCAGGAATATCTAAGAGGACAGTGCTTCTGACTGGAATGGAAG 841 GCCTTGATATGATGGATGAAGAAACTGTGGAGGATTTAGTTAGCATTCACTTTCAACGGG 901 AGAAGAATGGAGGTGGTGAAGTCGATGTGGTCAAATGTTCTCTAGGTCAACCTTACATAG 961 CATACTTTGAAGAATAGACTTAACAGAATCATGAAAACTATAGCTTTTTAACCCGGATTA 1021?CTGTAAATGTTTGACAAAAATGAGTATCCTTTTCCTTAAAAAAATGAAAACTTTAATTCT 1081?TTACTATCATTTATTTTTAGATACAAAATATGTTTCCACGTTTTTGAATTCTTCTTTCTT 1141?TCAAACTGTGCTGCATGTTCACAAATGCAATAAGTGCACTGAATTAAAAAGTTTTGTTTA 1201?TAGAAAAAAAAAAAAAAAAAAAAAAA 1 M E A D K D D T Q Q I L K E H S P D E F 1 ATGGAAGCTGATAAAGATGACACACAACAAATTCTTAAGGAGCATTCGCCAGATGAATTT 21 I K D E Q N K G L I D E I T K K N I Q L 61 ATAAAAGATGAACAAAATAAGGGACTAATTGATGAAATTACAAAGAAAAATATTCAACTA 41 K K E I Q K L E T E L Q E A T K E F Q I 121 AAGAAGGAGATCCAAAAGCTTGAAACGGAGTTACAAGAGGCTACCAAAGAATTCCAGATT 61 K E D I P E T K M K F L S V E T P E N D 181 AAAGAGGATATTCCTGAAACAAAGATGAAATTCTTATCAGTTGAAACTCCTGAGAATGAC 81 S Q L S N I S C S F Q V S S K V P Y E I 241 AGCCAGTTGTCAAATATCTCCTGTTCATTTCAAGTGAGCTCGAAAGTTCCTTATGAGATA 101 Q K G Q A L I T F E K E E V A Q N V V S 301 CAAAAAGGACAAGCACTTATCACCTTTGAAAAAGAAGAAGTTGCTCAAAATGTGGTAAGC 121 M S K H H V Q I K D V N L E V T A K P V 361 ATGAGTAAACATCATGTACAGATAAAAGATGTAAATCTGGAGGTTACGGCCAAGCCAGTT 141 P L N S G V R F Q V Y V E V S K M K I N 421 CCATTAAATTCAGGAGTCAGATTCCAGGTTTATGTAGAAGTTTCTAAAATGAAAATCAAT 161 V T E I P D T L R E D Q M R D K L E L S 481 GTTACTGAAATTCCTGACACATTGCGTGAAGATCAAATGAGAGACAAGCTAGAACTGAGC 181 F C K S R H G G G E V E C V K Y D K R S 541 TTTTGTAAGTCCCGACACGGAGGAGGAGAGGTGGAATGCGTGAAGTACGATAAGCGGTCT 201 G S A V I T F V E T G V A D E I L K K K 601 GGAAGTGCTGTCATCACGTTTGTGGAAACTGGAGTTGCTGACGAGATTTTGAAGAAGAAA 221 D Y P L Y T D H S C H R V T V S P Y I E 661 GACTATCCTCTTTATACAGATCATAGCTGCCATAGAGTTACTGTTTCTCCGTACATAGAA 241 K H L K K F Q V F S G I S K R T V L L T	SEQ?ID?NO：50

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	721 AAACACTTGAAAAAGTTTCAGGTATTTTCAGGAATATCTAAGAGGACAGTGCTTCTGACT 261 G M E G L D M M D E E T V E D L V S I H 781 GGAATGGAAGGCCTTGATATGATGGATGAAGAAACTGTGGAGGATTTAGTTAGCATTCAC 281 F Q R E K N G G G E V D V V K C S L G Q 841 TTTCAACGGGAGAAGAATGGAGGTGGTGAAGTCGATGTGGTCAAATGTTCTCTAGGTCAA 301 P Y I A Y F E E - 901 CCTTACATAGCATACTTTGAAGAATAG
WBC013G08_V1.3_AT	Homo sapiens cDNA FLJ16386 fis, clone TRACH2000862 mediumly is similar to the purine nucleoside acid binding protein mRNA that mouse is inferred	1 AGAACTCACATCGGATGATTCAGGCATGGCTCTGCTAACACTTTATTAAAAGCATGGATT 61 AATTTTACTTCCAAGTTTATTTTTACTGCACCGTCCCATTTGTGGAAACAACTAGCTTAC 121 TCAGCTTTTTTTTCCTTTTATAAAGGAAAGAACAGAAAAGTAAAAGGAGGAAAGAAAACA 181 AGAGGTGAGTGAGGCAACTGAAAACTGTTCTTGGACCTGCGGTGCTATAGAGCAGGCTCT 241 TCTAGGTTGGCAGTTGCCATGGAATCTGGACCCAAAATGTTGGCCCCCGTTTGCCTGGTG 301 GAAAATAACAATGAGCAGCTATTGGTGAACCAGCAAGCTATACAGATTCTTGAAAAGATT 361 TCTCAGCCAGTGGTGGTGGTGGCCATTGTAGGACTGTACCGTACAGGGAAATCCTACTTG 421 ATGAACCATCTGGCAGGACAGAATCATGGCTTCCCTCTGGGCTCCACGGTGCAGTCTGAA 481 ACCAAGGGCATCTGGATGTGGTGCGTGCCCCACCCATCCAAGCCAAACCACACCCTGGTC 541 CTTCTGGACACCGAAGGTCTGGGCGATGTGGAAAAGGGTGACCCTAAGAATGACTCCTGG 601 ATCTTTGCCCTGGCTGTGCTCCTGTGCAGCACCTTTGTCTACAACAGCATGAGCACCATC 661 AACCACCAGGCCCTGGAGCAGCTGCATTATGTGACAGAGCTCACAGAGCTCATCAGGGCA 721 AAGTCTTCCCCAAGACCTGATGAAGTACAAGATTCCACAGAGTTTGTGAGTTTCTTTCCA 781 GACTTTATCTGGACTGTACGGGATTTCACCCTGGAGCTGAAGTTAGACGGTCACCCTATC 841 ACAGAAGATGAGTACTTGGAGAATGCCTTGAAGCTGATTCCAGGCAAGAATCCCAAAGTC 901 CAAGCGTCCAATCTACCCAGAGAGTGCATCAGGCTATTCTTTCCAAAACGGAAATGTTTT 961 GTATTTGACCGGCCAATAAACGACAAAGCACTCCTAGCTGACATTGAGAATGTGTCTGAA 1021?AACGAACTGGATTCTAAATTCCAAGAACAAATAAACAAGTTCTGTTCTCACATCTTCACC 1081?CATGCAAGACCTAAGACTCTTAGAGAGGGAATCATGGTCACTGGGAATCGGCTGAGGACT 1141?CTGGTGGTGACCTATGTGGATACCATCAATACTGGAGCAGTGCCTTGTTTGGAGAATGCA 1201?GTGAGAACTCTGGCCCAACTTGAGAACTCAGTGGCCATGCAGAAGGCAGCGGACCATTAC 1261?AGTGAGCAGATGGCCGAGAAATTGAAGTTGCCCACAGACACACTCCAGGAGCTGCTGGAC 1321?GTGCACACAGCCTGTGAGAGAGAGGCCATTGCATTTTTCATGGAGCACTCCTTCAAGGAT 1381?GAAAATCAGGAATTCCAGAAGAAGTTCATGGAAACCACAATGAATAAGAAGGGGGATTTC 1441?TTGCTGCAGAATGAAGAGTCATCTGTTCAATACTGCCAGGCTAAACTCAATGAGCTCTCA 1501?AAGGGACTAATGGAAAGTATCTCAGCAGGAAGTTTCTCTGTTCCTGGAGGGCACAAGCTC 1561?TACATGGAAACAAAGGAAAGGATTGAACAGGACTATTGGCAAGTTCCCAGGAAAGGAGTA 1621?AAGGCAAAAGAGGTCTTCCAGAGGTTCCTGGAGTCACAGATGGTGATAGAGGAATCCATC 1681?TTGCAGTCAGATAAAGCCCTCACTGATAGAGAGAAGGCAGTAGCAGTGGATCGGGCCAAG 1741?AAGGAGGCAGCTGAGAAGGAACAGGAACTTTTAAAACAGAAATTACAGGAGCAGCAGCAA 1801?CAGATGGAGGCTCAAGATAAGAGTCGCAAGGAAAACATAGCCCAACTGAAGGAGAAGCTG 1861?CAGATGGAGAGAGAACACCTACTGAGAGAGCAGATTATGATGTTGGAGCACACGCAGAAG 1921?GTCCAAAATGATTGGCTTCATGAAGGATTTAAGAAGAAGTATGAGGAGATGAATGCAGAG 1981?ATAAGTCAATTTAAACGTATGATTGATACTACAAAAAATGATGATACTCCCTGGATTGCA 2041?CGAACCTTGGACAACCTTGCCGATGAGCTAACTGCAATATTGTCTGCTCCTGCTAAATTA 2101?ATTGGTCATGGTGTCAAAGGTGTGAGCTCACTCTTTAAAAAGCATAAGCTCCCCTTTTAA 2161?GGATATTATAGATTGTACATATATGCTTTGGACTATTTTTGATCTGTATGTTTTTCATTT	SEQ?ID?NO：51

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2221?TCATTCAGCAAGTTTTTTTTTTTTTCAGAGTCTTACTCTGTTGCCCAGGCTGGAGTACAG 2281?TGGTGCAATCTCAGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGAGATTCACCTGCCTC 2341?AGCCCCCTAGTAGCTGGGATTATAGGTGTACACCACCACACCCAGCTAATTTTTGTATTT 2401?TTAGTAGAGATGGGGTTTCACTATGTTGGCCAGGCTGGTCTCGAACTCTTGACCTCAAAT 2461?GATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGTTTACAGGCATGAGCCACCATGCCCAG 2521?CCCTCATTTAGCAAAGTTTTAAACATGAAAAGTGCTTATTAGAGGATATCAGTGCCTGGC 2581?CCACATGAGAGAACAGATCCATACACACTTTGAAAAACTTTGTTCACTTTTAGGAAATAT 2641?AATTTTGAAAAATCATTTACATACAAGAGGTCCACTGAGGCATTGCTTTTAATGGCAAAA 2701?TATTGCAATGTACTTGAATGTCCTTCACATTAGATTGGTAAGATAAATTTTAGTATGTGC 2761?ATGTACTGGAATATTATATAGCCAGTAAACAAATTGACAATGAAGCTCTATTTGTACCAG 2821?TAAAGAATGGTCTTGAAGAGACATTGTAAAATGA 1 M E S G P K M L A P V C L V E N N N E Q 1 ATGGAATCTGGACCCAAAATGTTGGCCCCCGTTTGCCTGGTGGAAAATAACAATGAGCAG 21 L L V N Q Q A I Q I L E K I S Q P V V V 61 CTATTGGTGAACCAGCAAGCTATACAGATTCTTGAAAAGATTTCTCAGCCAGTGGTGGTG 41 V A I V G L Y R T G K S Y L M N H L A G 121 GTGGCCATTGTAGGACTGTACCGTACAGGGAAATCCTACTTGATGAACCATCTGGCAGGA 61 Q N H G F P L G S T V Q S E T K G I W M 181 CAGAATCATGGCTTCCCTCTGGGCTCCACGGTGCAGTCTGAAACCAAGGGCATCTGGATG 81 W C V P H P S K P N H T L V L L D T E G 241 TGGTGCGTGCCCCACCCATCCAAGCCAAACCACACCCTGGTCCTTCTGGACACCGAAGGT 101 L G D V E K G D P K N D S W I F A L A V 301 CTGGGCGATGTGGAAAAGGGTGACCCTAAGAATGACTCCTGGATCTTTGCCCTGGCTGTG 121 L L C S T F V Y N S M S T I N H Q A L E 361 CTCCTGTGCAGCACCTTTGTCTACAACAGCATGAGCACCATCAACCACCAGGCCCTGGAG 141 Q L H Y V T E L T E L I R A K S S P R P 421 CAGCTGCATTATGTGACAGAGCTCACAGAGCTCATCAGGGCAAAGTCTTCCCCAAGACCT 161 D E V Q D S T E F V S F F P D F I W T V 481 GATGAAGTACAAGATTCCACAGAGTTTGTGAGTTTCTTTCCAGACTTTATCTGGACTGTA 181 R D F T L E L K L D G H P I T E D E Y L 541 CGGGATTTCACCCTGGAGCTGAAGTTAGACGGTCACCCTATCACAGAAGATGAGTACTTG 201 E N A L K L I P G K N P K V Q A S N L P 601 GAGAATGCCTTGAAGCTGATTCCAGGCAAGAATCCCAAAGTCCAAGCGTCCAATCTACCC 221 R E C I R L F F P K R K C F V F D R P I 661 AGAGAGTGCATCAGGCTATTCTTTCCAAAACGGAAATGTTTTGTATTTGACCGGCCAATA	SEQ?ID?NO：52

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			241 N D K A L L A D I E N V S E N E L D S K 721 AACGACAAAGCACTCCTAGCTGACATTGAGAATGTGTCTGAAAACGAACTGGATTCTAAA 261 F Q E Q I N K F C S H I F T H A R P K T 781 TTCCAAGAACAAATAAACAAGTTCTGTTCTCACATCTTCACCCATGCAAGACCTAAGACT 281 L R E G I M V T G N R L R T L V V T Y V 841 CTTAGAGAGGGAATCATGGTCACTGGGAATCGGCTGAGGACTCTGGTGGTGACCTATGTG 301 D T I N T G A V P C L E N A V R T L A Q 901 GATACCATCAATACTGGAGCAGTGCCTTGTTTGGAGAATGCAGTGAGAACTCTGGCCCAA 321 L E N S V A M Q K A A D H Y S E Q M A E 961 CTTGAGAACTCAGTGGCCATGCAGAAGGCAGCGGACCATTACAGTGAGCAGATGGCCGAG 341 K L K L P T D T L Q E L L D V H T A C E 1021?AAATTGAAGTTGCCCACAGACACACTCCAGGAGCTGCTGGACGTGCACACAGCCTGTGAG 361 R E A I A F F M E H S F K D E N Q E F Q 1081?AGAGAGGCCATTGCATTTTTCATGGAGCACTCCTTCAAGGATGAAAATCAGGAATTCCAG 381 K K F M E T T M N K K G D F L L Q N E E 1141?AAGAAGTTCATGGAAACCACAATGAATAAGAAGGGGGATTTCTTGCTGCAGAATGAAGAG 401 S S V Q Y C Q A K L N E L S K G L M E S 1201?TCATCTGTTCAATACTGCCAGGCTAAACTCAATGAGCTCTCAAAGGGACTAATGGAAAGT 421 I S A G S F S V P G G H K L Y M E T K E 1261?ATCTCAGCAGGAAGTTTCTCTGTTCCTGGAGGGCACAAGCTCTACATGGAAACAAAGGAA 441 R I E Q D Y W Q V P R K G V K A K E V F 1321?AGGATTGAACAGGACTATTGGCAAGTTCCCAGGAAAGGAGTAAAGGCAAAAGAGGTCTTC 461 Q R F L E S Q M V I E E S I L Q S D K A 1381?CAGAGGTTCCTGGAGTCACAGATGGTGATAGAGGAATCCATCTTGCAGTCAGATAAAGCC 481 L T D R E K A V A V D R A K K E A A E K 1441?CTCACTGATAGAGAGAAGGCAGTAGCAGTGGATCGGGCCAAGAAGGAGGCAGCTGAGAAG 501 E Q E L L K Q K L Q E Q Q Q Q M E A Q D 1501?GAACAGGAACTTTTAAAACAGAAATTACAGGAGCAGCAGCAACAGATGGAGGCTCAAGAT 521 K S R K E N I A Q L K E K L Q M E R E H 1561?AAGAGTCGCAAGGAAAACATAGCCCAACTGAAGGAGAAGCTGCAGATGGAGAGAGAACAC 541 L L R E Q I M M L E H T Q K V Q N D W L 1621?CTACTGAGAGAGCAGATTATGATGTTGGAGCACACGCAGAAGGTCCAAAATGATTGGCTT 561 H E G F K K K Y E E M N A E I S Q F K R

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	1681?CATGAAGGATTTAAGAAGAAGTATGAGGAGATGAATGCAGAGATAAGTCAATTTAAACGT 581 M I D T T K N D D T P W I A R T L D N L 1741?ATGATTGATACTACAAAAAATGATGATACTCCCTGGATTGCACGAACCTTGGACAACCTT 601 A D E L T A I L S A P A K L I G H G V K 1801?GCCGATGAGCTAACTGCAATATTGTCTGCTCCTGCTAAATTAATTGGTCATGGTGTCAAA 621 G V S S L F K K H K L P F - 1861?GGTGTGAGCTCACTCTTTAAAAAGCATAAGCTCCCCTTTTAA
BM735096	Homo sapiens CD79A antigen (immunoglobulin (Ig) be correlated with α) (CD79A), transcript variant 1	1 ATGCCTGGGGGTCCAGGAGTCCTCCAAGCTCTGCCTGCCACCATCTTCCTCCTCTTCCTG 61 CTGTCTGCTGTCTACCTGGGCCCTGGGTGCCAGGCCCTGTGGATGCACAAGGTCCCAGCA 121 TCATTGATGGTGAGCCTGGGGGAAGACGCCCACTTCCAATGCCCGCACAATAGCAGCAAC 181 AACGCCAACGTCACCTGGTGGCGCGTCCTCCATGGCAACTACACGTGGCCCCCTGAGTTC 241 TTGGGCCCGGGCGAGGACCCCAATGAGCCGCTCCCCAGACCCTTCCTGGACATGGGGGAG 301 GGCACCAAGAACAACATCATCACAGCCGAGGGGATCATCCTGCTGTTCTGCGCAGTGGTG 361 CCTGGGACGCTGCTGCTGTTCAGGAAACGATGGCAGAACTTGAAGTTCGGGCCAGACATC 421 CAGGATGACTACGAAGATGAGAATCTTTATGAGGGCCTGAACCTCGATGACTGTTCCATG 481 TACGAGGACATCTCCCGGGGCCTCCAGGGCACCTACCAGGACGTGGGCAGCCTCCACATC 541 GGAGACGTCCAGCTGGAGAAGCCGTGA 1 M P G G P G V L Q A L P A T I F L L F L 1 ATGCCTGGGGGTCCAGGAGTCCTCCAAGCTCTGCCTGCCACCATCTTCCTCCTCTTCCTG 21 L S A V Y L G P G C Q A L W M H K V P A 61 CTGTCTGCTGTCTACCTGGGCCCTGGGTGCCAGGCCCTGTGGATGCACAAGGTCCCAGCA 41 S L M V S L G E D A H F Q C P H N S S N 121 TCATTGATGGTGAGCCTGGGGGAAGACGCCCACTTCCAATGCCCGCACAATAGCAGCAAC 61 N A N V T W W R V L H G N Y T W P P E F 181 AACGCCAACGTCACCTGGTGGCGCGTCCTCCATGGCAACTACACGTGGCCCCCTGAGTTC 81 L G P G E D P N E P L P R P F L D M G E 241 TTGGGCCCGGGCGAGGACCCCAATGAGCCGCTCCCCAGACCCTTCCTGGACATGGGGGAG 101 G T K N N I I T A E G I I L L F C A V V 301 GGCACCAAGAACAACATCATCACAGCCGAGGGGATCATCCTGCTGTTCTGCGCAGTGGTG 121 P G T L L L F R K R W Q N L K F G P D I 361 CCTGGGACGCTGCTGCTGTTCAGGAAACGATGGCAGAACTTGAAGTTCGGGCCAGACATC 141 Q D D Y E D E N L Y E G L N L D D C S M 421 CAGGATGACTACGAAGATGAGAATCTTTATGAGGGCCTGAACCTCGATGACTGTTCCATG 161 Y E D I S R G L Q G T Y Q D V G S L H I	SEQ?ID?NO：53 SEQ?ID?NO：54

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	481 TACGAGGACATCTCCCGGGGCCTCCAGGGCACCTACCAGGACGTGGGCAGCCTCCACATC 181 G D V Q L E K P - 541 GGAGACGTCCAGCTGGAGAAGCCGTGA
GI1305528.V1.3_AT	Horse Mx albumen homology thing mRNA.	1 GGCACGAGTGGAGAACAGCTCTGCATTTCTGTCCAAGCAGTCAGCGGTCCATCGTCAAGT 61 AAAGGAAGCTATATTGGAGATAACTGAACCGATAAAGGAAGAAGATGGTTCATTCTGAAG 121 CGAAAATGACAAGACCTGATTCAGCTTCCGCATCCAAGCAACAATTACTAAATGGAAATG 181 CTGACATACAGGAGACAAATCAGAAAAGAAGCATTGAGAAAAACCTGTGTAGCCAGTATG 241 AGGAGAAGGTACGCCCATGCATTGATCTCATCGACTCCCTGCGGGCTCTGGGTGTGGAGC 301 AGGACCTGGCCCTGCCTGCCATCGCCGTCATCGGGGACCAGAGCTCGGGCAAGAGCTCTG 361 TGCTGGAAGCTCTTTCAGGGGTCGCCCTTCCCAGAGGCAGTGGTATTGTGACAAGATGTC 421 CTCTGGTGCTGAAACTGAAAAGACTGGTGAAAGAAGATGAGTGGAAAGGCAAAGTCAGCT 481 ACCGGGATATCGAGGTTGAGATTTCAAATGCTTTGGATGTGGAAGAGCAAGTCAGAAAAG 541 CCCAGAATGTCCTTGCTGGGGAAGGAGTGGGAATCAGTCAGGAGCTAGTCACTCTGGAAG 601 TCAGCTCTCCTCATGTCCCGGATCTGACCCTGATCGACCTTCCTGGCATCACCAGGGTGG 661 CCGTGGGCAATCAGCCAGCCGACATCGGACGTCAGATCAAGACACTCATCAGGAAGTACA 721 TCCAGAGGCAAGAGACGATCAACCTGGTGGTGGTCCCCAGTAACGTGGACATCGCCACCA 781 CGGAGGCGCTGAGCATGGCTCAGGAGGTGGACCCCGAGGGAGACAGGACCATAGGAATCT 841 TGACAAAGCCTGACCTGGTGGACAAAGGCACCGAGGAGCAGGTGGTAGACGTGGTGCGAA 901 ACCTCATCTGCCACCTGAAGAAGGGTTATATGATCGTCAAGTGCCGGGGCCAGCAGGACA 961 TCCAGGACCGACTGAGCCTGGCTGAGGCTCTGCAGAGAGAGAAGGCCTTCTTTGAGGAAA 1021?ACCCATATTTCAGGGGCCTTCTGGAGGAAGGAAGAGCCTCGGTCCCCTGCCTGGCGGAGA 1081?GGCTGACCACTGAACTCATCACGCACATCAGTAAATCTCTGCCCCTGTTAGAAAATCAAA 1141?TAAAGGAAAGTTACCAGAATCTATCAGACGAGTTACAAAAATATGGCACCGACATCCCAG 1201?AAGATGAAACTGAAAAAACGTTCTTCCTGATAGTGAAAATTACTACATTTAATCAGAACA 1261?TCACCTCTTTCGTACAAGGGGAGGAACTTGTAGGACCCAATGACACTCGGCTGTTTAACA 1321?AAATCCGACAGGAGTTCCAGAAATGGAGTGGGGTGATTGAAAACAATTTCCGAAAAGGTG 1381?GCGAAGCTATCCGTAGACAGATCTGGACATTTGAAAATCAGTATCGTGGCAGAGAGCTAC 1441?CAGGATTTGTGAATTACAGGACATTTGAGACGATCATCAAACAGCAAATCCAGTTGCTGG 1501?AAGAGCCAGCCATTGATATGCTGCACAGGATAAGTGATCTGGTCCGGGATACCTTCACAA 1561?AAGTTTCAGAAAAAAATTTCAGTGAATTTTTCAACCTCCACAGAACCACCAAGTCCAAAC 1621?TTGAAGACATTAAATTAGAACAAGAAAATGAAGCTGAGAAGTCGATCCGACTCCACTTCC 1681?AAATGGAGAAGATCGTCTACTGCCAAGACCACGTTTACCGGGGCACGTTACAGAAGGTCA 1741?GAGAGAATGAAATGGAGGAGGAGAAGAAGAAAAAAACAATCAACGTCTGGGGTCAAAACA 1801?CTTCCACAGAGTCCTCGATGGCAGAAATCTTGGAGCATCTCAACGCCTACCAGCACGAGG 1861?CCGGCAACCGCCTCTCGACCCACATCCCCTTGATCATCCAGTTCTTCGTCCTCCAGACAT 1921?TCGGCCAGCAGCTGCAGAAGTCCATGCTGCAGCTCCTGCAGGACAGGGACACCTACGACT 1981?GGCTCCTGAAGGAGCGCAACGACACCTGTGACAAGAGGAAGTTCCTGAAGGAGCGGCTTG 2041?CTCGGCTGGCCCAGGCTCGGCGCCGGTTAGCCAAGTTCCCGGGTTAAATCGGGCTCTCTG 2101?TCTCAGCCTCATGTCTCCATGCACATCTCCAGGGAGCGGAGGCCCAGCATCTCTCCCCAA 2161?CAGCCACACCATCATTAGTTACCCATTCACAGATACCCGAGCGGTTACGGGTCAGGCTTG 2221?GTGGTCACTGTCTGTGCTTGTCCTTTAGTGGATAAGGATGCGCTAAGAACCTGTGATGAG 2281?CGATTTGGTTTCAAGCATTGAGACTAGAGCCCCGCCTTCATGTAGCATATGCTTTAGACT 2341?GAATGAGCAGTGCCATTTTCTGGTTAGGAGAAATGGTTTTCTACCCCCAGGATTGGTCCT 2401?CGTCTCCAGACTCTCTCCATCTCTTTATCAGAGACCGATGTACGTGCAGCATCATGGAAC 2461?GGTTATTTTCGGTTTTTTTGTGTTGTCCTTTCGCATACCCAGTGTTTTAGGCGTGTGAGT 2521?GCTGCTTGTGTGAATGCTTGTAGATGCCATGTTTCATCTATTTGTAATAAACTTTTTTCT	SEQ?ID?NO：55

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2581?ACTAGAAAAAAAAAAAAAAAAAAAAAAA 1 M V H S E A K M T R P D S A S A S K Q Q 1 ATGGTTCATTCTGAAGCGAAAATGACAAGACCTGATTCAGCTTCCGCATCCAAGCAACAA 21 L L N G N A D I Q E T N Q K R S I E K N 61 TTACTAAATGGAAATGCTGACATACAGGAGACAAATCAGAAAAGAAGCATTGAGAAAAAC 41 L C S Q Y E E K V R P C I D L I D S L R 121 CTGTGTAGCCAGTATGAGGAGAAGGTACGCCCATGCATTGATCTCATCGACTCCCTGCGG 61 A L G V E Q D L A L P A I A V I G D Q S 181 GCTCTGGGTGTGGAGCAGGACCTGGCCCTGCCTGCCATCGCCGTCATCGGGGACCAGAGC 81 S G K S S V L E A L S G V A L P R G S G 241 TCGGGCAAGAGCTCTGTGCTGGAAGCTCTTTCAGGGGTCGCCCTTCCCAGAGGCAGTGGT 101 I V T R C P L V L K L K R L V K E D E W 301 ATTGTGACAAGATGTCCTCTGGTGCTGAAACTGAAAAGACTGGTGAAAGAAGATGAGTGG 121 K G K V S Y R D I E V E I S N A L D V E 361 AAAGGCAAAGTCAGCTACCGGGATATCGAGGTTGAGATTTCAAATGCTTTGGATGTGGAA 141 E Q V R K A Q N V L A G E G V G I S Q E 421 GAGCAAGTCAGAAAAGCCCAGAATGTCCTTGCTGGGGAAGGAGTGGGAATCAGTCAGGAG 161 L V T L E V S S P H V P D L T L I D L P 481 CTAGTCACTCTGGAAGTCAGCTCTCCTCATGTCCCGGATCTGACCCTGATCGACCTTCCT 181 G I T R V A V G N Q P A D I G R Q I K T 541 GGCATCACCAGGGTGGCCGTGGGCAATCAGCCAGCCGACATCGGACGTCAGATCAAGACA 201 L I R K Y I Q R Q E T I N L V V V P S N 601 CTCATCAGGAAGTACATCCAGAGGCAAGAGACGATCAACCTGGTGGTGGTCCCCAGTAAC 221 V D I A T T E A L S M A Q E V D P E G D 661 GTGGACATCGCCACCACGGAGGCGCTGAGCATGGCTCAGGAGGTGGACCCCGAGGGAGAC 241 R T I G I L T K P D L V D K G T E E Q V 721 AGGACCATAGGAATCTTGACAAAGCCTGACCTGGTGGACAAAGGCACCGAGGAGCAGGTG 261 V D V V R N L I C H L K K G Y M I V K C 781 GTAGACGTGGTGCGAAACCTCATCTGCCACCTGAAGAAGGGTTATATGATCGTCAAGTGC 281 R G Q Q D I Q D R L S L A E A L Q R E K 841 CGGGGCCAGCAGGACATCCAGGACCGACTGAGCCTGGCTGAGGCTCTGCAGAGAGAGAAG 301 A F F E E N P Y F R G L L E E G R A S V	SEQ?ID?NO：56

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			901 GCCTTCTTTGAGGAAAACCCATATTTCAGGGGCCTTCTGGAGGAAGGAAGAGCCTCGGTC 321 P C L A E R L T T E L I T H I S K S L P 961 CCCTGCCTGGCGGAGAGGCTGACCACTGAACTCATCACGCACATCAGTAAATCTCTGCCC 341 L L E N Q I K E S Y Q N L S D E L Q K Y 1021?CTGTTAGAAAATCAAATAAAGGAAAGTTACCAGAATCTATCAGACGAGTTACAAAAATAT 361 G T D I P E D E T E K T F F L I V K I T 1081?GGCACCGACATCCCAGAAGATGAAACTGAAAAAACGTTCTTCCTGATAGTGAAAATTACT 381 T F N Q N I T S F V Q G E E L V G P N D 1141?ACATTTAATCAGAACATCACCTCTTTCGTACAAGGGGAGGAACTTGTAGGACCCAATGAC 401 T R L F N K I R Q E F Q K W S G V I E N 1201?ACTCGGCTGTTTAACAAAATCCGACAGGAGTTCCAGAAATGGAGTGGGGTGATTGAAAAC 421 N F R K G G E A I R R Q I W T F E N Q Y 1261?AATTTCCGAAAAGGTGGCGAAGCTATCCGTAGACAGATCTGGACATTTGAAAATCAGTAT 441 R G R E L P G F V N Y R T F E T I I K Q 1321?CGTGGCAGAGAGCTACCAGGATTTGTGAATTACAGGACATTTGAGACGATCATCAAACAG 461 Q I Q L L E E P A I D M L H R I S D L V 1381?CAAATCCAGTTGCTGGAAGAGCCAGCCATTGATATGCTGCACAGGATAAGTGATCTGGTC 481 R D T F T K V S E K N F S E F F N L H R 1441?CGGGATACCTTCACAAAAGTTTCAGAAAAAAATTTCAGTGAATTTTTCAACCTCCACAGA 501 T T K S K L E D I K L E Q E N E A E K S 1501?ACCACCAAGTCCAAACTTGAAGACATTAAATTAGAACAAGAAAATGAAGCTGAGAAGTCG 521 I R L H F Q M E K I V Y C Q D H V Y R G 1561?ATCCGACTCCACTTCCAAATGGAGAAGATCGTCTACTGCCAAGACCACGTTTACCGGGGC 541 T L Q K V R E N E M E E E K K K K T I N 1621?ACGTTACAGAAGGTCAGAGAGAATGAAATGGAGGAGGAGAAGAAGAAAAAAACAATCAAC 561 V W G Q N T S T E S S M A E I L E H L N 1681?GTCTGGGGTCAAAACACTTCCACAGAGTCCTCGATGGCAGAAATCTTGGAGCATCTCAAC 581 A Y Q H E A G N R L S T H I P L I I Q F 1741?GCCTACCAGCACGAGGCCGGCAACCGCCTCTCGACCCACATCCCCTTGATCATCCAGTTC 601 F V L Q T F G Q Q L Q K S M L Q L L Q D 1801?TTCGTCCTCCAGACATTCGGCCAGCAGCTGCAGAAGTCCATGCTGCAGCTCCTGCAGGAC 621 R D T Y D W L L K E R N D T C D K R K F 1861?AGGGACACCTACGACTGGCTCCTGAAGGAGCGCAACGACACCTGTGACAAGAGGAAGTTC

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	641 L K E R L A R L A Q A R R R L A K F P G 1921?CTGAAGGAGCGGCTTGCTCGGCTGGCCCAGGCTCGGCGCCGGTTAGCCAAGTTCCCGGGT 661 - 1981?TAA
WBC881.GRSP.V1.3_AT	Homo sapiens makorin, ring finger protein, 1, mRNA	1 AGCGCTCAGATACGCGACGCGTAGCAGGCGGGGACCGAACGGGTGCCTCAGTGTCCTTCC 61 CCTCCCCTCGCCTGGCCTCGCCGTCCTCTCCCCGCAGCCGGACCGGAACTATGTGATCCC 121 GGAAGTTCCGGGGCCTTTGCTGTGTGGGATAAACAGTAATGGCGGAGGCTGCAACTCCCG 181 GAACAACAGCCACAACATCAGGAGCAGGAGCGGCAGCGGCGACGGCGGCAGCAGCCTCCC 241 CCACCCCGATCCCCACAGTCACCGCCCCGTCCCTGGGGGCGGGCGGAGGGGGCGGCGGCA 301 GCGACGGCAGCGGCGGCGGCTGGACTAAACAGGTCACCTGCAGGTATTTTATGCATGGGG 361 TTTGTAAGGAAGGAGACAACTGTCGCTACTCGCATGACCTCTCTGACAGTCCGTATAGTG 421 TAGTGTGCAAGTATTTTCAGCGAGGGTACTGTATTTATGGAGACCGCTGCAGATATGAAC 481 ATAGCAAACCATTGAAACAGGAAGAAGCAACTGCTACAGAGCTAACTACAAAGTCATCCC 541 TTGCTGCTTCCTCAAGTCTCTCATCGATAGTTGGACCACTTGTTGAAATGAATACAGGCG 601 AAGCTGAGTCAAGAAATTCAAACTTTGCAACTGTAGGAGCAGGTTCAGAGGACTGGGTGA 661 ATGCTATTGAGTTTGTTCCTGGGCAACCCTACTGTGGCCGTACTGCGCCTTCCTGCACTG 721 AAGCACCCCTGCAGGGCTCAGTGACCAAGGAAGAATCAGAGAAAGAGCAAACCGCCGTGG 781 AGACAAAGAAGCAGCTGTGCCCCTATGCTGCAGTGGGAGAGTGCCGATACGGGGAGAACT 841 GTGTGTATCTCCACGGAGATTCTTGTGACATGTGTGGGCTGCAGCTCCTGCATCCAATGG 901 ATGCTGCCCAGAGATCGCAGCATATCAAATCGTGCATTGAGGCCCATGAGAAGGACATGG 961 AGCTCTCATTTGCCGTGCAGCGCAGCAAGGACATGGTGTGTGGGATCTGCATGGAGGTGG 1021?TCTATGAGAAAGCCAACCCCAGTGAGCGCCGCTTCGGGATCCTCTCCAACTGCAACCACA 1081?CCTACTGTCTCAAGTGCATTCGCAAGTGGAGGAGTGCTAAGCAATTTGAGAGCAAGATCA 1141?TAAAGTCCTGCCCAGAATGCCGGATCACATCTAACTTTGTCATTCCAAGTGAGTACTGGG 1201?TGGAGGAGAAAGAAGAGAAGCAGAAACTCATTCTGAAATACAAGGAGGCAATGAGCAACA 1261?AGGCGTGCAGGTATTTTGATGAAGGACGTGGGAGCTGCCCATTTGGAGGGAACTGTTTTT 1321?ACAAGCATGCGTACCCTGATGGCCGTAGAGAGGAGCCACAGAGACAGAAAGTGGGAACAT 1381?CAAGCAGATACCGGGCCCAACGAAGGAACCACTTCTGGGAACTCATTGAGGAAAGAGAGA 1441?ACAGCAACCCCTTTGACAACGATGAAGAAGAGGTTGTCACCTTTGAGCTGGGCGAGATGT 1501?TGCTTATGCTTTTGGCTGCAGGTGGGGACGACGAACTAACAGACTCTGAAGATGAGTGGG 1561?ACTTGTTTCATGATGAGCTGGAAGATTTTTATGACTTGGATCTATAGCAACCTTGCGTGG 1621?CGTGTGAACTGGTCTGCTGACCTCAGACAGCAGCTGTCCCCTGTGGTGGTGTGGCAGTGC 1681?CTGTGTTCTCTCCTAGGCAGGCCTCTCAACTCCAGGTGCTGTCCTAAGAATTTTTACCCA 1741?GGGCCTGTCTTCTCAACCCCTCACCTTTCCCTGAGGAGTGTGTTGTTTTCCCTGTTGAAA 1801?AAAGTTACAAAAATAAATCTTAAAGTTAGTTTTTTGTAACACGAATTTAACTGTCAGACA 1861?GTTAGTGTAGGTGTGTTGCGTCATCTGTTTTCAACCAGATTGCATTTATGGACTTTTCAC 1921?ACACTCATTTTGAGGACCCCAGGTTCAAAAGTAAAAGCAGTGGCCCTGCTTTGGGGTCCA 1981?AGAATAGGAGTGATGGGTGAAGGGACCTAAGCTGGCCAATAGCCCTCTGCCCCAGACATG 2041?GGATGTGGATCCTTGAGGTTTCTGGTGAAATCTGCACATCTGTGTTTTTATATCTGTTCC 2101?CTACCCTGTAATCCCTACCACGTGCACTTGTTCTGTGGTTTTGGTCTCTTGTTTAATTGC 2161?ACACAAGTAATACTACTGGGTAACCAGAATCAGGTGTGAATGTGTTGAGATTTTTTACTG 2221?TTTTGCATGATAGGAAAATTGAGAAAGAATACGTATAAAAGATAGAGAGGCATAACATCA 2281?ATGCAGAGTTGGAAGTTGGCTCCCAAGGGCTGACATGGTGTGAGTGTGTGGGTGTGTGAT 2341?AAGCTTCTCATCCCTGCATAGATGCAGTATTCTTAGCCTTAGTAGAAAAACCTGGTTTAG 2401?TGGTTTAAGCCTTGTGTGGCAGATAGATCTTAAAGGGCAAAGCAGTATATTGGTAGTTGT	SEQ?ID?NO：57

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2461?CAATATAGCAGTGCTAGCTCTGTCTATATAAATAGAGAAATGGGGTTAGCCATAGAGGTT 2521?AAAACTACCTGGTTATCCCATATAATAACACAAACTGGGTCTCGAATACACAGTTGTATT 2581?TAATGTTTTCTGATCCCCCAGCCGTCCCAGCCCACGCACTTTTTCACAAACGTTTGTCCT 2641?CGTTGAGGGTTTCGTTCTCGGGTTTTTGTGTTTGTTTTTGTGGGTATTGCCTCATTCCAT 2701?CCCTGAGCTTTGCAGGTAGACAGATGTGATTCAGAACTATGTTCCAGGGTGTTCCTTGTA 2761?GGAGTAATTGGTTTGCAGTAAGAAGTCACACTTTTCCACTAAAGGGGAGGAGGTGGTAAT 2821?CTACGAGACAAGCTAAAGTTAAGTTGTTAGAAGAATTCCTTGATTGGAATTTTAGCTTTG 2881?CATTTTGTTGCTCTCTTTCCTGGAAATAATTCGGAGACGCTCCTGATTTGTCCATCTACT 2941?GCTTTGGTTCCTTGGATCCACCCATTCTTTCACTTTAAGAAAAACAAGTAATTGTTGCAG 3001?AGGTCTCTGTATTTTGCAGCTGCCCTTTTGTAAGAAGCACTTTTCCCAAATAAAACAATG 3061?AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 M A E A A T P G T T A T T S G A G A A A 1 ATGGCGGAGGCTGCAACTCCCGGAACAACAGCCACAACATCAGGAGCAGGAGCGGCAGCG 21 A T A A A A S P T P I P T V T A P S L G 61 GCGACGGCGGCAGCAGCCTCCCCCACCCCGATCCCCACAGTCACCGCCCCGTCCCTGGGG 41 A G G G G G G S D G S G G G W T K Q V T 121 GCGGGCGGAGGGGGCGGCGGCAGCGACGGCAGCGGCGGCGGCTGGACTAAACAGGTCACC 61 C R Y F M H G V C K E G D N C R Y S H D 181 TGCAGGTATTTTATGCATGGGGTTTGTAAGGAAGGAGACAACTGTCGCTACTCGCATGAC 81 L S D S P Y S V V C K Y F Q R G Y C I Y 241 CTCTCTGACAGTCCGTATAGTGTAGTGTGCAAGTATTTTCAGCGAGGGTACTGTATTTAT 101 G D R C R Y E H S K P L K Q E E A T A T 301 GGAGACCGCTGCAGATATGAACATAGCAAACCATTGAAACAGGAAGAAGCAACTGCTACA 121 E L T T K S S L A A S S S L S S I V G P 361 GAGCTAACTACAAAGTCATCCCTTGCTGCTTCCTCAAGTCTCTCATCGATAGTTGGACCA 141 L V E M N T G E A E S R N S N F A T V G 421 CTTGTTGAAATGAATACAGGCGAAGCTGAGTCAAGAAATTCAAACTTTGCAACTGTAGGA 161 A G S E D W V N A I E F V P G Q P Y C G 481 GCAGGTTCAGAGGACTGGGTGAATGCTATTGAGTTTGTTCCTGGGCAACCCTACTGTGGC 181 R T A P S C T E A P L Q G S V T K E E S 541 CGTACTGCGCCTTCCTGCACTGAAGCACCCCTGCAGGGCTCAGTGACCAAGGAAGAATCA 201 E K E Q T A V E T K K Q L C P Y A A V G 601 GAGAAAGAGCAAACCGCCGTGGAGACAAAGAAGCAGCTGTGCCCCTATGCTGCAGTGGGA 221 E C R Y G E N C V Y L H G D S C D M C G 661 GAGTGCCGATACGGGGAGAACTGTGTGTATCTCCACGGAGATTCTTGTGACATGTGTGGG	SEQ?ID?NO：58

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	241 L Q L L H P M D A A Q R S Q H I K S C I 721 CTGCAGCTCCTGCATCCAATGGATGCTGCCCAGAGATCGCAGCATATCAAATCGTGCATT 261 E A H E K D M E L S F A V Q R S K D M V 781 GAGGCCCATGAGAAGGACATGGAGCTCTCATTTGCCGTGCAGCGCAGCAAGGACATGGTG 281 C G I C M E V V Y E K A N P S E R R F G 841 TGTGGGATCTGCATGGAGGTGGTCTATGAGAAAGCCAACCCCAGTGAGCGCCGCTTCGGG 301 I L S N C N H T Y C L K C I R K W R S A 901 ATCCTCTCCAACTGCAACCACACCTACTGTCTCAAGTGCATTCGCAAGTGGAGGAGTGCT 321 K Q F E S K I I K S C P E C R I T S N F 961 AAGCAATTTGAGAGCAAGATCATAAAGTCCTGCCCAGAATGCCGGATCACATCTAACTTT 341 V I P S E Y W V E E K E E K Q K L I L K 1021?GTCATTCCAAGTGAGTACTGGGTGGAGGAGAAAGAAGAGAAGCAGAAACTCATTCTGAAA 361 Y K E A M S N K A C R Y F D E G R G S C 1081?TACAAGGAGGCAATGAGCAACAAGGCGTGCAGGTATTTTGATGAAGGACGTGGGAGCTGC 381 P F G G N C F Y K H A Y P D G R R E E P 1141?CCATTTGGAGGGAACTGTTTTTACAAGCATGCGTACCCTGATGGCCGTAGAGAGGAGCCA 401 Q R Q K V G T S S R Y R A Q R R N H F W 1201?CAGAGACAGAAAGTGGGAACATCAAGCAGATACCGGGCCCAACGAAGGAACCACTTCTGG 421 E L I E E R E N S N P F D N D E E E V V 1261?GAACTCATTGAGGAAAGAGAGAACAGCAACCCCTTTGACAACGATGAAGAAGAGGTTGTC 441 T F E L G E M L L M L L A A G G D D E L 1321?ACCTTTGAGCTGGGCGAGATGTTGCTTATGCTTTTGGCTGCAGGTGGGGACGACGAACTA 461 T D S E D E W D L F H D E L E D F Y D L 1381?ACAGACTCTGAAGATGAGTGGGACTTGTTTCATGATGAGCTGGAAGATTTTTATGACTTG 481 D L - 1441?GATCTATAG
WBC44.V1.3_AT	Homo sapiens B aggressive lymphoma gene, mRNA.	1 GAGCGGCCTGCCGGAAGTGGGCCACCATATCTGGAAACTACAGTCTATGCTTTGAAGCGC 61 AAAAGGGAATAAACATTTAAAGACTCCCCCGGGGACCTGGAGGATGGACTTTTCCATGGT 121 GGCCGGAGCAGCAGCTTACAATGAAAAATCAGAGACTGGTGCTCTTGGAGAAAACTATAG 181 TTGGCAAATTCCCATTAACCACAATGACTTCAAAATTTTAAAAAATAATGAGCGTCAGCT 241 GTGTGAAGTCCTCCAGAATAAGTTTGGCTGTATCTCTACCCTGGTCTCTCCAGTTCAGGA 301 AGGCAACAGCAAATCTCTGCAAGTGTTCAGAAAAATGCTGACTCCTAGGATAGAGTTATC 361 AGTCTGGAAAGATGACCTCACCACACATGCTGTTGATGCTGTGGTGAATGCAGCCAATGA 421 AGATCTTCTGCATGGGGGAGGCCTGGCCCTGGCCCTGGTAAAAGCTGGTGGATTTGAAAT 481 CCAAGAAGAGAGCAAACAGTTTGTTGCCAGATATGGTAAAGTGTCAGCTGGTGAGATAGC	SEQ?ID?NO：59

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			541 TGTCACGGGAGCAGGGAGGCTTCCCTGCAAACAGATCATCCATGCTGTTGGGCCTCGGTG 601 GATGGAATGGGATAAACAGGGATGTACTGGAAAGCTGCAGAGGGCCATTGTAAGTATTCT 661 GAATTATGTCATCTATAAAAATACTCACATTAAGACAGTAGCAATTCCAGCCTTGAGCTC 721 TGGGATTTTTCAGTTCCCTCTGAATTTGTGTACAAAGACTATTGTAGAGACTATCCGGGT 781 TAGTTTGCAAGGGAAGCCAATGATGAGTAATTTGAAAGAAATTCACCTGGTGAGCAATGA 841 GGACCCTACTGTTGCTGCCTTTAAAGCTGCTTCAGAATTCATCCTAGGGAAGAGTGAGCT 901 GGGACAAGAAACCACCCCTTCTTTCAATGCAATGGTCGTGAACAACCTGACCCTCCAGAT 961 TGTCCAGGGCCACATTGAATGGCAGACGGCAGATGTAATTGTTAATTCTGTAAACCCACA 1021?TGATATTACAGTTGGACCTGTGGCAAAGTCAATTCTACAACAAGCAGGAGTTGAAATGAA 1081?ATCGGAATTTCTTGCCACAAAGGCTAAACAGTTTCAACGGTCCCAGTTGGTACTGGTCAC 1141?AAAAGGATTTAACTTGTTCTGTAAATATATATACCATGTACTGTGGCATTCAGAATTTCC 1201?TAAACCTCAGATATTAAAACATGCAATGAAGGAGTGTTTGGAAAAATGCATTGAGCAAAA 1261?TATAACTTCCATTTCCTTTCCTGCCCTTGGGACTGGAAACATGGAAATAAAGAAGGAAAC 1321?AGCAGCAGAGATTTTGTTTGATGAAGTTTTAACATTTGCCAAAGACCATGTAAAACACCA 1381?GTTAACTGTAAAATTTGTGATCTTTCCAACAGATTTGGAGATATATAAGGCTTTCAGTTC 1441?TGAAATGGCAAAGAGGTCCAAGATGCTGAGTTTGAACAATTACAGTGTCCCCCAGTCAAC 1501?CAGAGAGGAGAAAAGAGAAAATGGGCTTGAAGCTAGATCTCCTGCCATCAATCTGATGGG 1561?ATTCAACGTGGAAGAGATGTATGAGGCCCACGCATGGATCCAAAGAATCCTGAGTCTCCA 1621?GAACCACCACATCATTGAGAATAATCATATTCTGTACCTTGGGAGAAAGGAACATGACAT 1681?TTTGTCTCAGCTTCAGAAAACTTCAAGTGTCTCCATCACAGAAATTATCAGCCCAGGAAG 1741?GACAGAGTTAGAGATTGAAGGAGCCCGGGCTGACCTCATTGAGGTGGTTATGAACATTGA 1801?AGATATGCTTTGTAAAGTACAGGAGGAAATGGCAAGGAAAAAGGAGCGAGGCCTTTGGCG 1861?CTCGTTAGGACAGTGGACTATTCAGCAACAAAAAACCCAAGACGAAATGAAAGAAAATAT 1921?CATATTTCTGAAATGTCCTGTGCCTCCAACTCAAGAGCTTCTAGATCAAAAGAAACAGTT 1981?TGAAAAATGTGGTTTGCAGGTTCTAAAGGTGGAGAAGATAGACAATGAGGTCCTTATGGC 2041?TGCCTTTCAAAGAAAGAAGAAAATGATGGAAGAAAAACTGCACAGGCAACCTGTGAGCCA 2101?TAGGCTGTTTCAGCAAGTCCCATACCAGTTCTGTGAAGTGGTTTGCAGAGTTGGCTTTCA 2161?AAGAATGTACTCGGTGCCCCACGACCCAAAGTATGGACCTGGCATATACTTCACCAAGAA 2221?TCTCAAAAATCTAGCATCCCAGTTCAAGAAAACGTCTGCCACAGATAAGCTGATCTATGT 2281?GTTTGAGGCTGAAGTACTCACAGGCTCCTTCTGTGAGGGTCATCAGTTAAATATTGTTCC 2341?CCCACGATTGAGTACTGATGCCATAGATAGCCATGACAGTGTGGTTGACAATGTCTCCAG 2401?CCCTGAAACCTTTGTTATTTTTAGTGGCACGCAGGCTATGCCCCAATATTTGTGGACTTG 2461?CACCCAGGATCATGTAGGGCCAGAGGATTACTCATTAGGACAAATGTTGCCGTCTCCACA 2521?GCAGCTTGGGAAGAGATTCGTAAGTGGCAGCCCTGTTGACTAACTTCTGCATAATTTTAA 2581?CAACTGGCATGGCCCTGCTTTGGAGAAACTAACGAAATATTGACCATCAATGACTCAAAG 2641?ACTGGTCTGAATATGTCAAATGGCTCTGGATAGACTGAATGGGTTACTGAAGGGGCCAGC 2701?CACATACTAGCATCTTGGTGCCTTCGTCTTTGTTTTCATCTCTTGGGGGTGGGGTGGGTA 2761?GATACTAACTAAAACACTCTCAGGACCTTCCTTCCTCTTGCAGTTGTTCTTTAATCTCCT 2821?TTACTAGAGGAGATAAATATTTTGCATATAATGAAGAAATTTTTCTAGTATATAATTCAA 2881?GCCCTCTATTTTTTAAAATGGTGATAGTATAAAAATGTTAGGATAACAGAATGATTTTAG 2941?ATTTTCCAGAGAATATTATAAAGTGCTTTAGGTATGAAAATAAATCATCTTTGTCTGATT 3001?AAAAAAAAAAAAAAAA 1 M D F S M V A G A A A Y N E K S E T G A 1 ATGGACTTTTCCATGGTGGCCGGAGCAGCAGCTTACAATGAAAAATCAGAGACTGGTGCT 21 L G E N Y S W Q I P I N H N D F K I L K 61 CTTGGAGAAAACTATAGTTGGCAAATTCCCATTAACCACAATGACTTCAAAATTTTAAAA	SEQ?ID?NO：60

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			41 N N E R Q L C E V L Q N K F G C I S T L 121 AATAATGAGCGTCAGCTGTGTGAAGTCCTCCAGAATAAGTTTGGCTGTATCTCTACCCTG 61 V S P V Q E G N S K S L Q V F R K M L T 181 GTCTCTCCAGTTCAGGAAGGCAACAGCAAATCTCTGCAAGTGTTCAGAAAAATGCTGACT 81 P R I E L S V W K D D L T T H A V D A V 241 CCTAGGATAGAGTTATCAGTCTGGAAAGATGACCTCACCACACATGCTGTTGATGCTGTG 101 V N A A N E D L L H G G G L A L A L V K 301 GTGAATGCAGCCAATGAAGATCTTCTGCATGGGGGAGGCCTGGCCCTGGCCCTGGTAAAA 121 A G G F E I Q E E S K Q F V A R Y G K V 361 GCTGGTGGATTTGAAATCCAAGAAGAGAGCAAACAGTTTGTTGCCAGATATGGTAAAGTG 141 S A G E I A V T G A G R L P C K Q I I H 421 TCAGCTGGTGAGATAGCTGTCACGGGAGCAGGGAGGCTTCCCTGCAAACAGATCATCCAT 161 A V G P R W M E W D K Q G C T G K L Q R 481 GCTGTTGGGCCTCGGTGGATGGAATGGGATAAACAGGGATGTACTGGAAAGCTGCAGAGG 181 A I V S I L N Y V I Y K N T H I K T V A 541 GCCATTGTAAGTATTCTGAATTATGTCATCTATAAAAATACTCACATTAAGACAGTAGCA 201 I P A L S S G I F Q F P L N L C T K T I 601 ATTCCAGCCTTGAGCTCTGGGATTTTTCAGTTCCCTCTGAATTTGTGTACAAAGACTATT 221 V E T I R V S L Q G K P M M S N L K E I 661 GTAGAGACTATCCGGGTTAGTTTGCAAGGGAAGCCAATGATGAGTAATTTGAAAGAAATT 241 H L V S N E D P T V A A F K A A S E F I 721 CACCTGGTGAGCAATGAGGACCCTACTGTTGCTGCCTTTAAAGCTGCTTCAGAATTCATC 261 L G K S E L G Q E T T P S F N A M V V N 781 CTAGGGAAGAGTGAGCTGGGACAAGAAACCACCCCTTCTTTCAATGCAATGGTCGTGAAC 281 N L T L Q I V Q G H I E W Q T A D V I V 841 AACCTGACCCTCCAGATTGTCCAGGGCCACATTGAATGGCAGACGGCAGATGTAATTGTT 301 N S V N P H D I T V G P V A K S I L Q Q 901 AATTCTGTAAACCCACATGATATTACAGTTGGACCTGTGGCAAAGTCAATTCTACAACAA 321 A G V E M K S E F L A T K A K Q F Q R S 961 GCAGGAGTTGAAATGAAATCGGAATTTCTTGCCACAAAGGCTAAACAGTTTCAACGGTCC 341 Q L V L V T K G F N L F C K Y I Y H V L 1021?CAGTTGGTACTGGTCACAAAAGGATTTAACTTGTTCTGTAAATATATATACCATGTACTG

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			361 W H S E F P K P Q I L K H A M K E C L E 1081?TGGCATTCAGAATTTCCTAAACCTCAGATATTAAAACATGCAATGAAGGAGTGTTTGGAA 381 K C I E Q N I T S I S F P A L G T G N M 1141?AAATGCATTGAGCAAAATATAACTTCCATTTCCTTTCCTGCCCTTGGGACTGGAAACATG 401 E I K K E T A A E I L F D E V L T F A K 1201?GAAATAAAGAAGGAAACAGCAGCAGAGATTTTGTTTGATGAAGTTTTAACATTTGCCAAA 421 D H V K H Q L T V K F V I F P T D L E I 1261?GACCATGTAAAACACCAGTTAACTGTAAAATTTGTGATCTTTCCAACAGATTTGGAGATA 441 Y K A F S S E M A K R S K M L S L N N Y 1321?TATAAGGCTTTCAGTTCTGAAATGGCAAAGAGGTCCAAGATGCTGAGTTTGAACAATTAC 461 S V P Q S T R E E K R E N G L E A R S P 1381?AGTGTCCCCCAGTCAACCAGAGAGGAGAAAAGAGAAAATGGGCTTGAAGCTAGATCTCCT 481 A I N L M G F N V E E M Y E A H A W I Q 1441?GCCATCAATCTGATGGGATTCAACGTGGAAGAGATGTATGAGGCCCACGCATGGATCCAA 501 R I L S L Q N H H I I E N N H I L Y L G 1501?AGAATCCTGAGTCTCCAGAACCACCACATCATTGAGAATAATCATATTCTGTACCTTGGG 521 R K E H D I L S Q L Q K T S S V S I T E 1561?AGAAAGGAACATGACATTTTGTCTCAGCTTCAGAAAACTTCAAGTGTCTCCATCACAGAA 541 I I S P G R T E L E I E G A R A D L I E 1621?ATTATCAGCCCAGGAAGGACAGAGTTAGAGATTGAAGGAGCCCGGGCTGACCTCATTGAG 561 V V M N I E D M L C K V Q E E M A R K K 1681?GTGGTTATGAACATTGAAGATATGCTTTGTAAAGTACAGGAGGAAATGGCAAGGAAAAAG 581 E R G L W R S L G Q W T I Q Q Q K T Q D 1741?GAGCGAGGCCTTTGGCGCTCGTTAGGACAGTGGACTATTCAGCAACAAAAAACCCAAGAC 601 E M K E N I I F L K C P V P P T Q E L L 1801?GAAATGAAAGAAAATATCATATTTCTGAAATGTCCTGTGCCTCCAACTCAAGAGCTTCTA 621 D Q K K Q F E K C G L Q V L K V E K I D 1861?GATCAAAAGAAACAGTTTGAAAAATGTGGTTTGCAGGTTCTAAAGGTGGAGAAGATAGAC 641 N E V L M A A F Q R K K K M M E E K L H 1921?AATGAGGTCCTTATGGCTGCCTTTCAAAGAAAGAAGAAAATGATGGAAGAAAAACTGCAC 661 R Q P V S H R L F Q Q V P Y Q F C E V V 1981?AGGCAACCTGTGAGCCATAGGCTGTTTCAGCAAGTCCCATACCAGTTCTGTGAAGTGGTT 681 C R V G F Q R M Y S V P H D P K Y G P G

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	2041?TGCAGAGTTGGCTTTCAAAGAATGTACTCGGTGCCCCACGACCCAAAGTATGGACCTGGC 701 I Y F T K N L K N L A S Q F K K T S A T 2101?ATATACTTCACCAAGAATCTCAAAAATCTAGCATCCCAGTTCAAGAAAACGTCTGCCACA 721 D K L I Y V F E A E V L T G S F C E G H 2161?GATAAGCTGATCTATGTGTTTGAGGCTGAAGTACTCACAGGCTCCTTCTGTGAGGGTCAT 741 Q L N I V P P R L S T D A I D S H D S V 2221?CAGTTAAATATTGTTCCCCCACGATTGAGTACTGATGCCATAGATAGCCATGACAGTGTG 761 V D N V S S P E T F V I F S G T Q A M P 2281?GTTGACAATGTCTCCAGCCCTGAAACCTTTGTTATTTTTAGTGGCACGCAGGCTATGCCC 781 Q Y L W T C T Q D H V G P E D Y S L G Q 2341?CAATATTTGTGGACTTGCACCCAGGATCATGTAGGGCCAGAGGATTACTCATTAGGACAA 801 M L P S P Q Q L G K R F V S G S P V D - 2401?ATGTTGCCGTCTCCACAGCAGCTTGGGAAGAGATTCGTAAGTGGCAGCCCTGTTGACTAA
WBC041C11	Homo sapiens copine I	1 ACCAGGCAAATATTCCATTCAGCATTACAAAGATGGATGTTCTTCAGTTCCTAGAAGGAA 61 TCCCAGTGGATGAAAATGCTGTACATGTTCTTGTTGATAACAATGGGCAAGGTCTAGGAC 121 AGGCATTGGTTCAGTTTAAAAATGAAGATGATGCACATGGCCCACTGCGTGACCTTGGTT 181 CAGCTGTCCATTTCCTGTGACCATCTCATTGACAAGGACATCGGCTCCAAGTCTGACCCA 241 CTCTGCGTCCTTTTACAGGATGTGGGAGGGGGCAGCTGGGCTGAGCTTGGCCGGACTGAA 301 CGGGTGCGGAACTGCTCAAGCCCTGAGTTCTCCAAGACTCTACAGCTTGAGTACCGCTTT 361 GAGACAGTCCAGAAGCTACGCTTTGGAATCTATGACATAGACAACAAGACGCCAGAGCTG 421 AGGGATGATGACTTCCTAGGGGGTGCTGAGTGTTCCCTAGGACAGATTGTGTCCAGCCAG 481 GTACTGACTCTCCCCTTGATGCTGAAGCCTGGAAAACCTGCTGGGCGGGGGACCATCACG 541 GTCTCAGCTCAGGAATTAAAGGACAATCGTGTAGTAACCATGGAGGTAGAGGCCAGAAAC 601 CTAGATAAGAAGGACTTCCTGGGAAAATCAGATCCATTTCTGGAGTTCTTCCGCCAGGGT 661 GATGGGAAATGGCACCTGGTGTACAGATCTGAGGTCATCAAGAACAACCTGAACCCTACA 721 TGGAAGCGTTTCTCAGTCCCCGTTCAGCATTTCTGTGGTGGGAACCCCAGCACACCCATC 781 CAGGTGCAATGCTCCGATTATGACAGTGACGGGTCACATGATCTCATCGGTACCTTCCAC 841 ACCAGCTTGGCCCAGCTGCAGGCAGTCCCGGCTGAGTTTGAATGCATCCACCCTGAGAAG 901 CAGCAGAAAAAGAAAAGCTACAAGAACTCTGGAACTATCCGTGTCAAGATTTGTCGGGTA 961 GAAACAGAGTACTCCTTTCTGGACTATGTGATGGGAGGCTGTCAGATCAACTTCACTGTG 1021?GGCGTGGACTTCACTGGCTCCAATGGAGACCCCTCCTCACCTGACTCCCTACACTACCTG 1081?AGTCCAACAGGGGTCAATGAGTACCTGATGGCACTGTGGAGTGTGGGCAGCGTGGTTCAG 1141?GACTATGACTCAGACAAGCTGTTCCCTGCATTTGGATTTGGGGCCCAGGTTCCCCCTGAC 1201?TGGCAGGTCTCGCATGAATTTGCCTTGAATTTCAACCCCAGTAACCCCTACTGTGCAGGC 1261?ATCCAGGGCATTGTGGATGCCTACCGCCAAGCCCTGCCCCAAGTTCGCCTCTATGGCCCT 1321?ACCAACTTTGCACCCATCATCAACCATGTGGCCAGGTTTGCAGCCCAGGCTGCACATCAG 1381?GGGACTGCCTCGCAATACTTCATGCTGTTGCTGCTGACTGATGGTGCTGTGACGGATGTG 1441?GAAGCCACACGTGAGGCTGTGGTGCGTGCCTCGAACCTGCCCATGTCAGTGATCATTGTG 1501?GGTGTGGGTGGTGCTGACTTTGAGGCCATGGAGCAGCTGGACGCTGATGGTGGACCCCTG 1561?CATACACGTTCTGGGCAGGCTGCTGCCCGCGACATTGTGCAGTTTGTACCCTACCGCCGG 1621?TTCCAGAATGCCCCTCGGGAGGCATTGGCACAGACCGTGCTCGCAGAAGTGCCCACACAA	SEQ?ID?NO：61

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1681?CTGGTCTCATACTTCAGGGCCCAGGGTTGGGCCCCGCTCAAGCCACTTCCACCCTCAGCC 1741?AAGGATCCTGCACAGGCCCCCCAGGCCTAGGTTCCCTTGGAGGCTGTGGCAAGTCCTCAA 1801?TCCTGTGTCCCAGAGGTCCCTNTGGGCCACAACCCAACCCTTCTCACTCTCCTCAGTGCT 1861?AGCACTTTGTATTTTTTGATACTTTTATACTTGTTTCTGCTTTTGCTGCTCTTGATCCCA 1921?CCTTTGCTCCTGACAACCCTCATTCAATAAAGACCAGTGAAGACCAAAAAAAAAAAAAAA 1981?AAAAA 1 M A H C V T L V Q L S I S C D H L I D K 1 ATGGCCCACTGCGTGACCTTGGTTCAGCTGTCCATTTCCTGTGACCATCTCATTGACAAG 21 D I G S K S D P L C V L L Q D V G G G S 61 GACATCGGCTCCAAGTCTGACCCACTCTGCGTCCTTTTACAGGATGTGGGAGGGGGCAGC 41 W A E L G R T E R V R N C S S P E F S K 121 TGGGCTGAGCTTGGCCGGACTGAACGGGTGCGGAACTGCTCAAGCCCTGAGTTCTCCAAG 61 T L Q L E Y R F E T V Q K L R F G I Y D 181 ACTCTACAGCTTGAGTACCGCTTTGAGACAGTCCAGAAGCTACGCTTTGGAATCTATGAC 81 I D N K T P E L R D D D F L G G A E C S 241 ATAGACAACAAGACGCCAGAGCTGAGGGATGATGACTTCCTAGGGGGTGCTGAGTGTTCC 101 L G Q I V S S Q V L T L P L M L K P G K 301 CTAGGACAGATTGTGTCCAGCCAGGTACTGACTCTCCCCTTGATGCTGAAGCCTGGAAAA 121 P A G R G T I T V S A Q E L K D N R V V 361 CCTGCTGGGCGGGGGACCATCACGGTCTCAGCTCAGGAATTAAAGGACAATCGTGTAGTA 141 T M E V E A R N L D K K D F L G K S D P 421 ACCATGGAGGTAGAGGCCAGAAACCTAGATAAGAAGGACTTCCTGGGAAAATCAGATCCA 161 F L E F F R Q G D G K W H L V Y R S E V 481 TTTCTGGAGTTCTTCCGCCAGGGTGATGGGAAATGGCACCTGGTGTACAGATCTGAGGTC 181 I K N N L N P T W K R F S V P V Q H F C 541 ATCAAGAACAACCTGAACCCTACATGGAAGCGTTTCTCAGTCCCCGTTCAGCATTTCTGT 201 G G N P S T P I Q V Q C S D Y D S D G S 601 GGTGGGAACCCCAGCACACCCATCCAGGTGCAATGCTCCGATTATGACAGTGACGGGTCA 221 H D L I G T F H T S L A Q L Q A V P A E 661 CATGATCTCATCGGTACCTTCCACACCAGCTTGGCCCAGCTGCAGGCAGTCCCGGCTGAG 241 F E C I H P E K Q Q K K K S Y K N S G T 721 TTTGAATGCATCCACCCTGAGAAGCAGCAGAAAAAGAAAAGCTACAAGAACTCTGGAACT 261 I R V K I C R V E T E Y S F L D Y V M G 781 ATCCGTGTCAAGATTTGTCGGGTAGAAACAGAGTACTCCTTTCTGGACTATGTGATGGGA	SEQ?ID?NO：62

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	281 G C Q I N F T V G V D F T G S N G D P S 841 GGCTGTCAGATCAACTTCACTGTGGGCGTGGACTTCACTGGCTCCAATGGAGACCCCTCC 301 S P D S L H Y L S P T G V N E Y L M A L 901 TCACCTGACTCCCTACACTACCTGAGTCCAACAGGGGTCAATGAGTACCTGATGGCACTG 321 W S V G S V V Q D Y D S D K L F P A F G 961 TGGAGTGTGGGCAGCGTGGTTCAGGACTATGACTCAGACAAGCTGTTCCCTGCATTTGGA 341 F G A Q V P P D W Q V S H E F A L N F N 1021?TTTGGGGCCCAGGTTCCCCCTGACTGGCAGGTCTCGCATGAATTTGCCTTGAATTTCAAC 361 P S N P Y C A G I Q G I V D A Y R Q A L 1081?CCCAGTAACCCCTACTGTGCAGGCATCCAGGGCATTGTGGATGCCTACCGCCAAGCCCTG 381 P Q V R L Y G P T N F A P I I N H V A R 1141?CCCCAAGTTCGCCTCTATGGCCCTACCAACTTTGCACCCATCATCAACCATGTGGCCAGG 401 F A A Q A A H Q G T A S Q Y F M L L L L 1201?TTTGCAGCCCAGGCTGCACATCAGGGGACTGCCTCGCAATACTTCATGCTGTTGCTGCTG 421 T D G A V T D V E A T R E A V V R A S N 1261?ACTGATGGTGCTGTGACGGATGTGGAAGCCACACGTGAGGCTGTGGTGCGTGCCTCGAAC 441 L P M S V I I V G V G G A D F E A M E Q 1321?CTGCCCATGTCAGTGATCATTGTGGGTGTGGGTGGTGCTGACTTTGAGGCCATGGAGCAG 461 L D A D G G P L H T R S G Q A A A R D I 1381?CTGGACGCTGATGGTGGACCCCTGCATACACGTTCTGGGCAGGCTGCTGCCCGCGACATT 481 V Q F V P Y R R F Q N A P R E A L A Q T 1441?GTGCAGTTTGTACCCTACCGCCGGTTCCAGAATGCCCCTCGGGAGGCATTGGCACAGACC 501 V L A E V P T Q L V S Y F R A Q G W A P 1501?GTGCTCGCAGAAGTGCCCACACAACTGGTCTCATACTTCAGGGCCCAGGGTTGGGCCCCG 521 L K P L P P S A K D P A Q A P Q A - 1561?CTCAAGCCACTTCCACCCTCAGCCAAGGATCCTGCACAGGCCCCCCAGGCCTAG
WBC036C09_V1.3_AT	Homo sapiens delta sleep inducing peptide, immunoreactant, mRNA.	1 GAAGGCCGGAAGCTTACCAGCCGAGAAGGAATTCCTAGCTAGCTTCAGAGCCGGTGCCTC 61 CGGAGCCAGCGTGGTGGCCATAGACAACAAGATCGAACAGGCCATGGATCTGGTGAAGAA 121 TCATCTGATGTATGCTGTGAGAGAGGAGGTGGAGATCCTGAAGGAGCAGATCCGAGAGCT 181 GGTGGAGAAGAACTCCCAGCTAGAGCGTGAGAACACCCTGTTGAAGACCCTGGCAAGCCC 241 AGAGCAGCTGGAGAAGTTCCAGTCCTGTCTGAGCCCTGAAGAGCCAGCTCCCGAATCCCC 301 ACAAGTGCCCGAGGCCCCTGGTGGTTCTGCGGTGTAAGTGGCTCTGTCCTCAGGGTGGGC 361 AGAGCCACTAAACTTGTTTTACCTAGTTCTTTCCAGTTTGTTTTTGGCTCCCCAAGCATC 421 ATCTCACGAGGAGAACTTTACACCTAGCACAGCTGGTGCCAAGAGATGTCCCAAGGACAT 481 GGCCACCTGGGTCCACTCCAGTGACAGACCCCTGACAAAGAGCAAGTCCCTGGAGGCTGA	SEQ?ID?NO：63

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	541 GTTGCATGGGGTCTTGTCACCCCAAGCCAGTGAGCCTCTAATGCCACCGCGCCCTAGGGG 601 CTCCCAGAGCCTGGGCAACTTAGCTGTGACTGGCAAAGGAGAAAGGTAGTTTGAGATGTG 661 ACGCCAGTTAGTTCCAGAAAGTATCAGGGGTCTGTTTTTCATTTCCATGGACATCTTCAG 721 CAGCTTCACCTGACAATGACTGTTCCTATGAAGAAGCCACTTGTGTTTTAAGCAGAGGCA 781 ACCTCTCTCTTTTCCCCCGCCTCGCCAAGGCAGGGCCACAGATGGGAGAGATTGAGCCAA 841 GTCAGCCTTCTGTTGGTTAATATGGTCTAATGCATGGCTTTGTGCACAGCCCAGTGTGGG 901 ATTACGGCTTTGGGATGACCGCTTACAAAGTTCTGTTTGGTTAGTATTGGCATAGTTTTT 961 CTATATAGCCATACATGCGTATATATACCCATAGGGCTAGATCTATATCTTAGTGTAGCG 1021?ATGTATACATATACACATACACCTACGTGTCGAAGGGCCTAACCAGCTTTGGGAATATTG 1081?ACTGGTTCCTTATCTCTTAAGGCTAATTCTTTGACTGTGTTCATTTACCAAGTTGATCCA 1141?GTTTGTCCTTTAGGTTAAATAAGACTAAAGCGTAAAGACAGGGAGGGGGCCAGCCTCTGA 1201?ATGTGGCCACAGATGCCTTGCTGCTGCAACCCTTGCCCCATCTGTCCCCTGAAGACTTGT 1261?GAGGTCCTCTTTTGAAAGCCAAACCCACCATTCACTGGTGCTGACTACAAAGAATGGGTT 1321?TGAGAGAAGATCAGCTAGGACTTCACAGTGTCATTTGAAAACGTTTTTTGTTTTGTTTTG 1381?TAATTATTGTGGAAAACTTTCAAGTGAACAGAAGGATGGTGTCCTACTGTGGATGAGGGA 1441?TGAACAAGGGGATGGCTTTGATCCAATGGAGCCTGGGAGGTGTGCCCAGAAAGCTTGTCT 1501?GTAGCGGGTTTTGTGAGAGTGAACACTTTCCACTTTCTGACACCTGATCCTGATGTATGT 1561?TTCCAGGATTTGGATTTTGATTTTTCAGATGTAGCTTGAAATTTCAATAAACTTTGCTCT 1621?GTTTTTCTAAAAATAAAAAAAAAAAAAAA 1 M D L V K N H L M Y A V R E E V E I L K 1 ATGGATCTGGTGAAGAATCATCTGATGTATGCTGTGAGAGAGGAGGTGGAGATCCTGAAG 21 E Q I R E L V E K N S Q L E R E N T L L 61 GAGCAGATCCGAGAGCTGGTGGAGAAGAACTCCCAGCTAGAGCGTGAGAACACCCTGTTG 41 K T L A S P E Q L E K F Q S C L S P E E 121 AAGACCCTGGCAAGCCCAGAGCAGCTGGAGAAGTTCCAGTCCTGTCTGAGCCCTGAAGAG 61 P A P E S P Q V P E A P G G S A V - 181 CCAGCTCCCGAATCCCCACAAGTGCCCGAGGCCCCTGGTGGTTCTGCGGTGTAA	SEQ?ID?NO：64
WBC285	No homology	1 CTCAGAAAATGCACTCAGACACCGTAATCAGTGGAGCTGCGATCTTATGTACATTTCTAC 61 TCTAAAACCTATTTTAAATTTTATCATCTACCGCATGCTATTTCATCTCCTCTCGTCCTC 121 TCCCCCTTGTATTTATTAGAGGCTGGCTATGGATTTCTGTCCCTGAGAGCACCTTCCTAA 181 CAATGAAGTGTACTTGGCAGTCGCTCACGGTGAATAAGGATTGGAGGATATTCTGCAAGG 241 AAAATGGATAGCCTTGTTTCCTCTGTATGAGAGAAATATTTGAGGTAAAATAGACTAATA 301 ATTTCTCAAAGTAGAAGTTTTGAGGGTTGCTTTTGCATAGAGAAGTTGGAAACTCCTTGA 361 AGTGATAGAAAGCGTGTGGGATATTATAATTATTGTTATTTCCCGCCCTGGCAGGCCGCC 421 GCGGGTTTTCTCTTTCCGTGTGCCAGCATCCTTCGAGGTTCAAGGCCACTTCATGTTTTT 481 CTTCTGCTTTCTCCACACTGACTTTTTTTGATTTTCATGAGGGGTCTGAGAGAGAAAGCC 541 TCCCAGAACCCACTCTCAGTGCTTCCAGCCCTCATTCTTTGATGGATGTTCATGCAATTT 601 TCTCATTATTTTTCTGTCAGCATTCACAGAAACAGTGTAAAGTACTTTATTTCAAAGCCA 661 TTATGTTAGTTTACTCCATAATAATCTAAGCTGTGTATTCCTTTTCTGATTTGAATTTAG 721 TAATAACATATTTTTAAAGATAAGTCGAAAAGATTTCCTGAATAAATTTTCGATGACAAC 781 TGCTTAAGGTTCAGTTTTTTCCCCTCCTTTAATCTCTCTTATTGGACCGCGGGTTTATCT 841 ACTTGATTTAAGTTATCATTTCTTTCTGCACACTTTTAAAACAAACCCTGTGAACTTCTC	SEQ?ID?NO：65		SEQ?ID?NO：64

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	901 TTGGGA NON?CONTIGUOUS 1 GCATGCCCCAACCCAACCCCTGGCCCAAGCCACCCCCAAGGGGATGATCCAGAAACTGCT 61 TGAAGGCAAGAGTTTCTGAAAATTCTCTTCTCTCCCTCCTGTAAAGGTTTGCATATTTTA 121 AATTCTGTTCTTTCCACAACCCCTCAGCTTCTGGATATAATTTGTGCATAATTGTGTATC 181 CTCCTCAAGATTCATCTCCCTCTTCCTTCTCCACCCTTTCTTCAGGTGGAATTTTCTGGG 241 TGTCTGATGTTTACACTTTTCCAGACGAGAGTTAAGGGGCCCCTCCCATTTTCTGTCAGA 301 TCGTGGATTTCTTTTCCTGTATTGCTTTGGAACTGCAAAACAGATTCTTCTCACCGATGG 361 TAGTGTAGAAATCTTCAGGAAAGATGTAAAGATTTTTTAAATGCCTCAAAGTGTGGACTT 421 TCTAGATGGTCCCAATATGTCAGTTGCTGTTCTAAAAAAAAAATGTAAAAATCAGATTTC 481 TTAGTTTGGTAGGATTAAAAATTATTTCTGGTGCAGTATTCTTTCCGTGATATGGCATTG 541 GTGGTCTTGCCTGTATTTTCAGGTAAGCTTTTGGTTGTGTATGTAACTGAACTTTAAAAT 601 TTCCGGTGCGTTTTATCGGACTGATTCAATTTAGAGGAAGATAAAGGGTGCTGCTCTGAG 661 GCTAGGAGATAGTTTTTGAGGTAAAAAAAAAAAAAAAAAA	SEQ?ID?NO：66
WBC030G08_V1.3_AT	Homo sapiens chromosome 6 open reading frame 72, mRNA.	1 GGGGGCCCTCTGCCCGGGTTGTCCAAGATGGAGGGCGCTCCACCGGGGTCGCTCGCCCTC 61 CGGCTCCTGCTGTTCGTGGCGCTACCCGCCTCCGGCTGGCTGACGACGGGCGCCCCCGAG 121 CCGCCGCCGCTGTCCGGAGCCCCACAGGACGGCATCAGAATTAATGTAACTACACTGAAA 181 GATGATGGGGACATATCTAAACAGCAGGTTGTTCTTAACATAACCTATGAGAGTGGACAG 241 GTCTATGTAAATGACCTCCCTGTAAATAGTGGGGTCACCCGAATCAGCTGTCAGACTTTG 301 ATAGTGAAGAATGAAAATCTAGGAAATTTGGAGGAAAAAGAATATTTTGGAATTGTCACT 361 GTAAGGATTTTAGTTCATGAGTGGCCTATGACATCTGGTTCCAGTTTGCAACTAATTGTC 421 ATTCAAGAAGAAGTAGTAGAGATTGATGGAAAACAAGCTCAACAAAAGGATGTCACTGAA 481 ATTGATATTTTAGTTAAGAACCAGGGAGTAATCAGACATACAAACTACACCCTGCCTTTG 541 GAAGAAAGCATGCTGTACTCCATTTCCCGAGACAATGACGTTTTGTTTACCCTTCCCAAC 601 CTCTCCAAAAAAGTAGAAAGTGTTAGTTCGTTGCAGACCACCAGCCAGTACCCCATCAGG 661 AGCGTGGAGACCACCGTAGAAGGAGAGGCTCTACCTGGCAAATTACCTGAGACTCCTCTC 721 AGAGCAGAGCCTCCGTTTCCCTATAAGGTGATGTGTCAGTGGATGGAGAGGTTCAGGAAG 781 GACCTGTGCAGGTTCTGGAGCAGCGTTTGCCCAGTGTTCTTCATGTTTTTGAATGTCATG 841 GTGGTCGGAAATATAGGAGCAGCTGTGGTCATAACCATCTTAAAGGTGCTTTTCCCAGTT 901 TGTGAATACAAAGGAATTCTTCAGTTGGATAAAGTGAATGTTATACCTGTGACAGCTATC 961 AACGTACATCCAGATGGTCCTGAGAAAACAGTGGAAAACCGTGGAGATAAAACATGTGTT 1021?TAAAACACCGTCTCAAATCATTGACTTTGAATTAGTCTTTTGGCTCTAAATTTGCCACTT 1081?GAATATAATTTTCTTTAAATCATTAAGAATCAGTTTCAAAAAAAAAAAAAAAAAAAAAAA 1141?AAAAAA 1 M E G A P P G S L A L R L L L F V A L P 1 ATGGAGGGCGCTCCACCGGGGTCGCTCGCCCTCCGGCTCCTGCTGTTCGTGGCGCTACCC 21 A S G W L T T G A P E P P P L S G A P Q 61 GCCTCCGGCTGGCTGACGACGGGCGCCCCCGAGCCGCCGCCGCTGTCCGGAGCCCCACAG 41 D G I R I N V T T L K D D G D I S K Q Q 121 GACGGCATCAGAATTAATGTAACTACACTGAAAGATGATGGGGACATATCTAAACAGCAG 61 V V L N I T Y E S G Q V Y V N D L P V N 181 GTTGTTCTTAACATAACCTATGAGAGTGGACAGGTCTATGTAAATGACCTCCCTGTAAAT	SEQ?ID?NO：67 SEQ?ID?NO：68		SEQ?ID?NO：66

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	81 S G V T R I S C Q T L I V K N E N L G N 241 AGTGGGGTCACCCGAATCAGCTGTCAGACTTTGATAGTGAAGAATGAAAATCTAGGAAAT 101 L E E K E Y F G I V T V R I L V H E W P 301 TTGGAGGAAAAAGAATATTTTGGAATTGTCACTGTAAGGATTTTAGTTCATGAGTGGCCT 121 M T S G S S L Q L I V I Q E E V V E I D 361 ATGACATCTGGTTCCAGTTTGCAACTAATTGTCATTCAAGAAGAAGTAGTAGAGATTGAT 141 G K Q A Q Q K D V T E I D I L V K N Q G 421 GGAAAACAAGCTCAACAAAAGGATGTCACTGAAATTGATATTTTAGTTAAGAACCAGGGA 161 V I R H T N Y T L P L E E S M L Y S I S 481 GTAATCAGACATACAAACTACACCCTGCCTTTGGAAGAAAGCATGCTGTACTCCATTTCC 181 R D N D V L F T L P N L S K K V E S V S 541 CGAGACAATGACGTTTTGTTTACCCTTCCCAACCTCTCCAAAAAAGTAGAAAGTGTTAGT 201 S L Q T T S Q Y P I R S V E T T V E G E 601 TCGTTGCAGACCACCAGCCAGTACCCCATCAGGAGCGTGGAGACCACCGTAGAAGGAGAG 221 A L P G K L P E T P L R A E P P F P Y K 661 GCTCTACCTGGCAAATTACCTGAGACTCCTCTCAGAGCAGAGCCTCCGTTTCCCTATAAG 241 V M C Q W M E R F R K D L C R F W S S V 721 GTGATGTGTCAGTGGATGGAGAGGTTCAGGAAGGACCTGTGCAGGTTCTGGAGCAGCGTT 261 C P V F F M F L N V M V V G N I G A A V 781 TGCCCAGTGTTCTTCATGTTTTTGAATGTCATGGTGGTCGGAAATATAGGAGCAGCTGTG 281 V I T I L K V L F P V C E Y K G I L Q L 841 GTCATAACCATCTTAAAGGTGCTTTTCCCAGTTTGTGAATACAAAGGAATTCTTCAGTTG 301 D K V N V I P V T A I N V H P D G P E K 901 GATAAAGTGAATGTTATACCTGTGACAGCTATCAACGTACATCCAGATGGTCCTGAGAAA 321 T V E N R G D K T C V - 961 ACAGTGGAAAACCGTGGAGATAAAACATGTGTTTAA
WBC024D07	Homo sapiens's heat shock 70kDa albumen 8, transcript variant 1	1 CTCTTGGGTTTTTTGTGGCTTCCTTCGTTATTGGAGCCAGGCCTACACGCCAGCAACCAT 61 GTCCAAGGGACCTGCAGTTGGTATTGATCTTGGCACCACCTACTCTTGTGTGGGTGTTTT 121 CCAGCACGGAAAAGTCGAGATAATTGCCAATGATCAGGGAAACCGAACCACTCCAAGCTA 181 TGTCGCCTTTACGGACACTGAACGGTTGATCGGTGATGCCGCAAAGAATCAAGTTGCAAT 241 GAACCCCACCAACACAGTTTTTGATGCCAAACGTCTGATTGGACGCAGATTTGATGATGC 301 TGTTGTCCAGTCTGATATGAAACATTGGCCCTTTATGGTGGTGAATGATGCTGGCAGGCC 361 CAAGGTCCAAGTAGAATACAAGGGAGAGACCAAAAGCTTCTATCCAGAGGAGGTGTCTTC 421 TATGGTTCTGACAAAGATGAAGGAAATTGCAGAAGCCTACCTTGGGAAGACTGTTACCAA	SEQ?ID?NO：69

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			481 TGCTGTGGTCACAGTGCCAGCTTACTTTAATGACTCTCAGCGTCAGGCTACCAAAGATGC 541 TGGAACTATTGCTGGTCTCAATGTACTTAGAATTATTAATGAGCCAACTGCTGCTGCTAT 601 TGCTTACGGCTTAGACAAAAAGGTTGGAGCAGAAAGAAACGTGCTCATCTTTGACCTGGG 661 AGGTGGCACTTTTGATGTGTCAATCCTCACTATTGAGGATGGAATCTTTGAGGTCAAGTC 721 TACAGCTGGAGACACCCACTTGGGTGGAGAAGATTTTGACAACCGAATGGTCAACCATTT 781 TATTGCTGAGTTTAAGCGCAAGCATAAGAAGGACATCAGTGAGAACAAGAGAGCTGTAAG 841 ACGCCTCCGTACTGCTTGTGAACGTGCTAAGCGTACCCTCTCTTCCAGCACCCAGGCCAG 901 TATTGAGATCGATTCTCTCTATGAAGGAATCGACTTCTATACCTCCATTACCCGTGCCCG 961 ATTTGAAGAACTGAATGCTGACCTGTTCCGTGGCACCCTGGACCCAGTAGAGAAAGCCCT 1021?TCGAGATGCCAAACTAGACAAGTCACAGATTCATGATATTGTCCTGGTTGGTGGTTCTAC 1081?TCGTATCCCCAAGATTCAGAAGCTTCTCCAAGACTTCTTCAATGGAAAAGAACTGAATAA 1141?GAGCATCAACCCTGATGAAGCTGTTGCTTATGGTGCAGCTGTCCAGGCAGCCATCTTGTC 1201?TGGAGACAAGTCTGAGAATGTTCAAGATTTGCTGCTCTTGGATGTCACTCCTCTTTCCCT 1261?TGGTATTGAAACTGCTGGTGGAGTCATGACTGTCCTCATCAAGCGTAATACCACCATTCC 1321?TACCAAGCAGACACAGACCTTCACTACCTATTCTGACAACCAGCCTGGTGTGCTTATTCA 1381?GGTTTATGAAGGCGAGCGTGCCATGACAAAGGATAACAACCTGCTTGGCAAGTTTGAACT 1441?CACAGGCATACCTCCTGCACCCCGAGGTGTTCCTCAGATTGAAGTCACTTTTGACATTGA 1501?TGCCAATGGTATACTCAATGTCTCTGCTGTGGACAAGAGTACGGGAAAAGAGAACAAGAT 1561?TACTATCACTAATGACAAGGGCCGTTTGAGCAAGGAAGACATTGAACGTATGGTCCAGGA 1621?AGCTGAGAAGTACAAAGCTGAAGATGAGAAGCAGAGGGACAAGGTGTCATCCAAGAATTC 1681?ACTTGAGTCCTATGCCTTCAACATGAAAGCAACTGTTGAAGATGAGAAACTTCAAGGCAA 1741?GATTAACGATGAGGACAAACAGAAGATTCTGGACAAGTGTAATGAAATTATCAACTGGCT 1801?TGATAAGAATCAGACTGCCGAGAAGGAAGAATTTGAACATCAACAGAAAGAGCTGGAGAA 1861?AGTTTGCAACCCCATCATCACCAAGCTGTACCAGAGTGCAGGAGGCATGCCAGGAGGAAT 1921?GCCTGGGGGATTTCCTGGTGGTGGAGCTCCTCCCTCTGGTGGTGCTTCCTCAGGGCCCAC 1981?CATTGAAGAGGTTGATTAAGCCAACCAAGTGTAGATGTAGCATTGTTCCACACATTTAAA 2041?ACATTTGAAGGACCTAAATTCGTAGCAAATTCTGTGGCAGTTTTAAAAAGTTAAGCTGCT 2101?ATAGTAAGTTACTGGGCATTCTCAATACTTGAATATGGAACATATGCACAGGGGAAGGAA 2161?ATAACATTGCACTTTATAAACACTGTATTGTAAGTGGAAAATGCAATGTCTTAAATAAAA 2221?CTATTTAAAATTGGCACCATAAACAAAAAAAAAAAAAAA 1 M S K G P A V G I D L G T T Y S C V G V 1 ATGTCCAAGGGACCTGCAGTTGGTATTGATCTTGGCACCACCTACTCTTGTGTGGGTGTT 21 F Q H G K V E I I A N D Q G N R T T P S 61 TTCCAGCACGGAAAAGTCGAGATAATTGCCAATGATCAGGGAAACCGAACCACTCCAAGC 41 Y V A F T D T E R L I G D A A K N Q V A 121 TATGTCGCCTTTACGGACACTGAACGGTTGATCGGTGATGCCGCAAAGAATCAAGTTGCA 61 M N P T N T V F D A K R L I G R R F D D 181 ATGAACCCCACCAACACAGTTTTTGATGCCAAACGTCTGATTGGACGCAGATTTGATGAT 81 A V V Q S D M K H W P F M V V N D A G R 241 GCTGTTGTCCAGTCTGATATGAAACATTGGCCCTTTATGGTGGTGAATGATGCTGGCAGG 101 P K V Q V E Y K G E T K S F Y P E E V S 301 CCCAAGGTCCAAGTAGAATACAAGGGAGAGACCAAAAGCTTCTATCCAGAGGAGGTGTCT	SEQ?ID?NO：70

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			121 S M V L T K M K E I A E A Y L G K T V T 361 TCTATGGTTCTGACAAAGATGAAGGAAATTGCAGAAGCCTACCTTGGGAAGACTGTTACC 141 N A V V T V P A Y F N D S Q R Q A T K D 421 AATGCTGTGGTCACAGTGCCAGCTTACTTTAATGACTCTCAGCGTCAGGCTACCAAAGAT 161 A G T I A G L N V L R I I N E P T A A A 481 GCTGGAACTATTGCTGGTCTCAATGTACTTAGAATTATTAATGAGCCAACTGCTGCTGCT 181 I A Y G L D K K V G A E R N V L I F D L 541 ATTGCTTACGGCTTAGACAAAAAGGTTGGAGCAGAAAGAAACGTGCTCATCTTTGACCTG 201 G G G T F D V S I L T I E D G I F E V K 601 GGAGGTGGCACTTTTGATGTGTCAATCCTCACTATTGAGGATGGAATCTTTGAGGTCAAG 221 S T A G D T H L G G E D F D N R M V N H 661 TCTACAGCTGGAGACACCCACTTGGGTGGAGAAGATTTTGACAACCGAATGGTCAACCAT 241 F I A E F K R K H K K D I S E N K R A V 721 TTTATTGCTGAGTTTAAGCGCAAGCATAAGAAGGACATCAGTGAGAACAAGAGAGCTGTA 261 R R L R T A C E R A K R T L S S S T Q A 781 AGACGCCTCCGTACTGCTTGTGAACGTGCTAAGCGTACCCTCTCTTCCAGCACCCAGGCC 281 S I E I D S L Y E G I D F Y T S I T R A 841 AGTATTGAGATCGATTCTCTCTATGAAGGAATCGACTTCTATACCTCCATTACCCGTGCC 301 R F E E L N A D L F R G T L D P V E K A 901 CGATTTGAAGAACTGAATGCTGACCTGTTCCGTGGCACCCTGGACCCAGTAGAGAAAGCC 321 L R D A K L D K S Q I H D I V L V G G S 961 CTTCGAGATGCCAAACTAGACAAGTCACAGATTCATGATATTGTCCTGGTTGGTGGTTCT 341 T R I P K I Q K L L Q D F F N G K E L N 1021?ACTCGTATCCCCAAGATTCAGAAGCTTCTCCAAGACTTCTTCAATGGAAAAGAACTGAAT 361 K S I N P D E A V A Y G A A V Q A A I L 1081?AAGAGCATCAACCCTGATGAAGCTGTTGCTTATGGTGCAGCTGTCCAGGCAGCCATCTTG 381 S G D K S E N V Q D L L L L D V T P L S 1141?TCTGGAGACAAGTCTGAGAATGTTCAAGATTTGCTGCTCTTGGATGTCACTCCTCTTTCC 401 L G I E T A G G V M T V L I K R N T T I 1201?CTTGGTATTGAAACTGCTGGTGGAGTCATGACTGTCCTCATCAAGCGTAATACCACCATT 421 P T K Q T Q T F T T Y S D N Q P G V L I 1261?CCTACCAAGCAGACACAGACCTTCACTACCTATTCTGACAACCAGCCTGGTGTGCTTATT 441 Q V Y E G E R A M T K D N N L L G K F E

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	1321?CAGGTTTATGAAGGCGAGCGTGCCATGACAAAGGATAACAACCTGCTTGGCAAGTTTGAA 461 L T G I P P A P R G V P Q I E V T F D I 1381?CTCACAGGCATACCTCCTGCACCCCGAGGTGTTCCTCAGATTGAAGTCACTTTTGACATT 481 D A N G I L N V S A V D K S T G K E N K 1441?GATGCCAATGGTATACTCAATGTCTCTGCTGTGGACAAGAGTACGGGAAAAGAGAACAAG 501 I T I T N D K G R L S K E D I E R M V Q 1501?ATTACTATCACTAATGACAAGGGCCGTTTGAGCAAGGAAGACATTGAACGTATGGTCCAG 521 E A E K Y K A E D E K Q R D K V S S K N 1561?GAAGCTGAGAAGTACAAAGCTGAAGATGAGAAGCAGAGGGACAAGGTGTCATCCAAGAAT 541 S L E S Y A F N M K A T V E D E K L Q G 1621?TCACTTGAGTCCTATGCCTTCAACATGAAAGCAACTGTTGAAGATGAGAAACTTCAAGGC 561 K I N D E D K Q K I L D K C N E I I N W 1681?AAGATTAACGATGAGGACAAACAGAAGATTCTGGACAAGTGTAATGAAATTATCAACTGG 581 L D K N Q T A E K E E F E H Q Q K E L E 1741?CTTGATAAGAATCAGACTGCCGAGAAGGAAGAATTTGAACATCAACAGAAAGAGCTGGAG 601 K V C N P I I T K L Y Q S A G G M P G G 1801?AAAGTTTGCAACCCCATCATCACCAAGCTGTACCAGAGTGCAGGAGGCATGCCAGGAGGA 621 M P G G F P G G G A P P S G G A S S G P 1861?ATGCCTGGGGGATTTCCTGGTGGTGGAGCTCCTCCCTCTGGTGGTGCTTCCTCAGGGCCC 641 T I E E V D - 1921?ACCATTGAAGAGGTTGATTAA
WBC031E09_V1.3_AT	People EV12 protein gene, exons 1.	1 TAATAGAAATTAAAATGCTTCTTCATACATAGCTGAATAGAAAAGAATTTGTTGAGAAGG 61 AATTCAGGGTAGCGAATATTAGGCATAAGCTTGTAGTTTACTTGTAACATCTCAACACTA 121 TCTTTTAACTACAATTACCAAAAACTAGGATCCATTATTCTTTCACAAACTAACAAATTA 181 TATTGCTATCCCAACAGATTGCCAAGTATGCCCACGGACATGGAACACACAGGACATTAC 241 CTACATCTTGCCTTTCTGATGACAACAGTTTTTTCTTTGTCTCCTGGAACAAAAGCAAAC 301 TATACCCGTCTGTGGGCTAACAGTACTTCTTCCTGGGATTCAGTTATTCAAAACAAGACA 361 GGCAGAAACAAAAATGAAAACATTAATATAAACCCTGCAACTCCTGAAGTAGATAAAAAA 421 GATAACTCTACAAGCATGCCTGAAATAGCAACATCAGCTCACATTGTACCCTTAACTCCT 481 AAATCTCAACCGGAGCTTTATATACCTTCTGTTGTCAGGAACAGTTCTCCAACAGTACAG 541 AGCATTGAAAACACAAGCAAGAGTCACAGTGAAATTTTCAAAAAAGATGTCTGTGAGGAA 601 AACTACAACAAAATCGCTATGCTAGTTTGTGTAATTATAATTGCAGTGCTTTTTCTTATC 661 TGTACCCTTCTATTTCTATCAACTGTGGTTCTGGCAAACAAAGTCTCATCTCTCAGACGA 721 TCAAAACAAGCAGGCAAACGTCAGCCTAGAAGCAACGGCGATTTTCTGGCAAGCAGTGGT 781 CTATGGCCTGCTGACTCAGATACTTGGAAAAGAGCAAAACAGCTCACAGGGCCCCACCTA 841 ATGATGCCATCTACTGGAGCACTCACAGCTACAATGGAAAGAAAAGATGAAGAAAGAACT 901 GAAAAACTCACTAACTGATGCTTTAGTGAAGAAAAATGCAAAGTGGCTATGAGAAAGTTT	SEQ?ID?NO：71

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			961 AGAGTAAAAATGAAGTCAGTTTGATATTTAATGCCAACAGGTTGGTCTGATGGTCTGAAA 1021?TCTGATGGGCAGGCCTTGCGATTTAAAATGAAGCAGGTGAGAAGGGGAGAAGCATGCCTG 1081?CTTACTTAATGACTGAAACTGTGCACTTTTGTTCTGACACTGAATATCTTAAAGAGCAAA 1141?TAATAAAACAACCAAGCATCTGGGGAAGGTTTTGAAGATGACTTGAAGGAACTGACTAAT 1201?AGAAAGGGTCAATTAAATAAATATTTCCTGTTCCATAATAGTAGTTAGATGATCTTTGTT 1261?CGAATGTAATTAAATTTTGAAAAGTTTTAGCATGTCCTTAGAGGCAAGTATATGCTTCAA 1321?CACCTAACAGAAGTAAAAATTCTAATGCATAGAGATGAACTGTATAGTTTAATGGTACCT 1381?TCTTTGCTGAATGTGACAGAATCCATACCAGCTCATGTATCAACACAGCTAATTTTAAGC 1441?AGGATGTTTTCATCTTTACATATGGCACATATAAAAAGGTGCTTTTCTACTATTAATATT 1501?AAATTAAAACCTTTACTTTTGTATAATAAATTAAAACTCAGAATAAACCTGTGACCACGT 1561?ATATTTGCATTCACTTTATTACTTTAGAGAACACATTGTAAAGATCAATAAGAAATAGAG 1621?CACAACTAAAATAAATAAGATTTATAGCCACACCAATAGGCTAGTGTAAACGAAAGTATG 1681?TTTCACTGTTTATGATTAATAATATTCATCTTTTCTATAAATACTACTTACTGGAACATT 1741?AACAACAAGTCCAAAGGTTGATTAATTTTGACTCAGGAGCAGAGCTATGATTATA 1 M P T D M E H T G H Y L H L A F L M T T 1 ATGCCCACGGACATGGAACACACAGGACATTACCTACATCTTGCCTTTCTGATGACAACA 21 V F S L S P G T K A N Y T R L W A N S T 61 GTTTTTTCTTTGTCTCCTGGAACAAAAGCAAACTATACCCGTCTGTGGGCTAACAGTACT 41 S S W D S V I Q N K T G R N K N E N I N 121 TCTTCCTGGGATTCAGTTATTCAAAACAAGACAGGCAGAAACAAAAATGAAAACATTAAT 61 I N P A T P E V D K K D N S T S M P E I 181 ATAAACCCTGCAACTCCTGAAGTAGATAAAAAAGATAACTCTACAAGCATGCCTGAAATA 81 A T S A H I V P L T P K S Q P E L Y I P 241 GCAACATCAGCTCACATTGTACCCTTAACTCCTAAATCTCAACCGGAGCTTTATATACCT 101 S V V R N S S P T V Q S I E N T S K S H 301 TCTGTTGTCAGGAACAGTTCTCCAACAGTACAGAGCATTGAAAACACAAGCAAGAGTCAC 121 S E I F K K D V C E E N Y N K I A M L V 361 AGTGAAATTTTCAAAAAAGATGTCTGTGAGGAAAACTACAACAAAATCGCTATGCTAGTT 141 C V I I I A V L F L I C T L L F L S T V 421 TGTGTAATTATAATTGCAGTGCTTTTTCTTATCTGTACCCTTCTATTTCTATCAACTGTG 161 V L A N K V S S L R R S K Q A G K R Q P 481 GTTCTGGCAAACAAAGTCTCATCTCTCAGACGATCAAAACAAGCAGGCAAACGTCAGCCT 181 R S N G D F L A S S G L W P A D S D T W 541 AGAAGCAACGGCGATTTTCTGGCAAGCAGTGGTCTATGGCCTGCTGACTCAGATACTTGG 201 K R A K Q L T G P H L M M P S T G A L T 601 AAAAGAGCAAAACAGCTCACAGGGCCCCACCTAATGATGCCATCTACTGGAGCACTCACA	SEQ?ID?NO：72

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	221 A T M E R K D E E R T E K L T N - 661 GCTACAATGGAAAGAAAAGATGAAGAAAGAACTGAAAAACTCACTAACTGA
BM734613	Homo sapiens's senilism protein relative protein mRNA.	1 CGGTGCCGCGGGGATGGCGGGAGCCGGAGCTGGAGCCGGAGCTCGCGGCGGAGCGGCGGC 61 GGGGGTCGAGGCTCGAGCTCGCGATCCACCGCCCGCGCACCGCGCACATCCTCGCCACCC 121 TCGGCCTGCGGCTCAGCCCTCGGCCCGCAGGATGGATGGCGGGTCAGGGGGCCTGGGGTC 181 TGGGGACAACGCCCCGACCACTGAGGCTCTTTTCGTGGCACTGGGCGCGGGCGTGACGGC 241 GCTCAGCCATCCCCTGCTCTACGTGAAGCTGCTCATCCAGGTGGGTCATGAGCCGATGCC 301 CCCCACCCTTGGGACCAATGTGCTGGGGAGGAAGGTCCTCTATCTGCCGAGCTTCTTCAC 361 CTACGCCAAGTACATCGTGCAAGTGGATGGTAAGATAGGGCTGTTCCGAGGCCTGAGTCC 421 CCGGCTGATGTCCAACGCCCTCTCTACTGTGACTCGGGGTAGCATGAAGAAGGTTTTCCC 481 TCCAGATGAGATTGAGCAGGTTTCCAACAAGGATGATATGAAGACTTCCCTGAAGAAAGT 541 TGTGAAGGAGACCTCCTACGAGATGATGATGCAGTGTGTGTCCCGCATGTTGGCCCACCC 601 CCTGCATGTCATCTCAATGCGCTGCATGGTCCAGTTTGTGGGACGGGAGGCCAAGTACAG 661 TGGTGTGCTGAGCTCCATTGGGAAGATTTTCAAAGAGGAAGGGCTGCTGGGATTCTTCGT 721 TGGATTAATCCCTCACCTCCTGGGCGATGTGGTTTTCTTGTGGGGCTGTAACCTGCTGGC 781 CCACTTCATCAATGCCTACCTGGTGGATGACAGCGTGAGTGACACCCCAGGGGGGCTGGG 841 AAACGACCAGAATCCAGGTTCCCAGTTCAGCCAGGCCCTGGCCATCCGGAGCTATACCAA 901 GTTCGTGATGGGGATTGCAGTGAGCATGCTGACCTACCCCTTCCTGCTAGTTGGCGACCT 961 CATGGCTGTGAACAACTGCGGGCTGCAAGCTGGGCTCCCCCCTTACTCCCCAGTGTTCAA 1021?ATCCTGGATTCACTGCTGGAAGTACCTGAGTGTGCAGGGCCAGCTCTTCCGAGGCTCCAG 1081?CCTGCTTTTCCGCCGGGTGTCATCAGGATCATGCTTTGCCCTGGAGTAACCTGAATCATC 1141?TAAAAAACACGGTCTCAACCTGGCCACCGTGGGTGAGGCCTGACCACCTTGGGACACCTG 1201?CAAGACGACTCCAACCCAACAACAACCAGATGTGCTCCAGCCCAGCCGGGCTTCAGTTCC 1261?ATATTTGCCATGTGTCTGTCCAGATGTGGGGTTGAGCGGGGGTGGGGCTGCACCCAGTGG 1321?ATTGGGTCACCCGGCAGACCTAGGGAAGGTGAGGCGAGGTGGGGAGTTGGCAGAATCCCC 1381?ATACCTCGCAGATTTGCTGAGTCTGTCTTGTGCAGAGGGCCAGAGAACGACTTGTGGAGG 1441?CCTAGGTTGGATGGGAAAGGCTCGCGGGGTCAGGTCCCACCCCGTCTACCCCTCCAGTCA 1501?GCCCAGCGCCCATCCTGCAGCTCAGCTGGGAGCACTGCCCTCCTGCTTTGTACATAGGGC 1561?GTGATCCCCTTTCACCAGGCCACCACCATGTCCAGGCCTGTGCCAGGAAGCCATTGCTCA 1621?GTTCTACCTTTGTTTTTCTCAACACTACCTTTTTGATACGAAGGCAGCACCTTCGGAATG 1681?TGAAATCATGTACTGCTCAGAATGTGTCCCTCTCATCAAGTGCTCATTGGTTTAATGGTG 1741?ACGCCTCCTGTGCAGGATCTGGTCACCTGTGCATTTGTGAACACCCAGGAATTAGGCAGA 1801?TCACCGTCTCTTGTCTACCCAGTTTAACAATTTGTGATAAGATTTGACCGTTTCTCCCTC 1861?AAATAAATGTATTGGTGATTTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 M A G A G A G A G A R G G A A A G V E A 1 ATGGCGGGAGCCGGAGCTGGAGCCGGAGCTCGCGGCGGAGCGGCGGCGGGGGTCGAGGCT 21 R A R D P P P A H R A H P R H P R P A A 61 CGAGCTCGCGATCCACCGCCCGCGCACCGCGCACATCCTCGCCACCCTCGGCCTGCGGCT 41 Q P S A R R M D G G S G G L G S G D N A 121 CAGCCCTCGGCCCGCAGGATGGATGGCGGGTCAGGGGGCCTGGGGTCTGGGGACAACGCC 61 P T T E A L F V A L G A G V T A L S H P 181 CCGACCACTGAGGCTCTTTTCGTGGCACTGGGCGCGGGCGTGACGGCGCTCAGCCATCCC	SEQ?ID?NO：73 SEQ?ID?NO：74

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	81 L L Y V K L L I Q V G H E P M P P T L G 241 CTGCTCTACGTGAAGCTGCTCATCCAGGTGGGTCATGAGCCGATGCCCCCCACCCTTGGG 101 T N V L G R K V L Y L P S F F T Y A K Y 301 ACCAATGTGCTGGGGAGGAAGGTCCTCTATCTGCCGAGCTTCTTCACCTACGCCAAGTAC 121 I V Q V D G K I G L F R G L S P R L M S 361 ATCGTGCAAGTGGATGGTAAGATAGGGCTGTTCCGAGGCCTGAGTCCCCGGCTGATGTCC 141 N A L S T V T R G S M K K V F P P D E I 421 AACGCCCTCTCTACTGTGACTCGGGGTAGCATGAAGAAGGTTTTCCCTCCAGATGAGATT 161 E Q V S N K D D M K T S L K K V V K E T 481 GAGCAGGTTTCCAACAAGGATGATATGAAGACTTCCCTGAAGAAAGTTGTGAAGGAGACC 181 S Y E M M M Q C V S R M L A H P L H V I 541 TCCTACGAGATGATGATGCAGTGTGTGTCCCGCATGTTGGCCCACCCCCTGCATGTCATC 201 S M R C M V Q F V G R E A K Y S G V L S 601 TCAATGCGCTGCATGGTCCAGTTTGTGGGACGGGAGGCCAAGTACAGTGGTGTGCTGAGC 221 S I G K I F K E E G L L G F F V G L I P 661 TCCATTGGGAAGATTTTCAAAGAGGAAGGGCTGCTGGGATTCTTCGTTGGATTAATCCCT 241 H L L G D V V F L W G C N L L A H F I N 721 CACCTCCTGGGCGATGTGGTTTTCTTGTGGGGCTGTAACCTGCTGGCCCACTTCATCAAT 261 A Y L V D D S V S D T P G G L G N D Q N 781 GCCTACCTGGTGGATGACAGCGTGAGTGACACCCCAGGGGGGCTGGGAAACGACCAGAAT 281 P G S Q F S Q A L A I R S Y T K F V M G 841 CCAGGTTCCCAGTTCAGCCAGGCCCTGGCCATCCGGAGCTATACCAAGTTCGTGATGGGG 301 I A V S M L T Y P F L L V G D L M A V N 901 ATTGCAGTGAGCATGCTGACCTACCCCTTCCTGCTAGTTGGCGACCTCATGGCTGTGAAC 321 N C G L Q A G L P P Y S P V F K S W I H 961 AACTGCGGGCTGCAAGCTGGGCTCCCCCCTTACTCCCCAGTGTTCAAATCCTGGATTCAC 341 C W K Y L S V Q G Q L F R G S S L L F R 1021?TGCTGGAAGTACCTGAGTGTGCAGGGCCAGCTCTTCCGAGGCTCCAGCCTGCTTTTCCGC 361 R V S S G S C F A L E - 1081?CGGGTGTCATCAGGATCATGCTTTGCCCTGGAGTAA
WBC012F12_V1.3_AT	No homology	1 GACCACAACTGAAATGTGCAACTGTGCACTNGGGGGGATTNTGGGGAGAAAAAAAAAGCA 61 GGAAAAAATGTATCTTTAACAGATAAGATCTTTTTAACAAAACCATGGTATCATTGTCAC 121 TTGCCAAAATTAATGATTTCCTTAATTAGCATATAATAATCAGTCTGTATTCAGTTTTCC	SEQ?ID?NO：75

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 TTTCAAAAATATCTTTCTGCTGGTTGTTTAAATGAGGATCCAACACTGCATTTAGTTGCT 241 GTCTCTTTTACTCTATAACATTGACCCCTGTCTTTAATTTCTTTCCTCTTCCCAGTTATT 301 TGAGAAGGGAACTGGATCATATATCCTGTAGAATTTCCTTCGTTCAGGTTTTGACTGACG 361 GTATCCACATGATGTCTAGTTAGAACTAGAAGGTTGATTTGATTCTGGTTCAAAAATTTT 421 TTCCAAGAATACTCCATAGGTGATGCTATATACTTTCTTTTGCATCACGTCCTGAGGAAC 481 ACGATGTCTGGTTGTTCCACTGTTGGTGATGTCTGGATTGATCGGTGGTTTCTAGTGGTG 541 TCATCTACTATAAAGCTTCCTATCTATCTTTCACCCAATGGTTTGAGCAACCATTGATGA 601 TTGTTACCTGAATCCATTATTTTATTAGGGGTTGCAAAACAGTGACTTTTGGATTCTATC 661 AAACCTCTTGCATTTATCATCTGTGATTCTTGTAGAAAGAAGAACTTTGTCTAAAGCTGA 721 TTGGGAAAGATGGAATAAATAATTAATTTATTCATCTTTAGAATGAGTTGGTGCCCTAAC 781 AACCTCCAAAGGTGATAAATGAGGTCTTCGTTTTCTAAGTAGGGGTATGACTAAACCAGT 841 ACTTTGAAACAGTGTGTTTTAGAATGGGCTG NON?CONTIGUOUS 1 AACAGTTGATGGACATTTGGTTTGTTTCTACTTTCCTGCTATTATGAACAATGCTACTAT 61 GAATATTCGTGTACAAGTGTCACGTGGACATATTTCCATTTCTCTCGTGTGTACACCTAG 121 CAGTGGAAATGCTGAGTCATACTGTAACTCCTTCCTCCTAACTTTGCATATCAAAGTTAT 181 GTTCGGAACTCAGATTCAGTGCTACTTCTATAGTGTTCTGCCATCTCACACTCAGAACGA 241 AACTCCCCTCTAGTACTCCCAGTGTTGAGTGCCTCAGTATTGCGCTTACCAGTTTGCCCT 301 GGAGCTGTTATTCCTGCGTGGCTGTTCTCCTCCTACTGTGAATTTCTGGAAAGCAGGGAC 361 AGGCTCTCATTTTTGTCTGTCCCAAGACAGCGACTGTACCGCCCTGCATAAAGCAGGAAC 421 TCTGTAAGTCCTTTCGAACGGGTGGGTAATACAAGTGTTAAGAATTTCATGTGCTTGATT 481 CTATAAAATGTGTTTAATATTAAATAATAATAATGTTCACTTTCAAATTTCAACAATTAA 541 ATGTTTGTCAAATAACATTTAAAGTAAAGGTGTATAAGGTAAACCAGTTTGGTACATTAA 601 AGTCTATTTTATTTTAAAAAAAAA	SEQ?ID?NO：76
BM734661	The people UbA52 suprarenal gland mRNA of ubiquitin-52 amino acid fusion rotein	1 GACGCAGACATGCAGATCTTTGTGAAGACCCTGACGGGCAAGACCATCACCCTCGAGGTT 61 GAGCCCAGTGACACCATTGAGAATGTTAAAGCTAAAATCCAAGACAAGGAGGGCATCCCA 121 CCTGACCAGCAGCGTTTGATTTTTGCCGGCAAACAGCTGGAGGACGGCCGCACTCTCTCA 181 GACTACAATATCCAGAAAGAGTCCACCCTGCACTTGGTGCTCCGCCTGCGGGGCGGCATC 241 ATTGAGCCTTCCCTCCGCCAGCTCGCCCAGAAATACAACTGCGACAAGATGATTTGCCGC 301 AAGTGTTATGCTCGCCTGCACCCTCGTGCTGTCAACTGCCGCAAGAAGAAGTGCGGCCAC 361 ACCAACAACCTGCGCCCCAAGAAGAAGGTCAAATAAGGTTGTTCTTTCCTTGAAGGGCAG 421 CCTCCTGCCCAGGCCCCATGGCCCTGGGGCCTCAATAAAGTTTCCCTTTCATTGACTGGA 481 AAAAAAAAAAAAAAA 1 M Q I F V K T L T G K T I T L E V E P S 1 ATGCAGATCTTTGTGAAGACCCTGACGGGCAAGACCATCACCCTCGAGGTTGAGCCCAGT 21 D T I E N V K A K I Q D K E G I P P D Q 61 GACACCATTGAGAATGTTAAAGCTAAAATCCAAGACAAGGAGGGCATCCCACCTGACCAG 41 Q R L I F A G K Q L E D G R T L S D Y N 121 CAGCGTTTGATTTTTGCCGGCAAACAGCTGGAGGACGGCCGCACTCTCTCAGACTACAAT 61 I Q K E S T L H L V L R L R G G I I E P 181 ATCCAGAAAGAGTCCACCCTGCACTTGGTGCTCCGCCTGCGGGGCGGCATCATTGAGCCT 81 S L R Q L A Q K Y N C D K M I C R K C Y	SEQ?ID?NO：77 SEQ?ID?NO：78		SEQ?ID?NO：76

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	241 TCCCTCCGCCAGCTCGCCCAGAAATACAACTGCGACAAGATGATTTGCCGCAAGTGTTAT 101 A R L H P R A V N C R K K K C G H T N N 301 GCTCGCCTGCACCCTCGTGCTGTCAACTGCCGCAAGAAGAAGTGCGGCCACACCAACAAC 121 L R P K K K V K - 361 CTGCGCCCCAAGAAGAAGGTCAAATAA
WBC022G05	Homo sapiens ELOVL family member 5, prolongation (the FEN1/Elo2 of longer chain fatty acid, the SUR4/Elo3-sample, yeast) (ELOVL5)	1 CCAACCCCGGCCTAGGCTCTCCACCGCATCGGATTCTGGAATTTACGATCACGAAAGTTC 61 TATTGTCCCGCGATTGGCTCCCGGGCCGCATGACATCATAGCGCTTGATTCATCCTTCGG 121 GTCCCGATTGGCTGGCCGCGCCATTGTGACGTCACGGTCAGCCCACGTTCTGATTGTAGA 181 TAGCCGGCGCCTTCCTCTTCCCATCGCGCGGGTCCTAGCCACCGGTGTCTCCTTCTACAT 241 CCGCCTCTGCGCCGGCTGCCACCCGCGCTCCCTCCGCCGCCGCCGCCTTGCTGCTGCTCA 301 AAGCTGCTGCCGCCCCTTGGGCTAAAAGGTTTTCAAATGGAACATTTTGATGCATCACTT 361 AGTACCTATTTCAAGGCATTGCTAGGCCCTCGAGATACTAGAGTAAAAGGATGGTTTCTT 421 CTGGACAATTATATACCCACATTTATCTGCTCTGTCATATATTTACTAATTGTATGGCTG 481 GGACCAAAATACATGAGGAATAAACAGCCATTCTCTTGCCGGGGGATTTTAGTGGTGTAT 541 AACCTTGGACTCACACTGCTGTCTCTGTATATGTTCTGTGAGTTAGTAACAGGAGTATGG 601 GAAGGCAAATACAACTTCTTCTGTCAGGGCACACGCACCGCAGGAGAATCAGATATGAAG 661 ATTATCCGTGTCCTCTGGTGGTACTACTTCTCCAAACTCATAGAATTTATGGACACTTTC 721 TTCTTCATCCTGCGCAAGAACAACCACCAGATCACGGTCCTGCACGTCTACCACCATGCC 781 TCGATGCTGAACATCTGGTGGTTTGTGATGAACTGGGTCCCCTGCGGCCACTCTTATTTT 841 GGTGCCACACTTAATAGCTTCATCCACGTCCTCATGTACTCTTACTATGGTTTGTCGTCA 901 GTCCCTTCCATGCGTCCATACCTCTGGTGGAAGAAGTACATCACTCAGGGGCAGCTGCTT 961 CAGTTTGTGCTGACAATCATCCAGACCAGCTGCGGGGTCATCTGGCCGTGCACATTCCCT 1021?CTTGGTTGGTTGTATTTCCAGATTGGATACATGATTTCCCTGATTGCTCTCTTCACAAAC 1081?TTCTACATTCAGACCTACAACAAGAAAGGGGCCTCCCGAAGGAAAGACCACCTGAAGGAC 1141?CACCAGAATGGGTCCATGGCTGCTGTGAATGGACACACCAACAGCTTTTCACCCCTGGAA 1201?AACAATGTGAAGCCAAGGAAGCTGCGGAAGGATTGAAGTCAAAGAATTGAAACCCTCCAA 1261?ACCACGTCATCTGATTGTAAGCACAATATGAGTTGTGCCCCAATGCTCGTTAACAGCTGC 1321?TGTAACTAGTCTGGCCTACAATAGTGTGATTCATGTAGGACTTCTTTCATCAATTCAAAA 1381?CCCCTAGAAAACGTATACAGATTATATAAGTAGGGATAAGATTTCTAACATTTCTGGGCT 1441?CTCTGACCCCTGCGCTAGACTGTGGAAAGGGAGTATTATTATAGTATACAACACTGCTGT 1501?TGCCTTATTAGTTATAACATGATAGGTGCTGAATTGTGATTCACAATTTAAAAACACTGT 1561?AATCCAAACTTTTTTTTTTAACTGTAGATCATGCATGTGATTGTAAATGTAAATTTGTAC 1621?AATGTTGTTATGGTAGAGAAACACACATGCCTTAAAATTTAAAAAGCAGGGCCCAAAGCT 1681?TATTAGTTTAAATTAGGGTATGTTTCAAGTTTGTATTAATTTGTAATAGCTCTGTTTAGA 1741?AAAAATCAAAGACCATGATTTATGAAACTAATGTGACATAATTTCCAGTGACTTGTTGAT 1801?GTGAAATCAGACACGGCACCTTCAGTTTTGTACTATTGGCTTTGAATCAAGCAGGCTCAA 1861?ATCTAGTGGAACAGTCAGTTTAACTTTTTAACAGATCTTATTTTTTTATTTTGAGTGCCA 1921?CTATTAATGTAAAAAGGGGGGGGCTCTACAGCAGTCGTGATGAAACTTAAATATATATTC 1981?TTTGTCCTCGAGATTTTAGGAAGGGTGTAGGGTGAGTAGGCCATTTTTAATTTCTGAAGT 2041?GCTAAGTGTTTTTATACAGCAAACAAAAAGTCAATTTTGCTTTCCACCAGTGCGAGAGAG 2101?GATGTATACTTTTCAAGAGAGATGATTGCCTATTTACCGTTTGACAGAGTCCCGTAGATG 2161?AGCAATGGGGAACTGGTTGCCAGGGTCTAAATTTGGATTGATTTATGCACTGTTATCTGT 2221?TTTGACACAGATTTCCTTGTAAAATGTGCCTAGTTTACCAAAATTAACAAAGGGGGGGAA 2281?AGGACCTTAGAACTTTTTAAGGTAAAATCAAATATAGCTACAGCATAAGAGAATCGAGAA 2341?ATTTGATAGAGGTAACTTGTTTAATGTAAATCTAATAGTACTTGTAATTTCTTTCTGCTT	SEQ?ID?NO：79

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	2401?AGAATCTAAAGATGTGTTTAGAACCTCTTGTTTAAAAATAATAGACTGCTTATCATAAAA 2461?TCACATCTCACACATTTGAGGCAGTGGTCAAACAGGTAAAGCCTATGATGTGTGTCATTT 2521?TAAAGTGTCGGAATTTAGCCTCTGAATACCTTCTCCATTGGGGGAAAGATATTCTTGGAA 2581?CCACTCATGACATATCTTAGAAGGTCATTGACAATGTATAAACTAATTGTTGGTTTGATA 2641?TTTATGTAAATATCAGTTTACCATGCTTTAATTTTGCACATTCGTACTATAGGGAGCCTA 2701?TTGGTTCTCTATTAGTCTTGTGGGTTTTCTGTTTGAAAAGGAGTCATGGCATCTGTTTAC 2761?ATTTACCTTATCAAACCTAGAATGTGTATATTTATAAATGTATGTCTTCATTGCTAGGTA 2821?CTAATTTGCAGATGTCTTTACATATTTCAATACAGAAACTATAACATTCAATAGTGTGCT 2881?GTCAAAGTGTGCTTAGCTCACCTGGATATACCTACATTGTTAAATGTCTAAACAGTAATC 2941?ATTAAAACATTTTTGATTACCTGTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 3001?AAA 1 MEHFDASLSTYFKALLGPRDTRVKGWFLLDNYIPTFICSVIYLLIVWLGPKYMRNKQPFS 61 CRGILVVYNLGLTLLSLYMFCELVTGVWEGKYNFFCQGTRTAGESDMKIIRVLWWYYFSK 121 LIEFMDTFFFILRKNNHQITVLHVYHHASMLNIWWFVMNWVPCGHSYFGATLNSFIHVLM 181 YSYYGLSSVPSMRPYLWWKKYITQGQLLQFVLTIIQTSCGVIWPCTFPLGWLYFQIGYMI 241 SLIALFTNFYIQTYNKKGASRRKDHLKDHQNGSMAAVNGHTNSFSPLENNVKPRKLRKD-	SEQ?ID?NO：80
WBC032G11_V1.3_AT	Homo sapiens cDNA FLJ20073 fis, clone COL02320.	1 AAAATTTGAAGACAAGATGGGCACCTACTCTACAATTCTGATAAAAACAGAGGTCATCGA 61 ATGTGGGAACTACTGTGGAGTACGCATCATTCACTCTTTGATTGCAGAGTTCTCACTGGA 121 AGAATTGAAGAAAAGCTATCACCTGAATAAAAGTCAAATTATGTTGGATATGCTAACTGA 181 GAATTTGTTCTTCGATACTGGTATGGGAAAAAGTAAATTTTTGCAAGATATGCACACACT 241 CCTACTCACAAGACACCGCGATGAACATGAAGGTGAAACAGGAAATTGGTTTTCCCCATT 301 TATTGAAGCATTACATAAAGATGAAGGAAATGAAGCAGTTGAAGCTGTATTGCTTGAAAG 361 TATCCATCGGTTCAACCCAAATGCATTCATTTGCCAAGCGTTGGCAAGACATTTCTACAT 421 TAAAAAGAAGGACTTTGGCAATGCTCTAAACTGGGCAAAACAAGCAAAAATCATAGAACC 481 TGACAATTCTTATATCTCAGATACACTGGGTCAAGTCTACAAAAGTAAAATAAGATGGTG 541 GATAGAGGAAAACGGAGGAAACGGGAACATTTCAGTTGATGATCTAATTGCTCTTTTGGA 601 TTTAGCAGAACATGCCTCAAGTGCATTCAAAGAATCTCAACAGCAAAGTGAAGATAGAGA 661 GTATGAAGTGAAGGAAAGATTGTATCCGAAGTCAAAAAGGCGGTATGATACTTACAATAT 721 AGCTGGTTATCAAGGAGAGATAGAAGTTGGGCTTTACACAATCCAAATTCTCCAGCTCAT 781 TCCTTTTTTTGATAATAAAAATGAGCTATCTAAAAGATATATGGTCAATTTTGTATCAGG 841 AAGTAGTGATATTCCAGGGGATCCAAACAATGAATATAAATTAGCCCTCAAAAACTATAT 901 TCCTTATTTAACTAAATTGAAATTTTCTTTGAAAAAGTCCTTTGATTTTTTTGATGAATA 961 CTTTGTCCTGCTAAAACCCAGGAACAATATTAAGCAAAATGAAGAGGCCAAAACTCGGAG 1021?AAAGGTGGCTGGATATTTTAAGAAATATGTAGATATATTTTGTCTCTTAGAAGAATCACA 1081?AAACAACACAGGTCTTGGATCAAAGTTCAGTGAGCCACTTCAAGTAGAGAGATGCAGGAG 1141?AAACCTAGTAGCTTTAAAAGCAGACAAGTTTTCTGGGCTCTTGGAATATCTTATCAAAAG 1201?TCAAGAGGATGCTATAAGCACTATGAAATGTATAGTGAACGAATATACTTTTCTCTTAGA 1261?ACAATGCACTGTCAAAATCCAGTCAAAAGAAAAGCTAAATTTCATCTTGGCCAACATTAT 1321?TCTCTCCTGTATCCAACCTACCTCCAGATTAGTAAAGCCAGTTGAAAAACTAAAAGATCA 1381?GCTTCGAGAAGTCTTGCAACCAATAGGACTGACTTATCAGTTTTCAGAACCGTATTTTCT 1441?AGCTTCCCTCTTATTCTGGCCAGAAAATCAACAACTAGATCAACATTCTGAACAAATGAA 1501?AGAGTATGCTCAAGCACTAAAAAATTCTTTCAAGGGGCAATATAAACATATGCATCGTAC	SEQ?ID?NO：81		SEQ?ID?NO：80

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1561?AAAGCAACCAATTGCATATTTCTTTCTTGGAAAAGGTAAAAGACTGGAAAGACTTGTTCA 1621?CAAAGGAAAAATTGACCAGTGCTTTAAGAAGACACCAGATATTAATTCCTTGTGGCAGAG 1681?TGGAGATGTGTGGAAGGAGGAAAAAGTCCAAGAACTTTTGCTTCGTTTACAAGGTCGAGC 1741?TGAAAACAATTGTTTATATATAGAATATGGAATCAATGAAAAAATCACAATACCCATCAC 1801?TCCCGCTTTTTTAGGTCAACTTAGAAGTGGCAGAAGCATAGAGAAGGTGTCTTTTTACCT 1861?GGGATTTCCCATTGGAGGCCCACTTGCTTATGACATTGAAATTGTTTAAGAGCCTGATAT 1921?TCTTCCTCCAAGAATTTGATCTCAGTACCCATTTAATTTTTTTGGACTCAAGATCTATGC 1981?TTTAAACCGGCAAGGTTATAGATACAGCCTCTAGCTCTTCAGATCTGTACATGCAGTATT 2041?TAATTTCCTCTTAAACATGTTATGAGTTCTACAAGGACAATAGTGAAAAAGGAAGGAGTG 2101?AGATATATGAAAAGTAGCAAATATGTTCCTTGGTTTGGTTAACATCATTGATGACAAAAT 2161?AATAAGGAGCTATGACTGGAGTCAGGAGAAGTTAGTGTAATAAGCTGGCTACACAGAACC 2221?CCACTACTTACCAGGCATGGATTGAAGAAGATTGTCTACTCAAATGGCATTTAGACATTA 2281?GAATGTCTGGGAAAATATTTCTCAAAGACAGCAAAAACCTCTCAAACTGAGGAGCAACAT 2341?TTATTCTTACTAAGCAGATCATCAATGTATCATGTGCTTGGCACTCAAGGATCTTCCAAA 2401?ACAGAGGACCAACCAGTCTTCTGAAGGTCATGCCCACAGAAGTCATCGGACCTTACCAAA 2461?GTAGGTTGGAGAATTAGATTGCCTTTTCATGCAGTGAGATTCAGTTAAGCAAAAATGAAA 2521?TTTGTCTCTATAGCTAATTAGCTTATCAACTCCCCTCCAAACAAACAATTAAAAAAAAAA 2581?CATACAGACACTCAAATTCCACAAGCTAATGAATAAAAAGGATTCCTGTGAAAAGGCTAA 2641?TGAGTCACCCATCCAGGAGATCCCAACGTACTAGCAAGTATACATATAACCTACACACTG 2701?AACAAGCACAATCACTGAGATGTAATCAAAATGTAATTTTCCCTAATAAAATTATGGATA 2761?TGGGCAATTGTCAATGGTTGCCAAAACCATTAAGTGGAAAGCTGATTAAAAAACAAAAAT 2821?TTCTAATGGATTTATCAGACTGTCCTAAATCCTGATCAATATTAACACTGCAGAGAGACA 2881?GCCAGACATTGTGGGCCTCGAAGTGCTACAGGAGTGCACACATCACCTGGAGATAGTCTT 2941?GCCAAATAATTGAACCTGAATCTGATCAAGCCTCTGGATCTTATTTGCAATTCAAAAGAA 3001?ATTTTAAAAAAATCCTACTAACACCACCACAAATATGCAATCAGCAATATCCAGAAAGGG 3061?GAAATTCACAGGACAAAAACCTGGTTTTCTTTTTTGGTTTCTTCAACCAAAAAAGAAAGA 3121?AATTGCAAAGGACCAAAAAAATGTTGGGGAATCTATACATTATAAGGGACTTAACAACTA 3181?AAGGGCAACATATAGACTTTAGATCCTAATTTGAGCAAAATCTAAAATCAATTATTAGGC 3241?AATCAGAAAAATTTGAACACAGACTAGATATTTGAGGATATTAAGGTACTATATTATTGA 3301?AGATTCCATGGTTATGTTTTTTAAAGAGTTCATGCCTTTTAGAGATACATACTAAAGTAT 3361?TTGTAAATAAATGACATGATCTAGAAAAAAAAAAAAAAAA 1 M G T Y S T I L I K T E V I E C G N Y C 1 ATGGGCACCTACTCTACAATTCTGATAAAAACAGAGGTCATCGAATGTGGGAACTACTGT 21 G V R I I H S L I A E F S L E E L K K S 61 GGAGTACGCATCATTCACTCTTTGATTGCAGAGTTCTCACTGGAAGAATTGAAGAAAAGC 41 Y H L N K S Q I M L D M L T E N L F F D 121 TATCACCTGAATAAAAGTCAAATTATGTTGGATATGCTAACTGAGAATTTGTTCTTCGAT 61 T G M G K S K F L Q D M H T L L L T R H 181 ACTGGTATGGGAAAAAGTAAATTTTTGCAAGATATGCACACACTCCTACTCACAAGACAC 81 R D E H E G E T G N W F S P F I E A L H 241 CGCGATGAACATGAAGGTGAAACAGGAAATTGGTTTTCCCCATTTATTGAAGCATTACAT 101 K D E G N E A V E A V L L E S I H R F N	SEQ?ID?NO：82

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			301 AAAGATGAAGGAAATGAAGCAGTTGAAGCTGTATTGCTTGAAAGTATCCATCGGTTCAAC 121 P N A F I C Q A L A R H F Y I K K K D F 361 CCAAATGCATTCATTTGCCAAGCGTTGGCAAGACATTTCTACATTAAAAAGAAGGACTTT 141 G N A L N W A K Q A K I I E P D N S Y I 421 GGCAATGCTCTAAACTGGGCAAAACAAGCAAAAATCATAGAACCTGACAATTCTTATATC 161 S D T L G Q V Y K S K I R W W I E E N G 481 TCAGATACACTGGGTCAAGTCTACAAAAGTAAAATAAGATGGTGGATAGAGGAAAACGGA 181 G N G N I S V D D L I A L L D L A E H A 541 GGAAACGGGAACATTTCAGTTGATGATCTAATTGCTCTTTTGGATTTAGCAGAACATGCC 201 S S A F K E S Q Q Q S E D R E Y E V K E 601 TCAAGTGCATTCAAAGAATCTCAACAGCAAAGTGAAGATAGAGAGTATGAAGTGAAGGAA 221 R L Y P K S K R R Y D T Y N I A G Y Q G 661 AGATTGTATCCGAAGTCAAAAAGGCGGTATGATACTTACAATATAGCTGGTTATCAAGGA 241 E I E V G L Y T I Q I L Q L I P F F D N 721 GAGATAGAAGTTGGGCTTTACACAATCCAAATTCTCCAGCTCATTCCTTTTTTTGATAAT 261 K N E L S K R Y M V N F V S G S S D I P 781 AAAAATGAGCTATCTAAAAGATATATGGTCAATTTTGTATCAGGAAGTAGTGATATTCCA 281 G D P N N E Y K L A L K N Y I P Y L T K 841 GGGGATCCAAACAATGAATATAAATTAGCCCTCAAAAACTATATTCCTTATTTAACTAAA 301 L K F S L K K S F D F F D E Y F V L L K 901 TTGAAATTTTCTTTGAAAAAGTCCTTTGATTTTTTTGATGAATACTTTGTCCTGCTAAAA 321 P R N N I K Q N E E A K T R R K V A G Y 961 CCCAGGAACAATATTAAGCAAAATGAAGAGGCCAAAACTCGGAGAAAGGTGGCTGGATAT 341 F K K Y V D I F C L L E E S Q N N T G L 1021?TTTAAGAAATATGTAGATATATTTTGTCTCTTAGAAGAATCACAAAACAACACAGGTCTT 361 G S K F S E P L Q V E R C R R N L V A L 1081?GGATCAAAGTTCAGTGAGCCACTTCAAGTAGAGAGATGCAGGAGAAACCTAGTAGCTTTA 381 K A D K F S G L L E Y L I K S Q E D A I 1141?AAAGCAGACAAGTTTTCTGGGCTCTTGGAATATCTTATCAAAAGTCAAGAGGATGCTATA 401 S T M K C I V N E Y T F L L E Q C T V K 1201?AGCACTATGAAATGTATAGTGAACGAATATACTTTTCTCTTAGAACAATGCACTGTCAAA 421 I Q S K E K L N F I L A N I I L S C I Q 1261?ATCCAGTCAAAAGAAAAGCTAAATTTCATCTTGGCCAACATTATTCTCTCCTGTATCCAA

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	441 P T S R L V K P V E K L K D Q L R E V L 1321?CCTACCTCCAGATTAGTAAAGCCAGTTGAAAAACTAAAAGATCAGCTTCGAGAAGTCTTG 461 Q P I G L T Y Q F S E P Y F L A S L L F 1381?CAACCAATAGGACTGACTTATCAGTTTTCAGAACCGTATTTTCTAGCTTCCCTCTTATTC 481 W P E N Q Q L D Q H S E Q M K E Y A Q A 1441?TGGCCAGAAAATCAACAACTAGATCAACATTCTGAACAAATGAAAGAGTATGCTCAAGCA 501 L K N S F K G Q Y K H M H R T K Q P I A 1501?CTAAAAAATTCTTTCAAGGGGCAATATAAACATATGCATCGTACAAAGCAACCAATTGCA 521 Y F F L G K G K R L E R L V H K G K I D 1561?TATTTCTTTCTTGGAAAAGGTAAAAGACTGGAAAGACTTGTTCACAAAGGAAAAATTGAC 541 Q C F K K T P D I N S L W Q S G D V W K 1621?CAGTGCTTTAAGAAGACACCAGATATTAATTCCTTGTGGCAGAGTGGAGATGTGTGGAAG 561 E E K V Q E L L L R L Q G R A E N N C L 1681?GAGGAAAAAGTCCAAGAACTTTTGCTTCGTTTACAAGGTCGAGCTGAAAACAATTGTTTA 581 Y I E Y G I N E K I T I P I T P A F L G 1741?TATATAGAATATGGAATCAATGAAAAAATCACAATACCCATCACTCCCGCTTTTTTAGGT 601 Q L R S G R S I E K V S F Y L G F P I G 1801?CAACTTAGAAGTGGCAGAAGCATAGAGAAGGTGTCTTTTTACCTGGGATTTCCCATTGGA 621 G P L A Y D I E I V - 1861?GGCCCACTTGCTTATGACATTGAAATTGTTTAA
WBC028A02	No homology	1 CTCACACAGTAGCCATAGTGGTCTTTCTAAAGGCTTAATCAGAGTAGATCATTTCTTTGC 61 TTAAAACCTTTCAACGGTTTTCTGTTACGCTAAGAATAAAAACCCAAACTCTTAAGTATA 121 GCCAGCAAGGCCCCACTTCCCTGGCTGTCTCTCTGACTCCTTTGCGTCCTGCTTACTGTG 181 CTTCAGCCACGCTGGCTTCCTTGCTGCTGATCCTGCTTGATCACCAGCTTGATCCTGTCC 241 CGCTGGTGTACTCCAAGATAACTGGTCAGTTGGTCCTGTCCCAGGGGCTTTGTCCTTCTG 301 TCTTCTTTTTCAGTCTGCTTCCCCTAGATGCTCGCCAGCTGCTTCCTTTTCCCTGTTCTA 361 GTCTCAACTCAAAGGTCACTGTGCTAGAGAAGCTTTCTTCAGCCACCCAGCAGATCAGCA 421 CCCTCTTCATCACTGTCCACCACAGTGTCTTTCTCTGTCTTCCTCATGGCTCTCAAACTG 481 TCTTATTCGTTATTGATGGGTTTTTTTTCATCTTTCTGTCCCCATTAACATATAAGCTTT 541 TTAAGAGCAGAGACTTTCTTTTCACCACGCCTAAAACAGGACCTACCACATATTGAATGT 601 TGAACAGATATTTATTGACTGACTAGTAAAAATGCATCTTTGAACTTAAAATGAATGTGT 661 TTTGTGAAGTATGGCAAAAGCCAATTTGGGAGTATTTGTGCTTTAAATTTCAAAAGTTGC 721 AAATACAGGCTGTGTTGAAGGCATTTTAGGAATCAGACAGACTCTGGGAATTTAAATCGT 781 TGTTCTGC NON?CONTIGUOUS 1 AGTGTAGGAGTTCAGTAGGGATGTGTATTTTAATGTGCACCTATTTTAGGGCATTGACAT 61 ACAGAGTGAAGCAAGGTGGCCACCTATTTTATTGTGAGCTCTTCCTAGGAAGGCTCCTAT 121 TTCAGCAGTTTGGTCTGGCTAACTTTAAATGGAACAGCTAAGCTGACGTTGGCAGGCATT	SEQ?ID?NO：83 SEQ?ID?NO：84

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 CAAATTCATGTCTCCTTGGGGCCAATCTGTTCTATTTTGTGCCATGAAACTTCAGCTGTT 241 GAGCAAAGAGCAACTTAGCTGTCTCATCCCAAAAATCTAGAACAAGTCTAAAGATCTATG 301 CAGAAGAGTGGGAAGGTAAATTATGGTATCTCCTTAGGACAGAATTTTATGAATTTATTG 361 AAAGATATAGGAAAGAAGCATTTAAGAAGTCTAGAGGAGGGGCTGGCCTTGTGGCATAGT 421 GGTTAAGTTTAGTGCACTCCCCTTCAGTGACCCGGGTTCACAGATTTGGATCCTGGATGC 481 AGACCTAGGCCAGTCATCAGCCATGCTGATGACCCACATGCAAATAAAGGAAGATTGGCA 541 CAGATGTTAGCTCAGGGCTAATCTTCCTCAGCAAAAAAAAAA
WBC024E03_V1.3_AT	Homo sapiens's transcription factor ISGF-3 mRNA.	1 ATTAAACCTCTCGCCGAGCCCCTCCGCAGACTCTGCGCCGGAAAGTTTCATTTGCTGTAT 61 GCCATCCTCGAGAGCTGTCTAGGTTAACGTTCGCACTCTGTGTATATAACCTCGACAGTC 121 TTGGCACCTAACGTGCTGTGCGTAGCTGCTCCTTTGGTTGAATCCCCAGGCCCTTGTTGG 181 GGCACAAGGTGGCAGGATGTCTCAGTGGTACGAACTTCAGCAGCTTGACTCAAAATTCCT 241 GGAGCAGGTTCACCAGCTTTATGATGACAGTTTTCCCATGGAAATCAGACAGTACCTGGC 301 ACAGTGGTTAGAAAAGCAAGACTGGGAGCACGCTGCCAATGATGTTTCATTTGCCACCAT 361 CCGTTTTCATGACCTCCTGTCACAGCTGGATGATCAATATAGTCGCTTTTCTTTGGAGAA 421 TAACTTCTTGCTACAGCATAACATAAGGAAAAGCAAGCGTAATCTTCAGGATAATTTTCA 481 GGAAGACCCAATCCAGATGTCTATGATCATTTACAGCTGTCTGAAGGAAGAAAGGAAAAT 541 TCTGGAAAACGCCCAGAGATTTAATCAGGCTCAGTCGGGGAATATTCAGAGCACAGTGAT 601 GTTAGACAAACAGAAAGAGCTTGACAGTAAAGTCAGAAATGTGAAGGACAAGGTTATGTG 661 TATAGAGCATGAAATCAAGAGCCTGGAAGATTTACAAGATGAATATGACTTCAAATGCAA 721 AACCTTGCAGAACAGAGAACACGAGACCAATGGTGTGGCAAAGAGTGATCAGAAACAAGA 781 ACAGCTGTTACTCAAGAAGATGTATTTAATGCTTGACAATAAGAGAAAGGAAGTAGTTCA 841 CAAAATAATAGAGTTGCTGAATGTCACTGAACTTACCCAGAATGCCCTGATTAATGATGA 901 ACTAGTGGAGTGGAAGCGGAGACAGCAGAGCGCCTGTATTGGGGGGCCGCCCAATGCTTG 961 CTTGGATCAGCTGCAGAACTGGTTCACTATAGTTGCGGAGAGTCTGCAGCAAGTTCGGCA 1021?GCAGCTTAAAAAGTTGGAGGAATTGGAACAGAAATACACCTACGAACATGACCCTATCAC 1081?AAAAAACAAACAAGTGTTATGGGACCGCACCTTCAGTCTTTTCCAGCAGCTCATTCAGAG 1141?CTCGTTTGTGGTGGAAAGACAGCCCTGCATGCCAACGCACCCTCAGAGGCCGCTGGTCTT 1201?GAAGACAGGGGTCCAGTTCACTGTGAAGTTGAGACTGTTGGTGAAATTGCAAGAGCTGAA 1261?TTATAATTTGAAAGTCAAAGTCTTATTTGATAAAGATGTGAATGAGAGAAATACAGTAAA 1321?AGGATTTAGGAAGTTCAACATTTTGGGCACGCACACAAAAGTGATGAACATGGAGGAGTC 1381?CACCAATGGCAGTCTGGCGGCTGAATTTCGGCACCTGCAATTGAAAGAACAGAAAAATGC 1441?TGGCACCAGAACGAATGAGGGTCCTCTCATCGTTACTGAAGAGCTTCACTCCCTTAGTTT 1501?TGAAACCCAATTGTGCCAGCCTGGTTTGGTAATTGACCTCGAGACGACCTCTCTGCCCGT 1561?TGTGGTGATCTCCAACGTCAGCCAGCTCCCGAGCGGTTGGGCCTCCATCCTTTGGTACAA 1621?CATGCTGGTGGCGGAACCCAGGAATCTGTCCTTCTTCCTGACTCCACCATGTGCACGATG 1681?GGCTCAGCTTTCAGAAGTGCTGAGTTGGCAGTTTTCTTCTGTCACCAAAAGAGGTCTCAA 1741?TGTGGACCAGCTGAACATGTTGGGAGAGAAGCTTCTTGGTCCTAACGCCAGCCCCGATGG 1801?TCTCATTCCGTGGACGAGGTTTTGTAAGGAAAATATAAATGATAAAAATTTTCCCTTCTG 1861?GCTTTGGATTGAAAGCATCCTAGAACTCATTAAAAAACACCTGCTCCCTCTCTGGAATGA 1921?TGGGTGCATCATGGGCTTCATCAGCAAGGAGCGAGAGCGTGCCCTGTTGAAGGACCAGCA 1981?GCCGGGGACCTTCCTGCTGCGGTTCAGTGAGAGCTCCCGGGAAGGGGCCATCACGTTCAC 2041?GTGGGTGGAGCGCTCCCAGAACGGAGGAGAGCCTTACTTTCATGCGGTCGAACCCTACAC 2101?GAAGAAAGAACTTTCTGCTGTTACTTTTCCTGATATCATTCGCAATTACAAAGTCATGGC 2161?TGCTGAAAATATTCCAGAGAATCCCCTGAAGTATCTGTATCCAAATATTGATAAGGACCA 2221?TGCCTTCGGAAAGTATTACTCCAGGCCCAAGGAAGCTCCAGAACCAATGGAACTTGATGG 2281?CCCTAAAGGAACTGGATACATCAAGACTGAATTGATTTCTGTGTCTGAAGTTCACCCTTC 2341?TCGACTTCAGACTACAGACAACCTTCTTCCCATGTCTCCTGAGGAGTTTGACGAGGTGTC	SEQ?ID?NO：85

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			2401?TCGCATAGTGGGCTCTGTGGAATTCGACATGATGAACGCAGTATAGAGCATGAATTTTAC 2461?TCATCTTCCCTGGCGACATTTTTCCCTCCCATCTGTGATTCCCTCCTGCTGGTCTGTTCC 2521?TTCACATCCTGTGTTTCTAGGGAAAGGAAAGCAAGGCTGACAAATTTGCTGCAACCTGTT 2581?GATAGCAAGTGGATTTTTCCCTCATTCAGAAACATCTGTTACTCTGAAGGGCTTCATGCA 2641?TCTTATTAAAGGTAAAATTGAGAGACCCTCTCCACAGAGTGGGTTTGACAAACGAACAAC 2701?ATTCAGATACACCCACAACCTCAGGACTAGAGTGCGAGTCCCTCGGGAAAGGGGAGAAGT 2761?CGAGCAGCGTGTGGCAAATACTATGCATAAAGTCAGTGCCCAACGGTTATGGGTTGTTGG 2821?ATAAATCAGTGGTTATTTAGGGAACTGCTTGACGTAGGAACGGTAAATTTCTGTGGGAGA 2881?ATTCTTACATGTTTTCTTTGCTTTAAGTGTAACTGGCAGTTTTCCATTGGTTTACCTGTG 2941?AAATAGTTCAAAGCCAAGTTTATATACAATTATATCAGTCCTCTTTCAAAGGTAGCCATC 3001?ATGGATCTGGTAGGGGGAAAATGTGTATTTTATTACATCTTTCACATTGGCTATTTAAAG 3061?ACAAAGACAAATTCTGTTTCTTGAGAAGAGAATATTAGCTTTTCTGTTTGTTATGGGTTT 3121?ATGATACTGGCTAATATCAATAGAAGGAAGTACCTTTTCCAAATTCACAAGTTGTGTTTG 3181?ATATCCAAAGCTGAATACATTCTGCTTTCATCTTGGTCACATACAATTATTTTTACAGTT 3241?CTCCCAAGGGAGTTAGGCTATTCACAACCACTCATTCAAAAAGTTGAAATTAATCATAGA 3301?TGTAGACAAACTCAAATCTAATTCATGTTTTTTAAATGGGTTAATTTGTCTTTATTGTTA 3361?TTAGCTGGTATTTAGTCTATTAGCCACAAAATTGGGAAAGGAGTAGAAAAAGCAGTAACT 3421?GACAACTTGAATAATACACCAGAGATAATATGAGAATCAGATCATTTCAAAACTCATTTC 3481?CTATGTAACTGCATTAAGAATTGCATATTTTTCACTGATAAATGTGTTTTTCACATTTGC 3541?GAATGGTTCCATTCTCTCTCCTGTACTTTTTCCAGACACTTTTTTGAGTGGATGATGTTT 3601?CGTGAAGTATACTGTATTTTTACCTTTTTCCTTCCTTATCACTGACACAAAAAGTAGATT 3661?AAGAGATGGGTTTGACAAGGTTCTTCCCTTTTACATACTGCTGTCTATGTGGCTGTATCT 3721?TGTTTTTCCACTACTGCTACCACAACTATATTATCATGCAAATGCTGTATTCTTCTTTGG 3781?TGGAGATAAAGATTTCTTGAGTTTTGTTTTAAAATTAAAGCTAAAGTATCTGTATTGCAT 3841?TAAATATAATATCGACACAGTGCTTTCCGTGGCACTGCATACAATCTGAGGCCTCCTCTC 3901?TCAGTTTTTATATAGATGGCGAGAACCTAAGTTTCAGTTGATTTTACAATTGAAATGACT 3961?AAAAAACAAAGAAGACAACATTAAAAACAATATTGTTTCTA 1 M S Q W Y E L Q Q L D S K F L E Q V H Q 1 ATGTCTCAGTGGTACGAACTTCAGCAGCTTGACTCAAAATTCCTGGAGCAGGTTCACCAG 21 L Y D D S F P M E I R Q Y L A Q W L E K 61 CTTTATGATGACAGTTTTCCCATGGAAATCAGACAGTACCTGGCACAGTGGTTAGAAAAG 41 Q D W E H A A N D V S F A T I R F H D L 121 CAAGACTGGGAGCACGCTGCCAATGATGTTTCATTTGCCACCATCCGTTTTCATGACCTC 61 L S Q L D D Q Y S R F S L E N N F L L Q 181 CTGTCACAGCTGGATGATCAATATAGTCGCTTTTCTTTGGAGAATAACTTCTTGCTACAG 81 H N I R K S K R N L Q D N F Q E D P I Q 241 CATAACATAAGGAAAAGCAAGCGTAATCTTCAGGATAATTTTCAGGAAGACCCAATCCAG 101 M S M I I Y S C L K E E R K I L E N A Q 301 ATGTCTATGATCATTTACAGCTGTCTGAAGGAAGAAAGGAAAATTCTGGAAAACGCCCAG 121 R F N Q A Q S G N I Q S T V M L D K Q K 361 AGATTTAATCAGGCTCAGTCGGGGAATATTCAGAGCACAGTGATGTTAGACAAACAGAAA	SEQ?ID?NO：86

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			141 E L D S K V R N V K D K V M C I E H E I 421 GAGCTTGACAGTAAAGTCAGAAATGTGAAGGACAAGGTTATGTGTATAGAGCATGAAATC 161 K S L E D L Q D E Y D F K C K T L Q N R 481 AAGAGCCTGGAAGATTTACAAGATGAATATGACTTCAAATGCAAAACCTTGCAGAACAGA 181 E H E T N G V A K S D Q K Q E Q L L L K 541 GAACACGAGACCAATGGTGTGGCAAAGAGTGATCAGAAACAAGAACAGCTGTTACTCAAG 201 K M Y L M L D N K R K E V V H K I I E L 601 AAGATGTATTTAATGCTTGACAATAAGAGAAAGGAAGTAGTTCACAAAATAATAGAGTTG 221 L N V T E L T Q N A L I N D E L V E W K 661 CTGAATGTCACTGAACTTACCCAGAATGCCCTGATTAATGATGAACTAGTGGAGTGGAAG 241 R R Q Q S A C I G G P P N A C L D Q L Q 721 CGGAGACAGCAGAGCGCCTGTATTGGGGGGCCGCCCAATGCTTGCTTGGATCAGCTGCAG 261 N W F T I V A E S L Q Q V R Q Q L K K L 781 AACTGGTTCACTATAGTTGCGGAGAGTCTGCAGCAAGTTCGGCAGCAGCTTAAAAAGTTG 281 E E L E Q K Y T Y E H D P I T K N K Q V 841 GAGGAATTGGAACAGAAATACACCTACGAACATGACCCTATCACAAAAAACAAACAAGTG 301 L W D R T F S L F Q Q L I Q S S F V V E 901 TTATGGGACCGCACCTTCAGTCTTTTCCAGCAGCTCATTCAGAGCTCGTTTGTGGTGGAA 321 R Q P C M P T H P Q R P L V L K T G V Q 961 AGACAGCCCTGCATGCCAACGCACCCTCAGAGGCCGCTGGTCTTGAAGACAGGGGTCCAG 341 F T V K L R L L V K L Q E L N Y N L K V 1021?TTCACTGTGAAGTTGAGACTGTTGGTGAAATTGCAAGAGCTGAATTATAATTTGAAAGTC 361 K V L F D K D V N E R N T V K G F R K F 1081?AAAGTCTTATTTGATAAAGATGTGAATGAGAGAAATACAGTAAAAGGATTTAGGAAGTTC 381 N I L G T H T K V M N M E E S T N G S L 1141?AACATTTTGGGCACGCACACAAAAGTGATGAACATGGAGGAGTCCACCAATGGCAGTCTG 401 A A E F R H L Q L K E Q K N A G T R T N 1201?GCGGCTGAATTTCGGCACCTGCAATTGAAAGAACAGAAAAATGCTGGCACCAGAACGAAT 421 E G P L I V T E E L H S L S F E T Q L C 1261?GAGGGTCCTCTCATCGTTACTGAAGAGCTTCACTCCCTTAGTTTTGAAACCCAATTGTGC 441 Q P G L V I D L E T T S L P V V V I S N 1321?CAGCCTGGTTTGGTAATTGACCTCGAGACGACCTCTCTGCCCGTTGTGGTGATCTCCAAC

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	461 V S Q L P S G W A S I L W Y N M L V A E 1381?GTCAGCCAGCTCCCGAGCGGTTGGGCCTCCATCCTTTGGTACAACATGCTGGTGGCGGAA 481 P R N L S F F L T P P C A R W A Q L S E 1441?CCCAGGAATCTGTCCTTCTTCCTGACTCCACCATGTGCACGATGGGCTCAGCTTTCAGAA 501 V L S W Q F S S V T K R G L N V D Q L N 1501?GTGCTGAGTTGGCAGTTTTCTTCTGTCACCAAAAGAGGTCTCAATGTGGACCAGCTGAAC 521 M L G E K L L G P N A S P D G L I P W T 1561?ATGTTGGGAGAGAAGCTTCTTGGTCCTAACGCCAGCCCCGATGGTCTCATTCCGTGGACG 541 R F C K E N I N D K N F P F W L W I E S 1621?AGGTTTTGTAAGGAAAATATAAATGATAAAAATTTTCCCTTCTGGCTTTGGATTGAAAGC 561 I L E L I K K H L L P L W N D G C I M G 1681?ATCCTAGAACTCATTAAAAAACACCTGCTCCCTCTCTGGAATGATGGGTGCATCATGGGC 581 F I S K E R E R A L L K D Q Q P G T F L 1741?TTCATCAGCAAGGAGCGAGAGCGTGCCCTGTTGAAGGACCAGCAGCCGGGGACCTTCCTG 601 L R F S E S S R E G A I T F T W V E R S 1801?CTGCGGTTCAGTGAGAGCTCCCGGGAAGGGGCCATCACGTTCACGTGGGTGGAGCGCTCC 621 Q N G G E P Y F H A V E P Y T K K E L S 1861?CAGAACGGAGGAGAGCCTTACTTTCATGCGGTCGAACCCTACACGAAGAAAGAACTTTCT 641 A V T F P D I I R N Y K V M A A E N I P 1921?GCTGTTACTTTTCCTGATATCATTCGCAATTACAAAGTCATGGCTGCTGAAAATATTCCA 661 E N P L K Y L Y P N I D K D H A F G K Y 1981?GAGAATCCCCTGAAGTATCTGTATCCAAATATTGATAAGGACCATGCCTTCGGAAAGTAT 681 Y S R P K E A P E P M E L D G P K G T G 2041?TACTCCAGGCCCAAGGAAGCTCCAGAACCAATGGAACTTGATGGCCCTAAAGGAACTGGA 701 Y I K T E L I S V S E V H P S R L Q T T 2101?TACATCAAGACTGAATTGATTTCTGTGTCTGAAGTTCACCCTTCTCGACTTCAGACTACA 721 D N L L P M S P E E F D E V S R I V G S 2161?GACAACCTTCTTCCCATGTCTCCTGAGGAGTTTGACGAGGTGTCTCGCATAGTGGGCTCT 741 V E F D M M N A V - 2221?GTGGAATTCGACATGATGAACGCAGTATAG
BM734607.V1.3_AT	The homo sapiens mRNA of XIAP correlation factor-1	1 ATGGAAGGAGACTTCTCGGTGTGCAGGAACTGTAAAAGACATGTAGTCTCTGCCAACTTC 61 ACCCTCCATGAGGCTTACTGCCTGCGGTTCCTGGTCCTGTGTCCGGAGTGTGAGGAGCCT 121 GTCCCCAAGGAAACCATGGAGGAGCACTGCAAGCTTGAGCACCAGGAGGTCGGGTGTGCA	SEQ?ID?NO：87

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			181 ATGTGTCAGCAGAGCGTGCCGAAGCACTCGCTGGAGCTTCATGAGGCCACGGAATGCAGG 241 GACCGCCCCGTTGCGTGTCAGTTCTGTGAGCTGGCCGTGCGCCTCAGTAAGGCAGAGATC 301 CATGAGTACCACTGTGGCAGCCGGACTCAGCTCTGCCCAGACTGCGACCAGCCCATCATG 361 CTCCGAGCGCTGGCCCAGCACAAGGACGTGTGTCAGGGCAAACAGGCCCAGCTTGGGAAA 421 GGGAAGGAAATTTCAGCTCCTGAATGCAAATTCAGCTGTTGGTATTGCAACGAAATGATT 481 CCAGGAGATAAGTATTCCCACCACGTGGATAAATGTCGCACAGTCTCAGAGTCTGTGAAA 541 TATTTTCCAGTTGGAAAGCCAAGAATTCCTCCTCCATCCCTTCCAAGCCAGGCTGCTGAA 601 GATCAATCTTCCACGGCAGAGAAAGATGTCCGTCCAAAGACAAGAAGTATAAACAGATTT 661 CCTCTTCATTCTGAAAGTTCATCAAAGAAAGCACCAAGAAGCAAAAACAAAACCTTGGAT 721 CCACTTTTGATGTCAGAGCCCAAGCCCAGGACCAGCTCCCCTAGAGGAGATAAAGCAGCC 781 TATGACATTCTGAGGAGATGTTCTCAGTGTGGCATCCTGCTTCCCCTGCCGATCCTAAAT 841 CAACATCAGGAGAAATGCCGGTGGTTAGCTTCATCAAAAAGGAAAACAAGTGAGAAATTT 901 CAGCTAGATTTGGAAAAGGAAAGGTACTACAAATTCAAAAGATTTCACTTTTAACACTGG 961 CATTCCTGCCTACTTGCTGTGGTGGTCTTGTGAAAGGTGATGGGTTTTATTCGTTGGGCT 1021?TTAAAAGAAAAGGTTTGGCAGAACTAAAAACAAAACTCACGTATCATCTCAATAGATACA 1081?GAAAAGGCTTTTGATAAAATTCAACTTGACTTCATGTTAAAAACCCTCAACAAACCAGGC 1141?GTCGAAGGAACATACCTCAAAATAATAAGAGCCATCTATGACAAAACCACAGCCAACATC 1201?ATACTGAATGAGCAAAAGCTGGAGCATTACTCTTGAGAAGTAGAACAAGGCACTTCAGTC 1261?CTATTCAACATAGTACTGGAAGTCTCGCCACAGCAATCAGGCAAGAGAAAGAAGTAAAAG 1321?GCACCC 1 M E G D F S V C R N C K R H V V S A N F 1 ATGGAAGGAGACTTCTCGGTGTGCAGGAACTGTAAAAGACATGTAGTCTCTGCCAACTTC 21 T L H E A Y C L R F L V L C P E C E E P 61 ACCCTCCATGAGGCTTACTGCCTGCGGTTCCTGGTCCTGTGTCCGGAGTGTGAGGAGCCT 41 V P K E T M E E H C K L E H Q E V G C A 121 GTCCCCAAGGAAACCATGGAGGAGCACTGCAAGCTTGAGCACCAGGAGGTCGGGTGTGCA 61 M C Q Q S V P K H S L E L H E A T E C R 181 ATGTGTCAGCAGAGCGTGCCGAAGCACTCGCTGGAGCTTCATGAGGCCACGGAATGCAGG 81 D R P V A C Q F C E L A V R L S K A E I 241 GACCGCCCCGTTGCGTGTCAGTTCTGTGAGCTGGCCGTGCGCCTCAGTAAGGCAGAGATC 101 H E Y H C G S R T Q L C P D C D Q P I M 301 CATGAGTACCACTGTGGCAGCCGGACTCAGCTCTGCCCAGACTGCGACCAGCCCATCATG 121 L R A L A Q H K D V C Q G K Q A Q L G K 361 CTCCGAGCGCTGGCCCAGCACAAGGACGTGTGTCAGGGCAAACAGGCCCAGCTTGGGAAA 141 G K E I S A P E C K F S C W Y C N E M I 421 GGGAAGGAAATTTCAGCTCCTGAATGCAAATTCAGCTGTTGGTATTGCAACGAAATGATT 161 P G D K Y S H H V D K C R T V S E S V K 481 CCAGGAGATAAGTATTCCCACCACGTGGATAAATGTCGCACAGTCTCAGAGTCTGTGAAA	SEQ?ID?NO：88

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 Y F P V G K P R I P P P S L P S Q A A E 541 TATTTTCCAGTTGGAAAGCCAAGAATTCCTCCTCCATCCCTTCCAAGCCAGGCTGCTGAA 201 D Q S S T A E K D V R P K T R S I N R F 601 GATCAATCTTCCACGGCAGAGAAAGATGTCCGTCCAAAGACAAGAAGTATAAACAGATTT 221 P L H S E S S S K K A P R S K N K T L D 661 CCTCTTCATTCTGAAAGTTCATCAAAGAAAGCACCAAGAAGCAAAAACAAAACCTTGGAT 241 P L L M S E P K P R T S S P R G D K A A 721 CCACTTTTGATGTCAGAGCCCAAGCCCAGGACCAGCTCCCCTAGAGGAGATAAAGCAGCC 261 Y D I L R R C S Q C G I L L P L P I L N 781 TATGACATTCTGAGGAGATGTTCTCAGTGTGGCATCCTGCTTCCCCTGCCGATCCTAAAT 281 Q H Q E K C R W L A S S K R K T S E K F 841 CAACATCAGGAGAAATGCCGGTGGTTAGCTTCATCAAAAAGGAAAACAAGTGAGAAATTT 301 Q L D L E K E R Y Y K F K R F H F - 901 CAGCTAGATTTGGAAAAGGAAAGGTACTACAAATTCAAAAGATTTCACTTTTAA
Foe1268	Myo-inositol 1-phosphate synthase A1	1 ATGGGGATGGGGATGCTGAGGCCCAGTGGAATCCCCCGGCCCCAAGATGCCAGCAGGGAC 61 GGCTGTCCTTGTCCCATCCTCCAGCTCTCCCCGATGGAGGCCTCAGCCGAGTTCGTGGTC 121 GAGAGCCCCGACGTGGTCTACGGCCCCAGACGCCATCGAGGCTCAGTGTACCCCACGTCC 181 ACGCGCTTCACCTTTCGGACCGCCCGGCAGGTGCCCCGGCTCGGGGTCATGCTCGTCGGC 241 TGGGGCGGGAACAACGGCTCCACGCTCACCGCCGCCGTGCTGGCCAACCGGCTGCGCCTG 301 TCCTGGCCCACGCGCACCGGCCGCAAGGAGGCCAACTACTACGGCTCGCTGACGCAGGCG 361 GGCACCGTTAGCCTGGGCTTGGACGCCGAGGGCCAGGAGGTGTTCGTGCCCTTCAGCGCA 421 CTGCTGCCCATGGTGGCACCCGACGACCTCGTGTTCGACGGCTGGGACATATCGTCGCTG 481 AACCTGGCTGAGGCGATGAGGCGTGCACAGGTGCTGGACTGGGGGCTGCAGGAGCAACTG 541 TGGCCACACTTGGAGGCTCTGCGCCCTCGGCCCTCCGTCTACATCCCCGAATTCATCGCA 601 GCCAACCAGAGTGTGCGAGCTGACAATCTCATACTGTGCACGCGCGCACAGCAGCTGGAG 661 CAGATCCGTAGGGACATCCGTGACTTCCGATCCAGTGCTGGGCTAGACAAAGTCATCGTG 721 CTGTGGACCGCAAACACGGAGCGCTTCTGCGAAGTCATCCCCGGCCTCAATGATACTGCT 781 GAGAACCTGCTGCGTACCATCCAGCTGGGCCTGGAGGTGTCGCCCTCCACTCTTTTTGCT 841 GTGGCCAGCATCTTGGAGGGCTGTGCCTTCCTCAACGGGTCCCCGCAGAACACGCTGGTG 901 CCTGGGGCGCTTGAGCTCGCCCGTCAGCGACGTGTCTTCGTGGGTGGAGATGACTTCAAG 961 TCAGGCCAAACCAAGGTCAAGTCCGTGCTGGTGGACTTCCTTATCGGCTCTGGCCTCAAG 1021?ACCATGTCCATCGTGAGCTACAACCACCTGGGCAACAATGACGGGCAGAACCTGTCGGCA 1081?CCGCCGCAGTTCCGTTCCAAGGAGGTGTCCAAGAGCAGCGTGGTAGACGACATGGTGCAG 1141?AGCAACCCTGTGCTCTATGCACCCGGCGAGGAGCCCGACCACTGTGTGGTCATCAAGTAC 1201?GTGCCATACGTGGGCGACAGCAAGCGTGCGTTGGATGAGTACACCTCGGAGCTGATGCTG 1261?GGCGGCACCAACACGCTGGTGCTGCACAACACCTGTGAGGACTCCCTCCTGGCCGCACCC 1321?ATCATGCTGGACCTGGTGCTGCTGACCGAGCTGTGCCAGCGCGTGAGCTTCTGCACCGAT 1381?GCCGACCCAGAGCCGCAGGGCTTCCACTCCGTGCTGTCCCTGCTCAGCTTCCTATTCAAG 1441?GCGCCACTCGTGCCGCCGGGCAGCCCTGTGGTCAATGCCCTCTTCCGCCAGCGCAGCTGC 1501?ATCGAGAATATCCTCAGGGCCTGTGTGGGGCTCCCCCCACAGAACCACATGCTTCTGGAG 1561?CACAAGATGGAGCGCCCTGGCCTCAAGCGAGTGGGGCCTATGGTTGCTGCCTGCCCTGTG	SEQ?ID?NO：89

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	1621?CCCTGCAAGAAAGGACCAGCGCCAACTGCCCCCAATGGCTGTACGGGTGATGCCAATGGG 1681?CACTCGCAGGCTGAGGCACCCCAGATGCCCACCACTTAAGGCCATGGCCATCCTTCTCCC 1741?CCCAAACTGTTGCCTCTGTTGCCCCTCAGGACCCAACCCTTCCAAGACCCTAAAGACAAT 1801?AAAACCAGTGCTACAATCA 1 MGMGMLRPSGIPRPQDASRDGCPCPILQLSPMEASAEFVVESPDVVYGPRRHRGSVYPTS 61 TRFTFRTARQVPRLGVMLVGWGGNNGSTLTAAVLANRLRLSWPTRTGRKEANYYGSLTQA 121 GTVSLGLDAEGQEVFVPFSALLPMVAPDDLVFDGWDISSLNLAEAMRRAQVLDWGLQEQL 181 WPHLEALRPRPSVYIPEFIAANQSVRADNLILCTRAQQLEQIRRDIRDFRSSAGLDKVIV 241 LWTANTERFCEVIPGLNDTAENLLRTIQLGLEVSPSTLFAVASILEGCAFLNGSPQNTLV 301 PGALELARQRRVFVGGDDFKSGQTKVKSVLVDFLIGSGLKTMSIVSYNHLGNNDGQNLSA 361 PPQFRSKEVSKSSVVDDMVQSNPVLYAPGEEPDHCVVIKYVPYVGDSKRALDEYTSELML 421 GGTNTLVLHNTCEDSLLAAPIMLDLVLLTELCQRVSFCTDADPEPQGFHSVLSLLSFLFK 481 APLVPPGSPVVNALFRQRSCIENILRACVGLPPQNHMLLEHKMERPGLKRVGPMVAACPV 541 PCKKGPAPTAPNGCTGDANGHSQAEAPQMPTT-	SEQ?ID?NO：90
WBC035E08	Homo sapiens's ubiquitin conjugate enzyme E2D 1 (UBC4/5 homologue)	1 GGGGACACTCGCGCACACTCGCGCTCGGGCGCACACGGAGCAGGGACCGGCGCCCGGAGC 61 GAGCCAGGGAGCGGCTAACCGGGGACCCACCGCGCGGAGCCAGCCTAGCTGCCAGCGAGC 121 CCAACCCGCGACGACCCACGCCCCTGAGCCCCGCAGCCGACCCCTGCCGGCCGGTGTCCC 181 CACCGCCATCCCTGACCCATGGCGCTGAAGAGGATTCAGAAAGAATTGAGTGATCTACAG 241 CGCGATCCACCTGCTCACTGTTCAGCTGGACCTGTGGGAGATGACTTGTTCCACTGGCAA 301 GCCACTATTATGGGGCCTCCTGATAGCGCATATCAAGGTGGAGTCTTCTTTCTCACTGTA 361 CATTTTCCGACAGATTATCCTTTTAAACCACCAAAGATTGCTTTCACAACAAAAATTTAC 421 CATCCAAACATAAACAGTAATGGAAGTATTTGTCTCGATATTCTGAGGTCACAATGGTCA 481 CCAGCTCTGACTGTATCAAAAGTTTTATTGTCCATATGTTCTCTACTTTGTGATCCTAAT 541 CCAGATGACCCCTTAGTACCAGATATTGCACAAATCTATAAATCAGACAAAGAAAAATAC 601 AACAGACATGCAAGAGAATGGACTCAGAAATATGCAATGTAAAAATCAAAAACATTTTCA 661 TATATACCAGAGTACTGTAAAATCTAGGTTTTTTTCAACATTAGCAGTAAATTGAGCACT 721 GTTTACTGTTTCATTGTACCATGAAACCATTTGATTTTTACCCATTTTAAATGTGTTTCT 781 GAAGCAAGACAAAACAAACTTCCAAAAATACCCTTAAGACTGTGATGAGAGCATTTATCA 841 TTTTGTATGCATTGAGAAAGACATTTATTATGGTTTTTAAGATACTTGGACATCTGCATC 901 TTCAGCTTACAAGATCTACAATGCAGCTGAAAAGCAACCAAATTATTTTTTGCTGAAACT 961 AGATGTTTTTACATGAGAAATACTGTATGTGTTGTCTAAGATGTCAGTTTTATAAATCTG 1021?TATTCAGATTTCATTCTTTGTTAGCTCACTTTATAATTTGTATTTTTTTACTGTATAGAC 1081?TAAATATATTCTATTTACATGTATGTCAACTCATTACTTTTTTCCTGTGAACAGTATTGA 1141?AAAACCCCAACGGCTGATAATTAAGTGAATTAACTGTGTCTCCCTTGTCTTAGGATATTC 1201?TGTAGATTGATTGCAGATTTCTTAAATCTGAAATGATCTTTACACTGTAATTCTCAGCAT	SEQ?ID?NO：91		SEQ?ID?NO：90

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1261?ACTGATTATGGAGAAACACTTGTTTTGATTTTGTTATACTTGACTTAACTTTATTGCAAT 1321?GTGAATTAATTGCACTGCTAAGTAGGAAGATGTGTAACTTTTATTTGTTGCTATTCACAT 1381?TTGAATTTTTTCCTGTATAGGCAATATTATATTGACACCTTTTACAGATCTTACTGTAGC 1441?TTTTTCCATATAAATAAAATGCTTTTTCTACTATTTGTCTTGATTACTTAAAAAAATAAA 1501?AATATAAGTAAGGATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1 M A L K R I Q K E L S D L Q R D P P A H 1 ATGGCGCTGAAGAGGATTCAGAAAGAATTGAGTGATCTACAGCGCGATCCACCTGCTCAC 21 C S A G P V G D D L F H W Q A T I M G P 61 TGTTCAGCTGGACCTGTGGGAGATGACTTGTTCCACTGGCAAGCCACTATTATGGGGCCT 41 P D S A Y Q G G V F F L T V H F P T D Y 121 CCTGATAGCGCATATCAAGGTGGAGTCTTCTTTCTCACTGTACATTTTCCGACAGATTAT 61 P F K P P K I A F T T K I Y H P N I N S 181 CCTTTTAAACCACCAAAGATTGCTTTCACAACAAAAATTTACCATCCAAACATAAACAGT 81 N G S I C L D I L R S Q W S P A L T V S 241 AATGGAAGTATTTGTCTCGATATTCTGAGGTCACAATGGTCACCAGCTCTGACTGTATCA 101 K V L L S I C S L L C D P N P D D P L V 301 AAAGTTTTATTGTCCATATGTTCTCTACTTTGTGATCCTAATCCAGATGACCCCTTAGTA 121 P D I A Q I Y K S D K E K Y N R H A R E 361 CCAGATATTGCACAAATCTATAAATCAGACAAAGAAAAATACAACAGACATGCAAGAGAA 141 W T Q K Y A M - 421 TGGACTCAGAAATATGCAATGTAA	SEQ?ID?NO：92
BM734719.V1.3_AT	No homology	1 AGTCCTCTCGATGAAGCTTCTTCCCACCTAGAAAGAAGTCCTCTCTGAGACTCAAGGGCT 61 AAGGCAAGGTCTTCCAGAAAACAAGGCTTTGACTCCAAGAACAGAGGTGATGGGGAGACT 121 TCTTGGCTCGGCGGGGAAAGGAGGACGCCAATGGGTCAAACTAACTCTGAATCCCTCCCT 181 CCATCTCTCTTTTTCCACTGTCGTCAGAGCCAACAAGAAATGACAGCCTCCAAGCCTTCC 241 TAAAAGCACACTTGCCCCCGCCTGCCACCTCTCCTCAGGCTGCTGCCCTCCCAGGCGCTC 301 CACAGCGAAGGGGTGTGGTGTTTCCTGCAGGCCAGGCCAGCTGCCTCAGCCCCGCCAAAA 361 CTGTGTTCCCAGCCAGCGCTCTGGAGCAGGGATGACGTGTGGCCAGCCCTTCTCAGGTCT 421 CAGCTCTGCTGGGATGGGAGGAGAGGCCAGGGAGAAAGGTTAGGGGCCCAGGGGTGGGTG 481 ACAACGCTGGCTGCTGAAAGCCCATGAGCTGCTTCTTTGTTCTCTGTCACGGGACAAAAA 541 TCTCTCATCCTATTCTGCTTTCAGTTCATTAAGAGAGCACATTTTACTCATACACAAATA 601 AAAGTTTTCCCTTGTGGAAACAACAGCTTTAAAAGAAAGG	SEQ?ID?NO：93				SEQ?ID?NO：92
BM734719.V1.3_AT	No homology		SEQ?ID?NO：93	BM781127.V1.3_AT	Homo sapiens's acid phosphatase 5, tartrate resistance (ACP5), mRNA.	1 AGGGAATAAAGGCTCAGGGACCGGCAGTTCTACTCTAGAGCCCACCAGCCTCTCAGAGCC 61 TCCGGTGACTGGCCTGTGTCTCCCCCTGGATGGACATGTGGACGGCGCTGCTCATCCTGC 121 AAGCCTTGTTGCTACCCTCCCTGGCTGATGGTGCCACCCCTGCCCTGCGCTTTGTAGCCG 181 TGGGTGACTGGGGAGGGGTCCCCAATGCCCCATTCCACACGGCCCGGGAAATGGCCAATG 241 CCAAGGAGATCGCTCGGACTGTGCAGATCCTGGGTGCAGACTTCATCCTGTCTCTAGGGG	SEQ?ID?NO：94

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			301 ACAATTTTTACTTCACTGGTGTGCAAGACATCAATGACAAGAGGTTCCAGGAGACCTTTG 361 AGGACGTATTCTCTGACCGCTCCCTTCGCAAAGTGCCCTGGTACGTGCTAGCCGGAAACC 421 ATGACCACCTTGGCAATGTCTCTGCCCAGATTGCATACTCTAAGATCTCCAAGCGCTGGA 481 ACTTCCCCAGCCCTTTCTACCGCCTGCACTTCAAGATCCCACAGACCAATGTGTCTGTGG 541 CCATTTTTATGCTGGACACAGTGACACTATGTGGCAACTCAGATGACTTCCTCAGCCAGC 601 AGCCTGAGAGGCCCCGAGACGTGAAGCTGGCCCGCACACAGCTGTCCTGGCTCAAGAAAC 661 AGCTGGCCGCGGCCAAGGAGGACTACGTGCTGGTGGCTGGCCACTACCCAATATGGTCCA 721 TCGCGGAGCACGGGCCCACCCACTGCCTCGTCAAGCAGCTGCTGCCACTGCTGGCCATGC 781 ACAAGGTCACCGCCTACCTGTGTGGCCACGACCACAACCTGCAGTACCTTCAAGACGAGA 841 ACGGCATAGGCTTTGTGCTAAGCGGCGCTGGGAACTTCATGGACCCCTCGACGAAGCACG 901 CACGCAAGGTCCCCAATGGCTACCTGCGCTTCCACCACGGGACCAACACCTCCATGGGTG 961 GCTTTGCCTACGTGGAGATCAGCCCCAAAGAGATGACCGTCACTTACATCGAAGCTTCGG 1021?GCAAGTCCCTGTTCAAGACCAGGCTGCCCAGGAGAGCAAGGCCCTGAACTCCCATGACTG 1081?CCCAGCTCTGAGGCCCGATCTCCACTGTTGGGTGGGTGGCCTGCCGGGACCCTGCTCACA 1141?GGCAGGCTTTTCCTCCAACCTGTGGCGCTGCAGCAGGGCAGGAAGGGGAAACACAGCTGA 1201?TGAACTGTGGTGCCACGTGGCCCTTGTGGCAAGGATGCCCACGGATGTGAAACACACATG 1261?GACATGTGTCCCAGCCACAGTGTTATGCTCTGTGGCTGGCTCACCTTTGCTGAGTTCCGG 1321?GGTGCAATGGGGGAGGGAGGGAGGGAAAGCTTCCTCCTAAATCAAGCATCTTTCTGTTAC 1381?TGATGTTCAATAAAAGAATAGTTGCCAAGGCTG 1 M D M W T A L L I L Q A L L L P S L A D 1 ATGGACATGTGGACGGCGCTGCTCATCCTGCAAGCCTTGTTGCTACCCTCCCTGGCTGAT 21 G A T P A L R F V A V G D W G G V P N A 61 GGTGCCACCCCTGCCCTGCGCTTTGTAGCCGTGGGTGACTGGGGAGGGGTCCCCAATGCC 41 P F H T A R E M A N A K E I A R T V Q I 121 CCATTCCACACGGCCCGGGAAATGGCCAATGCCAAGGAGATCGCTCGGACTGTGCAGATC 61 L G A D F I L S L G D N F Y F T G V Q D 181 CTGGGTGCAGACTTCATCCTGTCTCTAGGGGACAATTTTTACTTCACTGGTGTGCAAGAC 81 I N D K R F Q E T F E D V F S D R S L R 241 ATCAATGACAAGAGGTTCCAGGAGACCTTTGAGGACGTATTCTCTGACCGCTCCCTTCGC 101 K V P W Y V L A G N H D H L G N V S A Q 301 AAAGTGCCCTGGTACGTGCTAGCCGGAAACCATGACCACCTTGGCAATGTCTCTGCCCAG 121 I A Y S K I S K R W N F P S P F Y R L H 361 ATTGCATACTCTAAGATCTCCAAGCGCTGGAACTTCCCCAGCCCTTTCTACCGCCTGCAC 141 F K I P Q T N V S V A I F M L D T V T L 421 TTCAAGATCCCACAGACCAATGTGTCTGTGGCCATTTTTATGCTGGACACAGTGACACTA 161 C G N S D D F L S Q Q P E R P R D V K L 481 TGTGGCAACTCAGATGACTTCCTCAGCCAGCAGCCTGAGAGGCCCCGAGACGTGAAGCTG 181 A R T Q L S W L K K Q L A A A K E D Y V	SEQ?ID?NO：95

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	541 GCCCGCACACAGCTGTCCTGGCTCAAGAAACAGCTGGCCGCGGCCAAGGAGGACTACGTG 201 L V A G H Y P I W S I A E H G P T H C L 601 CTGGTGGCTGGCCACTACCCAATATGGTCCATCGCGGAGCACGGGCCCACCCACTGCCTC 221 V K Q L L P L L A M H K V T A Y L C G H 661 GTCAAGCAGCTGCTGCCACTGCTGGCCATGCACAAGGTCACCGCCTACCTGTGTGGCCAC 241 D H N L Q Y L Q D E N G I G F V L S G A 721 GACCACAACCTGCAGTACCTTCAAGACGAGAACGGCATAGGCTTTGTGCTAAGCGGCGCT 261 G N F M D P S T K H A R K V P N G Y L R 781 GGGAACTTCATGGACCCCTCGACGAAGCACGCACGCAAGGTCCCCAATGGCTACCTGCGC 281 F H H G T N T S M G G F A Y V E I S P K 841 TTCCACCACGGGACCAACACCTCCATGGGTGGCTTTGCCTACGTGGAGATCAGCCCCAAA 301 E M T V T Y I E A S G K S L F K T R L P 901 GAGATGACCGTCACTTACATCGAAGCTTCGGGCAAGTCCCTGTTCAAGACCAGGCTGCCC 321 R R A R P - 961 AGGAGAGCAAGGCCCTGA
WBC048H02.bFSP_20021 501.esd	Homo sapiens's guanine-nucleotide-binding protein (G albumen), beta polypeptides 2-sample 1 (GNB2L1), mRNA.	1 CTGCAAGGCGGCGGCAGGAGAGGTTGTGGTGCTAGTTTCTCTAAGCCATCCAGTGCCATC 61 CTCGTCGCTGCAGCGACACCGCTCTCGCCGCCGCCATGACTGAGCAGATGACCCTTCGTG 121 GCACCCTCAAGGGCCACAACGGCTGGGTAACCCAGATCGCTACCACCCCGCAGTTCCCAG 181 ACATGATACTGTCGGCCTCGCGAGACAAGACCATCATCATGTGGAAGCTGACCAGGGATG 241 AGACCAACTACGGCATCCCACAGCGTGCTCTTCGAGGTCACTCCCACTTTGTTAGTGACG 301 TGGTGATCTCTTCAGATGGCCAGTTTGCCCTCTCAGGCTCCTGGGATGGAACGCTTCGCC 361 TCTGGGATCTCACAACGGGCACCACCACACGCCGATTTGTGGGCCATACCAAGGATGTGC 421 TGAGTGTGGCATTCTCCTCTGACAACCGGCAGATTGTCTCTGGCTCCCGAGATAAAACCA 481 TCAAGCTATGGAATACTCTGGGTGTATGCAAATACACTGTCCAGGATGAGAGCCACTCGG 541 AGTGGGTGTCTTGTGTCCGCTTCTCACCCAACAGTAGCAATCCCATCATTGTCTCCTGTG 601 GCTGGGACAAGCTAGTCAAGGTGTGGAATTTGGCAAACTGCAAGCTGAAGACCAATCACA 661 TCGGCCACACAGGCTACCTGAACACTGTCACTGTCTCTCCGGATGGATCCCTCTGTGCTT 721 CTGGAGGCAAGGATGGCCAGGCCATGCTTTGGGATTTAAATGAAGGCAAGCACCTTTACA 781 CACTAGATGGTGGGGACATCATCAACGCCTTGTGCTTCAGTCCCAATCGCTACTGGCTCT 841 GTGCTGCCACAGGCCCCAGCATCAAGATCTGGGACTTGGAGGGCAAGATCATTGTAGATG 901 AACTGAAGCAAGAAGTTATCAGTACCAGCAGCAAGGCAGAGCCACCCCAGTGCACTTCTC 961 TTGCCTGGTCTGCTGATGGCCAGACTCTGTTTGCTGGCTACACGGACAACCTGGTGAGAG 1021?TGTGGCAGGTGACCATCGGCACCCGCTAGAAATACATGGCAAGCTTTAGAAATAAAAAAA 1081?AAATGGCTTTTC 1 M T E Q M T L R G T L K G H N G W V T Q 1 ATGACTGAGCAGATGACCCTTCGTGGCACCCTCAAGGGCCACAACGGCTGGGTAACCCAG 21 I A T T P Q F P D M I L S A S R D K T I 61 ATCGCTACCACCCCGCAGTTCCCAGACATGATACTGTCGGCCTCGCGAGACAAGACCATC	SEQ?ID?NO：96 SEQ?ID?NO：97

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	41 I M W K L T R D E T N Y G I P Q R A L R 121 ATCATGTGGAAGCTGACCAGGGATGAGACCAACTACGGCATCCCACAGCGTGCTCTTCGA 61 G H S H F V S D V V I S S D G Q F A L S 181 GGTCACTCCCACTTTGTTAGTGACGTGGTGATCTCTTCAGATGGCCAGTTTGCCCTCTCA 81 G S W D G T L R L W D L T T G T T T R R 241 GGCTCCTGGGATGGAACGCTTCGCCTCTGGGATCTCACAACGGGCACCACCACACGCCGA 101 F V G H T K D V L S V A F S S D N R Q I 301 TTTGTGGGCCATACCAAGGATGTGCTGAGTGTGGCATTCTCCTCTGACAACCGGCAGATT 121 V S G S R D K T I K L W N T L G V C K Y 361 GTCTCTGGCTCCCGAGATAAAACCATCAAGCTATGGAATACTCTGGGTGTATGCAAATAC 141 T V Q D E S H S E W V S C V R F S P N S 421 ACTGTCCAGGATGAGAGCCACTCGGAGTGGGTGTCTTGTGTCCGCTTCTCACCCAACAGT 161 S N P I I V S C G W D K L V K V W N L A 481 AGCAATCCCATCATTGTCTCCTGTGGCTGGGACAAGCTAGTCAAGGTGTGGAATTTGGCA 181 N C K L K T N H I G H T G Y L N T V T V 541 AACTGCAAGCTGAAGACCAATCACATCGGCCACACAGGCTACCTGAACACTGTCACTGTC 201 S P D G S L C A S G G K D G Q A M L W D 601 TCTCCGGATGGATCCCTCTGTGCTTCTGGAGGCAAGGATGGCCAGGCCATGCTTTGGGAT 221 L N E G K H L Y T L D G G D I I N A L C 661 TTAAATGAAGGCAAGCACCTTTACACACTAGATGGTGGGGACATCATCAACGCCTTGTGC 241 F S P N R Y W L C A A T G P S I K I W D 721 TTCAGTCCCAATCGCTACTGGCTCTGTGCTGCCACAGGCCCCAGCATCAAGATCTGGGAC 261 L E G K I I V D E L K Q E V I S T S S K 781 TTGGAGGGCAAGATCATTGTAGATGAACTGAAGCAAGAAGTTATCAGTACCAGCAGCAAG 281 A E P P Q C T S L A W S A D G Q T L F A 841 GCAGAGCCACCCCAGTGCACTTCTCTTGCCTGGTCTGCTGATGGCCAGACTCTGTTTGCT 301 G Y T D N L V R V W Q V T I G T R - 901 GGCTACACGGACAACCTGGTGAGAGTGTGGCAGGTGACCATCGGCACCCGCTAG
B1961469	No homology	1 GATTCCGGATGAGCCACCCAGCCCTTCTGGCCCTGCTGTGGCTCGCCCAAAAGTCGCCCA 61 AGAAGAAAGGATCACTCCAGCATCCAGTGACAACCTGAACCCCCAAATAAAAGTCAAAGA 121 AGACACTCAAGAAATGCCCTGTGCTCCCTCAGGCCCAGTGCAAGTGATACGAGATGATTC 181 TCCTGAACCAAATGATGCAGAAGAGCCCCAGGAGGCATCCAGCACACCTCCCACAAAGAA 241 AGGAAAGAAAAGAAAAAGAAATGTGTGGTCAATTCCAAAGAAGAGATATCATAAAAAAAG	SEQ?ID?NO：98

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			301 CCTCCCAAAAGGGACAGTCTCACCTGGGGATGAAATCCAAGAGAAGCTCCAAGTGGTGGA 361 TCAGGCAACTCAAAAGAAGGACGACTCAACCAGGAACTCAAAGGTCACGACAAGGGTCCA 421 AAAAGCCAGGACTGGATGTGCCCAAACATCTGGACCAGAGGAGGTCAGTGATGACGCTTC 481 AGAAGTG NON?CONGIGUOUS 1 GACCTTGATGTTTGGATGATTACAAACCAAAAGTGTCAGAAATAGAGTACTCTGATTTGA 61 AAAGCAAATATGGTACTGAAATAGACAAGAACAGTATGTGAAAGGGCTAGAAGATCATCC 121 TTGGTTGAACATTAAGTATACCTCAATTCAACATGCTCACTATCAGTAGCAGCAGAATGG 181 AACAATTGTTTGAACTGAGCTTTGTCTCTGCAGCACCTCCCTCCAGGTCAAAATGGCAGT 241 CATCCATTGGCTGCACCAGCTGTTCCTCCTCACCCTTCTTTATGTGCTTAGATACGTGCT 301 CCAGACACAAGTCCCATTCATGAGCTTCCTGTTAGATGTGAACCTCCAGCAGAGGCAACG 361 CTTCCTCTCCCATCTTGCCCTGAAGGCTGGCCTGCCCCTTGGCTGGATTCATTCAAAGTT 421 GATAAAGCAATGGTCCTCAATTCTGTTTATTGGTAAACCATCTTTTCCATGCTGATTTGA 481 AACACGTTAGAT	SEQ?ID?NO：99
WBC021A01	No homology	1 GACAATGTTTGTGCTTGATTGCTCCTTTAAATCCAGCGTGCCATTGATTCTGCATGCCCA 61 CCTCATCCTGGCCTTCCTGATGGAAATAGGTTAAGAGAACCAGTCCTGTCTTCACCCTCG 121 AGAGAAACTTAGGTGAGGCTGGTCAGTTCAGTGCTTTCTTAGTGCATGTCTGCTGTATGT 181 TTCTGGCACCCATGCCCAACCAGGTTTTTAGAGATTTCAGACATCTTAAAGATGCAAATG 241 CTTCCCAGCATTTTTGTTTGTGTAGCCCTGCTTGCTTTAGCGTATGCTTGAATAAAAAGC 301 ATTGCAGCTAAGGCAGCTGTAAGAAAAAGGTACTTCTTCAGAAGTAAGCAACTCATCTTT 361 AAAGCACCCTCAAATGAATTTTGTTTTTCCTTCTTATGTTGAGGTAGAGTCAAAATAGAT 421 GGTGTTTTATTTTTTGCTGTTTGGGTTACCAGCTCTGTGGACTCTCCGACCTTCCCTTCC 481 CAGTTCACACATTTCCATTAGGATGCAGCCTGCTGGATGTATGCATTTCACCCCGAGTCC 541 ATCGGTCAGCCAGTACACATTGAGTGCCTGCTTTCAGTCAAGGCAGCTGATGTGAGGGGC 601 TCATCGTGTTGGCAGCAATATCCCAGCAGCAGTCTTTTTCTATTCTCCCTGTCTTGGATG 661 CTCCGGGGGGTATCAGGCATCTTGGCTGCTTGAAGCCTGGGCCCTCAGCCCTTTGCATTC 721 TCCTTANAGAGGAGGCCTGCTGCCCTTCTCTTTCTGGGTCGGAACTTCTCATTCTTGGCA 781 TGTTTCTGGACTACATGCATATGGGCAGCTATTCATTAATCTGCAGAACCCAATGTCAGC 841 CATCCATGATGTCTGGAGCGGGTAGCATTCGTTTCAAAGAAGCCTCGTTTCTCGGGGAGG 901 GCGATTCTGTCTATACTTTGAAGGGGGTGTATTTACCCCCATACCCC NON?CONTIGUOUS 1 CTCAAACCCAAGCCAAGGGTAATTTTTACTTGAAACTAGGAGAGTGGGGAAGACACTAGA 61 GAGAAGGGGTGAGTCGTGCAGGTGGGCCACCTGCCCCTGGTGTCTGTCCACGTCACTGAG 121 TGCTGTGAGCCAGTGCCTTTCCTGCACCTGAACATGGAGCCCGCTCTTCCCGCCTGGGTG 181 AAGAGACCTCGCTGCCCAGGGGTAGACCTTGAAGAAGGTGTCTTGGAGAGCCCAGAGGAC 241 ACTCACGTATTCAGGTGCCCATTTTAAGCATCTTTAAAATATTTTATAGATAAAAGCATG 301 CCCTTTCCTGTCGGTGCCACCAGTGGTGCAGTTCCATCCATTCTGAATGGAAAAGTGGAG 361 CCTGCCAGTGCTTTCCTGGGTCACTCCTTCATCTCCCTTGATGTGGTGTCCCCTCCCCCT 421 CCCGTCCATTTCACTGTCGTGGCTGGATAGCAGAGGGCACCATGTAGTCCTGACGCAGTC 481 CTGTGTGATTCCGTGATCAGTTTTTTCTGTAACTGTCCTTCCAAACCAGTTGATGTTTGG 541 AAATTAGGGAAAAAATTAAATTCTCACCAATGGTTGCTGTTACAGTTAAATCAATAAAGA 601 TCTTGAGTATCAAAAAAAAAAAAAAAAAAAAAAA	SEQ?ID?NO：100 SEQ?ID?NO：101				SEQ?ID?NO：99
WBC021A01	No homology		SEQ?ID?NO：100 SEQ?ID?NO：101	B1961499	Homo sapiens SUI1 isomer	1 CGGCACGAGCGCCGCCGAGGATTCAGCAGCCTCCCCCTTGAGCCCCCTCGCTTCCCGACG 61 TTCCGTTCCCCCCTGCCCGCCTTCTCCCGCCACCGCCGCCGCCGCCTTCCGCAGGCCGTT 121 TCCACCGAGGAAAAGGAATCGTATCGTATGTCCGCTATCCAGAACCTCCACTCTTTCGAC	SEQ?ID?NO：102

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 CCCTTTGCTGATGCAAGTAAGGGTGATGACCTGCTTCCTGCTGGCACTGAGGATTATATC 241 CATATAAGAATTCAACAGAGAAACGGCAGGAAGACCCTTACTACTGTCCAAGGGATCGCT 301 GATGATTACGATAAAAAGAAACTAGTGAAGGCGTTTAAGAAAAAGTTTGCCTGCAATGGT 361 ACTGTAATTGAGCATCCGGAATATGGAGAAGTAATTCAGCTACAGGGTGACCAACGCAAG 421 AACATATGCCAGTTCCTCGTAGAGATTGGACTGGCTAAGGACGATCAGCTGAAGGTTCAT 481 GGGTTTTAAGTGCTTGTGGCTCACTGAAGCTTAAGTGAGGATTTCCTTGCAATGAGTAGA 541 ATTTCCCTTCTCTCCCTTGTCACAGGTTTAAAAACCTCACAGCTTGTATAATGTAACCAT 601 TTGGGGTCCGCTTTTAACTTGGACTAGTGTAACTCCTTCATGCAATAAACTGAAAAGAGC 661 CATGCTGTCTAGTCTTGAAGTCCCTCATTTAAACAGAGGTCAAGCAATAGGCGCCTGGCA 721 GTGTCAAGCCTGAAACCAAGCAATACCGTCATGTTTCAGCCAAGCCCAGAGCCCTAAGAT 781 TACAAACAACTATGGCCGGAACCTCCTCAGCTCTCCCTCTGCAGAGTTCCCTACCCTAAG 841 AGAATGTTACCACCTGAACAGTCCTCGGTGAATCTGAGAGGAGAGGATGGGGTAAGGCAG 901 AAGCACCAGCTGTACTACTAGAAGGGAGCTTTTGGTGGTAGATCCCCTGGTGTCTCCAAC 961 CTGACTAGGTGGACAGAGCTCAAAGAGGCCCTCTTACCGCTAGCGAGGTGATAGGACATC 1021?TGGCTTGCCACAAAGGTCTGTTCGACCAGACATATCCTAGCTAAGGGATGTCCAAACATC 1081?AGAATGTGAGGCCAACCTTCTATCAGAGTTAAACTTTTGACAAGGGAACAAATCTCAAAC 1141?TGATCCATCAGTCATGTAGCTAGCTGTAGAGCTTGCAACTTAATAGCAGCAGCTGCCCAA 1201?TGCCATGTGAAGTAACAAACTGGTTTTTGGTTTTTTTTTCCCCTTCAGTTTTAATGTTAT 1261?GTGTAATGTATTTAAACCCTTATTTAAATAAAACTTGTTTTCAGAAAAAAAAAAAAAAAA 1321?AAAA 1 M S A I Q N L H S F D P F A D A S K G D 1 ATGTCCGCTATCCAGAACCTCCACTCTTTCGACCCCTTTGCTGATGCAAGTAAGGGTGAT 21 D L L P A G T E D Y I H I R I Q Q R N G 61 GACCTGCTTCCTGCTGGCACTGAGGATTATATCCATATAAGAATTCAACAGAGAAACGGC 41 R K T L T T V Q G I A D D Y D K K K L V 121 AGGAAGACCCTTACTACTGTCCAAGGGATCGCTGATGATTACGATAAAAAGAAACTAGTG 61 K A F K K K F A C N G T V I E H P E Y G 181 AAGGCGTTTAAGAAAAAGTTTGCCTGCAATGGTACTGTAATTGAGCATCCGGAATATGGA 81 E V I Q L Q G D Q R K N I C Q F L V E I 241 GAAGTAATTCAGCTACAGGGTGACCAACGCAAGAACATATGCCAGTTCCTCGTAGAGATT 101 G L A K D D Q L K V H G F - 301 GGACTGGCTAAGGACGATCAGCTGAAGGTTCATGGGTTTTAA	SEQ?ID?NO：103
B1961690.V1.3_AT	Homo sapiens's eukaryotic translation starts the factor 3, subunit 5 ε, 47kDa mRNA.	1 ATGGCCACACCGGCGGTACCAGTAAGTGCTCCTCCGGCCACGCCAACCCCAGTCCCGGCG 61 GCGGCCCCAGCCTCAGTTCCAGCGCCAACGCCAGCACCGGCTGCGGCTCCGGTTCCCGCT 121 GCGGCTCCAGCCTCATCCTCAGACCCGGCGGCAGCGGCGACTGCGACCGCGGCTCCCGGC 181 CAGCCCCCGGCCTCGGCGCCAGCCCCAGCGCAGACCCCGGCGCAGTCTTTGCCGGGTCCT 241 GCTCTCCCGGGCCCCTTCCCCGGCGGCCGCGTGGTCCGCCTGCACCCGGTCATTTTGGCC 301 TCCATCGTGGACAGCTACGAGCGACGCAACGAGGGCGCTGCCCGCGTTATCGGGACCCTG 361 CTCGGAACCGGTGACAAGCACTCTGTGGAAGTCACCAATTGCTTTTCAGTGCCACACAAC 421 GAGTCAGAAGATGAGGTGGCTGTTGACATGGAATTTGCTAAGAACATGTATGAATTGCAC 481 AAGAAGGTCTCTCCAAATGAGCTCATCCTGGGCTGGTACGCTACGGGCCATGACATCACA	SEQ?ID?NO：104		SEQ?ID?NO：103

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			541 GAGCACTCTGTGCTGATCCATGAGTACTACAGCCGGGAAGCCCCCAACCCCATTCACCTC 601 ACTGTGGACACGAGCCTCCAGAACGGCCGCATGAGCATCAAGGCCTATGTCAGCACTTTA 661 ATGGGTGTCCCTGGGAGGACCATGGGGGTGATGTTCACACCTCTGACAGTGAAATATGCA 721 TATTATGACACAGAACGCATCGGAGTTGACCTGATCATGAAGACCTGTTTTAGCCCCAAC 781 CGGGTGATCGGACTCTCAAGTGACTTGCAGCAAGTAGGAGGGGCGTCGGCTCGCATCCAG 841 GATGCCCTAAGCACAGTGTTGCAGTACGCAGAGGATGTACTGTCTGGAAAGGTGTCAGCT 901 GACAATACAGTGGGCCGCTTCTTGATGAGTCTGGTTAACCAAGTACCCAAGATAGTTCCT 961 GATGACTTCGAGACCATGCTCAACAGCAACATCAATGACCTGCTGATGGTGACCTACTTG 1021?GCCAATCTCACACAATCACAAATTGCCCTCAATGAGAAACTCGTAAACCTGTAG 1 M A T P A V P V S A P P A T P T P V P A 1 ATGGCCACACCGGCGGTACCAGTAAGTGCTCCTCCGGCCACGCCAACCCCAGTCCCGGCG 21 A A P A S V P A P T P A P A A A P V P A 61 GCGGCCCCAGCCTCAGTTCCAGCGCCAACGCCAGCACCGGCTGCGGCTCCGGTTCCCGCT 41 A A P A S S S D P A A A A T A T A A P G 121 GCGGCTCCAGCCTCATCCTCAGACCCGGCGGCAGCGGCGACTGCGACCGCGGCTCCCGGC 61 Q P P A S A P A P A Q T P A Q S L P G P 181 CAGCCCCCGGCCTCGGCGCCAGCCCCAGCGCAGACCCCGGCGCAGTCTTTGCCGGGTCCT 81 A L P G P F P G G R V V R L H P V I L A 241 GCTCTCCCGGGCCCCTTCCCCGGCGGCCGCGTGGTCCGCCTGCACCCGGTCATTTTGGCC 101 S I V D S Y E R R N E G A A R V I G T L 301 TCCATCGTGGACAGCTACGAGCGACGCAACGAGGGCGCTGCCCGCGTTATCGGGACCCTG 121 L G T G D K H S V E V T N C F S V P H N 361 CTCGGAACCGGTGACAAGCACTCTGTGGAAGTCACCAATTGCTTTTCAGTGCCACACAAC 141 E S E D E V A V D M E F A K N M Y E L H 421 GAGTCAGAAGATGAGGTGGCTGTTGACATGGAATTTGCTAAGAACATGTATGAATTGCAC 161 K K V S P N E L I L G W Y A T G H D I T 481 AAGAAGGTCTCTCCAAATGAGCTCATCCTGGGCTGGTACGCTACGGGCCATGACATCACA 181 E H S V L I H E Y Y S R E A P N P I H L 541 GAGCACTCTGTGCTGATCCATGAGTACTACAGCCGGGAAGCCCCCAACCCCATTCACCTC 201 T V D T S L Q N G R M S I K A Y V S T L 601 ACTGTGGACACGAGCCTCCAGAACGGCCGCATGAGCATCAAGGCCTATGTCAGCACTTTA 221 M G V P G R T M G V M F T P L T V K Y A 661 ATGGGTGTCCCTGGGAGGACCATGGGGGTGATGTTCACACCTCTGACAGTGAAATATGCA 241 Y Y D T E R I G V D L I M K T C F S P N 721 TATTATGACACAGAACGCATCGGAGTTGACCTGATCATGAAGACCTGTTTTAGCCCCAAC	SEQ?ID?NO：105

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			261 R V I G L S S D L Q Q V G G A S A R I Q 781 CGGGTGATCGGACTCTCAAGTGACTTGCAGCAAGTAGGAGGGGCGTCGGCTCGCATCCAG 281 D A L S T V L Q Y A E D V L S G K V S A 841 GATGCCCTAAGCACAGTGTTGCAGTACGCAGAGGATGTACTGTCTGGAAAGGTGTCAGCT 301 D N T V G R F L M S L V N Q V P K I V P 901 GACAATACAGTGGGCCGCTTCTTGATGAGTCTGGTTAACCAAGTACCCAAGATAGTTCCT 321 D D F E T M L N S N I N D L L M V T Y L 961 GATGACTTCGAGACCATGCTCAACAGCAACATCAATGACCTGCTGATGGTGACCTACTTG 341 A N L T Q S Q I A L N E K L V N L - 1021?GCCAATCTCACACAATCACAAATTGCCCTCAATGAGAAACTCGTAAACCTGTAG
WBC016C12	No homology	1 TCCCCAGGCTGCCGAAGCGGAGTGCACGAACTTAACTGCTGCACCACCAGGCTGGCCCCT 61 TGATCCATTTCTTTTTTCTTTTTTGAAGAAGATTATCCCTGAGCTAACATCCACCACCAA 121 TCCTCCTCTTTTTGCTGAGGAAGACTGGTCCTGAGCTAACATCCATGCCCATCCTCCTCT 181 ACTTTATATATGGGACGCCTACCACAGCATGGCTTGCCAAGTGGTGCCATATGGGCACCT 241 GGGATCCGAACTGGCGAACCCTGGGCCGCCGAAGCGGAACATGCGCTCTTAACTGCTGCG 301 CCACCCGGCCGGCCCCTATATGTTTCTTGACAGGGTAGATAATTTGTTTAGGGAACTACA 361 ATTCTGTTCTTTAACTATGTACCATAAAGAATGTGATTAAAGTACTTGAAAAGTAACTTC 421 TTCAAACTTAGTTTTTTATAAAATATGCAGATCTAAAAGTCACTGTCAAGATAAGTCTGA 481 ATTAGTTCTCTTATGGTCCTACTTCTAAAACTGAAGGTTTTGTGTGCAAAGGAATCCTTT 541 CTGGATAAGACGGGATTCCCTTTACCCTCTGTCCACGGGGCTTTATGTTAACTGTGAGGC 601 CGCATGTGTCCGTCACTGGCACCCCGGTCCCACCGGGATGTGTGGGAGCCTCCAGGCTGT 661 CCCAGTGTTAATTGTATTTACAGCAGGCCTACTAGACCAGCAGGAAGCATCGCACATGTC 721 ACATTGCACATGGGAGCTCAGGTCCTGAAGTCAGGCTTCTGTCTGTGCTGTCCTTCCTGT 781 TTGTGGGTTGCTGGTTCTCCACTGGGGTCCTTCAAAAGCAGCCCCACCCACACCTCCCCA 841 TTCTATTCACTCTGCTGCCTGTGTTAATATTTCTAAAAGATTTTTAATACATTAAACTCT 901 TACCTACGATTACTGTGGAATGGGATATACTGTTAATTAGAA NON?CONGIGUOUS 1 TCTGTTCTTTAACTATGTACCATAAAGAATGTGATTAAAGTACTTGAAAAGTAACTTCTT 61 CAAACTTAGTTTTTTATAAAATATGCAGATCTAAAAGTCACTGTCAAGATAAGTCTGAAT 121 TAGTTCTCTTATGGTCCTACTTCTAAAACTGAAGGTTTTGTGTGCAAAGGAATCCTTTCT 181 GGATAAGACGGGATTCCCTTTACCCTCTGTCCACGGGGCTTTATGTTAACTGTGAGGCCG 241 CATGTGTCCGTCACTGGCACCCCGGTCCCACCGGGATGTGTGGGAGCCTCCAGGCTGTCC 301 CAGTGTTAATTGTATTTACAGCAGGCCTACTAGACCAGCAGGAAGCATCGCACATGTCAC 361 ATTGCACATGGGAGCTCAGGTCCTGAAGTCAGGCTTCTGTCTGTGCTGTCCTTCCTGTTT 421 GTGGGTTGCTGGTTCTCCACTGGGGTCCTTCAGAAGCAGCCCCACCCACACCTCCCCATT 481 CTATTCACTCTGCTGCCTGTGTTAATATTTCTAAAAGATTTTTAATACATTAAACTCTTA 541 CCTACGATTACTGTGGAATGGGATATACTGTTAATTAGAAATATATTTTTATTTAAAAAA 601 ATTATATTCAGAATACAACTAGAATAGACCAAAAAAAAAAAA	SEQ?ID?NO：106 SEQ?ID?NO：107
WBC016C12	No homology		SEQ?ID?NO：106 SEQ?ID?NO：107	WBC032C03	No homology	1 GGGAGCCCTCACAGGGCTTCAGTGTAAGGGGGACTGAGCCATCGAAAGCTCATTGCCAGA 61 AGGATACCATTTTTGGCTCTCCCTCTTCACTACCAGTACACAGTTTGACCCAGTGGCCAC	SEQ?ID?NO：108

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	121 TGGTTCACAGTACGCCACGTCACTGCCATCCCATGAAACAGTTTGTTCCCAGGCCGTGCA 181 GAATCCTGGAGTGGCATGCTGACCAGAATGGCTTGCTTCTGCAGAGGATGCTGCCCCGTG 241 ACTTAGCTGCTGCCTCCAGCTTCTTGCTTAAGAACTTACTAAAGGGACTTCCTTCCCATT 301 AAAACCCCAATAGCAACTCTCCCTAAATTTGTTGATTCTCTGCTAGGCCTGAGAATCTGA 361 ATTAACATCTCTTGAAGCCAAACTCCGCCTCTTGTGCTTTTTTTGCTTTGGATAAAGGAG 421 TTTTTCTTTAGAAACAGTGCCAAGAATGACAAGATATAAAAAACTAATTTTAAAGAAAAT 481 GCCTAACAGGTTTTTAATACAGTAATCACTGTAATTATCACTTTCTTTTCTAGTTCCTTG 541 GTTTTCAGCTCAGGCTGCATTCTCTAACTCATACTGTGAAGAAAGAGGTGTTTTTGATTC 601 AGAAATATATGAAATCTACATAGTCTTAATTTGTAAAAAATAAAGAAAATTCCTTAACCT 661 TTAAAAAAAAAAAAAAAAAAA
WBC028D07_V1.3_AT	People's guanine nucleotide binding protein isotype II (GBP-2) mRNA	1 AGTAAAAGTCCACAGTTACCGTGAGAGAAAAAAAGAGGAGAAAGCAGTGCAGCCAAACTC 61 GGAAGAAAAGAGAGGAGGAAAAGGACTCGACTTTCACATTGGAACAACCTTCTTTCCAGT 121 GCTAAGGCTCTCTGATCTGGGGAACAACACCTGGACATGGCTCCAGAGATCAACTTGCCG 181 GGCCCAATGAGCCTCATTGATAACACTAAAGGGCAGCTGGTGGTGAATCCAGAAGCTCTG 241 AAGATCCTATCTGCAATTACGCAGCCTGTGGTGGTGGTGGCGATTGTGGGCCTCTATCGC 301 ACAGGCAAATCCTACCTGATGAACAAGCTGGCTGGGAAGAAAAACGGCTTCTCTCTAGGC 361 TCCACAGTGAAGTCTCACACCAAGGGAATCTGGATGTGGTGTGTGCCTCATCCCAAGAAG 421 CCAGAACACACCCTAGTTCTGCTCGACACTGAGGGCCTGGGAGATATAGAGAAGGGTGAC 481 AATGAGAATGACTCCTGGATCTTTGCCTTGGCCATCCTCCTGAGCAGCACCTTCGTGTAC 541 AATAGCATGGGAACCATCAACCAGCAGGCCATGGACCAACTGCACTACGTGACAGAGCTG 601 ACAGAGCGAATCAGGGCAAAATCCTCACCCAGTAACAGTGAGCTTGAAGACTCAGCTGAC 661 TTCGTGAGCTTCTTTCCAACCTTTGTGTGGACTCTGAGAGATTTCTCCCTGGAGCTAGAA 721 GCCAATGGAGAACCCATCACTGCTGACGAGTACCTGGAGCTGTCACTGAAGCTAAAGAAA 781 GGTACTGATGAAAAAAGCAAAAGCTTTAATGAACCTCGGTTGTGCATCCGAAAGTTCTTC 841 CCAAAGAAGAAGTGCTTCATCTTTGACCGTCCCGCTCCCAGGAAGTACCTTGTCCAACTG 901 GAGAAGCTACAGGAGGAAGATCTGGACCCTGAATTCAGAGAACAAGTTGCAGACTTCTGC 961 TCCTACATCTTCAGCCATTCCAAAGCCAAGACTCTCTCAGGCGGCATCATAGTCAATGGG 1021?CCTCGTCTGGAGAGCCTGGTGCTGACCTATGTCAATGCCATCAGCAGTGGGGATCTTCCC 1081?TGCATGGAGAATGCAGTCCTGGCCTTGGCCCAGATAGAGAACTCGGCCGCAGTACAAAAG 1141?GCCGTGGCCCACTATGATCAGCAGATGGGCCAGAGGGTGAAGCTGCCCACGGAAACCCTC 1201?CAGGAGCTTCTGGACCTGCACAGGGCCAACGAGAAAGAGGCCATTGAAGTCTTCATGAAA 1261?AATTCTTTCAAGGATGTGGAACAAAAGTTCCAGAAGGAATTAGGGGCCCAGTTAGAAGCA 1321?AAGCGAGATGACTTTTGTAAGCAGAACATGCAAGCGTCATCAGATCGTTGCATGGCATTA 1381?CTTCAGGATATTTTTGGTCCTCTAGAAGAAGAGGTGAAGCAAGGGGCATTTTCTAAACCG 1441?GGAGGTTATCATCTCTTTATTCAGAAGAAACAGGAGCTGAAGAATAAGTACTACCAGGTG 1501?CCCAGGAAGGGGATACAGGCAGAGGACATGCTGAAGAAGTACTTGGAATCCAAGGAAGAC 1561?GTGGCTGATGCGCTTCTCCGGACTGACCAGTCACTCTCAGAAAAGGAAAAGGAGATTGAA 1621?GTGGAACGTATAAAGGCTGAATCTGCAGAAGCTGCAACGAAAATGTTGGAGGAAATCCAA 1681?AAGAAGAATCAGCAGATGATGGAACAGAAAGAAAAGAGTTATCAGGAACACGTGAAACAA 1741?TTGACTGAGAAGATGGAGAGAGATAGGGCCCAGCTGCTGGCAGAGCAGGAGAGGACTCTC 1801?GCTCTTAAACTTCAGGAACAGGAACGACTTCTCAAGGAAGGATTCCAGAACGAGAGCAGG 1861?AAACTTCAAAAAGACATATGGGATATCCAGATGAGAAGCAAATCATTGGAGCCAATATGT 1921?AACATACTCTAAAAGTCCAAGGAGCAAAATTTGCCTGTCCAGCTCCCTCTCCCCAAGAAA 1981?CAACATGAATGAGCAACTTCAGAGTGTCAAACAACTGCCATTAAACTTAACTCAAAATCA 2041?TGATGCTTCCATTTTTGTTGAGCTATAAAATTTGCAAAGTTTGCAAAGTAAAGGTTAAGT 2101?ATGAGGTCAATGTTTT	SEQ?ID?NO：109

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1 M A P E I N L P G P M S L I D N T K G Q 1 ATGGCTCCAGAGATCAACTTGCCGGGCCCAATGAGCCTCATTGATAACACTAAAGGGCAG 21 L V V N P E A L K I L S A I T Q P V V V 61 CTGGTGGTGAATCCAGAAGCTCTGAAGATCCTATCTGCAATTACGCAGCCTGTGGTGGTG 41 V A I V G L Y R T G K S Y L M N K L A G 121 GTGGCGATTGTGGGCCTCTATCGCACAGGCAAATCCTACCTGATGAACAAGCTGGCTGGG 61 K K N G F S L G S T V K S H T K G I W M 181 AAGAAAAACGGCTTCTCTCTAGGCTCCACAGTGAAGTCTCACACCAAGGGAATCTGGATG 81 W C V P H P K K P E H T L V L L D T E G 241 TGGTGTGTGCCTCATCCCAAGAAGCCAGAACACACCCTAGTTCTGCTCGACACTGAGGGC 101 L G D I E K G D N E N D S W I F A L A I 301 CTGGGAGATATAGAGAAGGGTGACAATGAGAATGACTCCTGGATCTTTGCCTTGGCCATC 121 L L S S T F V Y N S M G T I N Q Q A M D 361 CTCCTGAGCAGCACCTTCGTGTACAATAGCATGGGAACCATCAACCAGCAGGCCATGGAC 141 Q L H Y V T E L T E R I R A K S S P S N 421 CAACTGCACTACGTGACAGAGCTGACAGAGCGAATCAGGGCAAAATCCTCACCCAGTAAC 161 S E L E D S A D F V S F F P T F V W T L 481 AGTGAGCTTGAAGACTCAGCTGACTTCGTGAGCTTCTTTCCAACCTTTGTGTGGACTCTG 181 R D F S L E L E A N G E P I T A D E Y L 541 AGAGATTTCTCCCTGGAGCTAGAAGCCAATGGAGAACCCATCACTGCTGACGAGTACCTG 201 E L S L K L K K G T D E K S K S F N E P 601 GAGCTGTCACTGAAGCTAAAGAAAGGTACTGATGAAAAAAGCAAAAGCTTTAATGAACCT 221 R L C I R K F F P K K K C F I F D R P A 661 CGGTTGTGCATCCGAAAGTTCTTCCCAAAGAAGAAGTGCTTCATCTTTGACCGTCCCGCT 241 P R K Y L V Q L E K L Q E E D L D P E F 721 CCCAGGAAGTACCTTGTCCAACTGGAGAAGCTACAGGAGGAAGATCTGGACCCTGAATTC 261 R E Q V A D F C S Y I F S H S K A K T L 781 AGAGAACAAGTTGCAGACTTCTGCTCCTACATCTTCAGCCATTCCAAAGCCAAGACTCTC 281 S G G I I V N G P R L E S L V L T Y V N 841 TCAGGCGGCATCATAGTCAATGGGCCTCGTCTGGAGAGCCTGGTGCTGACCTATGTCAAT 301 A I S S G D L P C M E N A V L A L A Q I 901 GCCATCAGCAGTGGGGATCTTCCCTGCATGGAGAATGCAGTCCTGGCCTTGGCCCAGATA	SEQ?ID?NO：110

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	321 E N S A A V Q K A V A H Y D Q Q M G Q R 961 GAGAACTCGGCCGCAGTACAAAAGGCCGTGGCCCACTATGATCAGCAGATGGGCCAGAGG 341 V K L P T E T L Q E L L D L H R A N E K 1021?GTGAAGCTGCCCACGGAAACCCTCCAGGAGCTTCTGGACCTGCACAGGGCCAACGAGAAA 361 E A I E V F M K N S F K D V E Q K F Q K 1081?GAGGCCATTGAAGTCTTCATGAAAAATTCTTTCAAGGATGTGGAACAAAAGTTCCAGAAG 381 E L G A Q L E A K R D D F C K Q N M Q A 1141?GAATTAGGGGCCCAGTTAGAAGCAAAGCGAGATGACTTTTGTAAGCAGAACATGCAAGCG 401 S S D R C M A L L Q D I F G P L E E E V 1201?TCATCAGATCGTTGCATGGCATTACTTCAGGATATTTTTGGTCCTCTAGAAGAAGAGGTG 421 K Q G A F S K P G G Y H L F I Q K K Q E 1261?AAGCAAGGGGCATTTTCTAAACCGGGAGGTTATCATCTCTTTATTCAGAAGAAACAGGAG 441 L K N K Y Y Q V P R K G I Q A E D M L K 1321?CTGAAGAATAAGTACTACCAGGTGCCCAGGAAGGGGATACAGGCAGAGGACATGCTGAAG 461 K Y L E S K E D V A D A L L R T D Q S L 1381?AAGTACTTGGAATCCAAGGAAGACGTGGCTGATGCGCTTCTCCGGACTGACCAGTCACTC 481 S E K E K E I E V E R I K A E S A E A A 1441?TCAGAAAAGGAAAAGGAGATTGAAGTGGAACGTATAAAGGCTGAATCTGCAGAAGCTGCA 501 T K M L E E I Q KK N Q Q M M E Q K E K 1501?ACGAAAATGTTGGAGGAAATCCAAAAGAAGAATCAGCAGATGATGGAACAGAAAGAAAAG 521 S Y Q E H V K Q L T E K M E R D R A Q L 1561?AGTTATCAGGAACACGTGAAACAATTGACTGAGAAGATGGAGAGAGATAGGGCCCAGCTG 541 L A E Q E R T L A L K L Q E Q E R L L K 1621?CTGGCAGAGCAGGAGAGGACTCTCGCTCTTAAACTTCAGGAACAGGAACGACTTCTCAAG 561 E G F Q N E S R K L Q K D I W D I Q M R 1681?GAAGGATTCCAGAACGAGAGCAGGAAACTTCAAAAAGACATATGGGATATCCAGATGAGA 581 S K S L E P I C N I L - 1741?AGCAAATCATTGGAGCCAATATGTAACATACTCTAA
WBC010B02_V1.3_AT	Homo sapiens C-type agglutinant protein CLL-1mRNA, encoding sequence fully.	1 GGGTGATTGGTACAGTAGGTTTATAAACAGAAGTTTAAACTTGTAAGCTTAAGCTTCCGT 61 TTATAAACAGAAGTTTAAAATTATAGGTCCTGTTTAACATTCAGCTCTGTTAACTCACTC 121 ATCTTTTTGTGTTTTTACACTTTGTCAAGATTTCTTTACATATTCATCAATGTCTGAAGA 181 AGTTACTTATGCAGATCTTCAATTCCAGAACTCCAGTGAGATGGAAAAAATCCCAGAAAT 241 TGGCAAATTTGGGGAAAAAGCACCTCCAGCTCCCTCTCATGTATGGCGTCCAGCAGCCTT 301 GTTTCTGACTCTTCTGTGTCTTCTGCTGCTGACTGGACTGGGAGTCTTAGGAAGCATGTT	SEQ?ID?NO：111

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			361 TTATATAACTTTGAAGACAGAAGTGGGAAAATTGAATGAACTACAAAATTTTAAAGAAGA 421 ACTTCAGAGAAATATTTCTATACAACTGATGCATAACATGAATAATTCTGAGAAGATCAG 481 GAACCTCTCTATCACACTGCAAGAAATAGCCACCAAATTTTGTCATGAGCTGTATAGAAA 541 CAATCAAGAGCACAAATGTAAACCTTGCCCAAAGCAATGGATATGGCATGAAGACAGCTG 601 TTATTTCCTAAGTGATGATGTCCAAACATGGCAGGAGAGTAAAATGGCCTGTGCTGCTCA 661 GAATGCCAGCCTGTTGAAGATAAACAACAAAAATGCATTGGAATTTATAAAATCCCAGAG 721 TAGATCATATGACTATTGGCTGGGATTATCTCCTGAAGAAGATTCCACTCGTGGTATGAG 781 AGTGGATAATATAATCAACTCCTCTGCCTGGGTTATAAGAAACGCACCTGACTTAAATAA 841 CATGTATTGTGGATATATAAATAGACTATATGTTCAATATTATCACTGCACTTATAAACA 901 AAGAATGATATGTGAGAAGATGGCCAATCCAGTGCAGCTTGGTTCTACATATTTTAGGGA 961 GGCATGAGGCATCAATCAAATACATTGAAGGAGTGTAGGGGGTGGGGGTTCTAGGCTATA 1021?GGTAAATTTAAATATTTTCTGGTTGACAATTAGTTGAGTTTGTCTGAAGACCTGGGATTT 1081?TATCATGCAGATGAAACATCCAGGTAGCAAGCTTCAGAGAGAATAGACTGTGAATGTTAA 1141?TGCCAGAGAGGTATAATGAAGCATGTCCCACCTCCCACTTTCCATCATGGCCTGAACCCT 1201?GGAGGAAGAGGAAGTCCATTCAGATAGTTGTGGGGGGCCTTCGAATTTTCATTTTCATTT 1261?ACGTTCTTCCCCTTCTGGCCAAGATTTGCCAGAGGCAACATCAAAAACCAGCAAATTTTA 1321?ATTTTGTCCCACAGCGTTGCTAGGGTGGCATGGCTCCCCATCTCGGGTCCATCCTATACT 1381?TCCATGGGACTCCCTATGGCTGAAGGCCTTATGAGTCAAAGGACTTATAGCCAATTGATT 1441?GTTCTAGGCCAGGTAAGAATGGATATGGACATGCATTTATTACCTCTTAAAATTATTATT 1501?TTAAGTAAAAGCCAATAAACAAAAACGAAAAGGCAAAAAAAAAAAAAAAAAAAAAAAAAA 1561?AAAAAA 1 M S E E V T Y A D L Q F Q N S S E M E K 1 ATGTCTGAAGAAGTTACTTATGCAGATCTTCAATTCCAGAACTCCAGTGAGATGGAAAAA 21 I P E I G K F G E K A P P A P S H V W R 61 ATCCCAGAAATTGGCAAATTTGGGGAAAAAGCACCTCCAGCTCCCTCTCATGTATGGCGT 41 P A A L F L T L L C L L L L T G L G V L 121 CCAGCAGCCTTGTTTCTGACTCTTCTGTGTCTTCTGCTGCTGACTGGACTGGGAGTCTTA 61 G S M F Y I T L K T E V G K L N E L Q N 181 GGAAGCATGTTTTATATAACTTTGAAGACAGAAGTGGGAAAATTGAATGAACTACAAAAT 81 F K E E L Q R N I S I Q L M H N M N N S 241 TTTAAAGAAGAACTTCAGAGAAATATTTCTATACAACTGATGCATAACATGAATAATTCT 101 E K I R N L S I T L Q E I A T K F C H E 301 GAGAAGATCAGGAACCTCTCTATCACACTGCAAGAAATAGCCACCAAATTTTGTCATGAG 121 L Y R N N Q E H K C K P C P K Q W I W H 361 CTGTATAGAAACAATCAAGAGCACAAATGTAAACCTTGCCCAAAGCAATGGATATGGCAT 141 E D S C Y F L S D D V Q T W Q E S K M A 421 GAAGACAGCTGTTATTTCCTAAGTGATGATGTCCAAACATGGCAGGAGAGTAAAATGGCC 161 C A A Q N A S L L K I N N K N A L E F I 481 TGTGCTGCTCAGAATGCCAGCCTGTTGAAGATAAACAACAAAAATGCATTGGAATTTATA	SEQ?ID?NO：112

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:	181 K S Q S R S Y D Y W L G L S P E E D S T 541 AAATCCCAGAGTAGATCATATGACTATTGGCTGGGATTATCTCCTGAAGAAGATTCCACT 201 R G M R V D N I I N S S A W V I R N A P 601 CGTGGTATGAGAGTGGATAATATAATCAACTCCTCTGCCTGGGTTATAAGAAACGCACCT 221 D L N N M Y C G Y I N R L Y V Q Y Y H C 661 GACTTAAATAACATGTATTGTGGATATATAAATAGACTATATGTTCAATATTATCACTGC 241 T Y K Q R M I C E K M A N P V Q L G S T 721 ACTTATAAACAAAGAATGATATGTGAGAAGATGGCCAATCCAGTGCAGCTTGGTTCTACA 261 Y F R E A - 781 TATTTTAGGGAGGCATGA
B1961567.V1.3_AT	Homo sapiens's leucine aminopeptidase(LAP) 3, mRNA.	1 GGCCGAGCCGACAAGATGTTCTTGCTGCCTCTTCCGGCTGCGGGGCGAGTAGTCGTCCGA 61 CGTCTGGCCGTGAGACGTTTCGGGAGCCGGAGTCTCTCCACCGCAGACATGACGAAGGGC 121 CTTGTTTTAGGAATCTATTCCAAAGAAAAAGAAGATGATGTGCCACAGTTCACAAGTGCA 181 GGAGAGAATTTTGATAAATTGTTAGCTGGAAAGCTGAGAGAGACTTTGAACATATCTGGA 241 CCACCTCTGAAGGCAGGGAAGACTCGAACCTTTTATGGTCTGCATCAGGACTTCCCCAGC 301 GTGGTGCTAGTTGGCCTCGGCAAAAAGGCAGCTGGAATCGACGAACAGGAAAACTGGCAT 361 GAAGGCAAAGAAAACATCAGAGCTGCTGTTGCAGCGGGGTGCAGGCAGATTCAAGACCTG 421 GAGCTCTCGTCTGTGGAGGTGGATCCCTGTGGAGACGCTCAGGCTGCTGCGGAGGGAGCG 481 GTGCTTGGTCTCTATGAATACGATGACCTAAAGCAAAAAAAGAAGATGGCTGTGTCGGCA 541 AAGCTCTATGGAAGTGGGGATCAGGAGGCCTGGCAGAAAGGAGTCCTGTTTGCTTCTGGG 601 CAGAACTTGGCACGCCAATTGATGGAGACGCCAGCCAATGAGATGACGCCAACCAGATTT 661 GCCGAAATTATTGAGAAGAATCTCAAAAGTGCTAGTAGTAAAACCGAGGTCCATATCAGA 721 CCCAAGTCTTGGATTGAGGAACAGGCAATGGGATCATTCCTCAGTGTGGCCAAAGGATCT 781 GACGAGCCCCCAGTCTTCTTGGAAATTCACTACAAAGGCAGCCCCAATGCAAACGAACCA 841 CCCCTGGTGTTTGTTGGGAAAGGAATTACCTTTGACAGTGGTGGTATCTCCATCAAGGCT 901 TCTGCAAATATGGACCTCATGAGGGCTGACATGGGAGGAGCTGCAACTATATGCTCAGCC 961 ATCGTGTCTGCTGCAAAGCTTAATTTGCCCATTAATATTATAGGTCTGGCCCCTCTTTGT 1021?GAAAATATGCCCAGCGGCAAGGCCAACAAGCCGGGGGATGTTGTTAGAGCCAAAAACGGG 1081?AAGACCATCCAGGTTGATAACACTGATGCTGAGGGGAGGCTCATACTGGCTGATGCGCTC 1141?TGTTACGCACACACGTTTAACCCGAAGGTCATCCTCAATGCCGCCACCTTAACAGGTGCC 1201?ATGGATGTAGCTTTGGGATCAGGTGCCACTGGGGTCTTTACCAATTCATCCTGGCTCTGG 1261?AACAAACTCTTCGAGGCCAGCATTGAAACAGGGGACCGCGTCTGGAGGATGCCTCTCTTT 1321?GACCATTATACTAGACAGGTTGTCGATTGCCAACTTGCTGATGTTAATAACATCGGAAAG 1381?TATAGATCTGCAGGAGCATGTACAGCTGCAGCATTCCTGAAGGAATTTGTGACTCATCCT 1441?AAGTGGGCGCATTTAGACATAGCAGGAGTGATGACTAACAAAGATGAGATTCCGTATCTG 1501?CGTAAAGGCATGACCGGGAGGCCCACGAGGACCCTGATAGAGTTCTTGCTTCGGTTCAGT 1561?CAAGACAAAGCTTAGTTCAGATACTCTAAAATGCCTTCATTCTGTCTTAAATTGGACAGT 1621?TGAACTTAAAAGGTTTTTGAATAAATGGATGAAAATCTTTTAACGGAGACAAAGGATGGT 1681?ATTTAAAAATGTAGAACACAATGAAATTTGTATGCCTTGATTTTTTTTTCATTTCACACA 1741?AAGATTTATAAAGGTAAAGTTAATATCTTACTTGATAAGGATTTTTAAGATACTCTATAA 1801?ATGATTAATTTTTTAAAAACTACCTAATCATTTTTCAGAGTGTATGTTTTTAATTGAGTG 1861?AAATTGTATTTCGGATTTGTGATGCTAGGAACATGAGCAAACTGAAAATTACTATGCACT	SEQ?ID?NO：113

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			1921?TGTCAGAAACAATAAATGCAACTTGTTGTGCAAAAAAAAAAAAAAAAAAA 1 M F L L P L P A A G R V V V R R L A V R 1 ATGTTCTTGCTGCCTCTTCCGGCTGCGGGGCGAGTAGTCGTCCGACGTCTGGCCGTGAGA 21 R F G S R S L S T A D M T K G L V L G I 61 CGTTTCGGGAGCCGGAGTCTCTCCACCGCAGACATGACGAAGGGCCTTGTTTTAGGAATC 41 Y S K E K E D D V P Q F T S A G E N F D 121 TATTCCAAAGAAAAAGAAGATGATGTGCCACAGTTCACAAGTGCAGGAGAGAATTTTGAT 61 K L L A G K L R E T L N I S G P P L K A 181 AAATTGTTAGCTGGAAAGCTGAGAGAGACTTTGAACATATCTGGACCACCTCTGAAGGCA 81 G K T R T F Y G L H Q D F P S V V L V G 241 GGGAAGACTCGAACCTTTTATGGTCTGCATCAGGACTTCCCCAGCGTGGTGCTAGTTGGC 101 L G K K A A G I D E Q E N W H E G K E N 301 CTCGGCAAAAAGGCAGCTGGAATCGACGAACAGGAAAACTGGCATGAAGGCAAAGAAAAC 121 I R A A V A A G C R Q I Q D L E L S S V 361 ATCAGAGCTGCTGTTGCAGCGGGGTGCAGGCAGATTCAAGACCTGGAGCTCTCGTCTGTG 141 E V D P C G D A Q A A A E G A V L G L Y 421 GAGGTGGATCCCTGTGGAGACGCTCAGGCTGCTGCGGAGGGAGCGGTGCTTGGTCTCTAT 161 E Y D D L K Q K K K M A V S A K L Y G S 481 GAATACGATGACCTAAAGCAAAAAAAGAAGATGGCTGTGTCGGCAAAGCTCTATGGAAGT 181 G D Q E A W Q K G V L F A S G Q N L A R 541 GGGGATCAGGAGGCCTGGCAGAAAGGAGTCCTGTTTGCTTCTGGGCAGAACTTGGCACGC 201 Q L M E T P A N E M T P T R F A E I I E 601 CAATTGATGGAGACGCCAGCCAATGAGATGACGCCAACCAGATTTGCCGAAATTATTGAG 221 K N L K S A S S K T E V H I R P K S W I 661 AAGAATCTCAAAAGTGCTAGTAGTAAAACCGAGGTCCATATCAGACCCAAGTCTTGGATT 241 E E Q A M G S F L S V A K G S D E P P V 721 GAGGAACAGGCAATGGGATCATTCCTCAGTGTGGCCAAAGGATCTGACGAGCCCCCAGTC 261 F L E I H Y K G S P N A N E P P L V F V 781 TTCTTGGAAATTCACTACAAAGGCAGCCCCAATGCAAACGAACCACCCCTGGTGTTTGTT 281 G K G I T F D S G G I S I K A S A N M D 841 GGGAAAGGAATTACCTTTGACAGTGGTGGTATCTCCATCAAGGCTTCTGCAAATATGGAC 301 L M R A D M G G A A T I C S A I V S A A	SEQ?ID?NO：114

Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:
Gene	The GenBank homology	The aminoacid sequence of dna sequence dna/deduction	Sequence identifier:			901 CTCATGAGGGCTGACATGGGAGGAGCTGCAACTATATGCTCAGCCATCGTGTCTGCTGCA 321 K L N L P I N I I G L A P L C E N M P S 961 AAGCTTAATTTGCCCATTAATATTATAGGTCTGGCCCCTCTTTGTGAAAATATGCCCAGC 341 G K A N K P G D V V R A K N G K T I Q V 1021?GGCAAGGCCAACAAGCCGGGGGATGTTGTTAGAGCCAAAAACGGGAAGACCATCCAGGTT 361 D N T D A E G R L I L A D A L C Y A H T 1081?GATAACACTGATGCTGAGGGGAGGCTCATACTGGCTGATGCGCTCTGTTACGCACACACG 381 F N P K V I L N A A T L T G A M D V A L 1141?TTTAACCCGAAGGTCATCCTCAATGCCGCCACCTTAACAGGTGCCATGGATGTAGCTTTG 401 G S G A T G V F T N S S W L W N K L F E 1201?GGATCAGGTGCCACTGGGGTCTTTACCAATTCATCCTGGCTCTGGAACAAACTCTTCGAG 421 A S I E T G D R V W R M P L F D H Y T R 1261?GCCAGCATTGAAACAGGGGACCGCGTCTGGAGGATGCCTCTCTTTGACCATTATACTAGA 441 Q V V D C Q L A D V N N I G K Y R S A G 1321?CAGGTTGTCGATTGCCAACTTGCTGATGTTAATAACATCGGAAAGTATAGATCTGCAGGA 461 A C T A A A F L K E F V T H P K W A H L 1381?GCATGTACAGCTGCAGCATTCCTGAAGGAATTTGTGACTCATCCTAAGTGGGCGCATTTA 481 D I A G V M T N K D E I P Y L R K G M T 1441?GACATAGCAGGAGTGATGACTAACAAAGATGAGATTCCGTATCTGCGTAAAGGCATGACC 501 G R P T R T L I E F L L R F S Q D K A - 1501?GGGAGGCCCACGAGGACCCTGATAGAGTTCTTGCTTCGGTTCAGTCAAGACAAAGCTTAG

Table 2

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961054.V1.3_at	CAACGTGTTGAGATCATTGCCACAA	SEQ?ID?NO：115
B1961054.V1.3_at	GAATCCAGAGTCCAAGACCGTCAAG	SEQ?ID?NO：116	B1961054.V1.3_at	CAACGTGTTGAGATCATTGCCACAA	SEQ?ID?NO：115
B1961054.V1.3_at	GAATCCAGAGTCCAAGACCGTCAAG	SEQ?ID?NO：116	B1961054.V1.3_at	GGTCTAAAAGATCTCCTCGAACACT	SEQ?ID?NO：117
B1961054.V1.3_at	GGTACTACTGATACGGATGGCCCAA	SEQ?ID?NO：118	B1961054.V1.3_at	GGTCTAAAAGATCTCCTCGAACACT	SEQ?ID?NO：117
B1961054.V1.3_at	GGTACTACTGATACGGATGGCCCAA	SEQ?ID?NO：118	B1961054.V1.3_at	GCCATCATTTCCCTGCATACAGTAT	SEQ?ID?NO：119
B1961054.V1.3_at	ATATGTCAAGCCCTAATTGTCCCCG	SEQ?ID?NO：120	B1961054.V1.3_at	GCCATCATTTCCCTGCATACAGTAT	SEQ?ID?NO：119
B1961054.V1.3_at	ATATGTCAAGCCCTAATTGTCCCCG	SEQ?ID?NO：120	B1961054.V1.3_at	TAATTGTCCCCGGATTGCAGTTCTC	SEQ?ID?NO：121
B1961054.V1.3_at	GTTCTCCTAAGATGACCAACCAGTC	SEQ?ID?NO：122	B1961054.V1.3_at	TAATTGTCCCCGGATTGCAGTTCTC	SEQ?ID?NO：121
B1961054.V1.3_at	GTTCTCCTAAGATGACCAACCAGTC	SEQ?ID?NO：122	B1961054.V1.3_at	AATTAGCTGCTACTACTCCTGCAGG	SEQ?ID?NO：123
B1961054.V1.3_at	ATGGTTCATCATCCTGAGCTGTTCA	SEQ?ID?NO：124	B1961054.V1.3_at	AATTAGCTGCTACTACTCCTGCAGG	SEQ?ID?NO：123
B1961054.V1.3_at	ATGGTTCATCATCCTGAGCTGTTCA	SEQ?ID?NO：124	B1961054.V1.3_at	TCAGTAGTAACTCTGCCTTGGCACT	SEQ?ID?NO：125
B1961434.V1.3_at	GAAAGATCTTCACTCCATGGACTTC	SEQ?ID?NO：126	B1961054.V1.3_at	TCAGTAGTAACTCTGCCTTGGCACT	SEQ?ID?NO：125
B1961434.V1.3_at	GAAAGATCTTCACTCCATGGACTTC	SEQ?ID?NO：126	B1961434.V1.3_at	TCACTCCATGGACTTCTACTGCCAT	SEQ?ID?NO：127
B1961434.V1.3_at	AAGGAGCCCATATTCTTCCAATGGT	SEQ?ID?NO：128	B1961434.V1.3_at	TCACTCCATGGACTTCTACTGCCAT	SEQ?ID?NO：127
B1961434.V1.3_at	AAGGAGCCCATATTCTTCCAATGGT	SEQ?ID?NO：128	B1961434.V1.3_at	TTCTTCCAATGGTTATATACACAAA	SEQ?ID?NO：129
B1961434.V1.3_at	GAAGTCTTAGATGTACATATTTCTT	SEQ?ID?NO：130	B1961434.V1.3_at	TTCTTCCAATGGTTATATACACAAA	SEQ?ID?NO：129
B1961434.V1.3_at	GAAGTCTTAGATGTACATATTTCTT	SEQ?ID?NO：130	B1961434.V1.3_at	CATATTTCTTACATTGTTTTCAGTG	SEQ?ID?NO：131
B1961434.V1.3_at	GTGTTTATGGAATAACTTACGTGAT	SEQ?ID?NO：132	B1961434.V1.3_at	CATATTTCTTACATTGTTTTCAGTG	SEQ?ID?NO：131
B1961434.V1.3_at	GTGTTTATGGAATAACTTACGTGAT	SEQ?ID?NO：132	B1961434.V1.3_at	GTACTACACATGAATGACCAATAGG	SEQ?ID?NO：133
B1961434.V1.3_at	GAAATCTAGATATATGTTCTGCATG	SEQ?ID?NO：134	B1961434.V1.3_at	GTACTACACATGAATGACCAATAGG	SEQ?ID?NO：133
B1961434.V1.3_at	GAAATCTAGATATATGTTCTGCATG	SEQ?ID?NO：134	B1961434.V1.3_at	ATATGTTCTGCATGATATGTAAGAC	SEQ?ID?NO：135
B1961434.V1.3_at	AAATATGCTGGATGTTTTTCAAAAT	SEQ?ID?NO：136	B1961434.V1.3_at	ATATGTTCTGCATGATATGTAAGAC	SEQ?ID?NO：135
B1961434.V1.3_at	AAATATGCTGGATGTTTTTCAAAAT	SEQ?ID?NO：136	B1961434.V1.3_s_at	GCACTATACTATAAACTATGCTGAG	SEQ?ID?NO：137
B1961434.V1.3_s_at	AACTATGCTGAGGTGCTACATTCTT	SEQ?ID?NO：138	B1961434.V1.3_s_at	GCACTATACTATAAACTATGCTGAG	SEQ?ID?NO：137
B1961434.V1.3_s_at	AACTATGCTGAGGTGCTACATTCTT	SEQ?ID?NO：138	B1961434.V1.3_s_at	GCTGAGGTGCTACATTCTTAGTAAA	SEQ?ID?NO：139
B1961434.V1.3_s_at	GTAAATGTGCCAAGACCTAGTCCTG	SEQ?ID?NO：140	B1961434.V1.3_s_at	GCTGAGGTGCTACATTCTTAGTAAA	SEQ?ID?NO：139
B1961434.V1.3_s_at	GTAAATGTGCCAAGACCTAGTCCTG	SEQ?ID?NO：140	B1961434.V1.3_s_at	AAGACCTAGTCCTGCTACTGACACT	SEQ?ID?NO：141
B1961434.V1.3_s_at	TGCTACTGACACTTTCCTCGCCTTG	SEQ?ID?NO：142	B1961434.V1.3_s_at	AAGACCTAGTCCTGCTACTGACACT	SEQ?ID?NO：141
B1961434.V1.3_s_at	TGCTACTGACACTTTCCTCGCCTTG	SEQ?ID?NO：142	B1961434.V1.3_s_at	CTCGCCTTGCCTATACTCTAAAGGT	SEQ?ID?NO：143
B1961434.V1.3_s_at	TAAAGGTTCTCAACGGATCTTTCCA	SEQ?ID?NO：144	B1961434.V1.3_s_at	CTCGCCTTGCCTATACTCTAAAGGT	SEQ?ID?NO：143
B1961434.V1.3_s_at	TAAAGGTTCTCAACGGATCTTTCCA	SEQ?ID?NO：144	B1961434.V1.3_s_at	GATCTTTCCACCTCTGGGCTTATCA	SEQ?ID?NO：145
B1961434.V1.3_s_at	GGGCTTATCAGAGTTCTCAGATCTC	SEQ?ID?NO：146	B1961434.V1.3_s_at	GATCTTTCCACCTCTGGGCTTATCA	SEQ?ID?NO：145
B1961434.V1.3_s_at	GGGCTTATCAGAGTTCTCAGATCTC	SEQ?ID?NO：146	B1961434.V1.3_s_at	GCAATAATACAATCTGCTTTTTTAA	SEQ?ID?NO：147
B1961438.V1.3_at	GTGGGCAGAGACTTGGCATCATTGT	SEQ?ID?NO：148	B1961434.V1.3_s_at	GCAATAATACAATCTGCTTTTTTAA	SEQ?ID?NO：147
B1961438.V1.3_at	GTGGGCAGAGACTTGGCATCATTGT	SEQ?ID?NO：148	B1961438.V1.3_at	GGCATCATTGTCATCCAGCAAATAA	SEQ?ID?NO：149
B1961438.V1.3_at	TCAGTCTCCCCTAGTCCAGAAAAGG	SEQ?ID?NO：150	B1961438.V1.3_at	GGCATCATTGTCATCCAGCAAATAA	SEQ?ID?NO：149
B1961438.V1.3_at	TCAGTCTCCCCTAGTCCAGAAAAGG	SEQ?ID?NO：150	B1961438.V1.3_at	CAGAAAAGGGCCTCACCTGCCAGGG	SEQ?ID?NO：151
B1961438.V1.3_at	TGCGCATTGCTTTCCAAGGAGCCTT	SEQ?ID?NO：152	B1961438.V1.3_at	CAGAAAAGGGCCTCACCTGCCAGGG	SEQ?ID?NO：151
B1961438.V1.3_at	TGCGCATTGCTTTCCAAGGAGCCTT	SEQ?ID?NO：152	B1961438.V1.3_at	AAGGAGCCTTCTTGAGGTCACTGCA	SEQ?ID?NO：153
B1961438.V1.3_at	GAGGTCACTGCATTTGATCTTCATG	SEQ?ID?NO：154	B1961438.V1.3_at	AAGGAGCCTTCTTGAGGTCACTGCA	SEQ?ID?NO：153
B1961438.V1.3_at	GAGGTCACTGCATTTGATCTTCATG	SEQ?ID?NO：154	B1961438.V1.3_at	TTTGATCTTCATGGCGGCACCTGGA	SEQ?ID?NO：155

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961438.V1.3_at	GACATGAGCGTTTGTGTTTGCTTTA	SEQ?ID?NO：156
B1961438.V1.3_at	ATCCAGGGTGGAGTCTATGCAGAAA	SEQ?ID?NO：157	B1961438.V1.3_at	GACATGAGCGTTTGTGTTTGCTTTA	SEQ?ID?NO：156
B1961438.V1.3_at	ATCCAGGGTGGAGTCTATGCAGAAA	SEQ?ID?NO：157	B1961438.V1.3_at	GAAATGACCCATAATCCAGCAACGC	SEQ?ID?NO：158
B1961469.V1.3_at	GGGCTAGAAGATCATCCTTGGTTGA	SEQ?ID?NO：159	B1961438.V1.3_at	GAAATGACCCATAATCCAGCAACGC	SEQ?ID?NO：158
B1961469.V1.3_at	GGGCTAGAAGATCATCCTTGGTTGA	SEQ?ID?NO：159	B1961469.V1.3_at	AATTCAACATGCTCACTATCAGTAG	SEQ?ID?NO：160
B1961469.V1.3_at	TGAACTGAGCTTTGTCTCTGCAGCA	SEQ?ID?NO：161	B1961469.V1.3_at	AATTCAACATGCTCACTATCAGTAG	SEQ?ID?NO：160
B1961469.V1.3_at	TGAACTGAGCTTTGTCTCTGCAGCA	SEQ?ID?NO：161	B1961469.V1.3_at	AATGGCAGTCATCCATTGGCTGCAC	SEQ?ID?NO：162
B1961469.V1.3_at	TCCTCACCCTTCTTTATGTGCTTAG	SEQ?ID?NO：163	B1961469.V1.3_at	AATGGCAGTCATCCATTGGCTGCAC	SEQ?ID?NO：162
B1961469.V1.3_at	TCCTCACCCTTCTTTATGTGCTTAG	SEQ?ID?NO：163	B1961469.V1.3_at	ATGTGCTTAGATACGTGCTCCAGAC	SEQ?ID?NO：164
B1961469.V1.3_at	AAGTCCCATTCATGAGCTTCCTGTT	SEQ?ID?NO：165	B1961469.V1.3_at	ATGTGCTTAGATACGTGCTCCAGAC	SEQ?ID?NO：164
B1961469.V1.3_at	AAGTCCCATTCATGAGCTTCCTGTT	SEQ?ID?NO：165	B1961469.V1.3_at	GCTTCCTGTTAGATGTGAACCTCCA	SEQ?ID?NO：166
B1961469.V1.3_at	GTGAACCTCCAGCAGAGGCAACGCT	SEQ?ID?NO：167	B1961469.V1.3_at	GCTTCCTGTTAGATGTGAACCTCCA	SEQ?ID?NO：166
B1961469.V1.3_at	GTGAACCTCCAGCAGAGGCAACGCT	SEQ?ID?NO：167	B1961469.V1.3_at	TGCCCCTTGGCTGGATTCATTCAAA	SEQ?ID?NO：168
B1961469.V1.3_at	GCAATGGTCCTCAATTCTGTTTATT	SEQ?ID?NO：169	B1961469.V1.3_at	TGCCCCTTGGCTGGATTCATTCAAA	SEQ?ID?NO：168
B1961469.V1.3_at	GCAATGGTCCTCAATTCTGTTTATT	SEQ?ID?NO：169	B1961481.V1.3_at	ACTGACAGTTGAAACGATCAATGGA	SEQ?ID?NO：170
B1961481.V1.3_at	TCAATGGAATGATCAGCACAAACAG	SEQ?ID?NO：171	B1961481.V1.3_at	ACTGACAGTTGAAACGATCAATGGA	SEQ?ID?NO：170
B1961481.V1.3_at	TCAATGGAATGATCAGCACAAACAG	SEQ?ID?NO：171	B1961481.V1.3_at	TGTGATATCCTCTATATCTAAGATA	SEQ?ID?NO：172
B1961481.V1.3_at	ATAACATGTACTCTCTCTATATATA	SEQ?ID?NO：173	B1961481.V1.3_at	TGTGATATCCTCTATATCTAAGATA	SEQ?ID?NO：172
B1961481.V1.3_at	ATAACATGTACTCTCTCTATATATA	SEQ?ID?NO：173	B1961481.V1.3_at	GCTGTTACTGGAAAGATGACCGCAA	SEQ?ID?NO：174
B1961481.V1.3_at	GATGACCGCAAGAAGTTGATTTTTT	SEQ?ID?NO：175	B1961481.V1.3_at	GCTGTTACTGGAAAGATGACCGCAA	SEQ?ID?NO：174
B1961481.V1.3_at	GATGACCGCAAGAAGTTGATTTTTT	SEQ?ID?NO：175	B1961481.V1.3_at	GAAGTTGATTTTTTATCTACCAGAA	SEQ?ID?NO：176
B1961481.V1.3_at	ATCTACCAGAAGTTTTCTTCGCTGT	SEQ?ID?NO：177	B1961481.V1.3_at	GAAGTTGATTTTTTATCTACCAGAA	SEQ?ID?NO：176
B1961481.V1.3_at	ATCTACCAGAAGTTTTCTTCGCTGT	SEQ?ID?NO：177	B1961481.V1.3_at	TTTCTTCGCTGTGTTTTAAGTCGGC	SEQ?ID?NO：178
B1961481.V1.3_at	TTTAAGTCGGCGATCTGCTTTGATC	SEQ?ID?NO：179	B1961481.V1.3_at	TTTCTTCGCTGTGTTTTAAGTCGGC	SEQ?ID?NO：178
B1961481.V1.3_at	TTTAAGTCGGCGATCTGCTTTGATC	SEQ?ID?NO：179	B1961481.V1.3_at	TGCTTTGATCGTTTTGTTCGCTTCT	SEQ?ID?NO：180
B1961499.V1.3_at	GTCTAGTCTTGAAGTCCCTCATTTA	SEQ?ID?NO：181	B1961481.V1.3_at	TGCTTTGATCGTTTTGTTCGCTTCT	SEQ?ID?NO：180
B1961499.V1.3_at	GTCTAGTCTTGAAGTCCCTCATTTA	SEQ?ID?NO：181	B1961499.V1.3_at	TAATGTGATGTTTCGGCCAAGCCCA	SEQ?ID?NO：182
B1961499.V1.3_at	GAGTTCCCTGCCCTGAGAGAATGTC	SEQ?ID?NO：183	B1961499.V1.3_at	TAATGTGATGTTTCGGCCAAGCCCA	SEQ?ID?NO：182
B1961499.V1.3_at	GAGTTCCCTGCCCTGAGAGAATGTC	SEQ?ID?NO：183	B1961499.V1.3_at	GAGAGAATGTCACCACCTGAGCAGC	SEQ?ID?NO：184
B1961499.V1.3_at	AAGAGTGATGCCCTGGTGTCTCCAG	SEQ?ID?NO：185	B1961499.V1.3_at	GAGAGAATGTCACCACCTGAGCAGC	SEQ?ID?NO：184
B1961499.V1.3_at	AAGAGTGATGCCCTGGTGTCTCCAG	SEQ?ID?NO：185	B1961499.V1.3_at	GGTGATAGGACATCTGGCTTGCCAG	SEQ?ID?NO：186
B1961499.V1.3_at	GGCTTGCCAGCGAGGTCTTTTTGAC	SEQ?ID?NO：187	B1961499.V1.3_at	GGTGATAGGACATCTGGCTTGCCAG	SEQ?ID?NO：186
B1961499.V1.3_at	GGCTTGCCAGCGAGGTCTTTTTGAC	SEQ?ID?NO：187	B1961499.V1.3_at	AGGCCACCCTTCTAGCAGAGTTAAA	SEQ?ID?NO：188
B1961499.V1.3_at	TATGTGTCAGTCACGTAGCCAGCTG	SEQ?ID?NO：189	B1961499.V1.3_at	AGGCCACCCTTCTAGCAGAGTTAAA	SEQ?ID?NO：188
B1961499.V1.3_at	TATGTGTCAGTCACGTAGCCAGCTG	SEQ?ID?NO：189	B1961499.V1.3_at	AGAACTTGCGGCTTGACTAGCAGCA	SEQ?ID?NO：190
B1961499.V1.3_at	CAGCTGCCCAATGCCATGTGAAGTA	SEQ?ID?NO：191	B1961499.V1.3_at	AGAACTTGCGGCTTGACTAGCAGCA	SEQ?ID?NO：190
B1961499.V1.3_at	CAGCTGCCCAATGCCATGTGAAGTA	SEQ?ID?NO：191	B1961550.V1.3_at	AGCTCGTGCCGTTCTGTGAGACTTG	SEQ?ID?NO：192
B1961550.V1.3_at	GAGACTTGTCTTTCCCACGAAATAG	SEQ?ID?NO：193	B1961550.V1.3_at	AGCTCGTGCCGTTCTGTGAGACTTG	SEQ?ID?NO：192
B1961550.V1.3_at	GAGACTTGTCTTTCCCACGAAATAG	SEQ?ID?NO：193	B1961550.V1.3_at	AGACAACTCTTCCACGGCACAGATG	SEQ?ID?NO：194
B1961550.V1.3_at	AGACACAGTGCCGTACATCAATCAG	SEQ?ID?NO：195	B1961550.V1.3_at	AGACAACTCTTCCACGGCACAGATG	SEQ?ID?NO：194
B1961550.V1.3_at	AGACACAGTGCCGTACATCAATCAG	SEQ?ID?NO：195	B1961550.V1.3_at	TCAGCACGGCTTTAATCGCAGTTAT	SEQ?ID?NO：196
B1961550.V1.3_at	GAACGTATTTCGCTGTTGATGCCAG	SEQ?ID?NO：197	B1961550.V1.3_at	TCAGCACGGCTTTAATCGCAGTTAT	SEQ?ID?NO：196
B1961550.V1.3_at	GAACGTATTTCGCTGTTGATGCCAG	SEQ?ID?NO：197	B1961550.V1.3_at	GATGCCAGTTATTCTGCTAACGATG	SEQ?ID?NO：198
B1961550.V1.3_at	GTGCGAGTACTTACAGGAGTCTACA	SEQ?ID?NO：199	B1961550.V1.3_at	GATGCCAGTTATTCTGCTAACGATG	SEQ?ID?NO：198
B1961550.V1.3_at	GTGCGAGTACTTACAGGAGTCTACA	SEQ?ID?NO：199	B1961550.V1.3_at	GAGTCTACACAGTTGGACACGCAGC	SEQ?ID?NO：200

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961550.V1.3_at	TACGGATCTGTTTGACTCTGTCACA	SEQ?ID?NO：201
B1961550.V1.3_at	GATACACGGCATCCAAAGCTATTTG	SEQ?ID?NO：202	B1961550.V1.3_at	TACGGATCTGTTTGACTCTGTCACA	SEQ?ID?NO：201
B1961550.V1.3_at	GATACACGGCATCCAAAGCTATTTG	SEQ?ID?NO：202	B1961567.V1.3_at	GGACCGCGTCTGGAGGATGCCTCTC	SEQ?ID?NO：203
B1961567.V1.3_at	TGCCTCTCTTTGACCATTATACTAG	SEQ?ID?NO：204	B1961567.V1.3_at	GGACCGCGTCTGGAGGATGCCTCTC	SEQ?ID?NO：203
B1961567.V1.3_at	TGCCTCTCTTTGACCATTATACTAG	SEQ?ID?NO：204	B1961567.V1.3_at	TTGTCGATTGCCAACTTGCTGATGT	SEQ?ID?NO：205
B1961567.V1.3_at	GAGCATGTACAGCTGCAGCATTCCT	SEQ?ID?NO：206	B1961567.V1.3_at	TTGTCGATTGCCAACTTGCTGATGT	SEQ?ID?NO：205
B1961567.V1.3_at	GAGCATGTACAGCTGCAGCATTCCT	SEQ?ID?NO：206	B1961567.V1.3_at	TGTGACTCATCCTAAGTGGGCGCAT	SEQ?ID?NO：207
B1961567.V1.3_at	TGGGCGCATTTAGACATAGCAGGAG	SEQ?ID?NO：208	B1961567.V1.3_at	TGTGACTCATCCTAAGTGGGCGCAT	SEQ?ID?NO：207
B1961567.V1.3_at	TGGGCGCATTTAGACATAGCAGGAG	SEQ?ID?NO：208	B1961567.V1.3_at	GAGATTCCGTATCTGCGTAAAGGCA	SEQ?ID?NO：209
B1961567.V1.3_at	ACGAGGACCCTGATAGAGTTCTTGC	SEQ?ID?NO：210	B1961567.V1.3_at	GAGATTCCGTATCTGCGTAAAGGCA	SEQ?ID?NO：209
B1961567.V1.3_at	ACGAGGACCCTGATAGAGTTCTTGC	SEQ?ID?NO：210	B1961567.V1.3_at	AGAGTTCTTGCTTCGGTTCAGTCAA	SEQ?ID?NO：211
B1961567.V1.3_at	AAATGCCTTCATTCTGTCTTAAGTG	SEQ?ID?NO：212	B1961567.V1.3_at	AGAGTTCTTGCTTCGGTTCAGTCAA	SEQ?ID?NO：211
B1961567.V1.3_at	AAATGCCTTCATTCTGTCTTAAGTG	SEQ?ID?NO：212	B1961567.V1.3_at	AAAACTAATGGCTTGCTTGGCAAAG	SEQ?ID?NO：213
B1961581.V1.3_at	TACTGTCACCTATCAAGCGTCTTAA	SEQ?ID?NO：214	B1961567.V1.3_at	AAAACTAATGGCTTGCTTGGCAAAG	SEQ?ID?NO：213
B1961581.V1.3_at	TACTGTCACCTATCAAGCGTCTTAA	SEQ?ID?NO：214	B1961581.V1.3_at	ACGGGCATCTGCTTTTGAGTGACTT	SEQ?ID?NO：215
B1961581.V1.3_at	GTTGCATTCTCATCTGCTAAATTGG	SEQ?ID?NO：216	B1961581.V1.3_at	ACGGGCATCTGCTTTTGAGTGACTT	SEQ?ID?NO：215
B1961581.V1.3_at	GTTGCATTCTCATCTGCTAAATTGG	SEQ?ID?NO：216	B1961581.V1.3_at	GCTGAAAGAGATGAGTGCCCACCCT	SEQ?ID?NO：217
B1961581.V1.3_at	TGGACTCGCTTCAGCAGTGACGGGC	SEQ?ID?NO：218	B1961581.V1.3_at	GCTGAAAGAGATGAGTGCCCACCCT	SEQ?ID?NO：217
B1961581.V1.3_at	TGGACTCGCTTCAGCAGTGACGGGC	SEQ?ID?NO：218	B1961581.V1.3_at	TTGGAGGTCGCGTGCTTCAGTCTCG	SEQ?ID?NO：219
B1961581.V1.3_at	GTCTCGCGCTGATAGATGGTGTCCA	SEQ?ID?NO：220	B1961581.V1.3_at	TTGGAGGTCGCGTGCTTCAGTCTCG	SEQ?ID?NO：219
B1961581.V1.3_at	GTCTCGCGCTGATAGATGGTGTCCA	SEQ?ID?NO：220	B1961581.V1.3_at	TCCCGCCAGCTGAGAGTGAGCCAAA	SEQ?ID?NO：221
B1961581.V1.3_at	AAACTCCCAGCTTTCGGTCCAGAAG	SEQ?ID?NO：222	B1961581.V1.3_at	TCCCGCCAGCTGAGAGTGAGCCAAA	SEQ?ID?NO：221
B1961581.V1.3_at	AAACTCCCAGCTTTCGGTCCAGAAG	SEQ?ID?NO：222	B1961581.V1.3_at	GAATTCAGATCACTCACTCGGGAAA	SEQ?ID?NO：223
B1961581.V1.3_at	GTGTCAAGCAAGTCCTCAAACGGCA	SEQ?ID?NO：224	B1961581.V1.3_at	GAATTCAGATCACTCACTCGGGAAA	SEQ?ID?NO：223
B1961581.V1.3_at	GTGTCAAGCAAGTCCTCAAACGGCA	SEQ?ID?NO：224	B1961659.V1.3_at	CTACCCAGGGACTTTCTGACAGTAT	SEQ?ID?NO：225
B1961659.V1.3_at	TGAGTTTCTAAGTCAGCTTCCAGCT	SEQ?ID?NO：226	B1961659.V1.3_at	CTACCCAGGGACTTTCTGACAGTAT	SEQ?ID?NO：225
B1961659.V1.3_at	TGAGTTTCTAAGTCAGCTTCCAGCT	SEQ?ID?NO：226	B1961659.V1.3_at	TTCCAGCTGTGTTTCATCTCCTTCA	SEQ?ID?NO：227
B1961659.V1.3_at	ATCTCCTTCACCTGCATTTTATTTG	SEQ?ID?NO：228	B1961659.V1.3_at	TTCCAGCTGTGTTTCATCTCCTTCA	SEQ?ID?NO：227
B1961659.V1.3_at	ATCTCCTTCACCTGCATTTTATTTG	SEQ?ID?NO：228	B1961659.V1.3_at	AAGCATGGTTTGTTCACTCCTTCAA	SEQ?ID?NO：229
B1961659.V1.3_at	TTTCCTCCACTAAGCAGATGATCCT	SEQ?ID?NO：230	B1961659.V1.3_at	AAGCATGGTTTGTTCACTCCTTCAA	SEQ?ID?NO：229
B1961659.V1.3_at	TTTCCTCCACTAAGCAGATGATCCT	SEQ?ID?NO：230	B1961659.V1.3_at	TGGATTCCCGCTGGAGCAGTGCTAC	SEQ?ID?NO：231
B1961659.V1.3_at	CCTCTGTTCCGGTGATTGGTTTGTT	SEQ?ID?NO：232	B1961659.V1.3_at	TGGATTCCCGCTGGAGCAGTGCTAC	SEQ?ID?NO：231
B1961659.V1.3_at	CCTCTGTTCCGGTGATTGGTTTGTT	SEQ?ID?NO：232	B1961659.V1.3_at	GATTGGTTTGTTCCTTTCTTGTATC	SEQ?ID?NO：233
B1961659.V1.3_at	ACAACTACACGATCCCAGAGACATA	SEQ?ID?NO：234	B1961659.V1.3_at	GATTGGTTTGTTCCTTTCTTGTATC	SEQ?ID?NO：233
B1961659.V1.3_at	ACAACTACACGATCCCAGAGACATA	SEQ?ID?NO：234	B1961659.V1.3_at	GTTAATTCCAGCTGACGAGAGACCA	SEQ?ID?NO：235
B1961690.V1.3_at	AGCATCAAGGCCTATGTCAGCACTT	SEQ?ID?NO：236	B1961659.V1.3_at	GTTAATTCCAGCTGACGAGAGACCA	SEQ?ID?NO：235
B1961690.V1.3_at	AGCATCAAGGCCTATGTCAGCACTT	SEQ?ID?NO：236	B1961690.V1.3_at	GTGATGTTCACACCTCTGACAGTGA	SEQ?ID?NO：237
B1961690.V1.3_at	AACGCATCGGAGTTGACCTGATCAT	SEQ?ID?NO：238	B1961690.V1.3_at	GTGATGTTCACACCTCTGACAGTGA	SEQ?ID?NO：237
B1961690.V1.3_at	AACGCATCGGAGTTGACCTGATCAT	SEQ?ID?NO：238	B1961690.V1.3_at	TCATGAAGACCTGTTTTAGCCCCAA	SEQ?ID?NO：239
B1961690.V1.3_at	GGGTGATCGGACTCTCAAGTGACTT	SEQ?ID?NO：240	B1961690.V1.3_at	TCATGAAGACCTGTTTTAGCCCCAA	SEQ?ID?NO：239
B1961690.V1.3_at	GGGTGATCGGACTCTCAAGTGACTT	SEQ?ID?NO：240	B1961690.V1.3_at	CTGACAATACAGTGGGCCGCTTCTT	SEQ?ID?NO：241
B1961690.V1.3_at	GCCGCTTCTTGATGAGTCTGGTTAA	SEQ?ID?NO：242	B1961690.V1.3_at	CTGACAATACAGTGGGCCGCTTCTT	SEQ?ID?NO：241
B1961690.V1.3_at	GCCGCTTCTTGATGAGTCTGGTTAA	SEQ?ID?NO：242	B1961690.V1.3_at	GTTCCTGATGACTTCGAGACCATGC	SEQ?ID?NO：243
B1961690.V1.3_at	TGATGGTGACCTACTTGGCCAATCT	SEQ?ID?NO：244	B1961690.V1.3_at	GTTCCTGATGACTTCGAGACCATGC	SEQ?ID?NO：243
B1961690.V1.3_at	TGATGGTGACCTACTTGGCCAATCT	SEQ?ID?NO：244	B1961690.V1.3_at	TGGCCAATCTCACACAATCACAAAT	SEQ?ID?NO：245

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961690.V1.3_at	GTAAACCTGTGAATGGGCCCCAATC	SEQ?ID?NO：246
B1961693.V1.3_at	TACTTTTCACATGGGCCCCTCTATG	SEQ?ID?NO：247	B1961690.V1.3_at	GTAAACCTGTGAATGGGCCCCAATC	SEQ?ID?NO：246
B1961693.V1.3_at	TACTTTTCACATGGGCCCCTCTATG	SEQ?ID?NO：247	B1961693.V1.3_at	CCTCTATGTGACCTGCTTAGGGTAA	SEQ?ID?NO：248
B1961693.V1.3_at	GACCTGCTTAGGGTAAGTATCACCA	SEQ?ID?NO：249	B1961693.V1.3_at	CCTCTATGTGACCTGCTTAGGGTAA	SEQ?ID?NO：248
B1961693.V1.3_at	GACCTGCTTAGGGTAAGTATCACCA	SEQ?ID?NO：249	B1961693.V1.3_at	GTATCACCAGGGATTTATGTATTTA	SEQ?ID?NO：250
B1961693.V1.3_at	AATAGTTTTCTTGAGCAGCTGCTGG	SEQ?ID?NO：251	B1961693.V1.3_at	GTATCACCAGGGATTTATGTATTTA	SEQ?ID?NO：250
B1961693.V1.3_at	AATAGTTTTCTTGAGCAGCTGCTGG	SEQ?ID?NO：251	B1961693.V1.3_at	TCTTGAGCAGCTGCTGGGATCTGCT	SEQ?ID?NO：252
B1961693.V1.3_at	GAAGCTTTGCTAATAATCCATTTAT	SEQ?ID?NO：253	B1961693.V1.3_at	TCTTGAGCAGCTGCTGGGATCTGCT	SEQ?ID?NO：252
B1961693.V1.3_at	GAAGCTTTGCTAATAATCCATTTAT	SEQ?ID?NO：253	B1961693.V1.3_at	AATCCATTTATATGGGCTGAATTAT	SEQ?ID?NO：254
B1961693.V1.3_at	GCTATAAATTGATCAAGGCCACTTT	SEQ?ID?NO：255	B1961693.V1.3_at	AATCCATTTATATGGGCTGAATTAT	SEQ?ID?NO：254
B1961693.V1.3_at	GCTATAAATTGATCAAGGCCACTTT	SEQ?ID?NO：255	B1961693.V1.3_at	AAGGCCACTTTATTATGGAATCCCA	SEQ?ID?NO：256
B1961693.V1.3_at	ATTATGGAATCCCATCTGCTACCCT	SEQ?ID?NO：257	B1961693.V1.3_at	AAGGCCACTTTATTATGGAATCCCA	SEQ?ID?NO：256
B1961693.V1.3_at	ATTATGGAATCCCATCTGCTACCCT	SEQ?ID?NO：257	B1961697.V1.3_at	AAACTTATGTCCTCAGTTCCATCTG	SEQ?ID?NO：258
B1961697.V1.3_at	AACCCAATGGCACCTTCAGCAGTAA	SEQ?ID?NO：259	B1961697.V1.3_at	AAACTTATGTCCTCAGTTCCATCTG	SEQ?ID?NO：258
B1961697.V1.3_at	AACCCAATGGCACCTTCAGCAGTAA	SEQ?ID?NO：259	B1961697.V1.3_at	GAATTTTACCCCATCATATACCTGA	SEQ?ID?NO：260
B1961697.V1.3_at	ATATGTTTTCCTGCAGCCTTATAAG	SEQ?ID?NO：261	B1961697.V1.3_at	GAATTTTACCCCATCATATACCTGA	SEQ?ID?NO：260
B1961697.V1.3_at	ATATGTTTTCCTGCAGCCTTATAAG	SEQ?ID?NO：261	B1961697.V1.3_at	GTTTTCATGCTAAACCTGGCCATTT	SEQ?ID?NO：262
B1961697.V1.3_at	GGCCATTTCAGATCTCTTGTTCACA	SEQ?ID?NO：263	B1961697.V1.3_at	GTTTTCATGCTAAACCTGGCCATTT	SEQ?ID?NO：262
B1961697.V1.3_at	GGCCATTTCAGATCTCTTGTTCACA	SEQ?ID?NO：263	B1961697.V1.3_at	GTCTTATTCCCTATATGTCAACATG	SEQ?ID?NO：264
B1961697.V1.3_at	CATCTATTTCCTGACTGTGCTGAGT	SEQ?ID?NO：265	B1961697.V1.3_at	GTCTTATTCCCTATATGTCAACATG	SEQ?ID?NO：264
B1961697.V1.3_at	CATCTATTTCCTGACTGTGCTGAGT	SEQ?ID?NO：265	B1961697.V1.3_at	TTGTGCGTTTCCTGGCAACTGTTCA	SEQ?ID?NO：266
B1961697.V1.3_at	AAGTGCCTGGATTCTATGTGGGATC	SEQ?ID?NO：267	B1961697.V1.3_at	TTGTGCGTTTCCTGGCAACTGTTCA	SEQ?ID?NO：266
B1961697.V1.3_at	AAGTGCCTGGATTCTATGTGGGATC	SEQ?ID?NO：267	B1961697.V1.3_at	GGATCTTTATTATGGCTTCGTCAGC	SEQ?ID?NO：268
B1961698.V1.3_at	TTCAAATTTAGCTGGAAATCCTGTA	SEQ?ID?NO：269	B1961697.V1.3_at	GGATCTTTATTATGGCTTCGTCAGC	SEQ?ID?NO：268
B1961698.V1.3_at	TTCAAATTTAGCTGGAAATCCTGTA	SEQ?ID?NO：269	B1961698.V1.3_at	AAATCCTGTATTTTGCTGTTGTTGC	SEQ?ID?NO：270
B1961698.V1.3_at	TTTTGCTGTTGTTGCTAAATCTTGC	SEQ?ID?NO：271	B1961698.V1.3_at	AAATCCTGTATTTTGCTGTTGTTGC	SEQ?ID?NO：270
B1961698.V1.3_at	TTTTGCTGTTGTTGCTAAATCTTGC	SEQ?ID?NO：271	B1961698.V1.3_at	TAAATCTTGCAACCCTAGTCTGCTG	SEQ?ID?NO：272
B1961698.V1.3_at	TAGTCTGCTGCCCAGGATCCATGAG	SEQ?ID?NO：273	B1961698.V1.3_at	TAAATCTTGCAACCCTAGTCTGCTG	SEQ?ID?NO：272
B1961698.V1.3_at	TAGTCTGCTGCCCAGGATCCATGAG	SEQ?ID?NO：273	B1961698.V1.3_at	ATCCATGAGTCCCTGTTCAACTAAG	SEQ?ID?NO：274
B1961698.V1.3_at	GTTCAACTAAGCCTTGGTTTCTTCT	SEQ?ID?NO：275	B1961698.V1.3_at	ATCCATGAGTCCCTGTTCAACTAAG	SEQ?ID?NO：274
B1961698.V1.3_at	GTTCAACTAAGCCTTGGTTTCTTCT	SEQ?ID?NO：275	B1961698.V1.3_at	TGGTTTCTTCTTTAATCCTAAACTG	SEQ?ID?NO：276
B1961698.V1.3_at	GGAGAAAAGCATCAGCCACTATCCT	SEQ?ID?NO：277	B1961698.V1.3_at	TGGTTTCTTCTTTAATCCTAAACTG	SEQ?ID?NO：276
B1961698.V1.3_at	GGAGAAAAGCATCAGCCACTATCCT	SEQ?ID?NO：277	B1961698.V1.3_at	ACTATCCTCCCTCACAGAGAGCTGA	SEQ?ID?NO：278
B1961698.V1.3_at	GGACTGGTGGAAGCACATTAACTTA	SEQ?ID?NO：279	B1961698.V1.3_at	ACTATCCTCCCTCACAGAGAGCTGA	SEQ?ID?NO：278
B1961698.V1.3_at	GGACTGGTGGAAGCACATTAACTTA	SEQ?ID?NO：279	B1961707.V1.3_at	TGTTCTTATCAGTCATGGGCCATCC	SEQ?ID?NO：280
B1961707.V1.3_at	TGGGCCATCCGCAGGGTAGCAAGAT	SEQ?ID?NO：281	B1961707.V1.3_at	TGTTCTTATCAGTCATGGGCCATCC	SEQ?ID?NO：280
B1961707.V1.3_at	TGGGCCATCCGCAGGGTAGCAAGAT	SEQ?ID?NO：281	B1961707.V1.3_at	AGTCATTCTACTTTTAGCACGTGTC	SEQ?ID?NO：282
B1961707.V1.3_at	AGCACGTGTCCATGGGCTACAATTG	SEQ?ID?NO：283	B1961707.V1.3_at	AGTCATTCTACTTTTAGCACGTGTC	SEQ?ID?NO：282
B1961707.V1.3_at	AGCACGTGTCCATGGGCTACAATTG	SEQ?ID?NO：283	B1961707.V1.3_at	ATTGGTTGGCTTGACCAAGGTCTGC	SEQ?ID?NO：284
B1961707.V1.3_at	CAAGGTCTGCATGTGGAATGTCCGT	SEQ?ID?NO：285	B1961707.V1.3_at	ATTGGTTGGCTTGACCAAGGTCTGC	SEQ?ID?NO：284
B1961707.V1.3_at	CAAGGTCTGCATGTGGAATGTCCGT	SEQ?ID?NO：285	B1961707.V1.3_at	GGAATGTCCGTGATCTCTTAACTAC	SEQ?ID?NO：286
B1961707.V1.3_at	TAGACAGGGCCAAGACTAGCACAAG	SEQ?ID?NO：287	B1961707.V1.3_at	GGAATGTCCGTGATCTCTTAACTAC	SEQ?ID?NO：286
B1961707.V1.3_at	TAGACAGGGCCAAGACTAGCACAAG	SEQ?ID?NO：287	B1961707.V1.3_at	GGATGCCCTCATTTTGAAGTCGTGC	SEQ?ID?NO：288
B1961707.V1.3_at	GAGTGTCTTCTTAAATTCTTTGCCT	SEQ?ID?NO：289	B1961707.V1.3_at	GGATGCCCTCATTTTGAAGTCGTGC	SEQ?ID?NO：288
B1961707.V1.3_at	GAGTGTCTTCTTAAATTCTTTGCCT	SEQ?ID?NO：289	B1961707.V1.3_at	TAAATTCTTTGCCTCACTCTAGTGC	SEQ?ID?NO：290

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961708.V1.3_at	CGAGCCTTCTTTGGGTCCCAGAATA	SEQ?ID?NO：291
B1961708.V1.3_at	AATAACTTCTGTGCCTTCAATCTGA	SEQ?ID?NO：292	B1961708.V1.3_at	CGAGCCTTCTTTGGGTCCCAGAATA	SEQ?ID?NO：291
B1961708.V1.3_at	AATAACTTCTGTGCCTTCAATCTGA	SEQ?ID?NO：292	B1961708.V1.3_at	AACACTACCTCAGCTGGTCAATGCT	SEQ?ID?NO：293
B1961708.V1.3_at	GTCAATGCTCCTGGGTGTGGGCACC	SEQ?ID?NO：294	B1961708.V1.3_at	AACACTACCTCAGCTGGTCAATGCT	SEQ?ID?NO：293
B1961708.V1.3_at	GTCAATGCTCCTGGGTGTGGGCACC	SEQ?ID?NO：294	B1961708.V1.3_at	ACTAGTCCTAGGCATCATGGCGGTG	SEQ?ID?NO：295
B1961708.V1.3_at	ATGCTGCTGGCAGGAGGCCTGTTTA	SEQ?ID?NO：296	B1961708.V1.3_at	ACTAGTCCTAGGCATCATGGCGGTG	SEQ?ID?NO：295
B1961708.V1.3_at	ATGCTGCTGGCAGGAGGCCTGTTTA	SEQ?ID?NO：296	B1961708.V1.3_at	GCCTGTTTATGCTGCTGGGCCACAA	SEQ?ID?NO：297
B1961708.V1.3_at	GGGCCACAAGCGGTACTCAGAATAC	SEQ?ID?NO：298	B1961708.V1.3_at	GCCTGTTTATGCTGCTGGGCCACAA	SEQ?ID?NO：297
B1961708.V1.3_at	GGGCCACAAGCGGTACTCAGAATAC	SEQ?ID?NO：298	B1961708.V1.3_at	AATTGAGACCCACTCTCTAGAGGGA	SEQ?ID?NO：299
B1961708.V1.3_at	GAAGGACATTACTGGACCTGCCTTG	SEQ?ID?NO：300	B1961708.V1.3_at	AATTGAGACCCACTCTCTAGAGGGA	SEQ?ID?NO：299
B1961708.V1.3_at	GAAGGACATTACTGGACCTGCCTTG	SEQ?ID?NO：300	B1961708.V1.3_at	GCTCCCTTCTTGCTTTTATGCAGAA	SEQ?ID?NO：301
B1961711.V1.3_at	CCGTTCGCGTGCACCCAGGGAGGAC	SEQ?ID?NO：302	B1961708.V1.3_at	GCTCCCTTCTTGCTTTTATGCAGAA	SEQ?ID?NO：301
B1961711.V1.3_at	CCGTTCGCGTGCACCCAGGGAGGAC	SEQ?ID?NO：302	B1961711.V1.3_at	TGCACCCAGGGAGGACTCGGAGTCC	SEQ?ID?NO：303
B1961711.V1.3_at	CATTTTCTTCTGGTCGCCGTGGTCA	SEQ?ID?NO：304	B1961711.V1.3_at	TGCACCCAGGGAGGACTCGGAGTCC	SEQ?ID?NO：303
B1961711.V1.3_at	CATTTTCTTCTGGTCGCCGTGGTCA	SEQ?ID?NO：304	B1961711.V1.3_at	GTCGCCGTGGTCACCCACAGGAAGG	SEQ?ID?NO：305
B1961711.V1.3_at	CAGCCTGGGTTTTCTCGGGCGGCTC	SEQ?ID?NO：306	B1961711.V1.3_at	GTCGCCGTGGTCACCCACAGGAAGG	SEQ?ID?NO：305
B1961711.V1.3_at	CAGCCTGGGTTTTCTCGGGCGGCTC	SEQ?ID?NO：306	B1961711.V1.3_at	CAGGTCTCAGCCTGTGAGGACTGCG	SEQ?ID?NO：307
B1961711.V1.3_at	GACTGCGGCGAGTCTGGAGACCCCA	SEQ?ID?NO：308	B1961711.V1.3_at	CAGGTCTCAGCCTGTGAGGACTGCG	SEQ?ID?NO：307
B1961711.V1.3_at	GACTGCGGCGAGTCTGGAGACCCCA	SEQ?ID?NO：308	B1961711.V1.3_at	TCTTCGGGACTGTGTGGACCCACGA	SEQ?ID?NO：309
B1961711.V1.3_at	GTGTGGACCCACGAGGGCCATCTGC	SEQ?ID?NO：310	B1961711.V1.3_at	TCTTCGGGACTGTGTGGACCCACGA	SEQ?ID?NO：309
B1961711.V1.3_at	GTGTGGACCCACGAGGGCCATCTGC	SEQ?ID?NO：310	B1961711.V1.3_at	GAGGGCCATCTGCTGACAGAGCAAC	SEQ?ID?NO：311
B1961711.V1.3_at	GTGGGCTCTGTCTGGTTCACAGAGC	SEQ?ID?NO：312	B1961711.V1.3_at	GAGGGCCATCTGCTGACAGAGCAAC	SEQ?ID?NO：311
B1961711.V1.3_at	GTGGGCTCTGTCTGGTTCACAGAGC	SEQ?ID?NO：312	B1961718.V1.3_at	AGGAGGTGCCTCACGACTGTCCTGG	SEQ?ID?NO：313
B1961718.V1.3_at	GAGGGACCTCATGCCAAGGGTGCCC	SEQ?ID?NO：314	B1961718.V1.3_at	AGGAGGTGCCTCACGACTGTCCTGG	SEQ?ID?NO：313
B1961718.V1.3_at	GAGGGACCTCATGCCAAGGGTGCCC	SEQ?ID?NO：314	B1961718.V1.3_at	GCCTGACCCGGCCATAGAGGAAATC	SEQ?ID?NO：315
B1961718.V1.3_at	CAAGATCTTGGTGTTGTCTGGGAAA	SEQ?ID?NO：316	B1961718.V1.3_at	GCCTGACCCGGCCATAGAGGAAATC	SEQ?ID?NO：315
B1961718.V1.3_at	CAAGATCTTGGTGTTGTCTGGGAAA	SEQ?ID?NO：316	B1961718.V1.3_at	TGGGAAAAGCACGTTCAGCGCCCAC	SEQ?ID?NO：317
B1961718.V1.3_at	ATGAAAACACGCAGCTCGTTGGCTC	SEQ?ID?NO：318	B1961718.V1.3_at	TGGGAAAAGCACGTTCAGCGCCCAC	SEQ?ID?NO：317
B1961718.V1.3_at	ATGAAAACACGCAGCTCGTTGGCTC	SEQ?ID?NO：318	B1961718.V1.3_at	TTGGCTCCTGAGACCCCGGAGGACA	SEQ?ID?NO：319
B1961718.V1.3_at	CAGCGAGGAGGCACAGCACACGGTC	SEQ?ID?NO：320	B1961718.V1.3_at	TTGGCTCCTGAGACCCCGGAGGACA	SEQ?ID?NO：319
B1961718.V1.3_at	CAGCGAGGAGGCACAGCACACGGTC	SEQ?ID?NO：320	B1961718.V1.3_at	AGCCTGACCCGCTGGGCGACAGAGT	SEQ?ID?NO：321
B1961718.V1.3_at	GTCACAGTTCCAGAGACACTTGAGT	SEQ?ID?NO：322	B1961718.V1.3_at	AGCCTGACCCGCTGGGCGACAGAGT	SEQ?ID?NO：321
B1961718.V1.3_at	GTCACAGTTCCAGAGACACTTGAGT	SEQ?ID?NO：322	B1961718.V1.3_at	AGATTTGTACACTTCTCTCGTAGAA	SEQ?ID?NO：323
B1961720.V1.3_at	AGCCTCAATCTGCTGTTAGTCCTAA	SEQ?ID?NO：324	B1961718.V1.3_at	AGATTTGTACACTTCTCTCGTAGAA	SEQ?ID?NO：323
B1961720.V1.3_at	AGCCTCAATCTGCTGTTAGTCCTAA	SEQ?ID?NO：324	B1961720.V1.3_at	AATGGGCTAGCAAAGGCCATCTTCT	SEQ?ID?NO：325
B1961720.V1.3_at	GCCATCTTCTCACTACTTGGATAGA	SEQ?ID?NO：326	B1961720.V1.3_at	AATGGGCTAGCAAAGGCCATCTTCT	SEQ?ID?NO：325
B1961720.V1.3_at	GCCATCTTCTCACTACTTGGATAGA	SEQ?ID?NO：326	B1961720.V1.3_at	AAACTCCTGTACCTTGTTTGCAGTG	SEQ?ID?NO：327
B1961720.V1.3_at	GTGGCAAATACATTTCCCAGCAGGC	SEQ?ID?NO：328	B1961720.V1.3_at	AAACTCCTGTACCTTGTTTGCAGTG	SEQ?ID?NO：327
B1961720.V1.3_at	GTGGCAAATACATTTCCCAGCAGGC	SEQ?ID?NO：328	B1961720.V1.3_at	TTCCCAGCAGGCCTTTATTGATTGT	SEQ?ID?NO：329
B1961720.V1.3_at	TTGTACTAACCTCAAAGCTGCTGGA	SEQ?ID?NO：330	B1961720.V1.3_at	TTCCCAGCAGGCCTTTATTGATTGT	SEQ?ID?NO：329
B1961720.V1.3_at	TTGTACTAACCTCAAAGCTGCTGGA	SEQ?ID?NO：330	B1961720.V1.3_at	GTCCATTTGGTTGATGAGCTCTGCC	SEQ?ID?NO：331
B1961720.V1.3_at	GAGCTCTGCCATTTTGGAACCTAAT	SEQ?ID?NO：332	B1961720.V1.3_at	GTCCATTTGGTTGATGAGCTCTGCC	SEQ?ID?NO：331
B1961720.V1.3_at	GAGCTCTGCCATTTTGGAACCTAAT	SEQ?ID?NO：332	B1961720.V1.3_at	GGAACCTAATCTCTACTCTTTAGCT	SEQ?ID?NO：333
B1961720.V1.3_at	AGCTACATATGCCATCTACAGGTCC	SEQ?ID?NO：334	B1961720.V1.3_at	GGAACCTAATCTCTACTCTTTAGCT	SEQ?ID?NO：333
B1961720.V1.3_at	AGCTACATATGCCATCTACAGGTCC	SEQ?ID?NO：334	B1961724.V1.3_at	CACGGGAAGGTGGAAGTTTCAGACA	SEQ?ID?NO：335

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961724.V1.3_at	TGAGGGCATTCAAATTGTCTTTTTT	SEQ?ID?NO：336
B1961724.V1.3_at	TTTTTTCCATCCTCGTCTGTCAGTT	SEQ?ID?NO：337	B1961724.V1.3_at	TGAGGGCATTCAAATTGTCTTTTTT	SEQ?ID?NO：336
B1961724.V1.3_at	TTTTTTCCATCCTCGTCTGTCAGTT	SEQ?ID?NO：337	B1961724.V1.3_at	CTCGTCTGTCAGTTTCCCTGAAAAA	SEQ?ID?NO：338
B1961724.V1.3_at	AAATTCATATTCCAGTGCCTATCCG	SEQ?ID?NO：339	B1961724.V1.3_at	CTCGTCTGTCAGTTTCCCTGAAAAA	SEQ?ID?NO：338
B1961724.V1.3_at	AAATTCATATTCCAGTGCCTATCCG	SEQ?ID?NO：339	B1961724.V1.3_at	AGTGCCTATCCGTGGGATCCTTCAC	SEQ?ID?NO：340
B1961724.V1.3_at	GATCCTTCACGTTCTTTGACATTGA	SEQ?ID?NO：341	B1961724.V1.3_at	AGTGCCTATCCGTGGGATCCTTCAC	SEQ?ID?NO：340
B1961724.V1.3_at	GATCCTTCACGTTCTTTGACATTGA	SEQ?ID?NO：341	B1961724.V1.3_at	AAAAAGAGAACTCACCTCGCTCTTC	SEQ?ID?NO：342
B1961724.V1.3_at	TGTGCCCCTCTGATACTGGCAGATG	SEQ?ID?NO：343	B1961724.V1.3_at	AAAAAGAGAACTCACCTCGCTCTTC	SEQ?ID?NO：342
B1961724.V1.3_at	TGTGCCCCTCTGATACTGGCAGATG	SEQ?ID?NO：343	B1961724.V1.3_at	GATACTGGCAGATGCCTCTTCCTCT	SEQ?ID?NO：344
B1961724.V1.3_at	ACGCACGCACCCCAGTGGTGGGTTC	SEQ?ID?NO：345	B1961724.V1.3_at	GATACTGGCAGATGCCTCTTCCTCT	SEQ?ID?NO：344
B1961724.V1.3_at	ACGCACGCACCCCAGTGGTGGGTTC	SEQ?ID?NO：345	B1961731.V1.3_at	GAGAAACTCCTAAGTTCCTGTGGAA	SEQ?ID?NO：346
B1961731.V1.3_at	AACCTATGGTGGCTGTGAAGGCCCT	SEQ?ID?NO：347	B1961731.V1.3_at	GAGAAACTCCTAAGTTCCTGTGGAA	SEQ?ID?NO：346
B1961731.V1.3_at	AACCTATGGTGGCTGTGAAGGCCCT	SEQ?ID?NO：347	B1961731.V1.3_at	AGGCCCTGATGCCATGTATGTCAAA	SEQ?ID?NO：348
B1961731.V1.3_at	AATTGATATCCTCTGATGGCCATGA	SEQ?ID?NO：349	B1961731.V1.3_at	AGGCCCTGATGCCATGTATGTCAAA	SEQ?ID?NO：348
B1961731.V1.3_at	AATTGATATCCTCTGATGGCCATGA	SEQ?ID?NO：349	B1961731.V1.3_at	GAGAACACGCACTAACATCAGGAAC	SEQ?ID?NO：350
B1961731.V1.3_at	TGAGTGGCCCAGGTCAGTTTGCTGA	SEQ?ID?NO：351	B1961731.V1.3_at	GAGAACACGCACTAACATCAGGAAC	SEQ?ID?NO：350
B1961731.V1.3_at	TGAGTGGCCCAGGTCAGTTTGCTGA	SEQ?ID?NO：351	B1961731.V1.3_at	TAGAGAGATCCCTTCACATGTGTTG	SEQ?ID?NO：352
B1961731.V1.3_at	AAGGTTCGCTACACTAACAGCTCCA	SEQ?ID?NO：353	B1961731.V1.3_at	TAGAGAGATCCCTTCACATGTGTTG	SEQ?ID?NO：352
B1961731.V1.3_at	AAGGTTCGCTACACTAACAGCTCCA	SEQ?ID?NO：353	B1961731.V1.3_at	AGCTCCACGGAGATTCCTGAATTCC	SEQ?ID?NO：354
B1961731.V1.3_at	CCTGAATTCCCAATTGCACCTGAAA	SEQ?ID?NO：355	B1961731.V1.3_at	AGCTCCACGGAGATTCCTGAATTCC	SEQ?ID?NO：354
B1961731.V1.3_at	CCTGAATTCCCAATTGCACCTGAAA	SEQ?ID?NO：355	B1961731.V1.3_at	ACTGGAACTGCTGATGGCTGCGAAC	SEQ?ID?NO：356
B1961732.V1.3_at	AGACCTGCATATTCGGTGACCTTAA	SEQ?ID?NO：357	B1961731.V1.3_at	ACTGGAACTGCTGATGGCTGCGAAC	SEQ?ID?NO：356
B1961732.V1.3_at	AGACCTGCATATTCGGTGACCTTAA	SEQ?ID?NO：357	B1961732.V1.3_at	GTAGAGAACACTGATTCCCAATCCC	SEQ?ID?NO：358
B1961732.V1.3_at	TCCCACCCAGAGATTAGTTTTCGTT	SEQ?ID?NO：359	B1961732.V1.3_at	GTAGAGAACACTGATTCCCAATCCC	SEQ?ID?NO：358
B1961732.V1.3_at	TCCCACCCAGAGATTAGTTTTCGTT	SEQ?ID?NO：359	B1961732.V1.3_at	GTTTTCGTTGCAACATGGAACAGTT	SEQ?ID?NO：360
B1961732.V1.3_at	GGAAGTTAACGATCTGCCCGGGTCT	SEQ?ID?NO：361	B1961732.V1.3_at	GTTTTCGTTGCAACATGGAACAGTT	SEQ?ID?NO：360
B1961732.V1.3_at	GGAAGTTAACGATCTGCCCGGGTCT	SEQ?ID?NO：361	B1961732.V1.3_at	CGATCTGCCCGGGTCTAGAGGAAGA	SEQ?ID?NO：362
B1961732.V1.3_at	AGGAAGACCAGGAACGCCTTGCCAT	SEQ?ID?NO：363	B1961732.V1.3_at	CGATCTGCCCGGGTCTAGAGGAAGA	SEQ?ID?NO：362
B1961732.V1.3_at	AGGAAGACCAGGAACGCCTTGCCAT	SEQ?ID?NO：363	B1961732.V1.3_at	TTGCCATCGGCAGAAGCGTCGTTGA	SEQ?ID?NO：364
B1961732.V1.3_at	TCGTTGATGCGAGCTGGATGTCCTC	SEQ?ID?NO：365	B1961732.V1.3_at	TTGCCATCGGCAGAAGCGTCGTTGA	SEQ?ID?NO：364
B1961732.V1.3_at	TCGTTGATGCGAGCTGGATGTCCTC	SEQ?ID?NO：365	B1961732.V1.3_at	GGATGTCCTCCTTTTCAGTAGAAAC	SEQ?ID?NO：366
B1961732.V1.3_at	GTGAACTGCACATTGATCCCATTTT	SEQ?ID?NO：367	B1961732.V1.3_at	GGATGTCCTCCTTTTCAGTAGAAAC	SEQ?ID?NO：366
B1961732.V1.3_at	GTGAACTGCACATTGATCCCATTTT	SEQ?ID?NO：367	B1961735.V1.3_at	AAAGCTGTGCCTCCGAGCAAGCAAA	SEQ?ID?NO：368
B1961735.V1.3_at	AGCAAAAAGAGTTCGCCCATGGATC	SEQ?ID?NO：369	B1961735.V1.3_at	AAAGCTGTGCCTCCGAGCAAGCAAA	SEQ?ID?NO：368
B1961735.V1.3_at	AGCAAAAAGAGTTCGCCCATGGATC	SEQ?ID?NO：369	B1961735.V1.3_at	GAGTTCGCCCATGGATCGAAACAGT	SEQ?ID?NO：370
B1961735.V1.3_at	GGATCGAAACAGTGACGAGTTCCGT	SEQ?ID?NO：371	B1961735.V1.3_at	GAGTTCGCCCATGGATCGAAACAGT	SEQ?ID?NO：370
B1961735.V1.3_at	GGATCGAAACAGTGACGAGTTCCGT	SEQ?ID?NO：371	B1961735.V1.3_at	GACGAGTTCCGTCAACGCAGAGAGA	SEQ?ID?NO：372
B1961735.V1.3_at	GAGAGAGGAACATCATGGCCGTGAA	SEQ?ID?NO：373	B1961735.V1.3_at	GACGAGTTCCGTCAACGCAGAGAGA	SEQ?ID?NO：372
B1961735.V1.3_at	GAGAGAGGAACATCATGGCCGTGAA	SEQ?ID?NO：373	B1961735.V1.3_at	TCATGGCCGTGAAAAAGAGCCGGTT	SEQ?ID?NO：374
B1961735.V1.3_at	AAGAGCCGGTTGAAAAGCAAGCAGA	SEQ?ID?NO：375	B1961735.V1.3_at	TCATGGCCGTGAAAAAGAGCCGGTT	SEQ?ID?NO：374
B1961735.V1.3_at	AAGAGCCGGTTGAAAAGCAAGCAGA	SEQ?ID?NO：375	B1961735.V1.3_at	AGCAAGCAGAAAGCGCAGGATACAC	SEQ?ID?NO：376
B1961735.V1.3_at	TACACTGCAGAGAGTGAATCAGCTT	SEQ?ID?NO：377	B1961735.V1.3_at	AGCAAGCAGAAAGCGCAGGATACAC	SEQ?ID?NO：376
B1961735.V1.3_at	TACACTGCAGAGAGTGAATCAGCTT	SEQ?ID?NO：377	B1961735.V1.3_at	GAAGAGAATGATCGCTTGGAAGCAA	SEQ?ID?NO：378
B1961737.V1.3_at	GAATGAGTAGCTTTCTGATGCTCTG	SEQ?ID?NO：379	B1961735.V1.3_at	GAAGAGAATGATCGCTTGGAAGCAA	SEQ?ID?NO：378
B1961737.V1.3_at	GAATGAGTAGCTTTCTGATGCTCTG	SEQ?ID?NO：379	B1961737.V1.3_at	TGATGCTCTGTATGTCAAACCCACC	SEQ?ID?NO：380

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961737.V1.3_at	ACCCCTGGCCCAAGAAATTGCAGTC	SEQ?ID?NO：381
B1961737.V1.3_at	AAACTGCCCTTTGTCCTCAAAGAAG	SEQ?ID?NO：382	B1961737.V1.3_at	ACCCCTGGCCCAAGAAATTGCAGTC	SEQ?ID?NO：381
B1961737.V1.3_at	AAACTGCCCTTTGTCCTCAAAGAAG	SEQ?ID?NO：382	B1961737.V1.3_at	TATCTGCCTTGTTCTTATCAACTTG	SEQ?ID?NO：383
B1961737.V1.3_at	TCTAACCGTGTTTTGTTGGCTACAG	SEQ?ID?NO：384	B1961737.V1.3_at	TATCTGCCTTGTTCTTATCAACTTG	SEQ?ID?NO：383
B1961737.V1.3_at	TCTAACCGTGTTTTGTTGGCTACAG	SEQ?ID?NO：384	B1961737.V1.3_at	AAGTGCCCTAATTGAATGTGTTTGA	SEQ?ID?NO：385
B1961737.V1.3_at	GTGTTTGAATGTTATCCTTGCACAA	SEQ?ID?NO：386	B1961737.V1.3_at	AAGTGCCCTAATTGAATGTGTTTGA	SEQ?ID?NO：385
B1961737.V1.3_at	GTGTTTGAATGTTATCCTTGCACAA	SEQ?ID?NO：386	B1961737.V1.3_at	AAATGTTTTACCTCACTGTTGGACA	SEQ?ID?NO：387
B1961737.V1.3_at	ACATTCCAAGCTTTTCAACTCTAGG	SEQ?ID?NO：388	B1961737.V1.3_at	AAATGTTTTACCTCACTGTTGGACA	SEQ?ID?NO：387
B1961737.V1.3_at	ACATTCCAAGCTTTTCAACTCTAGG	SEQ?ID?NO：388	B1961737.V1.3_at	AGTCATATGTTTTCCTGTATTGTAA	SEQ?ID?NO：389
B1961738.V1.3_at	GATTTTGCCTTTGGTTTGGGTCTCA	SEQ?ID?NO：390	B1961737.V1.3_at	AGTCATATGTTTTCCTGTATTGTAA	SEQ?ID?NO：389
B1961738.V1.3_at	GATTTTGCCTTTGGTTTGGGTCTCA	SEQ?ID?NO：390	B1961738.V1.3_at	TTAATCTTTTTTCTGGCTTCTTCTG	SEQ?ID?NO：391
B1961738.V1.3_at	TGGCTTCTTCTGCATGTTCTAGGAA	SEQ?ID?NO：392	B1961738.V1.3_at	TTAATCTTTTTTCTGGCTTCTTCTG	SEQ?ID?NO：391
B1961738.V1.3_at	TGGCTTCTTCTGCATGTTCTAGGAA	SEQ?ID?NO：392	B1961738.V1.3_at	AGAGTTGTATGTATTCTTCCCGGAA	SEQ?ID?NO：393
B1961738.V1.3_at	TTCCCGGAATTTGGCAGACTTCTCG	SEQ?ID?NO：394	B1961738.V1.3_at	AGAGTTGTATGTATTCTTCCCGGAA	SEQ?ID?NO：393
B1961738.V1.3_at	TTCCCGGAATTTGGCAGACTTCTCG	SEQ?ID?NO：394	B1961738.V1.3_at	AAACAGCTTACTGGCGCTTTCCAAT	SEQ?ID?NO：395
B1961738.V1.3_at	CTCCCCTGTGGATGTGTTGATTGCA	SEQ?ID?NO：396	B1961738.V1.3_at	AAACAGCTTACTGGCGCTTTCCAAT	SEQ?ID?NO：395
B1961738.V1.3_at	CTCCCCTGTGGATGTGTTGATTGCA	SEQ?ID?NO：396	B1961738.V1.3_at	GATTTTATCTCCAACTTGTGCCTGT	SEQ?ID?NO：397
B1961738.V1.3_at	GGATAAGTGGCCTGCTGGACCTGCT	SEQ?ID?NO：398	B1961738.V1.3_at	GATTTTATCTCCAACTTGTGCCTGT	SEQ?ID?NO：397
B1961738.V1.3_at	GGATAAGTGGCCTGCTGGACCTGCT	SEQ?ID?NO：398	B1961738.V1.3_at	GCTGCATGATTTCACCACTGGTCAA	SEQ?ID?NO：399
B1961738.V1.3_at	TAAACTGAAGCACCTTGGCCATCTG	SEQ?ID?NO：400	B1961738.V1.3_at	GCTGCATGATTTCACCACTGGTCAA	SEQ?ID?NO：399
B1961738.V1.3_at	TAAACTGAAGCACCTTGGCCATCTG	SEQ?ID?NO：400	B1961739.V1.3_at	GCTGGATCCCTCACAGGGCTGGGAA	SEQ?ID?NO：401
B1961739.V1.3_at	GGCAATGGGAGTACACTTTGATGAC	SEQ?ID?NO：402	B1961739.V1.3_at	GCTGGATCCCTCACAGGGCTGGGAA	SEQ?ID?NO：401
B1961739.V1.3_at	GGCAATGGGAGTACACTTTGATGAC	SEQ?ID?NO：402	B1961739.V1.3_at	GTGATTATTTCCGTAGTGACCCTGC	SEQ?ID?NO：403
B1961739.V1.3_at	AGTGACCCTGCCTGGGAGGCTCAGA	SEQ?ID?NO：404	B1961739.V1.3_at	GTGATTATTTCCGTAGTGACCCTGC	SEQ?ID?NO：403
B1961739.V1.3_at	AGTGACCCTGCCTGGGAGGCTCAGA	SEQ?ID?NO：404	B1961739.V1.3_at	GCAGGCAGGGATCAGACGTCATTAT	SEQ?ID?NO：405
B1961739.V1.3_at	ATGAACACAGTGATGGGCGGCAGTC	SEQ?ID?NO：406	B1961739.V1.3_at	GCAGGCAGGGATCAGACGTCATTAT	SEQ?ID?NO：405
B1961739.V1.3_at	ATGAACACAGTGATGGGCGGCAGTC	SEQ?ID?NO：406	B1961739.V1.3_at	TCGCCCCATGAGTGTCCCTTTGAGG	SEQ?ID?NO：407
B1961739.V1.3_at	AAGAGGGATGCTGCATTTCTCAGCT	SEQ?ID?NO：408	B1961739.V1.3_at	TCGCCCCATGAGTGTCCCTTTGAGG	SEQ?ID?NO：407
B1961739.V1.3_at	AAGAGGGATGCTGCATTTCTCAGCT	SEQ?ID?NO：408	B1961739.V1.3_at	GCATTTCTCAGCTGGGCAGTAATCA	SEQ?ID?NO：409
B1961739.V1.3_at	GCAGTAATCAACTTAATGGTCCTTT	SEQ?ID?NO：410	B1961739.V1.3_at	GCATTTCTCAGCTGGGCAGTAATCA	SEQ?ID?NO：409
B1961739.V1.3_at	GCAGTAATCAACTTAATGGTCCTTT	SEQ?ID?NO：410	B1961739.V1.3_at	ATGGTCCTTTTAAAATGTCTGTGTA	SEQ?ID?NO：411
B1961740.V1.3_at	GTTATCATGGCCACAAACCGAATAG	SEQ?ID?NO：412	B1961739.V1.3_at	ATGGTCCTTTTAAAATGTCTGTGTA	SEQ?ID?NO：411
B1961740.V1.3_at	GTTATCATGGCCACAAACCGAATAG	SEQ?ID?NO：412	B1961740.V1.3_at	TTGGACCCAGCACTTATCAGACCAG	SEQ?ID?NO：413
B1961740.V1.3_at	AGACCAGGCCGCATTGACAGGAAGA	SEQ?ID?NO：414	B1961740.V1.3_at	TTGGACCCAGCACTTATCAGACCAG	SEQ?ID?NO：413
B1961740.V1.3_at	AGACCAGGCCGCATTGACAGGAAGA	SEQ?ID?NO：414	B1961740.V1.3_at	CCCCTGCCTGATGAGAAGACCAAGA	SEQ?ID?NO：415
B1961740.V1.3_at	AGAAGCGCATCTTTCAGATCCACAC	SEQ?ID?NO：416	B1961740.V1.3_at	CCCCTGCCTGATGAGAAGACCAAGA	SEQ?ID?NO：415
B1961740.V1.3_at	AGAAGCGCATCTTTCAGATCCACAC	SEQ?ID?NO：416	B1961740.V1.3_at	AGATCCACACCAGCAGGATGACGCT	SEQ?ID?NO：417
B1961740.V1.3_at	GATGACGCTGGCTGACGACGTTACC	SEQ?ID?NO：418	B1961740.V1.3_at	AGATCCACACCAGCAGGATGACGCT	SEQ?ID?NO：417
B1961740.V1.3_at	GATGACGCTGGCTGACGACGTTACC	SEQ?ID?NO：418	B1961740.V1.3_at	GTTACCCTGGACGACTTGATCATGG	SEQ?ID?NO：419
B1961740.V1.3_at	ATGGCTAAAGACGACCTGTCCGGTG	SEQ?ID?NO：420	B1961740.V1.3_at	GTTACCCTGGACGACTTGATCATGG	SEQ?ID?NO：419
B1961740.V1.3_at	ATGGCTAAAGACGACCTGTCCGGTG	SEQ?ID?NO：420	B1961740.V1.3_at	TGTCCGGTGCCGACATCAAGGCAAT	SEQ?ID?NO：421
B1961740.V1.3_at	AGAAGCTGGTCTGATGGCCTTGAGA	SEQ?ID?NO：422	B1961740.V1.3_at	TGTCCGGTGCCGACATCAAGGCAAT	SEQ?ID?NO：421
B1961740.V1.3_at	AGAAGCTGGTCTGATGGCCTTGAGA	SEQ?ID?NO：422	B1961742.V1.3_at	CTTTGAGTTGATGCGGGAGCCATGC	SEQ?ID?NO：423
B1961742.V1.3_at	CGGCATCACTTATGACCGCAAAGAC	SEQ?ID?NO：424	B1961742.V1.3_at	CTTTGAGTTGATGCGGGAGCCATGC	SEQ?ID?NO：423
B1961742.V1.3_at	CGGCATCACTTATGACCGCAAAGAC	SEQ?ID?NO：424	B1961742.V1.3_at	ACCGCAAAGACATCGAGGAGCACCT	SEQ?ID?NO：425

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961742.V1.3_at	AGGAGCACCTGCAGCGTGTAGGCCA	SEQ?ID?NO：426
B1961742.V1.3_at	GTGTAGGCCACTTTGACCCTGTGAC	SEQ?ID?NO：427	B1961742.V1.3_at	AGGAGCACCTGCAGCGTGTAGGCCA	SEQ?ID?NO：426
B1961742.V1.3_at	GTGTAGGCCACTTTGACCCTGTGAC	SEQ?ID?NO：427	B1961742.V1.3_at	CATCCCTAACCTGGCCATGAAAGAG	SEQ?ID?NO：428
B1961742.V1.3_at	AAGAGGTCATCGACGCATTCATCTC	SEQ?ID?NO：429	B1961742.V1.3_at	CATCCCTAACCTGGCCATGAAAGAG	SEQ?ID?NO：428
B1961742.V1.3_at	AAGAGGTCATCGACGCATTCATCTC	SEQ?ID?NO：429	B1961742.V1.3_at	ATTCATCTCCGAGAACGGCTGGGTG	SEQ?ID?NO：430
B1961742.V1.3_at	TGCCTGGTAACCTGGCCCTAGAGGG	SEQ?ID?NO：431	B1961742.V1.3_at	ATTCATCTCCGAGAACGGCTGGGTG	SEQ?ID?NO：430
B1961742.V1.3_at	TGCCTGGTAACCTGGCCCTAGAGGG	SEQ?ID?NO：431	B1961742.V1.3_at	GTACAGAGTTTGTGTCCCTGGATCC	SEQ?ID?NO：432
B1961742.V1.3_at	ATCAGTTCTGCTGCTGGGCCGTGAG	SEQ?ID?NO：433	B1961742.V1.3_at	GTACAGAGTTTGTGTCCCTGGATCC	SEQ?ID?NO：432
B1961742.V1.3_at	ATCAGTTCTGCTGCTGGGCCGTGAG	SEQ?ID?NO：433	B1961743.V1.3_at	AATGGGCTCCGTCATGATCTTATGT	SEQ?ID?NO：434
B1961743.V1.3_at	TTCCTTCAAATCTGAGGCTTGCCTG	SEQ?ID?NO：435	B1961743.V1.3_at	AATGGGCTCCGTCATGATCTTATGT	SEQ?ID?NO：434
B1961743.V1.3_at	TTCCTTCAAATCTGAGGCTTGCCTG	SEQ?ID?NO：435	B1961743.V1.3_at	GCAGAGCGCCTGTGATTTGGCTCAA	SEQ?ID?NO：436
B1961743.V1.3_at	GATTTGGCTCAAGACTCCTGTATGA	SEQ?ID?NO：437	B1961743.V1.3_at	GCAGAGCGCCTGTGATTTGGCTCAA	SEQ?ID?NO：436
B1961743.V1.3_at	GATTTGGCTCAAGACTCCTGTATGA	SEQ?ID?NO：437	B1961743.V1.3_at	GAAAATGCTGCTCTTCTAAGTCCTT	SEQ?ID?NO：438
B1961743.V1.3_at	CTAAGTCCTTTGTGGCTTGTAAGTG	SEQ?ID?NO：439	B1961743.V1.3_at	GAAAATGCTGCTCTTCTAAGTCCTT	SEQ?ID?NO：438
B1961743.V1.3_at	CTAAGTCCTTTGTGGCTTGTAAGTG	SEQ?ID?NO：439	B1961743.V1.3_at	GAATTTCATCCAAATGTTACCCTGT	SEQ?ID?NO：440
B1961743.V1.3_at	TGTTACCCTGTAATACTGGCATTTA	SEQ?ID?NO：441	B1961743.V1.3_at	GAATTTCATCCAAATGTTACCCTGT	SEQ?ID?NO：440
B1961743.V1.3_at	TGTTACCCTGTAATACTGGCATTTA	SEQ?ID?NO：441	B1961743.V1.3_at	TCTTCCTCACCCTTTTTACAGTGGA	SEQ?ID?NO：442
B1961743.V1.3_at	TAATAATTGGAACATCCTGCCCCTT	SEQ?ID?NO：443	B1961743.V1.3_at	TCTTCCTCACCCTTTTTACAGTGGA	SEQ?ID?NO：442
B1961743.V1.3_at	TAATAATTGGAACATCCTGCCCCTT	SEQ?ID?NO：443	B1961743.V1.3_at	CAATCCTAGTTGTCTACCTTCTTTT	SEQ?ID?NO：444
B1961745.V1.3_at	GATAGACTGAGTCCACGTCTCCTTA	SEQ?ID?NO：445	B1961743.V1.3_at	CAATCCTAGTTGTCTACCTTCTTTT	SEQ?ID?NO：444
B1961745.V1.3_at	GATAGACTGAGTCCACGTCTCCTTA	SEQ?ID?NO：445	B1961745.V1.3_at	AGGTCTATATATAAGGTGGCCCCAC	SEQ?ID?NO：446
B1961745.V1.3_at	ACATTGCCTGCTAACTTGACTTCTT	SEQ?ID?NO：447	B1961745.V1.3_at	AGGTCTATATATAAGGTGGCCCCAC	SEQ?ID?NO：446
B1961745.V1.3_at	ACATTGCCTGCTAACTTGACTTCTT	SEQ?ID?NO：447	B1961745.V1.3_at	GCTCGGCTTATGTCAGTATTCTCTG	SEQ?ID?NO：448
B1961745.V1.3_at	TTTGCCTTCATGTGCCAAGCTTGAA	SEQ?ID?NO：449	B1961745.V1.3_at	GCTCGGCTTATGTCAGTATTCTCTG	SEQ?ID?NO：448
B1961745.V1.3_at	TTTGCCTTCATGTGCCAAGCTTGAA	SEQ?ID?NO：449	B1961745.V1.3_at	GATTTGATTTCCTGAGTGACCTGTC	SEQ?ID?NO：450
B1961745.V1.3_at	TGACCTGTCTGCTTTCGATGTGCCA	SEQ?ID?NO：451	B1961745.V1.3_at	GATTTGATTTCCTGAGTGACCTGTC	SEQ?ID?NO：450
B1961745.V1.3_at	TGACCTGTCTGCTTTCGATGTGCCA	SEQ?ID?NO：451	B1961745.V1.3_at	TAGTTCATCTTTCATCTCATTCGTG	SEQ?ID?NO：452
B1961745.V1.3_at	GGGTCAAGTCTTTTCAGGTGTTTAT	SEQ?ID?NO：453	B1961745.V1.3_at	TAGTTCATCTTTCATCTCATTCGTG	SEQ?ID?NO：452
B1961745.V1.3_at	GGGTCAAGTCTTTTCAGGTGTTTAT	SEQ?ID?NO：453	B1961745.V1.3_at	AAATGATTTTGTGTTCCCTTCCCAT	SEQ?ID?NO：454
B1961745.V1.3_at	AAGCCCAGTGTATTGTACTTCACCC	SEQ?ID?NO：455	B1961745.V1.3_at	AAATGATTTTGTGTTCCCTTCCCAT	SEQ?ID?NO：454
B1961745.V1.3_at	AAGCCCAGTGTATTGTACTTCACCC	SEQ?ID?NO：455	B1961746.V1.3_at	TGTGCAGTCCCACATGCTCATGGTG	SEQ?ID?NO：456
B1961746.V1.3_at	TCCAGGAGGCCTGTCATGTCCAGCA	SEQ?ID?NO：457	B1961746.V1.3_at	TGTGCAGTCCCACATGCTCATGGTG	SEQ?ID?NO：456
B1961746.V1.3_at	TCCAGGAGGCCTGTCATGTCCAGCA	SEQ?ID?NO：457	B1961746.V1.3_at	AGTGGGCACACTCCTGAAGCAGCTG	SEQ?ID?NO：458
B1961746.V1.3_at	GGAAGGGCCACGTGTGCACCAGCTC	SEQ?ID?NO：459	B1961746.V1.3_at	AGTGGGCACACTCCTGAAGCAGCTG	SEQ?ID?NO：458
B1961746.V1.3_at	GGAAGGGCCACGTGTGCACCAGCTC	SEQ?ID?NO：459	B1961746.V1.3_at	ACGACGGTCTTCTTGTCCATGAAGG	SEQ?ID?NO：460
B1961746.V1.3_at	TGAAGGCCACCTTGAACAGCAGAGG	SEQ?ID?NO：461	B1961746.V1.3_at	ACGACGGTCTTCTTGTCCATGAAGG	SEQ?ID?NO：460
B1961746.V1.3_at	TGAAGGCCACCTTGAACAGCAGAGG	SEQ?ID?NO：461	B1961746.V1.3_at	TGCCGCGTGCTCAGGAACACAAGCG	SEQ?ID?NO：462
B1961746.V1.3_at	AGGAAGCCACCTCGCTGTAACAGGA	SEQ?ID?NO：463	B1961746.V1.3_at	TGCCGCGTGCTCAGGAACACAAGCG	SEQ?ID?NO：462
B1961746.V1.3_at	AGGAAGCCACCTCGCTGTAACAGGA	SEQ?ID?NO：463	B1961746.V1.3_at	GTAACAGGACAGACCAACCGAGCAC	SEQ?ID?NO：464
B1961746.V1.3_at	AACCGAGCACCTGTCACGAGAGGAA	SEQ?ID?NO：465	B1961746.V1.3_at	GTAACAGGACAGACCAACCGAGCAC	SEQ?ID?NO：464
B1961746.V1.3_at	AACCGAGCACCTGTCACGAGAGGAA	SEQ?ID?NO：465	B1961746.V1.3_at	AAAGCAGCCAGTGGTCACCGTGGGA	SEQ?ID?NO：466
B1961755.V1.3_at	ATTCTCCAAGAAATAGCCTACTCAA	SEQ?ID?NO：467	B1961746.V1.3_at	AAAGCAGCCAGTGGTCACCGTGGGA	SEQ?ID?NO：466
B1961755.V1.3_at	ATTCTCCAAGAAATAGCCTACTCAA	SEQ?ID?NO：467	B1961755.V1.3_at	TAGCTGAGAACTTCCCAAACCTGGG	SEQ?ID?NO：468
B1961755.V1.3_at	GAAGACAACAGACCTCCGAACTATA	SEQ?ID?NO：469	B1961755.V1.3_at	TAGCTGAGAACTTCCCAAACCTGGG	SEQ?ID?NO：468
B1961755.V1.3_at	GAAGACAACAGACCTCCGAACTATA	SEQ?ID?NO：469	B1961755.V1.3_at	AAAGACCTTCTCCAAGGCATATATT	SEQ?ID?NO：470

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961755.V1.3_at	TAAGGGCAGCAAGGCAGAGGACAAT	SEQ?ID?NO：471
B1961755.V1.3_at	AAAGGGACTCCTATCAGGCTTTCAG	SEQ?ID?NO：472	B1961755.V1.3_at	TAAGGGCAGCAAGGCAGAGGACAAT	SEQ?ID?NO：471
B1961755.V1.3_at	AAAGGGACTCCTATCAGGCTTTCAG	SEQ?ID?NO：472	B1961755.V1.3_at	CTTTCAGTGGATTTCTCAGCAGATA	SEQ?ID?NO：473
B1961755.V1.3_at	TCAGCAGATACCTTACAGGCTAGGA	SEQ?ID?NO：474	B1961755.V1.3_at	CTTTCAGTGGATTTCTCAGCAGATA	SEQ?ID?NO：473
B1961755.V1.3_at	TCAGCAGATACCTTACAGGCTAGGA	SEQ?ID?NO：474	B1961755.V1.3_at	GAGGACAAAAACTTTCAGCCAAGAA	SEQ?ID?NO：475
B1961755.V1.3_at	AGCCAAGAATACTCTATCCAGTGAA	SEQ?ID?NO：476	B1961755.V1.3_at	GAGGACAAAAACTTTCAGCCAAGAA	SEQ?ID?NO：475
B1961755.V1.3_at	AGCCAAGAATACTCTATCCAGTGAA	SEQ?ID?NO：476	B1961755.V1.3_at	GCTAAGGGAGTTTATCACCACAAGA	SEQ?ID?NO：477
B1961756.V1.3_at	CATTTCCACCCCAACATAGAGTAGT	SEQ?ID?NO：478	B1961755.V1.3_at	GCTAAGGGAGTTTATCACCACAAGA	SEQ?ID?NO：477
B1961756.V1.3_at	CATTTCCACCCCAACATAGAGTAGT	SEQ?ID?NO：478	B1961756.V1.3_at	GAGTAGTATTTGCTTTTTAGTCCAT	SEQ?ID?NO：479
B1961756.V1.3_at	TGCTTTTTAGTCCATTTTGTTTTCA	SEQ?ID?NO：480	B1961756.V1.3_at	GAGTAGTATTTGCTTTTTAGTCCAT	SEQ?ID?NO：479
B1961756.V1.3_at	TGCTTTTTAGTCCATTTTGTTTTCA	SEQ?ID?NO：480	B1961756.V1.3_at	ATATCGATCAGAGTCATTCTTTTGT	SEQ?ID?NO：481
B1961756.V1.3_at	CAGAGTCATTCTTTTGTTCATTGAA	SEQ?ID?NO：482	B1961756.V1.3_at	ATATCGATCAGAGTCATTCTTTTGT	SEQ?ID?NO：481
B1961756.V1.3_at	CAGAGTCATTCTTTTGTTCATTGAA	SEQ?ID?NO：482	B1961756.V1.3_at	CATACCCCTAAACCAACCAGGATTG	SEQ?ID?NO：483
B1961756.V1.3_at	AGGATTGGAAGGTACCACCGCTGGT	SEQ?ID?NO：484	B1961756.V1.3_at	CATACCCCTAAACCAACCAGGATTG	SEQ?ID?NO：483
B1961756.V1.3_at	AGGATTGGAAGGTACCACCGCTGGT	SEQ?ID?NO：484	B1961756.V1.3_at	AAGGTACCACCGCTGGTGCTGCCTT	SEQ?ID?NO：485
B1961756.V1.3_at	TCCCACAGCCTGTAACTTAATGTTT	SEQ?ID?NO：486	B1961756.V1.3_at	AAGGTACCACCGCTGGTGCTGCCTT	SEQ?ID?NO：485
B1961756.V1.3_at	TCCCACAGCCTGTAACTTAATGTTT	SEQ?ID?NO：486	B1961756.V1.3_at	GTAACTTAATGTTTTGTACTTCAAT	SEQ?ID?NO：487
B1961756.V1.3_at	GTGATGGTTAGAAACTTCGTGTATA	SEQ?ID?NO：488	B1961756.V1.3_at	GTAACTTAATGTTTTGTACTTCAAT	SEQ?ID?NO：487
B1961756.V1.3_at	GTGATGGTTAGAAACTTCGTGTATA	SEQ?ID?NO：488	B1961770.V1.3_at	GTGACTATTTCACTTGACCCTTTTT	SEQ?ID?NO：489
B1961770.V1.3_at	TACCAAGACCCTGTGAGCTGTGTGT	SEQ?ID?NO：490	B1961770.V1.3_at	GTGACTATTTCACTTGACCCTTTTT	SEQ?ID?NO：489
B1961770.V1.3_at	TACCAAGACCCTGTGAGCTGTGTGT	SEQ?ID?NO：490	B1961770.V1.3_at	GCTGTGTGTTTATTTCCCTCAATGA	SEQ?ID?NO：491
B1961770.V1.3_at	CCAGTCACTGCCTGTTGGAGAACAT	SEQ?ID?NO：492	B1961770.V1.3_at	GCTGTGTGTTTATTTCCCTCAATGA	SEQ?ID?NO：491
B1961770.V1.3_at	CCAGTCACTGCCTGTTGGAGAACAT	SEQ?ID?NO：492	B1961770.V1.3_at	GAACATGTCTGCATTGTGAGCCACT	SEQ?ID?NO：493
B1961770.V1.3_at	ATGGCATGTCAAACCACGCTTGAAT	SEQ?ID?NO：494	B1961770.V1.3_at	GAACATGTCTGCATTGTGAGCCACT	SEQ?ID?NO：493
B1961770.V1.3_at	ATGGCATGTCAAACCACGCTTGAAT	SEQ?ID?NO：494	B1961770.V1.3_at	GTGTCAGGTGATAGGGCTTGTCCCC	SEQ?ID?NO：495
B1961770.V1.3_at	GGGCTTGTCCCCTGATAAAGCTTAG	SEQ?ID?NO：496	B1961770.V1.3_at	GTGTCAGGTGATAGGGCTTGTCCCC	SEQ?ID?NO：495
B1961770.V1.3_at	GGGCTTGTCCCCTGATAAAGCTTAG	SEQ?ID?NO：496	B1961770.V1.3_at	TAAAGCTTAGTATCTCCTCTCATGC	SEQ?ID?NO：497
B1961770.V1.3_at	CTCTCATGCCTAGTGCTTCAGAATA	SEQ?ID?NO：498	B1961770.V1.3_at	TAAAGCTTAGTATCTCCTCTCATGC	SEQ?ID?NO：497
B1961770.V1.3_at	CTCTCATGCCTAGTGCTTCAGAATA	SEQ?ID?NO：498	B1961770.V1.3_at	GTTGACAACTGTGACTGCACCCAAA	SEQ?ID?NO：499
B1961775.V1.3_at	TACGTCAGGTTTCAGCTACATTCGC	SEQ?ID?NO：500	B1961770.V1.3_at	GTTGACAACTGTGACTGCACCCAAA	SEQ?ID?NO：499
B1961775.V1.3_at	TACGTCAGGTTTCAGCTACATTCGC	SEQ?ID?NO：500	B1961775.V1.3_at	TGATAAGCTGCTTCGATCGCAAAGA	SEQ?ID?NO：501
B1961775.V1.3_at	TCAGGCTCCTGAACCCACAGAAAGG	SEQ?ID?NO：502	B1961775.V1.3_at	TGATAAGCTGCTTCGATCGCAAAGA	SEQ?ID?NO：501
B1961775.V1.3_at	TCAGGCTCCTGAACCCACAGAAAGG	SEQ?ID?NO：502	B1961775.V1.3_at	AAGGGCATCTTCAGACGTAGTCACC	SEQ?ID?NO：503
B1961775.V1.3_at	GACAAAAACCTCATCCATGCCAATG	SEQ?ID?NO：504	B1961775.V1.3_at	AAGGGCATCTTCAGACGTAGTCACC	SEQ?ID?NO：503
B1961775.V1.3_at	GACAAAAACCTCATCCATGCCAATG	SEQ?ID?NO：504	B1961775.V1.3_at	AACATGTGGGTTCTGCAATTGGGAC	SEQ?ID?NO：505
B1961775.V1.3_at	ACATCAGTTACAGTGGCAGTGCCGT	SEQ?ID?NO：506	B1961775.V1.3_at	AACATGTGGGTTCTGCAATTGGGAC	SEQ?ID?NO：505
B1961775.V1.3_at	ACATCAGTTACAGTGGCAGTGCCGT	SEQ?ID?NO：506	B1961775.V1.3_at	AGTCCTCCTCTGTGTGTTATGTAAG	SEQ?ID?NO：507
B1961775.V1.3_at	CTCTCCAGATTTGCAGGCTCATTAT	SEQ?ID?NO：508	B1961775.V1.3_at	AGTCCTCCTCTGTGTGTTATGTAAG	SEQ?ID?NO：507
B1961775.V1.3_at	CTCTCCAGATTTGCAGGCTCATTAT	SEQ?ID?NO：508	B1961775.V1.3_at	TCATTATGAACGTGTGGCCCCAGAC	SEQ?ID?NO：509
B1961775.V1.3_at	GGCCCCAGACTGATGCTTGAGCTAA	SEQ?ID?NO：510	B1961775.V1.3_at	TCATTATGAACGTGTGGCCCCAGAC	SEQ?ID?NO：509
B1961775.V1.3_at	GGCCCCAGACTGATGCTTGAGCTAA	SEQ?ID?NO：510	B1961778.V1.3_at	AGCGGCACGAGTTAGCTCAGGACAA	SEQ?ID?NO：511
B1961778.V1.3_at	GAATTAGCTTGCTGCTTTATTCAGA	SEQ?ID?NO：512	B1961778.V1.3_at	AGCGGCACGAGTTAGCTCAGGACAA	SEQ?ID?NO：511
B1961778.V1.3_at	GAATTAGCTTGCTGCTTTATTCAGA	SEQ?ID?NO：512	B1961778.V1.3_at	GCAGGCCCTGAGATGGACAAGAGAT	SEQ?ID?NO：513
B1961778.V1.3_at	GGTACTGTGATCCTGTTGTGTTAAC	SEQ?ID?NO：514	B1961778.V1.3_at	GCAGGCCCTGAGATGGACAAGAGAT	SEQ?ID?NO：513
B1961778.V1.3_at	GGTACTGTGATCCTGTTGTGTTAAC	SEQ?ID?NO：514	B1961778.V1.3_at	ATACCAAGCTGAGCGGATGCCAGAG	SEQ?ID?NO：515

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961778.V1.3_at	GTGGACCCAAAGCAGCTGGCTGTTT	SEQ?ID?NO：516
B1961778.V1.3_at	ATGTGCCTGGCTTTTTGCCTACAAA	SEQ?ID?NO：517	B1961778.V1.3_at	GTGGACCCAAAGCAGCTGGCTGTTT	SEQ?ID?NO：516
B1961778.V1.3_at	ATGTGCCTGGCTTTTTGCCTACAAA	SEQ?ID?NO：517	B1961778.V1.3_at	AACGATTTAAGTCAGCCCACAGGAT	SEQ?ID?NO：518
B1961778.V1.3_at	CACAGGATTTTTAGCTCAGCCCATG	SEQ?ID?NO：519	B1961778.V1.3_at	AACGATTTAAGTCAGCCCACAGGAT	SEQ?ID?NO：518
B1961778.V1.3_at	CACAGGATTTTTAGCTCAGCCCATG	SEQ?ID?NO：519	B1961778.V1.3_at	GAACTGGAGCAGCACCTACATGCCA	SEQ?ID?NO：520
B1961778.V1.3_at	TGAACCCTCAAGCTCAGGCTCTTAG	SEQ?ID?NO：521	B1961778.V1.3_at	GAACTGGAGCAGCACCTACATGCCA	SEQ?ID?NO：520
B1961778.V1.3_at	TGAACCCTCAAGCTCAGGCTCTTAG	SEQ?ID?NO：521	B1961783.V1.3_at	ATTGTTGACATTTAGCTCTGCCTGC	SEQ?ID?NO：522
B1961783.V1.3_at	TTTTCTCTTCTTCCATGGCTAATCA	SEQ?ID?NO：523	B1961783.V1.3_at	ATTGTTGACATTTAGCTCTGCCTGC	SEQ?ID?NO：522
B1961783.V1.3_at	TTTTCTCTTCTTCCATGGCTAATCA	SEQ?ID?NO：523	B1961783.V1.3_at	AGGACCTCTCATCATCTCAAGGTGA	SEQ?ID?NO：524
B1961783.V1.3_at	GACTACAGTTGTGGTCACCCTTGGC	SEQ?ID?NO：525	B1961783.V1.3_at	AGGACCTCTCATCATCTCAAGGTGA	SEQ?ID?NO：524
B1961783.V1.3_at	GACTACAGTTGTGGTCACCCTTGGC	SEQ?ID?NO：525	B1961783.V1.3_at	TGCCTTCCCAGCTTAGATCTTTGAA	SEQ?ID?NO：526
B1961783.V1.3_at	ACCACCTTTGTATCCTTTTTGCTAG	SEQ?ID?NO：527	B1961783.V1.3_at	TGCCTTCCCAGCTTAGATCTTTGAA	SEQ?ID?NO：526
B1961783.V1.3_at	ACCACCTTTGTATCCTTTTTGCTAG	SEQ?ID?NO：527	B1961783.V1.3_at	AATGGCATCTTTTACTCAGTCACAA	SEQ?ID?NO：528
B1961783.V1.3_at	AACAAACTCTTAGCCATTCCCTATT	SEQ?ID?NO：529	B1961783.V1.3_at	AATGGCATCTTTTACTCAGTCACAA	SEQ?ID?NO：528
B1961783.V1.3_at	AACAAACTCTTAGCCATTCCCTATT	SEQ?ID?NO：529	B1961783.V1.3_at	GGCATTTAAATTCCCAGGCAGGTAC	SEQ?ID?NO：530
B1961783.V1.3_at	AGGTACCCTCTCTGTGGCTAGAAAT	SEQ?ID?NO：531	B1961783.V1.3_at	GGCATTTAAATTCCCAGGCAGGTAC	SEQ?ID?NO：530
B1961783.V1.3_at	AGGTACCCTCTCTGTGGCTAGAAAT	SEQ?ID?NO：531	B1961783.V1.3_at	GTTCTTTACAGCCATTGTTCTTGTG	SEQ?ID?NO：532
B1961785.V1.3_at	AGAATTCCAGCTGCAGCGGTTCGAT	SEQ?ID?NO：533	B1961783.V1.3_at	GTTCTTTACAGCCATTGTTCTTGTG	SEQ?ID?NO：532
B1961785.V1.3_at	AGAATTCCAGCTGCAGCGGTTCGAT	SEQ?ID?NO：533	B1961785.V1.3_at	GGTTCGATGCGGAAGCCGCGCCAAT	SEQ?ID?NO：534
B1961785.V1.3_at	GCTCGCGAAATAGGCGTCCGATTCC	SEQ?ID?NO：535	B1961785.V1.3_at	GGTTCGATGCGGAAGCCGCGCCAAT	SEQ?ID?NO：534
B1961785.V1.3_at	GCTCGCGAAATAGGCGTCCGATTCC	SEQ?ID?NO：535	B1961785.V1.3_at	GATTCCTCCCGTGTGACGGGACTCA	SEQ?ID?NO：536
B1961785.V1.3_at	GGCCCAGGGACTTCCAGTGCAGCAC	SEQ?ID?NO：537	B1961785.V1.3_at	GATTCCTCCCGTGTGACGGGACTCA	SEQ?ID?NO：536
B1961785.V1.3_at	GGCCCAGGGACTTCCAGTGCAGCAC	SEQ?ID?NO：537	B1961785.V1.3_at	CCTTGGCCGATTCGGCATTGGTGTA	SEQ?ID?NO：538
B1961785.V1.3_at	CATTGGTGTAGAAGACGAGTCCCCG	SEQ?ID?NO：539	B1961785.V1.3_at	CCTTGGCCGATTCGGCATTGGTGTA	SEQ?ID?NO：538
B1961785.V1.3_at	CATTGGTGTAGAAGACGAGTCCCCG	SEQ?ID?NO：539	B1961785.V1.3_at	GGATCGAGGCCCTTCAGCAGCACCA	SEQ?ID?NO：540
B1961785.V1.3_at	GGGTCCGACGACAATGTGAAGTCCT	SEQ?ID?NO：541	B1961785.V1.3_at	GGATCGAGGCCCTTCAGCAGCACCA	SEQ?ID?NO：540
B1961785.V1.3_at	GGGTCCGACGACAATGTGAAGTCCT	SEQ?ID?NO：541	B1961785.V1.3_at	TCTCTTAACCGATCGATGGCCATTT	SEQ?ID?NO：542
B1961785.V1.3_at	ATGGCCATTTTCTTCCCTGTGGCAG	SEQ?ID?NO：543	B1961785.V1.3_at	TCTCTTAACCGATCGATGGCCATTT	SEQ?ID?NO：542
B1961785.V1.3_at	ATGGCCATTTTCTTCCCTGTGGCAG	SEQ?ID?NO：543	B1961786.V1.3_at	GTCCTGACCCTGTGCTGGTGAATGG	SEQ?ID?NO：544
B1961786.V1.3_at	GGACTACATCCTCAAGGGCAGCAAT	SEQ?ID?NO：545	B1961786.V1.3_at	GTCCTGACCCTGTGCTGGTGAATGG	SEQ?ID?NO：544
B1961786.V1.3_at	GGACTACATCCTCAAGGGCAGCAAT	SEQ?ID?NO：545	B1961786.V1.3_at	GCAGCAATTGGAGCCAGTGCCTAGA	SEQ?ID?NO：546
B1961786.V1.3_at	AGTGCCTAGAGGACCACACCTGGAT	SEQ?ID?NO：547	B1961786.V1.3_at	GCAGCAATTGGAGCCAGTGCCTAGA	SEQ?ID?NO：546
B1961786.V1.3_at	AGTGCCTAGAGGACCACACCTGGAT	SEQ?ID?NO：547	B1961786.V1.3_at	AAAAGCAGACACTGTGGCCATCCCG	SEQ?ID?NO：548
B1961786.V1.3_at	GGGTATCCAGCTCATGGCTGTTTTA	SEQ?ID?NO：549	B1961786.V1.3_at	AAAAGCAGACACTGTGGCCATCCCG	SEQ?ID?NO：548
B1961786.V1.3_at	GGGTATCCAGCTCATGGCTGTTTTA	SEQ?ID?NO：549	B1961786.V1.3_at	GGAGAAGACTTCACCTCAGGATCTA	SEQ?ID?NO：550
B1961786.V1.3_at	ACTTAGTGGGCACACGGGACCAACA	SEQ?ID?NO：551	B1961786.V1.3_at	GGAGAAGACTTCACCTCAGGATCTA	SEQ?ID?NO：550
B1961786.V1.3_at	ACTTAGTGGGCACACGGGACCAACA	SEQ?ID?NO：551	B1961786.V1.3_at	ACTTCCAGTCTGTGAGTTGATCCAA	SEQ?ID?NO：552
B1961786.V1.3_at	CAGCTCCACAGACCGAGTGCGAGAA	SEQ?ID?NO：553	B1961786.V1.3_at	ACTTCCAGTCTGTGAGTTGATCCAA	SEQ?ID?NO：552
B1961786.V1.3_at	CAGCTCCACAGACCGAGTGCGAGAA	SEQ?ID?NO：553	B1961786.V1.3_at	TGTTGCCCTGACATTGTAGCTAAAC	SEQ?ID?NO：554
B1961792.V1.3_at	TTCCACACCTACCTTAGACTTTAAT	SEQ?ID?NO：555	B1961786.V1.3_at	TGTTGCCCTGACATTGTAGCTAAAC	SEQ?ID?NO：554
B1961792.V1.3_at	TTCCACACCTACCTTAGACTTTAAT	SEQ?ID?NO：555	B1961792.V1.3_at	GAACCTCAGCCATTTTCAATTACAG	SEQ?ID?NO：556
B1961792.V1.3_at	AAACTTCACTCCGTGTGTAGGGACG	SEQ?ID?NO：557	B1961792.V1.3_at	GAACCTCAGCCATTTTCAATTACAG	SEQ?ID?NO：556
B1961792.V1.3_at	AAACTTCACTCCGTGTGTAGGGACG	SEQ?ID?NO：557	B1961792.V1.3_at	TAGGATAGGTTGTCTGCACCTCCCA	SEQ?ID?NO：558
B1961792.V1.3_at	AGAATTCTTGCTCCCTTGCTGCTGT	SEQ?ID?NO：559	B1961792.V1.3_at	TAGGATAGGTTGTCTGCACCTCCCA	SEQ?ID?NO：558
B1961792.V1.3_at	AGAATTCTTGCTCCCTTGCTGCTGT	SEQ?ID?NO：559	B1961792.V1.3_at	ATACTAAAGGATGGCCAGCTGCTTC	SEQ?ID?NO：560

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961792.V1.3_at	GGTTTTCATTTACTGCAGCTGCTAG	SEQ?ID?NO：561
B1961792.V1.3_at	GGAATTGCACTCAGACGTGACATTT	SEQ?ID?NO：562	B1961792.V1.3_at	GGTTTTCATTTACTGCAGCTGCTAG	SEQ?ID?NO：561
B1961792.V1.3_at	GGAATTGCACTCAGACGTGACATTT	SEQ?ID?NO：562	B1961792.V1.3_at	GTGACATTTCAGTTCATCTCTGCTA	SEQ?ID?NO：563
B1961792.V1.3_at	CTATGTGTCAGTTCTGTCAGCTGCA	SEQ?ID?NO：564	B1961792.V1.3_at	GTGACATTTCAGTTCATCTCTGCTA	SEQ?ID?NO：563
B1961792.V1.3_at	CTATGTGTCAGTTCTGTCAGCTGCA	SEQ?ID?NO：564	B1961792.V1.3_at	GTCAGCTGCAGGTTCTTGTATAATG	SEQ?ID?NO：565
B1961795.V1.3_at	TGAAGGCTAGACATGTGGCACCCAG	SEQ?ID?NO：566	B1961792.V1.3_at	GTCAGCTGCAGGTTCTTGTATAATG	SEQ?ID?NO：565
B1961795.V1.3_at	TGAAGGCTAGACATGTGGCACCCAG	SEQ?ID?NO：566	B1961795.V1.3_at	GGCACCCAGCGATACAGTTCTTATG	SEQ?ID?NO：567
B1961795.V1.3_at	CTTATGTTTAATGTGGCCTTGGTCC	SEQ?ID?NO：568	B1961795.V1.3_at	GGCACCCAGCGATACAGTTCTTATG	SEQ?ID?NO：567
B1961795.V1.3_at	CTTATGTTTAATGTGGCCTTGGTCC	SEQ?ID?NO：568	B1961795.V1.3_at	GTGGCCTTGGTCCTACAAAGATTAG	SEQ?ID?NO：569
B1961795.V1.3_at	AAAGATTAGCTACCTCTGTCCTGAA	SEQ?ID?NO：570	B1961795.V1.3_at	GTGGCCTTGGTCCTACAAAGATTAG	SEQ?ID?NO：569
B1961795.V1.3_at	AAAGATTAGCTACCTCTGTCCTGAA	SEQ?ID?NO：570	B1961795.V1.3_at	GGAGCTTGCACATAGATACTTCAGT	SEQ?ID?NO：571
B1961795.V1.3_at	AAATGAGATTCGATTTGGCCCTCGC	SEQ?ID?NO：572	B1961795.V1.3_at	GGAGCTTGCACATAGATACTTCAGT	SEQ?ID?NO：571
B1961795.V1.3_at	AAATGAGATTCGATTTGGCCCTCGC	SEQ?ID?NO：572	B1961795.V1.3_at	CTCGCTGCTACAGAAGCCAGGCAAT	SEQ?ID?NO：573
B1961795.V1.3_at	GCCAGGCAATGCTCTGACTTACTGA	SEQ?ID?NO：574	B1961795.V1.3_at	CTCGCTGCTACAGAAGCCAGGCAAT	SEQ?ID?NO：573
B1961795.V1.3_at	GCCAGGCAATGCTCTGACTTACTGA	SEQ?ID?NO：574	B1961795.V1.3_at	AGTACCATGTGGCTCGGGCACGCAA	SEQ?ID?NO：575
B1961795.V1.3_at	GAAACTTTTGGAACAGAGGGCTCAG	SEQ?ID?NO：576	B1961795.V1.3_at	AGTACCATGTGGCTCGGGCACGCAA	SEQ?ID?NO：575
B1961795.V1.3_at	GAAACTTTTGGAACAGAGGGCTCAG	SEQ?ID?NO：576	B1961798.V1.3_at	AGTTTACCACCCTCCAGAAGATAGT	SEQ?ID?NO：577
B1961798.V1.3_at	CCAGGTCAGGAACTCGGCTACAGAA	SEQ?ID?NO：578	B1961798.V1.3_at	AGTTTACCACCCTCCAGAAGATAGT	SEQ?ID?NO：577
B1961798.V1.3_at	CCAGGTCAGGAACTCGGCTACAGAA	SEQ?ID?NO：578	B1961798.V1.3_at	ACAGAAGCCCTCTTGTGGCTGAAGA	SEQ?ID?NO：579
B1961798.V1.3_at	GGACATCCAGACAGCCTTGAATAAC	SEQ?ID?NO：580	B1961798.V1.3_at	ACAGAAGCCCTCTTGTGGCTGAAGA	SEQ?ID?NO：579
B1961798.V1.3_at	GGACATCCAGACAGCCTTGAATAAC	SEQ?ID?NO：580	B1961798.V1.3_at	GGGCAGCTCCATCCTATGAAGATTT	SEQ?ID?NO：581
B1961798.V1.3_at	ATGAAGATTTTGTGGCCGCGTTAAC	SEQ?ID?NO：582	B1961798.V1.3_at	GGGCAGCTCCATCCTATGAAGATTT	SEQ?ID?NO：581
B1961798.V1.3_at	ATGAAGATTTTGTGGCCGCGTTAAC	SEQ?ID?NO：582	B1961798.V1.3_at	AGGTGACCACCAGAAAGCAGCTTTC	SEQ?ID?NO：583
B1961798.V1.3_at	GATGCAGAGGGATCTCAGCCTTTAC	SEQ?ID?NO：584	B1961798.V1.3_at	AGGTGACCACCAGAAAGCAGCTTTC	SEQ?ID?NO：583
B1961798.V1.3_at	GATGCAGAGGGATCTCAGCCTTTAC	SEQ?ID?NO：584	B1961798.V1.3_at	AGCTGGCGATACTGGACACTTTATA	SEQ?ID?NO：585
B1961798.V1.3_at	ACACTTTATACGAGGTCCACGGACT	SEQ?ID?NO：586	B1961798.V1.3_at	AGCTGGCGATACTGGACACTTTATA	SEQ?ID?NO：585
B1961798.V1.3_at	ACACTTTATACGAGGTCCACGGACT	SEQ?ID?NO：586	B1961798.V1.3_at	TATGACGTCTGCAGGACAGGGCCAC	SEQ?ID?NO：587
B1961799.V1.3_at	AAGAAGGCCGGGTCTGTTTCTCTTG	SEQ?ID?NO：588	B1961798.V1.3_at	TATGACGTCTGCAGGACAGGGCCAC	SEQ?ID?NO：587
B1961799.V1.3_at	AAGAAGGCCGGGTCTGTTTCTCTTG	SEQ?ID?NO：588	B1961799.V1.3_at	GTTTCTCTTGGTACCCTTCAGAGTA	SEQ?ID?NO：589
B1961799.V1.3_at	GAAGATTTCCTGTTACACGGCTCTC	SEQ?ID?NO：590	B1961799.V1.3_at	GTTTCTCTTGGTACCCTTCAGAGTA	SEQ?ID?NO：589
B1961799.V1.3_at	GAAGATTTCCTGTTACACGGCTCTC	SEQ?ID?NO：590	B1961799.V1.3_at	GGCTCTCCCTCAAATACAATTACAA	SEQ?ID?NO：591
B1961799.V1.3_at	GCACCTGTTGAGCATCTGTGACCAA	SEQ?ID?NO：592	B1961799.V1.3_at	GGCTCTCCCTCAAATACAATTACAA	SEQ?ID?NO：591
B1961799.V1.3_at	GCACCTGTTGAGCATCTGTGACCAA	SEQ?ID?NO：592	B1961799.V1.3_at	GAATTGTCCCAGGATCCTTACTAAG	SEQ?ID?NO：593
B1961799.V1.3_at	AAGGGTGTTTCAGCTGATTCGCCAC	SEQ?ID?NO：594	B1961799.V1.3_at	GAATTGTCCCAGGATCCTTACTAAG	SEQ?ID?NO：593
B1961799.V1.3_at	AAGGGTGTTTCAGCTGATTCGCCAC	SEQ?ID?NO：594	B1961799.V1.3_at	TTTGGGTTCCTTGGTTTCATCGCCG	SEQ?ID?NO：595
B1961799.V1.3_at	CTTGGGTCCCACTGAACTTTGTGAA	SEQ?ID?NO：596	B1961799.V1.3_at	TTTGGGTTCCTTGGTTTCATCGCCG	SEQ?ID?NO：595
B1961799.V1.3_at	CTTGGGTCCCACTGAACTTTGTGAA	SEQ?ID?NO：596	B1961799.V1.3_at	TTGTGAATTCCTGTGTTCGCATCTT	SEQ?ID?NO：597
B1961799.V1.3_at	ATCTTCTGTTCCTGGAAGGTGTCCT	SEQ?ID?NO：598	B1961799.V1.3_at	TTGTGAATTCCTGTGTTCGCATCTT	SEQ?ID?NO：597
B1961799.V1.3_at	ATCTTCTGTTCCTGGAAGGTGTCCT	SEQ?ID?NO：598	B1961800.V1.3_at	TGTCCTGCAGGAACCCAAGCTTGAA	SEQ?ID?NO：599
B1961800.V1.3_at	AAGCTTGAACCCAGCGGCTGCTACA	SEQ?ID?NO：600	B1961800.V1.3_at	TGTCCTGCAGGAACCCAAGCTTGAA	SEQ?ID?NO：599
B1961800.V1.3_at	AAGCTTGAACCCAGCGGCTGCTACA	SEQ?ID?NO：600	B1961800.V1.3_at	AAGAGTCACAAACTGTCTCCATCAC	SEQ?ID?NO：601
B1961800.V1.3_at	GAGCTGGCCCTCAACGAGCTGGTGA	SEQ?ID?NO：602	B1961800.V1.3_at	AAGAGTCACAAACTGTCTCCATCAC	SEQ?ID?NO：601
B1961800.V1.3_at	GAGCTGGCCCTCAACGAGCTGGTGA	SEQ?ID?NO：602	B1961800.V1.3_at	GCTTCAGCCCTAAGGAGGTGTTGGT	SEQ?ID?NO：603
B1961800.V1.3_at	TGCTCTGGCTGCAAGGGCACGAGAA	SEQ?ID?NO：604	B1961800.V1.3_at	GCTTCAGCCCTAAGGAGGTGTTGGT	SEQ?ID?NO：603
B1961800.V1.3_at	TGCTCTGGCTGCAAGGGCACGAGAA	SEQ?ID?NO：604	B1961800.V1.3_at	AAGCTGCCCCGCGAGAAGTACCTGG	SEQ?ID?NO：605

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961800.V1.3_at	GAAGTACCTGGTCTTTAAGCCCCTG	SEQ?ID?NO：606
B1961800.V1.3_at	AGACGTCTTCTCCTGCATGGTGGGC	SEQ?ID?NO：607	B1961800.V1.3_at	GAAGTACCTGGTCTTTAAGCCCCTG	SEQ?ID?NO：606
B1961800.V1.3_at	AGACGTCTTCTCCTGCATGGTGGGC	SEQ?ID?NO：607	B1961800.V1.3_at	GAGCTTCACCCAGAAGTCTATCGAC	SEQ?ID?NO：608
B1961800.V1.3_at	ATGTCAACGTGTCCGTGGTCATGGC	SEQ?ID?NO：609	B1961800.V1.3_at	GAGCTTCACCCAGAAGTCTATCGAC	SEQ?ID?NO：608
B1961800.V1.3_at	ATGTCAACGTGTCCGTGGTCATGGC	SEQ?ID?NO：609	B1961805.V1.3_at	TGTCATACAGTGTCCAAAACCCCAG	SEQ?ID?NO：610
B1961805.V1.3_at	GCGACAAGAACCTCATTGACTCCAT	SEQ?ID?NO：611	B1961805.V1.3_at	TGTCATACAGTGTCCAAAACCCCAG	SEQ?ID?NO：610
B1961805.V1.3_at	GCGACAAGAACCTCATTGACTCCAT	SEQ?ID?NO：611	B1961805.V1.3_at	TTGACTCCATGGACCAAGCAGCCTT	SEQ?ID?NO：612
B1961805.V1.3_at	GAACCCCAAATTTGAGAGGCTCCTG	SEQ?ID?NO：613	B1961805.V1.3_at	TTGACTCCATGGACCAAGCAGCCTT	SEQ?ID?NO：612
B1961805.V1.3_at	GAACCCCAAATTTGAGAGGCTCCTG	SEQ?ID?NO：613	B1961805.V1.3_at	AAAAGTGAGGTTCCCAGACATGCCG	SEQ?ID?NO：614
B1961805.V1.3_at	ATTGTTGTGATTTCTGCTGCTGCCC	SEQ?ID?NO：615	B1961805.V1.3_at	AAAAGTGAGGTTCCCAGACATGCCG	SEQ?ID?NO：614
B1961805.V1.3_at	ATTGTTGTGATTTCTGCTGCTGCCC	SEQ?ID?NO：615	B1961805.V1.3_at	TTATCGTCCCCAGGAGGGTCCTTGG	SEQ?ID?NO：616
B1961805.V1.3_at	GCCTGGCTGGGCTCTTATGGTACTT	SEQ?ID?NO：617	B1961805.V1.3_at	TTATCGTCCCCAGGAGGGTCCTTGG	SEQ?ID?NO：616
B1961805.V1.3_at	GCCTGGCTGGGCTCTTATGGTACTT	SEQ?ID?NO：617	B1961805.V1.3_at	TATGGTACTTCCTCTGTGAACTGTG	SEQ?ID?NO：618
B1961805.V1.3_at	ACTGTGTGTGAATTTGCCTTTCCTC	SEQ?ID?NO：619	B1961805.V1.3_at	TATGGTACTTCCTCTGTGAACTGTG	SEQ?ID?NO：618
B1961805.V1.3_at	ACTGTGTGTGAATTTGCCTTTCCTC	SEQ?ID?NO：619	B1961805.V1.3_at	AAATCCTGTGTTTTGTTACTTGAAT	SEQ?ID?NO：620
B1961806.V1.3_at	AAAGCAGTGATACCTCCAGAGCAGT	SEQ?ID?NO：621	B1961805.V1.3_at	AAATCCTGTGTTTTGTTACTTGAAT	SEQ?ID?NO：620
B1961806.V1.3_at	AAAGCAGTGATACCTCCAGAGCAGT	SEQ?ID?NO：621	B1961806.V1.3_at	AGCAGTGAGCTCTCTCGGCACCTAA	SEQ?ID?NO：622
B1961806.V1.3_at	TCGGCACCTAAGCAGTGCTTTCTAT	SEQ?ID?NO：623	B1961806.V1.3_at	AGCAGTGAGCTCTCTCGGCACCTAA	SEQ?ID?NO：622
B1961806.V1.3_at	TCGGCACCTAAGCAGTGCTTTCTAT	SEQ?ID?NO：623	B1961806.V1.3_at	TTTCTATACTGTTCCTCACCAAAAG	SEQ?ID?NO：624
B1961806.V1.3_at	AAGAACCAGTGCTCCCTGGAGAAAT	SEQ?ID?NO：625	B1961806.V1.3_at	TTTCTATACTGTTCCTCACCAAAAG	SEQ?ID?NO：624
B1961806.V1.3_at	AAGAACCAGTGCTCCCTGGAGAAAT	SEQ?ID?NO：625	B1961806.V1.3_at	ATGGCTGATTCCATGTCAGGAGCTT	SEQ?ID?NO：626
B1961806.V1.3_at	AAAGTAAAACTGAGCCTGGGACATC	SEQ?ID?NO：627	B1961806.V1.3_at	ATGGCTGATTCCATGTCAGGAGCTT	SEQ?ID?NO：626
B1961806.V1.3_at	AAAGTAAAACTGAGCCTGGGACATC	SEQ?ID?NO：627	B1961806.V1.3_at	GCCTGGGACATCTTGTTGGGCCAAA	SEQ?ID?NO：628
B1961806.V1.3_at	GAATAGTGCTCACAGACAACTTTGA	SEQ?ID?NO：629	B1961806.V1.3_at	GCCTGGGACATCTTGTTGGGCCAAA	SEQ?ID?NO：628
B1961806.V1.3_at	GAATAGTGCTCACAGACAACTTTGA	SEQ?ID?NO：629	B1961806.V1.3_at	TAAAAGGGCTCCCACTGGACACATT	SEQ?ID?NO：630
B1961806.V1.3_at	GGACACATTCAGTACAGTTTGAGCA	SEQ?ID?NO：631	B1961806.V1.3_at	TAAAAGGGCTCCCACTGGACACATT	SEQ?ID?NO：630
B1961806.V1.3_at	GGACACATTCAGTACAGTTTGAGCA	SEQ?ID?NO：631	B1961810.V1.3_at	GAAATGTTGTACCTATCTGGGCACT	SEQ?ID?NO：632
B1961810.V1.3_at	GTTGTACCTATCTGGGCACTACAGA	SEQ?ID?NO：633	B1961810.V1.3_at	GAAATGTTGTACCTATCTGGGCACT	SEQ?ID?NO：632
B1961810.V1.3_at	GTTGTACCTATCTGGGCACTACAGA	SEQ?ID?NO：633	B1961810.V1.3_at	GCACTACAGAAGATGCATAGGCCTT	SEQ?ID?NO：634
B1961810.V1.3_at	AGATGCATAGGCCTTCCAGAGCTCA	SEQ?ID?NO：635	B1961810.V1.3_at	GCACTACAGAAGATGCATAGGCCTT	SEQ?ID?NO：634
B1961810.V1.3_at	AGATGCATAGGCCTTCCAGAGCTCA	SEQ?ID?NO：635	B1961810.V1.3_at	AGGCCTTCCAGAGCTCACAGAGGAA	SEQ?ID?NO：636
B1961810.V1.3_at	AATGCTTCAAGAGGCATGGTCCTCA	SEQ?ID?NO：637	B1961810.V1.3_at	AGGCCTTCCAGAGCTCACAGAGGAA	SEQ?ID?NO：636
B1961810.V1.3_at	AATGCTTCAAGAGGCATGGTCCTCA	SEQ?ID?NO：637	B1961810.V1.3_at	AGGCATGGTCCTCAGAAATTATTCT	SEQ?ID?NO：638
B1961810.V1.3_at	ATTATTCTGGAATGCCGTTTCACTT	SEQ?ID?NO：639	B1961810.V1.3_at	AGGCATGGTCCTCAGAAATTATTCT	SEQ?ID?NO：638
B1961810.V1.3_at	ATTATTCTGGAATGCCGTTTCACTT	SEQ?ID?NO：639	B1961810.V1.3_at	GGAATGCCGTTTCACTTGTATCAAC	SEQ?ID?NO：640
B1961810.V1.3_at	GCCGTTTCACTTGTATCAACATCAT	SEQ?ID?NO：641	B1961810.V1.3_at	GGAATGCCGTTTCACTTGTATCAAC	SEQ?ID?NO：640
B1961810.V1.3_at	GCCGTTTCACTTGTATCAACATCAT	SEQ?ID?NO：641	B1961810.V1.3_at	TCAACATCATGTTCCTGGTTCAGTT	SEQ?ID?NO：642
B1961812.V1.3_at	GGGCCTCCAGCCTTTGCCGCAAGTG	SEQ?ID?NO：643	B1961810.V1.3_at	TCAACATCATGTTCCTGGTTCAGTT	SEQ?ID?NO：642
B1961812.V1.3_at	GGGCCTCCAGCCTTTGCCGCAAGTG	SEQ?ID?NO：643	B1961812.V1.3_at	AGCCTTTGCCGCAAGTGCCTCGGTG	SEQ?ID?NO：644
B1961812.V1.3_at	CAAGTGCCTCGGTGCCCGCTGGGTC	SEQ?ID?NO：645	B1961812.V1.3_at	AGCCTTTGCCGCAAGTGCCTCGGTG	SEQ?ID?NO：644
B1961812.V1.3_at	CAAGTGCCTCGGTGCCCGCTGGGTC	SEQ?ID?NO：645	B1961812.V1.3_at	CCCACCGCAAGGAGGACTCAGGACA	SEQ?ID?NO：646
B1961812.V1.3_at	AAGGAGGACTCAGGACAGCCCTCCA	SEQ?ID?NO：647	B1961812.V1.3_at	CCCACCGCAAGGAGGACTCAGGACA	SEQ?ID?NO：646
B1961812.V1.3_at	AAGGAGGACTCAGGACAGCCCTCCA	SEQ?ID?NO：647	B1961812.V1.3_at	ACCCACAGAGCTTTTCCTCCTGGAC	SEQ?ID?NO：648
B1961812.V1.3_at	GCCGCCGGAAGGAAAGAGCTTGCCC	SEQ?ID?NO：649	B1961812.V1.3_at	ACCCACAGAGCTTTTCCTCCTGGAC	SEQ?ID?NO：648
B1961812.V1.3_at	GCCGCCGGAAGGAAAGAGCTTGCCC	SEQ?ID?NO：649	B1961812.V1.3_at	GAAGGAAAGAGCTTGCCCGCTCCTA	SEQ?ID?NO：650

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961812.V1.3_at	TTGCCCGCTCCTACAGGACGTTTAT	SEQ?ID?NO：651
B1961812.V1.3_at	GCTCCTACAGGACGTTTATTTTTCT	SEQ?ID?NO：652	B1961812.V1.3_at	TTGCCCGCTCCTACAGGACGTTTAT	SEQ?ID?NO：651
B1961812.V1.3_at	GCTCCTACAGGACGTTTATTTTTCT	SEQ?ID?NO：652	B1961812.V1.3_at	CAGGACGTTTATTTTTCTCTTGCCA	SEQ?ID?NO：653
B1961814.V1.3_s_at	GCCAGGAGACGGTCGCCCAGATCAA	SEQ?ID?NO：654	B1961812.V1.3_at	CAGGACGTTTATTTTTCTCTTGCCA	SEQ?ID?NO：653
B1961814.V1.3_s_at	GCCAGGAGACGGTCGCCCAGATCAA	SEQ?ID?NO：654	B1961814.V1.3_s_at	GAAAGTCAGAGGTCAGACTCCCAAG	SEQ?ID?NO：655
B1961814.V1.3_s_at	CAGAGGTCAGACTCCCAAGGTGGCC	SEQ?ID?NO：656	B1961814.V1.3_s_at	GAAAGTCAGAGGTCAGACTCCCAAG	SEQ?ID?NO：655
B1961814.V1.3_s_at	CAGAGGTCAGACTCCCAAGGTGGCC	SEQ?ID?NO：656	B1961814.V1.3_s_at	AGGGCATCGCTGCAGAAGATCAAGT	SEQ?ID?NO：657
B1961814.V1.3_s_at	GATCAAGTCGTGCTCTTGGCAGGCA	SEQ?ID?NO：658	B1961814.V1.3_s_at	AGGGCATCGCTGCAGAAGATCAAGT	SEQ?ID?NO：657
B1961814.V1.3_s_at	GATCAAGTCGTGCTCTTGGCAGGCA	SEQ?ID?NO：658	B1961814.V1.3_s_at	GCCCCTGGAGGATGAGGCTACTCTG	SEQ?ID?NO：659
B1961814.V1.3_s_at	GGAGGCTCTGACCACTCTGGAAGTA	SEQ?ID?NO：660	B1961814.V1.3_s_at	GCCCCTGGAGGATGAGGCTACTCTG	SEQ?ID?NO：659
B1961814.V1.3_s_at	GGAGGCTCTGACCACTCTGGAAGTA	SEQ?ID?NO：660	B1961814.V1.3_s_at	TGACCACTCTGGAAGTAGCCGGCCG	SEQ?ID?NO：661
B1961814.V1.3_s_at	AGCCGGCCGCATGCTTGGAGGTAAA	SEQ?ID?NO：662	B1961814.V1.3_s_at	TGACCACTCTGGAAGTAGCCGGCCG	SEQ?ID?NO：661
B1961814.V1.3_s_at	AGCCGGCCGCATGCTTGGAGGTAAA	SEQ?ID?NO：662	B1961814.V1.3_s_at	GAGGTAAAGTCCATGGCTCCCTAGC	SEQ?ID?NO：663
B1961814.V1.3_s_at	CCTAGCCCGTGCTGGGAAAGTCAGA	SEQ?ID?NO：664	B1961814.V1.3_s_at	GAGGTAAAGTCCATGGCTCCCTAGC	SEQ?ID?NO：663
B1961814.V1.3_s_at	CCTAGCCCGTGCTGGGAAAGTCAGA	SEQ?ID?NO：664	B1961815.V1.3_at	GCAGATGCCAGCTTCAGTTTAGAGA	SEQ?ID?NO：665
B1961815.V1.3_at	GAATGAAGCTCGTGGTTCGCAGACT	SEQ?ID?NO：666	B1961815.V1.3_at	GCAGATGCCAGCTTCAGTTTAGAGA	SEQ?ID?NO：665
B1961815.V1.3_at	GAATGAAGCTCGTGGTTCGCAGACT	SEQ?ID?NO：666	B1961815.V1.3_at	GTTCGCAGACTGTCTCAACAGCATT	SEQ?ID?NO：667
B1961815.V1.3_at	ATAACATGTTCAAGTGCGCCTAGTG	SEQ?ID?NO：668	B1961815.V1.3_at	GTTCGCAGACTGTCTCAACAGCATT	SEQ?ID?NO：667
B1961815.V1.3_at	ATAACATGTTCAAGTGCGCCTAGTG	SEQ?ID?NO：668	B1961815.V1.3_at	GCCTAGTGTTTTTGCTACCACAATC	SEQ?ID?NO：669
B1961815.V1.3_at	TGGAAACTCTTTCTTCATGTACAGA	SEQ?ID?NO：670	B1961815.V1.3_at	GCCTAGTGTTTTTGCTACCACAATC	SEQ?ID?NO：669
B1961815.V1.3_at	TGGAAACTCTTTCTTCATGTACAGA	SEQ?ID?NO：670	B1961815.V1.3_at	GAAGCCTCAAGTGACCTGTTTTTAA	SEQ?ID?NO：671
B1961815.V1.3_at	GTGGACAATAACTTTCCCTTCCCAG	SEQ?ID?NO：672	B1961815.V1.3_at	GAAGCCTCAAGTGACCTGTTTTTAA	SEQ?ID?NO：671
B1961815.V1.3_at	GTGGACAATAACTTTCCCTTCCCAG	SEQ?ID?NO：672	B1961815.V1.3_at	TCCCAGTGGTTCTCATCTTAACGTA	SEQ?ID?NO：673
B1961815.V1.3_at	TCGAATCTTATGTGACCCATCTCTT	SEQ?ID?NO：674	B1961815.V1.3_at	TCCCAGTGGTTCTCATCTTAACGTA	SEQ?ID?NO：673
B1961815.V1.3_at	TCGAATCTTATGTGACCCATCTCTT	SEQ?ID?NO：674	B1961815.V1.3_at	GACCCATCTCTTCTTGAATCTTTTT	SEQ?ID?NO：675
B1961816.V1.3_at	GGGCATGTGCCTCCATCAGACACAG	SEQ?ID?NO：676	B1961815.V1.3_at	GACCCATCTCTTCTTGAATCTTTTT	SEQ?ID?NO：675
B1961816.V1.3_at	GGGCATGTGCCTCCATCAGACACAG	SEQ?ID?NO：676	B1961816.V1.3_at	ATCAGACACAGCCAAGCTCTCCTGG	SEQ?ID?NO：677
B1961816.V1.3_at	GCTCTGACCTACAGCTTTGTGTTGA	SEQ?ID?NO：678	B1961816.V1.3_at	ATCAGACACAGCCAAGCTCTCCTGG	SEQ?ID?NO：677
B1961816.V1.3_at	GCTCTGACCTACAGCTTTGTGTTGA	SEQ?ID?NO：678	B1961816.V1.3_at	ATAGCTTGCGGCAGGTGGCACATGC	SEQ?ID?NO：679
B1961816.V1.3_at	GTGGCACATGCCACGCAGACGAGGC	SEQ?ID?NO：680	B1961816.V1.3_at	ATAGCTTGCGGCAGGTGGCACATGC	SEQ?ID?NO：679
B1961816.V1.3_at	GTGGCACATGCCACGCAGACGAGGC	SEQ?ID?NO：680	B1961816.V1.3_at	GGAAGTGCATCAGACCAGCGGCCAT	SEQ?ID?NO：681
B1961816.V1.3_at	GCAAAGTTCAGTGGGCAGCGCAGCA	SEQ?ID?NO：682	B1961816.V1.3_at	GGAAGTGCATCAGACCAGCGGCCAT	SEQ?ID?NO：681
B1961816.V1.3_at	GCAAAGTTCAGTGGGCAGCGCAGCA	SEQ?ID?NO：682	B1961816.V1.3_at	ATGGTGCCCCTGTAGGCCTCTGGGA	SEQ?ID?NO：683
B1961816.V1.3_at	CAGCAGGCAGGAGACGGCCAAGCCA	SEQ?ID?NO：684	B1961816.V1.3_at	ATGGTGCCCCTGTAGGCCTCTGGGA	SEQ?ID?NO：683
B1961816.V1.3_at	CAGCAGGCAGGAGACGGCCAAGCCA	SEQ?ID?NO：684	B1961816.V1.3_at	TTGGCTTCGGCCTCCTTAAGAAAGG	SEQ?ID?NO：685
B1961816.V1.3_at	TTAAGAAAGGGAGACACTGCCCGCA	SEQ?ID?NO：686	B1961816.V1.3_at	TTGGCTTCGGCCTCCTTAAGAAAGG	SEQ?ID?NO：685
B1961816.V1.3_at	TTAAGAAAGGGAGACACTGCCCGCA	SEQ?ID?NO：686	B1961817.V1.3_at	ACATCTTTTGCCTTGTTCATGGTCA	SEQ?ID?NO：687
B1961817.V1.3_at	GGTCATCTGGATCATCTTTTACACT	SEQ?ID?NO：688	B1961817.V1.3_at	ACATCTTTTGCCTTGTTCATGGTCA	SEQ?ID?NO：687
B1961817.V1.3_at	GGTCATCTGGATCATCTTTTACACT	SEQ?ID?NO：688	B1961817.V1.3_at	TACACTGCCATCCACTATGACTGAT	SEQ?ID?NO：689
B1961817.V1.3_at	ATGACTGATGGTGTACAGGCCCCAC	SEQ?ID?NO：690	B1961817.V1.3_at	TACACTGCCATCCACTATGACTGAT	SEQ?ID?NO：689
B1961817.V1.3_at	ATGACTGATGGTGTACAGGCCCCAC	SEQ?ID?NO：690	B1961817.V1.3_at	GACCCTCTTACTTACAGCACAGAAA	SEQ?ID?NO：691
B1961817.V1.3_at	AAGACCCATGTTTCCTGGACTGAGA	SEQ?ID?NO：692	B1961817.V1.3_at	GACCCTCTTACTTACAGCACAGAAA	SEQ?ID?NO：691
B1961817.V1.3_at	AAGACCCATGTTTCCTGGACTGAGA	SEQ?ID?NO：692	B1961817.V1.3_at	GATTATTCATCACCAACCATTTCTT	SEQ?ID?NO：693
B1961817.V1.3_at	GAAACACCTGTTTGCTGATTGGAGC	SEQ?ID?NO：694	B1961817.V1.3_at	GATTATTCATCACCAACCATTTCTT	SEQ?ID?NO：693
B1961817.V1.3_at	GAAACACCTGTTTGCTGATTGGAGC	SEQ?ID?NO：694	B1961817.V1.3_at	GATGCACCTCTGGATCCGGATGAAA	SEQ?ID?NO：695

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961817.V1.3_at	ATTAAATTGTCTTCCTCACTTCCGT	SEQ?ID?NO：696
B1961817.V1.3_at	TCACTTCCGTCAGGTGTACAGTTTT	SEQ?ID?NO：697	B1961817.V1.3_at	ATTAAATTGTCTTCCTCACTTCCGT	SEQ?ID?NO：696
B1961817.V1.3_at	TCACTTCCGTCAGGTGTACAGTTTT	SEQ?ID?NO：697	B1961827.V1.3_at	GGACGTGCCCAAGCAGAACTCGCAG	SEQ?ID?NO：698
B1961827.V1.3_at	GAGCGCTTCCAGAACCTCGACAGGA	SEQ?ID?NO：699	B1961827.V1.3_at	GGACGTGCCCAAGCAGAACTCGCAG	SEQ?ID?NO：698
B1961827.V1.3_at	GAGCGCTTCCAGAACCTCGACAGGA	SEQ?ID?NO：699	B1961827.V1.3_at	GGTCTGGACTCGCTGCACAAGAACA	SEQ?ID?NO：700
B1961827.V1.3_at	AGAACAGCGTCAGCCAGATCTCGGT	SEQ?ID?NO：701	B1961827.V1.3_at	GGTCTGGACTCGCTGCACAAGAACA	SEQ?ID?NO：700
B1961827.V1.3_at	AGAACAGCGTCAGCCAGATCTCGGT	SEQ?ID?NO：701	B1961827.V1.3_at	GGGAAAGGCCAAGTGCTCGCAGTTC	SEQ?ID?NO：702
B1961827.V1.3_at	GCAGTTCTGCACTACGGGCATGGAC	SEQ?ID?NO：703	B1961827.V1.3_at	GGGAAAGGCCAAGTGCTCGCAGTTC	SEQ?ID?NO：702
B1961827.V1.3_at	GCAGTTCTGCACTACGGGCATGGAC	SEQ?ID?NO：703	B1961827.V1.3_at	GAGCTTGGAATCAGCCTTGAAGGAC	SEQ?ID?NO：704
B1961827.V1.3_at	TGACCTGCCAGGATTATGTTGCCCT	SEQ?ID?NO：705	B1961827.V1.3_at	GAGCTTGGAATCAGCCTTGAAGGAC	SEQ?ID?NO：704
B1961827.V1.3_at	TGACCTGCCAGGATTATGTTGCCCT	SEQ?ID?NO：705	B1961827.V1.3_at	ACGGTCGCTTTGCTGAATGTTTCTA	SEQ?ID?NO：706
B1961827.V1.3_at	GTGGGAAGCTTTTCTTACCTGTTGA	SEQ?ID?NO：707	B1961827.V1.3_at	ACGGTCGCTTTGCTGAATGTTTCTA	SEQ?ID?NO：706
B1961827.V1.3_at	GTGGGAAGCTTTTCTTACCTGTTGA	SEQ?ID?NO：707	B1961827.V1.3_at	TGAAGGAACACGTGCCTTTTTCTTA	SEQ?ID?NO：708
B1961830.V1.3_at	TCCCAGCGAGAACCAACACTGAGTC	SEQ?ID?NO：709	B1961827.V1.3_at	TGAAGGAACACGTGCCTTTTTCTTA	SEQ?ID?NO：708
B1961830.V1.3_at	TCCCAGCGAGAACCAACACTGAGTC	SEQ?ID?NO：709	B1961830.V1.3_at	GGAACCTGGCACTTTCGTCGGCAGC	SEQ?ID?NO：710
B1961830.V1.3_at	TTTCGTCGGCAGCTGCAGCTTCTGG	SEQ?ID?NO：711	B1961830.V1.3_at	GGAACCTGGCACTTTCGTCGGCAGC	SEQ?ID?NO：710
B1961830.V1.3_at	TTTCGTCGGCAGCTGCAGCTTCTGG	SEQ?ID?NO：711	B1961830.V1.3_at	TTCTGGCTGCTTTTTTGGAGGTTCT	SEQ?ID?NO：712
B1961830.V1.3_at	TTTGGAGGTTCTTGGCCTGGACCCA	SEQ?ID?NO：713	B1961830.V1.3_at	TTCTGGCTGCTTTTTTGGAGGTTCT	SEQ?ID?NO：712
B1961830.V1.3_at	TTTGGAGGTTCTTGGCCTGGACCCA	SEQ?ID?NO：713	B1961830.V1.3_at	TCTTGGCCTGGACCCATGGGCTTCG	SEQ?ID?NO：714
B1961830.V1.3_at	CGTGCCATGCCATACTGTCACTCAG	SEQ?ID?NO：715	B1961830.V1.3_at	TCTTGGCCTGGACCCATGGGCTTCG	SEQ?ID?NO：714
B1961830.V1.3_at	CGTGCCATGCCATACTGTCACTCAG	SEQ?ID?NO：715	B1961830.V1.3_at	TGTCACTCAGCCACATCAGTGTTTG	SEQ?ID?NO：716
B1961830.V1.3_at	ACATCAGTGTTTGTCCCACCAAGGG	SEQ?ID?NO：717	B1961830.V1.3_at	TGTCACTCAGCCACATCAGTGTTTG	SEQ?ID?NO：716
B1961830.V1.3_at	ACATCAGTGTTTGTCCCACCAAGGG	SEQ?ID?NO：717	B1961830.V1.3_at	AGTGTTTGTCCCACCAAGGGAGGTG	SEQ?ID?NO：718
B1961830.V1.3_at	ATGGGTCACCCACATCTGTGCTTGG	SEQ?ID?NO：719	B1961830.V1.3_at	AGTGTTTGTCCCACCAAGGGAGGTG	SEQ?ID?NO：718
B1961830.V1.3_at	ATGGGTCACCCACATCTGTGCTTGG	SEQ?ID?NO：719	B1961841.V1.3_at	AAGAAGTGCTCAGCAGCGACACTGC	SEQ?ID?NO：720
B1961841.V1.3_at	TAGGCTCTCTTGTGTCCGTCATGTG	SEQ?ID?NO：721	B1961841.V1.3_at	AAGAAGTGCTCAGCAGCGACACTGC	SEQ?ID?NO：720
B1961841.V1.3_at	TAGGCTCTCTTGTGTCCGTCATGTG	SEQ?ID?NO：721	B1961841.V1.3_at	GTCCGTCATGTGCTTGTGAACACTA	SEQ?ID?NO：722
B1961841.V1.3_at	CTAAATTGTGAGACAGCAGCCTGTG	SEQ?ID?NO：723	B1961841.V1.3_at	GTCCGTCATGTGCTTGTGAACACTA	SEQ?ID?NO：722
B1961841.V1.3_at	CTAAATTGTGAGACAGCAGCCTGTG	SEQ?ID?NO：723	B1961841.V1.3_at	ACAAGATTTGTTCACGTCTCAACCC	SEQ?ID?NO：724
B1961841.V1.3_at	GTGTCTGCATTAGTATTGGCATACT	SEQ?ID?NO：725	B1961841.V1.3_at	ACAAGATTTGTTCACGTCTCAACCC	SEQ?ID?NO：724
B1961841.V1.3_at	GTGTCTGCATTAGTATTGGCATACT	SEQ?ID?NO：725	B1961841.V1.3_at	TGACCTGTGTTCTCTTCCCTGATTG	SEQ?ID?NO：726
B1961841.V1.3_at	CCCTGATTGACTGTTCCAGCAGAGA	SEQ?ID?NO：727	B1961841.V1.3_at	TGACCTGTGTTCTCTTCCCTGATTG	SEQ?ID?NO：726
B1961841.V1.3_at	CCCTGATTGACTGTTCCAGCAGAGA	SEQ?ID?NO：727	B1961841.V1.3_at	ATGTCTTTACTTCATGCTCCACTGA	SEQ?ID?NO：728
B1961841.V1.3_at	GAGCTGCAGTTTCTTAGTGCCTTAT	SEQ?ID?NO：729	B1961841.V1.3_at	ATGTCTTTACTTCATGCTCCACTGA	SEQ?ID?NO：728
B1961841.V1.3_at	GAGCTGCAGTTTCTTAGTGCCTTAT	SEQ?ID?NO：729	B1961841.V1.3_at	AATTCTTGCCATGAGGGATTGACGG	SEQ?ID?NO：730
B1961847.V1.3_at	CCGCCGAAGCGGAGTTGTGTGAACT	SEQ?ID?NO：731	B1961841.V1.3_at	AATTCTTGCCATGAGGGATTGACGG	SEQ?ID?NO：730
B1961847.V1.3_at	CCGCCGAAGCGGAGTTGTGTGAACT	SEQ?ID?NO：731	B1961847.V1.3_at	CAGCCCCTCATTTCTTTTTGATGAA	SEQ?ID?NO：732
B1961847.V1.3_at	AAGATTGTCTCTGATAAGTGGCTCA	SEQ?ID?NO：733	B1961847.V1.3_at	CAGCCCCTCATTTCTTTTTGATGAA	SEQ?ID?NO：732
B1961847.V1.3_at	AAGATTGTCTCTGATAAGTGGCTCA	SEQ?ID?NO：733	B1961847.V1.3_at	ATAAGTGGCTCAGAAGCTCCCATCT	SEQ?ID?NO：734
B1961847.V1.3_at	AGAAGCTCCCATCTGCTGGTGCAGG	SEQ?ID?NO：735	B1961847.V1.3_at	ATAAGTGGCTCAGAAGCTCCCATCT	SEQ?ID?NO：734
B1961847.V1.3_at	AGAAGCTCCCATCTGCTGGTGCAGG	SEQ?ID?NO：735	B1961847.V1.3_at	GGTGCAGGGTTTTCTGAGGCTCTTC	SEQ?ID?NO：736
B1961847.V1.3_at	TTTCTGAGGCTCTTCTTCCTGAGCA	SEQ?ID?NO：737	B1961847.V1.3_at	GGTGCAGGGTTTTCTGAGGCTCTTC	SEQ?ID?NO：736
B1961847.V1.3_at	TTTCTGAGGCTCTTCTTCCTGAGCA	SEQ?ID?NO：737	B1961847.V1.3_at	ACTCCGTGCTTTTCGTGTGCGTACC	SEQ?ID?NO：738
B1961847.V1.3_at	GCCTCCACATCAAGGGACAGTTTGT	SEQ?ID?NO：739	B1961847.V1.3_at	ACTCCGTGCTTTTCGTGTGCGTACC	SEQ?ID?NO：738
B1961847.V1.3_at	GCCTCCACATCAAGGGACAGTTTGT	SEQ?ID?NO：739	B1961847.V1.3_at	CAGTTTGTTTGTGCTTGTTTTTCTA	SEQ?ID?NO：740

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961847.V1.3_at	CTAATGACATAAATTCCCTGAAGAG	SEQ?ID?NO：741
B1961848.V1.3_at	TCAGAGAAAATGCTGCCGCAACCTC	SEQ?ID?NO：742	B1961847.V1.3_at	CTAATGACATAAATTCCCTGAAGAG	SEQ?ID?NO：741
B1961848.V1.3_at	TCAGAGAAAATGCTGCCGCAACCTC	SEQ?ID?NO：742	B1961848.V1.3_at	TGCTTCCAGGGCTGTACATAGTTGG	SEQ?ID?NO：743
B1961848.V1.3_at	ACTGCGTGGGTCAACTCAGTGTCCA	SEQ?ID?NO：744	B1961848.V1.3_at	TGCTTCCAGGGCTGTACATAGTTGG	SEQ?ID?NO：743
B1961848.V1.3_at	ACTGCGTGGGTCAACTCAGTGTCCA	SEQ?ID?NO：744	B1961848.V1.3_at	TCAGTGTCCACTTCGATGCTTGTAT	SEQ?ID?NO：745
B1961848.V1.3_at	CTTCGATGCTTGTATGTTTGGGTTT	SEQ?ID?NO：746	B1961848.V1.3_at	TCAGTGTCCACTTCGATGCTTGTAT	SEQ?ID?NO：745
B1961848.V1.3_at	CTTCGATGCTTGTATGTTTGGGTTT	SEQ?ID?NO：746	B1961848.V1.3_at	GTTTGGGTTTCGCATCTTCATTAAA	SEQ?ID?NO：747
B1961848.V1.3_at	GGGCAGCTCAGATCAGCCTGGGCCA	SEQ?ID?NO：748	B1961848.V1.3_at	GTTTGGGTTTCGCATCTTCATTAAA	SEQ?ID?NO：747
B1961848.V1.3_at	GGGCAGCTCAGATCAGCCTGGGCCA	SEQ?ID?NO：748	B1961848.V1.3_at	GGATGAACCCTCAGGGCAGGGCACA	SEQ?ID?NO：749
B1961848.V1.3_at	AGAGCTGGCCCTGCATTCGCCTGGA	SEQ?ID?NO：750	B1961848.V1.3_at	GGATGAACCCTCAGGGCAGGGCACA	SEQ?ID?NO：749
B1961848.V1.3_at	AGAGCTGGCCCTGCATTCGCCTGGA	SEQ?ID?NO：750	B1961848.V1.3_at	GACCCTGAGCCGTCCATGGAAGCAG	SEQ?ID?NO：751
B1961848.V1.3_at	ATGGAAGCAGGGACCTTTTCTCCCG	SEQ?ID?NO：752	B1961848.V1.3_at	GACCCTGAGCCGTCCATGGAAGCAG	SEQ?ID?NO：751
B1961848.V1.3_at	ATGGAAGCAGGGACCTTTTCTCCCG	SEQ?ID?NO：752	B1961850.V1.3_at	AAGATTATACCATTCCCTTGGAATA	SEQ?ID?NO：753
B1961850.V1.3_at	GAATATTTTCTTCCTAATGTCAGAG	SEQ?ID?NO：754	B1961850.V1.3_at	AAGATTATACCATTCCCTTGGAATA	SEQ?ID?NO：753
B1961850.V1.3_at	GAATATTTTCTTCCTAATGTCAGAG	SEQ?ID?NO：754	B1961850.V1.3_at	ATGTCAGAGCTTTTCCTGCATTATT	SEQ?ID?NO：755
B1961850.V1.3_at	GCTTTCTGAGTTGGGATGCTTTGAC	SEQ?ID?NO：756	B1961850.V1.3_at	ATGTCAGAGCTTTTCCTGCATTATT	SEQ?ID?NO：755
B1961850.V1.3_at	GCTTTCTGAGTTGGGATGCTTTGAC	SEQ?ID?NO：756	B1961850.V1.3_at	GTATCACCTATTTTTAAAGCTGCTT	SEQ?ID?NO：757
B1961850.V1.3_at	AAAGCTGCTTTGTTAGGTTCCTTAT	SEQ?ID?NO：758	B1961850.V1.3_at	GTATCACCTATTTTTAAAGCTGCTT	SEQ?ID?NO：757
B1961850.V1.3_at	AAAGCTGCTTTGTTAGGTTCCTTAT	SEQ?ID?NO：758	B1961850.V1.3_at	GTTCCTTATGTTTTAACTGTCTTAG	SEQ?ID?NO：759
B1961850.V1.3_at	GTCTTAGTTTCCATTTCATTCTCTT	SEQ?ID?NO：760	B1961850.V1.3_at	GTTCCTTATGTTTTAACTGTCTTAG	SEQ?ID?NO：759
B1961850.V1.3_at	GTCTTAGTTTCCATTTCATTCTCTT	SEQ?ID?NO：760	B1961850.V1.3_at	ATCAACTTCATGGTCTTGTTTTTAC	SEQ?ID?NO：761
B1961850.V1.3_at	GTATTGCATGTATTTAGGACCTATC	SEQ?ID?NO：762	B1961850.V1.3_at	ATCAACTTCATGGTCTTGTTTTTAC	SEQ?ID?NO：761
B1961850.V1.3_at	GTATTGCATGTATTTAGGACCTATC	SEQ?ID?NO：762	B1961850.V1.3_at	AAGTGTCCTATTCACTACTTGTTAA	SEQ?ID?NO：763
B1961853.V1.3_at	GAAAATGTATGCCTGCGCCAAGTTT	SEQ?ID?NO：764	B1961850.V1.3_at	AAGTGTCCTATTCACTACTTGTTAA	SEQ?ID?NO：763
B1961853.V1.3_at	GAAAATGTATGCCTGCGCCAAGTTT	SEQ?ID?NO：764	B1961853.V1.3_at	TGCTGAGCCGATCACTGTCTGCAGT	SEQ?ID?NO：765
B1961853.V1.3_at	GAAACGACCGGAGACACTGACAGAT	SEQ?ID?NO：766	B1961853.V1.3_at	TGCTGAGCCGATCACTGTCTGCAGT	SEQ?ID?NO：765
B1961853.V1.3_at	GAAACGACCGGAGACACTGACAGAT	SEQ?ID?NO：766	B1961853.V1.3_at	GATGAGACCCTCAGCAGCTTGGCAG	SEQ?ID?NO：767
B1961853.V1.3_at	AAACCAGCGCCATTTCAAGGGACAT	SEQ?ID?NO：768	B1961853.V1.3_at	GATGAGACCCTCAGCAGCTTGGCAG	SEQ?ID?NO：767
B1961853.V1.3_at	AAACCAGCGCCATTTCAAGGGACAT	SEQ?ID?NO：768	B1961853.V1.3_at	GGGACATCGACACAGCAGCCAAGTT	SEQ?ID?NO：769
B1961853.V1.3_at	TTGGGACTGTATTTGGGAGCCTCAT	SEQ?ID?NO：770	B1961853.V1.3_at	GGGACATCGACACAGCAGCCAAGTT	SEQ?ID?NO：769
B1961853.V1.3_at	TTGGGACTGTATTTGGGAGCCTCAT	SEQ?ID?NO：770	B1961853.V1.3_at	GGAGCCTCATCATTGGTTATGCCAG	SEQ?ID?NO：771
B1961853.V1.3_at	TTATGCCAGGAACCCTTCTCTGAAG	SEQ?ID?NO：772	B1961853.V1.3_at	GGAGCCTCATCATTGGTTATGCCAG	SEQ?ID?NO：771
B1961853.V1.3_at	TTATGCCAGGAACCCTTCTCTGAAG	SEQ?ID?NO：772	B1961853.V1.3_at	TTTGCCTGATGGTGGCCTTTCTCAT	SEQ?ID?NO：773
B1961853.V1.3_at	TTCGCCATGTGAAGAAGCCGTCTCC	SEQ?ID?NO：774	B1961853.V1.3_at	TTTGCCTGATGGTGGCCTTTCTCAT	SEQ?ID?NO：773
B1961853.V1.3_at	TTCGCCATGTGAAGAAGCCGTCTCC	SEQ?ID?NO：774	B1961856.V1.3_at	CACGAGGGAAGAGGGTCTCCTTCCA	SEQ?ID?NO：775
B1961856.V1.3_at	GAACAATTTAATTTCTTGGCCGTGT	SEQ?ID?NO：776	B1961856.V1.3_at	CACGAGGGAAGAGGGTCTCCTTCCA	SEQ?ID?NO：775
B1961856.V1.3_at	GAACAATTTAATTTCTTGGCCGTGT	SEQ?ID?NO：776	B1961856.V1.3_at	GGCCGTGTTTAGTAACAGTTCCTAT	SEQ?ID?NO：777
B1961856.V1.3_at	ACAGTTCCTATGCATGGTTTTTAAC	SEQ?ID?NO：778	B1961856.V1.3_at	GGCCGTGTTTAGTAACAGTTCCTAT	SEQ?ID?NO：777
B1961856.V1.3_at	ACAGTTCCTATGCATGGTTTTTAAC	SEQ?ID?NO：778	B1961856.V1.3_at	ACCTGATTCTGCCTCTTTAATGAAT	SEQ?ID?NO：779
B1961856.V1.3_at	GAAACTCAATGCCTTATGTGCTCAC	SEQ?ID?NO：780	B1961856.V1.3_at	ACCTGATTCTGCCTCTTTAATGAAT	SEQ?ID?NO：779
B1961856.V1.3_at	GAAACTCAATGCCTTATGTGCTCAC	SEQ?ID?NO：780	B1961856.V1.3_at	TTATGTGCTCACTCAGTTTCCCTTC	SEQ?ID?NO：781
B1961856.V1.3_at	AGTTTCCCTTCTGCAGCTTGTTTTT	SEQ?ID?NO：782	B1961856.V1.3_at	TTATGTGCTCACTCAGTTTCCCTTC	SEQ?ID?NO：781
B1961856.V1.3_at	AGTTTCCCTTCTGCAGCTTGTTTTT	SEQ?ID?NO：782	B1961856.V1.3_at	GCTTGTTTTTTCTCACTATCTGTAT	SEQ?ID?NO：783
B1961856.V1.3_at	ATGCTGGCAAAACCTCTAAGACTGT	SEQ?ID?NO：784	B1961856.V1.3_at	GCTTGTTTTTTCTCACTATCTGTAT	SEQ?ID?NO：783
B1961856.V1.3_at	ATGCTGGCAAAACCTCTAAGACTGT	SEQ?ID?NO：784	B1961856.V1.3_at	GAAAGTTGATTTGTCCTAGTGCAAA	SEQ?ID?NO：785

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961864.V1.3_at	AGACAGGTGGCTCCAAGACGTCGTC	SEQ?ID?NO：786
B1961864.V1.3_at	GACGTCGTCGACAGTTAAGAGCACC	SEQ?ID?NO：787	B1961864.V1.3_at	AGACAGGTGGCTCCAAGACGTCGTC	SEQ?ID?NO：786
B1961864.V1.3_at	GACGTCGTCGACAGTTAAGAGCACC	SEQ?ID?NO：787	B1961864.V1.3_at	AAGAGCACCCCGTCTGGGAAGAGGT	SEQ?ID?NO：788
B1961864.V1.3_at	GGTACAAGTTTGTGGCCACCGGACA	SEQ?ID?NO：789	B1961864.V1.3_at	AAGAGCACCCCGTCTGGGAAGAGGT	SEQ?ID?NO：788
B1961864.V1.3_at	GGTACAAGTTTGTGGCCACCGGACA	SEQ?ID?NO：789	B1961864.V1.3_at	GTAGACGAAGGCTCGGCACCCTAGG	SEQ?ID?NO：790
B1961864.V1.3_at	TGGCCTGCCGAAGAAGCTGCTTCCA	SEQ?ID?NO：791	B1961864.V1.3_at	GTAGACGAAGGCTCGGCACCCTAGG	SEQ?ID?NO：790
B1961864.V1.3_at	TGGCCTGCCGAAGAAGCTGCTTCCA	SEQ?ID?NO：791	B1961864.V1.3_at	TGGCTCTGCCTCTTATAAGCTCAGG	SEQ?ID?NO：792
B1961864.V1.3_at	TAAGCTCAGGCTGGCAGCTGGCTAA	SEQ?ID?NO：793	B1961864.V1.3_at	TGGCTCTGCCTCTTATAAGCTCAGG	SEQ?ID?NO：792
B1961864.V1.3_at	TAAGCTCAGGCTGGCAGCTGGCTAA	SEQ?ID?NO：793	B1961864.V1.3_at	AACTCCCAAGGAAGGTGCAGCCTGT	SEQ?ID?NO：794
B1961864.V1.3_at	GGACCTCATGGTCAAGAGCCAGTGA	SEQ?ID?NO：795	B1961864.V1.3_at	AACTCCCAAGGAAGGTGCAGCCTGT	SEQ?ID?NO：794
B1961864.V1.3_at	GGACCTCATGGTCAAGAGCCAGTGA	SEQ?ID?NO：795	B1961864.V1.3_at	TGAGCTGGATGCTTAGGCCCTACAT	SEQ?ID?NO：796
B1961865.V1.3_at	AGTTTCATCATCAGGGTCCGGGTGG	SEQ?ID?NO：797	B1961864.V1.3_at	TGAGCTGGATGCTTAGGCCCTACAT	SEQ?ID?NO：796
B1961865.V1.3_at	AGTTTCATCATCAGGGTCCGGGTGG	SEQ?ID?NO：797	B1961865.V1.3_at	TAGGTTGTCAGGGTTTACTGCCTTC	SEQ?ID?NO：798
B1961865.V1.3_at	TTAGCTCTTTTTTCCCTGCATTCTA	SEQ?ID?NO：799	B1961865.V1.3_at	TAGGTTGTCAGGGTTTACTGCCTTC	SEQ?ID?NO：798
B1961865.V1.3_at	TTAGCTCTTTTTTCCCTGCATTCTA	SEQ?ID?NO：799	B1961865.V1.3_at	CCCTGCATTCTAGCAATTCGTGATT	SEQ?ID?NO：800
B1961865.V1.3_at	GGGAAGAAGCAAGACCTCTCCTCAG	SEQ?ID?NO：801	B1961865.V1.3_at	CCCTGCATTCTAGCAATTCGTGATT	SEQ?ID?NO：800
B1961865.V1.3_at	GGGAAGAAGCAAGACCTCTCCTCAG	SEQ?ID?NO：801	B1961865.V1.3_at	AGACTTTGTCTCTGGGTTTCATCCT	SEQ?ID?NO：802
B1961865.V1.3_at	CTGTCACTCTAGGAGGGTTCGTGCT	SEQ?ID?NO：803	B1961865.V1.3_at	AGACTTTGTCTCTGGGTTTCATCCT	SEQ?ID?NO：802
B1961865.V1.3_at	CTGTCACTCTAGGAGGGTTCGTGCT	SEQ?ID?NO：803	B1961865.V1.3_at	GAAGAGACATTAGCTCCTTGTTCCC	SEQ?ID?NO：804
B1961865.V1.3_at	TTTTCCCCACGGGTTTGGTGCACAG	SEQ?ID?NO：805	B1961865.V1.3_at	GAAGAGACATTAGCTCCTTGTTCCC	SEQ?ID?NO：804
B1961865.V1.3_at	TTTTCCCCACGGGTTTGGTGCACAG	SEQ?ID?NO：805	B1961865.V1.3_at	TTCCCATGTCCGCTCAGATGAGGAT	SEQ?ID?NO：806
B1961865.V1.3_at	TTTTTTCTTTTCTTGCCTGACCTCA	SEQ?ID?NO：807	B1961865.V1.3_at	TTCCCATGTCCGCTCAGATGAGGAT	SEQ?ID?NO：806
B1961865.V1.3_at	TTTTTTCTTTTCTTGCCTGACCTCA	SEQ?ID?NO：807	B1961872.V1.3_at	TATGCTCTGTGTATAAGGATGAATT	SEQ?ID?NO：808
B1961872.V1.3_at	GAGTTGTCATTTTCTCTTCACTGGA	SEQ?ID?NO：809	B1961872.V1.3_at	TATGCTCTGTGTATAAGGATGAATT	SEQ?ID?NO：808
B1961872.V1.3_at	GAGTTGTCATTTTCTCTTCACTGGA	SEQ?ID?NO：809	B1961872.V1.3_at	GTCATTTTCTCTTCACTGGATGTTT	SEQ?ID?NO：810
B1961872.V1.3_at	TCTCTTCACTGGATGTTTATTTATA	SEQ?ID?NO：811	B1961872.V1.3_at	GTCATTTTCTCTTCACTGGATGTTT	SEQ?ID?NO：810
B1961872.V1.3_at	TCTCTTCACTGGATGTTTATTTATA	SEQ?ID?NO：811	B1961872.V1.3_at	AGATTTGACCTGTTCATGCGTCTGT	SEQ?ID?NO：812
B1961872.V1.3_at	GTTCATGCGTCTGTGGAGCAGCCCT	SEQ?ID?NO：813	B1961872.V1.3_at	AGATTTGACCTGTTCATGCGTCTGT	SEQ?ID?NO：812
B1961872.V1.3_at	GTTCATGCGTCTGTGGAGCAGCCCT	SEQ?ID?NO：813	B1961872.V1.3_at	TCCGTCTCCCGGCTATATAGTAATC	SEQ?ID?NO：814
B1961872.V1.3_at	GTAATCTTAGGTAGAGTGTTGCCTT	SEQ?ID?NO：815	B1961872.V1.3_at	TCCGTCTCCCGGCTATATAGTAATC	SEQ?ID?NO：814
B1961872.V1.3_at	GTAATCTTAGGTAGAGTGTTGCCTT	SEQ?ID?NO：815	B1961872.V1.3_at	TAGAGTGTTGCCTTGTGGGTTACCG	SEQ?ID?NO：816
B1961872.V1.3_at	TGGGTTACCGTTTGCTCTGAGACTT	SEQ?ID?NO：817	B1961872.V1.3_at	TAGAGTGTTGCCTTGTGGGTTACCG	SEQ?ID?NO：816
B1961872.V1.3_at	TGGGTTACCGTTTGCTCTGAGACTT	SEQ?ID?NO：817	B1961872.V1.3_at	TCTGAGACTTCTCGGATGGACCCAC	SEQ?ID?NO：818
B1961873.V1.3_at	ATGTTCAGTTCTAAGGAGTCCCAGC	SEQ?ID?NO：819	B1961872.V1.3_at	TCTGAGACTTCTCGGATGGACCCAC	SEQ?ID?NO：818
B1961873.V1.3_at	ATGTTCAGTTCTAAGGAGTCCCAGC	SEQ?ID?NO：819	B1961873.V1.3_at	ATGCCCAAACGTGGCCTGGAGGTGA	SEQ?ID?NO：820
B1961873.V1.3_at	GATTGCCAGATTCTACAAGCTGCAC	SEQ?ID?NO：821	B1961873.V1.3_at	ATGCCCAAACGTGGCCTGGAGGTGA	SEQ?ID?NO：820
B1961873.V1.3_at	GATTGCCAGATTCTACAAGCTGCAC	SEQ?ID?NO：821	B1961873.V1.3_at	AGCGGAGGTGTGAGCCCATTGCCAT	SEQ?ID?NO：822
B1961873.V1.3_at	CCATTGCCATGACAGTGCCTAGAAA	SEQ?ID?NO：823	B1961873.V1.3_at	AGCGGAGGTGTGAGCCCATTGCCAT	SEQ?ID?NO：822
B1961873.V1.3_at	CCATTGCCATGACAGTGCCTAGAAA	SEQ?ID?NO：823	B1961873.V1.3_at	TAGAAAGTCGGACCTGTTCCAGGAG	SEQ?ID?NO：824
B1961873.V1.3_at	ATTTCCCTCAAGGATGGCTACGTGC	SEQ?ID?NO：825	B1961873.V1.3_at	TAGAAAGTCGGACCTGTTCCAGGAG	SEQ?ID?NO：824
B1961873.V1.3_at	ATTTCCCTCAAGGATGGCTACGTGC	SEQ?ID?NO：825	B1961873.V1.3_at	AGACAGCACCAGAGGCCAGTGGCAC	SEQ?ID?NO：826
B1961873.V1.3_at	GGCACTCCTAGCTCGGATGCTGTAT	SEQ?ID?NO：827	B1961873.V1.3_at	AGACAGCACCAGAGGCCAGTGGCAC	SEQ?ID?NO：826
B1961873.V1.3_at	GGCACTCCTAGCTCGGATGCTGTAT	SEQ?ID?NO：827	B1961873.V1.3_at	AGATGAGGAAGCTCCAGGCCACTGT	SEQ?ID?NO：828
B1961873.V1.3_at	AGGCCACTGTGCAGGAGCTACAGAA	SEQ?ID?NO：829	B1961873.V1.3_at	AGATGAGGAAGCTCCAGGCCACTGT	SEQ?ID?NO：828
B1961873.V1.3_at	AGGCCACTGTGCAGGAGCTACAGAA	SEQ?ID?NO：829	B1961877.V1.3_at	GGAGCTGCTGTTCTTCAGACAGAGA	SEQ?ID?NO：830

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961877.V1.3_at	GACTCTGAGGCTGCTCCACAAGTAC	SEQ?ID?NO：831
B1961877.V1.3_at	ATAAGGGCGCCATCAAGTTCGTGCT	SEQ?ID?NO：832	B1961877.V1.3_at	GACTCTGAGGCTGCTCCACAAGTAC	SEQ?ID?NO：831
B1961877.V1.3_at	ATAAGGGCGCCATCAAGTTCGTGCT	SEQ?ID?NO：832	B1961877.V1.3_at	AAGACACGGTGGTCGCGATCATGGC	SEQ?ID?NO：833
B1961877.V1.3_at	GAAGGTCAACAAAGGCATCGGCATT	SEQ?ID?NO：834	B1961877.V1.3_at	AAGACACGGTGGTCGCGATCATGGC	SEQ?ID?NO：833
B1961877.V1.3_at	GAAGGTCAACAAAGGCATCGGCATT	SEQ?ID?NO：834	B1961877.V1.3_at	GCATCGGCATTGAAAACATCCACTA	SEQ?ID?NO：835
B1961877.V1.3_at	AATGAGCCTGCCAAGGAGTGCGCTT	SEQ?ID?NO：836	B1961877.V1.3_at	GCATCGGCATTGAAAACATCCACTA	SEQ?ID?NO：835
B1961877.V1.3_at	AATGAGCCTGCCAAGGAGTGCGCTT	SEQ?ID?NO：836	B1961877.V1.3_at	AAAGGAATGCGCTTGGGCTCCAGAC	SEQ?ID?NO：837
B1961877.V1.3_at	AATGCGCTTGGACTCAATGTGGACT	SEQ?ID?NO：838	B1961877.V1.3_at	AAAGGAATGCGCTTGGGCTCCAGAC	SEQ?ID?NO：837
B1961877.V1.3_at	AATGCGCTTGGACTCAATGTGGACT	SEQ?ID?NO：838	B1961877.V1.3_at	AATGTGGACTCTGCTGTATCTGTGT	SEQ?ID?NO：839
B1961877.V1.3_at	TGTCCGTGTCTGTGTGTGACAGCAT	SEQ?ID?NO：840	B1961877.V1.3_at	AATGTGGACTCTGCTGTATCTGTGT	SEQ?ID?NO：839
B1961877.V1.3_at	TGTCCGTGTCTGTGTGTGACAGCAT	SEQ?ID?NO：840	B1961879.V1.3_at	GAAAGGGTGCCTGTTGTCAATAAAC	SEQ?ID?NO：841
B1961879.V1.3_at	GAGCTATGGCGCCTCCAATGAAGGA	SEQ?ID?NO：842	B1961879.V1.3_at	GAAAGGGTGCCTGTTGTCAATAAAC	SEQ?ID?NO：841
B1961879.V1.3_at	GAGCTATGGCGCCTCCAATGAAGGA	SEQ?ID?NO：842	B1961879.V1.3_at	CAATGAAGGATCTGCCCAGGTGGCT	SEQ?ID?NO：843
B1961879.V1.3_at	ATTTGCAGTTGCTCCAGACTGGACT	SEQ?ID?NO：844	B1961879.V1.3_at	CAATGAAGGATCTGCCCAGGTGGCT	SEQ?ID?NO：843
B1961879.V1.3_at	ATTTGCAGTTGCTCCAGACTGGACT	SEQ?ID?NO：844	B1961879.V1.3_at	TAAGCAGTCTGGTTTTGTTCCCGAG	SEQ?ID?NO：845
B1961879.V1.3_at	GAGTCGATGTTTGACCGGCTTCTCA	SEQ?ID?NO：846	B1961879.V1.3_at	TAAGCAGTCTGGTTTTGTTCCCGAG	SEQ?ID?NO：845
B1961879.V1.3_at	GAGTCGATGTTTGACCGGCTTCTCA	SEQ?ID?NO：846	B1961879.V1.3_at	TGTGGCCTCCACTGCAGGAATCAAC	SEQ?ID?NO：847
B1961879.V1.3_at	GAATCAACCCTCTGCTGGTGAACAG	SEQ?ID?NO：848	B1961879.V1.3_at	TGTGGCCTCCACTGCAGGAATCAAC	SEQ?ID?NO：847
B1961879.V1.3_at	GAATCAACCCTCTGCTGGTGAACAG	SEQ?ID?NO：848	B1961879.V1.3_at	GCCTGTTTGCTGGAATGGACCTGAC	SEQ?ID?NO：849
B1961879.V1.3_at	TTCAGAATCTCCAGAATCTCCAGTC	SEQ?ID?NO：850	B1961879.V1.3_at	GCCTGTTTGCTGGAATGGACCTGAC	SEQ?ID?NO：849
B1961879.V1.3_at	TTCAGAATCTCCAGAATCTCCAGTC	SEQ?ID?NO：850	B1961879.V1.3_at	GGGCCTGCCCAACATGTTTGGATTG	SEQ?ID?NO：851
B1961880.V1.3_at	TGAGTTCGTCATCAGGGCCAAGTTC	SEQ?ID?NO：852	B1961879.V1.3_at	GGGCCTGCCCAACATGTTTGGATTG	SEQ?ID?NO：851
B1961880.V1.3_at	TGAGTTCGTCATCAGGGCCAAGTTC	SEQ?ID?NO：852	B1961880.V1.3_at	AGACCACCTTACAGCGGCGTTATGA	SEQ?ID?NO：853
B1961880.V1.3_at	TGCGGATACTTCCACAGGTCGGAGA	SEQ?ID?NO：854	B1961880.V1.3_at	AGACCACCTTACAGCGGCGTTATGA	SEQ?ID?NO：853
B1961880.V1.3_at	TGCGGATACTTCCACAGGTCGGAGA	SEQ?ID?NO：854	B1961880.V1.3_at	GAACCGCAGCGAGGAGTTTCTCATC	SEQ?ID?NO：855
B1961880.V1.3_at	TTCTCATCGCCGGACAACTATTGGA	SEQ?ID?NO：856	B1961880.V1.3_at	GAACCGCAGCGAGGAGTTTCTCATC	SEQ?ID?NO：855
B1961880.V1.3_at	TTCTCATCGCCGGACAACTATTGGA	SEQ?ID?NO：856	B1961880.V1.3_at	GGACGAGAAGCTGTACATCACCACC	SEQ?ID?NO：857
B1961880.V1.3_at	GAATGCTCAGTGTTTCCCTGTTCAT	SEQ?ID?NO：858	B1961880.V1.3_at	GGACGAGAAGCTGTACATCACCACC	SEQ?ID?NO：857
B1961880.V1.3_at	GAATGCTCAGTGTTTCCCTGTTCAT	SEQ?ID?NO：858	B1961880.V1.3_at	TGATTGCTTGTGGACGGACCAGCTC	SEQ?ID?NO：859
B1961880.V1.3_at	ACAGGCTCTGACAAGGGCTTCCAGA	SEQ?ID?NO：860	B1961880.V1.3_at	TGATTGCTTGTGGACGGACCAGCTC	SEQ?ID?NO：859
B1961880.V1.3_at	ACAGGCTCTGACAAGGGCTTCCAGA	SEQ?ID?NO：860	B1961880.V1.3_at	GAATCCTGTCTCCAGCAGAAGCTGA	SEQ?ID?NO：861
B1961880.V1.3_at	AGCTGAAGCTTGCACAGTGTTCACC	SEQ?ID?NO：862	B1961880.V1.3_at	GAATCCTGTCTCCAGCAGAAGCTGA	SEQ?ID?NO：861
B1961880.V1.3_at	AGCTGAAGCTTGCACAGTGTTCACC	SEQ?ID?NO：862	B1961882.V1.3_at	GCTTCCTGGAGCTGGCATACCGTGG	SEQ?ID?NO：863
B1961882.V1.3_at	AGCTGGCATACCGTGGTCTGCGCTA	SEQ?ID?NO：864	B1961882.V1.3_at	GCTTCCTGGAGCTGGCATACCGTGG	SEQ?ID?NO：863
B1961882.V1.3_at	AGCTGGCATACCGTGGTCTGCGCTA	SEQ?ID?NO：864	B1961882.V1.3_at	GAAAGAAGCCCCAGAGCCCTGGGTG	SEQ?ID?NO：865
B1961882.V1.3_at	GGTGCTTCCCTCCACTTTCAAGTTT	SEQ?ID?NO：866	B1961882.V1.3_at	GAAAGAAGCCCCAGAGCCCTGGGTG	SEQ?ID?NO：865
B1961882.V1.3_at	GGTGCTTCCCTCCACTTTCAAGTTT	SEQ?ID?NO：866	B1961882.V1.3_at	TTTCAAGTTTCATTCTCCTGCCTGT	SEQ?ID?NO：867
B1961882.V1.3_at	CATTCTCCTGCCTGTAGCAGGGAGA	SEQ?ID?NO：868	B1961882.V1.3_at	TTTCAAGTTTCATTCTCCTGCCTGT	SEQ?ID?NO：867
B1961882.V1.3_at	CATTCTCCTGCCTGTAGCAGGGAGA	SEQ?ID?NO：868	B1961882.V1.3_at	GAGAAAAAGCTCCTGTCTTCCTGTC	SEQ?ID?NO：869
B1961882.V1.3_at	TTCCTGTCCCCTGGACTGGGAGGTA	SEQ?ID?NO：870	B1961882.V1.3_at	GAGAAAAAGCTCCTGTCTTCCTGTC	SEQ?ID?NO：869
B1961882.V1.3_at	TTCCTGTCCCCTGGACTGGGAGGTA	SEQ?ID?NO：870	B1961882.V1.3_at	AGTATTAATTCCTGTGACTGCTCCC	SEQ?ID?NO：871
B1961882.V1.3_at	CTGGCCCAGCTCTGTGGTGGGCACT	SEQ?ID?NO：872	B1961882.V1.3_at	AGTATTAATTCCTGTGACTGCTCCC	SEQ?ID?NO：871
B1961882.V1.3_at	CTGGCCCAGCTCTGTGGTGGGCACT	SEQ?ID?NO：872	B1961882.V1.3_at	ACTGGGAAGAGCCTCAGTGGACCCC	SEQ?ID?NO：873
B1961885.V1.3_at	AATGCGGTGGCATCTTTACAGATAC	SEQ?ID?NO：874	B1961882.V1.3_at	ACTGGGAAGAGCCTCAGTGGACCCC	SEQ?ID?NO：873
B1961885.V1.3_at	AATGCGGTGGCATCTTTACAGATAC	SEQ?ID?NO：874	B1961885.V1.3_at	TTTTAAATCTCCAGGCTTCCCAAAT	SEQ?ID?NO：875

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961885.V1.3_at	TAACCAAGTCTGCTACTGGCACATC	SEQ?ID?NO：876
B1961885.V1.3_at	ACTCAAGTATGGTCAGCGTATTCAC	SEQ?ID?NO：877	B1961885.V1.3_at	TAACCAAGTCTGCTACTGGCACATC	SEQ?ID?NO：876
B1961885.V1.3_at	ACTCAAGTATGGTCAGCGTATTCAC	SEQ?ID?NO：877	B1961885.V1.3_at	GCGTATTCACCTGAGTTTTCTGGAC	SEQ?ID?NO：878
B1961885.V1.3_at	AGGTTGCTTGGCTGACTATGTTGAA	SEQ?ID?NO：879	B1961885.V1.3_at	GCGTATTCACCTGAGTTTTCTGGAC	SEQ?ID?NO：878
B1961885.V1.3_at	AGGTTGCTTGGCTGACTATGTTGAA	SEQ?ID?NO：879	B1961885.V1.3_at	CTAAGCGATGCTTCGGTGACCGCAG	SEQ?ID?NO：880
B1961885.V1.3_at	GTGACCGCAGGAGGTTTCCAAATCA	SEQ?ID?NO：881	B1961885.V1.3_at	CTAAGCGATGCTTCGGTGACCGCAG	SEQ?ID?NO：880
B1961885.V1.3_at	GTGACCGCAGGAGGTTTCCAAATCA	SEQ?ID?NO：881	B1961885.V1.3_at	TACAAGCACTACTTCTACGGGAAAT	SEQ?ID?NO：882
B1961885.V1.3_at	TATGGTTGTCTCTTTTGGAACCCCT	SEQ?ID?NO：883	B1961885.V1.3_at	TACAAGCACTACTTCTACGGGAAAT	SEQ?ID?NO：882
B1961885.V1.3_at	TATGGTTGTCTCTTTTGGAACCCCT	SEQ?ID?NO：883	B1961885.V1.3_at	GAACCCCTTTGATCTCAGTTTTGTA	SEQ?ID?NO：884
B1961890.V1.3_at	TGGCAATCCTCAGTACACGTACAAC	SEQ?ID?NO：885	B1961885.V1.3_at	GAACCCCTTTGATCTCAGTTTTGTA	SEQ?ID?NO：884
B1961890.V1.3_at	TGGCAATCCTCAGTACACGTACAAC	SEQ?ID?NO：885	B1961890.V1.3_at	GTACAACAATTGGTCTCCTCCGGTG	SEQ?ID?NO：886
B1961890.V1.3_at	TTTCCTGGAGAGATCGCATAGCGCT	SEQ?ID?NO：887	B1961890.V1.3_at	GTACAACAATTGGTCTCCTCCGGTG	SEQ?ID?NO：886
B1961890.V1.3_at	TTTCCTGGAGAGATCGCATAGCGCT	SEQ?ID?NO：887	B1961890.V1.3_at	TAGCGCTAGGATGACACTTGCAAAA	SEQ?ID?NO：888
B1961890.V1.3_at	AAAAGCTTGTGAACTCTGTCCAGAG	SEQ?ID?NO：889	B1961890.V1.3_at	TAGCGCTAGGATGACACTTGCAAAA	SEQ?ID?NO：888
B1961890.V1.3_at	AAAAGCTTGTGAACTCTGTCCAGAG	SEQ?ID?NO：889	B1961890.V1.3_at	AGATGACCAAGATGCCCCAGATGAG	SEQ?ID?NO：890
B1961890.V1.3_at	CCTGGCTCTCAGTATCAGCAGAATA	SEQ?ID?NO：891	B1961890.V1.3_at	AGATGACCAAGATGCCCCAGATGAG	SEQ?ID?NO：890
B1961890.V1.3_at	CCTGGCTCTCAGTATCAGCAGAATA	SEQ?ID?NO：891	B1961890.V1.3_at	GCAGTGAAGAAGTAGCCCCGCCTCA	SEQ?ID?NO：892
B1961890.V1.3_at	AAATGCGCGTAGTGAACTGGTTCCA	SEQ?ID?NO：893	B1961890.V1.3_at	GCAGTGAAGAAGTAGCCCCGCCTCA	SEQ?ID?NO：892
B1961890.V1.3_at	AAATGCGCGTAGTGAACTGGTTCCA	SEQ?ID?NO：893	B1961890.V1.3_at	AACCTTTTTCTGTGTCTGGCTAATA	SEQ?ID?NO：894
B1961890.V1.3_at	GAGTTTATTCACTGTCTTATCTGCA	SEQ?ID?NO：895	B1961890.V1.3_at	AACCTTTTTCTGTGTCTGGCTAATA	SEQ?ID?NO：894
B1961890.V1.3_at	GAGTTTATTCACTGTCTTATCTGCA	SEQ?ID?NO：895	B1961900.V1.3_at	GGTTTGTTTTTACTTGAGCCTGCCT	SEQ?ID?NO：896
B1961900.V1.3_at	TGAGCCTGCCTTTGTACCCTTTTTA	SEQ?ID?NO：897	B1961900.V1.3_at	GGTTTGTTTTTACTTGAGCCTGCCT	SEQ?ID?NO：896
B1961900.V1.3_at	TGAGCCTGCCTTTGTACCCTTTTTA	SEQ?ID?NO：897	B1961900.V1.3_at	GAACAGAGCCACACCGGTATTATAT	SEQ?ID?NO：898
B1961900.V1.3_at	GTTCTATTGCGTTTGCTGACTAAAT	SEQ?ID?NO：899	B1961900.V1.3_at	GAACAGAGCCACACCGGTATTATAT	SEQ?ID?NO：898
B1961900.V1.3_at	GTTCTATTGCGTTTGCTGACTAAAT	SEQ?ID?NO：899	B1961900.V1.3_at	AAAAGTCCACACAGCTCTCCTGTTT	SEQ?ID?NO：900
B1961900.V1.3_at	GTCTACGTTCACAGCCTCAAAAAAG	SEQ?ID?NO：901	B1961900.V1.3_at	AAAAGTCCACACAGCTCTCCTGTTT	SEQ?ID?NO：900
B1961900.V1.3_at	GTCTACGTTCACAGCCTCAAAAAAG	SEQ?ID?NO：901	B1961900.V1.3_at	AGAACACCTCCATCCTGTGATAAGT	SEQ?ID?NO：902
B1961900.V1.3_at	GGATTCAGCTTTACTCCTTTGTAAC	SEQ?ID?NO：903	B1961900.V1.3_at	AGAACACCTCCATCCTGTGATAAGT	SEQ?ID?NO：902
B1961900.V1.3_at	GGATTCAGCTTTACTCCTTTGTAAC	SEQ?ID?NO：903	B1961900.V1.3_at	GTTAAAAGGCTGACCCACGTGGCTT	SEQ?ID?NO：904
B1961900.V1.3_at	ACGTGGCTTTGCAGTGCTGTTCGTC	SEQ?ID?NO：905	B1961900.V1.3_at	GTTAAAAGGCTGACCCACGTGGCTT	SEQ?ID?NO：904
B1961900.V1.3_at	ACGTGGCTTTGCAGTGCTGTTCGTC	SEQ?ID?NO：905	B1961900.V1.3_at	GCTGTTCGTCCAGAAGCATGGCACA	SEQ?ID?NO：906
B1961910.V1.3_at	GACCATCCCCACTTTGCAGAAGAGG	SEQ?ID?NO：907	B1961900.V1.3_at	GCTGTTCGTCCAGAAGCATGGCACA	SEQ?ID?NO：906
B1961910.V1.3_at	GACCATCCCCACTTTGCAGAAGAGG	SEQ?ID?NO：907	B1961910.V1.3_at	GTGTGAAGTCACTGGCCAAAGCCGG	SEQ?ID?NO：908
B1961910.V1.3_at	GACAGAGTGACCCAAGCCTGAGGCC	SEQ?ID?NO：909	B1961910.V1.3_at	GTGTGAAGTCACTGGCCAAAGCCGG	SEQ?ID?NO：908
B1961910.V1.3_at	GACAGAGTGACCCAAGCCTGAGGCC	SEQ?ID?NO：909	B1961910.V1.3_at	GGGTCGGCTATCAGTATCCCGGCTA	SEQ?ID?NO：910
B1961910.V1.3_at	ATCCCGGCTACCGTGGATACCAGTA	SEQ?ID?NO：911	B1961910.V1.3_at	GGGTCGGCTATCAGTATCCCGGCTA	SEQ?ID?NO：910
B1961910.V1.3_at	ATCCCGGCTACCGTGGATACCAGTA	SEQ?ID?NO：911	B1961910.V1.3_at	GTGGATACCAGTACCTCCTGGAGCC	SEQ?ID?NO：912
B1961910.V1.3_at	GCGACTACCGGCACTGGAACGAGTG	SEQ?ID?NO：913	B1961910.V1.3_at	GTGGATACCAGTACCTCCTGGAGCC	SEQ?ID?NO：912
B1961910.V1.3_at	GCGACTACCGGCACTGGAACGAGTG	SEQ?ID?NO：913	B1961910.V1.3_at	TTCCAGCCACAGATGCAGGCCGTGC	SEQ?ID?NO：914
B1961910.V1.3_at	TGCGCGACAGGCAGTGGCACCACAA	SEQ?ID?NO：915	B1961910.V1.3_at	TTCCAGCCACAGATGCAGGCCGTGC	SEQ?ID?NO：914
B1961910.V1.3_at	TGCGCGACAGGCAGTGGCACCACAA	SEQ?ID?NO：915	B1961910.V1.3_at	AGTGGCACCACAAGGGCAGCTTCCC	SEQ?ID?NO：916
B1961910.V1.3_at	AAATGAGTCCACACTCCATGCCTGT	SEQ?ID?NO：917	B1961910.V1.3_at	AGTGGCACCACAAGGGCAGCTTCCC	SEQ?ID?NO：916
B1961910.V1.3_at	AAATGAGTCCACACTCCATGCCTGT	SEQ?ID?NO：917	B1961913.V1.3_at	GTACTAGCCCAAGCATCATCAATGA	SEQ?ID?NO：918
B1961913.V1.3_at	TGGTTTATTCCAGCTCGAGATCTCC	SEQ?ID?NO：919	B1961913.V1.3_at	GTACTAGCCCAAGCATCATCAATGA	SEQ?ID?NO：918
B1961913.V1.3_at	TGGTTTATTCCAGCTCGAGATCTCC	SEQ?ID?NO：919	B1961913.V1.3_at	GAGATCTCCCACAAACTATGGACCA	SEQ?ID?NO：920

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961913.V1.3_at	ATCAGTGATGGCTCTTCTCTGGAAG	SEQ?ID?NO：921
B1961913.V1.3_at	GTGGTCAAGAGCAATCTGAACCCAA	SEQ?ID?NO：922	B1961913.V1.3_at	ATCAGTGATGGCTCTTCTCTGGAAG	SEQ?ID?NO：921
B1961913.V1.3_at	GTGGTCAAGAGCAATCTGAACCCAA	SEQ?ID?NO：922	B1961913.V1.3_at	GGGCCCTCTTTTGGTGGATGTAGCA	SEQ?ID?NO：923
B1961913.V1.3_at	GGATGTAGCACAATTTCCACACTGT	SEQ?ID?NO：924	B1961913.V1.3_at	GGGCCCTCTTTTGGTGGATGTAGCA	SEQ?ID?NO：923
B1961913.V1.3_at	GGATGTAGCACAATTTCCACACTGT	SEQ?ID?NO：924	B1961913.V1.3_at	TAAAAGCTCTCTCTTGTCACTGTGT	SEQ?ID?NO：925
B1961913.V1.3_at	ACTGTGTTACACTTATGCATTGCCA	SEQ?ID?NO：926	B1961913.V1.3_at	TAAAAGCTCTCTCTTGTCACTGTGT	SEQ?ID?NO：925
B1961913.V1.3_at	ACTGTGTTACACTTATGCATTGCCA	SEQ?ID?NO：926	B1961913.V1.3_at	AGTTTTGTTAGTCTTGCATGCTTAA	SEQ?ID?NO：927
B1961913.V1.3_at	GAATTGGCCCCATGACTTGATGTGA	SEQ?ID?NO：928	B1961913.V1.3_at	AGTTTTGTTAGTCTTGCATGCTTAA	SEQ?ID?NO：927
B1961913.V1.3_at	GAATTGGCCCCATGACTTGATGTGA	SEQ?ID?NO：928	B1961919.V1.3_at	ATCAGTCCTGATTGCTATTTAATTT	SEQ?ID?NO：929
B1961919.V1.3_at	TGATGGGTTTTAAGTGTCTCATTAA	SEQ?ID?NO：930	B1961919.V1.3_at	ATCAGTCCTGATTGCTATTTAATTT	SEQ?ID?NO：929
B1961919.V1.3_at	TGATGGGTTTTAAGTGTCTCATTAA	SEQ?ID?NO：930	B1961919.V1.3_at	GAGAGCACTGAGTGCCAGGCACTGT	SEQ?ID?NO：931
B1961919.V1.3_at	GGGCTCCAAGCAATTAGACAGCAAG	SEQ?ID?NO：932	B1961919.V1.3_at	GAGAGCACTGAGTGCCAGGCACTGT	SEQ?ID?NO：931
B1961919.V1.3_at	GGGCTCCAAGCAATTAGACAGCAAG	SEQ?ID?NO：932	B1961919.V1.3_at	GCAAGATCACTATTAGAGTCAGACA	SEQ?ID?NO：933
B1961919.V1.3_at	GTCAGACAAAGTGTGTGCACATCTT	SEQ?ID?NO：934	B1961919.V1.3_at	GCAAGATCACTATTAGAGTCAGACA	SEQ?ID?NO：933
B1961919.V1.3_at	GTCAGACAAAGTGTGTGCACATCTT	SEQ?ID?NO：934	B1961919.V1.3_at	GCAGGTCAGTTGCTATTTATTGAAA	SEQ?ID?NO：935
B1961919.V1.3_at	ACATTTTTATGTTGAAGCTTCCCTT	SEQ?ID?NO：936	B1961919.V1.3_at	GCAGGTCAGTTGCTATTTATTGAAA	SEQ?ID?NO：935
B1961919.V1.3_at	ACATTTTTATGTTGAAGCTTCCCTT	SEQ?ID?NO：936	B1961919.V1.3_at	GAAGCTTCCCTTAGACATTTTATGT	SEQ?ID?NO：937
B1961919.V1.3_at	GGGCATAATGCCTGGTTTGATATTC	SEQ?ID?NO：938	B1961919.V1.3_at	GAAGCTTCCCTTAGACATTTTATGT	SEQ?ID?NO：937
B1961919.V1.3_at	GGGCATAATGCCTGGTTTGATATTC	SEQ?ID?NO：938	B1961919.V1.3_at	TATGCAATGTTTCTCTATCTGGAAC	SEQ?ID?NO：939
B1961921.V1.3_at	TGATGGTTCTTGTTCCACGAGGGCC	SEQ?ID?NO：940	B1961919.V1.3_at	TATGCAATGTTTCTCTATCTGGAAC	SEQ?ID?NO：939
B1961921.V1.3_at	TGATGGTTCTTGTTCCACGAGGGCC	SEQ?ID?NO：940	B1961921.V1.3_at	AAGGGCTGTGAGTATCTTCTCTCTT	SEQ?ID?NO：941
B1961921.V1.3_at	GGGTGCATTTACTCAGTGCCTGGCA	SEQ?ID?NO：942	B1961921.V1.3_at	AAGGGCTGTGAGTATCTTCTCTCTT	SEQ?ID?NO：941
B1961921.V1.3_at	GGGTGCATTTACTCAGTGCCTGGCA	SEQ?ID?NO：942	B1961921.V1.3_at	TGGTCCGTGGGAGCTCTGAATGCAA	SEQ?ID?NO：943
B1961921.V1.3_at	CACGTCGGTTTAGGTCAGGTCTCAA	SEQ?ID?NO：944	B1961921.V1.3_at	TGGTCCGTGGGAGCTCTGAATGCAA	SEQ?ID?NO：943
B1961921.V1.3_at	CACGTCGGTTTAGGTCAGGTCTCAA	SEQ?ID?NO：944	B1961921.V1.3_at	CAGGTCTCAATTCCTTTCTATGGGA	SEQ?ID?NO：945
B1961921.V1.3_at	TTCGGGCCATCAATAAATCAGTACT	SEQ?ID?NO：946	B1961921.V1.3_at	CAGGTCTCAATTCCTTTCTATGGGA	SEQ?ID?NO：945
B1961921.V1.3_at	TTCGGGCCATCAATAAATCAGTACT	SEQ?ID?NO：946	B1961921.V1.3_at	TGTGATTAAATGCAGCCCCTGGTGC	SEQ?ID?NO：947
B1961921.V1.3_at	CTCTCTTTCCTTGTGACGACAGACA	SEQ?ID?NO：948	B1961921.V1.3_at	TGTGATTAAATGCAGCCCCTGGTGC	SEQ?ID?NO：947
B1961921.V1.3_at	CTCTCTTTCCTTGTGACGACAGACA	SEQ?ID?NO：948	B1961921.V1.3_at	GACAACATGGTTTCTCTTGCCAGTG	SEQ?ID?NO：949
B1961921.V1.3_at	GCTGTCTGGGACTTGGTTTGTAAAA	SEQ?ID?NO：950	B1961921.V1.3_at	GACAACATGGTTTCTCTTGCCAGTG	SEQ?ID?NO：949
B1961921.V1.3_at	GCTGTCTGGGACTTGGTTTGTAAAA	SEQ?ID?NO：950	B1961922.V1.3_at	AGAACAAGTGACTCTGACCAGCAGG	SEQ?ID?NO：951
B1961922.V1.3_at	GACCAGCAGGTTTACCTTGTTGAAA	SEQ?ID?NO：952	B1961922.V1.3_at	AGAACAAGTGACTCTGACCAGCAGG	SEQ?ID?NO：951
B1961922.V1.3_at	GACCAGCAGGTTTACCTTGTTGAAA	SEQ?ID?NO：952	B1961922.V1.3_at	AATATTCCAATTCATTCTTGCCCCA	SEQ?ID?NO：953
B1961922.V1.3_at	GTGGAGAAGTTCTGCCCGACATAGA	SEQ?ID?NO：954	B1961922.V1.3_at	AATATTCCAATTCATTCTTGCCCCA	SEQ?ID?NO：953
B1961922.V1.3_at	GTGGAGAAGTTCTGCCCGACATAGA	SEQ?ID?NO：954	B1961922.V1.3_at	GCCCGACATAGATACCTTACAGATT	SEQ?ID?NO：955
B1961922.V1.3_at	AAGTGTCGATGTTTCACTTCCCCAA	SEQ?ID?NO：956	B1961922.V1.3_at	GCCCGACATAGATACCTTACAGATT	SEQ?ID?NO：955
B1961922.V1.3_at	AAGTGTCGATGTTTCACTTCCCCAA	SEQ?ID?NO：956	B1961922.V1.3_at	GTCAAGATTTTCTTCCTCCAAGAGT	SEQ?ID?NO：957
B1961922.V1.3_at	GGACATTTTTTGTGGACTTCCATAA	SEQ?ID?NO：958	B1961922.V1.3_at	GTCAAGATTTTCTTCCTCCAAGAGT	SEQ?ID?NO：957
B1961922.V1.3_at	GGACATTTTTTGTGGACTTCCATAA	SEQ?ID?NO：958	B1961922.V1.3_at	AGAATCCGTAACATACCAGTCTCCT	SEQ?ID?NO：959
B1961922.V1.3_at	AACGTTCAGTTTATGTGAGCACGAA	SEQ?ID?NO：960	B1961922.V1.3_at	AGAATCCGTAACATACCAGTCTCCT	SEQ?ID?NO：959
B1961922.V1.3_at	AACGTTCAGTTTATGTGAGCACGAA	SEQ?ID?NO：960	B1961922.V1.3_at	ATGGAAGAAGCCTCGCTGAGAGATT	SEQ?ID?NO：961
B1961928.V1.3_at	TGGTCATCATCGCAGTGGGTGCCTT	SEQ?ID?NO：962	B1961922.V1.3_at	ATGGAAGAAGCCTCGCTGAGAGATT	SEQ?ID?NO：961
B1961928.V1.3_at	TGGTCATCATCGCAGTGGGTGCCTT	SEQ?ID?NO：962	B1961928.V1.3_at	AGTGGGTGCCTTCCTCTTCCTGGTG	SEQ?ID?NO：963
B1961928.V1.3_at	TTCCTGGTGGCCTTTGTGGGCTGCT	SEQ?ID?NO：964	B1961928.V1.3_at	AGTGGGTGCCTTCCTCTTCCTGGTG	SEQ?ID?NO：963
B1961928.V1.3_at	TTCCTGGTGGCCTTTGTGGGCTGCT	SEQ?ID?NO：964	B1961928.V1.3_at	GGGCCTGCAAGGAGAACTACTGTCT	SEQ?ID?NO：965

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961928.V1.3_at	GGAGAACTACTGTCTTATGATCACG	SEQ?ID?NO：966
B1961928.V1.3_at	ACTGTCTTATGATCACGTTTGCCGT	SEQ?ID?NO：967	B1961928.V1.3_at	GGAGAACTACTGTCTTATGATCACG	SEQ?ID?NO：966
B1961928.V1.3_at	ACTGTCTTATGATCACGTTTGCCGT	SEQ?ID?NO：967	B1961928.V1.3_at	ATGATCACGTTTGCCGTCTTCCTGT	SEQ?ID?NO：968
B1961928.V1.3_at	TTCCTGTCTCTTATCACGCTGGTGG	SEQ?ID?NO：969	B1961928.V1.3_at	ATGATCACGTTTGCCGTCTTCCTGT	SEQ?ID?NO：968
B1961928.V1.3_at	TTCCTGTCTCTTATCACGCTGGTGG	SEQ?ID?NO：969	B1961928.V1.3_at	TCTTATCACGCTGGTGGAGGTGGCC	SEQ?ID?NO：970
B1961928.V1.3_at	GTGGCCGCAGCCATAGCTGGCTATG	SEQ?ID?NO：971	B1961928.V1.3_at	TCTTATCACGCTGGTGGAGGTGGCC	SEQ?ID?NO：970
B1961928.V1.3_at	GTGGCCGCAGCCATAGCTGGCTATG	SEQ?ID?NO：971	B1961928.V1.3_at	CATAGCTGGCTATGTCTTTAGAGAC	SEQ?ID?NO：972
B1961932.V1.3_at	TGTTACCCGAGTCTGACCCAGTCCT	SEQ?ID?NO：973	B1961928.V1.3_at	CATAGCTGGCTATGTCTTTAGAGAC	SEQ?ID?NO：972
B1961932.V1.3_at	TGTTACCCGAGTCTGACCCAGTCCT	SEQ?ID?NO：973	B1961932.V1.3_at	AGTCCTGGGTTAGCTGCCGCCATAT	SEQ?ID?NO：974
B1961932.V1.3_at	GCTGCCGCCATATCACTGGATTGGA	SEQ?ID?NO：975	B1961932.V1.3_at	AGTCCTGGGTTAGCTGCCGCCATAT	SEQ?ID?NO：974
B1961932.V1.3_at	GCTGCCGCCATATCACTGGATTGGA	SEQ?ID?NO：975	B1961932.V1.3_at	ATCACTGGATTGGATGCTGAGCCTA	SEQ?ID?NO：976
B1961932.V1.3_at	GATGCTGAGCCTAGAAACTGATCAA	SEQ?ID?NO：977	B1961932.V1.3_at	ATCACTGGATTGGATGCTGAGCCTA	SEQ?ID?NO：976
B1961932.V1.3_at	GATGCTGAGCCTAGAAACTGATCAA	SEQ?ID?NO：977	B1961932.V1.3_at	GAATGACTTAGGAGGCCCCAGGAAA	SEQ?ID?NO：978
B1961932.V1.3_at	AGGATTTGCCTAGAGAGGCCCGTTC	SEQ?ID?NO：979	B1961932.V1.3_at	GAATGACTTAGGAGGCCCCAGGAAA	SEQ?ID?NO：978
B1961932.V1.3_at	AGGATTTGCCTAGAGAGGCCCGTTC	SEQ?ID?NO：979	B1961932.V1.3_at	GTTCCTTCAACAGAGCTTCATCTAG	SEQ?ID?NO：980
B1961932.V1.3_at	AGAGCTTCATCTAGCTGGCACCAGA	SEQ?ID?NO：981	B1961932.V1.3_at	GTTCCTTCAACAGAGCTTCATCTAG	SEQ?ID?NO：980
B1961932.V1.3_at	AGAGCTTCATCTAGCTGGCACCAGA	SEQ?ID?NO：981	B1961932.V1.3_at	TGGCACCAGAGGCAGGATTGCACCT	SEQ?ID?NO：982
B1961932.V1.3_at	TTGCACCTGTGGTGGGTGCTTAGCC	SEQ?ID?NO：983	B1961932.V1.3_at	TGGCACCAGAGGCAGGATTGCACCT	SEQ?ID?NO：982
B1961932.V1.3_at	TTGCACCTGTGGTGGGTGCTTAGCC	SEQ?ID?NO：983	B1961932.V1.3_s_at	GAAATTGTGATTAGCCGGTAGTGAC	SEQ?ID?NO：984
B1961932.V1.3_s_at	AGTGACAGTTTGCTGTCAGGTCCCC	SEQ?ID?NO：985	B1961932.V1.3_s_at	GAAATTGTGATTAGCCGGTAGTGAC	SEQ?ID?NO：984
B1961932.V1.3_s_at	AGTGACAGTTTGCTGTCAGGTCCCC	SEQ?ID?NO：985	B1961932.V1.3_s_at	TGGGCCTCCTCTTAGGCATGGGATC	SEQ?ID?NO：986
B1961932.V1.3_s_at	ATGGGATCCCCAGAGTGGACCTGCC	SEQ?ID?NO：987	B1961932.V1.3_s_at	TGGGCCTCCTCTTAGGCATGGGATC	SEQ?ID?NO：986
B1961932.V1.3_s_at	ATGGGATCCCCAGAGTGGACCTGCC	SEQ?ID?NO：987	B1961932.V1.3_s_at	GCCAGTTTGTGCACCCATGGAGAGC	SEQ?ID?NO：988
B1961932.V1.3_s_at	ATGGAGAGCGTTGCTGGCAGCCATA	SEQ?ID?NO：989	B1961932.V1.3_s_at	GCCAGTTTGTGCACCCATGGAGAGC	SEQ?ID?NO：988
B1961932.V1.3_s_at	ATGGAGAGCGTTGCTGGCAGCCATA	SEQ?ID?NO：989	B1961932.V1.3_s_at	AGGGAGTGGGTCACAGCCCATGACC	SEQ?ID?NO：990
B1961932.V1.3_s_at	GGCATTCCAGACAGCTGACCCGGCA	SEQ?ID?NO：991	B1961932.V1.3_s_at	AGGGAGTGGGTCACAGCCCATGACC	SEQ?ID?NO：990
B1961932.V1.3_s_at	GGCATTCCAGACAGCTGACCCGGCA	SEQ?ID?NO：991	B1961932.V1.3_s_at	ACGTTTTGCCTGCACATGGCTCAGA	SEQ?ID?NO：992
B1961932.V1.3_s_at	AGACCTTGGGTCGAGTAACGCTTGT	SEQ?ID?NO：993	B1961932.V1.3_s_at	ACGTTTTGCCTGCACATGGCTCAGA	SEQ?ID?NO：992
B1961932.V1.3_s_at	AGACCTTGGGTCGAGTAACGCTTGT	SEQ?ID?NO：993	B1961932.V1.3_s_at	GAGTAACGCTTGTTTGTGTGTATCT	SEQ?ID?NO：994
B1961935.V1.3_at	TCATTGATTCCGTGTGTCACAGCAT	SEQ?ID?NO：995	B1961932.V1.3_s_at	GAGTAACGCTTGTTTGTGTGTATCT	SEQ?ID?NO：994
B1961935.V1.3_at	TCATTGATTCCGTGTGTCACAGCAT	SEQ?ID?NO：995	B1961935.V1.3_at	ATTTTCTGAAGAACCGCCTCACGAG	SEQ?ID?NO：996
B1961935.V1.3_at	ACGAGACTCATTGTTCTGCGTGTCC	SEQ?ID?NO：997	B1961935.V1.3_at	ATTTTCTGAAGAACCGCCTCACGAG	SEQ?ID?NO：996
B1961935.V1.3_at	ACGAGACTCATTGTTCTGCGTGTCC	SEQ?ID?NO：997	B1961935.V1.3_at	GTTCTGAAATTGTCACGCTCTGTAG	SEQ?ID?NO：998
B1961935.V1.3_at	GAGGACACGGTTTGTTCTCTGTGCA	SEQ?ID?NO：999	B1961935.V1.3_at	GTTCTGAAATTGTCACGCTCTGTAG	SEQ?ID?NO：998
B1961935.V1.3_at	GAGGACACGGTTTGTTCTCTGTGCA	SEQ?ID?NO：999	B1961935.V1.3_at	AAGGGAGCCCTGCACCTCAGAAGGA	SEQ?ID?NO：1000
B1961935.V1.3_at	ATTCCCTTGCCAGTGACTAGTTCTA	SEQ?ID?NO：1001	B1961935.V1.3_at	AAGGGAGCCCTGCACCTCAGAAGGA	SEQ?ID?NO：1000
B1961935.V1.3_at	ATTCCCTTGCCAGTGACTAGTTCTA	SEQ?ID?NO：1001	B1961935.V1.3_at	TGAGACCCAATTCAGGCCGATAAGA	SEQ?ID?NO：1002
B1961935.V1.3_at	TCTGGGCACGCTTGAGTCTGAATGT	SEQ?ID?NO：1003	B1961935.V1.3_at	TGAGACCCAATTCAGGCCGATAAGA	SEQ?ID?NO：1002
B1961935.V1.3_at	TCTGGGCACGCTTGAGTCTGAATGT	SEQ?ID?NO：1003	B1961935.V1.3_at	TACCAGCCCGATGTTGAACGCGACA	SEQ?ID?NO：1004
B1961935.V1.3_at	GATGGAACACACCTAAGCCCTGAGT	SEQ?ID?NO：1005	B1961935.V1.3_at	TACCAGCCCGATGTTGAACGCGACA	SEQ?ID?NO：1004
B1961935.V1.3_at	GATGGAACACACCTAAGCCCTGAGT	SEQ?ID?NO：1005	B1961938.V1.3_at	AGGAGCGAATCTGCAGGGTCTTCTC	SEQ?ID?NO：1006
B1961938.V1.3_at	CTGAGCTTTGAGGACTTTCTGGACC	SEQ?ID?NO：1007	B1961938.V1.3_at	AGGAGCGAATCTGCAGGGTCTTCTC	SEQ?ID?NO：1006
B1961938.V1.3_at	CTGAGCTTTGAGGACTTTCTGGACC	SEQ?ID?NO：1007	B1961938.V1.3_at	GACCTCCTCAGTGTGTTCAGTGACA	SEQ?ID?NO：1008
B1961938.V1.3_at	ATGCCTTCCGCATCTTTGACTTTGA	SEQ?ID?NO：1009	B1961938.V1.3_at	GACCTCCTCAGTGTGTTCAGTGACA	SEQ?ID?NO：1008
B1961938.V1.3_at	ATGCCTTCCGCATCTTTGACTTTGA	SEQ?ID?NO：1009	B1961938.V1.3_at	GAGATGACCTGAGCCAGCTCGTGAA	SEQ?ID?NO：1010

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	B1961938.V1.3_at	CACGGCTCAGTGCTTCCGAGATGAA	SEQ?ID?NO：1011
B1961938.V1.3_at	GGATGGGACCATCAATCTCTCTGAG	SEQ?ID?NO：1012	B1961938.V1.3_at	CACGGCTCAGTGCTTCCGAGATGAA	SEQ?ID?NO：1011
B1961938.V1.3_at	GGATGGGACCATCAATCTCTCTGAG	SEQ?ID?NO：1012	B1961938.V1.3_at	AATCTCTCTGAGTTCCAGCATGTCA	SEQ?ID?NO：1013
B1961938.V1.3_at	ACCAGACTTTGCAAGCTCCTTTAAG	SEQ?ID?NO：1014	B1961938.V1.3_at	AATCTCTCTGAGTTCCAGCATGTCA	SEQ?ID?NO：1013
B1961938.V1.3_at	ACCAGACTTTGCAAGCTCCTTTAAG	SEQ?ID?NO：1014	B1961938.V1.3_at	GCTCCTTTAAGATTGTCCTGTGACA	SEQ?ID?NO：1015
B1961938.V1.3_at	GACCAAGGTCATGCCTGTGTTGCCA	SEQ?ID?NO：1016	B1961938.V1.3_at	GCTCCTTTAAGATTGTCCTGTGACA	SEQ?ID?NO：1015
B1961938.V1.3_at	GACCAAGGTCATGCCTGTGTTGCCA	SEQ?ID?NO：1016	B1961940.V1.3_at	GAGCGGCACGAGTCTCAGACCTGAA	SEQ?ID?NO：1017
B1961940.V1.3_at	GCATGGACCGGATAGACTCTTGACT	SEQ?ID?NO：1018	B1961940.V1.3_at	GAGCGGCACGAGTCTCAGACCTGAA	SEQ?ID?NO：1017
B1961940.V1.3_at	GCATGGACCGGATAGACTCTTGACT	SEQ?ID?NO：1018	B1961940.V1.3_at	TTCTGCCCACAGTTTGTGATCTGCA	SEQ?ID?NO：1019
B1961940.V1.3_at	TGCAGAGTCCAGCTAGGGTAACCCT	SEQ?ID?NO：1020	B1961940.V1.3_at	TTCTGCCCACAGTTTGTGATCTGCA	SEQ?ID?NO：1019
B1961940.V1.3_at	TGCAGAGTCCAGCTAGGGTAACCCT	SEQ?ID?NO：1020	B1961940.V1.3_at	GAGCCAAAGTTTTCTCATTCTCCCT	SEQ?ID?NO：1021
B1961940.V1.3_at	AAATTCTCTCTCCATCTTTTCGGTG	SEQ?ID?NO：1022	B1961940.V1.3_at	GAGCCAAAGTTTTCTCATTCTCCCT	SEQ?ID?NO：1021
B1961940.V1.3_at	AAATTCTCTCTCCATCTTTTCGGTG	SEQ?ID?NO：1022	B1961940.V1.3_at	TTTTCGGTGCATTGGCCATGTTACT	SEQ?ID?NO：1023
B1961940.V1.3_at	GCCATGTTACTGTGCCAATAGTGTC	SEQ?ID?NO：1024	B1961940.V1.3_at	TTTTCGGTGCATTGGCCATGTTACT	SEQ?ID?NO：1023
B1961940.V1.3_at	GCCATGTTACTGTGCCAATAGTGTC	SEQ?ID?NO：1024	B1961940.V1.3_at	TAATTCTTGTTCCATCTGTTCTCAG	SEQ?ID?NO：1025
B1961940.V1.3_at	GCCTTGAACCCCACATAGGAGTTGT	SEQ?ID?NO：1026	B1961940.V1.3_at	TAATTCTTGTTCCATCTGTTCTCAG	SEQ?ID?NO：1025
B1961940.V1.3_at	GCCTTGAACCCCACATAGGAGTTGT	SEQ?ID?NO：1026	B1961940.V1.3_at	GTTACTCCTTGTAGTTGATCCTGAT	SEQ?ID?NO：1027
B1961941.V1.3_at	TGAAGCCCAATATGGTAACCCCAGG	SEQ?ID?NO：1028	B1961940.V1.3_at	GTTACTCCTTGTAGTTGATCCTGAT	SEQ?ID?NO：1027
B1961941.V1.3_at	TGAAGCCCAATATGGTAACCCCAGG	SEQ?ID?NO：1028	B1961941.V1.3_at	GATTGCCATGGCAACTGTCACGGCA	SEQ?ID?NO：1029
B1961941.V1.3_at	TGGGATCACCTTCCTATCTGGAGGC	SEQ?ID?NO：1030	B1961941.V1.3_at	GATTGCCATGGCAACTGTCACGGCA	SEQ?ID?NO：1029
B1961941.V1.3_at	TGGGATCACCTTCCTATCTGGAGGC	SEQ?ID?NO：1030	B1961941.V1.3_at	AGGAGGAGGCATCCATCAACCTCAA	SEQ?ID?NO：1031
B1961941.V1.3_at	GGAATATGTCAAGCGAGCCCTGGCC	SEQ?ID?NO：1032	B1961941.V1.3_at	AGGAGGAGGCATCCATCAACCTCAA	SEQ?ID?NO：1031
B1961941.V1.3_at	GGAATATGTCAAGCGAGCCCTGGCC	SEQ?ID?NO：1032	B1961941.V1.3_at	AAATACACCCCAAGTGGTCACGCTG	SEQ?ID?NO：1033
B1961941.V1.3_at	TTCATCTCTAACCATGCCTACTAAG	SEQ?ID?NO：1034	B1961941.V1.3_at	AAATACACCCCAAGTGGTCACGCTG	SEQ?ID?NO：1033
B1961941.V1.3_at	TTCATCTCTAACCATGCCTACTAAG	SEQ?ID?NO：1034	B1961941.V1.3_at	AGTGGAGGTATTCTAAGGCTGCCCC	SEQ?ID?NO：1035
B1961941.V1.3_at	AGGGCTTTAGGCTGTTCTTTCCCAT	SEQ?ID?NO：1036	B1961941.V1.3_at	AGTGGAGGTATTCTAAGGCTGCCCC	SEQ?ID?NO：1035
B1961941.V1.3_at	AGGGCTTTAGGCTGTTCTTTCCCAT	SEQ?ID?NO：1036	B1961941.V1.3_at	TTGCCTCCCTGGTGACATTGGTCTG	SEQ?ID?NO：1037
B1961941.V1.3_at	GTCTGTGGTATTGTCTGTGTATGCT	SEQ?ID?NO：1038	B1961941.V1.3_at	TTGCCTCCCTGGTGACATTGGTCTG	SEQ?ID?NO：1037
B1961941.V1.3_at	GTCTGTGGTATTGTCTGTGTATGCT	SEQ?ID?NO：1038	B1961946.V1.3_at	TTCATCATGCTCATCATACTCGTAC	SEQ?ID?NO：1039
B1961946.V1.3_at	TTGCCCCTTCGAAGAAATCACGTCA	SEQ?ID?NO：1040	B1961946.V1.3_at	TTCATCATGCTCATCATACTCGTAC	SEQ?ID?NO：1039
B1961946.V1.3_at	TTGCCCCTTCGAAGAAATCACGTCA	SEQ?ID?NO：1040	B1961946.V1.3_at	GGCACTCACACTTGGGCAGCATGTA	SEQ?ID?NO：1041
B1961946.V1.3_at	ATACATGTATCTATCTGTCCCTTCA	SEQ?ID?NO：1042	B1961946.V1.3_at	GGCACTCACACTTGGGCAGCATGTA	SEQ?ID?NO：1041
B1961946.V1.3_at	ATACATGTATCTATCTGTCCCTTCA	SEQ?ID?NO：1042	B1961946.V1.3_at	GTGTTTTTGTAGACTTCTGACCCAG	SEQ?ID?NO：1043
B1961946.V1.3_at	AAGAACGTACCATTGACTCAGCTCC	SEQ?ID?NO：1044	B1961946.V1.3_at	GTGTTTTTGTAGACTTCTGACCCAG	SEQ?ID?NO：1043
B1961946.V1.3_at	AAGAACGTACCATTGACTCAGCTCC	SEQ?ID?NO：1044	B1961946.V1.3_at	TGTTGGTACTCCCAGCAATGTCTAG	SEQ?ID?NO：1045
B1961946.V1.3_at	CAATGTCTAGCTGTGTGACCTTAGG	SEQ?ID?NO：1046	B1961946.V1.3_at	TGTTGGTACTCCCAGCAATGTCTAG	SEQ?ID?NO：1045
B1961946.V1.3_at	CAATGTCTAGCTGTGTGACCTTAGG	SEQ?ID?NO：1046	B1961946.V1.3_at	TTCTTCTATGAGATGGCGGCCACGA	SEQ?ID?NO：1047
B1961946.V1.3_at	AAAGGATGTGTAGCAGACCCCTGCC	SEQ?ID?NO：1048	B1961946.V1.3_at	TTCTTCTATGAGATGGCGGCCACGA	SEQ?ID?NO：1047
B1961946.V1.3_at	AAAGGATGTGTAGCAGACCCCTGCC	SEQ?ID?NO：1048	B1961946.V1.3_at	TGGCAGGTACTCAGTTGATCGTCGA	SEQ?ID?NO：1049
BM734452.V1.3_at	CCGACTCCAGCAGCACGTAGAAGTG	SEQ?ID?NO：1050	B1961946.V1.3_at	TGGCAGGTACTCAGTTGATCGTCGA	SEQ?ID?NO：1049
BM734452.V1.3_at	CCGACTCCAGCAGCACGTAGAAGTG	SEQ?ID?NO：1050	BM734452.V1.3_at	AGACTTTCCCAGGTTCGGGAGCTGC	SEQ?ID?NO：1051
BM734452.V1.3_at	GCTGCTGTGTCCAGAGGTGGCATTT	SEQ?ID?NO：1052	BM734452.V1.3_at	AGACTTTCCCAGGTTCGGGAGCTGC	SEQ?ID?NO：1051
BM734452.V1.3_at	GCTGCTGTGTCCAGAGGTGGCATTT	SEQ?ID?NO：1052	BM734452.V1.3_at	GGCATTTGACTATTTTTGACCAGGA	SEQ?ID?NO：1053
BM734452.V1.3_at	GTAAGCGCGAGGAAATCCTTTTTAT	SEQ?ID?NO：1054	BM734452.V1.3_at	GGCATTTGACTATTTTTGACCAGGA	SEQ?ID?NO：1053
BM734452.V1.3_at	GTAAGCGCGAGGAAATCCTTTTTAT	SEQ?ID?NO：1054	BM734452.V1.3_at	TTTTATTGTATTATCTTCCCTCCCT	SEQ?ID?NO：1055

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734452.V1.3_at	GGCTGCTGGGTCTGTTGTCAGTCCT	SEQ?ID?NO：1056
BM734452.V1.3_at	TGTCAGTCCTGCTGCTAACCTGGCA	SEQ?ID?NO：1057	BM734452.V1.3_at	GGCTGCTGGGTCTGTTGTCAGTCCT	SEQ?ID?NO：1056
BM734452.V1.3_at	TGTCAGTCCTGCTGCTAACCTGGCA	SEQ?ID?NO：1057	BM734452.V1.3_at	GCCGTGAGCTGCCATGTGCTTCTCA	SEQ?ID?NO：1058
BM734452.V1.3_at	CTCAGAGCTGCCCAAGTGGAGGCTC	SEQ?ID?NO：1059	BM734452.V1.3_at	GCCGTGAGCTGCCATGTGCTTCTCA	SEQ?ID?NO：1058
BM734452.V1.3_at	CTCAGAGCTGCCCAAGTGGAGGCTC	SEQ?ID?NO：1059	BM734452.V1.3_at	AAGTGGAGGCTCTAGCTGACTGCCT	SEQ?ID?NO：1060
BM734454.V1.3_at	GAGAAACTCCATTCTACCACTATGA	SEQ?ID?NO：1061	BM734452.V1.3_at	AAGTGGAGGCTCTAGCTGACTGCCT	SEQ?ID?NO：1060
BM734454.V1.3_at	GAGAAACTCCATTCTACCACTATGA	SEQ?ID?NO：1061	BM734454.V1.3_at	GTGTTCCTTTCGTTTTGGGTATCAT	SEQ?ID?NO：1062
BM734454.V1.3_at	GTTTTGGGTATCATCTTCCTGACTC	SEQ?ID?NO：1063	BM734454.V1.3_at	GTGTTCCTTTCGTTTTGGGTATCAT	SEQ?ID?NO：1062
BM734454.V1.3_at	GTTTTGGGTATCATCTTCCTGACTC	SEQ?ID?NO：1063	BM734454.V1.3_at	ATCATCTTCCTGACTCTGATTGGAG	SEQ?ID?NO：1064
BM734454.V1.3_at	GAGTTCAAGGAGCTCCAGTAATGAG	SEQ?ID?NO：1065	BM734454.V1.3_at	ATCATCTTCCTGACTCTGATTGGAG	SEQ?ID?NO：1064
BM734454.V1.3_at	GAGTTCAAGGAGCTCCAGTAATGAG	SEQ?ID?NO：1065	BM734454.V1.3_at	AAGGGACGCTGTTCCTGCATCAAGA	SEQ?ID?NO：1066
BM734454.V1.3_at	GCATCAAGACCAGCCAAGGGACGAT	SEQ?ID?NO：1067	BM734454.V1.3_at	AAGGGACGCTGTTCCTGCATCAAGA	SEQ?ID?NO：1066
BM734454.V1.3_at	GCATCAAGACCAGCCAAGGGACGAT	SEQ?ID?NO：1067	BM734454.V1.3_at	GACGATCCGCCCAAAACTGTTAAAG	SEQ?ID?NO：1068
BM734454.V1.3_at	TTAAACAGTTTGCTCCAAGCCCTTC	SEQ?ID?NO：1069	BM734454.V1.3_at	GACGATCCGCCCAAAACTGTTAAAG	SEQ?ID?NO：1068
BM734454.V1.3_at	TTAAACAGTTTGCTCCAAGCCCTTC	SEQ?ID?NO：1069	BM734454.V1.3_at	CAAGCCCTTCTTGTGAGACAACTGA	SEQ?ID?NO：1070
BM734454.V1.3_at	GTCTAAACCCAGATTCAGCAGAAGT	SEQ?ID?NO：1071	BM734454.V1.3_at	CAAGCCCTTCTTGTGAGACAACTGA	SEQ?ID?NO：1070
BM734454.V1.3_at	GTCTAAACCCAGATTCAGCAGAAGT	SEQ?ID?NO：1071	BM734455.V1.3_at	GGGACAGCCTGCTTGGCCATTGCAA	SEQ?ID?NO：1072
BM734455.V1.3_at	CTGCTTGGCCATTGCAAGCGGCATT	SEQ?ID?NO：1073	BM734455.V1.3_at	GGGACAGCCTGCTTGGCCATTGCAA	SEQ?ID?NO：1072
BM734455.V1.3_at	CTGCTTGGCCATTGCAAGCGGCATT	SEQ?ID?NO：1073	BM734455.V1.3_at	ATTGCAAGCGGCATTTACCTGCTGG	SEQ?ID?NO：1074
BM734455.V1.3_at	AAGCGGCATTTACCTGCTGGCGGCC	SEQ?ID?NO：1075	BM734455.V1.3_at	ATTGCAAGCGGCATTTACCTGCTGG	SEQ?ID?NO：1074
BM734455.V1.3_at	AAGCGGCATTTACCTGCTGGCGGCC	SEQ?ID?NO：1075	BM734455.V1.3_at	CCGTCCGTGGTGAGCAGTGGACCCC	SEQ?ID?NO：1076
BM734455.V1.3_at	CCCCAGCCGAGGTTTGCAAGAAGCT	SEQ?ID?NO：1077	BM734455.V1.3_at	CCGTCCGTGGTGAGCAGTGGACCCC	SEQ?ID?NO：1076
BM734455.V1.3_at	CCCCAGCCGAGGTTTGCAAGAAGCT	SEQ?ID?NO：1077	BM734455.V1.3_at	AGGTTTGCAAGAAGCTCAGCGAGGA	SEQ?ID?NO：1078
BM734455.V1.3_at	AGCGAGGAGGAGTCCGCGGCCGCCA	SEQ?ID?NO：1079	BM734455.V1.3_at	AGGTTTGCAAGAAGCTCAGCGAGGA	SEQ?ID?NO：1078
BM734455.V1.3_at	AGCGAGGAGGAGTCCGCGGCCGCCA	SEQ?ID?NO：1079	BM734455.V1.3_at	ATCCCGGTGACCGATGAGGTTGTGT	SEQ?ID?NO：1080
BM734455.V1.3_at	GTGACGGTGTGTGACCAGAGCCTCA	SEQ?ID?NO：1081	BM734455.V1.3_at	ATCCCGGTGACCGATGAGGTTGTGT	SEQ?ID?NO：1080
BM734455.V1.3_at	GTGACGGTGTGTGACCAGAGCCTCA	SEQ?ID?NO：1081	BM734455.V1.3_at	TGTGTGACCAGAGCCTCAAACCGCT	SEQ?ID?NO：1082
BM734457.V1.3_at	AGGCCCTACGGCTATGCCTGGCAGG	SEQ?ID?NO：1083	BM734455.V1.3_at	TGTGTGACCAGAGCCTCAAACCGCT	SEQ?ID?NO：1082
BM734457.V1.3_at	AGGCCCTACGGCTATGCCTGGCAGG	SEQ?ID?NO：1083	BM734457.V1.3_at	AGATCTGCAAGGTGGCAGTGGCCAC	SEQ?ID?NO：1084
BM734457.V1.3_at	GGCAGTGGCCACTCTGAGCCATGAG	SEQ?ID?NO：1085	BM734457.V1.3_at	AGATCTGCAAGGTGGCAGTGGCCAC	SEQ?ID?NO：1084
BM734457.V1.3_at	GGCAGTGGCCACTCTGAGCCATGAG	SEQ?ID?NO：1085	BM734457.V1.3_at	TGAGCCATGAGCAGATGATTGATCT	SEQ?ID?NO：1086
BM734457.V1.3_at	GATTGATCTGCTGAGAACATCCGTC	SEQ?ID?NO：1087	BM734457.V1.3_at	TGAGCCATGAGCAGATGATTGATCT	SEQ?ID?NO：1086
BM734457.V1.3_at	GATTGATCTGCTGAGAACATCCGTC	SEQ?ID?NO：1087	BM734457.V1.3_at	CTGCTGAGAACATCCGTCACGGTGA	SEQ?ID?NO：1088
BM734457.V1.3_at	CACGGTGAAGGTGGTCATTATCCCC	SEQ?ID?NO：1089	BM734457.V1.3_at	CTGCTGAGAACATCCGTCACGGTGA	SEQ?ID?NO：1088
BM734457.V1.3_at	CACGGTGAAGGTGGTCATTATCCCC	SEQ?ID?NO：1089	BM734457.V1.3_at	ATGATGACTGCACCCCACGGAGGAG	SEQ?ID?NO：1090
BM734457.V1.3_at	ACCCCACGGAGGAGTTGCTCTGAAA	SEQ?ID?NO：1091	BM734457.V1.3_at	ATGATGACTGCACCCCACGGAGGAG	SEQ?ID?NO：1090
BM734457.V1.3_at	ACCCCACGGAGGAGTTGCTCTGAAA	SEQ?ID?NO：1091	BM734457.V1.3_at	AGGAGTTGCTCTGAAACCTACCGCA	SEQ?ID?NO：1092
BM734457.V1.3_at	AACCTACCGCATGCCAGTGATGGAA	SEQ?ID?NO：1093	BM734457.V1.3_at	AGGAGTTGCTCTGAAACCTACCGCA	SEQ?ID?NO：1092
BM734457.V1.3_at	AACCTACCGCATGCCAGTGATGGAA	SEQ?ID?NO：1093	BM734458.V1.3_at	GATTCCTTCCAGCTGAGAGGATTAG	SEQ?ID?NO：1094
BM734458.V1.3_at	AATGGAAGGGTTGGGAGCACTTTCT	SEQ?ID?NO：1095	BM734458.V1.3_at	GATTCCTTCCAGCTGAGAGGATTAG	SEQ?ID?NO：1094
BM734458.V1.3_at	AATGGAAGGGTTGGGAGCACTTTCT	SEQ?ID?NO：1095	BM734458.V1.3_at	GGGCATACTCCTGAAGCCAGTTTTG	SEQ?ID?NO：1096
BM734458.V1.3_at	GTTTTGAAAAGCTCAATGGCACCAG	SEQ?ID?NO：1097	BM734458.V1.3_at	GGGCATACTCCTGAAGCCAGTTTTG	SEQ?ID?NO：1096
BM734458.V1.3_at	GTTTTGAAAAGCTCAATGGCACCAG	SEQ?ID?NO：1097	BM734458.V1.3_at	AATGGCACCAGAAAAGCAGTAAGAC	SEQ?ID?NO：1098
BM734458.V1.3_at	CTGGGCTAGATCAGAGAGGTCTCTC	SEQ?ID?NO：1099	BM734458.V1.3_at	AATGGCACCAGAAAAGCAGTAAGAC	SEQ?ID?NO：1098
BM734458.V1.3_at	CTGGGCTAGATCAGAGAGGTCTCTC	SEQ?ID?NO：1099	BM734458.V1.3_at	ATCAGAGAGGTCTCTCGGGCTGTGC	SEQ?ID?NO：1100

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734458.V1.3_at	AACAGCGGGCTCTGAGTTGTGTCTT	SEQ?ID?NO：1101
BM734458.V1.3_at	GCGGGCTCTGAGTTGTGTCTTAGAA	SEQ?ID?NO：1102	BM734458.V1.3_at	AACAGCGGGCTCTGAGTTGTGTCTT	SEQ?ID?NO：1101
BM734458.V1.3_at	GCGGGCTCTGAGTTGTGTCTTAGAA	SEQ?ID?NO：1102	BM734458.V1.3_at	AGAAGAGTCTCTTTGGCGTGGTCCA	SEQ?ID?NO：1103
BM734458.V1.3_at	TTGGCGTGGTCCACAGGACAGAGTT	SEQ?ID?NO：1104	BM734458.V1.3_at	AGAAGAGTCTCTTTGGCGTGGTCCA	SEQ?ID?NO：1103
BM734458.V1.3_at	TTGGCGTGGTCCACAGGACAGAGTT	SEQ?ID?NO：1104	BM734459.V1.3_at	ATTGTTGATGAGCTGTTTCCGCGTC	SEQ?ID?NO：1105
BM734459.V1.3_at	GATCAACAAGCTCCATCTGTGCAAA	SEQ?ID?NO：1106	BM734459.V1.3_at	ATTGTTGATGAGCTGTTTCCGCGTC	SEQ?ID?NO：1105
BM734459.V1.3_at	GATCAACAAGCTCCATCTGTGCAAA	SEQ?ID?NO：1106	BM734459.V1.3_at	GAGAGACGATTACAGCACCGCGCAG	SEQ?ID?NO：1107
BM734459.V1.3_at	AAGCGGAGGAGTACCTGTCCTTCGC	SEQ?ID?NO：1108	BM734459.V1.3_at	GAGAGACGATTACAGCACCGCGCAG	SEQ?ID?NO：1107
BM734459.V1.3_at	AAGCGGAGGAGTACCTGTCCTTCGC	SEQ?ID?NO：1108	BM734459.V1.3_at	GATGATTCTGATATACCTGCTTCCA	SEQ?ID?NO：1109
BM734459.V1.3_at	AAATGCTGCTGGGTCATATGCCAAC	SEQ?ID?NO：1110	BM734459.V1.3_at	GATGATTCTGATATACCTGCTTCCA	SEQ?ID?NO：1109
BM734459.V1.3_at	AAATGCTGCTGGGTCATATGCCAAC	SEQ?ID?NO：1110	BM734459.V1.3_at	ATATGCCAACCATTGAGCTCTTGAA	SEQ?ID?NO：1111
BM734459.V1.3_at	AGTACCATCTCATGCAGTTTGCTGA	SEQ?ID?NO：1112	BM734459.V1.3_at	ATATGCCAACCATTGAGCTCTTGAA	SEQ?ID?NO：1111
BM734459.V1.3_at	AGTACCATCTCATGCAGTTTGCTGA	SEQ?ID?NO：1112	BM734459.V1.3_at	TGTAAGCGAAGGCAATCTCCTCCTG	SEQ?ID?NO：1113
BM734459.V1.3_at	GAACGAGGCTCTCACAAAGCACGAG	SEQ?ID?NO：1114	BM734459.V1.3_at	TGTAAGCGAAGGCAATCTCCTCCTG	SEQ?ID?NO：1113
BM734459.V1.3_at	GAACGAGGCTCTCACAAAGCACGAG	SEQ?ID?NO：1114	BM734459.V1.3_at	AAAGCACGAGACCTTCTTCATTCGC	SEQ?ID?NO：1115
BM734461.V1.3_at	GGCTAGAGGATGACCGTGCGTGGCA	SEQ?ID?NO：1116	BM734459.V1.3_at	AAAGCACGAGACCTTCTTCATTCGC	SEQ?ID?NO：1115
BM734461.V1.3_at	GGCTAGAGGATGACCGTGCGTGGCA	SEQ?ID?NO：1116	BM734461.V1.3_at	AGGGCGCCGCCGACGGAGGCATGAT	SEQ?ID?NO：1117
BM734461.V1.3_at	GAGGCATGATGGACAGGGACCACAA	SEQ?ID?NO：1118	BM734461.V1.3_at	AGGGCGCCGCCGACGGAGGCATGAT	SEQ?ID?NO：1117
BM734461.V1.3_at	GAGGCATGATGGACAGGGACCACAA	SEQ?ID?NO：1118	BM734461.V1.3_at	AGAAGTATGTCTGGTCACTCGGGCC	SEQ?ID?NO：1119
BM734461.V1.3_at	GCCACATGATGACCCGCGGCGGGAT	SEQ?ID?NO：1120	BM734461.V1.3_at	AGAAGTATGTCTGGTCACTCGGGCC	SEQ?ID?NO：1119
BM734461.V1.3_at	GCCACATGATGACCCGCGGCGGGAT	SEQ?ID?NO：1120	BM734461.V1.3_at	ATGCAGGGCGGCTTCGGAGGCCAGA	SEQ?ID?NO：1121
BM734461.V1.3_at	TTAGGAGCCCCTTCAACTGTGTACA	SEQ?ID?NO：1122	BM734461.V1.3_at	ATGCAGGGCGGCTTCGGAGGCCAGA	SEQ?ID?NO：1121
BM734461.V1.3_at	TTAGGAGCCCCTTCAACTGTGTACA	SEQ?ID?NO：1122	BM734461.V1.3_at	GCCCCTTCAACTGTGTACAATACGT	SEQ?ID?NO：1123
BM734461.V1.3_at	TTTTTTATCTGCTGCCATATTGTAG	SEQ?ID?NO：1124	BM734461.V1.3_at	GCCCCTTCAACTGTGTACAATACGT	SEQ?ID?NO：1123
BM734461.V1.3_at	TTTTTTATCTGCTGCCATATTGTAG	SEQ?ID?NO：1124	BM734461.V1.3_at	ATCTGCTGCCATATTGTAGCTCAAT	SEQ?ID?NO：1125
BM734461.V1.3_at	GTAGCTCAATACAATGTGAATTTGT	SEQ?ID?NO：1126	BM734461.V1.3_at	ATCTGCTGCCATATTGTAGCTCAAT	SEQ?ID?NO：1125
BM734461.V1.3_at	GTAGCTCAATACAATGTGAATTTGT	SEQ?ID?NO：1126	BM734464.V1.3_at	GGACAAGCGTGTCAACGACCTGTTC	SEQ?ID?NO：1127
BM734464.V1.3_at	GTGTCAACGACCTGTTCCGCATCAT	SEQ?ID?NO：1128	BM734464.V1.3_at	GGACAAGCGTGTCAACGACCTGTTC	SEQ?ID?NO：1127
BM734464.V1.3_at	GTGTCAACGACCTGTTCCGCATCAT	SEQ?ID?NO：1128	BM734464.V1.3_at	ATCATCCCCGGCATTGGGAACTTCG	SEQ?ID?NO：1129
BM734464.V1.3_at	GCATTGGGAACTTCGGTGACCGTTA	SEQ?ID?NO：1130	BM734464.V1.3_at	ATCATCCCCGGCATTGGGAACTTCG	SEQ?ID?NO：1129
BM734464.V1.3_at	GCATTGGGAACTTCGGTGACCGTTA	SEQ?ID?NO：1130	BM734464.V1.3_at	GTGACCGTTACTTTGGGACCGATGC	SEQ?ID?NO：1131
BM734464.V1.3_at	GACCGATGCTGTCCCTGATGGCAGT	SEQ?ID?NO：1132	BM734464.V1.3_at	GTGACCGTTACTTTGGGACCGATGC	SEQ?ID?NO：1131
BM734464.V1.3_at	GACCGATGCTGTCCCTGATGGCAGT	SEQ?ID?NO：1132	BM734464.V1.3_at	ATGCTGTCCCTGATGGCAGTGACGA	SEQ?ID?NO：1133
BM734464.V1.3_at	AAGTGGCTTCCACGAGTTAGCTGTG	SEQ?ID?NO：1134	BM734464.V1.3_at	ATGCTGTCCCTGATGGCAGTGACGA	SEQ?ID?NO：1133
BM734464.V1.3_at	AAGTGGCTTCCACGAGTTAGCTGTG	SEQ?ID?NO：1134	BM734464.V1.3_at	AGTTAGCTGTGCAGGCTGAGCCACC	SEQ?ID?NO：1135
BM734464.V1.3_at	TTGGCTCTTGCTTTCCGAGTACAGA	SEQ?ID?NO：1136	BM734464.V1.3_at	AGTTAGCTGTGCAGGCTGAGCCACC	SEQ?ID?NO：1135
BM734464.V1.3_at	TTGGCTCTTGCTTTCCGAGTACAGA	SEQ?ID?NO：1136	BM734464.V1.3_at	CTTGCTTTCCGAGTACAGAGATGTT	SEQ?ID?NO：1137
BM734465.V1.3_at	ACCGGTGGGTCTTTAGCATCTGCAG	SEQ?ID?NO：1138	BM734464.V1.3_at	CTTGCTTTCCGAGTACAGAGATGTT	SEQ?ID?NO：1137
BM734465.V1.3_at	ACCGGTGGGTCTTTAGCATCTGCAG	SEQ?ID?NO：1138	BM734465.V1.3_at	TAGGTGGTCCGTGTCTCATCCAAGA	SEQ?ID?NO：1139
BM734465.V1.3_at	TCCAAGACTGATGAGGCCTGCTGCA	SEQ?ID?NO：1140	BM734465.V1.3_at	TAGGTGGTCCGTGTCTCATCCAAGA	SEQ?ID?NO：1139
BM734465.V1.3_at	TCCAAGACTGATGAGGCCTGCTGCA	SEQ?ID?NO：1140	BM734465.V1.3_at	AAGCTGACATCATCGGCCACAGGGA	SEQ?ID?NO：1141
BM734465.V1.3_at	AAGAGCGCGTCATAGTCCCGGAGGA	SEQ?ID?NO：1142	BM734465.V1.3_at	AAGCTGACATCATCGGCCACAGGGA	SEQ?ID?NO：1141
BM734465.V1.3_at	AAGAGCGCGTCATAGTCCCGGAGGA	SEQ?ID?NO：1142	BM734465.V1.3_at	GGAACCTCTTCTCCTGAAGCAAGGA	SEQ?ID?NO：1143
BM734465.V1.3_at	GGAACTCTTCGATGAAGCCCTGAAT	SEQ?ID?NO：1144	BM734465.V1.3_at	GGAACCTCTTCTCCTGAAGCAAGGA	SEQ?ID?NO：1143
BM734465.V1.3_at	GGAACTCTTCGATGAAGCCCTGAAT	SEQ?ID?NO：1144	BM734465.V1.3_at	GAATGTTGTCACAGCTGCTTTCCAA	SEQ?ID?NO：1145

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734465.V1.3_at	GAATGGGAGAGCCTCTGCCACAAGT	SEQ?ID?NO：1146
BM734465.V1.3_at	AAGCCTCCTCTTCTTAATTGCAGAC	SEQ?ID?NO：1147	BM734465.V1.3_at	GAATGGGAGAGCCTCTGCCACAAGT	SEQ?ID?NO：1146
BM734465.V1.3_at	AAGCCTCCTCTTCTTAATTGCAGAC	SEQ?ID?NO：1147	BM734465.V1.3_at	AATTGCAGACTCCAGTTCGGGAACT	SEQ?ID?NO：1148
BM734478.V1.3_at	TACAGCCCCTGGACCTTTTGAAGGA	SEQ?ID?NO：1149	BM734465.V1.3_at	AATTGCAGACTCCAGTTCGGGAACT	SEQ?ID?NO：1148
BM734478.V1.3_at	TACAGCCCCTGGACCTTTTGAAGGA	SEQ?ID?NO：1149	BM734478.V1.3_at	GAGTCTGGCTCCCAGGCTGAAGAAA	SEQ?ID?NO：1150
BM734478.V1.3_at	TATACTCGGCCACAGCTAAAGCTTT	SEQ?ID?NO：1151	BM734478.V1.3_at	GAGTCTGGCTCCCAGGCTGAAGAAA	SEQ?ID?NO：1150
BM734478.V1.3_at	TATACTCGGCCACAGCTAAAGCTTT	SEQ?ID?NO：1151	BM734478.V1.3_at	TTTCACTTTTCTCCTTCGGAAGCAA	SEQ?ID?NO：1152
BM734478.V1.3_at	GCAAAACTGGCCTGTACGAGATCCC	SEQ?ID?NO：1153	BM734478.V1.3_at	TTTCACTTTTCTCCTTCGGAAGCAA	SEQ?ID?NO：1152
BM734478.V1.3_at	GCAAAACTGGCCTGTACGAGATCCC	SEQ?ID?NO：1153	BM734478.V1.3_at	GATCCCCTGTTAAAACTTCTCGGCG	SEQ?ID?NO：1154
BM734478.V1.3_at	AATTGTTGTATTTCTCTCTGCTTCC	SEQ?ID?NO：1155	BM734478.V1.3_at	GATCCCCTGTTAAAACTTCTCGGCG	SEQ?ID?NO：1154
BM734478.V1.3_at	AATTGTTGTATTTCTCTCTGCTTCC	SEQ?ID?NO：1155	BM734478.V1.3_at	TAACAGCTTTGTGATGTTCCCGCTT	SEQ?ID?NO：1156
BM734478.V1.3_at	TTTCTTTCTTCCTAACAGCCAGATT	SEQ?ID?NO：1157	BM734478.V1.3_at	TAACAGCTTTGTGATGTTCCCGCTT	SEQ?ID?NO：1156
BM734478.V1.3_at	TTTCTTTCTTCCTAACAGCCAGATT	SEQ?ID?NO：1157	BM734478.V1.3_at	CAGCCAGATTGCTTTTCCCATAAAG	SEQ?ID?NO：1158
BM734478.V1.3_at	TTGAGAATCTCAAGCCATGTGCATT	SEQ?ID?NO：1159	BM734478.V1.3_at	CAGCCAGATTGCTTTTCCCATAAAG	SEQ?ID?NO：1158
BM734478.V1.3_at	TTGAGAATCTCAAGCCATGTGCATT	SEQ?ID?NO：1159	BM734480.V1.3_at	AATGCTTTGCAAGTCCTGTGCCAAA	SEQ?ID?NO：1160
BM734480.V1.3_at	AAAGCTGGCCTGAGGACCACTTGCA	SEQ?ID?NO：1161	BM734480.V1.3_at	AATGCTTTGCAAGTCCTGTGCCAAA	SEQ?ID?NO：1160
BM734480.V1.3_at	AAAGCTGGCCTGAGGACCACTTGCA	SEQ?ID?NO：1161	BM734480.V1.3_at	TAGGCACAGCAGCAGTAGCTCCTTT	SEQ?ID?NO：1162
BM734480.V1.3_at	TTCCATTATCTCCTTCAACTCAGAA	SEQ?ID?NO：1163	BM734480.V1.3_at	TAGGCACAGCAGCAGTAGCTCCTTT	SEQ?ID?NO：1162
BM734480.V1.3_at	TTCCATTATCTCCTTCAACTCAGAA	SEQ?ID?NO：1163	BM734480.V1.3_at	AGAAAGGGTTTCTGTCTCCAGCCAC	SEQ?ID?NO：1164
BM734480.V1.3_at	GGCGAGACCCCTTGATTGGCAAAGA	SEQ?ID?NO：1165	BM734480.V1.3_at	AGAAAGGGTTTCTGTCTCCAGCCAC	SEQ?ID?NO：1164
BM734480.V1.3_at	GGCGAGACCCCTTGATTGGCAAAGA	SEQ?ID?NO：1165	BM734480.V1.3_at	AGACCCGACATGTTTTAGGCCCTCA	SEQ?ID?NO：1166
BM734480.V1.3_at	GCCCTCACCAGTGTTGTCTTAGGTA	SEQ?ID?NO：1167	BM734480.V1.3_at	AGACCCGACATGTTTTAGGCCCTCA	SEQ?ID?NO：1166
BM734480.V1.3_at	GCCCTCACCAGTGTTGTCTTAGGTA	SEQ?ID?NO：1167	BM734480.V1.3_at	GTCTTAGGTATCAACTGCTGCTCTG	SEQ?ID?NO：1168
BM734480.V1.3_at	AGCCAGCCTATTTTTCAGTGCACAT	SEQ?ID?NO：1169	BM734480.V1.3_at	GTCTTAGGTATCAACTGCTGCTCTG	SEQ?ID?NO：1168
BM734480.V1.3_at	AGCCAGCCTATTTTTCAGTGCACAT	SEQ?ID?NO：1169	BM734480.V1.3_at	CAAGGTGCTATCTGCTCTGGAAGTT	SEQ?ID?NO：1170
BM734482.V1.3_at	ATTTCCTGTGGTGTTCATTTTGAGC	SEQ?ID?NO：1171	BM734480.V1.3_at	CAAGGTGCTATCTGCTCTGGAAGTT	SEQ?ID?NO：1170
BM734482.V1.3_at	ATTTCCTGTGGTGTTCATTTTGAGC	SEQ?ID?NO：1171	BM734482.V1.3_at	TAGCAAACCTTCTATGCTCTCAGTG	SEQ?ID?NO：1172
BM734482.V1.3_at	TCAGTGCTTCCCAGAGAACATCAGG	SEQ?ID?NO：1173	BM734482.V1.3_at	TAGCAAACCTTCTATGCTCTCAGTG	SEQ?ID?NO：1172
BM734482.V1.3_at	TCAGTGCTTCCCAGAGAACATCAGG	SEQ?ID?NO：1173	BM734482.V1.3_at	AGATTCTCACGTGCCTTTGGGATCG	SEQ?ID?NO：1174
BM734482.V1.3_at	GAAGGGTTCAACAACACGAGGTCTT	SEQ?ID?NO：1175	BM734482.V1.3_at	AGATTCTCACGTGCCTTTGGGATCG	SEQ?ID?NO：1174
BM734482.V1.3_at	GAAGGGTTCAACAACACGAGGTCTT	SEQ?ID?NO：1175	BM734482.V1.3_at	ACGAGGTCTTGATCTGGACTTCAGA	SEQ?ID?NO：1176
BM734482.V1.3_at	GAATCAATGGTGCTGTGCTGTCAAT	SEQ?ID?NO：1177	BM734482.V1.3_at	ACGAGGTCTTGATCTGGACTTCAGA	SEQ?ID?NO：1176
BM734482.V1.3_at	GAATCAATGGTGCTGTGCTGTCAAT	SEQ?ID?NO：1177	BM734482.V1.3_at	TGCTGTCAATGGCTACTCGGTGGAA	SEQ?ID?NO：1178
BM734482.V1.3_at	AAGGGTTGCCCCAGAATAAATCTCT	SEQ?ID?NO：1179	BM734482.V1.3_at	TGCTGTCAATGGCTACTCGGTGGAA	SEQ?ID?NO：1178
BM734482.V1.3_at	AAGGGTTGCCCCAGAATAAATCTCT	SEQ?ID?NO：1179	BM734482.V1.3_at	AAATCTCTGGATTAACTCTCCCGGG	SEQ?ID?NO：1180
BM734482.V1.3_at	GCAGGGTGCCGTTTCGGTACCAAGA	SEQ?ID?NO：1181	BM734482.V1.3_at	AAATCTCTGGATTAACTCTCCCGGG	SEQ?ID?NO：1180
BM734482.V1.3_at	GCAGGGTGCCGTTTCGGTACCAAGA	SEQ?ID?NO：1181	BM734485.V1.3_at	GACACAAACTTTCAGACCATAGCAA	SEQ?ID?NO：1182
BM734485.V1.3_at	TGTATGACAAGGACTGCCAGGCCCA	SEQ?ID?NO：1183	BM734485.V1.3_at	GACACAAACTTTCAGACCATAGCAA	SEQ?ID?NO：1182
BM734485.V1.3_at	TGTATGACAAGGACTGCCAGGCCCA	SEQ?ID?NO：1183	BM734485.V1.3_at	AGGCCCATCCATTAACGCTAGTTGG	SEQ?ID?NO：1184
BM734485.V1.3_at	TTAACGCTAGTTGGGTTCACTCCTC	SEQ?ID?NO：1185	BM734485.V1.3_at	AGGCCCATCCATTAACGCTAGTTGG	SEQ?ID?NO：1184
BM734485.V1.3_at	TTAACGCTAGTTGGGTTCACTCCTC	SEQ?ID?NO：1185	BM734485.V1.3_at	ATCTCAAATTTCCTCGATTTCACCA	SEQ?ID?NO：1186
BM734485.V1.3_at	GATTTCACCAAGAGCCTATTGCCTT	SEQ?ID?NO：1187	BM734485.V1.3_at	ATCTCAAATTTCCTCGATTTCACCA	SEQ?ID?NO：1186
BM734485.V1.3_at	GATTTCACCAAGAGCCTATTGCCTT	SEQ?ID?NO：1187	BM734485.V1.3_at	GAGCCTATTGCCTTCAAGTTTTTAT	SEQ?ID?NO：1188
BM734485.V1.3_at	AAATGTCTGGATTTTCAGCTTCTGT	SEQ?ID?NO：1189	BM734485.V1.3_at	GAGCCTATTGCCTTCAAGTTTTTAT	SEQ?ID?NO：1188
BM734485.V1.3_at	AAATGTCTGGATTTTCAGCTTCTGT	SEQ?ID?NO：1189	BM734485.V1.3_at	GTGGGAGTGTTCTCCAAACACGGGA	SEQ?ID?NO：1190

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734485.V1.3_at	TGCTGGACAGCCCAACTGAATGGTG	SEQ?ID?NO：1191
BM734485.V1.3_at	GGTGATACTGACCACACTTGCCATA	SEQ?ID?NO：1192	BM734485.V1.3_at	TGCTGGACAGCCCAACTGAATGGTG	SEQ?ID?NO：1191
BM734485.V1.3_at	GGTGATACTGACCACACTTGCCATA	SEQ?ID?NO：1192	BM734496.V1.3_at	TGGGTTGCTGCCACAACATGGCTGC	SEQ?ID?NO：1193
BM734496.V1.3_at	GAGTGATGTGGGTCCACACCCAGGA	SEQ?ID?NO：1194	BM734496.V1.3_at	TGGGTTGCTGCCACAACATGGCTGC	SEQ?ID?NO：1193
BM734496.V1.3_at	GAGTGATGTGGGTCCACACCCAGGA	SEQ?ID?NO：1194	BM734496.V1.3_at	GGAGCTGAACCCTGGGCTGCTGAAT	SEQ?ID?NO：1195
BM734496.V1.3_at	GCCAGCCCCTACAAGTCATTTTTTA	SEQ?ID?NO：1196	BM734496.V1.3_at	GGAGCTGAACCCTGGGCTGCTGAAT	SEQ?ID?NO：1195
BM734496.V1.3_at	GCCAGCCCCTACAAGTCATTTTTTA	SEQ?ID?NO：1196	BM734496.V1.3_at	ACTTTCAGTGACATAGGCTGCCTTT	SEQ?ID?NO：1197
BM734496.V1.3_at	GGCTGCCTTTTCTAAACTAATCCTT	SEQ?ID?NO：1198	BM734496.V1.3_at	ACTTTCAGTGACATAGGCTGCCTTT	SEQ?ID?NO：1197
BM734496.V1.3_at	GGCTGCCTTTTCTAAACTAATCCTT	SEQ?ID?NO：1198	BM734496.V1.3_at	ACAGAGTCTTGATTTCTGCACCCCA	SEQ?ID?NO：1199
BM734496.V1.3_at	GCACCCCATCTTTACCTTTGAGGAA	SEQ?ID?NO：1200	BM734496.V1.3_at	ACAGAGTCTTGATTTCTGCACCCCA	SEQ?ID?NO：1199
BM734496.V1.3_at	GCACCCCATCTTTACCTTTGAGGAA	SEQ?ID?NO：1200	BM734496.V1.3_at	GGCCAGCCCGGTGATGTAATGATTA	SEQ?ID?NO：1201
BM734496.V1.3_at	AAGTTTGCACACTCCACTTCAGTGG	SEQ?ID?NO：1202	BM734496.V1.3_at	GGCCAGCCCGGTGATGTAATGATTA	SEQ?ID?NO：1201
BM734496.V1.3_at	AAGTTTGCACACTCCACTTCAGTGG	SEQ?ID?NO：1202	BM734496.V1.3_at	AGTGGCCTGGGATTCACCAGTTCAG	SEQ?ID?NO：1203
BM734501.V1.3_at	AAGAGAATGTAGTTCCCTCCTCAGG	SEQ?ID?NO：1204	BM734496.V1.3_at	AGTGGCCTGGGATTCACCAGTTCAG	SEQ?ID?NO：1203
BM734501.V1.3_at	AAGAGAATGTAGTTCCCTCCTCAGG	SEQ?ID?NO：1204	BM734501.V1.3_at	CAGGCTTTCGTGGTTAGCTTACCGA	SEQ?ID?NO：1205
BM734501.V1.3_at	GGTACAAGCCGAGCTGCCAGGGAAT	SEQ?ID?NO：1206	BM734501.V1.3_at	CAGGCTTTCGTGGTTAGCTTACCGA	SEQ?ID?NO：1205
BM734501.V1.3_at	GGTACAAGCCGAGCTGCCAGGGAAT	SEQ?ID?NO：1206	BM734501.V1.3_at	ACAGTCTTGCTGTCCAGGGAACCAA	SEQ?ID?NO：1207
BM734501.V1.3_at	GTCCGTTTTCAGTTCTATCTCCAAA	SEQ?ID?NO：1208	BM734501.V1.3_at	ACAGTCTTGCTGTCCAGGGAACCAA	SEQ?ID?NO：1207
BM734501.V1.3_at	GTCCGTTTTCAGTTCTATCTCCAAA	SEQ?ID?NO：1208	BM734501.V1.3_at	TAACAGGCCCTTGGCACAGCAAGAT	SEQ?ID?NO：1209
BM734501.V1.3_at	AGCAAGATCCTTTCTGCAGGCTGAT	SEQ?ID?NO：1210	BM734501.V1.3_at	TAACAGGCCCTTGGCACAGCAAGAT	SEQ?ID?NO：1209
BM734501.V1.3_at	AGCAAGATCCTTTCTGCAGGCTGAT	SEQ?ID?NO：1210	BM734501.V1.3_at	AAAAACGATTCTGTCTCCTTCAAAG	SEQ?ID?NO：1211
BM734501.V1.3_at	GAGTACTTGTTTTCTGACTTGTCCA	SEQ?ID?NO：1212	BM734501.V1.3_at	AAAAACGATTCTGTCTCCTTCAAAG	SEQ?ID?NO：1211
BM734501.V1.3_at	GAGTACTTGTTTTCTGACTTGTCCA	SEQ?ID?NO：1212	BM734501.V1.3_at	AATGCACTATGCTTGATCGCCGATT	SEQ?ID?NO：1213
BM734501.V1.3_at	GTATAACGTCGTTGCCTTTATTTGT	SEQ?ID?NO：1214	BM734501.V1.3_at	AATGCACTATGCTTGATCGCCGATT	SEQ?ID?NO：1213
BM734501.V1.3_at	GTATAACGTCGTTGCCTTTATTTGT	SEQ?ID?NO：1214	BM734502.V1.3_at	ATGAGCTGGAGGCACTTCTACCTTT	SEQ?ID?NO：1215
BM734502.V1.3_at	TACCTTTGTGGGTCCCTTATTCTAT	SEQ?ID?NO：1216	BM734502.V1.3_at	ATGAGCTGGAGGCACTTCTACCTTT	SEQ?ID?NO：1215
BM734502.V1.3_at	TACCTTTGTGGGTCCCTTATTCTAT	SEQ?ID?NO：1216	BM734502.V1.3_at	GACTTCTAAAAGCTCATGGGCCCTA	SEQ?ID?NO：1217
BM734502.V1.3_at	GGCCCTGCCATTACGTGGATACTGT	SEQ?ID?NO：1218	BM734502.V1.3_at	GACTTCTAAAAGCTCATGGGCCCTA	SEQ?ID?NO：1217
BM734502.V1.3_at	GGCCCTGCCATTACGTGGATACTGT	SEQ?ID?NO：1218	BM734502.V1.3_at	GGATACTGTGCCTTTAGCTGTAACA	SEQ?ID?NO：1219
BM734502.V1.3_at	TAACACCGAGCCTGTATCCTTTAAT	SEQ?ID?NO：1220	BM734502.V1.3_at	GGATACTGTGCCTTTAGCTGTAACA	SEQ?ID?NO：1219
BM734502.V1.3_at	TAACACCGAGCCTGTATCCTTTAAT	SEQ?ID?NO：1220	BM734502.V1.3_at	TGATTTCATTCAGGCATGCTCATCT	SEQ?ID?NO：1221
BM734502.V1.3_at	AAATGGGACCCAGCTCTCTTGGTGA	SEQ?ID?NO：1222	BM734502.V1.3_at	TGATTTCATTCAGGCATGCTCATCT	SEQ?ID?NO：1221
BM734502.V1.3_at	AAATGGGACCCAGCTCTCTTGGTGA	SEQ?ID?NO：1222	BM734502.V1.3_at	GTGAGCCAGGATCTCTTTACGTTTA	SEQ?ID?NO：1223
BM734502.V1.3_at	TATTGTTTTAACTCTCTTCCCAGGT	SEQ?ID?NO：1224	BM734502.V1.3_at	GTGAGCCAGGATCTCTTTACGTTTA	SEQ?ID?NO：1223
BM734502.V1.3_at	TATTGTTTTAACTCTCTTCCCAGGT	SEQ?ID?NO：1224	BM734502.V1.3_at	TTCAAACTTTTCTGATCCCAGCCTA	SEQ?ID?NO：1225
BM734506.V1.3_at	GAACCTGTTGGATGACCTTGTAACT	SEQ?ID?NO：1226	BM734502.V1.3_at	TTCAAACTTTTCTGATCCCAGCCTA	SEQ?ID?NO：1225
BM734506.V1.3_at	GAACCTGTTGGATGACCTTGTAACT	SEQ?ID?NO：1226	BM734506.V1.3_at	GAGAGAGACTACTTCTGGCATCCTT	SEQ?ID?NO：1227
BM734506.V1.3_at	AGAACCAGATCTCATCAGGTCCAGC	SEQ?ID?NO：1228	BM734506.V1.3_at	GAGAGAGACTACTTCTGGCATCCTT	SEQ?ID?NO：1227
BM734506.V1.3_at	AGAACCAGATCTCATCAGGTCCAGC	SEQ?ID?NO：1228	BM734506.V1.3_at	TAAGCGAGGAGTACCCAACCCTTGG	SEQ?ID?NO：1229
BM734506.V1.3_at	GATGAAATCCGGCAGCAGCAGCAGA	SEQ?ID?NO：1230	BM734506.V1.3_at	TAAGCGAGGAGTACCCAACCCTTGG	SEQ?ID?NO：1229
BM734506.V1.3_at	GATGAAATCCGGCAGCAGCAGCAGA	SEQ?ID?NO：1230	BM734506.V1.3_at	TTTCCTCCATCATAAGTCGCCAGAA	SEQ?ID?NO：1231
BM734506.V1.3_at	ATGACCTTGCCAACCTGGTGGAGAA	SEQ?ID?NO：1232	BM734506.V1.3_at	TTTCCTCCATCATAAGTCGCCAGAA	SEQ?ID?NO：1231
BM734506.V1.3_at	ATGACCTTGCCAACCTGGTGGAGAA	SEQ?ID?NO：1232	BM734506.V1.3_at	GATTTTATTGCTGCTCGTGGCTATT	SEQ?ID?NO：1233
BM734506.V1.3_at	GTGGCTATTGTGGTCGTCGCAGTCT	SEQ?ID?NO：1234	BM734506.V1.3_at	GATTTTATTGCTGCTCGTGGCTATT	SEQ?ID?NO：1233
BM734506.V1.3_at	GTGGCTATTGTGGTCGTCGCAGTCT	SEQ?ID?NO：1234	BM734506.V1.3_at	TCGCAGTCTGGCCTACCAAGTAGTG	SEQ?ID?NO：1235

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734506.V1.3_at	AGTTCAGTGCCCTTTTGGTACACGA	SEQ?ID?NO：1236
BM734508.V1.3_at	AGGTCTCCGTCTGCTTTCTTTTTTG	SEQ?ID?NO：1237	BM734506.V1.3_at	AGTTCAGTGCCCTTTTGGTACACGA	SEQ?ID?NO：1236
BM734508.V1.3_at	AGGTCTCCGTCTGCTTTCTTTTTTG	SEQ?ID?NO：1237	BM734508.V1.3_at	AGGCTTTAGGCCACAGGCAGCTTCT	SEQ?ID?NO：1238
BM734508.V1.3_at	CAAGGTGGCCAGATGGTTCCAGGAC	SEQ?ID?NO：1239	BM734508.V1.3_at	AGGCTTTAGGCCACAGGCAGCTTCT	SEQ?ID?NO：1238
BM734508.V1.3_at	CAAGGTGGCCAGATGGTTCCAGGAC	SEQ?ID?NO：1239	BM734508.V1.3_at	GTTCCAGGACCACAGTGTCTTTATT	SEQ?ID?NO：1240
BM734508.V1.3_at	ATTTTTAACTGTTTGCCACTGCTGC	SEQ?ID?NO：1241	BM734508.V1.3_at	GTTCCAGGACCACAGTGTCTTTATT	SEQ?ID?NO：1240
BM734508.V1.3_at	ATTTTTAACTGTTTGCCACTGCTGC	SEQ?ID?NO：1241	BM734508.V1.3_at	TGGAGTACTCTCTGCCCCAGACTAG	SEQ?ID?NO：1242
BM734508.V1.3_at	GCCCCAGACTAGCAGGAGTGAGTTC	SEQ?ID?NO：1243	BM734508.V1.3_at	TGGAGTACTCTCTGCCCCAGACTAG	SEQ?ID?NO：1242
BM734508.V1.3_at	GCCCCAGACTAGCAGGAGTGAGTTC	SEQ?ID?NO：1243	BM734508.V1.3_at	AGCGCTGATTCTCCCCGCAGTGTTG	SEQ?ID?NO：1244
BM734508.V1.3_at	GGGCATACCTTCTAACTGAGCAGTA	SEQ?ID?NO：1245	BM734508.V1.3_at	AGCGCTGATTCTCCCCGCAGTGTTG	SEQ?ID?NO：1244
BM734508.V1.3_at	GGGCATACCTTCTAACTGAGCAGTA	SEQ?ID?NO：1245	BM734508.V1.3_at	GCACGAGCCTGGGAACTGCTTTTAT	SEQ?ID?NO：1246
BM734508.V1.3_at	AATTTATCTCTGTGACCTGCTAGGG	SEQ?ID?NO：1247	BM734508.V1.3_at	GCACGAGCCTGGGAACTGCTTTTAT	SEQ?ID?NO：1246
BM734508.V1.3_at	AATTTATCTCTGTGACCTGCTAGGG	SEQ?ID?NO：1247	BM734510.V1.3_at	ACGAGCGGCACGAGCCGAAGATGGC	SEQ?ID?NO：1248
BM734510.V1.3_at	GCGGCACGAGCCGAAGATGGCGGAG	SEQ?ID?NO：1249	BM734510.V1.3_at	ACGAGCGGCACGAGCCGAAGATGGC	SEQ?ID?NO：1248
BM734510.V1.3_at	GCGGCACGAGCCGAAGATGGCGGAG	SEQ?ID?NO：1249	BM734510.V1.3_at	GGGCAGGTCCTGGTGCTGGATGGCC	SEQ?ID?NO：1250
BM734510.V1.3_at	CAGGTCCTGGTGCTGGATGGCCGGG	SEQ?ID?NO：1251	BM734510.V1.3_at	GGGCAGGTCCTGGTGCTGGATGGCC	SEQ?ID?NO：1250
BM734510.V1.3_at	CAGGTCCTGGTGCTGGATGGCCGGG	SEQ?ID?NO：1251	BM734510.V1.3_at	GCCTGGCGGCCATCGTGGCCAAGCA	SEQ?ID?NO：1252
BM734510.V1.3_at	GCCATCGTGGCCAAGCAGGTGCTGC	SEQ?ID?NO：1253	BM734510.V1.3_at	GCCTGGCGGCCATCGTGGCCAAGCA	SEQ?ID?NO：1252
BM734510.V1.3_at	GCCATCGTGGCCAAGCAGGTGCTGC	SEQ?ID?NO：1253	BM734510.V1.3_at	CCATCGTGGCCAAGCAGGTGCTGCT	SEQ?ID?NO：1254
BM734510.V1.3_at	CATCGTGGCCAAGCAGGTGCTGCTG	SEQ?ID?NO：1255	BM734510.V1.3_at	CCATCGTGGCCAAGCAGGTGCTGCT	SEQ?ID?NO：1254
BM734510.V1.3_at	CATCGTGGCCAAGCAGGTGCTGCTG	SEQ?ID?NO：1255	BM734510.V1.3_at	AAGCAGGTGCTGCTGGGCCGGAAGG	SEQ?ID?NO：1256
BM734510.V1.3_at	GCTGCTGGGCCGGAAGGTGGTGGTC	SEQ?ID?NO：1257	BM734510.V1.3_at	AAGCAGGTGCTGCTGGGCCGGAAGG	SEQ?ID?NO：1256
BM734510.V1.3_at	GCTGCTGGGCCGGAAGGTGGTGGTC	SEQ?ID?NO：1257	BM734510.V1.3_at	CTTCCTCCGCAAGCCTACACGAAAG	SEQ?ID?NO：1258
BM734511.V1.3_at	ATCTCTTTCCTCATTTTCCTGATAG	SEQ?ID?NO：1259	BM734510.V1.3_at	CTTCCTCCGCAAGCCTACACGAAAG	SEQ?ID?NO：1258
BM734511.V1.3_at	ATCTCTTTCCTCATTTTCCTGATAG	SEQ?ID?NO：1259	BM734511.V1.3_at	GATGAGGATGGCCTTCCTGTTTCAC	SEQ?ID?NO：1260
BM734511.V1.3_at	ATCTTCTCAATCTTTCTTTACCGGG	SEQ?ID?NO：1261	BM734511.V1.3_at	GATGAGGATGGCCTTCCTGTTTCAC	SEQ?ID?NO：1260
BM734511.V1.3_at	ATCTTCTCAATCTTTCTTTACCGGG	SEQ?ID?NO：1261	BM734511.V1.3_at	AATACGCTTGGCACTGATGGGCACT	SEQ?ID?NO：1262
BM734511.V1.3_at	CAGACCCCGGATGCTATTTATTCAA	SEQ?ID?NO：1263	BM734511.V1.3_at	AATACGCTTGGCACTGATGGGCACT	SEQ?ID?NO：1262
BM734511.V1.3_at	CAGACCCCGGATGCTATTTATTCAA	SEQ?ID?NO：1263	BM734511.V1.3_at	GTTTGAATGAGTCCTTCGTGGGCCA	SEQ?ID?NO：1264
BM734511.V1.3_at	AGGCTTATCTTTTTGTCTAGTGCAA	SEQ?ID?NO：1265	BM734511.V1.3_at	GTTTGAATGAGTCCTTCGTGGGCCA	SEQ?ID?NO：1264
BM734511.V1.3_at	AGGCTTATCTTTTTGTCTAGTGCAA	SEQ?ID?NO：1265	BM734511.V1.3_at	TTTACCTAAATACTTCCAGCTCCTT	SEQ?ID?NO：1266
BM734511.V1.3_at	AAGCTCAGTACACTAATGCCTCATC	SEQ?ID?NO：1267	BM734511.V1.3_at	TTTACCTAAATACTTCCAGCTCCTT	SEQ?ID?NO：1266
BM734511.V1.3_at	AAGCTCAGTACACTAATGCCTCATC	SEQ?ID?NO：1267	BM734511.V1.3_at	ATGCCTCATCTTAGCAGTGATTTTG	SEQ?ID?NO：1268
BM734511.V1.3_at	AAACCTGACTGAGTTTTCCTGTCTA	SEQ?ID?NO：1269	BM734511.V1.3_at	ATGCCTCATCTTAGCAGTGATTTTG	SEQ?ID?NO：1268
BM734511.V1.3_at	AAACCTGACTGAGTTTTCCTGTCTA	SEQ?ID?NO：1269	BM734513.V1.3_at	GAGGCTTGAAAACACACCACATTGA	SEQ?ID?NO：1270
BM734513.V1.3_at	ACCACATTGAAAATCCTGCCACAGC	SEQ?ID?NO：1271	BM734513.V1.3_at	GAGGCTTGAAAACACACCACATTGA	SEQ?ID?NO：1270
BM734513.V1.3_at	ACCACATTGAAAATCCTGCCACAGC	SEQ?ID?NO：1271	BM734513.V1.3_at	TAAGCACTGGCTTCGTAGGAAACCA	SEQ?ID?NO：1272
BM734513.V1.3_at	CATACGCCGGCCGTCTTGGAAAAGA	SEQ?ID?NO：1273	BM734513.V1.3_at	TAAGCACTGGCTTCGTAGGAAACCA	SEQ?ID?NO：1272
BM734513.V1.3_at	CATACGCCGGCCGTCTTGGAAAAGA	SEQ?ID?NO：1273	BM734513.V1.3_at	AGAACTAGCTTTTCTGCCTTTTGGC	SEQ?ID?NO：1274
BM734513.V1.3_at	GCCTGGCCTTTGCTACTGGTAAGAA	SEQ?ID?NO：1275	BM734513.V1.3_at	AGAACTAGCTTTTCTGCCTTTTGGC	SEQ?ID?NO：1274
BM734513.V1.3_at	GCCTGGCCTTTGCTACTGGTAAGAA	SEQ?ID?NO：1275	BM734513.V1.3_at	AAGATGGAGCCTGGGTCTCAAGCCC	SEQ?ID?NO：1276
BM734513.V1.3_at	TGTACCTTTGCCACACTGTATGTGT	SEQ?ID?NO：1277	BM734513.V1.3_at	AAGATGGAGCCTGGGTCTCAAGCCC	SEQ?ID?NO：1276
BM734513.V1.3_at	TGTACCTTTGCCACACTGTATGTGT	SEQ?ID?NO：1277	BM734513.V1.3_at	GAGGCTGAGGGATTCTTTCCAGTCT	SEQ?ID?NO：1278
BM734513.V1.3_at	GGTATCCACATTCTCAACTTCAAGT	SEQ?ID?NO：1279	BM734513.V1.3_at	GAGGCTGAGGGATTCTTTCCAGTCT	SEQ?ID?NO：1278
BM734513.V1.3_at	GGTATCCACATTCTCAACTTCAAGT	SEQ?ID?NO：1279	BM734513.V1.3_at	AGTCATTGCAGTTTCTTTTTCCCAG	SEQ?ID?NO：1280

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734514.V1.3_at	ACGTGTTCAGGGTTTGGTTGGCTCA	SEQ?ID?NO：1281
BM734514.V1.3_at	GGTTGGCTCAACTCCAAACTCAATA	SEQ?ID?NO：1282	BM734514.V1.3_at	ACGTGTTCAGGGTTTGGTTGGCTCA	SEQ?ID?NO：1281
BM734514.V1.3_at	GGTTGGCTCAACTCCAAACTCAATA	SEQ?ID?NO：1282	BM734514.V1.3_at	TGATTACCAATATGATCTCCCGTCC	SEQ?ID?NO：1283
BM734514.V1.3_at	TGATCTCCCGTCCAGTAGCGTGGGA	SEQ?ID?NO：1284	BM734514.V1.3_at	TGATTACCAATATGATCTCCCGTCC	SEQ?ID?NO：1283
BM734514.V1.3_at	TGATCTCCCGTCCAGTAGCGTGGGA	SEQ?ID?NO：1284	BM734514.V1.3_at	AGGTATTTCCTCTGTGGTGCCATAG	SEQ?ID?NO：1285
BM734514.V1.3_at	GGAGCAGTTCCATCTCACTGTGTAA	SEQ?ID?NO：1286	BM734514.V1.3_at	AGGTATTTCCTCTGTGGTGCCATAG	SEQ?ID?NO：1285
BM734514.V1.3_at	GGAGCAGTTCCATCTCACTGTGTAA	SEQ?ID?NO：1286	BM734514.V1.3_at	ACGAATTGGAAAGCCGACCCGCAAG	SEQ?ID?NO：1287
BM734514.V1.3_at	GACCCGCAAGGGAGCTTGTCTATTG	SEQ?ID?NO：1288	BM734514.V1.3_at	ACGAATTGGAAAGCCGACCCGCAAG	SEQ?ID?NO：1287
BM734514.V1.3_at	GACCCGCAAGGGAGCTTGTCTATTG	SEQ?ID?NO：1288	BM734514.V1.3_at	AAGGAACCTTTGATAGCCGCTGTAT	SEQ?ID?NO：1289
BM734514.V1.3_at	TTTGATAGCCGCTGTATCTGCTCAG	SEQ?ID?NO：1290	BM734514.V1.3_at	AAGGAACCTTTGATAGCCGCTGTAT	SEQ?ID?NO：1289
BM734514.V1.3_at	TTTGATAGCCGCTGTATCTGCTCAG	SEQ?ID?NO：1290	BM734514.V1.3_at	TATCTGCTCAGCCATGTCCACATTT	SEQ?ID?NO：1291
BM734515.V1.3_at	GTGCCGGCTCATTCAGCCAGAAAAT	SEQ?ID?NO：1292	BM734514.V1.3_at	TATCTGCTCAGCCATGTCCACATTT	SEQ?ID?NO：1291
BM734515.V1.3_at	GTGCCGGCTCATTCAGCCAGAAAAT	SEQ?ID?NO：1292	BM734515.V1.3_at	CAGAAAATAAATCTCCCACCCGTGT	SEQ?ID?NO：1293
BM734515.V1.3_at	TCCCACCCGTGTTTGACTTTGAAGA	SEQ?ID?NO：1294	BM734515.V1.3_at	CAGAAAATAAATCTCCCACCCGTGT	SEQ?ID?NO：1293
BM734515.V1.3_at	TCCCACCCGTGTTTGACTTTGAAGA	SEQ?ID?NO：1294	BM734515.V1.3_at	ACTTTGAAGACTCCACCAGGTCGTG	SEQ?ID?NO：1295
BM734515.V1.3_at	GAGAGCTTGGGAACTGCGATAACTT	SEQ?ID?NO：1296	BM734515.V1.3_at	ACTTTGAAGACTCCACCAGGTCGTG	SEQ?ID?NO：1295
BM734515.V1.3_at	GAGAGCTTGGGAACTGCGATAACTT	SEQ?ID?NO：1296	BM734515.V1.3_at	GCGATAACTTTCTGGGAGCTTTGGT	SEQ?ID?NO：1297
BM734515.V1.3_at	TCTCCGTACACGCATGACACATGTT	SEQ?ID?NO：1298	BM734515.V1.3_at	GCGATAACTTTCTGGGAGCTTTGGT	SEQ?ID?NO：1297
BM734515.V1.3_at	TCTCCGTACACGCATGACACATGTT	SEQ?ID?NO：1298	BM734515.V1.3_at	CATGTTCGCCATATTACGTTTTATC	SEQ?ID?NO：1299
BM734515.V1.3_at	TATAACAAACACACACCCTACATTT	SEQ?ID?NO：1300	BM734515.V1.3_at	CATGTTCGCCATATTACGTTTTATC	SEQ?ID?NO：1299
BM734515.V1.3_at	TATAACAAACACACACCCTACATTT	SEQ?ID?NO：1300	BM734515.V1.3_at	TTCACATGGTTCTTAGGCCACATCC	SEQ?ID?NO：1301
BM734515.V1.3_at	GGCCACATCCCTCTTTATAAAAATT	SEQ?ID?NO：1302	BM734515.V1.3_at	TTCACATGGTTCTTAGGCCACATCC	SEQ?ID?NO：1301
BM734515.V1.3_at	GGCCACATCCCTCTTTATAAAAATT	SEQ?ID?NO：1302	BM734516.V1.3_at	GGGCCTGTTAGGTCATCTGTTTCAG	SEQ?ID?NO：1303
BM734516.V1.3_at	GTTTCAGCATTTGTCAACTTCTTGA	SEQ?ID?NO：1304	BM734516.V1.3_at	GGGCCTGTTAGGTCATCTGTTTCAG	SEQ?ID?NO：1303
BM734516.V1.3_at	GTTTCAGCATTTGTCAACTTCTTGA	SEQ?ID?NO：1304	BM734516.V1.3_at	GGAAAATCTTCAATGGCTTCAACCA	SEQ?ID?NO：1305
BM734516.V1.3_at	ACCAAGTCTTGGCAGCACTGTGCAA	SEQ?ID?NO：1306	BM734516.V1.3_at	GGAAAATCTTCAATGGCTTCAACCA	SEQ?ID?NO：1305
BM734516.V1.3_at	ACCAAGTCTTGGCAGCACTGTGCAA	SEQ?ID?NO：1306	BM734516.V1.3_at	TAGACTCATTTTTCAGGCTAGCCTG	SEQ?ID?NO：1307
BM734516.V1.3_at	GCGCCGAAACGTCTGCATCAAGGTG	SEQ?ID?NO：1308	BM734516.V1.3_at	TAGACTCATTTTTCAGGCTAGCCTG	SEQ?ID?NO：1307
BM734516.V1.3_at	GCGCCGAAACGTCTGCATCAAGGTG	SEQ?ID?NO：1308	BM734516.V1.3_at	ATTCGGCACGAGTAGGATTGTCACA	SEQ?ID?NO：1309
BM734516.V1.3_at	AGTGGTATCTTACTCTGGCAGTTAC	SEQ?ID?NO：1310	BM734516.V1.3_at	ATTCGGCACGAGTAGGATTGTCACA	SEQ?ID?NO：1309
BM734516.V1.3_at	AGTGGTATCTTACTCTGGCAGTTAC	SEQ?ID?NO：1310	BM734516.V1.3_at	TGGCAGTTACCAGACTACCTTAAAA	SEQ?ID?NO：1311
BM734516.V1.3_at	GTGAGCCTTCTGTGTATGATCTGTC	SEQ?ID?NO：1312	BM734516.V1.3_at	TGGCAGTTACCAGACTACCTTAAAA	SEQ?ID?NO：1311
BM734516.V1.3_at	GTGAGCCTTCTGTGTATGATCTGTC	SEQ?ID?NO：1312	BM734516.V1.3_at	ATGATCTGTCTGTTCCTGTTTCAAA	SEQ?ID?NO：1313
BM734517.V1.3_at	AATTTTCTCCTAGTCTGTAGCTTTT	SEQ?ID?NO：1314	BM734516.V1.3_at	ATGATCTGTCTGTTCCTGTTTCAAA	SEQ?ID?NO：1313
BM734517.V1.3_at	AATTTTCTCCTAGTCTGTAGCTTTT	SEQ?ID?NO：1314	BM734517.V1.3_at	TGTAGCTTTTCTTTTCACGTGTTAA	SEQ?ID?NO：1315
BM734517.V1.3_at	GAAGCCCGATTTATCCATTTGTTCT	SEQ?ID?NO：1316	BM734517.V1.3_at	TGTAGCTTTTCTTTTCACGTGTTAA	SEQ?ID?NO：1315
BM734517.V1.3_at	GAAGCCCGATTTATCCATTTGTTCT	SEQ?ID?NO：1316	BM734517.V1.3_at	GACATGCCCTTGGTGTGGTATCTAA	SEQ?ID?NO：1317
BM734517.V1.3_at	GGATATCCATTTATTCTAGCACCAT	SEQ?ID?NO：1318	BM734517.V1.3_at	GACATGCCCTTGGTGTGGTATCTAA	SEQ?ID?NO：1317
BM734517.V1.3_at	GGATATCCATTTATTCTAGCACCAT	SEQ?ID?NO：1318	BM734517.V1.3_at	AAGGCTGTTTATTCTCCATTGCATT	SEQ?ID?NO：1319
BM734517.V1.3_at	CATTGCCTTTGCACCTTTGTACAAA	SEQ?ID?NO：1320	BM734517.V1.3_at	AAGGCTGTTTATTCTCCATTGCATT	SEQ?ID?NO：1319
BM734517.V1.3_at	CATTGCCTTTGCACCTTTGTACAAA	SEQ?ID?NO：1320	BM734517.V1.3_at	GTAGGCTTATTTCTGGACTCTGTTC	SEQ?ID?NO：1321
BM734517.V1.3_at	GTTCTGTTCCTTTTCTCTGTTTATA	SEQ?ID?NO：1322	BM734517.V1.3_at	GTAGGCTTATTTCTGGACTCTGTTC	SEQ?ID?NO：1321
BM734517.V1.3_at	GTTCTGTTCCTTTTCTCTGTTTATA	SEQ?ID?NO：1322	BM734517.V1.3_at	AGACAGGTAGTGTTAGCCCTCCAAC	SEQ?ID?NO：1323
BM734517.V1.3_at	TGGCTATTCTAGGTCATTTGCATTT	SEQ?ID?NO：1324	BM734517.V1.3_at	AGACAGGTAGTGTTAGCCCTCCAAC	SEQ?ID?NO：1323
BM734517.V1.3_at	TGGCTATTCTAGGTCATTTGCATTT	SEQ?ID?NO：1324	BM734518.V1.3_at	AGCAACTGGCACAAGGGCTGGGACT	SEQ?ID?NO：1325

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734518.V1.3_at	GGGACTGGACCTCAGGGTCTAACAA	SEQ?ID?NO：1326
BM734518.V1.3_at	TAACAAGTGTCCAGCTGAGGCCACC	SEQ?ID?NO：1327	BM734518.V1.3_at	GGGACTGGACCTCAGGGTCTAACAA	SEQ?ID?NO：1326
BM734518.V1.3_at	TAACAAGTGTCCAGCTGAGGCCACC	SEQ?ID?NO：1327	BM734518.V1.3_at	CTGCCGCACATTTGAGTCCTACTTC	SEQ?ID?NO：1328
BM734518.V1.3_at	GCTGCCCTGTGTGAGGAACTCTGGA	SEQ?ID?NO：1329	BM734518.V1.3_at	CTGCCGCACATTTGAGTCCTACTTC	SEQ?ID?NO：1328
BM734518.V1.3_at	GCTGCCCTGTGTGAGGAACTCTGGA	SEQ?ID?NO：1329	BM734518.V1.3_at	GGAGTCACTCCTACAAGGTCAGCAA	SEQ?ID?NO：1330
BM734518.V1.3_at	AGGTCAGCAACTACCGCCGAGGGAG	SEQ?ID?NO：1331	BM734518.V1.3_at	GGAGTCACTCCTACAAGGTCAGCAA	SEQ?ID?NO：1330
BM734518.V1.3_at	AGGTCAGCAACTACCGCCGAGGGAG	SEQ?ID?NO：1331	BM734518.V1.3_at	TGCATCCAGATGTGGTTCGACCCGG	SEQ?ID?NO：1332
BM734518.V1.3_at	GAGGTTCTATGCCTTGGCCATGACT	SEQ?ID?NO：1333	BM734518.V1.3_at	TGCATCCAGATGTGGTTCGACCCGG	SEQ?ID?NO：1332
BM734518.V1.3_at	GAGGTTCTATGCCTTGGCCATGACT	SEQ?ID?NO：1333	BM734518.V1.3_at	AGCTTTGATGACCAGGCTAGGCTCA	SEQ?ID?NO：1334
BM734518.V1.3_at	TAGGCTCAGCTCAGCTCCTAAGCAT	SEQ?ID?NO：1335	BM734518.V1.3_at	AGCTTTGATGACCAGGCTAGGCTCA	SEQ?ID?NO：1334
BM734518.V1.3_at	TAGGCTCAGCTCAGCTCCTAAGCAT	SEQ?ID?NO：1335	BM734519.V1.3_at	AACCACAACGTGAATTTGCAACAGG	SEQ?ID?NO：1336
BM734519.V1.3_at	GAACCAAAACTTCTAAGGCCCTGCT	SEQ?ID?NO：1337	BM734519.V1.3_at	AACCACAACGTGAATTTGCAACAGG	SEQ?ID?NO：1336
BM734519.V1.3_at	GAACCAAAACTTCTAAGGCCCTGCT	SEQ?ID?NO：1337	BM734519.V1.3_at	GGGTCAGCCATTTTTAATGATCTCG	SEQ?ID?NO：1338
BM734519.V1.3_at	TGATCTCGGATGACCAAACCAGCCT	SEQ?ID?NO：1339	BM734519.V1.3_at	GGGTCAGCCATTTTTAATGATCTCG	SEQ?ID?NO：1338
BM734519.V1.3_at	TGATCTCGGATGACCAAACCAGCCT	SEQ?ID?NO：1339	BM734519.V1.3_at	ATGACCAAACCAGCCTTCGGAGCGT	SEQ?ID?NO：1340
BM734519.V1.3_at	TCTGTCCTACTTCTGACTTTACTTG	SEQ?ID?NO：1341	BM734519.V1.3_at	ATGACCAAACCAGCCTTCGGAGCGT	SEQ?ID?NO：1340
BM734519.V1.3_at	TCTGTCCTACTTCTGACTTTACTTG	SEQ?ID?NO：1341	BM734519.V1.3_at	CTGACTTTACTTGTGGTGTGACCAT	SEQ?ID?NO：1342
BM734519.V1.3_at	GTGTGACCATGTTCATTATAATCTC	SEQ?ID?NO：1343	BM734519.V1.3_at	CTGACTTTACTTGTGGTGTGACCAT	SEQ?ID?NO：1342
BM734519.V1.3_at	GTGTGACCATGTTCATTATAATCTC	SEQ?ID?NO：1343	BM734519.V1.3_at	CAATCTTATTCCGAGCATTCCAGTA	SEQ?ID?NO：1344
BM734519.V1.3_at	GAGCATTCCAGTAACTTTTTTGTGT	SEQ?ID?NO：1345	BM734519.V1.3_at	CAATCTTATTCCGAGCATTCCAGTA	SEQ?ID?NO：1344
BM734519.V1.3_at	GAGCATTCCAGTAACTTTTTTGTGT	SEQ?ID?NO：1345	BM734519.V1.3_at	TTTGGCCTGTTTGATGTATGTGTGA	SEQ?ID?NO：1346
BM734526.V1.3_at	GTCTGGCCCGGTTCAAAAGCAACGT	SEQ?ID?NO：1347	BM734519.V1.3_at	TTTGGCCTGTTTGATGTATGTGTGA	SEQ?ID?NO：1346
BM734526.V1.3_at	GTCTGGCCCGGTTCAAAAGCAACGT	SEQ?ID?NO：1347	BM734526.V1.3_at	AGGGTTTTGAGTACATCTTGGCCAA	SEQ?ID?NO：1348
BM734526.V1.3_at	TAAAAGTCAACTTCCAGTCCTCTCT	SEQ?ID?NO：1349	BM734526.V1.3_at	AGGGTTTTGAGTACATCTTGGCCAA	SEQ?ID?NO：1348
BM734526.V1.3_at	TAAAAGTCAACTTCCAGTCCTCTCT	SEQ?ID?NO：1349	BM734526.V1.3_at	TTTTGGGCATCTACGGTGCACCAGG	SEQ?ID?NO：1350
BM734526.V1.3_at	GTTACCAACATCTGAGCCGAGTCTG	SEQ?ID?NO：1351	BM734526.V1.3_at	TTTTGGGCATCTACGGTGCACCAGG	SEQ?ID?NO：1350
BM734526.V1.3_at	GTTACCAACATCTGAGCCGAGTCTG	SEQ?ID?NO：1351	BM734526.V1.3_at	GAGTCTGCTTATTCTCACATTGGGC	SEQ?ID?NO：1352
BM734526.V1.3_at	AGGTGCAGTGACTTGCCCAGGGTCA	SEQ?ID?NO：1353	BM734526.V1.3_at	GAGTCTGCTTATTCTCACATTGGGC	SEQ?ID?NO：1352
BM734526.V1.3_at	AGGTGCAGTGACTTGCCCAGGGTCA	SEQ?ID?NO：1353	BM734526.V1.3_at	ACAGCGTGCGGGTGACATGGTCATA	SEQ?ID?NO：1354
BM734526.V1.3_at	TAAATGCTAGACTGTACGCTCCACG	SEQ?ID?NO：1355	BM734526.V1.3_at	ACAGCGTGCGGGTGACATGGTCATA	SEQ?ID?NO：1354
BM734526.V1.3_at	TAAATGCTAGACTGTACGCTCCACG	SEQ?ID?NO：1355	BM734526.V1.3_at	AGGGCAGGACCTGTGTTTTGTTGTC	SEQ?ID?NO：1356
BM734526.V1.3_at	TTGTTGTCCGATGTGTCCCAGGTAC	SEQ?ID?NO：1357	BM734526.V1.3_at	AGGGCAGGACCTGTGTTTTGTTGTC	SEQ?ID?NO：1356
BM734526.V1.3_at	TTGTTGTCCGATGTGTCCCAGGTAC	SEQ?ID?NO：1357	BM734529.V1.3_at	GAAGTGGAGTCTTTGCCTTTCCCAA	SEQ?ID?NO：1358
BM734529.V1.3_at	AGACTTTCAACAGCTCCCAAGATGT	SEQ?ID?NO：1359	BM734529.V1.3_at	GAAGTGGAGTCTTTGCCTTTCCCAA	SEQ?ID?NO：1358
BM734529.V1.3_at	AGACTTTCAACAGCTCCCAAGATGT	SEQ?ID?NO：1359	BM734529.V1.3_at	AAGATGTTTCCCACTTACACACTGG	SEQ?ID?NO：1360
BM734529.V1.3_at	ATCACCTTCCACCTAGGCAGAGAAG	SEQ?ID?NO：1361	BM734529.V1.3_at	AAGATGTTTCCCACTTACACACTGG	SEQ?ID?NO：1360
BM734529.V1.3_at	ATCACCTTCCACCTAGGCAGAGAAG	SEQ?ID?NO：1361	BM734529.V1.3_at	GAAGGGCAACTCCTAACAACCGGTG	SEQ?ID?NO：1362
BM734529.V1.3_at	ACAACCGGTGCACTGTGTAAACACT	SEQ?ID?NO：1363	BM734529.V1.3_at	GAAGGGCAACTCCTAACAACCGGTG	SEQ?ID?NO：1362
BM734529.V1.3_at	ACAACCGGTGCACTGTGTAAACACT	SEQ?ID?NO：1363	BM734529.V1.3_at	TGGTGCAACAGCTAGTTCCGTGCCT	SEQ?ID?NO：1364
BM734529.V1.3_at	AATGGGTACCCATAGCCACTGGTGG	SEQ?ID?NO：1365	BM734529.V1.3_at	TGGTGCAACAGCTAGTTCCGTGCCT	SEQ?ID?NO：1364
BM734529.V1.3_at	AATGGGTACCCATAGCCACTGGTGG	SEQ?ID?NO：1365	BM734529.V1.3_at	AGAGCATACGTCACACCAGGAACTG	SEQ?ID?NO：1366
BM734529.V1.3_at	AAGCATATTTCCTCCAGTTGGTTTC	SEQ?ID?NO：1367	BM734529.V1.3_at	AGAGCATACGTCACACCAGGAACTG	SEQ?ID?NO：1366
BM734529.V1.3_at	AAGCATATTTCCTCCAGTTGGTTTC	SEQ?ID?NO：1367	BM734529.V1.3_at	GGCAGTACCACATCACATGCTATAC	SEQ?ID?NO：1368
BM734531.V1.3_at	GAGTCACCCAAGGAACTTATGCAGA	SEQ?ID?NO：1369	BM734529.V1.3_at	GGCAGTACCACATCACATGCTATAC	SEQ?ID?NO：1368
BM734531.V1.3_at	GAGTCACCCAAGGAACTTATGCAGA	SEQ?ID?NO：1369	BM734531.V1.3_at	TTATGCAGATGCCATGTCCTCACTC	SEQ?ID?NO：1370

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734531.V1.3_at	GGAGCCAGGTGTCTGCATTTGAACA	SEQ?ID?NO：1371
BM734531.V1.3_at	GTCCTGTGGCTTTTGTGTGTCTCTC	SEQ?ID?NO：1372	BM734531.V1.3_at	GGAGCCAGGTGTCTGCATTTGAACA	SEQ?ID?NO：1371
BM734531.V1.3_at	GTCCTGTGGCTTTTGTGTGTCTCTC	SEQ?ID?NO：1372	BM734531.V1.3_at	ACCACTTCATGTTCTCTACAGAGCT	SEQ?ID?NO：1373
BM734531.V1.3_at	GGCCTTGCTTGAGAGAGGTCCATCC	SEQ?ID?NO：1374	BM734531.V1.3_at	ACCACTTCATGTTCTCTACAGAGCT	SEQ?ID?NO：1373
BM734531.V1.3_at	GGCCTTGCTTGAGAGAGGTCCATCC	SEQ?ID?NO：1374	BM734531.V1.3_at	GGTCACTTAGCAGCGACTTCTTGGA	SEQ?ID?NO：1375
BM734531.V1.3_at	ACAGAGCTGTCCAGAGCCGAGGCTG	SEQ?ID?NO：1376	BM734531.V1.3_at	GGTCACTTAGCAGCGACTTCTTGGA	SEQ?ID?NO：1375
BM734531.V1.3_at	ACAGAGCTGTCCAGAGCCGAGGCTG	SEQ?ID?NO：1376	BM734531.V1.3_at	CGTTGCCCGCTGTTGGTCATGACAA	SEQ?ID?NO：1377
BM734531.V1.3_at	AAACGAGTCCGAGGGCACAGCCAGG	SEQ?ID?NO：1378	BM734531.V1.3_at	CGTTGCCCGCTGTTGGTCATGACAA	SEQ?ID?NO：1377
BM734531.V1.3_at	AAACGAGTCCGAGGGCACAGCCAGG	SEQ?ID?NO：1378	BM734531.V1.3_at	GAGTCTCTGTCAGGATCCTTTTGAA	SEQ?ID?NO：1379
BM734533.V1.3_at	CTCGTGCCGTGTGCTGAGAGGCCCT	SEQ?ID?NO：1380	BM734531.V1.3_at	GAGTCTCTGTCAGGATCCTTTTGAA	SEQ?ID?NO：1379
BM734533.V1.3_at	CTCGTGCCGTGTGCTGAGAGGCCCT	SEQ?ID?NO：1380	BM734533.V1.3_at	AGGCACAGCCCCTGGAATCCTGAGC	SEQ?ID?NO：1381
BM734533.V1.3_at	GGAATCCTGAGCTGCCATGGGCTAC	SEQ?ID?NO：1382	BM734533.V1.3_at	AGGCACAGCCCCTGGAATCCTGAGC	SEQ?ID?NO：1381
BM734533.V1.3_at	GGAATCCTGAGCTGCCATGGGCTAC	SEQ?ID?NO：1382	BM734533.V1.3_at	ATGGGCTACCCCAAGACGTCCAGAG	SEQ?ID?NO：1383
BM734533.V1.3_at	GCTACCCCAAGACGTCCAGAGAAGA	SEQ?ID?NO：1384	BM734533.V1.3_at	ATGGGCTACCCCAAGACGTCCAGAG	SEQ?ID?NO：1383
BM734533.V1.3_at	GCTACCCCAAGACGTCCAGAGAAGA	SEQ?ID?NO：1384	BM734533.V1.3_at	GACAATGAACGTTGGAAGATCCGAT	SEQ?ID?NO：1385
BM734533.V1.3_at	TTGGAAGATCCGATTTCACAGCACT	SEQ?ID?NO：1386	BM734533.V1.3_at	GACAATGAACGTTGGAAGATCCGAT	SEQ?ID?NO：1385
BM734533.V1.3_at	TTGGAAGATCCGATTTCACAGCACT	SEQ?ID?NO：1386	BM734533.V1.3_at	GAACAGGTGTGTCAGTGTGCTCCCA	SEQ?ID?NO：1387
BM734533.V1.3_at	CACGATGACGATGAGGAGGAAGAAC	SEQ?ID?NO：1388	BM734533.V1.3_at	GAACAGGTGTGTCAGTGTGCTCCCA	SEQ?ID?NO：1387
BM734533.V1.3_at	CACGATGACGATGAGGAGGAAGAAC	SEQ?ID?NO：1388	BM734533.V1.3_at	GGAAGAACGTGCCACCTCAGGTCGA	SEQ?ID?NO：1389
BM734533.V1.3_at	ACGTGCCACCTCAGGTCGATTTAGG	SEQ?ID?NO：1390	BM734533.V1.3_at	GGAAGAACGTGCCACCTCAGGTCGA	SEQ?ID?NO：1389
BM734533.V1.3_at	ACGTGCCACCTCAGGTCGATTTAGG	SEQ?ID?NO：1390	BM734539.V1.3_at	GAGGCTGCCAGCACAGGGTGATCAC	SEQ?ID?NO：1391
BM734539.V1.3_at	ATCACAGCCCAAGCAGTGGAGGCCT	SEQ?ID?NO：1392	BM734539.V1.3_at	GAGGCTGCCAGCACAGGGTGATCAC	SEQ?ID?NO：1391
BM734539.V1.3_at	ATCACAGCCCAAGCAGTGGAGGCCT	SEQ?ID?NO：1392	BM734539.V1.3_at	GACAGATACCTGTGAACCCATCAGC	SEQ?ID?NO：1393
BM734539.V1.3_at	CGGTCTTCGGCAGCGGCTTTTTCAG	SEQ?ID?NO：1394	BM734539.V1.3_at	GACAGATACCTGTGAACCCATCAGC	SEQ?ID?NO：1393
BM734539.V1.3_at	CGGTCTTCGGCAGCGGCTTTTTCAG	SEQ?ID?NO：1394	BM734539.V1.3_at	GCTTTTTCAGCCGAGTGAGGACTCT	SEQ?ID?NO：1395
BM734539.V1.3_at	GAGGACTCTGGGTCCCACGCAGAGA	SEQ?ID?NO：1396	BM734539.V1.3_at	GCTTTTTCAGCCGAGTGAGGACTCT	SEQ?ID?NO：1395
BM734539.V1.3_at	GAGGACTCTGGGTCCCACGCAGAGA	SEQ?ID?NO：1396	BM734539.V1.3_at	AAGACCGTGGCCTCCTGGGAAGGCA	SEQ?ID?NO：1397
BM734539.V1.3_at	ATCTAAGTTCCAGAGCAGTTGACCT	SEQ?ID?NO：1398	BM734539.V1.3_at	AAGACCGTGGCCTCCTGGGAAGGCA	SEQ?ID?NO：1397
BM734539.V1.3_at	ATCTAAGTTCCAGAGCAGTTGACCT	SEQ?ID?NO：1398	BM734539.V1.3_at	GCAGTTGACCTGATGGGACGCTCTC	SEQ?ID?NO：1399
BM734539.V1.3_at	TTTGGTCTTAAGTGGATCTCGGGCA	SEQ?ID?NO：1400	BM734539.V1.3_at	GCAGTTGACCTGATGGGACGCTCTC	SEQ?ID?NO：1399
BM734539.V1.3_at	TTTGGTCTTAAGTGGATCTCGGGCA	SEQ?ID?NO：1400	BM734539.V1.3_at	CTGGCGTTTGACTACGAGCAGGAAC	SEQ?ID?NO：1401
BM734540.V1.3_at	GAAAGCACAGACTCTATATCCCTCA	SEQ?ID?NO：1402	BM734539.V1.3_at	CTGGCGTTTGACTACGAGCAGGAAC	SEQ?ID?NO：1401
BM734540.V1.3_at	GAAAGCACAGACTCTATATCCCTCA	SEQ?ID?NO：1402	BM734540.V1.3_at	TATATCCCTCATCGCATGGATCGTA	SEQ?ID?NO：1403
BM734540.V1.3_at	TGAGCAAAGCGGACCTCAGCCGGAA	SEQ?ID?NO：1404	BM734540.V1.3_at	TATATCCCTCATCGCATGGATCGTA	SEQ?ID?NO：1403
BM734540.V1.3_at	TGAGCAAAGCGGACCTCAGCCGGAA	SEQ?ID?NO：1404	BM734540.V1.3_at	AGCTTGTGCAGCTCCTGAATGGGCG	SEQ?ID?NO：1405
BM734540.V1.3_at	AGAGTTTTTCACTACCAGTTCCTGT	SEQ?ID?NO：1406	BM734540.V1.3_at	AGCTTGTGCAGCTCCTGAATGGGCG	SEQ?ID?NO：1405
BM734540.V1.3_at	AGAGTTTTTCACTACCAGTTCCTGT	SEQ?ID?NO：1406	BM734540.V1.3_at	AACTGTTGCTGGCTACTGGTTACAC	SEQ?ID?NO：1407
BM734540.V1.3_at	ATTCTTCATGTGCAGTGTCGACAGC	SEQ?ID?NO：1408	BM734540.V1.3_at	AACTGTTGCTGGCTACTGGTTACAC	SEQ?ID?NO：1407
BM734540.V1.3_at	ATTCTTCATGTGCAGTGTCGACAGC	SEQ?ID?NO：1408	BM734540.V1.3_at	GCACAGATTCTGCATTCAGTGGCAA	SEQ?ID?NO：1409
BM734540.V1.3_at	TCTGGCTTCAGGAACTCGGGCATAA	SEQ?ID?NO：1410	BM734540.V1.3_at	GCACAGATTCTGCATTCAGTGGCAA	SEQ?ID?NO：1409
BM734540.V1.3_at	TCTGGCTTCAGGAACTCGGGCATAA	SEQ?ID?NO：1410	BM734540.V1.3_at	AAAGACCATGTTGGCTGTCCGGAGC	SEQ?ID?NO：1411
BM734540.V1.3_at	TGTCCGGAGCACACATGGCTTAGAA	SEQ?ID?NO：1412	BM734540.V1.3_at	AAAGACCATGTTGGCTGTCCGGAGC	SEQ?ID?NO：1411
BM734540.V1.3_at	TGTCCGGAGCACACATGGCTTAGAA	SEQ?ID?NO：1412	BM734541.V1.3_at	TGAACATGCTTCAGATCTCCACGTT	SEQ?ID?NO：1413
BM734541.V1.3_at	TCTCCACGTTGCTCTGTAACATTAT	SEQ?ID?NO：1414	BM734541.V1.3_at	TGAACATGCTTCAGATCTCCACGTT	SEQ?ID?NO：1413
BM734541.V1.3_at	TCTCCACGTTGCTCTGTAACATTAT	SEQ?ID?NO：1414	BM734541.V1.3_at	TATTTGTTATCCCTGCTCTGCAATG	SEQ?ID?NO：1415

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734541.V1.3_at	AATGTAGTTCCCTGTTAGACCCAAG	SEQ?ID?NO：1416
BM734541.V1.3_at	GTGACACATGGCTTTCACTTCACAT	SEQ?ID?NO：1417	BM734541.V1.3_at	AATGTAGTTCCCTGTTAGACCCAAG	SEQ?ID?NO：1416
BM734541.V1.3_at	GTGACACATGGCTTTCACTTCACAT	SEQ?ID?NO：1417	BM734541.V1.3_at	ATGAGTGATGTCTGCCATGGGCACA	SEQ?ID?NO：1418
BM734541.V1.3_at	GTTGCAGATGTTTGGGATCCTCCCT	SEQ?ID?NO：1419	BM734541.V1.3_at	ATGAGTGATGTCTGCCATGGGCACA	SEQ?ID?NO：1418
BM734541.V1.3_at	GTTGCAGATGTTTGGGATCCTCCCT	SEQ?ID?NO：1419	BM734541.V1.3_at	TGTGCCCTCAATATGCTGTGTGTGC	SEQ?ID?NO：1420
BM734541.V1.3_at	CTGTGTGTGCCCTTTGGATGAAACT	SEQ?ID?NO：1421	BM734541.V1.3_at	TGTGCCCTCAATATGCTGTGTGTGC	SEQ?ID?NO：1420
BM734541.V1.3_at	CTGTGTGTGCCCTTTGGATGAAACT	SEQ?ID?NO：1421	BM734541.V1.3_at	AAGAATGGAAGCCTCTGGGCCTTTC	SEQ?ID?NO：1422
BM734541.V1.3_at	GGTGTGGACAGACTTCTTTTCCTCA	SEQ?ID?NO：1423	BM734541.V1.3_at	AAGAATGGAAGCCTCTGGGCCTTTC	SEQ?ID?NO：1422
BM734541.V1.3_at	GGTGTGGACAGACTTCTTTTCCTCA	SEQ?ID?NO：1423	BM734543.V1.3_at	GGCTTCTTCACGTAGAACCCGGGAG	SEQ?ID?NO：1424
BM734543.V1.3_at	ATTCAGAATCGAATCTCTTCTCCCT	SEQ?ID?NO：1425	BM734543.V1.3_at	GGCTTCTTCACGTAGAACCCGGGAG	SEQ?ID?NO：1424
BM734543.V1.3_at	ATTCAGAATCGAATCTCTTCTCCCT	SEQ?ID?NO：1425	BM734543.V1.3_at	CTTCCTGTTTTTCGGCTTTGTGAGA	SEQ?ID?NO：1426
BM734543.V1.3_at	GTTACCAACAAGACAGATCCTCGCT	SEQ?ID?NO：1427	BM734543.V1.3_at	CTTCCTGTTTTTCGGCTTTGTGAGA	SEQ?ID?NO：1426
BM734543.V1.3_at	GTTACCAACAAGACAGATCCTCGCT	SEQ?ID?NO：1427	BM734543.V1.3_at	GGGAATCTCAATACTCTTGTGGTCA	SEQ?ID?NO：1428
BM734543.V1.3_at	AAATCGTGGGTTGCTCTGTTCATAA	SEQ?ID?NO：1429	BM734543.V1.3_at	GGGAATCTCAATACTCTTGTGGTCA	SEQ?ID?NO：1428
BM734543.V1.3_at	AAATCGTGGGTTGCTCTGTTCATAA	SEQ?ID?NO：1429	BM734543.V1.3_at	GCTTTGCCTTCGTTCAGTACGTTAA	SEQ?ID?NO：1430
BM734543.V1.3_at	AATGAGAGAAATGCCCGTGCTGCTG	SEQ?ID?NO：1431	BM734543.V1.3_at	GCTTTGCCTTCGTTCAGTACGTTAA	SEQ?ID?NO：1430
BM734543.V1.3_at	AATGAGAGAAATGCCCGTGCTGCTG	SEQ?ID?NO：1431	BM734543.V1.3_at	GCAGAATGATCGCTGGCCAGGTTTT	SEQ?ID?NO：1432
BM734543.V1.3_at	TCAGCTCCTCTTTTGACTTGGACTA	SEQ?ID?NO：1433	BM734543.V1.3_at	GCAGAATGATCGCTGGCCAGGTTTT	SEQ?ID?NO：1432
BM734543.V1.3_at	TCAGCTCCTCTTTTGACTTGGACTA	SEQ?ID?NO：1433	BM734543.V1.3_at	GGATGTACAGTTACCCAGCACGTGT	SEQ?ID?NO：1434
BM734550.V1.3_at	TTTTGGTCCCTACTTCCAGCGTCAT	SEQ?ID?NO：1435	BM734543.V1.3_at	GGATGTACAGTTACCCAGCACGTGT	SEQ?ID?NO：1434
BM734550.V1.3_at	TTTTGGTCCCTACTTCCAGCGTCAT	SEQ?ID?NO：1435	BM734550.V1.3_at	GTCATTCCTGCCTATCACTTTGGAG	SEQ?ID?NO：1436
BM734550.V1.3_at	CTGCCTATCACTTTGGAGCGTGTGG	SEQ?ID?NO：1437	BM734550.V1.3_at	GTCATTCCTGCCTATCACTTTGGAG	SEQ?ID?NO：1436
BM734550.V1.3_at	CTGCCTATCACTTTGGAGCGTGTGG	SEQ?ID?NO：1437	BM734550.V1.3_at	CGAGATTTGGGCATTGCCAGCAGTT	SEQ?ID?NO：1438
BM734550.V1.3_at	CTTGTTTTTCCTGGGCAGCTTCCTT	SEQ?ID?NO：1439	BM734550.V1.3_at	CGAGATTTGGGCATTGCCAGCAGTT	SEQ?ID?NO：1438
BM734550.V1.3_at	CTTGTTTTTCCTGGGCAGCTTCCTT	SEQ?ID?NO：1439	BM734550.V1.3_at	GGCAGCTTCCTTGGGACAGAAACTT	SEQ?ID?NO：1440
BM734550.V1.3_at	CAAAGTTTTTGGTGACTTGTGGCTA	SEQ?ID?NO：1441	BM734550.V1.3_at	GGCAGCTTCCTTGGGACAGAAACTT	SEQ?ID?NO：1440
BM734550.V1.3_at	CAAAGTTTTTGGTGACTTGTGGCTA	SEQ?ID?NO：1441	BM734550.V1.3_at	TGAGTGTCCTTTTTCCCAGGGTGGG	SEQ?ID?NO：1442
BM734550.V1.3_at	ACAGCCGCCGTGCTGCAGCCTTGTG	SEQ?ID?NO：1443	BM734550.V1.3_at	TGAGTGTCCTTTTTCCCAGGGTGGG	SEQ?ID?NO：1442
BM734550.V1.3_at	ACAGCCGCCGTGCTGCAGCCTTGTG	SEQ?ID?NO：1443	BM734550.V1.3_at	GGTCCCCAGCTTCCCTGATGTAGGA	SEQ?ID?NO：1444
BM734550.V1.3_at	GCTTCCCTGATGTAGGAACCAGATT	SEQ?ID?NO：1445	BM734550.V1.3_at	GGTCCCCAGCTTCCCTGATGTAGGA	SEQ?ID?NO：1444
BM734550.V1.3_at	GCTTCCCTGATGTAGGAACCAGATT	SEQ?ID?NO：1445	BM734553.V1.3_at	GCAGCTTGGAAACGCACGGAAACCT	SEQ?ID?NO：1446
BM734553.V1.3_at	GGAAACCTATACTGAAGCCCAACAA	SEQ?ID?NO：1447	BM734553.V1.3_at	GCAGCTTGGAAACGCACGGAAACCT	SEQ?ID?NO：1446
BM734553.V1.3_at	GGAAACCTATACTGAAGCCCAACAA	SEQ?ID?NO：1447	BM734553.V1.3_at	GCGAGGCGACCTGTATCACGGAGAT	SEQ?ID?NO：1448
BM734553.V1.3_at	TGTCGGTAATGATGGCTTGCTGGAA	SEQ?ID?NO：1449	BM734553.V1.3_at	GCGAGGCGACCTGTATCACGGAGAT	SEQ?ID?NO：1448
BM734553.V1.3_at	TGTCGGTAATGATGGCTTGCTGGAA	SEQ?ID?NO：1449	BM734553.V1.3_at	GAATTCCGCGACGAAGCTTGCAGAA	SEQ?ID?NO：1450
BM734553.V1.3_at	AAAAGAGATCCAGGCCTTCTTCGAT	SEQ?ID?NO：1451	BM734553.V1.3_at	GAATTCCGCGACGAAGCTTGCAGAA	SEQ?ID?NO：1450
BM734553.V1.3_at	AAAAGAGATCCAGGCCTTCTTCGAT	SEQ?ID?NO：1451	BM734553.V1.3_at	AGGCCTTCTTCGATTGTGCTTCGAA	SEQ?ID?NO：1452
BM734553.V1.3_at	GGAGAAGCCTTTTCAATGACGGGAC	SEQ?ID?NO：1453	BM734553.V1.3_at	AGGCCTTCTTCGATTGTGCTTCGAA	SEQ?ID?NO：1452
BM734553.V1.3_at	GGAGAAGCCTTTTCAATGACGGGAC	SEQ?ID?NO：1453	BM734553.V1.3_at	ATGACGGGACTGTAGCTTTTGAGAA	SEQ?ID?NO：1454
BM734553.V1.3_at	GCACTGTTATACTTTCTTTGCAGAG	SEQ?ID?NO：1455	BM734553.V1.3_at	ATGACGGGACTGTAGCTTTTGAGAA	SEQ?ID?NO：1454
BM734553.V1.3_at	GCACTGTTATACTTTCTTTGCAGAG	SEQ?ID?NO：1455	BM734553.V1.3_at	TGTCCTTTGGAACCATTGTCTCTGT	SEQ?ID?NO：1456
BM734556.V1.3_at	GCACGAGTCAGTGTTCGCCATTTCA	SEQ?ID?NO：1457	BM734553.V1.3_at	TGTCCTTTGGAACCATTGTCTCTGT	SEQ?ID?NO：1456
BM734556.V1.3_at	GCACGAGTCAGTGTTCGCCATTTCA	SEQ?ID?NO：1457	BM734556.V1.3_at	GCCATTTCACGTTCGGTTCGGGAAG	SEQ?ID?NO：1458
BM734556.V1.3_at	GGAAGCTGGGAGTCCTGAGATCCAA	SEQ?ID?NO：1459	BM734556.V1.3_at	GCCATTTCACGTTCGGTTCGGGAAG	SEQ?ID?NO：1458
BM734556.V1.3_at	GGAAGCTGGGAGTCCTGAGATCCAA	SEQ?ID?NO：1459	BM734556.V1.3_at	GATATAGAAATCAACGGCGACGCAG	SEQ?ID?NO：1460

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734556.V1.3_at	GGCGACGCAGTGGATCTTCACATGA	SEQ?ID?NO：1461
BM734556.V1.3_at	AGAAGCTTTCTTTGTGGAGGAGACT	SEQ?ID?NO：1462	BM734556.V1.3_at	GGCGACGCAGTGGATCTTCACATGA	SEQ?ID?NO：1461
BM734556.V1.3_at	AGAAGCTTTCTTTGTGGAGGAGACT	SEQ?ID?NO：1462	BM734556.V1.3_at	ATGAAAAGCTTCCTGCTTACCTTGC	SEQ?ID?NO：1463
BM734556.V1.3_at	ACCTCACCAATTCCTACTGAAGATC	SEQ?ID?NO：1464	BM734556.V1.3_at	ATGAAAAGCTTCCTGCTTACCTTGC	SEQ?ID?NO：1463
BM734556.V1.3_at	ACCTCACCAATTCCTACTGAAGATC	SEQ?ID?NO：1464	BM734556.V1.3_at	TTAAAGATATTGACACCCGTTTGGT	SEQ?ID?NO：1465
BM734556.V1.3_at	GACCATCTCAGAGTTCAGACATCTC	SEQ?ID?NO：1466	BM734556.V1.3_at	TTAAAGATATTGACACCCGTTTGGT	SEQ?ID?NO：1465
BM734556.V1.3_at	GACCATCTCAGAGTTCAGACATCTC	SEQ?ID?NO：1466	BM734556.V1.3_at	GACATCTCACACATCTTAGACACGG	SEQ?ID?NO：1467
BM734557.V1.3_at	AAGCGTGCCCGCAAGGAGCTGCTCA	SEQ?ID?NO：1468	BM734556.V1.3_at	GACATCTCACACATCTTAGACACGG	SEQ?ID?NO：1467
BM734557.V1.3_at	AAGCGTGCCCGCAAGGAGCTGCTCA	SEQ?ID?NO：1468	BM734557.V1.3_at	GGAGCTGCTCAACTTTTACGCCTGG	SEQ?ID?NO：1469
BM734557.V1.3_at	GGCAGCACCGCGAGACCAAGATGGA	SEQ?ID?NO：1470	BM734557.V1.3_at	GGAGCTGCTCAACTTTTACGCCTGG	SEQ?ID?NO：1469
BM734557.V1.3_at	GGCAGCACCGCGAGACCAAGATGGA	SEQ?ID?NO：1470	BM734557.V1.3_at	AAGATGGAGCATCTCGCACAGCTGC	SEQ?ID?NO：1471
BM734557.V1.3_at	AGAGGATTGAACTGATGCGGGCCCA	SEQ?ID?NO：1472	BM734557.V1.3_at	AAGATGGAGCATCTCGCACAGCTGC	SEQ?ID?NO：1471
BM734557.V1.3_at	AGAGGATTGAACTGATGCGGGCCCA	SEQ?ID?NO：1472	BM734557.V1.3_at	AATGCTGGTCTCAGAGGCTGTGCCC	SEQ?ID?NO：1473
BM734557.V1.3_at	CGTCAAGCCGCCCAAAGATCTGAGG	SEQ?ID?NO：1474	BM734557.V1.3_at	AATGCTGGTCTCAGAGGCTGTGCCC	SEQ?ID?NO：1473
BM734557.V1.3_at	CGTCAAGCCGCCCAAAGATCTGAGG	SEQ?ID?NO：1474	BM734557.V1.3_at	GGGTGAAGGACCATGTCGCCCTCCA	SEQ?ID?NO：1475
BM734557.V1.3_at	ATTCTGGTGCTTCAGCAGTCCTGGG	SEQ?ID?NO：1476	BM734557.V1.3_at	GGGTGAAGGACCATGTCGCCCTCCA	SEQ?ID?NO：1475
BM734557.V1.3_at	ATTCTGGTGCTTCAGCAGTCCTGGG	SEQ?ID?NO：1476	BM734557.V1.3_at	AGCATGAGGACTTGGCCTTCAGGAA	SEQ?ID?NO：1477
BM734557.V1.3_at	TTCAGGAAGCCACTGGCCCAGGAGT	SEQ?ID?NO：1478	BM734557.V1.3_at	AGCATGAGGACTTGGCCTTCAGGAA	SEQ?ID?NO：1477
BM734557.V1.3_at	TTCAGGAAGCCACTGGCCCAGGAGT	SEQ?ID?NO：1478	BM734560.V1.3_at	GTGTTTCCACTTTGGCTCTATCACA	SEQ?ID?NO：1479
BM734560.V1.3_at	TTATTTTTGGTAAGTCCCTCTGCAG	SEQ?ID?NO：1480	BM734560.V1.3_at	GTGTTTCCACTTTGGCTCTATCACA	SEQ?ID?NO：1479
BM734560.V1.3_at	TTATTTTTGGTAAGTCCCTCTGCAG	SEQ?ID?NO：1480	BM734560.V1.3_at	AAGTCCCTCTGCAGTATCAGCTGGA	SEQ?ID?NO：1481
BM734560.V1.3_at	TGGAGTGTCCTTAGTACCACAGATT	SEQ?ID?NO：1482	BM734560.V1.3_at	AAGTCCCTCTGCAGTATCAGCTGGA	SEQ?ID?NO：1481
BM734560.V1.3_at	TGGAGTGTCCTTAGTACCACAGATT	SEQ?ID?NO：1482	BM734560.V1.3_at	GATTAGCCTAGCTCCCCATGAGAGA	SEQ?ID?NO：1483
BM734560.V1.3_at	AGGATCCACTAGAGGGCGGGTTACA	SEQ?ID?NO：1484	BM734560.V1.3_at	GATTAGCCTAGCTCCCCATGAGAGA	SEQ?ID?NO：1483
BM734560.V1.3_at	AGGATCCACTAGAGGGCGGGTTACA	SEQ?ID?NO：1484	BM734560.V1.3_at	GAGTAGTTGTGTACGCACGCTCACA	SEQ?ID?NO：1485
BM734560.V1.3_at	GTGCAAACAACCCAGACGTCGTCAG	SEQ?ID?NO：1486	BM734560.V1.3_at	GAGTAGTTGTGTACGCACGCTCACA	SEQ?ID?NO：1485
BM734560.V1.3_at	GTGCAAACAACCCAGACGTCGTCAG	SEQ?ID?NO：1486	BM734560.V1.3_at	GTAAACCAAGTGTGCTGTGTCCATA	SEQ?ID?NO：1487
BM734560.V1.3_at	TTAACTGACACATGCCACAACGGGA	SEQ?ID?NO：1488	BM734560.V1.3_at	GTAAACCAAGTGTGCTGTGTCCATA	SEQ?ID?NO：1487
BM734560.V1.3_at	TTAACTGACACATGCCACAACGGGA	SEQ?ID?NO：1488	BM734560.V1.3_at	ACCAGGTAAACCACTAGGCTGCCGG	SEQ?ID?NO：1489
BM734564.V1.3_at	GCAATGGTTCTGTCATCGGATCTAA	SEQ?ID?NO：1490	BM734560.V1.3_at	ACCAGGTAAACCACTAGGCTGCCGG	SEQ?ID?NO：1489
BM734564.V1.3_at	GCAATGGTTCTGTCATCGGATCTAA	SEQ?ID?NO：1490	BM734564.V1.3_at	ACTGAATAACCTTCCGGTGATCTCC	SEQ?ID?NO：1491
BM734564.V1.3_at	GGTGATCTCCAACATGACGGCCACA	SEQ?ID?NO：1492	BM734564.V1.3_at	ACTGAATAACCTTCCGGTGATCTCC	SEQ?ID?NO：1491
BM734564.V1.3_at	GGTGATCTCCAACATGACGGCCACA	SEQ?ID?NO：1492	BM734564.V1.3_at	GACGGCCACATTAGACAGTTGCTCA	SEQ?ID?NO：1493
BM734564.V1.3_at	GTTGCTCAGCAGCAGATGGCAGTTT	SEQ?ID?NO：1494	BM734564.V1.3_at	GACGGCCACATTAGACAGTTGCTCA	SEQ?ID?NO：1493
BM734564.V1.3_at	GTTGCTCAGCAGCAGATGGCAGTTT	SEQ?ID?NO：1494	BM734564.V1.3_at	GCAGTTTGGCTGCAGAAATGCCCAA	SEQ?ID?NO：1495
BM734564.V1.3_at	AACTAATTGCTATACCCACTGCAGC	SEQ?ID?NO：1496	BM734564.V1.3_at	GCAGTTTGGCTGCAGAAATGCCCAA	SEQ?ID?NO：1495
BM734564.V1.3_at	AACTAATTGCTATACCCACTGCAGC	SEQ?ID?NO：1496	BM734564.V1.3_at	TTACCAGCACCACCACAGGGACAAT	SEQ?ID?NO：1497
BM734564.V1.3_at	TCCCTCACGACGACTGTTGTTCAGG	SEQ?ID?NO：1498	BM734564.V1.3_at	TTACCAGCACCACCACAGGGACAAT	SEQ?ID?NO：1497
BM734564.V1.3_at	TCCCTCACGACGACTGTTGTTCAGG	SEQ?ID?NO：1498	BM734564.V1.3_at	GTTGTTCAGGCCACACCAAAGAGTC	SEQ?ID?NO：1499
BM734564.V1.3_at	GAGTCCTCCATTAAAACCCATTCAA	SEQ?ID?NO：1500	BM734564.V1.3_at	GTTGTTCAGGCCACACCAAAGAGTC	SEQ?ID?NO：1499
BM734564.V1.3_at	GAGTCCTCCATTAAAACCCATTCAA	SEQ?ID?NO：1500	BM734567.V1.3_at	TTGGTGTGCCAATCAAAGTCCTACA	SEQ?ID?NO：1501
BM734567.V1.3_at	AGGCCGAGGGCCACATTGTGACATG	SEQ?ID?NO：1502	BM734567.V1.3_at	TTGGTGTGCCAATCAAAGTCCTACA	SEQ?ID?NO：1501
BM734567.V1.3_at	AGGCCGAGGGCCACATTGTGACATG	SEQ?ID?NO：1502	BM734567.V1.3_at	GGTGTATCGTGGGAAGCTCATTGAA	SEQ?ID?NO：1503
BM734567.V1.3_at	CGGAGGACAACATGAACTGCCAGAT	SEQ?ID?NO：1504	BM734567.V1.3_at	GGTGTATCGTGGGAAGCTCATTGAA	SEQ?ID?NO：1503
BM734567.V1.3_at	CGGAGGACAACATGAACTGCCAGAT	SEQ?ID?NO：1504	BM734567.V1.3_at	GAGCAGGTGTACATCCGCGGCAGCA	SEQ?ID?NO：1505

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734567.V1.3_at	CAGCAAGATCCGCTTCCTGATTTTG	SEQ?ID?NO：1506
BM734567.V1.3_at	CCTGATTTTGCCTGACATGCTGAAA	SEQ?ID?NO：1507	BM734567.V1.3_at	CAGCAAGATCCGCTTCCTGATTTTG	SEQ?ID?NO：1506
BM734567.V1.3_at	CCTGATTTTGCCTGACATGCTGAAA	SEQ?ID?NO：1507	BM734567.V1.3_at	AAAGCTGCTATTTTGAAGGCCCAAG	SEQ?ID?NO：1508
BM734567.V1.3_at	GAACAGAACTTTGCCTCTATTTTTT	SEQ?ID?NO：1509	BM734567.V1.3_at	AAAGCTGCTATTTTGAAGGCCCAAG	SEQ?ID?NO：1508
BM734567.V1.3_at	GAACAGAACTTTGCCTCTATTTTTT	SEQ?ID?NO：1509	BM734567.V1.3_at	GGGTGTGTGCTTATGTATATGTCCT	SEQ?ID?NO：1510
BM734567.V1.3_at	TATGTCCTAGGTTTTCTTTTGTCAA	SEQ?ID?NO：1511	BM734567.V1.3_at	GGGTGTGTGCTTATGTATATGTCCT	SEQ?ID?NO：1510
BM734567.V1.3_at	TATGTCCTAGGTTTTCTTTTGTCAA	SEQ?ID?NO：1511	BM734568.V1.3_at	TCGTGCTTCCTGATTGGCTGGAGGA	SEQ?ID?NO：1512
BM734568.V1.3_at	GGGCTTTGTCACCTGAGCAGTGAAT	SEQ?ID?NO：1513	BM734568.V1.3_at	TCGTGCTTCCTGATTGGCTGGAGGA	SEQ?ID?NO：1512
BM734568.V1.3_at	GGGCTTTGTCACCTGAGCAGTGAAT	SEQ?ID?NO：1513	BM734568.V1.3_at	GTGAATTAATGTTGGCATCTGCTCC	SEQ?ID?NO：1514
BM734568.V1.3_at	TTGGCATCTGCTCCAAACACTTGGA	SEQ?ID?NO：1515	BM734568.V1.3_at	GTGAATTAATGTTGGCATCTGCTCC	SEQ?ID?NO：1514
BM734568.V1.3_at	TTGGCATCTGCTCCAAACACTTGGA	SEQ?ID?NO：1515	BM734568.V1.3_at	AACACTTGGAGGAGAGCCACGATTT	SEQ?ID?NO：1516
BM734568.V1.3_at	GGAATCGTCCTCATGCAGCAGATTA	SEQ?ID?NO：1517	BM734568.V1.3_at	AACACTTGGAGGAGAGCCACGATTT	SEQ?ID?NO：1516
BM734568.V1.3_at	GGAATCGTCCTCATGCAGCAGATTA	SEQ?ID?NO：1517	BM734568.V1.3_at	GCAGATTATGTTGGCTGATCCCCAT	SEQ?ID?NO：1518
BM734568.V1.3_at	ATCCGTGACTGCGTGATGTTTACTG	SEQ?ID?NO：1519	BM734568.V1.3_at	GCAGATTATGTTGGCTGATCCCCAT	SEQ?ID?NO：1518
BM734568.V1.3_at	ATCCGTGACTGCGTGATGTTTACTG	SEQ?ID?NO：1519	BM734568.V1.3_at	TGATGTTTACTGCACCTGGTGTGTA	SEQ?ID?NO：1520
BM734568.V1.3_at	GGGCACAGCGATGAACAAACAGACA	SEQ?ID?NO：1521	BM734568.V1.3_at	TGATGTTTACTGCACCTGGTGTGTA	SEQ?ID?NO：1520
BM734568.V1.3_at	GGGCACAGCGATGAACAAACAGACA	SEQ?ID?NO：1521	BM734568.V1.3_at	GGACTTACCCTGGTGGAGTTGACCT	SEQ?ID?NO：1522
BM734569.V1.3_at	AAAACTGTGCTGTCCTTGTGAGGTC	SEQ?ID?NO：1523	BM734568.V1.3_at	GGACTTACCCTGGTGGAGTTGACCT	SEQ?ID?NO：1522
BM734569.V1.3_at	AAAACTGTGCTGTCCTTGTGAGGTC	SEQ?ID?NO：1523	BM734569.V1.3_at	TGTGAGGTCACTGCCTGGACATGGC	SEQ?ID?NO：1524
BM734569.V1.3_at	GCTGCCTTCCTGTGCCCAGAAAGGA	SEQ?ID?NO：1525	BM734569.V1.3_at	TGTGAGGTCACTGCCTGGACATGGC	SEQ?ID?NO：1524
BM734569.V1.3_at	GCTGCCTTCCTGTGCCCAGAAAGGA	SEQ?ID?NO：1525	BM734569.V1.3_at	GGTCTTCCTCTTAAGGCCAGTTGAA	SEQ?ID?NO：1526
BM734569.V1.3_at	GTTGAAGATGGTCCCTTGCAGTTTC	SEQ?ID?NO：1527	BM734569.V1.3_at	GGTCTTCCTCTTAAGGCCAGTTGAA	SEQ?ID?NO：1526
BM734569.V1.3_at	GTTGAAGATGGTCCCTTGCAGTTTC	SEQ?ID?NO：1527	BM734569.V1.3_at	TTGCAGTTTCCCAAGTTAGGTTAGT	SEQ?ID?NO：1528
BM734569.V1.3_at	TAGTGATGTGAAATGCTCCTGCCCC	SEQ?ID?NO：1529	BM734569.V1.3_at	TTGCAGTTTCCCAAGTTAGGTTAGT	SEQ?ID?NO：1528
BM734569.V1.3_at	TAGTGATGTGAAATGCTCCTGCCCC	SEQ?ID?NO：1529	BM734569.V1.3_at	AGGCAATTGCTGGTTTTCTTCCCCA	SEQ?ID?NO：1530
BM734569.V1.3_at	TCTTCCCCAATTCTTTTCCAATTAG	SEQ?ID?NO：1531	BM734569.V1.3_at	AGGCAATTGCTGGTTTTCTTCCCCA	SEQ?ID?NO：1530
BM734569.V1.3_at	TCTTCCCCAATTCTTTTCCAATTAG	SEQ?ID?NO：1531	BM734569.V1.3_at	GCCTCACCCCTGTTGAGTTTTTAGT	SEQ?ID?NO：1532
BM734569.V1.3_at	AGTTTTTAGTCTCTTGTGCTGTGCC	SEQ?ID?NO：1533	BM734569.V1.3_at	GCCTCACCCCTGTTGAGTTTTTAGT	SEQ?ID?NO：1532
BM734569.V1.3_at	AGTTTTTAGTCTCTTGTGCTGTGCC	SEQ?ID?NO：1533	BM734573.V1.3_at	TGTACACCCTCTCTGTGTCTGGAGA	SEQ?ID?NO：1534
BM734573.V1.3_at	GTGGGACCTACGGAACATGGGCTAC	SEQ?ID?NO：1535	BM734573.V1.3_at	TGTACACCCTCTCTGTGTCTGGAGA	SEQ?ID?NO：1534
BM734573.V1.3_at	GTGGGACCTACGGAACATGGGCTAC	SEQ?ID?NO：1535	BM734573.V1.3_at	GGGAGTCCAGCCTCAAGTACCAGAC	SEQ?ID?NO：1536
BM734573.V1.3_at	GGGCATTTCCGAACAAGCAGGGTTA	SEQ?ID?NO：1537	BM734573.V1.3_at	GGGAGTCCAGCCTCAAGTACCAGAC	SEQ?ID?NO：1536
BM734573.V1.3_at	GGGCATTTCCGAACAAGCAGGGTTA	SEQ?ID?NO：1537	BM734573.V1.3_at	GTGGCAGTTGAGTACCTGGACCCAA	SEQ?ID?NO：1538
BM734573.V1.3_at	GAAGTACGCCTTCAAGTGTCACAGA	SEQ?ID?NO：1539	BM734573.V1.3_at	GTGGCAGTTGAGTACCTGGACCCAA	SEQ?ID?NO：1538
BM734573.V1.3_at	GAAGTACGCCTTCAAGTGTCACAGA	SEQ?ID?NO：1539	BM734573.V1.3_at	AGATTTACCCGGTCAATGCCATTTC	SEQ?ID?NO：1540
BM734573.V1.3_at	AAGCGACTGTGTCAGTTCCATCGGT	SEQ?ID?NO：1541	BM734573.V1.3_at	AGATTTACCCGGTCAATGCCATTTC	SEQ?ID?NO：1540
BM734573.V1.3_at	AAGCGACTGTGTCAGTTCCATCGGT	SEQ?ID?NO：1541	BM734573.V1.3_at	ATCGCATCACTTGCCTTCAGTAATG	SEQ?ID?NO：1542
BM734573.V1.3_at	GATGGGACTACACTTGCAATAGCAT	SEQ?ID?NO：1543	BM734573.V1.3_at	ATCGCATCACTTGCCTTCAGTAATG	SEQ?ID?NO：1542
BM734573.V1.3_at	GATGGGACTACACTTGCAATAGCAT	SEQ?ID?NO：1543	BM734573.V1.3_at	GGTATCTTCATTCGCCAAGTGACAG	SEQ?ID?NO：1544
BM734578.V1.3_at	ATGAGGTCAAAGCTGCTCGAGCCCG	SEQ?ID?NO：1545	BM734573.V1.3_at	GGTATCTTCATTCGCCAAGTGACAG	SEQ?ID?NO：1544
BM734578.V1.3_at	ATGAGGTCAAAGCTGCTCGAGCCCG	SEQ?ID?NO：1545	BM734578.V1.3_at	GAGCCCCTTCACGTGATGGATATTG	SEQ?ID?NO：1546
BM734578.V1.3_at	GCCCCGTCGCTCTGTGGAAATTGAA	SEQ?ID?NO：1547	BM734578.V1.3_at	GAGCCCCTTCACGTGATGGATATTG	SEQ?ID?NO：1546
BM734578.V1.3_at	GCCCCGTCGCTCTGTGGAAATTGAA	SEQ?ID?NO：1547	BM734578.V1.3_at	AATTGAAGCCTTCTCACAGCATTGC	SEQ?ID?NO：1548
BM734578.V1.3_at	GATTTATGCATTTGGCCGTCGTCAA	SEQ?ID?NO：1549	BM734578.V1.3_at	AATTGAAGCCTTCTCACAGCATTGC	SEQ?ID?NO：1548
BM734578.V1.3_at	GATTTATGCATTTGGCCGTCGTCAA	SEQ?ID?NO：1549	BM734578.V1.3_at	TCAAGGGAACATTGCCCACTTCACA	SEQ?ID?NO：1550

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734578.V1.3_at	GTACGTGGCAACTGAAGCTTTCTTG	SEQ?ID?NO：1551
BM734578.V1.3_at	CTTGTAGTTTGTTTCCCTGTTTGAG	SEQ?ID?NO：1552	BM734578.V1.3_at	GTACGTGGCAACTGAAGCTTTCTTG	SEQ?ID?NO：1551
BM734578.V1.3_at	CTTGTAGTTTGTTTCCCTGTTTGAG	SEQ?ID?NO：1552	BM734578.V1.3_at	GAGATATCTGACCTTAGCTTTTCCC	SEQ?ID?NO：1553
BM734578.V1.3_at	TGACTTTATTGTTTATCCCCTTCAC	SEQ?ID?NO：1554	BM734578.V1.3_at	GAGATATCTGACCTTAGCTTTTCCC	SEQ?ID?NO：1553
BM734578.V1.3_at	TGACTTTATTGTTTATCCCCTTCAC	SEQ?ID?NO：1554	BM734578.V1.3_at	GTAGCCATGGCAGCTTTTTGCAGTG	SEQ?ID?NO：1555
BM734583.V1.3_at	GCACAAAATAACCAAGAACATCCTC	SEQ?ID?NO：1556	BM734578.V1.3_at	GTAGCCATGGCAGCTTTTTGCAGTG	SEQ?ID?NO：1555
BM734583.V1.3_at	GCACAAAATAACCAAGAACATCCTC	SEQ?ID?NO：1556	BM734583.V1.3_at	AGAACATCCTCTTTTTTGGCAGATT	SEQ?ID?NO：1557
BM734583.V1.3_at	TTTGGCAGATTTGCCTCACCCTAAA	SEQ?ID?NO：1558	BM734583.V1.3_at	AGAACATCCTCTTTTTTGGCAGATT	SEQ?ID?NO：1557
BM734583.V1.3_at	TTTGGCAGATTTGCCTCACCCTAAA	SEQ?ID?NO：1558	BM734583.V1.3_at	ATTTGCCTCACCCTAAAATTGAAAG	SEQ?ID?NO：1559
BM734583.V1.3_at	AATTGAAAGGTTCTGTTTCTGCACA	SEQ?ID?NO：1560	BM734583.V1.3_at	ATTTGCCTCACCCTAAAATTGAAAG	SEQ?ID?NO：1559
BM734583.V1.3_at	AATTGAAAGGTTCTGTTTCTGCACA	SEQ?ID?NO：1560	BM734583.V1.3_at	GGTTCTGTTTCTGCACAGGATTTTG	SEQ?ID?NO：1561
BM734583.V1.3_at	CACAGGATTTTGTAATATGAGCTAT	SEQ?ID?NO：1562	BM734583.V1.3_at	GGTTCTGTTTCTGCACAGGATTTTG	SEQ?ID?NO：1561
BM734583.V1.3_at	CACAGGATTTTGTAATATGAGCTAT	SEQ?ID?NO：1562	BM734583.V1.3_at	TATGAGCTATAAGCCTCAGATTTGC	SEQ?ID?NO：1563
BM734583.V1.3_at	TAAGCCTCAGATTTGCTCTAGTGCC	SEQ?ID?NO：1564	BM734583.V1.3_at	TATGAGCTATAAGCCTCAGATTTGC	SEQ?ID?NO：1563
BM734583.V1.3_at	TAAGCCTCAGATTTGCTCTAGTGCC	SEQ?ID?NO：1564	BM734583.V1.3_at	TCAGATTTGCTCTAGTGCCCAAAAT	SEQ?ID?NO：1565
BM734583.V1.3_at	CTAGTGCCCAAAATTTAGAGACTTT	SEQ?ID?NO：1566	BM734583.V1.3_at	TCAGATTTGCTCTAGTGCCCAAAAT	SEQ?ID?NO：1565
BM734583.V1.3_at	CTAGTGCCCAAAATTTAGAGACTTT	SEQ?ID?NO：1566	BM734593.V1.3_at	TGACCTTGGAGAACCTCACTGCAGA	SEQ?ID?NO：1567
BM734593.V1.3_at	TGATCCCTTTTTCCAGGTTCAGGTG	SEQ?ID?NO：1568	BM734593.V1.3_at	TGACCTTGGAGAACCTCACTGCAGA	SEQ?ID?NO：1567
BM734593.V1.3_at	TGATCCCTTTTTCCAGGTTCAGGTG	SEQ?ID?NO：1568	BM734593.V1.3_at	AGGTTCAGGTGTTGGTTTCCTCAGC	SEQ?ID?NO：1569
BM734593.V1.3_at	ACAAGAGCTCTACGTGGACACCTGG	SEQ?ID?NO：1570	BM734593.V1.3_at	AGGTTCAGGTGTTGGTTTCCTCAGC	SEQ?ID?NO：1569
BM734593.V1.3_at	ACAAGAGCTCTACGTGGACACCTGG	SEQ?ID?NO：1570	BM734593.V1.3_at	GGACATTCCAGCCAACACCAAGGGT	SEQ?ID?NO：1571
BM734593.V1.3_at	TGCTCCTCATATTCCTGAAGGTGCC	SEQ?ID?NO：1572	BM734593.V1.3_at	GGACATTCCAGCCAACACCAAGGGT	SEQ?ID?NO：1571
BM734593.V1.3_at	TGCTCCTCATATTCCTGAAGGTGCC	SEQ?ID?NO：1572	BM734593.V1.3_at	TCAGTGCCGTCCTCTGGGTGAACAG	SEQ?ID?NO：1573
BM734593.V1.3_at	AGAGCCAGCCTGACCAAGAAAACCT	SEQ?ID?NO：1574	BM734593.V1.3_at	TCAGTGCCGTCCTCTGGGTGAACAG	SEQ?ID?NO：1573
BM734593.V1.3_at	AGAGCCAGCCTGACCAAGAAAACCT	SEQ?ID?NO：1574	BM734593.V1.3_at	CTCGCCCATCAATATCTTGTGCAGA	SEQ?ID?NO：1575
BM734593.V1.3_at	AGACCCTGAATCTGATATCCCTTTT	SEQ?ID?NO：1576	BM734593.V1.3_at	CTCGCCCATCAATATCTTGTGCAGA	SEQ?ID?NO：1575
BM734593.V1.3_at	AGACCCTGAATCTGATATCCCTTTT	SEQ?ID?NO：1576	BM734593.V1.3_at	TTTTCACCCTATTGCCAGAGACTTT	SEQ?ID?NO：1577
BM734597.V1.3_at	GCTGCTATACATTCACCGGTAAGAA	SEQ?ID?NO：1578	BM734593.V1.3_at	TTTTCACCCTATTGCCAGAGACTTT	SEQ?ID?NO：1577
BM734597.V1.3_at	GCTGCTATACATTCACCGGTAAGAA	SEQ?ID?NO：1578	BM734597.V1.3_at	AGAAGATCTCATCTCAGAGGCTGGG	SEQ?ID?NO：1579
BM734607.V1.3_at	AAGAGCATTGCGAGAGCGGGCACCA	SEQ?ID?NO：1580	BM734597.V1.3_at	AGAAGATCTCATCTCAGAGGCTGGG	SEQ?ID?NO：1579
BM734607.V1.3_at	AAGAGCATTGCGAGAGCGGGCACCA	SEQ?ID?NO：1580	BM734607.V1.3_at	CAATGTGTCAGCAGAGCGTGCCGAA	SEQ?ID?NO：1581
BM734607.V1.3_at	AAGCACTCGCTGGAGCTTCATGAGG	SEQ?ID?NO：1582	BM734607.V1.3_at	CAATGTGTCAGCAGAGCGTGCCGAA	SEQ?ID?NO：1581
BM734607.V1.3_at	AAGCACTCGCTGGAGCTTCATGAGG	SEQ?ID?NO：1582	BM734607.V1.3_at	TTGCGTGTCAGTTCTGTGAGCTGGC	SEQ?ID?NO：1583
BM734607.V1.3_at	TGGCCGTGCGCCTCAGTAAGGCAGA	SEQ?ID?NO：1584	BM734607.V1.3_at	TTGCGTGTCAGTTCTGTGAGCTGGC	SEQ?ID?NO：1583
BM734607.V1.3_at	TGGCCGTGCGCCTCAGTAAGGCAGA	SEQ?ID?NO：1584	BM734607.V1.3_at	GAGATCCATGAGTACCACTGTGGCA	SEQ?ID?NO：1585
BM734607.V1.3_at	TGGCCCAGCACAAGGACGTGTGTCA	SEQ?ID?NO：1586	BM734607.V1.3_at	GAGATCCATGAGTACCACTGTGGCA	SEQ?ID?NO：1585
BM734607.V1.3_at	TGGCCCAGCACAAGGACGTGTGTCA	SEQ?ID?NO：1586	BM734607.V1.3_at	GAGATAAGTATTCCCACCACGTGGA	SEQ?ID?NO：1587
BM734607.V1.3_at	TAAATGTCGCACAGTCTCAGAGTCT	SEQ?ID?NO：1588	BM734607.V1.3_at	GAGATAAGTATTCCCACCACGTGGA	SEQ?ID?NO：1587
BM734607.V1.3_at	TAAATGTCGCACAGTCTCAGAGTCT	SEQ?ID?NO：1588	BM734607.V1.3_at	GGAAAGCCAAGAATTCCTCCTCCAT	SEQ?ID?NO：1589
BM734607.V1.3_at	TCCAAGCCAGGCTGCTGAAGATCAA	SEQ?ID?NO：1590	BM734607.V1.3_at	GGAAAGCCAAGAATTCCTCCTCCAT	SEQ?ID?NO：1589
BM734607.V1.3_at	TCCAAGCCAGGCTGCTGAAGATCAA	SEQ?ID?NO：1590	BM734613.V1.3_at	CCAGTGGATTGGTCACCTGCTAGAC	SEQ?ID?NO：1591
BM734613.V1.3_at	GGCAGAATCCCCTTACTAAGCAGAT	SEQ?ID?NO：1592	BM734613.V1.3_at	CCAGTGGATTGGTCACCTGCTAGAC	SEQ?ID?NO：1591
BM734613.V1.3_at	GGCAGAATCCCCTTACTAAGCAGAT	SEQ?ID?NO：1592	BM734613.V1.3_at	GATTTGCTGAATCCGCTTTGTATCA	SEQ?ID?NO：1593
BM734613.V1.3_at	CTGCTTTGTACATAGGGCGTGATCC	SEQ?ID?NO：1594	BM734613.V1.3_at	GATTTGCTGAATCCGCTTTGTATCA	SEQ?ID?NO：1593
BM734613.V1.3_at	CTGCTTTGTACATAGGGCGTGATCC	SEQ?ID?NO：1594	BM734613.V1.3_at	CTGTGCCAGGAAGCCATTGCTCAGT	SEQ?ID?NO：1595

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734613.V1.3_at	ATTGCTCAGTTCTACCTTTGTTTTT	SEQ?ID?NO：1596
BM734613.V1.3_at	TGTACTGCTCAGAATGTGTCCCTCT	SEQ?ID?NO：1597	BM734613.V1.3_at	ATTGCTCAGTTCTACCTTTGTTTTT	SEQ?ID?NO：1596
BM734613.V1.3_at	TGTACTGCTCAGAATGTGTCCCTCT	SEQ?ID?NO：1597	BM734613.V1.3_at	ATTGGTTTAATGGTGACGCCTCCTG	SEQ?ID?NO：1598
BM734613.V1.3_at	GATCTGGTCACCTGTGCATTTGTGA	SEQ?ID?NO：1599	BM734613.V1.3_at	ATTGGTTTAATGGTGACGCCTCCTG	SEQ?ID?NO：1598
BM734613.V1.3_at	GATCTGGTCACCTGTGCATTTGTGA	SEQ?ID?NO：1599	BM734613.V1.3_at	GAATTAGGCAGATCACCGTCTCTTG	SEQ?ID?NO：1600
BM734613.V1.3_at	GTCTCTTGTCTACCCAGTTTAACAA	SEQ?ID?NO：1601	BM734613.V1.3_at	GAATTAGGCAGATCACCGTCTCTTG	SEQ?ID?NO：1600
BM734613.V1.3_at	GTCTCTTGTCTACCCAGTTTAACAA	SEQ?ID?NO：1601	BM734661.V1.3_at	GACGCAGACATGCAGATCTTTGTGA	SEQ?ID?NO：1602
BM734661.V1.3_at	ATCTTTGTGAAGACCCTGACGGGCA	SEQ?ID?NO：1603	BM734661.V1.3_at	GACGCAGACATGCAGATCTTTGTGA	SEQ?ID?NO：1602
BM734661.V1.3_at	ATCTTTGTGAAGACCCTGACGGGCA	SEQ?ID?NO：1603	BM734661.V1.3_at	GGTTGAGCCCAGTGACACCATTGAG	SEQ?ID?NO：1604
BM734661.V1.3_at	AGCAGCGTTTGATTTTTGCCGGCAA	SEQ?ID?NO：1605	BM734661.V1.3_at	GGTTGAGCCCAGTGACACCATTGAG	SEQ?ID?NO：1604
BM734661.V1.3_at	AGCAGCGTTTGATTTTTGCCGGCAA	SEQ?ID?NO：1605	BM734661.V1.3_at	TTTTGCCGGCAAACAGCTGGAGGAC	SEQ?ID?NO：1606
BM734661.V1.3_at	CACTCTCTCAGACTACAATATCCAG	SEQ?ID?NO：1607	BM734661.V1.3_at	TTTTGCCGGCAAACAGCTGGAGGAC	SEQ?ID?NO：1606
BM734661.V1.3_at	CACTCTCTCAGACTACAATATCCAG	SEQ?ID?NO：1607	BM734661.V1.3_at	ATTTGCCGCAAGTGTTATGCTCGCC	SEQ?ID?NO：1608
BM734661.V1.3_at	TCGTGCTGTCAACTGCCGCAAGAAG	SEQ?ID?NO：1609	BM734661.V1.3_at	ATTTGCCGCAAGTGTTATGCTCGCC	SEQ?ID?NO：1608
BM734661.V1.3_at	TCGTGCTGTCAACTGCCGCAAGAAG	SEQ?ID?NO：1609	BM734661.V1.3_at	GCAAGAAGAAGTGCGGCCACACCAA	SEQ?ID?NO：1610
BM734661.V1.3_at	AACCTGCGCCCCAAGAAGAAGGTCA	SEQ?ID?NO：1611	BM734661.V1.3_at	GCAAGAAGAAGTGCGGCCACACCAA	SEQ?ID?NO：1610
BM734661.V1.3_at	AACCTGCGCCCCAAGAAGAAGGTCA	SEQ?ID?NO：1611	BM734661.V1.3_at	GAAGGTCAAATAAGGCCCCTCCTCT	SEQ?ID?NO：1612
BM734719.V1.3_at	GAAGCTTCTTCCCACCTAGAAAGAA	SEQ?ID?NO：1613	BM734661.V1.3_at	GAAGGTCAAATAAGGCCCCTCCTCT	SEQ?ID?NO：1612
BM734719.V1.3_at	GAAGCTTCTTCCCACCTAGAAAGAA	SEQ?ID?NO：1613	BM734719.V1.3_at	AGAAGTCCTCTCTGAGACTCAAGGG	SEQ?ID?NO：1614
BM734719.V1.3_at	AAGGGCTAAGGCAAGGTCTTCCAGA	SEQ?ID?NO：1615	BM734719.V1.3_at	AGAAGTCCTCTCTGAGACTCAAGGG	SEQ?ID?NO：1614
BM734719.V1.3_at	AAGGGCTAAGGCAAGGTCTTCCAGA	SEQ?ID?NO：1615	BM734719.V1.3_at	ACGCCAATGGGTCAAACTAACTCTG	SEQ?ID?NO：1616
BM734719.V1.3_at	TTTCCACTGTCGTCAGAGCCAACAA	SEQ?ID?NO：1617	BM734719.V1.3_at	ACGCCAATGGGTCAAACTAACTCTG	SEQ?ID?NO：1616
BM734719.V1.3_at	TTTCCACTGTCGTCAGAGCCAACAA	SEQ?ID?NO：1617	BM734719.V1.3_at	CAAGAAATGACAGCCTCCAAGCCTT	SEQ?ID?NO：1618
BM734719.V1.3_at	AAGCCTTCCTAAAAGCACACTTGCC	SEQ?ID?NO：1619	BM734719.V1.3_at	CAAGAAATGACAGCCTCCAAGCCTT	SEQ?ID?NO：1618
BM734719.V1.3_at	AAGCCTTCCTAAAAGCACACTTGCC	SEQ?ID?NO：1619	BM734719.V1.3_at	GGTGACAACGCTGGCTGCTGAAAGC	SEQ?ID?NO：1620
BM734719.V1.3_at	AAAGCCCATGAGCTGCTTCTTTGTT	SEQ?ID?NO：1621	BM734719.V1.3_at	GGTGACAACGCTGGCTGCTGAAAGC	SEQ?ID?NO：1620
BM734719.V1.3_at	AAAGCCCATGAGCTGCTTCTTTGTT	SEQ?ID?NO：1621	BM734719.V1.3_at	TTCTTTGTTCTCTGTCACGGGACAA	SEQ?ID?NO：1622
BM734719.V1.3_at	AAAAATCTCTCATCCTATTCTGCTT	SEQ?ID?NO：1623	BM734719.V1.3_at	TTCTTTGTTCTCTGTCACGGGACAA	SEQ?ID?NO：1622
BM734719.V1.3_at	AAAAATCTCTCATCCTATTCTGCTT	SEQ?ID?NO：1623	BM734862.V1.3_at	AGCATTGTCATTCCTGTGGCGTGCG	SEQ?ID?NO：1624
BM734862.V1.3_at	TGGCGTGCGCACTCGTGACTAAGAG	SEQ?ID?NO：1625	BM734862.V1.3_at	AGCATTGTCATTCCTGTGGCGTGCG	SEQ?ID?NO：1624
BM734862.V1.3_at	TGGCGTGCGCACTCGTGACTAAGAG	SEQ?ID?NO：1625	BM734862.V1.3_at	CTCGTGACTAAGAGCCTGGTCCTTA	SEQ?ID?NO：1626
BM734862.V1.3_at	TTACTGTCCTGTTTGCTGTCACACA	SEQ?ID?NO：1627	BM734862.V1.3_at	CTCGTGACTAAGAGCCTGGTCCTTA	SEQ?ID?NO：1626
BM734862.V1.3_at	TTACTGTCCTGTTTGCTGTCACACA	SEQ?ID?NO：1627	BM734862.V1.3_at	GAAGTCATTTGGATCCTAGGCCCAT	SEQ?ID?NO：1628
BM734862.V1.3_at	ATGAGGATGACCTCTGATCTCCATC	SEQ?ID?NO：1629	BM734862.V1.3_at	GAAGTCATTTGGATCCTAGGCCCAT	SEQ?ID?NO：1628
BM734862.V1.3_at	ATGAGGATGACCTCTGATCTCCATC	SEQ?ID?NO：1629	BM734862.V1.3_at	ATCTACATCCATCTGGCAGTTGTGC	SEQ?ID?NO：1630
BM734862.V1.3_at	GGCAGCGACATGAGTTGGATCCGTT	SEQ?ID?NO：1631	BM734862.V1.3_at	ATCTACATCCATCTGGCAGTTGTGC	SEQ?ID?NO：1630
BM734862.V1.3_at	GGCAGCGACATGAGTTGGATCCGTT	SEQ?ID?NO：1631	BM734862.V1.3_at	ACAAAGGTTATTTCTGAGGCTCAGG	SEQ?ID?NO：1632
BM734862.V1.3_at	CCCTCATTTCACTGATGACCGTGGG	SEQ?ID?NO：1633	BM734862.V1.3_at	ACAAAGGTTATTTCTGAGGCTCAGG	SEQ?ID?NO：1632
BM734862.V1.3_at	CCCTCATTTCACTGATGACCGTGGG	SEQ?ID?NO：1633	BM734900.V1.3_at	GCTGGATTCCGCCTTTGAGGAGCCA	SEQ?ID?NO：1634
BM734900.V1.3_at	GAGGAGCCACTCACCAAGAAGATTT	SEQ?ID?NO：1635	BM734900.V1.3_at	GCTGGATTCCGCCTTTGAGGAGCCA	SEQ?ID?NO：1634
BM734900.V1.3_at	GAGGAGCCACTCACCAAGAAGATTT	SEQ?ID?NO：1635	BM734900.V1.3_at	GAAGATTTTCTTCTTCTCTGGGCGC	SEQ?ID?NO：1636
BM734900.V1.3_at	GTGTACACAGGCAAGTCGGCGCTAG	SEQ?ID?NO：1637	BM734900.V1.3_at	GAAGATTTTCTTCTTCTCTGGGCGC	SEQ?ID?NO：1636
BM734900.V1.3_at	GTGTACACAGGCAAGTCGGCGCTAG	SEQ?ID?NO：1637	BM734900.V1.3_at	TAGGCCCGAGGCGTCTGGACAAGCT	SEQ?ID?NO：1638
BM734900.V1.3_at	GTGTCAGCCCGGTGGACCAGATGTT	SEQ?ID?NO：1639	BM734900.V1.3_at	TAGGCCCGAGGCGTCTGGACAAGCT	SEQ?ID?NO：1638
BM734900.V1.3_at	GTGTCAGCCCGGTGGACCAGATGTT	SEQ?ID?NO：1639	BM734900.V1.3_at	ACGACGTCTTCCAGTACCGAGAGAA	SEQ?ID?NO：1640

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM734900.V1.3_at	ACTGGCGCGTGAGTTCCCGGAATGA	SEQ?ID?NO：1641
BM734900.V1.3_at	AAGTGGGCTACGTGAGCTTCGACCT	SEQ?ID?NO：1642	BM734900.V1.3_at	ACTGGCGCGTGAGTTCCCGGAATGA	SEQ?ID?NO：1641
BM734900.V1.3_at	AAGTGGGCTACGTGAGCTTCGACCT	SEQ?ID?NO：1642	BM734900.V1.3_at	GAAGGAGCCAGTTTGCCGGTTTCAA	SEQ?ID?NO：1643
BM734900.V1.3_at	GGTTTCAAACTGGTGGGTCTGTTCT	SEQ?ID?NO：1644	BM734900.V1.3_at	GAAGGAGCCAGTTTGCCGGTTTCAA	SEQ?ID?NO：1643
BM734900.V1.3_at	GGTTTCAAACTGGTGGGTCTGTTCT	SEQ?ID?NO：1644	BM735031.V1.3_at	ACTGAGCTTTTGTAAGTCCCGACAC	SEQ?ID?NO：1645
BM735031.V1.3_at	AGCGGTCTGGAAGTGCTGTCATCAC	SEQ?ID?NO：1646	BM735031.V1.3_at	ACTGAGCTTTTGTAAGTCCCGACAC	SEQ?ID?NO：1645
BM735031.V1.3_at	AGCGGTCTGGAAGTGCTGTCATCAC	SEQ?ID?NO：1646	BM735031.V1.3_at	ATCATAGCTGCCATAGAGTTACTGT	SEQ?ID?NO：1647
BM735031.V1.3_at	GAGTTACTGTTTCTCCGTACATAGA	SEQ?ID?NO：1648	BM735031.V1.3_at	ATCATAGCTGCCATAGAGTTACTGT	SEQ?ID?NO：1647
BM735031.V1.3_at	GAGTTACTGTTTCTCCGTACATAGA	SEQ?ID?NO：1648	BM735031.V1.3_at	AGAGGACAGTGCTTCTGACTGGAAT	SEQ?ID?NO：1649
BM735031.V1.3_at	GTTAGCATTCACTTTCAACGGGAGA	SEQ?ID?NO：1650	BM735031.V1.3_at	AGAGGACAGTGCTTCTGACTGGAAT	SEQ?ID?NO：1649
BM735031.V1.3_at	GTTAGCATTCACTTTCAACGGGAGA	SEQ?ID?NO：1650	BM735031.V1.3_at	TGTGGTCAAATGTTCTCTAGGTCAA	SEQ?ID?NO：1651
BM735031.V1.3_at	TAGGTCAACCTTACATAGCATACTT	SEQ?ID?NO：1652	BM735031.V1.3_at	TGTGGTCAAATGTTCTCTAGGTCAA	SEQ?ID?NO：1651
BM735031.V1.3_at	TAGGTCAACCTTACATAGCATACTT	SEQ?ID?NO：1652	BM735031.V1.3_at	AGCAAAATTGGAGCTTCTGAGCCCA	SEQ?ID?NO：1653
BM735031.V1.3_at	TGAGCCCAAATCACTGTCACTGTTT	SEQ?ID?NO：1654	BM735031.V1.3_at	AGCAAAATTGGAGCTTCTGAGCCCA	SEQ?ID?NO：1653
BM735031.V1.3_at	TGAGCCCAAATCACTGTCACTGTTT	SEQ?ID?NO：1654	BM735031.V1.3_at	TCTTTCTTTCAAACTGTGCTGCATG	SEQ?ID?NO：1655
BM735054.V1.3_at	GCTGGACTTCCATCACTGGGTGAGA	SEQ?ID?NO：1656	BM735031.V1.3_at	TCTTTCTTTCAAACTGTGCTGCATG	SEQ?ID?NO：1655
BM735054.V1.3_at	GCTGGACTTCCATCACTGGGTGAGA	SEQ?ID?NO：1656	BM735054.V1.3_at	GTGAGAGGCTCACCCTGTCATCCAA	SEQ?ID?NO：1657
BM735054.V1.3_at	GGGACACTGAATGGCTTCAACCTAC	SEQ?ID?NO：1658	BM735054.V1.3_at	GTGAGAGGCTCACCCTGTCATCCAA	SEQ?ID?NO：1657
BM735054.V1.3_at	GGGACACTGAATGGCTTCAACCTAC	SEQ?ID?NO：1658	BM735054.V1.3_at	AATGGCTTCAACCTACTGGGTGCGC	SEQ?ID?NO：1659
BM735054.V1.3_at	AGCCAAGGCTACTGCAGCTGTGGTT	SEQ?ID?NO：1660	BM735054.V1.3_at	AATGGCTTCAACCTACTGGGTGCGC	SEQ?ID?NO：1659
BM735054.V1.3_at	AGCCAAGGCTACTGCAGCTGTGGTT	SEQ?ID?NO：1660	BM735054.V1.3_at	GTCCTTAGCGGCCAAGATGATGTCC	SEQ?ID?NO：1661
BM735054.V1.3_at	AAGATGATGTCCACGGCCGCCATTG	SEQ?ID?NO：1662	BM735054.V1.3_at	GTCCTTAGCGGCCAAGATGATGTCC	SEQ?ID?NO：1661
BM735054.V1.3_at	AAGATGATGTCCACGGCCGCCATTG	SEQ?ID?NO：1662	BM735054.V1.3_at	GGTGGCCACTCTACAGTCCGTGGGA	SEQ?ID?NO：1663
BM735054.V1.3_at	CAAAGTCATCCTGGGCTCCACTGGG	SEQ?ID?NO：1664	BM735054.V1.3_at	GGTGGCCACTCTACAGTCCGTGGGA	SEQ?ID?NO：1663
BM735054.V1.3_at	CAAAGTCATCCTGGGCTCCACTGGG	SEQ?ID?NO：1664	BM735054.V1.3_at	TCATGGCACCCCTGTAATAGCTCCT	SEQ?ID?NO：1665
BM735054.V1.3_at	TCAGCCCCGCACAGGAGAGGACTGG	SEQ?ID?NO：1666	BM735054.V1.3_at	TCATGGCACCCCTGTAATAGCTCCT	SEQ?ID?NO：1665
BM735054.V1.3_at	TCAGCCCCGCACAGGAGAGGACTGG	SEQ?ID?NO：1666	BM735096.V1.3_at	AGAACAACATCATCACAGCCGAGGG	SEQ?ID?NO：1667
BM735096.V1.3_at	TGGGACGCTGCTGCTGTTCAGGAAA	SEQ?ID?NO：1668	BM735096.V1.3_at	AGAACAACATCATCACAGCCGAGGG	SEQ?ID?NO：1667
BM735096.V1.3_at	TGGGACGCTGCTGCTGTTCAGGAAA	SEQ?ID?NO：1668	BM735096.V1.3_at	GAAGTTCGGGCCAGACATCCAGGAT	SEQ?ID?NO：1669
BM735096.V1.3_at	GAGAATCTTTATGAGGGCCTGAACC	SEQ?ID?NO：1670	BM735096.V1.3_at	GAAGTTCGGGCCAGACATCCAGGAT	SEQ?ID?NO：1669
BM735096.V1.3_at	GAGAATCTTTATGAGGGCCTGAACC	SEQ?ID?NO：1670	BM735096.V1.3_at	AACCTCGATGACTGTTCCATGTACG	SEQ?ID?NO：1671
BM735096.V1.3_at	ACATCGGAGACGTCCAGCTGGAGAA	SEQ?ID?NO：1672	BM735096.V1.3_at	AACCTCGATGACTGTTCCATGTACG	SEQ?ID?NO：1671
BM735096.V1.3_at	ACATCGGAGACGTCCAGCTGGAGAA	SEQ?ID?NO：1672	BM735096.V1.3_at	ATCTGCTGTGCTTCCAATTTGTGTC	SEQ?ID?NO：1673
BM735096.V1.3_at	TGGAACGCGGTCTTTTCACAATCTT	SEQ?ID?NO：1674	BM735096.V1.3_at	ATCTGCTGTGCTTCCAATTTGTGTC	SEQ?ID?NO：1673
BM735096.V1.3_at	TGGAACGCGGTCTTTTCACAATCTT	SEQ?ID?NO：1674	BM735096.V1.3_at	ACAATCTTTCCTGGGAGTGTCCTGA	SEQ?ID?NO：1675
BM735096.V1.3_at	GGGTAATGAGCCCTTAATCGCTGCC	SEQ?ID?NO：1676	BM735096.V1.3_at	ACAATCTTTCCTGGGAGTGTCCTGA	SEQ?ID?NO：1675
BM735096.V1.3_at	GGGTAATGAGCCCTTAATCGCTGCC	SEQ?ID?NO：1676	BM735096.V1.3_at	GATTGTAGCAGCCTCGTTAGTGCCA	SEQ?ID?NO：1677
BM735170.V1.3_at	TCGTCCTCACTGTTTTTACCTTGAC	SEQ?ID?NO：1678	BM735096.V1.3_at	GATTGTAGCAGCCTCGTTAGTGCCA	SEQ?ID?NO：1677
BM735170.V1.3_at	TCGTCCTCACTGTTTTTACCTTGAC	SEQ?ID?NO：1678	BM735170.V1.3_at	TTTTTACCTTGACTTCAACTGCCCA	SEQ?ID?NO：1679
BM735170.V1.3_at	GCTGGAGCTGATTACTGAACTCGTA	SEQ?ID?NO：1680	BM735170.V1.3_at	TTTTTACCTTGACTTCAACTGCCCA	SEQ?ID?NO：1679
BM735170.V1.3_at	GCTGGAGCTGATTACTGAACTCGTA	SEQ?ID?NO：1680	BM735170.V1.3_at	TCGTATTTAATCTCTATTGCCAGTG	SEQ?ID?NO：1681
BM735170.V1.3_at	TATTTTTCTGATTGGTTTCCCCTCT	SEQ?ID?NO：1682	BM735170.V1.3_at	TCGTATTTAATCTCTATTGCCAGTG	SEQ?ID?NO：1681
BM735170.V1.3_at	TATTTTTCTGATTGGTTTCCCCTCT	SEQ?ID?NO：1682	BM735170.V1.3_at	TGGTTTCCCCTCTTATTGGAAGTAT	SEQ?ID?NO：1683
BM735170.V1.3_at	GGAATCATTTGAGGCTTTCAGGTTA	SEQ?ID?NO：1684	BM735170.V1.3_at	TGGTTTCCCCTCTTATTGGAAGTAT	SEQ?ID?NO：1683
BM735170.V1.3_at	GGAATCATTTGAGGCTTTCAGGTTA	SEQ?ID?NO：1684	BM735170.V1.3_at	TTAGCAAGAGCTATGGGCGTTACAT	SEQ?ID?NO：1685

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM735170.V1.3_at	GGCGTTACATGCTTGTTTTTTCCAA	SEQ?ID?NO：1686
BM735170.V1.3_at	GGGAGCTTTGGCATCTTTTTAGATT	SEQ?ID?NO：1687	BM735170.V1.3_at	GGCGTTACATGCTTGTTTTTTCCAA	SEQ?ID?NO：1686
BM735170.V1.3_at	GGGAGCTTTGGCATCTTTTTAGATT	SEQ?ID?NO：1687	BM735170.V1.3_at	ATCTCTATTTTCTTAATCCAGGGTA	SEQ?ID?NO：1688
BM735449.V1.3_at	GTAATATGATTTCCCTTTACTTCCT	SEQ?ID?NO：1689	BM735170.V1.3_at	ATCTCTATTTTCTTAATCCAGGGTA	SEQ?ID?NO：1688
BM735449.V1.3_at	GTAATATGATTTCCCTTTACTTCCT	SEQ?ID?NO：1689	BM735449.V1.3_at	TACCCTTCTGTTAAACTGCTGCTAC	SEQ?ID?NO：1690
BM735449.V1.3_at	GCTGCTACTGGAGTTCGCCTTTAAA	SEQ?ID?NO：1691	BM735449.V1.3_at	TACCCTTCTGTTAAACTGCTGCTAC	SEQ?ID?NO：1690
BM735449.V1.3_at	GCTGCTACTGGAGTTCGCCTTTAAA	SEQ?ID?NO：1691	BM735449.V1.3_at	GATTTGAAGTCCTTGGCATCCTGAA	SEQ?ID?NO：1692
BM735449.V1.3_at	GTTATATGCCATGTGCTTGTTATGA	SEQ?ID?NO：1693	BM735449.V1.3_at	GATTTGAAGTCCTTGGCATCCTGAA	SEQ?ID?NO：1692
BM735449.V1.3_at	GTTATATGCCATGTGCTTGTTATGA	SEQ?ID?NO：1693	BM735449.V1.3_at	TATGGTATGCCAGGAGACATTCTCC	SEQ?ID?NO：1694
BM735449.V1.3_at	GAGACATTCTCCTGATTTTCATTAT	SEQ?ID?NO：1695	BM735449.V1.3_at	TATGGTATGCCAGGAGACATTCTCC	SEQ?ID?NO：1694
BM735449.V1.3_at	GAGACATTCTCCTGATTTTCATTAT	SEQ?ID?NO：1695	BM735449.V1.3_at	AATGCTGTTCTTCTTATCTTTTATA	SEQ?ID?NO：1696
BM735449.V1.3_at	ATCAATTTCCGTTGTTTCGCTTGTC	SEQ?ID?NO：1697	BM735449.V1.3_at	AATGCTGTTCTTCTTATCTTTTATA	SEQ?ID?NO：1696
BM735449.V1.3_at	ATCAATTTCCGTTGTTTCGCTTGTC	SEQ?ID?NO：1697	BM735449.V1.3_at	GGTCTACATTAATTTTCCCCAGTCT	SEQ?ID?NO：1698
BM735449.V1.3_at	TAATTTTCCCCAGTCTGCATTAGAA	SEQ?ID?NO：1699	BM735449.V1.3_at	GGTCTACATTAATTTTCCCCAGTCT	SEQ?ID?NO：1698
BM735449.V1.3_at	TAATTTTCCCCAGTCTGCATTAGAA	SEQ?ID?NO：1699	BM780886.V1.3_at	AAGGACCTGTCCTGGCTGATTAGTT	SEQ?ID?NO：1700
BM780886.V1.3_at	CTGATTAGTTGAGGCTGGGACAGCT	SEQ?ID?NO：1701	BM780886.V1.3_at	AAGGACCTGTCCTGGCTGATTAGTT	SEQ?ID?NO：1700
BM780886.V1.3_at	CTGATTAGTTGAGGCTGGGACAGCT	SEQ?ID?NO：1701	BM780886.V1.3_at	GACAGCTGGAAGGATGACATGACAT	SEQ?ID?NO：1702
BM780886.V1.3_at	TCTACACAGCGCATTTTGGAGGACA	SEQ?ID?NO：1703	BM780886.V1.3_at	GACAGCTGGAAGGATGACATGACAT	SEQ?ID?NO：1702
BM780886.V1.3_at	TCTACACAGCGCATTTTGGAGGACA	SEQ?ID?NO：1703	BM780886.V1.3_at	CCCACACTGGGAAACTCTGCTGGTT	SEQ?ID?NO：1704
BM780886.V1.3_at	AAACTCTGCTGGTTCCTGGACGAGG	SEQ?ID?NO：1705	BM780886.V1.3_at	CCCACACTGGGAAACTCTGCTGGTT	SEQ?ID?NO：1704
BM780886.V1.3_at	AAACTCTGCTGGTTCCTGGACGAGG	SEQ?ID?NO：1705	BM780886.V1.3_at	TGACCGTGCCCTTCGAGAAGCATTC	SEQ?ID?NO：1706
BM780886.V1.3_at	GAAGCATTCGGCCTTGTAGCCAGCC	SEQ?ID?NO：1707	BM780886.V1.3_at	TGACCGTGCCCTTCGAGAAGCATTC	SEQ?ID?NO：1706
BM780886.V1.3_at	GAAGCATTCGGCCTTGTAGCCAGCC	SEQ?ID?NO：1707	BM780886.V1.3_at	GAAGAAAGCCGTGGCTGGGCCTTCT	SEQ?ID?NO：1708
BM780886.V1.3_at	CGGCGTTTGGCTTCCTTTCAGAAGA	SEQ?ID?NO：1709	BM780886.V1.3_at	GAAGAAAGCCGTGGCTGGGCCTTCT	SEQ?ID?NO：1708
BM780886.V1.3_at	CGGCGTTTGGCTTCCTTTCAGAAGA	SEQ?ID?NO：1709	BM780886.V1.3_at	GGCTTCCTTTCAGAAGAGCTGCCAC	SEQ?ID?NO：1710
BM781127.V1.3_at	CAATATGGTCCATCGCGGAGCACGG	SEQ?ID?NO：1711	BM780886.V1.3_at	GGCTTCCTTTCAGAAGAGCTGCCAC	SEQ?ID?NO：1710
BM781127.V1.3_at	CAATATGGTCCATCGCGGAGCACGG	SEQ?ID?NO：1711	BM781127.V1.3_at	CAACCTGCAGTACCTTCAAGACGAG	SEQ?ID?NO：1712
BM781127.V1.3_at	CATAGGCTTTGTGCTAAGCGGCGCT	SEQ?ID?NO：1713	BM781127.V1.3_at	CAACCTGCAGTACCTTCAAGACGAG	SEQ?ID?NO：1712
BM781127.V1.3_at	CATAGGCTTTGTGCTAAGCGGCGCT	SEQ?ID?NO：1713	BM781127.V1.3_at	AAGCGGCGCTGGGAACTTCATGGAC	SEQ?ID?NO：1714
BM781127.V1.3_at	GTGGCTTTGCCTACGTGGAGATCAG	SEQ?ID?NO：1715	BM781127.V1.3_at	AAGCGGCGCTGGGAACTTCATGGAC	SEQ?ID?NO：1714
BM781127.V1.3_at	GTGGCTTTGCCTACGTGGAGATCAG	SEQ?ID?NO：1715	BM781127.V1.3_at	GATCAGCCCCAAAGAGATGACCGTC	SEQ?ID?NO：1716
BM781127.V1.3_at	ATGACCGTCACTTACATCGAAGCTT	SEQ?ID?NO：1717	BM781127.V1.3_at	GATCAGCCCCAAAGAGATGACCGTC	SEQ?ID?NO：1716
BM781127.V1.3_at	ATGACCGTCACTTACATCGAAGCTT	SEQ?ID?NO：1717	BM781127.V1.3_at	AAGCTTCGGGCAAGTCCCTGTTCAA	SEQ?ID?NO：1718
BM781127.V1.3_at	TTCAAGACCAGGCTGCCCAGGAGAG	SEQ?ID?NO：1719	BM781127.V1.3_at	AAGCTTCGGGCAAGTCCCTGTTCAA	SEQ?ID?NO：1718
BM781127.V1.3_at	TTCAAGACCAGGCTGCCCAGGAGAG	SEQ?ID?NO：1719	BM781127.V1.3_at	GAAAGCAGCATGGACACCGGCCAGA	SEQ?ID?NO：1720
BM781127.V1.3_at	GAGGGAAATTTTCTCCTGGATTCAG	SEQ?ID?NO：1721	BM781127.V1.3_at	GAAAGCAGCATGGACACCGGCCAGA	SEQ?ID?NO：1720
BM781127.V1.3_at	GAGGGAAATTTTCTCCTGGATTCAG	SEQ?ID?NO：1721	BM781436.V1.3_at	GGCACGAGATCCAGTACCAGCTAGT	SEQ?ID?NO：1722
BM781436.V1.3_at	GCTAGTGGACATCTCTCAGGACAAC	SEQ?ID?NO：1723	BM781436.V1.3_at	GGCACGAGATCCAGTACCAGCTAGT	SEQ?ID?NO：1722
BM781436.V1.3_at	GCTAGTGGACATCTCTCAGGACAAC	SEQ?ID?NO：1723	BM781436.V1.3_at	AGGACAACGCCCTGCGGGATGAGAT	SEQ?ID?NO：1724
BM781436.V1.3_at	GACTATGAGCTCTTCGTGGAGGCTG	SEQ?ID?NO：1725	BM781436.V1.3_at	AGGACAACGCCCTGCGGGATGAGAT	SEQ?ID?NO：1724
BM781436.V1.3_at	GACTATGAGCTCTTCGTGGAGGCTG	SEQ?ID?NO：1725	BM781436.V1.3_at	GCAAAACACGCTGCAGGAGTTCCTG	SEQ?ID?NO：1726
BM781436.V1.3_at	GAGTTCCTGAAACTGGCCTAAGCCA	SEQ?ID?NO：1727	BM781436.V1.3_at	GCAAAACACGCTGCAGGAGTTCCTG	SEQ?ID?NO：1726
BM781436.V1.3_at	GAGTTCCTGAAACTGGCCTAAGCCA	SEQ?ID?NO：1727	BM781436.V1.3_at	GTGACCAATTCCCTGTTATTCCTAA	SEQ?ID?NO：1728
BM781436.V1.3_at	TATTCCTAACCTTCTGGCCTTGGAG	SEQ?ID?NO：1729	BM781436.V1.3_at	GTGACCAATTCCCTGTTATTCCTAA	SEQ?ID?NO：1728
BM781436.V1.3_at	TATTCCTAACCTTCTGGCCTTGGAG	SEQ?ID?NO：1729	BM781436.V1.3_at	TCCTTACCCACTAGTCTCAGAAATT	SEQ?ID?NO：1730

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	BM781436.V1.3_at	CTGACACTGGCTGATGGGCACCTAT	SEQ?ID?NO：1731
BM781436.V1.3_at	GGGCACCTATGTTGGTTCCATTAGC	SEQ?ID?NO：1732	BM781436.V1.3_at	CTGACACTGGCTGATGGGCACCTAT	SEQ?ID?NO：1731
BM781436.V1.3_at	GGGCACCTATGTTGGTTCCATTAGC	SEQ?ID?NO：1732	Foe1268.V1.3_at	ATCGGAGCTCATGATGGGCGGCACC	SEQ?ID?NO：1733
Foe1268.V1.3_at	AACACGCTGGTGCTGCATAACACAT	SEQ?ID?NO：1734	Foe1268.V1.3_at	ATCGGAGCTCATGATGGGCGGCACC	SEQ?ID?NO：1733
Foe1268.V1.3_at	AACACGCTGGTGCTGCATAACACAT	SEQ?ID?NO：1734	Foe1268.V1.3_at	AACACATGTGAGGACTCTCTCCTGG	SEQ?ID?NO：1735
Foe1268.V1.3_at	CATGCTGGATCTGGTACTGCTGACA	SEQ?ID?NO：1736	Foe1268.V1.3_at	AACACATGTGAGGACTCTCTCCTGG	SEQ?ID?NO：1735
Foe1268.V1.3_at	CATGCTGGATCTGGTACTGCTGACA	SEQ?ID?NO：1736	Foe1268.V1.3_at	AGAACTGTGCCAGCGTGTGAGCTTC	SEQ?ID?NO：1737
Foe1268.V1.3_at	AGCGCAGCTGCATCGAGAACATCCT	SEQ?ID?NO：1738	Foe1268.V1.3_at	AGAACTGTGCCAGCGTGTGAGCTTC	SEQ?ID?NO：1737
Foe1268.V1.3_at	AGCGCAGCTGCATCGAGAACATCCT	SEQ?ID?NO：1738	Foe1268.V1.3_at	AGAACATCCTAAGGGCCTGCGTGGG	SEQ?ID?NO：1739
Foe1268.V1.3_at	AGAACCACATGCTTCTGGAGCACAA	SEQ?ID?NO：1740	Foe1268.V1.3_at	AGAACATCCTAAGGGCCTGCGTGGG	SEQ?ID?NO：1739
Foe1268.V1.3_at	AGAACCACATGCTTCTGGAGCACAA	SEQ?ID?NO：1740	Foe1268.V1.3_at	TGGAGCACAAGATGGAGCGCCCCTG	SEQ?ID?NO：1741
Foe1268.V1.3_at	CAACGGCTGTGTCGGTGATGCCAAT	SEQ?ID?NO：1742	Foe1268.V1.3_at	TGGAGCACAAGATGGAGCGCCCCTG	SEQ?ID?NO：1741
Foe1268.V1.3_at	CAACGGCTGTGTCGGTGATGCCAAT	SEQ?ID?NO：1742	Foe1268.V1.3_at	AATGGTCATACAAAGGCCGAGGCAC	SEQ?ID?NO：1743
GI1305528.V1.3_at	AAGGAGCGCAACGACACCTGTGACA	SEQ?ID?NO：1744	Foe1268.V1.3_at	AATGGTCATACAAAGGCCGAGGCAC	SEQ?ID?NO：1743
GI1305528.V1.3_at	AAGGAGCGCAACGACACCTGTGACA	SEQ?ID?NO：1744	GI1305528.V1.3_at	AAGTTCCTGAAGGAGCGGCTTGCTC	SEQ?ID?NO：1745
GI1305528.V1.3_at	GTTAAATCGGGCTCTCTGTCTCAGC	SEQ?ID?NO：1746	GI1305528.V1.3_at	AAGTTCCTGAAGGAGCGGCTTGCTC	SEQ?ID?NO：1745
GI1305528.V1.3_at	GTTAAATCGGGCTCTCTGTCTCAGC	SEQ?ID?NO：1746	GI1305528.V1.3_at	TAGTTACCCATTCACAGATACCCGA	SEQ?ID?NO：1747
GI1305528.V1.3_at	GTCTGTGCTTGTCCTTTAGTGGATA	SEQ?ID?NO：1748	GI1305528.V1.3_at	TAGTTACCCATTCACAGATACCCGA	SEQ?ID?NO：1747
GI1305528.V1.3_at	GTCTGTGCTTGTCCTTTAGTGGATA	SEQ?ID?NO：1748	GI1305528.V1.3_at	AAGCATTGAGACTAGAGCCCCGCCT	SEQ?ID?NO：1749
GI1305528.V1.3_at	CCCGCCTTCATGTAGCATATGCTTT	SEQ?ID?NO：1750	GI1305528.V1.3_at	AAGCATTGAGACTAGAGCCCCGCCT	SEQ?ID?NO：1749
GI1305528.V1.3_at	CCCGCCTTCATGTAGCATATGCTTT	SEQ?ID?NO：1750	GI1305528.V1.3_at	GAGCAGTGCCATTTTCTGGTTAGGA	SEQ?ID?NO：1751
GI1305528.V1.3_at	TCAGAGACCGATGTACGTGCAGCAT	SEQ?ID?NO：1752	GI1305528.V1.3_at	GAGCAGTGCCATTTTCTGGTTAGGA	SEQ?ID?NO：1751
GI1305528.V1.3_at	TCAGAGACCGATGTACGTGCAGCAT	SEQ?ID?NO：1752	GI1305528.V1.3_at	TTTTTTGTGTTGTCCTTTCGCATAC	SEQ?ID?NO：1753
GI1305528.V1.3_at	GCATACCCAGTGTTTTAGGCGTGTG	SEQ?ID?NO：1754	GI1305528.V1.3_at	TTTTTTGTGTTGTCCTTTCGCATAC	SEQ?ID?NO：1753
GI1305528.V1.3_at	GCATACCCAGTGTTTTAGGCGTGTG	SEQ?ID?NO：1754	WBC004E01_V1.3_at	GGATGTATGCTCAAATGTTCTTTTA	SEQ?ID?NO：1755
WBC004E01_V1.3_at	GTTCTTTTAAATACCTCCTGATCAA	SEQ?ID?NO：1756	WBC004E01_V1.3_at	GGATGTATGCTCAAATGTTCTTTTA	SEQ?ID?NO：1755
WBC004E01_V1.3_at	GTTCTTTTAAATACCTCCTGATCAA	SEQ?ID?NO：1756	WBC004E01_V1.3_at	TTTACAACCTACTACAGACACCTGG	SEQ?ID?NO：1757
WBC004E01_V1.3_at	TCTGACCCTCCTTACTCTATTTTTT	SEQ?ID?NO：1758	WBC004E01_V1.3_at	TTTACAACCTACTACAGACACCTGG	SEQ?ID?NO：1757
WBC004E01_V1.3_at	TCTGACCCTCCTTACTCTATTTTTT	SEQ?ID?NO：1758	WBC004E01_V1.3_at	TTGTGTTTTTGAAAGCCTGTCTCCT	SEQ?ID?NO：1759
WBC004E01_V1.3_at	AAGCCTGTCTCCTCTTGTGAGAATG	SEQ?ID?NO：1760	WBC004E01_V1.3_at	TTGTGTTTTTGAAAGCCTGTCTCCT	SEQ?ID?NO：1759
WBC004E01_V1.3_at	AAGCCTGTCTCCTCTTGTGAGAATG	SEQ?ID?NO：1760	WBC004E01_V1.3_at	GAACATTTAGTCCTGTTTACGTTTG	SEQ?ID?NO：1761
WBC004E01_V1.3_at	TTACGTTTGTACTCCAGCACCAAGA	SEQ?ID?NO：1762	WBC004E01_V1.3_at	GAACATTTAGTCCTGTTTACGTTTG	SEQ?ID?NO：1761
WBC004E01_V1.3_at	TTACGTTTGTACTCCAGCACCAAGA	SEQ?ID?NO：1762	WBC004E01_V1.3_at	CAGTACCTGAACATAGAATCCACGT	SEQ?ID?NO：1763
WBC004E01_V1.3_at	GGGAAGACTGTTTCAACCAAGATTT	SEQ?ID?NO：1764	WBC004E01_V1.3_at	CAGTACCTGAACATAGAATCCACGT	SEQ?ID?NO：1763
WBC004E01_V1.3_at	GGGAAGACTGTTTCAACCAAGATTT	SEQ?ID?NO：1764	WBC004E01_V1.3_at	GGTTGGTGACATGCACTTAGGGATA	SEQ?ID?NO：1765
WBC005G04_V1.3_at	GATCCAAAGATTGAGGTCCCTACCA	SEQ?ID?NO：1766	WBC004E01_V1.3_at	GGTTGGTGACATGCACTTAGGGATA	SEQ?ID?NO：1765
WBC005G04_V1.3_at	GATCCAAAGATTGAGGTCCCTACCA	SEQ?ID?NO：1766	WBC005G04_V1.3_at	GAGGTCCCTACCAGAATTATCAAAA	SEQ?ID?NO：1767
WBC005G04_V1.3_at	TAATCTTCACAAACAAGCATCGGGA	SEQ?ID?NO：1768	WBC005G04_V1.3_at	GAGGTCCCTACCAGAATTATCAAAA	SEQ?ID?NO：1767
WBC005G04_V1.3_at	TAATCTTCACAAACAAGCATCGGGA	SEQ?ID?NO：1768	WBC005G04_V1.3_at	TATGGGTTGTTTGTGTTACATCAGA	SEQ?ID?NO：1769
WBC005G04_V1.3_at	GATAAACTTCGACTCTTCTGCTTTC	SEQ?ID?NO：1770	WBC005G04_V1.3_at	TATGGGTTGTTTGTGTTACATCAGA	SEQ?ID?NO：1769
WBC005G04_V1.3_at	GATAAACTTCGACTCTTCTGCTTTC	SEQ?ID?NO：1770	WBC005G04_V1.3_at	TCGACTCTTCTGCTTTCAATTGAGA	SEQ?ID?NO：1771
WBC005G04_V1.3_at	AGAGGCTGAAACTGACATGTGGAAA	SEQ?ID?NO：1772	WBC005G04_V1.3_at	TCGACTCTTCTGCTTTCAATTGAGA	SEQ?ID?NO：1771
WBC005G04_V1.3_at	AGAGGCTGAAACTGACATGTGGAAA	SEQ?ID?NO：1772	WBC005G04_V1.3_at	GTTTCATTCAGGTCATCAAGGCTAA	SEQ?ID?NO：1773
WBC005G04_V1.3_at	ATCTGAAGTGAAGAACCCTCCTCCA	SEQ?ID?NO：1774	WBC005G04_V1.3_at	GTTTCATTCAGGTCATCAAGGCTAA	SEQ?ID?NO：1773
WBC005G04_V1.3_at	ATCTGAAGTGAAGAACCCTCCTCCA	SEQ?ID?NO：1774	WBC005G04_V1.3_at	AGAACCCTCCTCCAAATCAATTGGG	SEQ?ID?NO：1775

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC005G04_V1.3_at	TTCAGCAGAAACAGCTCAGCACATT	SEQ?ID?NO：1776
WBC007A05_V1.3_at	GAAGGTCTACCAAGCTGTGCAGCAT	SEQ?ID?NO：1777	WBC005G04_V1.3_at	TTCAGCAGAAACAGCTCAGCACATT	SEQ?ID?NO：1776
WBC007A05_V1.3_at	GAAGGTCTACCAAGCTGTGCAGCAT	SEQ?ID?NO：1777	WBC007A05_V1.3_at	TGTGCAGCATAATCGAGCCACGGAA	SEQ?ID?NO：1778
WBC007A05_V1.3_at	TTATCTTGTGTTTTACTCCCTTTCA	SEQ?ID?NO：1779	WBC007A05_V1.3_at	TGTGCAGCATAATCGAGCCACGGAA	SEQ?ID?NO：1778
WBC007A05_V1.3_at	TTATCTTGTGTTTTACTCCCTTTCA	SEQ?ID?NO：1779	WBC007A05_V1.3_at	TACTCCCTTTCATGTGATGTTGCTG	SEQ?ID?NO：1780
WBC007A05_V1.3_at	GATGTTGCTGATTCGCTGCATTCTA	SEQ?ID?NO：1781	WBC007A05_V1.3_at	TACTCCCTTTCATGTGATGTTGCTG	SEQ?ID?NO：1780
WBC007A05_V1.3_at	GATGTTGCTGATTCGCTGCATTCTA	SEQ?ID?NO：1781	WBC007A05_V1.3_at	GTTGCGGATCCAATTCTGTACTGTT	SEQ?ID?NO：1782
WBC007A05_V1.3_at	AAAATTCTGTACTGGGAGGCTCAAC	SEQ?ID?NO：1783	WBC007A05_V1.3_at	GTTGCGGATCCAATTCTGTACTGTT	SEQ?ID?NO：1782
WBC007A05_V1.3_at	AAAATTCTGTACTGGGAGGCTCAAC	SEQ?ID?NO：1783	WBC007A05_V1.3_at	AAACGCATACCGTCTATGTCTACAA	SEQ?ID?NO：1784
WBC007A05_V1.3_at	GAAGACTGTGTTCCATCTGAGTGAA	SEQ?ID?NO：1785	WBC007A05_V1.3_at	AAACGCATACCGTCTATGTCTACAA	SEQ?ID?NO：1784
WBC007A05_V1.3_at	GAAGACTGTGTTCCATCTGAGTGAA	SEQ?ID?NO：1785	WBC007A05_V1.3_at	GTGAATATTTTAATCCTCTCCAGTG	SEQ?ID?NO：1786
WBC007A05_V1.3_at	AAAACGCACTGTATTGCTCCTGACT	SEQ?ID?NO：1787	WBC007A05_V1.3_at	GTGAATATTTTAATCCTCTCCAGTG	SEQ?ID?NO：1786
WBC007A05_V1.3_at	AAAACGCACTGTATTGCTCCTGACT	SEQ?ID?NO：1787	WBC007E09_V1.3_at	GGCTGTGTAAGTGACCTAATTAATA	SEQ?ID?NO：1788
WBC007E09_V1.3_at	AAGAGTATCGTCTTCCTACGCATAG	SEQ?ID?NO：1789	WBC007E09_V1.3_at	GGCTGTGTAAGTGACCTAATTAATA	SEQ?ID?NO：1788
WBC007E09_V1.3_at	AAGAGTATCGTCTTCCTACGCATAG	SEQ?ID?NO：1789	WBC007E09_V1.3_at	TAGGAAGCTTATTCTCTGGAGACAT	SEQ?ID?NO：1790
WBC007E09_V1.3_at	ATTGATACTCTCTGATTTAATCCAG	SEQ?ID?NO：1791	WBC007E09_V1.3_at	TAGGAAGCTTATTCTCTGGAGACAT	SEQ?ID?NO：1790
WBC007E09_V1.3_at	ATTGATACTCTCTGATTTAATCCAG	SEQ?ID?NO：1791	WBC007E09_V1.3_at	CCAGATCTGGGCTTATTTAACTAAA	SEQ?ID?NO：1792
WBC007E09_V1.3_at	ATATTCGACACTGCTGATTTTTTAA	SEQ?ID?NO：1793	WBC007E09_V1.3_at	CCAGATCTGGGCTTATTTAACTAAA	SEQ?ID?NO：1792
WBC007E09_V1.3_at	ATATTCGACACTGCTGATTTTTTAA	SEQ?ID?NO：1793	WBC007E09_V1.3_at	GATGCACTGCACTTTTGATATGTTT	SEQ?ID?NO：1794
WBC007E09_V1.3_at	GCCAAATATTTAGGTCTGTCACTGA	SEQ?ID?NO：1795	WBC007E09_V1.3_at	GATGCACTGCACTTTTGATATGTTT	SEQ?ID?NO：1794
WBC007E09_V1.3_at	GCCAAATATTTAGGTCTGTCACTGA	SEQ?ID?NO：1795	WBC007E09_V1.3_at	TAGTTTTGTGACCTTATTCTCCCCT	SEQ?ID?NO：1796
WBC007E09_V1.3_at	CCCCACTTCCTCTGCAAAAAGATTT	SEQ?ID?NO：1797	WBC007E09_V1.3_at	TAGTTTTGTGACCTTATTCTCCCCT	SEQ?ID?NO：1796
WBC007E09_V1.3_at	CCCCACTTCCTCTGCAAAAAGATTT	SEQ?ID?NO：1797	WBC007E09_V1.3_at	AAACGTGGTTTGCAAGGCATTCTAT	SEQ?ID?NO：1798
WBC008B04_V1.3_at	AGATATCCTGCCCTGTGTTTTATTC	SEQ?ID?NO：1799	WBC007E09_V1.3_at	AAACGTGGTTTGCAAGGCATTCTAT	SEQ?ID?NO：1798
WBC008B04_V1.3_at	AGATATCCTGCCCTGTGTTTTATTC	SEQ?ID?NO：1799	WBC008B04_V1.3_at	GTTTTATTCCTGTGTGTTAACCTCA	SEQ?ID?NO：1800
WBC008B04_V1.3_at	AGCAAGAAAGTCTGCCCTTTGCCAT	SEQ?ID?NO：1801	WBC008B04_V1.3_at	GTTTTATTCCTGTGTGTTAACCTCA	SEQ?ID?NO：1800
WBC008B04_V1.3_at	AGCAAGAAAGTCTGCCCTTTGCCAT	SEQ?ID?NO：1801	WBC008B04_V1.3_at	GCGTGTGCGCACGTACATGCATGAG	SEQ?ID?NO：1802
WBC008B04_V1.3_at	TGTGGTTTCCAGCTTTGCTGACAGT	SEQ?ID?NO：1803	WBC008B04_V1.3_at	GCGTGTGCGCACGTACATGCATGAG	SEQ?ID?NO：1802
WBC008B04_V1.3_at	TGTGGTTTCCAGCTTTGCTGACAGT	SEQ?ID?NO：1803	WBC008B04_V1.3_at	GAGAACTTAGCCTCCTAGTATCCAC	SEQ?ID?NO：1804
WBC008B04_V1.3_at	CAGTCTCAACTCTGGTTTCTCAAGA	SEQ?ID?NO：1805	WBC008B04_V1.3_at	GAGAACTTAGCCTCCTAGTATCCAC	SEQ?ID?NO：1804
WBC008B04_V1.3_at	CAGTCTCAACTCTGGTTTCTCAAGA	SEQ?ID?NO：1805	WBC008B04_V1.3_at	AAGATCTGTCACGTTGGCCTACTAA	SEQ?ID?NO：1806
WBC008B04_V1.3_at	GTTGGCCTACTAACTTGACGTCTTC	SEQ?ID?NO：1807	WBC008B04_V1.3_at	AAGATCTGTCACGTTGGCCTACTAA	SEQ?ID?NO：1806
WBC008B04_V1.3_at	GTTGGCCTACTAACTTGACGTCTTC	SEQ?ID?NO：1807	WBC008B04_V1.3_at	GATCGCCCAGCGTTTTTAGATTGTA	SEQ?ID?NO：1808
WBC008B04_V1.3_at	TTATCTCTTGCTTTGTTACTTTGGG	SEQ?ID?NO：1809	WBC008B04_V1.3_at	GATCGCCCAGCGTTTTTAGATTGTA	SEQ?ID?NO：1808
WBC008B04_V1.3_at	TTATCTCTTGCTTTGTTACTTTGGG	SEQ?ID?NO：1809	WBC009D04_V1.3_at	GCACCTCGAGTATCAGTTCATTCAT	SEQ?ID?NO：1810
WBC009D04_V1.3_at	ATTGTGCTGTTACCATGACTCACGC	SEQ?ID?NO：1811	WBC009D04_V1.3_at	GCACCTCGAGTATCAGTTCATTCAT	SEQ?ID?NO：1810
WBC009D04_V1.3_at	ATTGTGCTGTTACCATGACTCACGC	SEQ?ID?NO：1811	WBC009D04_V1.3_at	TGACTCACGCTCTTTGTTGACAGTT	SEQ?ID?NO：1812
WBC009D04_V1.3_at	AGGAGCCTGAGAATCTTGGTCCCTC	SEQ?ID?NO：1813	WBC009D04_V1.3_at	TGACTCACGCTCTTTGTTGACAGTT	SEQ?ID?NO：1812
WBC009D04_V1.3_at	AGGAGCCTGAGAATCTTGGTCCCTC	SEQ?ID?NO：1813	WBC009D04_V1.3_at	CTCCAACCTATGTGGCCCAAGTAAA	SEQ?ID?NO：1814
WBC009D04_V1.3_at	AACCAACTCCATTTGTTGCTCTGAA	SEQ?ID?NO：1815	WBC009D04_V1.3_at	CTCCAACCTATGTGGCCCAAGTAAA	SEQ?ID?NO：1814
WBC009D04_V1.3_at	AACCAACTCCATTTGTTGCTCTGAA	SEQ?ID?NO：1815	WBC009D04_V1.3_at	TCTCCAGGGTTTTCTACCTTTGACA	SEQ?ID?NO：1816
WBC009D04_V1.3_at	GAGAGATTTGCCCTGTGTTATCCTG	SEQ?ID?NO：1817	WBC009D04_V1.3_at	TCTCCAGGGTTTTCTACCTTTGACA	SEQ?ID?NO：1816
WBC009D04_V1.3_at	GAGAGATTTGCCCTGTGTTATCCTG	SEQ?ID?NO：1817	WBC009D04_V1.3_at	GTCATTAGGACAGCTTCCTTCTTCA	SEQ?ID?NO：1818
WBC009D04_V1.3_at	GCACAGCTTCCTTAGCATTTAGCAT	SEQ?ID?NO：1819	WBC009D04_V1.3_at	GTCATTAGGACAGCTTCCTTCTTCA	SEQ?ID?NO：1818
WBC009D04_V1.3_at	GCACAGCTTCCTTAGCATTTAGCAT	SEQ?ID?NO：1819	WBC009D04_V1.3_at	TTTTTAGTTCTCCTGCTTTTGCAAT	SEQ?ID?NO：1820

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC010B02_V1.3_at	GACAGCTGCTATGTACTACTTGAAG	SEQ?ID?NO：1821
WBC010B02_V1.3_at	GAGATGTTCTTCTCACAATGCCAGC	SEQ?ID?NO：1822	WBC010B02_V1.3_at	GACAGCTGCTATGTACTACTTGAAG	SEQ?ID?NO：1821
WBC010B02_V1.3_at	GAGATGTTCTTCTCACAATGCCAGC	SEQ?ID?NO：1822	WBC010B02_V1.3_at	AATGCCAGCCTGTTGAAGATTAAGA	SEQ?ID?NO：1823
WBC010B02_V1.3_at	GAATCATTGGCTGGGATTATCTCCC	SEQ?ID?NO：1824	WBC010B02_V1.3_at	AATGCCAGCCTGTTGAAGATTAAGA	SEQ?ID?NO：1823
WBC010B02_V1.3_at	GAATCATTGGCTGGGATTATCTCCC	SEQ?ID?NO：1824	WBC010B02_V1.3_at	TGACACACCCTACAAGCTCTTGGAT	SEQ?ID?NO：1825
WBC010B02_V1.3_at	GGATGAGACAATTAGCTCCTCTGAT	SEQ?ID?NO：1826	WBC010B02_V1.3_at	TGACACACCCTACAAGCTCTTGGAT	SEQ?ID?NO：1825
WBC010B02_V1.3_at	GGATGAGACAATTAGCTCCTCTGAT	SEQ?ID?NO：1826	WBC010B02_V1.3_at	CAATTAGCTCCTCTGATTGGTTCAG	SEQ?ID?NO：1827
WBC010B02_V1.3_at	CTGTCTGTGAGAAGTTGGCTAATCC	SEQ?ID?NO：1828	WBC010B02_V1.3_at	CAATTAGCTCCTCTGATTGGTTCAG	SEQ?ID?NO：1827
WBC010B02_V1.3_at	CTGTCTGTGAGAAGTTGGCTAATCC	SEQ?ID?NO：1828	WBC010B02_V1.3_at	GTAGTCAGTGCATTATTTTGCCTCA	SEQ?ID?NO：1829
WBC010B02_V1.3_at	ATTTTGCCTCAGCTATTATCCTGCA	SEQ?ID?NO：1830	WBC010B02_V1.3_at	GTAGTCAGTGCATTATTTTGCCTCA	SEQ?ID?NO：1829
WBC010B02_V1.3_at	ATTTTGCCTCAGCTATTATCCTGCA	SEQ?ID?NO：1830	WBC010B02_V1.3_at	GAGGGCATACATCTTGTGGACGATA	SEQ?ID?NO：1831
WBC010C05_V1.3_at	TGGTCACAGCCTCCATAAAACTGGT	SEQ?ID?NO：1832	WBC010B02_V1.3_at	GAGGGCATACATCTTGTGGACGATA	SEQ?ID?NO：1831
WBC010C05_V1.3_at	TGGTCACAGCCTCCATAAAACTGGT	SEQ?ID?NO：1832	WBC010C05_V1.3_at	AACTGGTAGGTTTTGCTCAACATAC	SEQ?ID?NO：1833
WBC010C05_V1.3_at	TATTTGTGAGCAATGGCCTCGCCTA	SEQ?ID?NO：1834	WBC010C05_V1.3_at	AACTGGTAGGTTTTGCTCAACATAC	SEQ?ID?NO：1833
WBC010C05_V1.3_at	TATTTGTGAGCAATGGCCTCGCCTA	SEQ?ID?NO：1834	WBC010C05_V1.3_at	TCGCCTACGTGTTAGCACATGTCGA	SEQ?ID?NO：1835
WBC010C05_V1.3_at	GGGTACTTCGATACACATGGCTAAA	SEQ?ID?NO：1836	WBC010C05_V1.3_at	TCGCCTACGTGTTAGCACATGTCGA	SEQ?ID?NO：1835
WBC010C05_V1.3_at	GGGTACTTCGATACACATGGCTAAA	SEQ?ID?NO：1836	WBC010C05_V1.3_at	AACACTTTTGTATGTCTTTCTGAAA	SEQ?ID?NO：1837
WBC010C05_V1.3_at	GAAGTAAAATGTCAGCCTCTCTCCT	SEQ?ID?NO：1838	WBC010C05_V1.3_at	AACACTTTTGTATGTCTTTCTGAAA	SEQ?ID?NO：1837
WBC010C05_V1.3_at	GAAGTAAAATGTCAGCCTCTCTCCT	SEQ?ID?NO：1838	WBC010C05_V1.3_at	GCTGCTGGCTTTTAACTTCTTTGTA	SEQ?ID?NO：1839
WBC010C05_V1.3_at	GGCTATTTTATCGTTTTCTCATTGT	SEQ?ID?NO：1840	WBC010C05_V1.3_at	GCTGCTGGCTTTTAACTTCTTTGTA	SEQ?ID?NO：1839
WBC010C05_V1.3_at	GGCTATTTTATCGTTTTCTCATTGT	SEQ?ID?NO：1840	WBC010C05_V1.3_at	TAATGAGTAACTTCTCCCACTGTGT	SEQ?ID?NO：1841
WBC010C05_V1.3_at	GGATCGTCTTTACTGTTTTACTCTC	SEQ?ID?NO：1842	WBC010C05_V1.3_at	TAATGAGTAACTTCTCCCACTGTGT	SEQ?ID?NO：1841
WBC010C05_V1.3_at	GGATCGTCTTTACTGTTTTACTCTC	SEQ?ID?NO：1842	WBC012F12_V1.3_at	TTGGTTTGTTTCTACTTTCCTGCTA	SEQ?ID?NO：1843
WBC012F12_V1.3_at	ATATTTCCATTTCTCTCGTGTGTAC	SEQ?ID?NO：1844	WBC012F12_V1.3_at	TTGGTTTGTTTCTACTTTCCTGCTA	SEQ?ID?NO：1843
WBC012F12_V1.3_at	ATATTTCCATTTCTCTCGTGTGTAC	SEQ?ID?NO：1844	WBC012F12_V1.3_at	CTTCCTCCTAACTTTGCATATCAAA	SEQ?ID?NO：1845
WBC012F12_V1.3_at	GGAACTCAGATTCAGTGCTACTTCT	SEQ?ID?NO：1846	WBC012F12_V1.3_at	CTTCCTCCTAACTTTGCATATCAAA	SEQ?ID?NO：1845
WBC012F12_V1.3_at	GGAACTCAGATTCAGTGCTACTTCT	SEQ?ID?NO：1846	WBC012F12_V1.3_at	ACTTCTATAGTGTTCTGCCATCTCA	SEQ?ID?NO：1847
WBC012F12_V1.3_at	AGTACTCCCAGTGTTGAGTGCCTCA	SEQ?ID?NO：1848	WBC012F12_V1.3_at	ACTTCTATAGTGTTCTGCCATCTCA	SEQ?ID?NO：1847
WBC012F12_V1.3_at	AGTACTCCCAGTGTTGAGTGCCTCA	SEQ?ID?NO：1848	WBC012F12_V1.3_at	GAGTGCCTCAGTATTGCGCTTACCA	SEQ?ID?NO：1849
WBC012F12_V1.3_at	TACCAGTTTGCCCTGGAGCTGTTAT	SEQ?ID?NO：1850	WBC012F12_V1.3_at	GAGTGCCTCAGTATTGCGCTTACCA	SEQ?ID?NO：1849
WBC012F12_V1.3_at	TACCAGTTTGCCCTGGAGCTGTTAT	SEQ?ID?NO：1850	WBC012F12_V1.3_at	TTCTCCTCCTACTGTGAATTTCTGG	SEQ?ID?NO：1851
WBC012F12_V1.3_at	AGGCTCTCATTTTTGTCTGTCCCAA	SEQ?ID?NO：1852	WBC012F12_V1.3_at	TTCTCCTCCTACTGTGAATTTCTGG	SEQ?ID?NO：1851
WBC012F12_V1.3_at	AGGCTCTCATTTTTGTCTGTCCCAA	SEQ?ID?NO：1852	WBC012F12_V1.3_at	GGAACTCTGTAAGTCCTTTCGAACG	SEQ?ID?NO：1853
WBC013G08_V1.3_at	TAGAGGGTATCAATGCCTGGCCCAT	SEQ?ID?NO：1854	WBC012F12_V1.3_at	GGAACTCTGTAAGTCCTTTCGAACG	SEQ?ID?NO：1853
WBC013G08_V1.3_at	TAGAGGGTATCAATGCCTGGCCCAT	SEQ?ID?NO：1854	WBC013G08_V1.3_at	AATGCCTGGCCCATGTTACATAGAA	SEQ?ID?NO：1855
WBC013G08_V1.3_at	AGGCATGTACACTTTGATATAGCAG	SEQ?ID?NO：1856	WBC013G08_V1.3_at	AATGCCTGGCCCATGTTACATAGAA	SEQ?ID?NO：1855
WBC013G08_V1.3_at	AGGCATGTACACTTTGATATAGCAG	SEQ?ID?NO：1856	WBC013G08_V1.3_at	GATATAGCAGGTTCACCTTAGGAAA	SEQ?ID?NO：1857
WBC013G08_V1.3_at	GTTCAGGCATTGCTTTAAACGATGA	SEQ?ID?NO：1858	WBC013G08_V1.3_at	GATATAGCAGGTTCACCTTAGGAAA	SEQ?ID?NO：1857
WBC013G08_V1.3_at	GTTCAGGCATTGCTTTAAACGATGA	SEQ?ID?NO：1858	WBC013G08_V1.3_at	TGAATTTAACACATCCATATACTGG	SEQ?ID?NO：1859
WBC013G08_V1.3_at	GGAAGACTATGTAGCCAGCAAGTAA	SEQ?ID?NO：1860	WBC013G08_V1.3_at	TGAATTTAACACATCCATATACTGG	SEQ?ID?NO：1859
WBC013G08_V1.3_at	GGAAGACTATGTAGCCAGCAAGTAA	SEQ?ID?NO：1860	WBC013G08_V1.3_at	AGTAAATTGACAGTGGAGCTCCATT	SEQ?ID?NO：1861
WBC013G08_V1.3_at	CAGTGGAGCTCCATTTTACAAATGT	SEQ?ID?NO：1862	WBC013G08_V1.3_at	AGTAAATTGACAGTGGAGCTCCATT	SEQ?ID?NO：1861
WBC013G08_V1.3_at	CAGTGGAGCTCCATTTTACAAATGT	SEQ?ID?NO：1862	WBC013G08_V1.3_at	GTGCAGTCTTACATGTGTACACATA	SEQ?ID?NO：1863
WBC013G08_V1.3_at	GAATACGTCTGGAATGATCCATTAG	SEQ?ID?NO：1864	WBC013G08_V1.3_at	GTGCAGTCTTACATGTGTACACATA	SEQ?ID?NO：1863
WBC013G08_V1.3_at	GAATACGTCTGGAATGATCCATTAG	SEQ?ID?NO：1864	WBC016C12_V1.3_at	GTTCTCTTATGGTCCTACTTCTAAA	SEQ?ID?NO：1865

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC016C12_V1.3_at	GCTTTATGTTAACTGTGAGGCCGCA	SEQ?ID?NO：1866
WBC016C12_V1.3_at	TGAGGCCGCATGTGTCCGTCACTGG	SEQ?ID?NO：1867	WBC016C12_V1.3_at	GCTTTATGTTAACTGTGAGGCCGCA	SEQ?ID?NO：1866
WBC016C12_V1.3_at	TGAGGCCGCATGTGTCCGTCACTGG	SEQ?ID?NO：1867	WBC016C12_V1.3_at	AGGCTGTCCCAGTGTTAATTGTATT	SEQ?ID?NO：1868
WBC016C12_V1.3_at	TTTACAGCAGGCCTACTAGACCAGC	SEQ?ID?NO：1869	WBC016C12_V1.3_at	AGGCTGTCCCAGTGTTAATTGTATT	SEQ?ID?NO：1868
WBC016C12_V1.3_at	TTTACAGCAGGCCTACTAGACCAGC	SEQ?ID?NO：1869	WBC016C12_V1.3_at	TAGACCAGCAGGAAGCATCGCACAT	SEQ?ID?NO：1870
WBC016C12_V1.3_at	GCATCGCACATGTCACATTGCACAT	SEQ?ID?NO：1871	WBC016C12_V1.3_at	TAGACCAGCAGGAAGCATCGCACAT	SEQ?ID?NO：1870
WBC016C12_V1.3_at	GCATCGCACATGTCACATTGCACAT	SEQ?ID?NO：1871	WBC016C12_V1.3_at	TTGCACATGGGAGCTCAGGTCCTGA	SEQ?ID?NO：1872
WBC016C12_V1.3_at	GTCCTGAAGTCAGGCTTCTGTCTGT	SEQ?ID?NO：1873	WBC016C12_V1.3_at	TTGCACATGGGAGCTCAGGTCCTGA	SEQ?ID?NO：1872
WBC016C12_V1.3_at	GTCCTGAAGTCAGGCTTCTGTCTGT	SEQ?ID?NO：1873	WBC016C12_V1.3_at	CTCTGCTGCCTGTGTTAATATTTCT	SEQ?ID?NO：1874
WBC016C12_V1.3_at	TAAACTCTTACCTACGATTACTGTG	SEQ?ID?NO：1875	WBC016C12_V1.3_at	CTCTGCTGCCTGTGTTAATATTTCT	SEQ?ID?NO：1874
WBC016C12_V1.3_at	TAAACTCTTACCTACGATTACTGTG	SEQ?ID?NO：1875	WBC020C09_V1.3_at	AAAGCCATTCCAGCATGTGTGTCCT	SEQ?ID?NO：1876
WBC020C09_V1.3_at	GTGCTGCCTCTAATCTAAGCTGGGT	SEQ?ID?NO：1877	WBC020C09_V1.3_at	AAAGCCATTCCAGCATGTGTGTCCT	SEQ?ID?NO：1876
WBC020C09_V1.3_at	GTGCTGCCTCTAATCTAAGCTGGGT	SEQ?ID?NO：1877	WBC020C09_V1.3_at	AAGCGACCCTCGAGATTCTGATGAC	SEQ?ID?NO：1878
WBC020C09_V1.3_at	GATGACAGTTTTGCCACTGAGCCGT	SEQ?ID?NO：1879	WBC020C09_V1.3_at	AAGCGACCCTCGAGATTCTGATGAC	SEQ?ID?NO：1878
WBC020C09_V1.3_at	GATGACAGTTTTGCCACTGAGCCGT	SEQ?ID?NO：1879	WBC020C09_V1.3_at	GTGAGGCCTGGGACAAGTATTTTCT	SEQ?ID?NO：1880
WBC020C09_V1.3_at	AGTATTTTCTTCTCTGCTTCAGTTT	SEQ?ID?NO：1881	WBC020C09_V1.3_at	GTGAGGCCTGGGACAAGTATTTTCT	SEQ?ID?NO：1880
WBC020C09_V1.3_at	AGTATTTTCTTCTCTGCTTCAGTTT	SEQ?ID?NO：1881	WBC020C09_V1.3_at	GTTTTCCTGAGTACAGTGTCACCAT	SEQ?ID?NO：1882
WBC020C09_V1.3_at	ATATCACACTAGAGACAGCCCCTTG	SEQ?ID?NO：1883	WBC020C09_V1.3_at	GTTTTCCTGAGTACAGTGTCACCAT	SEQ?ID?NO：1882
WBC020C09_V1.3_at	ATATCACACTAGAGACAGCCCCTTG	SEQ?ID?NO：1883	WBC020C09_V1.3_at	GACAGCCCCTTGTAAAGATCGTGTG	SEQ?ID?NO：1884
WBC020C09_V1.3_at	GAAGGGCTACATGATGCTCCTCTGC	SEQ?ID?NO：1885	WBC020C09_V1.3_at	GACAGCCCCTTGTAAAGATCGTGTG	SEQ?ID?NO：1884
WBC020C09_V1.3_at	GAAGGGCTACATGATGCTCCTCTGC	SEQ?ID?NO：1885	WBC020C09_V1.3_at	ACACACTCTCCTGGGTGTAGCTGGA	SEQ?ID?NO：1886
WBC021A01_V1.3_at	TGTCCACGTCACTGAGTGCTGTGAG	SEQ?ID?NO：1887	WBC020C09_V1.3_at	ACACACTCTCCTGGGTGTAGCTGGA	SEQ?ID?NO：1886
WBC021A01_V1.3_at	TGTCCACGTCACTGAGTGCTGTGAG	SEQ?ID?NO：1887	WBC021A01_V1.3_at	GAGAGCCCAGAGGACACTCACGTAT	SEQ?ID?NO：1888
WBC021A01_V1.3_at	ACTCACGTATTCAGGTGCCCATTTT	SEQ?ID?NO：1889	WBC021A01_V1.3_at	GAGAGCCCAGAGGACACTCACGTAT	SEQ?ID?NO：1888
WBC021A01_V1.3_at	ACTCACGTATTCAGGTGCCCATTTT	SEQ?ID?NO：1889	WBC021A01_V1.3_at	AGATAAAAGCATGCCCTTTCCTGTC	SEQ?ID?NO：1890
WBC021A01_V1.3_at	GGTGCAGTTCCATCCATTCTGAATG	SEQ?ID?NO：1891	WBC021A01_V1.3_at	AGATAAAAGCATGCCCTTTCCTGTC	SEQ?ID?NO：1890
WBC021A01_V1.3_at	GGTGCAGTTCCATCCATTCTGAATG	SEQ?ID?NO：1891	WBC021A01_V1.3_at	AAAAGTGGAGCCTGCCAGTGCTTTC	SEQ?ID?NO：1892
WBC021A01_V1.3_at	ATTTCACTGTCGTGGCTGGATAGCA	SEQ?ID?NO：1893	WBC021A01_V1.3_at	AAAAGTGGAGCCTGCCAGTGCTTTC	SEQ?ID?NO：1892
WBC021A01_V1.3_at	ATTTCACTGTCGTGGCTGGATAGCA	SEQ?ID?NO：1893	WBC021A01_V1.3_at	GAGGGCACCATGTAGTCCTGACGCA	SEQ?ID?NO：1894
WBC021A01_V1.3_at	GACGCAGTCCTGTGTGATTCCGTGA	SEQ?ID?NO：1895	WBC021A01_V1.3_at	GAGGGCACCATGTAGTCCTGACGCA	SEQ?ID?NO：1894
WBC021A01_V1.3_at	GACGCAGTCCTGTGTGATTCCGTGA	SEQ?ID?NO：1895	WBC021A01_V1.3_at	TTTCTGTAACTGTCCTTCCAAACCA	SEQ?ID?NO：1896
WBC021A01_V1.3_at	TCTCACCAATGGTTGCTGTTACAGT	SEQ?ID?NO：1897	WBC021A01_V1.3_at	TTTCTGTAACTGTCCTTCCAAACCA	SEQ?ID?NO：1896
WBC021A01_V1.3_at	TCTCACCAATGGTTGCTGTTACAGT	SEQ?ID?NO：1897	WBC022G05_V1.3_at	ACGTCAGTCTAATAGCACCTGTCAT	SEQ?ID?NO：1898
WBC022G05_V1.3_at	CACCTGTCATCTTTTCTGCTTAGAA	SEQ?ID?NO：1899	WBC022G05_V1.3_at	ACGTCAGTCTAATAGCACCTGTCAT	SEQ?ID?NO：1898
WBC022G05_V1.3_at	CACCTGTCATCTTTTCTGCTTAGAA	SEQ?ID?NO：1899	WBC022G05_V1.3_at	TTAGAACCGCTTATCTCGAAACGAT	SEQ?ID?NO：1900
WBC022G05_V1.3_at	TGAAATCATGTCTTGCACCCTTGAG	SEQ?ID?NO：1901	WBC022G05_V1.3_at	TTAGAACCGCTTATCTCGAAACGAT	SEQ?ID?NO：1900
WBC022G05_V1.3_at	TGAAATCATGTCTTGCACCCTTGAG	SEQ?ID?NO：1901	WBC022G05_V1.3_at	GTTTAGTCTCTGAATACCTTCTCCA	SEQ?ID?NO：1902
WBC022G05_V1.3_at	GGGACACATTCATTGAACCACTCAT	SEQ?ID?NO：1903	WBC022G05_V1.3_at	GTTTAGTCTCTGAATACCTTCTCCA	SEQ?ID?NO：1902
WBC022G05_V1.3_at	GGGACACATTCATTGAACCACTCAT	SEQ?ID?NO：1903	WBC022G05_V1.3_at	AACCACTCATGGCACATCTTAGAAG	SEQ?ID?NO：1904
WBC022G05_V1.3_at	GCACATTCATATCATAGGGAGCCGA	SEQ?ID?NO：1905	WBC022G05_V1.3_at	AACCACTCATGGCACATCTTAGAAG	SEQ?ID?NO：1904
WBC022G05_V1.3_at	GCACATTCATATCATAGGGAGCCGA	SEQ?ID?NO：1905	WBC022G05_V1.3_at	GGAGCCGACTGGTTCTCTTATTAGT	SEQ?ID?NO：1906
WBC022G05_V1.3_at	GTGTACTATCAGAGTGTGCTTTCGC	SEQ?ID?NO：1907	WBC022G05_V1.3_at	GGAGCCGACTGGTTCTCTTATTAGT	SEQ?ID?NO：1906
WBC022G05_V1.3_at	GTGTACTATCAGAGTGTGCTTTCGC	SEQ?ID?NO：1907	WBC022G05_V1.3_at	TGTGCTTTCGCTCATCTGGATATAC	SEQ?ID?NO：1908
WBC024D07_V1.3_at	AAGCAGCGGGACAAGGTGTCTTCTA	SEQ?ID?NO：1909	WBC022G05_V1.3_at	TGTGCTTTCGCTCATCTGGATATAC	SEQ?ID?NO：1908
WBC024D07_V1.3_at	AAGCAGCGGGACAAGGTGTCTTCTA	SEQ?ID?NO：1909	WBC024D07_V1.3_at	AATTCACTTGAGTCCTATGCATTCA	SEQ?ID?NO：1910

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC024D07_V1.3_at	GGCTTGACAAGAACCAGACTGCAGA	SEQ?ID?NO：1911
WBC024D07_V1.3_at	GGAGAAAGTTTGCAACCCCATCATT	SEQ?ID?NO：1912	WBC024D07_V1.3_at	GGCTTGACAAGAACCAGACTGCAGA	SEQ?ID?NO：1911
WBC024D07_V1.3_at	GGAGAAAGTTTGCAACCCCATCATT	SEQ?ID?NO：1912	WBC024D07_V1.3_at	ATTACCAAGCTGTACCAGAGTGCAG	SEQ?ID?NO：1913
WBC024D07_V1.3_at	GGTTTCCCTGGTGGTGGAGCTCCTC	SEQ?ID?NO：1914	WBC024D07_V1.3_at	ATTACCAAGCTGTACCAGAGTGCAG	SEQ?ID?NO：1913
WBC024D07_V1.3_at	GGTTTCCCTGGTGGTGGAGCTCCTC	SEQ?ID?NO：1914	WBC024D07_V1.3_at	GGTGGATTAAGCCAACCCGAGCATA	SEQ?ID?NO：1915
WBC024D07_V1.3_at	GCATAGATTTAGCATTGTTCCACAT	SEQ?ID?NO：1916	WBC024D07_V1.3_at	GGTGGATTAAGCCAACCCGAGCATA	SEQ?ID?NO：1915
WBC024D07_V1.3_at	GCATAGATTTAGCATTGTTCCACAT	SEQ?ID?NO：1916	WBC024D07_V1.3_at	TTTGTAGCAAATTCCATGGCAGTTT	SEQ?ID?NO：1917
WBC024D07_V1.3_at	ATAACTGGGCATTCTTGATACTTGA	SEQ?ID?NO：1918	WBC024D07_V1.3_at	TTTGTAGCAAATTCCATGGCAGTTT	SEQ?ID?NO：1917
WBC024D07_V1.3_at	ATAACTGGGCATTCTTGATACTTGA	SEQ?ID?NO：1918	WBC024D07_V1.3_at	GCACTTTATAGGCACTGTATTGTAA	SEQ?ID?NO：1919
WBC024E03_V1.3_at	GCTAAAGGCAAATTCTCTCTCTTGA	SEQ?ID?NO：1920	WBC024D07_V1.3_at	GCACTTTATAGGCACTGTATTGTAA	SEQ?ID?NO：1919
WBC024E03_V1.3_at	GCTAAAGGCAAATTCTCTCTCTTGA	SEQ?ID?NO：1920	WBC024E03_V1.3_at	GCTTTTCTGTTTGTTATGGGTTTAT	SEQ?ID?NO：1921
WBC024E03_V1.3_at	GAAGTACCTTTTCCAAATTCATGAG	SEQ?ID?NO：1922	WBC024E03_V1.3_at	GCTTTTCTGTTTGTTATGGGTTTAT	SEQ?ID?NO：1921
WBC024E03_V1.3_at	GAAGTACCTTTTCCAAATTCATGAG	SEQ?ID?NO：1922	WBC024E03_V1.3_at	CACAGCTGAATATATTCGGCCTTCA	SEQ?ID?NO：1923
WBC024E03_V1.3_at	TCGGCCTTCAACATGGTCACTAGTA	SEQ?ID?NO：1924	WBC024E03_V1.3_at	CACAGCTGAATATATTCGGCCTTCA	SEQ?ID?NO：1923
WBC024E03_V1.3_at	TCGGCCTTCAACATGGTCACTAGTA	SEQ?ID?NO：1924	WBC024E03_V1.3_at	AATTGTCTTCACAGTTCTCTCAAGG	SEQ?ID?NO：1925
WBC024E03_V1.3_at	GTTCTCTCAAGGGAGCCAGGCTATT	SEQ?ID?NO：1926	WBC024E03_V1.3_at	AATTGTCTTCACAGTTCTCTCAAGG	SEQ?ID?NO：1925
WBC024E03_V1.3_at	GTTCTCTCAAGGGAGCCAGGCTATT	SEQ?ID?NO：1926	WBC024E03_V1.3_at	TGACAACAGCTCTCTCAAGGCAAAT	SEQ?ID?NO：1927
WBC024E03_V1.3_at	CAAGGCAAATCCTCTTATTTTCCAA	SEQ?ID?NO：1928	WBC024E03_V1.3_at	TGACAACAGCTCTCTCAAGGCAAAT	SEQ?ID?NO：1927
WBC024E03_V1.3_at	CAAGGCAAATCCTCTTATTTTCCAA	SEQ?ID?NO：1928	WBC024E03_V1.3_at	GTGACCGACAAATCATTAACCAGAA	SEQ?ID?NO：1929
WBC024E03_V1.3_at	GAAAACTTGGCTGTGTAACTGCATT	SEQ?ID?NO：1930	WBC024E03_V1.3_at	GTGACCGACAAATCATTAACCAGAA	SEQ?ID?NO：1929
WBC024E03_V1.3_at	GAAAACTTGGCTGTGTAACTGCATT	SEQ?ID?NO：1930	WBC026C03_V1.3_at	GTAGTGGTATCTCATTGTAGTCTTA	SEQ?ID?NO：1931
WBC026C03_V1.3_at	GTAGTCTTAATTTGCGTTTCCTCAG	SEQ?ID?NO：1932	WBC026C03_V1.3_at	GTAGTGGTATCTCATTGTAGTCTTA	SEQ?ID?NO：1931
WBC026C03_V1.3_at	GTAGTCTTAATTTGCGTTTCCTCAG	SEQ?ID?NO：1932	WBC026C03_V1.3_at	TATGTTCTGTCTTTTTATGTGCTTA	SEQ?ID?NO：1933
WBC026C03_V1.3_at	TATGTGCTTATTTGCCGCCCATGTA	SEQ?ID?NO：1934	WBC026C03_V1.3_at	TATGTTCTGTCTTTTTATGTGCTTA	SEQ?ID?NO：1933
WBC026C03_V1.3_at	TATGTGCTTATTTGCCGCCCATGTA	SEQ?ID?NO：1934	WBC026C03_V1.3_at	ATGTATCTCTTTCTGCCTATTTTTG	SEQ?ID?NO：1935
WBC026C03_V1.3_at	GAGTACTAGATCTTTAGCAGCTATG	SEQ?ID?NO：1936	WBC026C03_V1.3_at	ATGTATCTCTTTCTGCCTATTTTTG	SEQ?ID?NO：1935
WBC026C03_V1.3_at	GAGTACTAGATCTTTAGCAGCTATG	SEQ?ID?NO：1936	WBC026C03_V1.3_at	AAGTCCCAATCTATAGCTTGCCTTT	SEQ?ID?NO：1937
WBC026C03_V1.3_at	GCTTGCCTTTTCATGCTTTCAGGGA	SEQ?ID?NO：1938	WBC026C03_V1.3_at	AAGTCCCAATCTATAGCTTGCCTTT	SEQ?ID?NO：1937
WBC026C03_V1.3_at	GCTTGCCTTTTCATGCTTTCAGGGA	SEQ?ID?NO：1938	WBC026C03_V1.3_at	GAAATCTTTGCCTAAACCAACATCA	SEQ?ID?NO：1939
WBC026C03_V1.3_at	GATTTTCTCTTGTGTTTTCTTCTAG	SEQ?ID?NO：1940	WBC026C03_V1.3_at	GAAATCTTTGCCTAAACCAACATCA	SEQ?ID?NO：1939
WBC026C03_V1.3_at	GATTTTCTCTTGTGTTTTCTTCTAG	SEQ?ID?NO：1940	WBC026C03_V1.3_at	TATCCAATTGTTCCATACTGTTTGT	SEQ?ID?NO：1941
WBC028A02_V1.3_at	AAGGTGGCCACCTATTTTATTGTGA	SEQ?ID?NO：1942	WBC026C03_V1.3_at	TATCCAATTGTTCCATACTGTTTGT	SEQ?ID?NO：1941
WBC028A02_V1.3_at	AAGGTGGCCACCTATTTTATTGTGA	SEQ?ID?NO：1942	WBC028A02_V1.3_at	TTTATTGTGAGCTCTTCCTAGGAAG	SEQ?ID?NO：1943
WBC028A02_V1.3_at	GGAAGGCTCCTATTTCAGCAGTTTG	SEQ?ID?NO：1944	WBC028A02_V1.3_at	TTTATTGTGAGCTCTTCCTAGGAAG	SEQ?ID?NO：1943
WBC028A02_V1.3_at	GGAAGGCTCCTATTTCAGCAGTTTG	SEQ?ID?NO：1944	WBC028A02_V1.3_at	CAGCAGTTTGGTCTGGCTAACTTTA	SEQ?ID?NO：1945
WBC028A02_V1.3_at	TAAGCTGACGTTGGCAGGCATTCAA	SEQ?ID?NO：1946	WBC028A02_V1.3_at	CAGCAGTTTGGTCTGGCTAACTTTA	SEQ?ID?NO：1945
WBC028A02_V1.3_at	TAAGCTGACGTTGGCAGGCATTCAA	SEQ?ID?NO：1946	WBC028A02_V1.3_at	GGCATTCAAATTCATGTCTCCTTGG	SEQ?ID?NO：1947
WBC028A02_V1.3_at	GGGCCAATCTGTTCTATTTTGTGCC	SEQ?ID?NO：1948	WBC028A02_V1.3_at	GGCATTCAAATTCATGTCTCCTTGG	SEQ?ID?NO：1947
WBC028A02_V1.3_at	GGGCCAATCTGTTCTATTTTGTGCC	SEQ?ID?NO：1948	WBC028A02_V1.3_at	AACTTAGCTGTCTCATCCCAAAAAT	SEQ?ID?NO：1949
WBC028A02_V1.3_at	GTGGTTAAGTTTAGTGCACTCCCCT	SEQ?ID?NO：1950	WBC028A02_V1.3_at	AACTTAGCTGTCTCATCCCAAAAAT	SEQ?ID?NO：1949
WBC028A02_V1.3_at	GTGGTTAAGTTTAGTGCACTCCCCT	SEQ?ID?NO：1950	WBC028A02_V1.3_at	GTGACCCGGGTTCACAGATTTGGAT	SEQ?ID?NO：1951
WBC028A02_V1.3_at	GGATCCTGGATGCAGACCTAGGCCA	SEQ?ID?NO：1952	WBC028A02_V1.3_at	GTGACCCGGGTTCACAGATTTGGAT	SEQ?ID?NO：1951
WBC028A02_V1.3_at	GGATCCTGGATGCAGACCTAGGCCA	SEQ?ID?NO：1952	WBC028D07_V1.3_at	AAGACGTGGCTGATGCGCTTCTCCG	SEQ?ID?NO：1953
WBC028D07_V1.3_at	GGACTGACCAGTCACTCTCAGAAAA	SEQ?ID?NO：1954	WBC028D07_V1.3_at	AAGACGTGGCTGATGCGCTTCTCCG	SEQ?ID?NO：1953
WBC028D07_V1.3_at	GGACTGACCAGTCACTCTCAGAAAA	SEQ?ID?NO：1954	WBC028D07_V1.3_at	AAAGGCTGAATCTGCAGAAGCTGCA	SEQ?ID?NO：1955

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC028D07_V1.3_at	ATAGGGCCCAGCTGCTGGCAGAGCA	SEQ?ID?NO：1956
WBC028D07_V1.3_at	GACTCTCGCTCTTAAACTTCAGGAA	SEQ?ID?NO：1957	WBC028D07_V1.3_at	ATAGGGCCCAGCTGCTGGCAGAGCA	SEQ?ID?NO：1956
WBC028D07_V1.3_at	GACTCTCGCTCTTAAACTTCAGGAA	SEQ?ID?NO：1957	WBC028D07_V1.3_at	GGAACAGGAACGACTTCTCAAGGAA	SEQ?ID?NO：1958
WBC028D07_V1.3_at	GCAGGAGATGCAGGCTATCCGAATG	SEQ?ID?NO：1959	WBC028D07_V1.3_at	GGAACAGGAACGACTTCTCAAGGAA	SEQ?ID?NO：1958
WBC028D07_V1.3_at	GCAGGAGATGCAGGCTATCCGAATG	SEQ?ID?NO：1959	WBC028D07_V1.3_at	AGCACCAGCTGGAGTATGTAACATA	SEQ?ID?NO：1960
WBC028D07_V1.3_at	ATGTAATTTCCTAACCATCTCTCCT	SEQ?ID?NO：1961	WBC028D07_V1.3_at	AGCACCAGCTGGAGTATGTAACATA	SEQ?ID?NO：1960
WBC028D07_V1.3_at	ATGTAATTTCCTAACCATCTCTCCT	SEQ?ID?NO：1961	WBC028D07_V1.3_at	TCTCTCCTCCACAAGCAATAAGCTG	SEQ?ID?NO：1962
WBC028D07_V1.3_at	GATGCTTCCATTTTTGTTGAGCTAT	SEQ?ID?NO：1963	WBC028D07_V1.3_at	TCTCTCCTCCACAAGCAATAAGCTG	SEQ?ID?NO：1962
WBC028D07_V1.3_at	GATGCTTCCATTTTTGTTGAGCTAT	SEQ?ID?NO：1963	WBC029A01_V1.3_at	ATGTGTTCATAAGTGCCAACCGACT	SEQ?ID?NO：1964
WBC029A01_V1.3_at	GCCAACCGACTAATTCATCAAACCA	SEQ?ID?NO：1965	WBC029A01_V1.3_at	ATGTGTTCATAAGTGCCAACCGACT	SEQ?ID?NO：1964
WBC029A01_V1.3_at	GCCAACCGACTAATTCATCAAACCA	SEQ?ID?NO：1965	WBC029A01_V1.3_at	AAACCAACTTGATACTTCAGACCTT	SEQ?ID?NO：1966
WBC029A01_V1.3_at	CAGACCTTCAAAACTGTGGCCTGAA	SEQ?ID?NO：1967	WBC029A01_V1.3_at	AAACCAACTTGATACTTCAGACCTT	SEQ?ID?NO：1966
WBC029A01_V1.3_at	CAGACCTTCAAAACTGTGGCCTGAA	SEQ?ID?NO：1967	WBC029A01_V1.3_at	GAGATGTACTCTCAGTGGCAGTATT	SEQ?ID?NO：1968
WBC029A01_V1.3_at	GTATTGAACTGCCTTATCTGTAAAT	SEQ?ID?NO：1969	WBC029A01_V1.3_at	GAGATGTACTCTCAGTGGCAGTATT	SEQ?ID?NO：1968
WBC029A01_V1.3_at	GTATTGAACTGCCTTATCTGTAAAT	SEQ?ID?NO：1969	WBC029A01_V1.3_at	TGTATAAATTATCCGTCCCTCCTGA	SEQ?ID?NO：1970
WBC029A01_V1.3_at	GGGATTATTGCCATCTTACACCATA	SEQ?ID?NO：1971	WBC029A01_V1.3_at	TGTATAAATTATCCGTCCCTCCTGA	SEQ?ID?NO：1970
WBC029A01_V1.3_at	GGGATTATTGCCATCTTACACCATA	SEQ?ID?NO：1971	WBC029A01_V1.3_at	GTAGCTTAATCATAATCTCACACTG	SEQ?ID?NO：1972
WBC029A01_V1.3_at	GAAGATTTTGCATCACTTTTGCTAT	SEQ?ID?NO：1973	WBC029A01_V1.3_at	GTAGCTTAATCATAATCTCACACTG	SEQ?ID?NO：1972
WBC029A01_V1.3_at	GAAGATTTTGCATCACTTTTGCTAT	SEQ?ID?NO：1973	WBC029A01_V1.3_at	GAATTTACGCCTTAATGTGTCATTA	SEQ?ID?NO：1974
WBC030G08_V1.3_at	GTGTTTAAAACACCGTCTCAAATCA	SEQ?ID?NO：1975	WBC029A01_V1.3_at	GAATTTACGCCTTAATGTGTCATTA	SEQ?ID?NO：1974
WBC030G08_V1.3_at	GTGTTTAAAACACCGTCTCAAATCA	SEQ?ID?NO：1975	WBC030G08_V1.3_at	ACTTTGAATTAGTCTTTTGGCTCTA	SEQ?ID?NO：1976
WBC030G08_V1.3_at	TTGGCTCTAAATTTGCCACTTGAAT	SEQ?ID?NO：1977	WBC030G08_V1.3_at	ACTTTGAATTAGTCTTTTGGCTCTA	SEQ?ID?NO：1976
WBC030G08_V1.3_at	TTGGCTCTAAATTTGCCACTTGAAT	SEQ?ID?NO：1977	WBC030G08_V1.3_at	GTTCACCTTATTCTATACCAGGGCT	SEQ?ID?NO：1978
WBC030G08_V1.3_at	TACCAGGGCTGGCTATTCAGATGAT	SEQ?ID?NO：1979	WBC030G08_V1.3_at	GTTCACCTTATTCTATACCAGGGCT	SEQ?ID?NO：1978
WBC030G08_V1.3_at	TACCAGGGCTGGCTATTCAGATGAT	SEQ?ID?NO：1979	WBC030G08_V1.3_at	AATGCCATGTGCCAATACTTTTCAA	SEQ?ID?NO：1980
WBC030G08_V1.3_at	GCCAATACTTTTCAAGGTGCCTTTG	SEQ?ID?NO：1981	WBC030G08_V1.3_at	AATGCCATGTGCCAATACTTTTCAA	SEQ?ID?NO：1980
WBC030G08_V1.3_at	GCCAATACTTTTCAAGGTGCCTTTG	SEQ?ID?NO：1981	WBC030G08_V1.3_at	AACGCTCGAGAACTTAACACTTATT	SEQ?ID?NO：1982
WBC030G08_V1.3_at	ATGATTTGACTGTATCCTGTACCAA	SEQ?ID?NO：1983	WBC030G08_V1.3_at	AACGCTCGAGAACTTAACACTTATT	SEQ?ID?NO：1982
WBC030G08_V1.3_at	ATGATTTGACTGTATCCTGTACCAA	SEQ?ID?NO：1983	WBC030G08_V1.3_at	GTATCCTGTACCAAGACTACTTACC	SEQ?ID?NO：1984
WBC030G08_V1.3_at	AGACTACTTACCTTGAATACACCAG	SEQ?ID?NO：1985	WBC030G08_V1.3_at	GTATCCTGTACCAAGACTACTTACC	SEQ?ID?NO：1984
WBC030G08_V1.3_at	AGACTACTTACCTTGAATACACCAG	SEQ?ID?NO：1985	WBC031E09_V1.3_at	CCAACAGGTTGGTCTGATGGTCTGA	SEQ?ID?NO：1986
WBC031E09_V1.3_at	AATCTGATGGGCAGGCCTTGCGATT	SEQ?ID?NO：1987	WBC031E09_V1.3_at	CCAACAGGTTGGTCTGATGGTCTGA	SEQ?ID?NO：1986
WBC031E09_V1.3_at	AATCTGATGGGCAGGCCTTGCGATT	SEQ?ID?NO：1987	WBC031E09_V1.3_at	GCATGCCTGCTTACTTAATGACTGA	SEQ?ID?NO：1988
WBC031E09_V1.3_at	AATGACTGAAACTGTGCACTTTTGT	SEQ?ID?NO：1989	WBC031E09_V1.3_at	GCATGCCTGCTTACTTAATGACTGA	SEQ?ID?NO：1988
WBC031E09_V1.3_at	AATGACTGAAACTGTGCACTTTTGT	SEQ?ID?NO：1989	WBC031E09_V1.3_at	GTGCACTTTTGTTCTGACACTGAAT	SEQ?ID?NO：1990
WBC031E09_V1.3_at	ATTTCCTGTTCCATAATAGTAGTTA	SEQ?ID?NO：1991	WBC031E09_V1.3_at	GTGCACTTTTGTTCTGACACTGAAT	SEQ?ID?NO：1990
WBC031E09_V1.3_at	ATTTCCTGTTCCATAATAGTAGTTA	SEQ?ID?NO：1991	WBC031E09_V1.3_at	AAGTTTTAGCATGTCCTTAGAGGCA	SEQ?ID?NO：1992
WBC031E09_V1.3_at	GGCAAGTATATGCTTCAACACCTAA	SEQ?ID?NO：1993	WBC031E09_V1.3_at	AAGTTTTAGCATGTCCTTAGAGGCA	SEQ?ID?NO：1992
WBC031E09_V1.3_at	GGCAAGTATATGCTTCAACACCTAA	SEQ?ID?NO：1993	WBC031E09_V1.3_at	GGTACCTTCTTTGCTGAATGTGACA	SEQ?ID?NO：1994
WBC031E09_V1.3_at	GTGACAGAATCCATACCAGCTCATG	SEQ?ID?NO：1995	WBC031E09_V1.3_at	GGTACCTTCTTTGCTGAATGTGACA	SEQ?ID?NO：1994
WBC031E09_V1.3_at	GTGACAGAATCCATACCAGCTCATG	SEQ?ID?NO：1995	WBC031E09_V1.3_at	GTTTTCATCTTTACATATGGCACAT	SEQ?ID?NO：1996
WBC032C03_V1.3_at	AAGGATACCATTTTTGGCTCTCCCT	SEQ?ID?NO：1997	WBC031E09_V1.3_at	GTTTTCATCTTTACATATGGCACAT	SEQ?ID?NO：1996
WBC032C03_V1.3_at	AAGGATACCATTTTTGGCTCTCCCT	SEQ?ID?NO：1997	WBC032C03_V1.3_at	AGTACACAGTTTGACCCAGTGGCCA	SEQ?ID?NO：1998
WBC032C03_V1.3_at	AGTGGCCACTGGTTCACAGTACGCC	SEQ?ID?NO：1999	WBC032C03_V1.3_at	AGTACACAGTTTGACCCAGTGGCCA	SEQ?ID?NO：1998
WBC032C03_V1.3_at	AGTGGCCACTGGTTCACAGTACGCC	SEQ?ID?NO：1999	WBC032C03_V1.3_at	TGAAACAGTTTGTTCCCAGGCCGTG	SEQ?ID?NO：2000

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC032C03_V1.3_at	AGAATCCTGGAGTGGCATGCTGACC	SEQ?ID?NO：2001
WBC032C03_V1.3_at	AATGGCTTGCTTCTGCAGAGGATGC	SEQ?ID?NO：2002	WBC032C03_V1.3_at	AGAATCCTGGAGTGGCATGCTGACC	SEQ?ID?NO：2001
WBC032C03_V1.3_at	AATGGCTTGCTTCTGCAGAGGATGC	SEQ?ID?NO：2002	WBC032C03_V1.3_at	TGCCTCCAGCTTCTTGCTTAAGAAC	SEQ?ID?NO：2003
WBC032C03_V1.3_at	AATTTGTTGATTCTCTGCTAGGCCT	SEQ?ID?NO：2004	WBC032C03_V1.3_at	TGCCTCCAGCTTCTTGCTTAAGAAC	SEQ?ID?NO：2003
WBC032C03_V1.3_at	AATTTGTTGATTCTCTGCTAGGCCT	SEQ?ID?NO：2004	WBC032C03_V1.3_at	ATCACTTTCTTTTCTAGTTCCTTGG	SEQ?ID?NO：2005
WBC032C03_V1.3_at	AGTTCCTTGGTTTTCAGCTCAGGCT	SEQ?ID?NO：2006	WBC032C03_V1.3_at	ATCACTTTCTTTTCTAGTTCCTTGG	SEQ?ID?NO：2005
WBC032C03_V1.3_at	AGTTCCTTGGTTTTCAGCTCAGGCT	SEQ?ID?NO：2006	WBC032C03_V1.3_at	AGGCTGCATTCTCTAACTCATACTG	SEQ?ID?NO：2007
WBC032G11_V1.3_at	GAAAATACACCCAAGCTCCAAGGCT	SEQ?ID?NO：2008	WBC032C03_V1.3_at	AGGCTGCATTCTCTAACTCATACTG	SEQ?ID?NO：2007
WBC032G11_V1.3_at	GAAAATACACCCAAGCTCCAAGGCT	SEQ?ID?NO：2008	WBC032G11_V1.3_at	TAATGAGTCACCCATCCAGGAGATC	SEQ?ID?NO：2009
WBC032G11_V1.3_at	GGAGATCCCAACGTACTAGCAAGTA	SEQ?ID?NO：2010	WBC032G11_V1.3_at	TAATGAGTCACCCATCCAGGAGATC	SEQ?ID?NO：2009
WBC032G11_V1.3_at	GGAGATCCCAACGTACTAGCAAGTA	SEQ?ID?NO：2010	WBC032G11_V1.3_at	AGACTGTCCTAAATCCTGATCAATA	SEQ?ID?NO：2011
WBC032G11_V1.3_at	ACATTGTGGGCCTCGAAGTGCTACA	SEQ?ID?NO：2012	WBC032G11_V1.3_at	AGACTGTCCTAAATCCTGATCAATA	SEQ?ID?NO：2011
WBC032G11_V1.3_at	ACATTGTGGGCCTCGAAGTGCTACA	SEQ?ID?NO：2012	WBC032G11_V1.3_at	AGGAGTGCACACATCACCTGGAGAT	SEQ?ID?NO：2013
WBC032G11_V1.3_at	GAACCTGAATCTGATCAAGCCTCTG	SEQ?ID?NO：2014	WBC032G11_V1.3_at	AGGAGTGCACACATCACCTGGAGAT	SEQ?ID?NO：2013
WBC032G11_V1.3_at	GAACCTGAATCTGATCAAGCCTCTG	SEQ?ID?NO：2014	WBC032G11_V1.3_at	AAGCCTCTGGATCTTGCTTCCAATT	SEQ?ID?NO：2015
WBC032G11_V1.3_at	TGCTCCTAAGTAATTCCATGTATGG	SEQ?ID?NO：2016	WBC032G11_V1.3_at	AAGCCTCTGGATCTTGCTTCCAATT	SEQ?ID?NO：2015
WBC032G11_V1.3_at	TGCTCCTAAGTAATTCCATGTATGG	SEQ?ID?NO：2016	WBC032G11_V1.3_at	GTTAATTATACTCCTCTCTTCTTTG	SEQ?ID?NO：2017
WBC032G11_V1.3_at	TCTCTTCTTTGGACTGTGCTTTTGA	SEQ?ID?NO：2018	WBC032G11_V1.3_at	GTTAATTATACTCCTCTCTTCTTTG	SEQ?ID?NO：2017
WBC032G11_V1.3_at	TCTCTTCTTTGGACTGTGCTTTTGA	SEQ?ID?NO：2018	WBC035E08_V1.3_at	GATACTTGGACATCTGCATCTTCAG	SEQ?ID?NO：2019
WBC035E08_V1.3_at	TCAGCTTACAAGATCTACAGTGCAT	SEQ?ID?NO：2020	WBC035E08_V1.3_at	GATACTTGGACATCTGCATCTTCAG	SEQ?ID?NO：2019
WBC035E08_V1.3_at	TCAGCTTACAAGATCTACAGTGCAT	SEQ?ID?NO：2020	WBC035E08_V1.3_at	GATTTCATTCTTTGTTAGCTCACTT	SEQ?ID?NO：2021
WBC035E08_V1.3_at	TGTCAACTCATTACTTTTTCCTGTG	SEQ?ID?NO：2022	WBC035E08_V1.3_at	GATTTCATTCTTTGTTAGCTCACTT	SEQ?ID?NO：2021
WBC035E08_V1.3_at	TGTCAACTCATTACTTTTTCCTGTG	SEQ?ID?NO：2022	WBC035E08_V1.3_at	GAATTAACTGTCTGTCTGCCTTGTC	SEQ?ID?NO：2023
WBC035E08_V1.3_at	CTGCCTTGTCTTAGGGTGTTCTGTA	SEQ?ID?NO：2024	WBC035E08_V1.3_at	GAATTAACTGTCTGTCTGCCTTGTC	SEQ?ID?NO：2023
WBC035E08_V1.3_at	CTGCCTTGTCTTAGGGTGTTCTGTA	SEQ?ID?NO：2024	WBC035E08_V1.3_at	GGTGTTCTGTAGATCGATTGCCGAT	SEQ?ID?NO：2025
WBC035E08_V1.3_at	TCGATTGCCGATTTCTTAAACCTGA	SEQ?ID?NO：2026	WBC035E08_V1.3_at	GGTGTTCTGTAGATCGATTGCCGAT	SEQ?ID?NO：2025
WBC035E08_V1.3_at	TCGATTGCCGATTTCTTAAACCTGA	SEQ?ID?NO：2026	WBC035E08_V1.3_at	AAACCTGAAATGATCTTTACACTGT	SEQ?ID?NO：2027
WBC035E08_V1.3_at	TATTGACACCTTTTACAGATCTTAA	SEQ?ID?NO：2028	WBC035E08_V1.3_at	AAACCTGAAATGATCTTTACACTGT	SEQ?ID?NO：2027
WBC035E08_V1.3_at	TATTGACACCTTTTACAGATCTTAA	SEQ?ID?NO：2028	WBC035E08_V1.3_at	GATCTTAATGTAGCTTTTTCCATAT	SEQ?ID?NO：2029
WBC036C09_V1.3_at	GTTGATCCAGTTTGTCCTTTAGGTT	SEQ?ID?NO：2030	WBC035E08_V1.3_at	GATCTTAATGTAGCTTTTTCCATAT	SEQ?ID?NO：2029
WBC036C09_V1.3_at	GTTGATCCAGTTTGTCCTTTAGGTT	SEQ?ID?NO：2030	WBC036C09_V1.3_at	GAATGTGGCCACAGATGCCTTGCTG	SEQ?ID?NO：2031
WBC036C09_V1.3_at	ATCTGTCCCCTGAAGACTTGTGAGG	SEQ?ID?NO：2032	WBC036C09_V1.3_at	GAATGTGGCCACAGATGCCTTGCTG	SEQ?ID?NO：2031
WBC036C09_V1.3_at	ATCTGTCCCCTGAAGACTTGTGAGG	SEQ?ID?NO：2032	WBC036C09_V1.3_at	GTGAGGTCCTCTTTTGAAAGCCAAA	SEQ?ID?NO：2033
WBC036C09_V1.3_at	AGCTAGGACTTCACATTGCCATTCA	SEQ?ID?NO：2034	WBC036C09_V1.3_at	GTGAGGTCCTCTTTTGAAAGCCAAA	SEQ?ID?NO：2033
WBC036C09_V1.3_at	AGCTAGGACTTCACATTGCCATTCA	SEQ?ID?NO：2034	WBC036C09_V1.3_at	TTGCCATTCAAAACTCTTCTCTCTT	SEQ?ID?NO：2035
WBC036C09_V1.3_at	AGAATGATTGCCTTGCTGGTGTCCT	SEQ?ID?NO：2036	WBC036C09_V1.3_at	TTGCCATTCAAAACTCTTCTCTCTT	SEQ?ID?NO：2035
WBC036C09_V1.3_at	AGAATGATTGCCTTGCTGGTGTCCT	SEQ?ID?NO：2036	WBC036C09_V1.3_at	GAACGGCTTTGACCTGACGGTGCCT	SEQ?ID?NO：2037
WBC036C09_V1.3_at	AGGGAGCTTGTCTCTAGCGGGTTCA	SEQ?ID?NO：2038	WBC036C09_V1.3_at	GAACGGCTTTGACCTGACGGTGCCT	SEQ?ID?NO：2037
WBC036C09_V1.3_at	AGGGAGCTTGTCTCTAGCGGGTTCA	SEQ?ID?NO：2038	WBC036C09_V1.3_at	GTGAACACTTTCCACTTTCTGACAC	SEQ?ID?NO：2039
WBC036C09_V1.3_at	TTCTGACACCTGATCCTGATGTATG	SEQ?ID?NO：2040	WBC036C09_V1.3_at	GTGAACACTTTCCACTTTCTGACAC	SEQ?ID?NO：2039
WBC036C09_V1.3_at	TTCTGACACCTGATCCTGATGTATG	SEQ?ID?NO：2040	WBC041B04_V1.3_at	GTGTTAACCATGAAAGTACTCGAAG	SEQ?ID?NO：2041
WBC041B04_V1.3_at	AAGGGTACATTTCTCCTATGGCCGA	SEQ?ID?NO：2042	WBC041B04_V1.3_at	GTGTTAACCATGAAAGTACTCGAAG	SEQ?ID?NO：2041
WBC041B04_V1.3_at	AAGGGTACATTTCTCCTATGGCCGA	SEQ?ID?NO：2042	WBC041B04_V1.3_at	CTATGGCCGATTTCAGGAATTTCAA	SEQ?ID?NO：2043
WBC041B04_V1.3_at	GAGAATCCTTCAGTTCATTCACAAA	SEQ?ID?NO：2044	WBC041B04_V1.3_at	CTATGGCCGATTTCAGGAATTTCAA	SEQ?ID?NO：2043
WBC041B04_V1.3_at	GAGAATCCTTCAGTTCATTCACAAA	SEQ?ID?NO：2044	WBC041B04_V1.3_at	ATAAAGCCCTGGAGGGCCCTGAGGC	SEQ?ID?NO：2045

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC041B04_V1.3_at	CCTGAGGCTCACTGCTGACTGAGAA	SEQ?ID?NO：2046
WBC041B04_V1.3_at	GACTGAGAACTCTGTGGAACATGAT	SEQ?ID?NO：2047	WBC041B04_V1.3_at	CCTGAGGCTCACTGCTGACTGAGAA	SEQ?ID?NO：2046
WBC041B04_V1.3_at	GACTGAGAACTCTGTGGAACATGAT	SEQ?ID?NO：2047	WBC041B04_V1.3_at	GGAACATGATCCTAGGCACTGAAGT	SEQ?ID?NO：2048
WBC041B04_V1.3_at	GGCACTGAAGTATCGACCACTTTCC	SEQ?ID?NO：2049	WBC041B04_V1.3_at	GGAACATGATCCTAGGCACTGAAGT	SEQ?ID?NO：2048
WBC041B04_V1.3_at	GGCACTGAAGTATCGACCACTTTCC	SEQ?ID?NO：2049	WBC041B04_V1.3_at	ACCACTTTCCTATTTCACCTGATTT	SEQ?ID?NO：2050
WBC041B04_V1.3_at	AGAATGGGACCATTTCTCTGTGAAT	SEQ?ID?NO：2051	WBC041B04_V1.3_at	ACCACTTTCCTATTTCACCTGATTT	SEQ?ID?NO：2050
WBC041B04_V1.3_at	AGAATGGGACCATTTCTCTGTGAAT	SEQ?ID?NO：2051	WBC041C11_V1.3_at	AGAGGACTGCCTCGCAATACTTCGT	SEQ?ID?NO：2052
WBC041C11_V1.3_at	AATACTTCGTGCTGTTGCTGCTGAC	SEQ?ID?NO：2053	WBC041C11_V1.3_at	AGAGGACTGCCTCGCAATACTTCGT	SEQ?ID?NO：2052
WBC041C11_V1.3_at	AATACTTCGTGCTGTTGCTGCTGAC	SEQ?ID?NO：2053	WBC041C11_V1.3_at	CTGCCCATGTCAGTGATCATCGTGG	SEQ?ID?NO：2054
WBC041C11_V1.3_at	AGCTGGACGCTGATGGTGGACCCCT	SEQ?ID?NO：2055	WBC041C11_V1.3_at	CTGCCCATGTCAGTGATCATCGTGG	SEQ?ID?NO：2054
WBC041C11_V1.3_at	AGCTGGACGCTGATGGTGGACCCCT	SEQ?ID?NO：2055	WBC041C11_V1.3_at	GCGTACACGCTCTGGGAAGGCATCT	SEQ?ID?NO：2056
WBC041C11_V1.3_at	AGGCATCTGCCCGTGACATAGTGCA	SEQ?ID?NO：2057	WBC041C11_V1.3_at	GCGTACACGCTCTGGGAAGGCATCT	SEQ?ID?NO：2056
WBC041C11_V1.3_at	AGGCATCTGCCCGTGACATAGTGCA	SEQ?ID?NO：2057	WBC041C11_V1.3_at	GACATAGTGCAGTTTGTGCCCTACC	SEQ?ID?NO：2058
WBC041C11_V1.3_at	AGAAGTACCTGCACAACTGGTCTCC	SEQ?ID?NO：2059	WBC041C11_V1.3_at	GACATAGTGCAGTTTGTGCCCTACC	SEQ?ID?NO：2058
WBC041C11_V1.3_at	AGAAGTACCTGCACAACTGGTCTCC	SEQ?ID?NO：2059	WBC041C11_V1.3_at	TCAGGCCTAGATTCCCTTGGAGGGT	SEQ?ID?NO：2060
WBC041C11_V1.3_at	AGGGTAAGCTGTGGCCAGTCCTCAG	SEQ?ID?NO：2061	WBC041C11_V1.3_at	TCAGGCCTAGATTCCCTTGGAGGGT	SEQ?ID?NO：2060
WBC041C11_V1.3_at	AGGGTAAGCTGTGGCCAGTCCTCAG	SEQ?ID?NO：2061	WBC041C11_V1.3_at	TATACTTGTTCCTGCTATTTCTGCT	SEQ?ID?NO：2062
WBC048H02_V1.3_at	TACACTGTCCAGGATGAGAGCCACT	SEQ?ID?NO：2063	WBC041C11_V1.3_at	TATACTTGTTCCTGCTATTTCTGCT	SEQ?ID?NO：2062
WBC048H02_V1.3_at	TACACTGTCCAGGATGAGAGCCACT	SEQ?ID?NO：2063	WBC048H02_V1.3_at	ATCATTGTCTCCTGTGGCTGGGACA	SEQ?ID?NO：2064
WBC048H02_V1.3_at	AGCTGAAGACCAATCACATCGGCCA	SEQ?ID?NO：2065	WBC048H02_V1.3_at	ATCATTGTCTCCTGTGGCTGGGACA	SEQ?ID?NO：2064
WBC048H02_V1.3_at	AGCTGAAGACCAATCACATCGGCCA	SEQ?ID?NO：2065	WBC048H02_V1.3_at	AGGCTACCTGAACACTGTCACTGTC	SEQ?ID?NO：2066
WBC048H02_V1.3_at	GATCCCTCTGTGCTTCTGGAGGCAA	SEQ?ID?NO：2067	WBC048H02_V1.3_at	AGGCTACCTGAACACTGTCACTGTC	SEQ?ID?NO：2066
WBC048H02_V1.3_at	GATCCCTCTGTGCTTCTGGAGGCAA	SEQ?ID?NO：2067	WBC048H02_V1.3_at	GGCCAGGCCATGCTTTGGGATTTAA	SEQ?ID?NO：2068
WBC048H02_V1.3_at	GGCAAGCACCTTTACACACTAGATG	SEQ?ID?NO：2069	WBC048H02_V1.3_at	GGCCAGGCCATGCTTTGGGATTTAA	SEQ?ID?NO：2068
WBC048H02_V1.3_at	GGCAAGCACCTTTACACACTAGATG	SEQ?ID?NO：2069	WBC048H02_V1.3_at	GGGACATCATCAACGCCTTGTGCTT	SEQ?ID?NO：2070
WBC048H02_V1.3_at	AGAAGTTATCAGTACCAGCAGCAAG	SEQ?ID?NO：2071	WBC048H02_V1.3_at	GGGACATCATCAACGCCTTGTGCTT	SEQ?ID?NO：2070
WBC048H02_V1.3_at	AGAAGTTATCAGTACCAGCAGCAAG	SEQ?ID?NO：2071	WBC048H02_V1.3_at	AGACTCTGTTTGCTGGCTACACGGA	SEQ?ID?NO：2072
WBC048H02_V1.3_at	ATCGGCACCCGCTAGAAATACATGG	SEQ?ID?NO：2073	WBC048H02_V1.3_at	AGACTCTGTTTGCTGGCTACACGGA	SEQ?ID?NO：2072
WBC048H02_V1.3_at	ATCGGCACCCGCTAGAAATACATGG	SEQ?ID?NO：2073	WBC285.gRSP.V1.3_at	GTTTCTGAAAATTCTCTTCTCTCCC	SEQ?ID?NO：2074
WBC285.gRSP.V1.3_at	CAACCCCTCAGCTTCTGGATATAAT	SEQ?ID?NO：2075	WBC285.gRSP.V1.3_at	GTTTCTGAAAATTCTCTTCTCTCCC	SEQ?ID?NO：2074
WBC285.gRSP.V1.3_at	CAACCCCTCAGCTTCTGGATATAAT	SEQ?ID?NO：2075	WBC285.gRSP.V1.3_at	GTGCATAATTGTGTATCCTCCTCAA	SEQ?ID?NO：2076
WBC285.gRSP.V1.3_at	GATGTTTACACTTTTCCAGACGAGA	SEQ?ID?NO：2077	WBC285.gRSP.V1.3_at	GTGCATAATTGTGTATCCTCCTCAA	SEQ?ID?NO：2076
WBC285.gRSP.V1.3_at	GATGTTTACACTTTTCCAGACGAGA	SEQ?ID?NO：2077	WBC285.gRSP.V1.3_at	CAGATCGTGGATTTCTTTTCCTGTA	SEQ?ID?NO：2078
WBC285.gRSP.V1.3_at	AACAGATTCTTCTCACCGATGGTAG	SEQ?ID?NO：2079	WBC285.gRSP.V1.3_at	CAGATCGTGGATTTCTTTTCCTGTA	SEQ?ID?NO：2078
WBC285.gRSP.V1.3_at	AACAGATTCTTCTCACCGATGGTAG	SEQ?ID?NO：2079	WBC285.gRSP.V1.3_at	GATGGTCCCAATATGTCAGTTGCTG	SEQ?ID?NO：2080
WBC285.gRSP.V1.3_at	CTGGTGCAGTATTCTTTCCGTGATA	SEQ?ID?NO：2081	WBC285.gRSP.V1.3_at	GATGGTCCCAATATGTCAGTTGCTG	SEQ?ID?NO：2080
WBC285.gRSP.V1.3_at	CTGGTGCAGTATTCTTTCCGTGATA	SEQ?ID?NO：2081	WBC285.gRSP.V1.3_at	ATTGGTGGTCTTGCCTGTATTTTCA	SEQ?ID?NO：2082
WBC285.gRSP.V1.3_at	CGGTGCGTTTTATCGGACTGATTCA	SEQ?ID?NO：2083	WBC285.gRSP.V1.3_at	ATTGGTGGTCTTGCCTGTATTTTCA	SEQ?ID?NO：2082
WBC285.gRSP.V1.3_at	CGGTGCGTTTTATCGGACTGATTCA	SEQ?ID?NO：2083	WBC285.gRSP.V1.3_at	ATAAAGGGTGCTGCTCTGAGGCTAG	SEQ?ID?NO：2084
WBC31.gFSP.V1.3_at	CAAGGCCCGTGATTTTTCTACCAGA	SEQ?ID?NO：2085	WBC285.gRSP.V1.3_at	ATAAAGGGTGCTGCTCTGAGGCTAG	SEQ?ID?NO：2084
WBC31.gFSP.V1.3_at	CAAGGCCCGTGATTTTTCTACCAGA	SEQ?ID?NO：2085	WBC31.gFSP.V1.3_at	GTGATTTTTCTACCAGACCTCACTG	SEQ?ID?NO：2086
WBC31.gFSP.V1.3_at	TACCAGACCTCACTGCTTTTGTGTT	SEQ?ID?NO：2087	WBC31.gFSP.V1.3_at	GTGATTTTTCTACCAGACCTCACTG	SEQ?ID?NO：2086
WBC31.gFSP.V1.3_at	TACCAGACCTCACTGCTTTTGTGTT	SEQ?ID?NO：2087	WBC31.gFSP.V1.3_at	GACCTCACTGCTTTTGTGTTTAGGA	SEQ?ID?NO：2088
WBC31.gFSP.V1.3_at	CTCACTGCTTTTGTGTTTAGGAAAG	SEQ?ID?NO：2089	WBC31.gFSP.V1.3_at	GACCTCACTGCTTTTGTGTTTAGGA	SEQ?ID?NO：2088
WBC31.gFSP.V1.3_at	CTCACTGCTTTTGTGTTTAGGAAAG	SEQ?ID?NO：2089	WBC31.gFSP.V1.3_at	GAAAGAGATCATATCTGCCCCAGCT	SEQ?ID?NO：2090

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC31.gFSP.V1.3_at	AGAGATCATATCTGCCCCAGCTGGA	SEQ?ID?NO：2091
WBC31.gFSP.V1.3_at	TGCCCCAGCTGGATGTTTCGAGGAT	SEQ?ID?NO：2092	WBC31.gFSP.V1.3_at	AGAGATCATATCTGCCCCAGCTGGA	SEQ?ID?NO：2091
WBC31.gFSP.V1.3_at	TGCCCCAGCTGGATGTTTCGAGGAT	SEQ?ID?NO：2092	WBC31.gFSP.V1.3_at	AGCTGGATGTTTCGAGGATCCTCCT	SEQ?ID?NO：2093
WBC31.gFSP.V1.3_at	GGATGTTTCGAGGATCCTCCTCCCT	SEQ?ID?NO：2094	WBC31.gFSP.V1.3_at	AGCTGGATGTTTCGAGGATCCTCCT	SEQ?ID?NO：2093
WBC31.gFSP.V1.3_at	GGATGTTTCGAGGATCCTCCTCCCT	SEQ?ID?NO：2094	WBC31.gFSP.V1.3_at	CTCCTCCCTCTAGACATTGGAAGAA	SEQ?ID?NO：2095
WBC31.gFSP.V1.3_s_at	AATGCAGATTGAGAGCTCCCTGTCC	SEQ?ID?NO：2096	WBC31.gFSP.V1.3_at	CTCCTCCCTCTAGACATTGGAAGAA	SEQ?ID?NO：2095
WBC31.gFSP.V1.3_s_at	AATGCAGATTGAGAGCTCCCTGTCC	SEQ?ID?NO：2096	WBC31.gFSP.V1.3_s_at	TGTCCTCAGCCCTGAACTGGGAATT	SEQ?ID?NO：2097
WBC31.gFSP.V1.3_s_at	AGGAGACTTAGCTCTACACGCTCAA	SEQ?ID?NO：2098	WBC31.gFSP.V1.3_s_at	TGTCCTCAGCCCTGAACTGGGAATT	SEQ?ID?NO：2097
WBC31.gFSP.V1.3_s_at	AGGAGACTTAGCTCTACACGCTCAA	SEQ?ID?NO：2098	WBC31.gFSP.V1.3_s_at	GTCTCTAGCCAACCAAACTCACAAG	SEQ?ID?NO：2099
WBC31.gFSP.V1.3_s_at	GTATAAGCCAGAGGCCCAGTGTTTC	SEQ?ID?NO：2100	WBC31.gFSP.V1.3_s_at	GTCTCTAGCCAACCAAACTCACAAG	SEQ?ID?NO：2099
WBC31.gFSP.V1.3_s_at	GTATAAGCCAGAGGCCCAGTGTTTC	SEQ?ID?NO：2100	WBC31.gFSP.V1.3_s_at	CAGTGTTTCCACCAGGCGTGGAGTA	SEQ?ID?NO：2101
WBC31.gFSP.V1.3_s_at	AGCTCTGGAGCTGTTAGTGCCTGGT	SEQ?ID?NO：2102	WBC31.gFSP.V1.3_s_at	CAGTGTTTCCACCAGGCGTGGAGTA	SEQ?ID?NO：2101
WBC31.gFSP.V1.3_s_at	AGCTCTGGAGCTGTTAGTGCCTGGT	SEQ?ID?NO：2102	WBC31.gFSP.V1.3_s_at	TAGTGCCTGGTGTAACTCTTGCCTC	SEQ?ID?NO：2103
WBC31.gFSP.V1.3_s_at	TAGCCCTGTGATTCTGTGCAAGTTA	SEQ?ID?NO：2104	WBC31.gFSP.V1.3_s_at	TAGTGCCTGGTGTAACTCTTGCCTC	SEQ?ID?NO：2103
WBC31.gFSP.V1.3_s_at	TAGCCCTGTGATTCTGTGCAAGTTA	SEQ?ID?NO：2104	WBC31.gFSP.V1.3_s_at	TATTGATTGATCTCTCTAAGCCTCA	SEQ?ID?NO：2105
WBC31.gFSP.V1.3_s_at	TAAGCCTCAATTTCCTCATCTGTGA	SEQ?ID?NO：2106	WBC31.gFSP.V1.3_s_at	TATTGATTGATCTCTCTAAGCCTCA	SEQ?ID?NO：2105
WBC31.gFSP.V1.3_s_at	TAAGCCTCAATTTCCTCATCTGTGA	SEQ?ID?NO：2106	WBC31.V1.3_s_at	AATGCAGATTGAGAGCTCCCTGTCC	SEQ?ID?NO：2107
WBC31.V1.3_s_at	TGTCCTCAGCCCTGAACTGGGAATT	SEQ?ID?NO：2108	WBC31.V1.3_s_at	AATGCAGATTGAGAGCTCCCTGTCC	SEQ?ID?NO：2107
WBC31.V1.3_s_at	TGTCCTCAGCCCTGAACTGGGAATT	SEQ?ID?NO：2108	WBC31.V1.3_s_at	AGGAGACTTAGCTCTACACGCTCAA	SEQ?ID?NO：2109
WBC31.V1.3_s_at	GTCTCTAGCCAACCAAACTCACAAG	SEQ?ID?NO：2110	WBC31.V1.3_s_at	AGGAGACTTAGCTCTACACGCTCAA	SEQ?ID?NO：2109
WBC31.V1.3_s_at	GTCTCTAGCCAACCAAACTCACAAG	SEQ?ID?NO：2110	WBC31.V1.3_s_at	GTATAAGCCAGAGGCCCAGTGTTTC	SEQ?ID?NO：2111
WBC31.V1.3_s_at	CAGTGTTTCCACCAGGCGTGGAGTA	SEQ?ID?NO：2112	WBC31.V1.3_s_at	GTATAAGCCAGAGGCCCAGTGTTTC	SEQ?ID?NO：2111
WBC31.V1.3_s_at	CAGTGTTTCCACCAGGCGTGGAGTA	SEQ?ID?NO：2112	WBC31.V1.3_s_at	AGCTCTGGAGCTGTTAGTGCCTGGT	SEQ?ID?NO：2113
WBC31.V1.3_s_at	TAGTGCCTGGTGTAACTCTTGCCTC	SEQ?ID?NO：2114	WBC31.V1.3_s_at	AGCTCTGGAGCTGTTAGTGCCTGGT	SEQ?ID?NO：2113
WBC31.V1.3_s_at	TAGTGCCTGGTGTAACTCTTGCCTC	SEQ?ID?NO：2114	WBC31.V1.3_s_at	TAGCCCTGTGATTCTGTGCAAGTTA	SEQ?ID?NO：2115
WBC31.V1.3_s_at	TATTGATTGATCTCTCTAAGCCTCA	SEQ?ID?NO：2116	WBC31.V1.3_s_at	TAGCCCTGTGATTCTGTGCAAGTTA	SEQ?ID?NO：2115
WBC31.V1.3_s_at	TATTGATTGATCTCTCTAAGCCTCA	SEQ?ID?NO：2116	WBC31.V1.3_s_at	TAAGCCTCAATTTCCTCATCTGTGA	SEQ?ID?NO：2117
WBC422.gRSP.V1.3_at	GGATGTGACTCCTGGTTATGTTCAG	SEQ?ID?NO：2118	WBC31.V1.3_s_at	TAAGCCTCAATTTCCTCATCTGTGA	SEQ?ID?NO：2117
WBC422.gRSP.V1.3_at	GGATGTGACTCCTGGTTATGTTCAG	SEQ?ID?NO：2118	WBC422.gRSP.V1.3_at	ATGTTCAGTGGACACTCTGCTTAGA	SEQ?ID?NO：2119
WBC422.gRSP.V1.3_at	AGATAGACGTGCTCCGGAAGATGGC	SEQ?ID?NO：2120	WBC422.gRSP.V1.3_at	ATGTTCAGTGGACACTCTGCTTAGA	SEQ?ID?NO：2119
WBC422.gRSP.V1.3_at	AGATAGACGTGCTCCGGAAGATGGC	SEQ?ID?NO：2120	WBC422.gRSP.V1.3_at	GATGGCAGGAACTACCAGCATGGAA	SEQ?ID?NO：2121
WBC422.gRSP.V1.3_at	AAATGTGTCATAGGCTGGAGGGCTA	SEQ?ID?NO：2122	WBC422.gRSP.V1.3_at	GATGGCAGGAACTACCAGCATGGAA	SEQ?ID?NO：2121
WBC422.gRSP.V1.3_at	AAATGTGTCATAGGCTGGAGGGCTA	SEQ?ID?NO：2122	WBC422.gRSP.V1.3_at	AGACTTTTCCTTCTTGTTACACTCA	SEQ?ID?NO：2123
WBC422.gRSP.V1.3_at	GTTACACTCAACAAGGGCATGACTT	SEQ?ID?NO：2124	WBC422.gRSP.V1.3_at	AGACTTTTCCTTCTTGTTACACTCA	SEQ?ID?NO：2123
WBC422.gRSP.V1.3_at	GTTACACTCAACAAGGGCATGACTT	SEQ?ID?NO：2124	WBC422.gRSP.V1.3_at	GACTTAACTGTGTATTTTGTCTTTA	SEQ?ID?NO：2125
WBC422.gRSP.V1.3_at	TGTCTTTACAATCCTTTAGTGCCTG	SEQ?ID?NO：2126	WBC422.gRSP.V1.3_at	GACTTAACTGTGTATTTTGTCTTTA	SEQ?ID?NO：2125
WBC422.gRSP.V1.3_at	TGTCTTTACAATCCTTTAGTGCCTG	SEQ?ID?NO：2126	WBC422.gRSP.V1.3_at	GGCTCATTTAATGTATGCTTGCTCA	SEQ?ID?NO：2127
WBC422.gRSP.V1.3_at	GTCTGTTTGCACATATTTTTAACCA	SEQ?ID?NO：2128	WBC422.gRSP.V1.3_at	GGCTCATTTAATGTATGCTTGCTCA	SEQ?ID?NO：2127
WBC422.gRSP.V1.3_at	GTCTGTTTGCACATATTTTTAACCA	SEQ?ID?NO：2128	WBC44.V1.3_at	AAGATCTGATCTTCAAAGCAGCCAG	SEQ?ID?NO：2129
WBC44.V1.3_at	TGGTAGGCAGAATGATGCCCTCCCC	SEQ?ID?NO：2130	WBC44.V1.3_at	AAGATCTGATCTTCAAAGCAGCCAG	SEQ?ID?NO：2129
WBC44.V1.3_at	TGGTAGGCAGAATGATGCCCTCCCC	SEQ?ID?NO：2130	WBC44.V1.3_at	GATGTCCACACTTTAATCTCCTGAA	SEQ?ID?NO：2131
WBC44.V1.3_at	GATGTGATTAAGGTTACCCTGCAGA	SEQ?ID?NO：2132	WBC44.V1.3_at	GATGTCCACACTTTAATCTCCTGAA	SEQ?ID?NO：2131
WBC44.V1.3_at	GATGTGATTAAGGTTACCCTGCAGA	SEQ?ID?NO：2132	WBC44.V1.3_at	CCAGGATTTTTCAGGTGGGCTCAAT	SEQ?ID?NO：2133
WBC44.V1.3_at	AAGAGAGAACCTTCCTAGCTGCTTC	SEQ?ID?NO：2134	WBC44.V1.3_at	CCAGGATTTTTCAGGTGGGCTCAAT	SEQ?ID?NO：2133
WBC44.V1.3_at	AAGAGAGAACCTTCCTAGCTGCTTC	SEQ?ID?NO：2134	WBC44.V1.3_at	ATATGATGCTCTGTGCTGGTTCTGA	SEQ?ID?NO：2135

The probe groups title	Probe sequence	Sequence identifier
The probe groups title	Probe sequence	Sequence identifier	WBC44.V1.3_at	GGATTGAAGCAAGCCTGCCAACACT	SEQ?ID?NO：2136
WBC44.V1.3_at	TGCCAACACTTCGATTTTAGCCTCA	SEQ?ID?NO：2137	WBC44.V1.3_at	GGATTGAAGCAAGCCTGCCAACACT	SEQ?ID?NO：2136
WBC44.V1.3_at	TGCCAACACTTCGATTTTAGCCTCA	SEQ?ID?NO：2137	WBC44.V1.3_at	TTAGCCTCAAGAGACCCATACCTGA	SEQ?ID?NO：2138
WBC44.V1.3_at	CCATACCTGACTTCTGACCTATAGA	SEQ?ID?NO：2139	WBC44.V1.3_at	TTAGCCTCAAGAGACCCATACCTGA	SEQ?ID?NO：2138
WBC44.V1.3_at	CCATACCTGACTTCTGACCTATAGA	SEQ?ID?NO：2139	WBC881.gRSP.V1.3_at	GCTGCTCTGTCGGTCTGTACAAATA	SEQ?ID?NO：2140
WBC881.gRSP.V1.3_at	AACACGACTGGGTCTCGAATACACA	SEQ?ID?NO：2141	WBC881.gRSP.V1.3_at	GCTGCTCTGTCGGTCTGTACAAATA	SEQ?ID?NO：2140
WBC881.gRSP.V1.3_at	AACACGACTGGGTCTCGAATACACA	SEQ?ID?NO：2141	WBC881.gRSP.V1.3_at	GTTTTTGTGGGTATTGCCTCATTCC	SEQ?ID?NO：2142
WBC881.gRSP.V1.3_at	ATTCCATCCCTGAGCTTTGCAGGTA	SEQ?ID?NO：2143	WBC881.gRSP.V1.3_at	GTTTTTGTGGGTATTGCCTCATTCC	SEQ?ID?NO：2142
WBC881.gRSP.V1.3_at	ATTCCATCCCTGAGCTTTGCAGGTA	SEQ?ID?NO：2143	WBC881.gRSP.V1.3_at	AACTATGTTCCAGGGTGTTCCTTGT	SEQ?ID?NO：2144
WBC881.gRSP.V1.3_at	TTTGTTGCTCTCTTTCCTGGAAATA	SEQ?ID?NO：2145	WBC881.gRSP.V1.3_at	AACTATGTTCCAGGGTGTTCCTTGT	SEQ?ID?NO：2144
WBC881.gRSP.V1.3_at	TTTGTTGCTCTCTTTCCTGGAAATA	SEQ?ID?NO：2145	WBC881.gRSP.V1.3_at	GAGACGCTCCTGATTTGTCCATCTA	SEQ?ID?NO：2146
WBC881.gRSP.V1.3_at	ATCTACTGCTTTGGTTCCTTGGATC	SEQ?ID?NO：2147	WBC881.gRSP.V1.3_at	GAGACGCTCCTGATTTGTCCATCTA	SEQ?ID?NO：2146
WBC881.gRSP.V1.3_at	ATCTACTGCTTTGGTTCCTTGGATC	SEQ?ID?NO：2147	WBC881.gRSP.V1.3_at	ATCCACCCATTCTTTCACTTTAAGA	SEQ?ID?NO：2148
WBC881.gRSP.V1.3_at	GAGGTCTCTGTATTTTGCAGCTGCC	SEQ?ID?NO：2149	WBC881.gRSP.V1.3_at	ATCCACCCATTCTTTCACTTTAAGA	SEQ?ID?NO：2148
WBC881.gRSP.V1.3_at	GAGGTCTCTGTATTTTGCAGCTGCC	SEQ?ID?NO：2149	WBC881.gRSP.V1.3_at	TTTGCAGCTGCCCTTTTGTAAGAAG	SEQ?ID?NO：2150

Table 3

The amino acid subclass

Subclass	Amino acid
Subclass	Amino acid	The charged little polarity of acid alkalescence/neutral polarity/big hydrophobicity aromatic series affects the residue of chain orientation	Aspartic acid, L-glutamic acid non-annularity: arginine, Methionin; Ring-type: Histidine aspartic acid, L-glutamic acid, arginine, Methionin, the Histidine glycine, Serine, L-Ala, Threonine, the proline(Pro) l-asparagine, Histidine, glutamine, halfcystine, Serine, the Threonine l-asparagine, glutamine tyrosine, Xie Ansuan, Isoleucine, leucine, methionine(Met), phenylalanine, the tryptophane tryptophane, tyrosine, phenylalanine glycine and proline(Pro)

Table 4

Exemplary and preferred amino acids replaces

Original residue	Exemplary replacement	The preferred replacement
Original residue	Exemplary replacement	The preferred replacement	Ala Arg Asn Asp Cys Gln Glu Gly His Ile Leu Lys Met Phe Pro Ser Thr Trp Tyr Val	Val、Leu、Ile Lys、Gln、Asn Gln、His、Lys、Arg Glu Ser Asn、His、Lys， Asp、Lys Pro Asn、Gln、Lys、Arg Leu、Val、Met、Ala、Phe、Norleu Norleu、Ile、Val、Met、Ala、Phe Arg、Gln、Asn Leu、Ile、Phe Leu、Val、Ile、Ala Gly Thr Ser Tyr Trp、Phe、Thr、Ser Ile、Leu、Met、Phe、Ala、Norleu	Val Lys Gln Glu Ser Asn Asp Pro Arg Leu Ile Arg Leu Leu Gly Thr Ser Tyr Phe Leu

Table 5

Gene ordering according to the P value

The gene title	Difference	SE	The T value	The P value
The gene title	Difference	SE	The T value	The P value	B1961481.V1.3_at WBC026C03_V1.3_at WBC005G04_V1.3_at WBC020C09_V1.3_at WBC007A05_V1.3_at B1961581.V1.3_at BM735170.V1.3_at WBC010C05_V1.3_at B1961434.V1.3_at WBC009D04_V1.3_at B1961434.V1.3_s_at BM780886.V1.3_at WBC004E01_V1.3_at B1961659.V1.3_at WBC008B04_V1.3_at B1961054.V1.3_at BM735449.V1.3_at WBC029A01_V1.3_at BM781436.V1.3_at BM735054.V1.3_at WBC31.V1.3_s_at BM734900.V1.3_at B1961438.V1.3_at B1961550.V1.3_at WBC31.gFSP.V1.3_s_at BM734862.V1.3_at WBC041B04_V1.3_at WBC422.gRSP.V1.3_at WBC007E09_V1.3_at BM735031.V1.3_at WBC013G08_V1.3_at BM735096.V1.3_at GI1305528.V1.3_at WBC881.gRSP.V1.3_at WBC44.V1.3_at WBC041C11_V1.3_at WBC036C09_V1.3_at WBC285.gRSP.V1.3_at WBC030G08_V1.3_at WBC024D07_V1.3_at WBC031E09_V1.3_at BM734613.V1.3_at WBC012F12_V1.3_at BM734661.V1.3_at WBC022G05_V1.3_at WBC032G11_V1.3_at WBC028A02_V1.3_at	1.666322507 1.150792386 0.894442963 -1.975434651 0.785659357 -0.451711505 1.433067223 1.441977213 3.424431972 0.592808107 3.161162105 -0.415531897 0.784558644 1.551889116 -0.678906889 3.826550139 1.170277871 0.879852727 -0.314495364 1.551493311 -0.680666497 -1.516282343 -0.440498303 1.3425348 -0.591039401 -0.437281772 2.184025458 2.280789862 0.843052247 1.059207378 1.604484661 -0.527142962 1.698015694 -0.462008718 0.616616596 -0.303160563 -0.403578085 -0.519857227 0.657348571 0.345066898 0.945682519 -0.195796173 1.423082668 -0.171573177 0.598971114 0.74658497 -0.471494416	0.155216771 0.126397807 0.099099842 0.227309869 0.094470794 0.055606081 0.18234517 0.189449588 0.456186048 0.081892899 0.439488349 0.057815618 0.110780118 0.219186785 0.097154867 0.547819858 0.167733159 0.127554003 0.045881808 0.228178727 0.100518591 0.22417215 0.065266955 0.199300914 0.087840965 0.065682696 0.331137896 0.346757118 0.12836437 0.161421311 0.246581348 0.08133936 0.262662758 0.071869337 0.095944624 0.047586732 0.063531632 0.082704672 0.104593529 0.054910514 0.150758028 0.031448406 0.230285511 0.027859225 0.097369199 0.122452588 0.077361546	10.735454 9.10452809 9.02567496 -8.690492245 8.31642587 -8.123419151 7.859090675 7.611403272 7.506656526 7.23882188 7.192823458 -7.187191162 7.082125009 7.080212956 -6.98788343 6.985051894 6.977021578 6.897884067 -6.854467519 6.799465195 -6.771548352 -6.763919336 -6.749178129 6.736219995 -6.72851668 -6.657488225 6.595516498 6.577485351 6.567649944 6.561756739 6.506918213 -6.48078572 6.464622952 -6.428453908 6.426796735 -6.370695093 -6.352396027 -6.28570571 6.284791949 6.284168071 6.272850147 -6.225948974 6.179644819 -6.158576752 6.151546063 6.096930933 -6.094687073	3.42E-12 1.76E-09 2.40E-09 8.93E-09 3.90E-08 8.36E-08 2.38E-07 6.36E-07 9.64E-07 2.79E-06 3.34E-06 3.42E-06 5.18E-06 5.22E-06 7.51E-06 7.60E-06 7.84E-06 1.07E-05 1.27E-05 1.58E-05 1.76E-05 1.82E-05 1.92E-05 2.02E-05 2.09E-05 2.76E-05 3.52E-05 3.78E-05 3.92E-05 4.01E-05 4.98E-05 5.51E-05 5.87E-05 6.76E-05 6.81E-05 8.48E-05 9.10E-05 0.000118084 0.000118467 0.000118717 0.000124039 0.00014889 0.000178261 0.000193428 0.000198726 0.000245632 0.0002477

The gene title	Difference	SE	The T value	The P value
The gene title	Difference	SE	The T value	The P value	WBC024E03_V1.3_at BM734607.V1.3_at Foe1268.V1.3_at WBC035E08_V1.3_at BM734719.V1.3_at BM781127.V1.3_at WBC048H02_V1.3_at B1961469.V1.3_at WBC021A01_V1.3_at B1961499.V1.3_at B1961690.V1.3_at WBC016C12_V1.3_at WBC032C03_V1.3_at WBC028D07_V1.3_at WBC010B02_V1.3_at B1961567.V1.3_at	0.478892417 1.687765982 -0.658520375 0.627315382 -0.480084044 -0.411205914 -0.147436743 0.597662751 -0.33752016 -0.204864013 -0.189758849 -0.403364998 -0.27218489 1.186413699 0.794652845 0.639519337	0.078794071 0.277888053 0.109329632 0.104346849 0.080066503 0.068820452 0.024739757 0.100424518 0.057261491 0.034949361 0.032616546 0.069604438 0.047411852 0.208543617 0.13993627 0.117658674	6.077772226 6.073546394 -6.023256108 6.011828676 -5.9960661 -5.975053959 -5.959506446 5.951362912 -5.894365583 -5.861738376 -5.817870785 -5.79510457 -5.740861829 5.689043457 5.678676762 5.435377724	0.000264421 0.000268705 0.000326329 0.000340982 0.000362314 0.000392606 0.000416788 0.00042997 0.00053523 0.000606722 0.000717784 0.000782617 0.000962987 0.001173814 0.001220044 0.003046977

Table 6

Gene ordering according to the T value

	Difference	SE	The T value	The P value
	Difference	SE	The T value	The P value	WBC020C09_V1.3_at B1961581.V1.3_at BM780886.V1.3_at WBC008B04_V1.3_at BM781436.V1.3_at WBC31.V1.3_s_at BM734900.V1.3_at B1961438.V1.3_at WBC31.gFSP.V1.3_s_at BM734862.V1.3_at BM735096.V1.3_at WBC881.gRSP.V1.3_at WBC041C11_V1.3_at WBC036C09_V1.3_at WBC285.gRSP.V1.3_at BM734613.V1.3_at BM734661.V1.3_at WBC028A02V_1.3_at Foe1268.V1.3_at BM734719.V1.3_at BM781127.V1.3_at WBC048H02_V1.3_at WBC021A01_V1.3_at B1961499.V1.3_at B1961690.V1.3_at WBC016C12_V1.3_at WBC032C03_V1.3_at B1961567.V1.3_at WBC010B02_V1.3_at WBC028D07_V1.3_at B1961469.V1.3_at WBC035E08_V1.3_at BM734607.V1.3_at WBC024E03_V1.3_at WBC032G11_V1.3_at WBC022G05_V1.3_at WBC012F12_V1.3_at WBC031E09_V1.3_at WBC024D07_V1.3_at WBC030G08_V1.3_at WBC44.V1.3_at GI1305528.V1.3_at WBC013G08V1.3_at BM735031.V1.3_at WBC007E09_V1.3_at WBC422.gRSP.V1.3_at WBC041B04_V1.3_at	-1.975434651 -0.451711505 -0.415531897 -0.678906889 -0.314495364 -0.680666497 -1.516282343 -0.440498303 -0.591039401 -0.437281772 -0.527142962 -0.462008718 -0.303160563 -0.403578085 -0.519857227 -0.195796173 -0.171573177 -0.471494416 -0.658520375 -0.480084044 -0.411205914 -0.147436743 -0.33752016 -0.204864013 -0.189758849 -0.403364998 -0.27218489 0.639519337 0.794652845 1.186413699 0.597662751 0.627315382 1.687765982 0.478892417 0.74658497 0.598971114 1.423082668 0.945682519 0.345066898 0.657348571 0.616616596 1.698015694 1.604484661 1.059207378 0.843052247 2.280789862 2.184025458	0.227309869 0.055606081 0.057815618 0.097154867 0.045881808 0.100518591 0.22417215 0.065266955 0.087840965 0.065682696 0.08133936 0.071869337 0.047586732 0.063531632 0.082704672 0.031448406 0.027859225 0.077361546 0.109329632 0.080066503 0.068820452 0.024739757 0.057261491 0.034949361 0.032616546 0.069604438 0.047411852 0.117658674 0.13993627 0.208543617 0.100424518 0.104346849 0.277888053 0.078794071 0.122452588 0.097369199 0.230285511 0.150758028 0.054910514 0.104593529 0.095944624 0.262662758 0.246581348 0.161421311 0.12836437 0.346757118 0.331137896	-8.690492245 -8.123419151 -7.187191162 -6.98788343 -6.854467519 -6.771548352 -6.763919336 -6.749178129 -6.72851668 -6.657488225 -6.48078572 -6.428453908 -6.370695093 -6.352396027 -6.28570571 -6.225948974 -6.158576752 -6.094687073 -6.023256108 -5.9960661 -5.975053959 -5.959506446 -5.894365583 -5.861738376 -5.817870785 -5.79510457 -5.740861829 5.435377724 5.678676762 5.689043457 5.951362912 6.011828676 6.073546394 6.077772226 6.096930933 6.151546063 6.179644819 6.272850147 6.284168071 6.284791949 6.426796735 6.464622952 6.506918213 6.561756739 6.567649944 6.577485351 6.595516498	8.93E-09 8.36E-08 3.42E-06 7.51E-06 1.27E-05 1.76E-05 1.82E-05 1.92E-05 2.09E-05 2.76E-05 5.51E-05 6.76E-05 8.48E-05 9.10E-05 0.000118084 0.00014889 0.000193428 0.0002477 0.000326329 0.000362314 0.000392606 0.000416788 0.00053523 0.000606722 0.000717784 0.000782617 0.000962987 0.003046977 0.001220044 0.001173814 0.00042997 0.000340982 0.000268705 0.000264421 0.000245632 0.000198726 0.000178261 0.000124039 0.000118717 0.000118467 6.81E-05 5.87E-05 4.98E-05 4.01E-05 3.92E-05 3.78E-05 3.52E-05

	Difference	SE	The T value	The P value
	Difference	SE	The T value	The P value	B1961550.V1.3_at BM735054.V1.3_at WBC029A01_V1.3_at BM735449.V1.3_at B1961054.V1.3_at B1961659.V1.3_at WBC004E01_V1.3_at B1961434.V1.3_s_at WBC009D04_V1.3_at B1961434.V1.3_at WBC010C05_V1.3_at BM735170.V1.3_at WBC007A05_V1.3_at WBC005G04_V1.3_at WBC026C03_V1.3_at B1961481.V1.3_at	1.3425348 1.551493311 0.879852727 1.170277871 3.826550139 1.551889116 0.784558644 3.161162105 0.592808107 3.424431972 1.441977213 1.433067223 0.785659357 0.894442963 1.150792386 1.666322507	0.199300914 0.228178727 0.127554003 0.167733159 0.547819858 0.219186785 0.110780118 0.439488349 0.081892899 0.456186048 0.189449588 0.18234517 0.094470794 0.099099842 0.126397807 0.155216771	6.736219995 6.799465195 6.897884067 6.977021578 6.985051894 7.080212956 7.082125009 7.192823458 7.23882188 7.506656526 7.611403272 7.859090675 8.31642587 9.02567496 9.10452809 10.735454	2.02E-05 1.58E-05 1.07E-05 7.84E-06 7.60E-06 5.22E-06 5.18E-06 3.34E-06 2.79E-06 9.64E-07 6.36E-07 2.38E-07 3.90E-08 2.40E-09 1.76E-09 3.42E-12

Table 7

EHV-1 group 1: the mean value of clinical and hematologic parameter

	The 0th day	The 2nd day	The 4th day	The 6th day	The 13rd day	The 20th day	F ratio	The P value
	The 0th day	The 2nd day	The 4th day	The 6th day	The 13rd day	The 20th day	F ratio	The P value	HR RR Temp PCV TSP Fib WCC Neuts Lymphs	52.45 27.48 38.15 34.4006 61.6314 1.8429 10.3866 5.491 4.0605	54.95 22.66 38.10 33.2173 61.9314 3.1263 12.3899 6.0105 5.5708	54.68 37.16 39.37 33.779 67.3297 2.1113 9.4875 4.933 4.0228	47.95 28.66 37.87 32.7173 60.1814 3.3763 11.1899 5.3505 5.2033	47.48 20.72 38.45 32.979 65.3297 0.9113 9.4695 3.927 4.3228	52.45 19.66 37.95 35.2173 65.9314 3.3763 9.4899 3.813 4.3983	3.79 3.06 9.81 0.535 4.563 5.871 4.443 3.331 5.736	0.019 0.04 0 0.747 0.009 0.003 0.01 0.03 0.003

The HR=heart rate, RR=respiration rate, Temp=rectal temperature, PCV=hematocrit cell volume (blood), TSP=total serum protein, Fib=fibrinogen, WCC=-white blood cell count(WBC), Neut=neutrophil, Lymphs=lymphocyte.

Table 8

My god	Sensitivity	Specificity	AUC-is original	AUC-Lloyd
My god	Sensitivity	Specificity	AUC-is original	AUC-Lloyd	2	1.000	0.800	1	0.886
4	1.000	0.800	1.000	0.941	2	1.000	0.800	1	0.886
4	1.000	0.800	1.000	0.941	13	0.667	0.400	0.500	0.467
20	0.500	0.800	0.700	0.645	13	0.667	0.400	0.500	0.467

Table 9

Organize the prediction classification and discriminating scoring of 2 young each sample of coltfoal

Date	Horse ID	The fate of test	Male/female	Gene expression index
Date	Horse ID	The fate of test	Male/female	Gene expression index	On May 19, on May 12,2003 on May 5,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	360 360 360 360 360 360 360 360 360 360	0 2 4 6 21 23 25 27 34 41	Negative positive negative	-0.09 0.43 -1.55 -1.73 -1.45 -0.91 -0.78 -1.52 -2.28 -2.74
On May 19, on May 12,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 28,2003 on April 12,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	362 362 362 362 362 362 362 362 362 362 362	0 2 4 6 13 20 21 23 25 34 41	Positive negative positive negative negative negative	1.69 0.96 -0.56 0.51 -1.45 -2.41 -1.31 -1.08 -1.97 -1.28 -2.33		360 360 360 360 360 360 360 360 360 360	0 2 4 6 21 23 25 27 34 41	Negative positive negative	-0.09 0.43 -1.55 -1.73 -1.45 -0.91 -0.78 -1.52 -2.28 -2.74
	362 362 362 362 362 362 362 362 362 362 362	0 2 4 6 13 20 21 23 25 34 41	Positive negative positive negative negative negative		On May 19, on May 12,2003 on May 5,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 28,2003 on April 14,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	364 364 364 364 364 364 364 364 364 364 364 364	0 2 4 6 13 20 21 23 25 27 34 41	Positive negative negative positive negative negative	0.45 -0.08 -1.03 -1.31 -1.02 -1.5 0.03 -0.32 -0.74 -1.56 -1.35 -1.51
On April 12, on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	366 366 366 366 366	0 2 4 6 13	Negative negative	-1.68 -1.42 -2.09 -1.68 -0.75		364 364 364 364 364 364 364 364 364 364 364 364	0 2 4 6 13 20 21 23 25 27 34 41	Positive negative negative positive negative negative

On May 19, on May 11,2003 on May 5,2003 on May 3,2003 on April 29,2003 on May 1,2003 2003 on the 28th April in 2003	366 366 366 366 366 366 366	20 21 23 25 27 34 41	Negative negative negative	-1.97 -0.76 -0.92 -1.34 -1.17 -1.41 -1.68
	366 366 366 366 366 366 366	20 21 23 25 27 34 41	Negative negative negative	-1.97 -0.76 -0.92 -1.34 -1.17 -1.41 -1.68	On May 19, on May 12,2003 on May 5,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 28,2003 on April 12,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	368 368 368 368 368 368 368 368 368 368 368 368	0 2 4 6 13 20 21 23 25 27 34 41	Positive negative negative positive negative negative	1.22 0.95 -2.02 -0.9 -2.08 -1.54 -1.97 -1.34 0.37 -0.48 -3.54 -1.96
On May 19, on May 12,2003 on May 5,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 28,2003 on April 12,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	369 369 369 369 369 369 369 369 369 369 369 369	0 2 4 6 13 20 21 23 25 27 34 41	Negative positive negative negative	-0.86 -1 1.18 -0.61 -1.14 -1.21 -1.19 -1.77 -1.19 -1.99 -1.53 -1.52		368 368 368 368 368 368 368 368 368 368 368 368	0 2 4 6 13 20 21 23 25 27 34 41	Positive negative negative positive negative negative
	369 369 369 369 369 369 369 369 369 369 369 369	0 2 4 6 13 20 21 23 25 27 34 41	Negative positive negative negative		On May 19, on May 12,2003 on May 5,2003 on May 3,2003 on May 1,2003 on April 29,2003 on April 28,2003 on April 12,2003 on April 14,2003 on April 10,2003 on April 12,2003 2003 on the 8th April in 2003	375 375 375 375 375 375 375 375 375 375 375 375	0 2 4 6 13 20 21 23 25 27 34 41	Negative positive positive negative	-2.15 1.97 1.66 0.66 -1.11 -0.6 -1.1 -2.47 -2.4 -0.67 -4.03 -1

Table 10

Two kinds of genes selecting

Sensitivity	Specificity	The result	Gene 1	Gene 2
Sensitivity	Specificity	The result	Gene 1	Gene 2	0.8913	0.8621	0.8800	WBC026C03	WBC881
0.8913	0.8621	0.8800	WBC026C03	WBC007A05	0.8913	0.8621	0.8800	WBC026C03	WBC881
0.8913	0.8621	0.8800	WBC026C03	WBC007A05	0.8913	0.8621	0.8800	WBC026C03	BM735054
0.8913	0.8621	0.8800	WBC012F12	WBC026C03	0.8913	0.8621	0.8800	WBC026C03	BM735054
0.8913	0.8621	0.8800	WBC012F12	WBC026C03	0.8913	0.8621	0.8800	WBC032G11	WBC026C03
0.8913	0.8621	0.8800	BM781127	WBC026C03	0.8913	0.8621	0.8800	WBC032G11	WBC026C03
0.8913	0.8621	0.8800	BM781127	WBC026C03	0.8913	0.8621	0.8800	B1961659	WBC026C03
0.8913	0.8621	0.8800	WBC026C03	BM734719	0.8913	0.8621	0.8800	B1961659	WBC026C03
0.8913	0.8621	0.8800	WBC026C03	BM734719	0.8913	0.8621	0.8800	WBC026C03	BM734719
0.8913	0.8621	0.8800	WBC007E09	WBC026C03	0.8913	0.8621	0.8800	WBC026C03	BM734719
0.8913	0.8621	0.8800	WBC007E09	WBC026C03	0.9130	0.8276	0.8800	B1961499	GI1305528
0.8913	0.8621	0.8800	B1961567	WBC026C03	0.9130	0.8276	0.8800	B1961499	GI1305528
0.8913	0.8621	0.8800	B1961567	WBC026C03	0.9130	0.8276	0.8800	GI1305528	B1961499
0.8913	0.8621	0.8800	WBC026C03	WBC032G11	0.9130	0.8276	0.8800	GI1305528	B1961499
0.8913	0.8621	0.8800	WBC026C03	WBC032G11	0.8913	0.8621	0.8800	WBC026C03	BM781127
0.8913	0.8621	0.8800	B1961567	WBC026C03	0.8913	0.8621	0.8800	WBC026C03	BM781127
0.8913	0.8621	0.8800	B1961567	WBC026C03	0.8913	0.8621	0.8800	WBC031E09	WBC026C03
0.8913	0.8621	0.8800	WBC026C03	WBC881	0.8913	0.8621	0.8800	WBC031E09	WBC026C03
0.8913	0.8621	0.8800	WBC026C03	WBC881	0.8913	0.8621	0.8800	BM735449	WBC026C03
0.9130	0.8276	0.8800	GI1305528	B1961499	0.8913	0.8621	0.8800	BM735449	WBC026C03

Table 11

Select 3 kinds of genes

Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3
Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	0.9348	0.8276	0.8933	WBC028A02	B1961499	WBC024D07
0.9348	0.7931	0.8800	BM780886	GI1305528	BM735096	0.9348	0.8276	0.8933	WBC028A02	B1961499	WBC024D07
0.9348	0.7931	0.8800	BM780886	GI1305528	BM735096	0.8913	0.8621	0.8800	WBC041C11	WBC026C03	BM734900
0.9348	0.7931	0.8800	WBC048H02	WBC020C09	BM734900	0.8913	0.8621	0.8800	WBC041C11	WBC026C03	BM734900
0.9348	0.7931	0.8800	WBC048H02	WBC020C09	BM734900	0.8913	0.8621	0.8800	WBC020C09	WBC026C03	WBC881
0.9130	0.8276	0.8800	WBC026C03	B1961581	BM735096	0.8913	0.8621	0.8800	WBC020C09	WBC026C03	WBC881
0.9130	0.8276	0.8800	WBC026C03	B1961581	BM735096	0.9565	0.7586	0.8800	WBC44	BM734862	B1961690
0.9565	0.7586	0.8800	B1961499	BM734607	WBC048H02	0.9565	0.7586	0.8800	WBC44	BM734862	B1961690
0.9565	0.7586	0.8800	B1961499	BM734607	WBC048H02	0.8913	0.8621	0.8800	WBC020C09	WBC007E09	WBC026C03
0.8913	0.8621	0.8800	WBC010B02	WBC026C03	WBC881	0.8913	0.8621	0.8800	WBC020C09	WBC007E09	WBC026C03
0.8913	0.8621	0.8800	WBC010B02	WBC026C03	WBC881	0.9130	0.8276	0.8800	Foe1268	WBC31	WBC048H02
0.9565	0.7586	0.8800	WBC041B04	B1961438	BM734862	0.9130	0.8276	0.8800	Foe1268	WBC31	WBC048H02
0.9565	0.7586	0.8800	WBC041B04	B1961438	BM734862	0.9130	0.8276	0.8800	WBC010C05	B1961438	WBC041B04
0.9130	0.8276	0.8800	WBC31	Foe1268	WBC048H02	0.9130	0.8276	0.8800	WBC010C05	B1961438	WBC041B04
0.9130	0.8276	0.8800	WBC31	Foe1268	WBC048H02	0.8913	0.8621	0.8800	WBC022G05	WBC048H02	WBC020C09
0.8913	0.8621	0.8800	WBC022G05	WBC048H02	B1961581	0.8913	0.8621	0.8800	WBC022G05	WBC048H02	WBC020C09
0.8913	0.8621	0.8800	WBC022G05	WBC048H02	B1961581	0.8913	0.8276	0.8667	WBC048H02	B1961054	BM735170
0.8913	0.8276	0.8667	BM735054	WBC026C03	BM735449	0.8913	0.8276	0.8667	WBC048H02	B1961054	BM735170
0.8913	0.8276	0.8667	BM735054	WBC026C03	BM735449	0.9130	0.7931	0.8667	WBC028A02	WBC048H02	B1961481
0.9130	0.7931	0.8667	WBC012F12	B1961499	BM734613	0.9130	0.7931	0.8667	WBC028A02	WBC048H02	B1961481

Table 12

Select 4 kinds of genes

Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4
Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	0.9348	0.8621	0.9067	B1961054	WBC009D04	B1961481	B1961499
0.9565	0.8276	0.9067	WBC009D04	WBC021A01	B1961499	WBC048H02	0.9348	0.8621	0.9067	B1961054	WBC009D04	B1961481	B1961499
0.9565	0.8276	0.9067	WBC009D04	WBC021A01	B1961499	WBC048H02	0.9348	0.8276	0.8933	WBC009D04	WBC422	BM734719	B1961481
0.9130	0.8621	0.8933	B1961469	B1961481	B1961434	WBC009D04	0.9348	0.8276	0.8933	WBC009D04	WBC422	BM734719	B1961481
0.9130	0.8621	0.8933	B1961469	B1961481	B1961434	WBC009D04	0.9565	0.7931	0.8933	WBC44	WBC016C12	B1961499	BM735096
0.9130	0.8276	0.8800	WBC048H02	B1961499	WBC31	WBC041B04	0.9565	0.7931	0.8933	WBC44	WBC016C12	B1961499	BM735096
0.9130	0.8276	0.8800	WBC048H02	B1961499	WBC31	WBC041B04	0.9130	0.8276	0.8800	WBC048H02	WBC026C03	WBC005G04	B1961581
0.9130	0.8276	0.8800	B1961499	WBC024D07	WBC005G04	WBC048H02	0.9130	0.8276	0.8800	WBC048H02	WBC026C03	WBC005G04	B1961581
0.9130	0.8276	0.8800	B1961499	WBC024D07	WBC005G04	WBC048H02	0.9348	0.7931	0.8800	BM735096	WBC010B02	WBC041B04	WBC024E03
0.9565	0.7586	0.8800	BM735054	WBC013G08	B1961690	BM735096	0.9348	0.7931	0.8800	BM735096	WBC010B02	WBC041B04	WBC024E03
0.9565	0.7586	0.8800	BM735054	WBC013G08	B1961690	BM735096	0.9130	0.8276	0.8800	B1961581	B1961438	GI1305528	WBC020C09
0.9348	0.7931	0.8800	B1961499	BM735054	WBC007A05	BM735096	0.9130	0.8276	0.8800	B1961581	B1961438	GI1305528	WBC020C09
0.9348	0.7931	0.8800	B1961499	BM735054	WBC007A05	BM735096	0.9130	0.8276	0.8800	WBC022G05	GI1305528	BM735096	BM734862
0.8913	0.8621	0.8800	WBC041C11	WBC048H02	WBC020C09	WBC030G08	0.9130	0.8276	0.8800	WBC022G05	GI1305528	BM735096	BM734862
0.8913	0.8621	0.8800	WBC041C11	WBC048H02	WBC020C09	WBC030G08	0.9348	0.7931	0.8800	WBC041B04	B1961659	WBC31	B1961499
0.9348	0.7931	0.8800	WBC022G05	B1961438	BM780886	B1961499	0.9348	0.7931	0.8800	WBC041B04	B1961659	WBC31	B1961499
0.9348	0.7931	0.8800	WBC022G05	B1961438	BM780886	B1961499	0.9130	0.8276	0.8800	WBC036C09	WBC285	B1961581	WBC041B04
0.8913	0.8621	0.8800	WBC026C03	BM734900	WBC032G11	WBC031E09	0.9130	0.8276	0.8800	WBC036C09	WBC285	B1961581	WBC041B04
0.8913	0.8621	0.8800	WBC026C03	BM734900	WBC032G11	WBC031E09	0.9130	0.8276	0.8800	BM735054	WBC022G05	WBC041C11	WBC048H02
0.9130	0.8276	0.8800	WBC048H02	WBC021A01	BM780886	BM735054	0.9130	0.8276	0.8800	BM735054	WBC022G05	WBC041C11	WBC048H02

Table 13

Select 5 kinds of genes

Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5
Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5	0.9348	0.8621	0.9067	BM734900	BM734719	WBC028D07	B1961481	WBC041B04
0.9348	0.8621	0.9067	WBC048H02	BM735096	WBC029A01	B1961581	WBC026C03	0.9348	0.8621	0.9067	BM734900	BM734719	WBC028D07	B1961481	WBC041B04
0.9348	0.8621	0.9067	WBC048H02	BM735096	WBC029A01	B1961581	WBC026C03	0.9348	0.8276	0.8933	WBC031E09	WBC029A01	B1961499	WBC048H02	WBC007A05
0.8913	0.8966	0.8933	WBC31	BM735054	B1961054	B1961481	WBC029A01	0.9348	0.8276	0.8933	WBC031E09	WBC029A01	B1961499	WBC048H02	WBC007A05
0.8913	0.8966	0.8933	WBC31	BM735054	B1961054	B1961481	WBC029A01	0.9130	0.8621	0.8933	B1961054	B1961481	BM735054	BM734607	BM735096
0.9565	0.7931	0.8933	B1961054	WBC009D04	WBC048H02	B1961438	B1961499	0.9130	0.8621	0.8933	B1961054	B1961481	BM735054	BM734607	BM735096
0.9565	0.7931	0.8933	B1961054	WBC009D04	WBC048H02	B1961438	B1961499	0.9348	0.8276	0.8933	B1961499	B1961481	B1961434	B1961690	WBC028D07
0.9348	0.8276	0.8933	B1961054	WBC009D04	WBC024D07	BM735449	B1961481	0.9348	0.8276	0.8933	B1961499	B1961481	B1961434	B1961690	WBC028D07
0.9348	0.8276	0.8933	B1961054	WBC009D04	WBC024D07	BM735449	B1961481	0.8913	0.8966	0.8933	WBC048H02	WBC022G05	B1961581	WBC44	WBC041C11
0.9130	0.8621	0.8933	BM735449	B1961434	WBC009D04	B1961481	BM734862	0.8913	0.8966	0.8933	WBC048H02	WBC022G05	B1961581	WBC44	WBC041C11
0.9130	0.8621	0.8933	BM735449	B1961434	WBC009D04	B1961481	BM734862	0.8913	0.8966	0.8933	WBC009D04	B1961481	BM734900	WBC285	B1961434
0.9348	0.8276	0.8933	B1961499	WBC012F12	WBC028D07	WBC041B04	BM735096	0.8913	0.8966	0.8933	WBC009D04	B1961481	BM734900	WBC285	B1961434
0.9348	0.8276	0.8933	B1961499	WBC012F12	WBC028D07	WBC041B04	BM735096	0.9348	0.7931	0.8800	WBC008B04	WBC048H02	BM734607	WBC007E09	WBC44
0.9130	0.8276	0.8800	BM735054	BM781436	BM735449	WBC028A02	B1961581	0.9348	0.7931	0.8800	WBC008B04	WBC048H02	BM734607	WBC007E09	WBC44
0.9130	0.8276	0.8800	BM735054	BM781436	BM735449	WBC028A02	B1961581	0.9348	0.7931	0.8800	WBC035E08	WBC285	WBC004E01	B1961499	BM734719
0.9348	0.7931	0.8800	WBC31	WBC022G05	BM735054	WBC007A05	WBC285	0.9348	0.7931	0.8800	WBC035E08	WBC285	WBC004E01	B1961499	BM734719
0.9348	0.7931	0.8800	WBC31	WBC022G05	BM735054	WBC007A05	WBC285	0.9565	0.7586	0.8800	WBC022G05	WBC021A01	B1961499	B1961438	WBC032C03
0.9130	0.8276	0.8800	B1961550	BM734613	BM780886	B1961581	BM735054	0.9565	0.7586	0.8800	WBC022G05	WBC021A01	B1961499	B1961438	WBC032C03
0.9130	0.8276	0.8800	B1961550	BM734613	BM780886	B1961581	BM735054	0.9130	0.8276	0.8800	WBC032G11	WBC024D07	BM781127	BM734613	B1961499
0.8913	0.8621	0.8800	WBC881	BM735449	BM781127	WBC026C03	WBC010B02	0.9130	0.8276	0.8800	WBC032G11	WBC024D07	BM781127	BM734613	B1961499

Table 14

Select 6 kinds of genes

Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5	Gene 6
Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5	Gene 6	0.9348	0.8966	0.9200	BM735096	WBC007E09	WBC041B04	WBC016C12	B1961054	B1961481
0.9348	0.8621	0.9067	WBC048H02	WBC041B04	GI1305528	B1961659	WBC422	B1961481	0.9348	0.8966	0.9200	BM735096	WBC007E09	WBC041B04	WBC016C12	B1961054	B1961481
0.9348	0.8621	0.9067	WBC048H02	WBC041B04	GI1305528	B1961659	WBC422	B1961481	0.9348	0.8621	0.9067	WBC009D04	B1961481	B1961567	B1961434	BM734862	B1961499
0.9130	0.8966	0.9067	B1961481	B1961581	WBC048H02	WBC035E08	B1961434	WBC009D04	0.9348	0.8621	0.9067	WBC009D04	B1961481	B1961567	B1961434	BM734862	B1961499
0.9130	0.8966	0.9067	B1961481	B1961581	WBC048H02	WBC035E08	B1961434	WBC009D04	0.9348	0.8621	0.9067	WBC005G04	BM734900	WBC020C09	B1961434	WBC009D04	B1961481
0.9565	0.8276	0.9067	WBC010B02	B1961434	WBC009D04	WBC041B04	WBC028A02	B1961481	0.9348	0.8621	0.9067	WBC005G04	BM734900	WBC020C09	B1961434	WBC009D04	B1961481
0.9565	0.8276	0.9067	WBC010B02	B1961434	WBC009D04	WBC041B04	WBC028A02	B1961481	0.9348	0.8621	0.9067	B1961659	WBC032G11	WBC048H02	BM735096	WBC041B04	B1961581
0.9348	0.8621	0.9067	BM735449	BM734661	BM734607	WBC285	BM735054	WBC022G05	0.9348	0.8621	0.9067	B1961659	WBC032G11	WBC048H02	BM735096	WBC041B04	B1961581
0.9348	0.8621	0.9067	BM735449	BM734661	BM734607	WBC285	BM735054	WBC022G05	0.9565	0.8276	0.9067	B1961690	WBC022G05	B1961499	WBC016C12	WBC013G08	B1961434
0.9348	0.8276	0.8933	GI1305528	BM734613	BM735096	BM734862	B1961499	BM780886	0.9565	0.8276	0.9067	B1961690	WBC022G05	B1961499	WBC016C12	WBC013G08	B1961434
0.9348	0.8276	0.8933	GI1305528	BM734613	BM735096	BM734862	B1961499	BM780886	0.9565	0.7931	0.8933	B1961438	WBC048H02	WBC028D07	B1961499	BM734900	B1961567
0.9130	0.8621	0.8933	WBC44	B1961659	WBC024E03	B1961581	BM734719	BM734661	0.9565	0.7931	0.8933	B1961438	WBC048H02	WBC028D07	B1961499	BM734900	B1961567
0.9130	0.8621	0.8933	WBC44	B1961659	WBC024E03	B1961581	BM734719	BM734661	0.9130	0.8621	0.8933	WBC422	B1961481	WBC007A05	WBC041B04	WBC005G04	BM734607
0.9130	0.8621	0.8933	B1961481	WBC024E03	WBC009D04	WBC032C03	Foe1268	WBC422	0.9130	0.8621	0.8933	WBC422	B1961481	WBC007A05	WBC041B04	WBC005G04	BM734607
0.9130	0.8621	0.8933	B1961481	WBC024E03	WBC009D04	WBC032C03	Foe1268	WBC422	0.9348	0.8276	0.8933	BM735449	B1961499	WBC028A02	WBC285	WBC44	WBC004E01
0.8913	0.8966	0.8933	WBC036C09	B1961581	WBC005G04	WBC048H02	B1961434	Foe1268	0.9348	0.8276	0.8933	BM735449	B1961499	WBC028A02	WBC285	WBC44	WBC004E01
0.8913	0.8966	0.8933	WBC036C09	B1961581	WBC005G04	WBC048H02	B1961434	Foe1268	0.8913	0.8621	0.8800	WBC005G04	WBC013G08	WBC048H02	WBC007E09	B1961581	WBC004E01
0.9348	0.7931	0.8800	BM735054	BM734661	B1961499	B1961054	BM780886	WBC031E09	0.8913	0.8621	0.8800	WBC005G04	WBC013G08	WBC048H02	WBC007E09	B1961581	WBC004E01
0.9348	0.7931	0.8800	BM735054	BM734661	B1961499	B1961054	BM780886	WBC031E09	0.9130	0.8276	0.8800	BM735054	WBC005G04	B1961434	WBC028D07	BM734719	B1961581
0.9130	0.8276	0.8800	B1961438	B1961581	WBC048H02	BM735054	BM735170	GI1305528	0.9130	0.8276	0.8800	BM735054	WBC005G04	B1961434	WBC028D07	BM734719	B1961581

Table 15

Select 7 kinds of genes

Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5	Gene 6	Gene 7
Sensitivity	Specificity	The result	Gene 1	Gene 2	Gene 3	Gene 4	Gene 5	Gene 6	Gene 7	0.9348	0.8621	0.9067	B1961434	BM781127	WBC31	WBC31	WBC030G08	WBC048H02	BM735054
0.9348	0.8621	0.9067	B1961481	WBC009D04	Foe1268	WBC016C12	WBC007E09	WBC035E08	B1961054	0.9348	0.8621	0.9067	B1961434	BM781127	WBC31	WBC31	WBC030G08	WBC048H02	BM735054
0.9348	0.8621	0.9067	B1961481	WBC009D04	Foe1268	WBC016C12	WBC007E09	WBC035E08	B1961054	0.9130	0.8966	0.9067	WBC022G05	WBC009D04	WBC021A01	B1961481	BM734719	WBC004E01	B1961434
0.9348	0.8276	0.8933	WBC008B04	BM735096	B1961434	BM735054	BM781127	WBC31	B1961567	0.9130	0.8966	0.9067	WBC022G05	WBC009D04	WBC021A01	B1961481	BM734719	WBC004E01	B1961434
0.9348	0.8276	0.8933	WBC008B04	BM735096	B1961434	BM735054	BM781127	WBC31	B1961567	0.9348	0.8276	0.8933	WBC028D07	B1961481	BM735031	B1961434	WBC048H02	B1961054	WBC009D04
0.9348	0.8276	0.8933	WBC041B04	BM781127	WBC032C03	WBC31	BM735054	B1961434	WBC030G08	0.9348	0.8276	0.8933	WBC028D07	B1961481	BM735031	B1961434	WBC048H02	B1961054	WBC009D04
0.9348	0.8276	0.8933	WBC041B04	BM781127	WBC032C03	WBC31	BM735054	B1961434	WBC030G08	0.9565	0.7931	0.8933	WBC31	WBC44	WBC007A05	BM735054	WBC048H02	B1961469	BM734607
0.9130	0.8621	0.8933	WBC008B04	WBC31	B1961499	B1961054	WBC048H02	WBC016C12	BM734719	0.9565	0.7931	0.8933	WBC31	WBC44	WBC007A05	BM735054	WBC048H02	B1961469	BM734607
0.9130	0.8621	0.8933	WBC008B04	WBC31	B1961499	B1961054	WBC048H02	WBC016C12	BM734719	0.9348	0.8276	0.8933	BM735054	B1961054	WBC422	WBC31	BM734661	WBC048H02	WBC007E09
0.9348	0.8276	0.8933	B1961690	BM734661	WBC009D04	WBC422	B1961481	B1961567	WBC031E09	0.9348	0.8276	0.8933	BM735054	B1961054	WBC422	WBC31	BM734661	WBC048H02	WBC007E09
0.9348	0.8276	0.8933	B1961690	BM734661	WBC009D04	WBC422	B1961481	B1961567	WBC031E09	0.9130	0.8621	0.8933	WBC048H02	WBC31	WBC024E03	WBC041C11	BM735054	B1961054	WBC31
0.9130	0.8621	0.8933	WBC022G05	B1961550	WBC009D04	B1961434	B1961481	B1961438	WBC024E03	0.9130	0.8621	0.8933	WBC048H02	WBC31	WBC024E03	WBC041C11	BM735054	B1961054	WBC31
0.9130	0.8621	0.8933	WBC022G05	B1961550	WBC009D04	B1961434	B1961481	B1961438	WBC024E03	0.9348	0.8276	0.8933	WBC041C11	WBC026C03	B1961690	WBC005G04	WBC032G11	B1961581	B1961499
0.9348	0.8276	0.8933	WBC005G04	B1961054	WBC004E01	BM781127	BM735096	B1961499	GI1305528	0.9348	0.8276	0.8933	WBC041C11	WBC026C03	B1961690	WBC005G04	WBC032G11	B1961581	B1961499
0.9348	0.8276	0.8933	WBC005G04	B1961054	WBC004E01	BM781127	BM735096	B1961499	GI1305528	0.9348	0.8276	0.8933	BM735096	WBC009D04	BM735054	WBC028D07	WBC041B04	WBC032G11	BM734719
0.9130	0.8621	0.8933	WBC008B04	BM780886	B1961438	BM735096	BM735054	WBC013G08	WBC007E09	0.9348	0.8276	0.8933	BM735096	WBC009D04	BM735054	WBC028D07	WBC041B04	WBC032G11	BM734719
0.9130	0.8621	0.8933	WBC008B04	BM780886	B1961438	BM735096	BM735054	WBC013G08	WBC007E09	0.9348	0.8276	0.8933	BM735096	B1961581	WBC31	WBC041B04	B1961434	WBC009D04	B1961690
0.9130	0.8621	0.8933	WBC020C09	BM735449	WBC009D04	B1961481	WBC022G05	B1961434	WBC036C09	0.9348	0.8276	0.8933	BM735096	B1961581	WBC31	WBC041B04	B1961434	WBC009D04	B1961690
0.9130	0.8621	0.8933	WBC020C09	BM735449	WBC009D04	B1961481	WBC022G05	B1961434	WBC036C09	0.8913	0.8621	0.8800	B1961054	WBC285	WBC026C03	WBC016C12	BM735054	WBC007A05	BM734661
0.9130	0.8276	0.8800	WBC008B04	B1961481	WBC009D04	B1961550	WBC422	WBC021A01	Foe1268	0.8913	0.8621	0.8800	B1961054	WBC285	WBC026C03	WBC016C12	BM735054	WBC007A05	BM734661

Table 16

Select 8 kinds of genes

Sensitivity	Specificity	The result	Gene (8)
Sensitivity	Specificity	The result	Gene (8)	0.9565	0.8621	0.9200	BM735054；B1961054；WBC009D04；B1961438；BM780886；BM735449；WBC020C09；WBC010B02
0.9348	0.8621	0.9067	BM735031；WBC032G11；BM734661；WBG44；B1961054；WBC028D07；B1961481；WBC009D04	0.9565	0.8621	0.9200
0.9348	0.8621	0.9067		0.9130	0.8966	0.9067	WBC029A01；B1961434；WBC041B04；GI1305528；B1961438；Foe1268；WBC048H02；WBC44
0.9565	0.8276	0.9067	WBC007E09；B1961581；BM781127；WBC010B02；BM734613；WBC005G04；B1961438；WBC009D04	0.9130	0.8966	0.9067
0.9565	0.8276	0.9067		0.9565	0.8276	0.9067	WBC026C03；WBC020C09；WBC285；BM781127；WBC010B02；WBC028A02；BM734719；WBC005G04
0.9565	0.7931	0.8933	WBC031E09；BM735096；WBC013G08；B1961434；WBC009D04；B1961499；WBC041B04；BM734900	0.9565	0.8276	0.9067
0.9565	0.7931	0.8933		0.8913	0.8966	0.8933	B1961434；B1961481；B1961438；WBC024E03；WBC009D04；B1961469；WBC036C09；BM734900
0.9130	0.8621	0.8933	BM781127；BM735096；BM734719；BM735031；B1961690；BM735054；B1961481；B1961434	0.8913	0.8966	0.8933
0.9130	0.8621	0.8933		0.9348	0.8276	0.8933	WBC007E09；WBC048H02；WBC036C09；WBC31；BM735054；WBC028D07；BM735096；B1961499
0.9130	0.8621	0.8933	WBC041C11；WBC041B04；WBC022G05；WBC422；B1961481；GI1305528；WBC030G08；WBC013G08	0.9348	0.8276	0.8933
0.9130	0.8621	0.8933		0.9348	0.8276	0.8933	B1961469；B1961690；WBC022G05；WBC010C05；B1961499；BM735054；WBC036C09；WBC028D07
0.9348	0.8276	0.8933	WBC008B04；BM781127；BM735096；WBC041B04；WBC032G11；WBC31；B1961438；WBC422	0.9348	0.8276	0.8933
0.9348	0.8276	0.8933		0.9130	0.8621	0.8933	BM734607；WBC026C03；WBC028D07；B1961581；BM735096；B1961690；WBC041C11；WBC010C05
0.9348	0.8276	0.8933	B1961438；WBC024D07；WBC422；BM735054；BM734607；BM734661；WBC031E09；WBC041B04	0.9130	0.8621	0.8933
0.9348	0.8276	0.8933		0.9565	0.7931	0.8933	BM780886；B1961438；B1961499；WBC004E01；WBC041C11；WBC036C09；B1961581；WBC032C03
0.9348	0.8276	0.8933	BM735096；WBC041B04；WBC31；B1961434；B1961581；B1961567；B1961469；WBC009D04	0.9565	0.7931	0.8933
0.9348	0.8276	0.8933		0.8913	0.8966	0.8933	WBC032G11；B1961481；WBC036C09；WBC005G04；WBC009D04；WBC016C12；WBC029A01；B1961434
0.9348	0.8276	0.8933	B1961054；GI1305528；BM735054；WBC024E03；WBC021A01；Foe1268；B1961581；BM735096	0.8913	0.8966	0.8933
0.9348	0.8276	0.8933		0.8913	0.8966	0.8933	B1961481；WBC009D04；WBC016C12；BM734661；WBC030G08；WBC010C05；WBC005G04；B1961434
0.8913	0.8966	0.8933	BM735031；Foe1268；B1961481；WBC004E01；WBC024E03；WBC048H02；WBC041B04；WBC010C05	0.8913	0.8966	0.8933

Table 17

Select 9 kinds of genes

Sensitivity	Specificity	The result	Gene (9)
Sensitivity	Specificity	The result	Gene (9)	0.9348	0.8966	0.9200	?WBC021A01；B1961499；WBC028D07；WBC009D04；WBC031E09；B1961054；B1961481；WBC31；BM780886
0.9348	0.8966	0.9200	?B1961659；BM735054；BM734719；B1961054；WBC024E03；B1961550；BM734900；B1961481；WBC31	0.9348	0.8966	0.9200
0.9348	0.8966	0.9200		0.9565	0.8621	0.9200	?BM734719；Foe1268；B1961567；WBC020C09；WBC007A05；GI1305528；WBC009D04；B1961481；B1961434
0.9348	0.8966	0.9200	?B1961481；B1961054；WBC008B04；WBC041C11；WBC009D04；WBC029A01；BM735031；WBC012F12；WBC041B04	0.9565	0.8621	0.9200
0.9348	0.8966	0.9200		0.9348	0.8621	0.9067	?BM735096；WBC31；WBC44；B1961434；BM734900；GI1305528；WBC024E03；BM734862；B1961481
0.9348	0.8621	0.9067	?WBC028D07；WBC035E08；WBC041B04；B1961438；WBC022G05；WBC020C09；G11305528；WBC024E03；WBC285	0.9348	0.8621	0.9067
0.9348	0.8621	0.9067		0.9348	0.8621	0.9067	?WBC31；WBC009D04；BM734719；B1961481；WBC030G08；B1961054；BM780886；WBC026C03；WBC024D07
0.9348	0.8621	0.9067	?B1961469；WBC028D07；BM735096；WBC007A05；BM781436；WBC041B04；WBC007E09；B1961581；B1961054	0.9348	0.8621	0.9067
0.9348	0.8621	0.9067		0.9130	0.8966	0.9067	?B1961054；WBC009D04；B1961567；WBC31；WBC016C12；WBC285；WBC44；B1961481；B1961434
0.8913	0.9310	0.9067	?WBC030G08；B1961567；GI1305528；B1961481；WBC422；B1961054；BM734900；BM734613；8M735054	0.9130	0.8966	0.9067
0.8913	0.9310	0.9067		0.9130	0.8966	0.9067	?WBC030G08；B1961434；BM734900；BM735054；BM781127；B1961550；WBC010C05；B1961581；WBC032G11
0.9348	0.8276	0.8933	?WBC048H02；WBC041C11；WBC31；WBC005G04；WBC032C03；WBC013G08；BM734862；B1961581；BM734613	0.9130	0.8966	0.9067
0.9348	0.8276	0.8933		0.9130	0.8621	0.8933	?WBC016C12；B1961499；B1961054；BM735096；WBC035E08；WBC022G05；WBC032G11；WBC048H02；BM734719
0.9565	0.7931	0.8933	?WBC009D04；WBC022G05；Foe1268；B1961434；B1961481；WBC012F12；BM735031；WBC016C12；B1961499	0.9130	0.8621	0.8933
0.9565	0.7931	0.8933		0.9348	0.8276	0.8933	?WBC31；B1961690；WBC422；WBC022G05；WBC020C09；B1961581；B1961438；WBC041B04；WBC024E03；BM780886；
0.8913	0.8966	0.8933	?B1961054；BM735170；GI1305528；WBC285；B1961659；WBC013G08；WBC007E09；BM735054	0.9348	0.8276	0.8933
0.8913	0.8966	0.8933		0.9130	0.8621	0.8933	?WBC036C09；BM735054；WBC028A02；BM780886；WBC030G08；B1961434；WBC048H02；WBC029A01；BM781436
0.9130	0.8621	0.8933	?BM781436；WBC041B04；B1961054；WBC024E03；BM734719；WBC44；B1961499；WBC028D07；WBC285	0.9130	0.8621	0.8933
0.9130	0.8621	0.8933		0.8913	0.8966	0.8933	?B1961567；B1961481；WBC032C03；WBC009D04；WBC016C12；BM734719；WBC008B04；WBC285；B1961434
0.9130	0.8621	0.8933	?BM735031；GI1305528；Foe1268；WBC422；WBC009D04；B1961481；BM734607；WBC041C11；B1961054	0.8913	0.8966	0.8933

Table 18

Select 10 kinds of genes

Sensitivity	Specificity	The result	Gene (10)
Sensitivity	Specificity	The result	Gene (10)	0.9348	0.9310	0.9333	WBC029A01；WBC009D04；BM735031；B1961550；BM735054；B1961054；BM780886；B1961659；B1961481；WBC041B04
0.9130	0.9310	0.9200	WBC009D04；WBC007E09；B1961054；BM735170；WBC026C03；WBC029A01；BM781127；WBC31；B1961550；B1961481	0.9348	0.9310	0.9333
0.9130	0.9310	0.9200		0.9348	0.8966	0.9200	B1961499；BM735096；B1961567；B1961434；BM734900；BM734719；WBC041B04；B1961054；B1961481；B1961659
0.9348	0.8966	0.9200	BM734607；WBC036C09；B1961469；WBC009D04；B1961054；WBC028D07；WBC030G08；B1961481；BM734862；BM735170	0.9348	0.8966	0.9200
0.9348	0.8966	0.9200		0.9130	0.9310	0.9200	WBC028D07；B1961434；B1961481；BM735096；GI1305528；BM735054；BM735170；WBC041B04；B1961550；WBC009D04
0.9130	0.8966	0.9067	BM735096；B1961499；BM734613；WBC048H02；WBC010C05；WBC032G11；WBC881；BM734900；WBC005G04；WBC041B04	0.9130	0.9310	0.9200
0.9130	0.8966	0.9067		0.9565	0.8276	0.9067	BM735054；BM734607；B1961438；BM734900；WBC881；BM735031；WBC007E09；WBC048H02；B1961054；WBC013G08
0.9348	0.8621	0.9067	WBC024E03；BM734607；WBC020C09；WBC007E09；B1961481；WBC005G04；WBC031E09；B1961438；WBC009D04；GI1305528	0.9565	0.8276	0.9067
0.9348	0.8621	0.9067		0.9348	0.8621	0.9067	BM735031；BM734607；BM734613；WBC012F12；WBC422；B1961054；WBC009D04；WBC022G05；B1961481；WBC030G08
0.8913	0.9310	0.9067	WBC285；WBC041C11；BM781436；WBC009D04；B1961054；BM735096；B1961434；B1961481；B1961550；WBC028A02	0.9348	0.8621	0.9067
0.8913	0.9310	0.9067		0.9348	0.8621	0.9067	BM734607；B1961434；BM734862；WBC041C11；BM734613；WBC009D04；BM735170；WBC028D07；B1961481；B1961567
0.9348	0.8621	0.9067	B1961499；WBC422；WBC009D04；B1961434；WBC022G05；BM780886；WBC44；B1961434；WBC036C09；B1961481	0.9348	0.8621	0.9067
0.9348	0.8621	0.9067		0.9348	0.8621	0.9067	WBC048H02；WBC036C09；BM735054；BM735096；B1961054；WBC31；BM734862；WBC010C05；WBC007E09；B1961434
0.9565	0.8276	0.9067	WBC007E09；WBC005G04；BM735096；WBC041B04；B1961499；WBC009D04；B1961690；WBC422；WBC024E03；BM735031	0.9348	0.8621	0.9067
0.9565	0.8276	0.9067		0.9348	0.8621	0.9067	B1961434；WBC029A01；WBC020C09；B1961581；BM734719；WBC005G04；BM781436；WBC007E09；B1961481；WBC009D04
0.9348	0.8621	0.9067	BM735096；B1961438；WBC028D07；WBC44；Foe1268；WBC007E09；WBC028A02；WBC048H02；BM781127；WBC022G05	0.9348	0.8621	0.9067
0.9348	0.8621	0.9067		0.9130	0.8966	0.9067	B1961481；BM735096；WBC048H02；B1961054；WBC012F12；BM734661；WBC881；BM735031；BM735054；GI1305528
0.9130	0.8966	0.9067	BM735054；WBC31；WBC036C09；B1961481；WBC285；B1961550；B1961054；B1961581；BM734900；B1961434	0.9130	0.8966	0.9067
0.9130	0.8966	0.9067		0.8913	0.8966	0.8933	B1961567；B1961481；WBC022G05；WBC028A02；B1961469；B1961054；WBC44；WBC881；BM735054；B1961581
0.9348	0.8276	0.8933	WBC036C09；WBC035E08；WBC041C11；BM734719；B1961659；WBC031E09；B1961481；B1961581；WBC422；BM735096	0.8913	0.8966	0.8933

Table 19

Select 20 kinds of genes

Sensitivity	Specificity	The result	Gene (20)
Sensitivity	Specificity	The result	Gene (20)	0.9130	0.8966	0.9067	WBC020C09；B1961054；B1961434；WBC012F12；B1961550；WBC422；WBC021A01；WBC022G05；WBC010B02；BM735096； WBC31；WBC026C03；BM734661；B1961690；GI1305528；BM734719；WBC009D04；WBC028D07；WBC041B04；B1961481
0.9130	0.8966	0.9067	BM735096；B1961054；BM735449；BM781436；WBC024E03；WBC010B02；B1961438；B1961567；WBC036C09；WBC004E01； WBC010C05；WBC881；BM734862；WBC032G11；WBC009D04；WBC016C12；B1961481；WBC007E09；Foe1268；BM780886	0.9130	0.8966	0.9067
0.9130	0.8966	0.9067		0.9130	0.8621	0.8933	B1961054；WBC029A01；WBC004E01；B1961659；WBC036C09；BM734719；WBC035E08；BM781127；BM735096；WBG44； B1961690；WBC422；WBC016C12；WBC009D04；WBC026C03；B1961481；BM735170；BM781436；BM734661；WBC013G08
0.9348	0.8276	0.8933	WBC021A01；BM734613；WBC009D04；WBC44；B1961438；BM780886；WBC024E03；WBC031E09；WBC020C09；WBC007A05； B1961550；WBC036C09；B1961659；WBC007E09；WBC030G08；B1961481；B1961054；Foe1268；WBC422；WBC024D07	0.9130	0.8621	0.8933
0.9348	0.8276	0.8933		0.9130	0.8621	0.8933	WBC031E09；WBC013G08；WBC041C11；WBC005G04；BM734613；WBC009D04；WBC028D07；WBC44；B1961434；BM780886； B1961550；BM781436；WBC029A01；B1961438；WBC024E03；BM734661；WBC31；B1961481；Foe1268；BM734900
0.9130	0.8621	0.8933	BM735031；WBC007A05；BM735054；WBC021A01；B1961054；BM735449；BM734607；GI1305528；WBC016C12；B1961438； B1961481；WBC024E03；B1961567；B1961550；WBC009D04；WBC035E08；WBC013G08；WBC032G11；WBC028A02；B1961434	0.9130	0.8621	0.8933
0.9130	0.8621	0.8933		0.8913	0.8966	0.8933	WBC031E09；WBC016C12；WBC013G08；WBC035E08；WBC009D04；B1961054；Foe1268；WBC032G11；B1961567；WBC881； B1961690；WBC029A01；GI1305528；WBC022G05；BM735170；WBC010B02；BM735054；B1961481；WBC012F12；WBC021A01
0.9130	0.8621	0.8933	WBC44；BM735096；WBC008B04；BM735449；WBC036C09；BM781436；B1961499；WBC285；B1961469；WBC032C03；Foe1268； WBC048H02；WBC028A02；WBC010C05；WBC009D04；WBC021A01；WBC026C03；WBC028D07；WBC010B02；WBC005G04	0.8913	0.8966	0.8933
0.9130	0.8621	0.8933		0.9348	0.8276	0.8933	WBC041C11；B1961054；WBC44；WBC009D04；WBC028D07；WBC012F12；B1961567；WBC024D07；WBC024E03；B1961481； WBC013G08；GI1305528；BM781127；B1961438；WBC020C09；B1961581；WBC021A01；B1961469；Foe1268；BM735031
0.9130	0.8621	0.8933	B1961659；WBC024D07；BM734719；B1961581；WBC31；B1961054；B1961499；WBC024E03；BM735170；WBC881；B1961469； B1961481；WBC031E09；BM735096；WBC009D04；WBC31；WBC028A02；WBC030G08；WBC012F12；WBC032C03	0.9348	0.8276	0.8933
0.9130	0.8621	0.8933		0.9130	0.8621	0.8933	WBC028A02；WBC008B04；B1961690；WBC028D07；WBC022G05；WBC030G08；B1961438；BM734661；B1961499；BM781127； WBC031E09；BM781436；GI1305528；WBC013G08；WBC004E01；B1961054；WBC021A01；WBC041B04；BM735031；BM734719
0.9565	0.7931	0.8933	B1961690；B1961481；WBC31；WBC024E03；BM734613；WBC007A05；BM734900；WBC026C03；BM735449；WBC041C11； WBC024D07；WBC007E09；WBC021A01；BM734719；WBC31；WBC041B04；B1961499；BM735170；WBC012F12；WBC028D07	0.9130	0.8621	0.8933
0.9565	0.7931	0.8933		0.9130	0.8621	0.8933	B1961481；B1961434；B1961567；WBC44；WBC881；WBC028A02；WBC010B02；WBC048H02；B1961438；BM734862； WBC009D04；WBC035E08；WBC31；BM734607；BM735054；BM734900；BM734661；BM781127；WBC013G08；WBC031E09
0.9130	0.8621	0.8933	WBC041B04；Foe1268；GI1305528；BM735054；WBC008B04；WBC009D04；WBC004E01；B1961481；WBC021A01；B1961054； BM735031；WBC007A05；WBC013G08；B1961499；B1961438；WBC31；WBC026C03；B1961469；WBC010C05；BM734661	0.9130	0.8621	0.8933
0.9130	0.8621	0.8933		0.9130	0.8621	0.8933	WBC022G05；WBC008B04；B1961434；B1961438；B1961054；WBC032G11；WBC016C12；WBC007A05；B1961567；WBC031E09； BM735449；WBC31；WBC005G04；WBC041C11；WBC028D07；WBC032C03；WBC041B04；WBC009D04；WBC010B02；B1961481
0.9130	0.8621	0.8933	WBC028D07；WBC010B02；WBC009D04；BM735449；BM734719；BM734862；BM735096；BM781436；B1961550；WBC008B04；	0.9130	0.8621	0.8933

Sensitivity	Specificity	The result	Gene (20)
Sensitivity	Specificity	The result	Gene (20)				BM734607；WBC016C12；WBC024E03；Foe1268；B1961438；BM781127；BM734613；B1961054；B1961481；WBC44
0.8913	0.8966	0.8933	B1961054；WBC041C11；WBC009D04；BM734661；WBC032C03；BM734719；WBC031E09；BM734607；BM735031；B1961550； B1961438；BM735449；WBC021A01；BM735054；BM781436；WBC028D07；B1961434；B1961581；WBC016C12；GI1305528
0.8913	0.8966	0.8933		0.9130	0.8621	0.8933	BM735449；WBC041B04；BM735031；BM735054；WBC007A05；WBC024E03；WBC016C12；WBC010C05；WBC022G05； WBC013G08；WBC422；B1961499；BM780886；WBC004E01；WBC012F12；BM781436；WBC007E09；GI1305528；BM735096； B1961567
0.9130	0.8621	0.8933	BM735031；WBC024D07；B1961054；B1961481；BM734862；BM734900；BM735170；B1961690；WBC004E01；BM781127； WBC881；B1961434；B1961659；WBC022G05；WBC44；WBC032C03；BM780886；WBC009D04；B1961499；WBC035E08	0.9130	0.8621	0.8933
0.9130	0.8621	0.8933		0.9130	0.8621	0.8933	B1961567；BM735170；BM734900；WBC881；WBC041B04；WBC009D04；WBC016C12；WBC048H02；B1961481；B1961054； BM734613；B1961659；BM734719；BM781436；WBC030G08；WBC024D07；WBC31；B1961581；WBC026C03；WBC422

Table 20

Selected 30 kinds of genes

Sensitivity	Specificity	The result	Gene (30)
Sensitivity	Specificity	The result	Gene (30)	0.9130	0.8276	0.8800	WBC012F12；BM781127；BM735449；BM734862；WBC007A05；WBC31；BM734900；WBC009D04；WBC041B04；B1961438； WBC032C03；B1961054；B1961434；WBC016C12；B1961481；B1961550；WBC024E03；WBC028D07；WBC022G05；BM734719； WBC005G04；WBC024D07；BM781436；WBC028A02；Foe1268；WBC010C05；WBC881；B1961659；WBC004E01；WBC048H02
0.9348	0.7931	0.8800	BM734661；B1961499；WBC005G04；BM735449；WBC44；B1961550；B1961581；WBC032C03；BM781436；BM734900； WBC036C09；BM781127；WBC035E08；WBC285；BM734607；B1961690；WBC007E09；WBC029A01；BM734613；WBC008B04； WBC048H02；WBC030G08；BM735096；WBC881；WBC009D04；BM734862；BM735031；WBC041B04；WBC026C03；BM735170	0.9130	0.8276	0.8800
0.9348	0.7931	0.8800		0.8913	0.8621	0.8800	WBC028A02；WBC032C03；WBC44；WBC005G04；BM735031；WBC028D07；WBC31；WBC009D04；WBC016C12；B1961481； BM780886；WBC048H02；BM735170；WBC31；WBC041B04；B1961438；BM735449；B1961690；B1961659；WBC012F12； B1961581；WBC035E08；BM734719；WBC010B02；B1961499；GI1305528；BM734607；WBC036C09；BM735096；WBC021A01
0.9130	0.8276	0.8800	WBC007E09；WBC44；BM734900；WBC035E08；WBC024E03；WBC009D04；BM734613；WBC041C11；WBC285；BM781127； BM734719；B1961581；WBC031E09；WBC032C03；WBC005G04；WBC036C09；WBC010C05；BM734862；BM735449；BM735096； B1961469；WBC020C09；WBC041B04；WBC008B04；BM781436；WBC028D07；B1961659；BM735031；GI1305528；B1961481	0.8913	0.8621	0.8800
0.9130	0.8276	0.8800		0.8913	0.8621	0.8800	WBC036C09；B1961438；BM735170；BM734862；WBC029A01；B1961659；WBC285；B1961550；WBC016C12；WBC007E09； B1961434；WBC028A02；WBC024E03；BM735096；BM734719；WBC035E08；WBC010C05；B1961567；BM735031；WBC007A05； B1961581；BM735054；WBC031E09；BM734900；WBC026C03；B1961054；GI1305528；WBC009D04；B1961481；WBC048H02
0.8696	0.8966	0.8800	WBC009D04；WBC010B02；WBC031E09；Foe1268；WBC422；B1961438；WBC881；WBC31；WBC285；BM734613；BM735054； B1961054；BM734900；BM781436；WBC024E03；WBC007A05；B1961499；B1961567；WBC041C11；BM735449；B1961434； WBC028D07；WBC012F12；WBC008B04；BM734661；WBC016C12；WBC041B04；WBC007E09；B1961481；WBC024D07	0.8913	0.8621	0.8800
0.8696	0.8966	0.8800		0.8913	0.8621	0.8800	WBC016C12；WBC007E09；BM734719；WBC020C09；WBC024D07；B1961499；B1961659；WBC030G08；WBC422；WBC881； BM734900；BM735449；BM734613；BM735054；BM734661；WBC005G04；BM735096；B1961550；WBC036C09；GI1305528； WBC012F12；WBC026C03；BM734862；WBC032G11；WBC010B02；WBC032C03；BM734607；B1961054；WBC022G05；B1961469
0.8696	0.8621	0.8667	BM781436；WBC032G11；WBC009D04；B1961434；BM735054；B1961567；WBC881；WBC008B04；WBC024D07；BM734719； WBC007E09；WBC035E08；WBC041B04；BM734607；WBC031E09；B1961690；WBC022G05；B1961481；GI1305528；BM735096； B1961054；WBC007A05；WBC020C09；BM735449；WBC048H02；WBC028A02；B1961469；WBC004E01；BM781127；WBC010B02	0.8913	0.8621	0.8800
0.8696	0.8621	0.8667		0.8913	0.8276	0.8667	WBC028A02；BM734613；BM734862；WBC007A05；WBC029A01；WBC004E01；BM735054；BM780886；WBC016C12；BM734900； WBC024D07；WBC028D07；BM734719；BM735170；WBC010B02；B1961434；B1961481；BM734607；WBC021A01；WBC026C03； BM781436；B1961659；WBC009D04；B1961438；B1961054；BM735449；WBC881；WBC036C09；WBC422；WBC005G04
0.9130	0.7931	0.8667	WBC035E08；WBC036C09；B1961438；B1961481；BM781436；BM734661；WBC285；BM734607；WBC010B02；BM734900； WBC026C03；WBC005G04；B1961659；B1961469；WBC881；WBC028D07；BM734719；B1961581；WBC028A02；BM735449； WBC024E03；WBC007E09；WBC31；GI1305528；BM734613；WBC008B04；B1961054；WBC032G11；WBC422；WBC032C03	0.8913	0.8276	0.8667
0.9130	0.7931	0.8667		0.8913	0.8276	0.8667	WBC041B04；WBC007A05；WBC032G11；BM734719；WBC44；WBC31；WBC010B02；B1961434；WBC028A02；B1961438；

Sensitivity	Specificity	The result	Gene (30)
Sensitivity	Specificity	The result	Gene (30)				B1961659；WBC881；BM735096；BM781127；WBC012F12；WBC030G08；B1961567；B1961690；B1961499；WBC021A01； WBC005G04；BM735054；B1961434；WBC035E08；WBC032C03；B1961054；B1961469；WBC008B04；GI1305528；BM781436
0.8696	0.8621	0.8667	WBC030G08；WBC44；WBC31；WBC024E03；B1961550；Foe1268；BM734719；WBC881；WBC022G05；WBC005G04；B1961499； WBC029A01；WBC032C03；WBC007A05；WBC021A01；WBC024D07；B1961481；WBC285；WBC?012F12；WBC028A02； WBC010B02；BM781127；WBC422；B1961054；WBC009D04；BM735449；WBC028D07；GI1305528；BM734661；B1961469
0.8696	0.8621	0.8667		0.8696	0.8621	0.8667	WBC007A05；GI1305528；B1961481；B1961567；WBC881；WBC010B02；WBC048H02；BM734862；WBC422；WBC031E09； WBC022G05；WBC007E09；WBC030G08；BM735096；WBC008B04；BM735054；WBC44；WBC004E01；WBC041C11； WBC035E08；BM780886；BM781127；BM781436；B1961054；B1961690；WBC032C03；WBC024D07；B1961659；WBC005G04； BM734719
0.8696	0.8621	0.8667	B1961054；WBC024E03；WBC010B02；WBC026C03；B1961690；BM781436；WBC31；BM780886；WBC31；GI1305528；BM735449； WBC041C11；WBC004E01；B1961481；WBC881；WBC285；WBC035E08；WBC007E09；WBC028A02；WBC005G04；WBC029A01； WBC041B04；B1961659；BM735031；WBC007A05；BM734719；WBC032C03；B1961567；BM734661；BM734862	0.8696	0.8621	0.8667
0.8696	0.8621	0.8667		0.9130	0.7931	0.8667	GI1305528；BM734607；BM735170；WBC008B04；Foe1268；WBC285；BM734613；WBC024E03；BM781436；B1961581；BM734719； WBC009D04；B1961054；B1961659；WBC028D07；WBC31；B1961567；B1961481；WBC032G11；WBC020C09；WBC010C05； B1961550；WBC031E09；BM735096；WBC004E01；WBC026C03；BM734661；BM781127；B1961469；B1961499
0.8913	0.8276	0.8667	WBC016C12；BM781127；WBC024E03；B1961567；WBC041B04；WBC009D04；WBC007A05；B1961550；WBC041C11；B1961690； WBC010C05；BM735449；BM735096；B1961499；B1961581；WBC881；B1961054；BM781436；WBC032G11；B1961469； WBC010B02；BM735054；WBC020C09；WBC021A01；WBC031E09；B1961481；B1961434；BM734661；WBC285；WBC013G08	0.9130	0.7931	0.8667
0.8913	0.8276	0.8667		0.8478	0.8966	0.8667	BM781436；WBC026C03；B1961690；WBC031E09；WBC009D04；BM735170；WBC44；B1961434；WBC022G05；BM735054； B1961499；WBC029A01；WBC041C11；WBC016C12；B1961567；WBC024E03；B1961054；WBC004E01；WBC31；B1961481； B1961469；BM734719；WBC032C03；WBC012F12；WBC008B04；WBC028A02；WBC041B04；BM734900；BM734661；WBC005G04
0.8696	0.8621	0.8667	WBC028D07；BM734900；WBC032C03；WBC010B02；WBC012F12；BM780886；WBC007E09；BM781127；WBC009D04；WBC31； BM735096；WBC022G05；B1961469；BM735031；BM735054；B1961499；GI1305528；BM735449；WBC020C09；WBC007A05； WBC021A01；WBC041B04；WBC026C03；B1961434；B1961054；B1961690；WBC028A02；WBC035E08；WBC285；B1961438	0.8478	0.8966	0.8667
0.8696	0.8621	0.8667		0.8913	0.8276	0.8667	WBC032C03；WBC029A01；BM781436；WBC31；WBC44；GI1305528；B1961481；WBC024D07；WBC028D07；B1961659； WBC026C03；WBC008B04；BM734900；BM780886；BM734719；WBC036C09；B1961438；WBC007E09；WBC041B04； WBC009D04；BM735096；BM734607；WBC004E01；BM781127；WBC020C09；WBC010B02；WBC422；B1961054；BM734661； BM735054
0.9130	0.7931	0.8667	Foe1268；WBC010B02；WBC032G11；BM735170；WBC022G05；WBC31；WBC030G08；BM734900；BM781127；BM781436； WBC041B04；BM734719；BM780886；BM734613；BM734862；WBC422；WBC029A01；WBC012F12；GI1305528；WBC021A01； B1961481；B1961469；B1961054；B1961581；WBC44；WBC009D04；WBC032C03；B1961438；WBC024D07；WBC013G08	0.8913	0.8276	0.8667

Table 21

Gene ontology

Gene	The GenBank homology	Uniprot	Component	Function	Process
Gene	The GenBank homology	Uniprot	Component	Function	Process
B1961481.V1.3_AT	No homology	NA	NA	NA	NA
B1961481.V1.3_AT	No homology	NA	NA	NA	NA	WBC026C03_V1.3_A T	The homo sapiens, Interferon, rabbit, but γ-induced protein 16, mRNA.	Q16666	Nuclear	DNA combination and transcription repression	To the reaction of virus, immunne response
WBC005G04_V1.3_A T	Homo sapiens's myelocyte nuclear differentiation antigen mRNA, encoding sequence fully	P41218	Nuclear	The DNA combination	Immunne response	WBC026C03_V1.3_A T		Q16666	Nuclear	DNA combination and transcription repression	To the reaction of virus, immunne response
WBC005G04_V1.3_A T		P41218	Nuclear	The DNA combination	Immunne response	WBC020C09_V1.3_A T	No homology	NA	NA	NA	NA
WBC007A05_V1.3_A T	Homo sapiens G albumen-coupled receptor 65, mRNA	Q8IYL9	Integrate with plasma membrane	Acceptor and signal transduction activity	Immunne response	WBC020C09_V1.3_A T	No homology	NA	NA	NA	NA
WBC007A05_V1.3_A T	Homo sapiens G albumen-coupled receptor 65, mRNA	Q8IYL9	Integrate with plasma membrane	Acceptor and signal transduction activity	Immunne response	B1961581	Homo sapiens NAD kinases accession number BC001709	O95544	Tenuigenin	The NAD+ kinase activity	The ATP metabolism
BM735170.V1.3_AT	No homology	NA	NA	NA	NA	B1961581	Homo sapiens NAD kinases accession number BC001709	O95544	Tenuigenin	The NAD+ kinase activity	The ATP metabolism
BM735170.V1.3_AT	No homology	NA	NA	NA	NA	WBC010C05	Putative protein matter ox analogue (LOC529385)	NA	NA	NA	NA
WBC009D04_V1.3_A T	Be positioned at the people mRNA of the X-CGD gene that relates to the granuloma disease on the chromosome x	P04839	Integrate with film	Melts combine, oxidoreductase activity	Inflammatory response, electron transport	WBC010C05	Putative protein matter ox analogue (LOC529385)	NA	NA	NA	NA
WBC009D04_V1.3_A T		P04839	Integrate with film	Melts combine, oxidoreductase activity	Inflammatory response, electron transport	B1961434.V1.3_AT / B1961054.V1.3_AT B1961434.V1.3_S_ AT	But the IP-10mRNA of interferon--inducible protein-10	P02778	Outside the born of the same parents	The chemokine activity	Immunne response
BM780886.V1.3_AT	Homo sapiens 6-phosphogluconolactonase, MRNA (C DNA cloning MGC:20013 IMAGE:4053022).	O59479	Endoplasmic reticulum	6-phosphogluconolactonase activity	Carbohydrate activity	B1961434.V1.3_AT / B1961054.V1.3_AT B1961434.V1.3_S_ AT	But the IP-10mRNA of interferon--inducible protein-10	P02778	Outside the born of the same parents	The chemokine activity	Immunne response
BM780886.V1.3_AT		O59479	Endoplasmic reticulum	6-phosphogluconolactonase activity	Carbohydrate activity	WBC004E01_V1.3_A T	Homo sapiens Apo-2 ligand mRNA, cds fully	P50591	Integrate with film	The TNF receptors bind	Immunne response
B1961659.V1.3_AT	No homology	NA	NA	NA	NA	WBC004E01_V1.3_A T	Homo sapiens Apo-2 ligand mRNA, cds fully	P50591	Integrate with film	The TNF receptors bind	Immunne response
B1961659.V1.3_AT	No homology	NA	NA	NA	NA	WBC008B04	No homology	NA	NA	NA	NA
BM735449.V1.3_AT	No homology	NA	NA	NA	NA	WBC008B04	No homology	NA	NA	NA	NA
BM735449.V1.3_AT	No homology	NA	NA	NA	NA	WBC029A01	Homo sapiens's apoptosis 10 (PDCD10), transcript variant 3	Q9BUL8	NA	NA	NA
BM781436.V1.3_AT	Homo sapiens SH3 structural domain associativity is rich in the albumen sample 3 of L-glutamic acid, mRNA	Q9H299	Nuclear	NA	NA	WBC029A01	Homo sapiens's apoptosis 10 (PDCD10), transcript variant 3	Q9BUL8	NA	NA	NA
BM781436.V1.3_AT		Q9H299	Nuclear	NA	NA	BM735054.V1.3_AT	Homo sapiens family with heart rate similarity 14, member A, mRNA (cDNA clone MGC:44913 IMAGE:5229498).	X9H2X8	Integrate with film	NA	Reaction to insect, parasite or pathogenic agent
WBC31	No homology	NA	NA	NA	NA	BM735054.V1.3_AT		X9H2X8	Integrate with film	NA	Reaction to insect, parasite or pathogenic agent
WBC31	No homology	NA	NA	NA	NA	BM734900	Homo sapiens's matrix metalloproteinase 9 (gelatinase B, the 92kDa gelatinase, 92kDa IV Collagen Type VI enzyme), mRNA (cDNA clone MGC:12688 IMAGE:4054882)	P14780	Outside the born of the same parents	Ionic bond, metal proteinase activity	Proteolysis

Gene	The GenBank homology	Uniprot	Component	Function	Process
Gene	The GenBank homology	Uniprot	Component	Function	Process	B1961438	No homology	NA	NA	NA	NA
B1961550.V1.3_AT	Homo sapiens cDNA FLJ40597 fis, clone THYMU2011118	NA	NA	NA	NA	B1961438	No homology	NA	NA	NA	NA
B1961550.V1.3_AT	Homo sapiens cDNA FLJ40597 fis, clone THYMU2011118	NA	NA	NA	NA	BM734862.V1.3_A	The homo sapiens who expresses on the myelocyte triggers acceptor 1, mRNA	Q9NP99	Integrate with film	Receptor active	Humoral response
WBC041B04_V1.3_A T	The proteinic people mRNA of interferon-induced 56-Kda is also referred to as IFIT-1	P09914	Tenuigenin	In conjunction with	Immunne response	BM734862.V1.3_A		Q9NP99	Integrate with film	Receptor active	Humoral response
WBC041B04_V1.3_A T		P09914	Tenuigenin	In conjunction with	Immunne response	WBC422.GRSP.V1.3 _AT	Homo sapiens's guanine nucleotide binding protein 5, mRNA.	Q96PP8	NA	The GTP combination	Immunne response
WBC007E09	Homo sapiens's sterol-C5-desaturase (ERG3 Δ-5-desaturase homologue, fungi)-sample, transcript variant 2 (SC5DL)	Q6GTM5	Integrate with film	Oxidoreductase activity	Lipid metabolism	WBC422.GRSP.V1.3 _AT	Homo sapiens's guanine nucleotide binding protein 5, mRNA.	Q96PP8	NA	The GTP combination	Immunne response
WBC007E09		Q6GTM5	Integrate with film	Oxidoreductase activity	Lipid metabolism	BM735031.V1.3_AT	Homo sapiens N-myc (and STAT) interactant, mRNA (cDNA clone MGC:5050 IMAGE:3452659)	Q13287	Tenuigenin	Transcribe the cofactor activity	Inflammatory response
WBC013G08_V1.3_A T	Homo sapiens cDNA FLJ16386 fis, clone TRACH2000862 mediumly is similar to the purine nucleoside acid binding protein mRNA that mouse is inferred	NA	NA	NA	NA	BM735031.V1.3_AT		Q13287	Tenuigenin	Transcribe the cofactor activity	Inflammatory response
WBC013G08_V1.3_A T		NA	NA	NA	NA	BM735096	Homo sapiens CD79A antigen (immunoglobulin (Ig) be correlated with α) (CD79A), transcript variant 1	P11912	Integrate with film	The transmembrane receptor activity	Defense is replied
GI1305528.V1.3_A T	Horse Mx protein homology thing mRNA.	P27594	NA	The GTP combination	Immunne response	BM735096		P11912	Integrate with film	The transmembrane receptor activity	Defense is replied
GI1305528.V1.3_A T	Horse Mx protein homology thing mRNA.	P27594	NA	The GTP combination	Immunne response	WBC881.GRSP.V1.3 _AT	Homo sapiens makorin, ring finger protein 1, mRNA (MKRN1)	Q9UHC7	The ubiquitin ligase mixture	Uiquitin-protease matter ligase enzyme is in conjunction with activity	The protein ubiquitinization
WBC44.V1.3_AT	Homo sapiens B aggressive lymphoma gene, mRNA.	Q8IXQ6	Nuclear	NAD+ADP-ribosyltransferase activity	Cell migration	WBC881.GRSP.V1.3 _AT	Homo sapiens makorin, ring finger protein 1, mRNA (MKRN1)	Q9UHC7	The ubiquitin ligase mixture		The protein ubiquitinization
WBC44.V1.3_AT	Homo sapiens B aggressive lymphoma gene, mRNA.	Q8IXQ6	Nuclear	NAD+ADP-ribosyltransferase activity	Cell migration	WBC041C11	Homo sapiens copine I (CPNE1)	Q99829	NA	Transport activity	The transhipment of vesica mediation
WBC036C09_V1.3_A T	Homo sapiens's Δ sleep inducing peptide, immunoreactant, mRNA.	NA	NA	NA	NA	WBC041C11	Homo sapiens copine I (CPNE1)	Q99829	NA	Transport activity	The transhipment of vesica mediation
WBC036C09_V1.3_A T		NA	NA	NA	NA	WBC285	No homology	NA	NA	NA	NA
WBC030G08_V1.3_A T	Homo sapiens chromosome 6 open reading frame 72, mRNA.	NA	NA	NA	NA	WBC285	No homology	NA	NA	NA	NA
WBC030G08_V1.3_A T	Homo sapiens chromosome 6 open reading frame 72, mRNA.	NA	NA	NA	NA	WBC024D07	Homo sapiens's heat shock 70kDa albumen 8, transcript variant 1 (HSPA8)	P11142	Cell surface, nuclear	The ATP combination	Protein folding
WBC031E09_V1.3_A T	People EV12 protein gene, exons 1	NA	NA	NA	NA	WBC024D07		P11142	Cell surface, nuclear	The ATP combination	Protein folding
WBC031E09_V1.3_A T	People EV12 protein gene, exons 1	NA	NA	NA	NA	BM734613	Homo sapiens's senilism protein relative protein mRNA.	Q9UJZ5	Integrate plastosome with film	Protein bound	Transhipment
WBC012F12_V1.3_A T	No homology	NA	NA	NA	NA	BM734613	Homo sapiens's senilism protein relative protein mRNA.	Q9UJZ5	Integrate plastosome with film	Protein bound	Transhipment
WBC012F12_V1.3_A T	No homology	NA	NA	NA	NA	BM734661	The people UbA52 suprarenal gland mRNA of ubiquitin-52 amino acid fusion rotein	P62987	Nuclear, rrna	Protein modification	Ribosomal structural constituent
WBC022G05	Homo sapiens ELOVL family member 5, the extension of longer chain fatty acid (FEN1/Elo2, SUR4/Elo3-sample, yeast) (ELOVL5)	Q7L2S5	NA	NA	NA	BM734661		P62987	Nuclear, rrna	Protein modification	Ribosomal structural constituent
WBC022G05		Q7L2S5	NA	NA	NA	WBC032G11_V1.3_A T	Homo sapiens cDNA FLJ20073 fis, clone COL02320	NA	NA	NA	NA
WBC028A02	No homology	NA	NA	NA	NA	WBC032G11_V1.3_A T	Homo sapiens cDNA FLJ20073 fis, clone COL02320	NA	NA	NA	NA
WBC028A02	No homology	NA	NA	NA	NA	WBC024E03_V1.3_A T	Homo sapiens's transcription factor ISGF-3mRNA.	Q00978	Tenuigenin, nuclear	Transcription factor	Immunne response

Gene	The GenBank homology	Uniprot	Component	Function	Process
Gene	The GenBank homology	Uniprot	Component	Function	Process	BM734607.V1.3_AT	The homo sapiens mRNA (BIRC4BP) of XIAP correlation factor-1.	Q6GPH4	NA	The zine ion combination	NA
Foe1268	Myo-inositol 1-phosphate synthase A1 (ISYNA1)	Q9NPH2	NA	Inositol-3-phosphate synthase activity	The inositol biosynthesizing	BM734607.V1.3_AT		Q6GPH4	NA	The zine ion combination	NA
Foe1268	Myo-inositol 1-phosphate synthase A1 (ISYNA1)	Q9NPH2	NA	Inositol-3-phosphate synthase activity	The inositol biosynthesizing	WBC035E08	Homo sapiens's ubiquitin-conjugate enzyme E2D 1 (UBC4/5 homologue	P51668	NA	The ligase enzyme activity	The ubiquitin circulation
BM734719.V1.3_AT	No homology	NA	NA	NA	NA	WBC035E08		P51668	NA	The ligase enzyme activity	The ubiquitin circulation
BM734719.V1.3_AT	No homology	NA	NA	NA	NA	BM781127.V1.3_AT	Homo sapiens's acid phosphatase 5, tartrate resistance (ACP5), mRNA	P13686	NA	Integrate lysosome with film	Hydrolytic enzyme activities
WBC048H02.bFSP_2 0021501.esd	Homo sapiens's guanine-nucleotide-binding protein (G albumen), beta polypeptides 2-sample 1 (GNB2L1), mRNA	Q6RW13	NA	NA	Receptor active	BM781127.V1.3_AT		P13686	NA	Integrate lysosome with film	Hydrolytic enzyme activities
WBC048H02.bFSP_2 0021501.esd		Q6RW13	NA	NA	Receptor active	B1961469	No homology	NA	NA	NA	NA
WBC021A01	No homology	NA	NA	NA	NA	B1961469	No homology	NA	NA	NA	NA
WBC021A01	No homology	NA	NA	NA	NA	B1961499	Homo sapiens SUI1 isomer (being also referred to as eIF1)	P41567	Tenuigenin	Translation starts active	The protein biosynthesizing
B1961690.V1.3_AT	Homo sapiens's eukaryotic translation starts the factor 3, subunit 5 ε, 47kDa mRNA. (EIF3S5)	O00303	Eukaryotic translation starts the factor 3 mixtures	Translation starts active	The protein biosynthesizing	B1961499	Homo sapiens SUI1 isomer (being also referred to as eIF1)	P41567	Tenuigenin	Translation starts active	The protein biosynthesizing
B1961690.V1.3_AT		O00303	Eukaryotic translation starts the factor 3 mixtures	Translation starts active	The protein biosynthesizing	WBC016C12	No homology	NA	NA	NA	NA
WBC032C03	No homology	NA	NA	NA	NA	WBC016C12	No homology	NA	NA	NA	NA
WBC032C03	No homology	NA	NA	NA	NA	WBC028D07_V1.3_A T	People's guanine nucleotide binding protein isotype II (GBP-2) mRNA	P32456	NA	The GTP combination	Immunne response
WBC010B02_V1.3_A T	Homo sapiens C-type agglutinant protein CLL-1mRNA, cds. fully	Q5QGZ9	NA	The sugar combination	NA	WBC028D07_V1.3_A T		P32456	NA	The GTP combination	Immunne response
WBC010B02_V1.3_A T		Q5QGZ9	NA	The sugar combination	NA	B1961567.V1.3_AT	Homo sapiens's leucine aminopeptidase(LAP) 3, mRNA.	P28838	Tenuigenin	Amino-peptidase activity	Proteolysis

Claims

1. the method for the existence of herpesvirus infection in the diagnostic test object, described method comprise detect in the tested object at least a be selected from following, the unconventionality expression of the herpesvirus infection of in immune system cell, expressing (HVI) marker gene: (a) a kind of gene, its polynucleotide expression product contains the nucleotide sequence that at least 50% sequence homogeny is arranged with following arbitrary sequence: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) a kind of gene, its polynucleotide expression product contain the nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (c) a kind of gene, its polynucleotide expression product contains to encode the nucleotide sequence of the polypeptide of at least 50% sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114 with at least a portion of following arbitrary sequence, wherein said part contains at least 15 amino-acid residues that adjoin of this sequence; (d) a kind of gene, its polynucleotide expression product contain at least under low preciseness condition the nucleotide sequence with (a) and (b), (c) described sequence or its complementary sequence hybridization.

2. the method for claim 1, it is characterized in that, comprise and detect the unconventionality expression that is selected from following HVI mark polynucleotide: (a) contain the polynucleotide that the nucleotide sequence of at least 50% sequence homogeny is arranged with following arbitrary sequence: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following arbitrary sequence have the polypeptide of at least 50% sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) contain at least under low preciseness condition polynucleotide with the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

3. the method for claim 1, it is characterized in that, comprise and detect the unconventionality expression that is selected from following HVI labeling polypeptide: (i) contain the polypeptide that has the aminoacid sequence of 50% sequence similarity with following arbitrary sequence at least: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; The polypeptide that (ii) contains the part of following arbitrary sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 5 contiguous amino acid residues of this sequence; At least 15 contiguous amino acid residues of (iii) amino acid contained sequence and following arbitrary sequence have the polypeptide of 30% similarity at least: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; The polypeptide that (iv) contains the part of following arbitrary sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 5 contiguous amino acid residues of this sequence, and with can and (i), (ii) or (iii) described sequence immune interactional antigen binding molecules takes place immunity takes place interacts.

4. the method for claim 1, it is characterized in that, detect described unconventionality expression by following steps: the level or the functionally active of at least a HVI marker gene expression product in the biological sample of (1) detection available from tested object, (2) level or the functionally active of corresponding expression product in the reference sample of the object of the level of detected each expression product or functionally active and one or more normal subjects or one or more no herpesvirus infections are made comparisons, wherein compare with the level or the functionally active of corresponding expression product in the reference sample, there is herpesvirus infection in the level of expression product or functionally active variant showing in this biological sample in the tested object.

5. method as claimed in claim 4, it is characterized in that, also comprise when this expression product or the detected level of each expression product or functionally active higher 10% the time than this corresponding expression product or the detected level of each corresponding expression product or functionally active, diagnosing has herpesvirus infection existence, stage or degree in this tested object.

6. method as claimed in claim 5, it is characterized in that, determine the existence of herpesvirus infection by the increase that detects at least a level that is selected from following HVI mark polynucleotide or functionally active: (a) contain the polynucleotide that have the nucleotide sequence of 50% sequence homogeny with following arbitrary sequence at least: SEQ ID NO:1,2,4,8,12,13,15,17,21,23,26,27,31,39,43,45,47,49,51,55,59,67,69,71,75,76,79,81,85,87,91,98,99109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,14,16,18,22,28,32,40,44,46,48,50,52,56,60,68,70,72,80,82,86,88,92,110,112 or 114; (c) contain the polynucleotide of nucleotide sequence that coding and following arbitrary sequence at least a portion have the polypeptide of 50% sequence similarity at least: SEQ ID NO:3,5,9,14,16,18,22,28,32,40,44,46,48,50,52,56,60,68,70,72,80,82,86,88,92,110,112 or 114, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

7. method as claimed in claim 4, it is characterized in that, also comprise when this expression product or the detected level of each expression product or functionally active lower 10% the time than this corresponding expression product or the detected level of each corresponding expression product or functionally active, diagnosing has herpesvirus infection existence, stage or degree in this tested object.

8. method as claimed in claim 7, it is characterized in that, determine the existence of herpesvirus infection by the reduction that detects at least a level that is selected from following HVI mark polynucleotide or functionally active: (a) contain the polynucleotide that have the nucleotide sequence of 50% sequence homogeny with following arbitrary sequence at least: SEQ ID NO:6,10,19,24,25,29,33,34,35,37,38,41,53,57,61,63,65,66,73,77,83,89,93,94,96,100,101,102,104,106,107 or 108,, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:11,20,30,36,42,54,58,62,64,74,78,90,95,97,103 or 105; (c) contain the polynucleotide of nucleotide sequence that coding and following arbitrary sequence at least a portion have the polypeptide of 50% sequence similarity at least: SEQ ID NO:11,20,30,36,42,54,58,62,64,74,78,90,95,97,103 or 105, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

9. method as claimed in claim 4, it is characterized in that, also comprise when this expression product or the detected level of each expression product or the corresponding expression product with this of functionally active or the detected level of each corresponding expression product or functionally active are same or similar, diagnose not have herpesvirus infection in this tested object.

10. method as claimed in claim 4 is characterized in that, the difference of detected level of the corresponding expression product with each of detected level of each expression product or functionally active or functionally active is no more than about 5%.

11. method as claimed in claim 4 is characterized in that, also comprises level or the functionally active of detection at least about each expression product of two kinds of HVI marker gene.

12. method as claimed in claim 4, it is characterized in that, comprise the level or the functionally active that detect each expression product that is selected from the relevant HVI marker gene of following at least a one-level: (a) contain the polynucleotide that have the nucleotide sequence of 50% sequence homogeny with following arbitrary sequence at least: SEQ IDNO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25 or 26, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20 or 22; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following sequence have the polypeptide of 50% sequence similarity at least: SEQ ID NO:3,5,9,11,14,16,18,20 or 22, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

13. method as claimed in claim 4, it is characterized in that, comprise the level or the functionally active that detect each expression product that is selected from the relevant HVI marker gene of following at least a secondary: (a) contain the polynucleotide that have the nucleotide sequence of at least 50% sequence homogeny with following arbitrary sequence: SEQID NO:27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61 or 63, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:28,30,32,36,40,42,44,46,48,50,52,56,58,60,62 or 64; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following arbitrary sequence have the polypeptide of 50% sequence similarity at least: SEQ ID NO:28,30,32,36,40,42,44,46,48,50,52,56,58,60,62 or 64, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

14. method as claimed in claim 4, it is characterized in that, comprise the level or the functionally active that detect each expression product that is selected from following at least a three grades of relevant HVI marker gene: (a) contain the polynucleotide that have the nucleotide sequence of at least 50% sequence homogeny with following arbitrary sequence: SEQID NO:65,66,67,69,71,73,75,76,77,79,81,83,84,85 or 87, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:68,70,72,74,78,80,82,86 or 88; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following arbitrary sequence have the polypeptide of 50% sequence similarity at least: SEQ ID NO:68,70,72,74,78,80,82,86 or 88, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

15. method as claimed in claim 4, it is characterized in that, comprise the level or the functionally active that detect each expression product that is selected from the relevant HVI marker gene of following at least a level Four: (a) contain the polynucleotide that have the nucleotide sequence of at least 50% sequence homogeny with following arbitrary sequence: SEQID NO:89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:90,92,95,97,103,105,110,112 or 114; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following arbitrary sequence have the polypeptide of 50% sequence similarity at least: SEQ ID NO:90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 15 contiguous amino acid residues of this sequence; (d) containing at least can be under low preciseness condition and the polynucleotide of the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.

16. method as claimed in claim 4 is characterized in that, described biological sample comprises blood.

17. method as claimed in claim 4 is characterized in that, described biological sample comprises peripheral blood.

18. method as claimed in claim 4 is characterized in that, described biological sample comprises white corpuscle.

19. method as claimed in claim 4 is characterized in that, described expression product is the RNA molecule.

20. method as claimed in claim 4 is characterized in that, described expression product is a polypeptide.

21. method as claimed in claim 4 is characterized in that, described expression product is identical with corresponding expression product.

22. method as claimed in claim 4 is characterized in that, described expression product is the variant of described corresponding expression product.

23. method as claimed in claim 4, it is characterized in that, described expression product or corresponding expression product are the DNA copies of target RNA or this target RNA, the available at least a nucleic acid probe of hybridizing with this target RNA or this DNA copy under low preciseness condition at least of its level detects, and this nucleic acid probe contains 15 contiguous nucleotides of certain HVI marker gene at least.

24. method as claimed in claim 23 is characterized in that, described target RNA or its DNA are copied level or the abundance stdn by the DNA copy that is present in reference RNA in the same sample or this reference RNA of detected level or abundance.

25. method as claimed in claim 23 is characterized in that, described nucleic acid probe is fixed on solid or the semi-solid upholder.

26. method as claimed in claim 23 is characterized in that, described nucleic acid probe constitutes the part of all nucleic acid probe space arrays.

27. method as claimed in claim 23 is characterized in that, detects the level that copies the bonded nucleic acid probe with described target RNA or described DNA by hybridization.

28. method as claimed in claim 23 is characterized in that, detects the level that copies the bonded nucleic acid probe with described target RNA or described DNA by nucleic acid amplification.

29. method as claimed in claim 23 is characterized in that, detects the level that copies the bonded nucleic acid probe with described target RNA or described DNA by the nuclease protection test.

30. method as claimed in claim 23 is characterized in that, the probe that is used to detect HVI mark polynucleotide contains just like SEQ ID NO:145-2150 the sequence shown in any.

31. method as claimed in claim 23 is characterized in that, described expression product or corresponding expression product are the target polypeptide, and the interactional at least a antigen binding molecules of the available and described target polypeptide immune of its level detects.

32. method as claimed in claim 23 is characterized in that, with the detected level of described target polypeptide by the level standardization that is present in the reference polypeptide in the same sample.

33. method as claimed in claim 23 is characterized in that, described antigen binding molecules is fixed on solid or the semi-solid upholder.

34. method as claimed in claim 23 is characterized in that, described antigen binding molecules forms the part of antigen binding molecules space array.

35. method as claimed in claim 23 is characterized in that, by the level of immunoassay detection with described target polypeptide bonded antigen binding molecules.

36. method as claimed in claim 4 is characterized in that, described expression product or corresponding expression product are the target polypeptide, and at least a substrate that the available and described target polypeptide reaction of its level produces reaction product detects.

37. method as claimed in claim 36 is characterized in that, with the detected functionally active of described target polypeptide by the functionally active stdn that is present in the reference polypeptide in the same sample.

38. method as claimed in claim 4, it is characterized in that, utilization comprises that the system in the terminal station that at least one is connected with the base station carries out described method, (a) accepts described data by network of communication from described terminal station in wherein said base station, wherein said data representedly detect or the parameter value of level of standardization or functionally active corresponding at least a expression product in the biological sample, (b) described data are made comparisons with representing in the reference sample at least a corresponding expression product data that pre-determine detected or level of standardization or functionally active, thereby measure and compare any difference of the level of expression product or functionally active in this biological sample with the level or the functionally active of corresponding expression product in the reference sample.

39. method as claimed in claim 38 is characterized in that, described base station can provide herpesvirus infection to exist, do not exist or the diagnosis of degree.

40. method as claimed in claim 38 is characterized in that, described base station also can will diagnose indication to be passed to described terminal station by network of communication.

41. the method for claim 1 is characterized in that, detects described unconventionality expression and shows have herpesvirus infection to exist or risk.

42. the method for claim 1 is characterized in that, described tested object is a horse.

43. treatment, the method of prevention or inhibition object generation herpesvirus infection, this method comprises the unconventionality expression of at least a HVI marker gene in the detected object, and give treatment or the relief of symptoms or the reverse of described object significant quantity or suppress the medicine of described object generation herpesvirus infection, wherein, group is down expressed and be selected to the HVI marker gene in immune cell: (a) a kind of gene, its polynucleotide expression product contains the nucleotide sequence that at least 50% sequence homogeny is arranged with following arbitrary sequence: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) a kind of gene, its polynucleotide expression product contain the nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (c) a kind of gene, its polynucleotide expression product contains to encode the nucleotide sequence of the polypeptide of at least 50% sequence similarity: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114 with at least a portion of following arbitrary sequence, wherein said part contains at least 15 amino-acid residues that adjoin of this sequence; (d) a kind of gene, its polynucleotide expression product contain at least under low preciseness condition the nucleotide sequence with (a) and (b), (c) described sequence or its complementary sequence hybridization.

44. isolating HVI mark polynucleotide, it is selected from: (a) contain the polynucleotide that have the nucleotide sequence of 50% sequence homogeny with following arbitrary sequence at least: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence; (b) contain the polynucleotide of a part that comprises following arbitrary sequence: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence, wherein said part contains at least 15 contiguous nucleotides of this sequence or complementary sequence; (c) at least can be under low preciseness condition and (a) or (b) polynucleotide of described sequence or its complementary sequence hybridization; (d) contain the polynucleotide of the part of following arbitrary sequence: SEQ ID NO:1,12,23,24,25,26,33,34,37,38,65,66,75,76,83,84,93,98,99,100,101,106,107 or 108, or its complementary sequence, wherein said part contain at least 15 contiguous nucleotides of this sequence or complementary sequence and at least under low preciseness condition with (a) and (b) or (c) described sequence or its complementary sequence hybridization.

45. one kind contains the nucleic acid construct thing that operability is connected in the described HVI mark of claim 44 polynucleotide of regulatory element, described regulatory element can be operated in host cell.

46. an isolating host cell, it contains nucleic acid construct thing as claimed in claim 45.

47. probe that contains at least under low preciseness condition with the nucleotide sequence of the described multi-nucleotide hybrid of claim 44.

48. probe as claimed in claim 47, it is characterized in that, described probe is basically by constituting corresponding at least a portion of the nucleotide sequence of arbitrary aminoacid sequence below the coding or with its complementary nucleotide sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part is to 15 Nucleotide of the youthful and the elderly.

49. probe as claimed in claim 47, it is characterized in that, described probe comprise can with the nucleotide sequence of at least a portion hybridization of the nucleotide sequence of the following arbitrary aminoacid sequence of coding: SEQID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part is to 15 Nucleotide of the youthful and the elderly.

50. probe as claimed in claim 47, it is characterized in that, described probe contains the nucleotide sequence that can hybridize with at least a portion of following sequence at least under low preciseness condition: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, wherein said part is to 15 Nucleotide of the youthful and the elderly.

51. probe as claimed in claim 47 is characterized in that, described probe comprises the sequence shown in arbitrary among the SEQ ID NO:145-2150.

52. a solid or semi-solid upholder, it comprises at least a probe as claimed in claim 47 that is fixed thereon.

53. one or more HVI mark polynucleotide as claimed in claim 44, or one or more probes as claimed in claim 47, or be selected from one or more following HVI labeling polypeptides, perhaps can in the preparation diagnosis object, there be application in the test kit of herpesvirus infection: (i) contain the polypeptide that has the aminoacid sequence of 50% sequence similarity with following arbitrary sequence at least: SEQ ID NO:3 with interactional one or more antigen binding molecules of these HVI labeling polypeptides immunity, 5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (ii) contain the polypeptide that has the aminoacid sequence of 50% sequence similarity with the expression of polypeptides product of HVI marker gene at least, described expression of polypeptides product contains following arbitrary sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (iii) above (i) or the (ii) part of described polypeptide, wherein said part comprises at least 5 contiguous amino acid residues of this polypeptide; (iv) contain the polypeptide that has the aminoacid sequence of 30% similarity with (i) or (ii) at least 15 contiguous amino acid residues of described polypeptide at least; With (iv) contain (i) or the (ii) polypeptide of the part of described polypeptide, wherein said part contain (i) or (ii) described polypeptide at least 5 contiguous amino acid residues and can with (i), (ii) or the interactional antigen binding molecules of (iii) described epi sequence immunity takes place interacts.

54. there is the method for herpesvirus infection in a diagnostic test object, it comprises the unconventionality expression that is selected from following at least a HVI mark polynucleotide in the immune system cell that detects tested object: (a) contain the polynucleotide that the nucleotide sequence of at least 50% sequence homogeny is arranged with following arbitrary sequence: SEQ ID NO:1,2,4,6,7,8,10,12,13,15,17,19,21,23,24,25,26,27,29,31,33,34,35,37,38,39,41,43,45,47,49,51,53,55,57,59,61,63,65,66,67,69,71,73,75,76,77,79,81,83,84,85,87,89,91,93,94,96,98,99,100,101,102,104,106,107,108,109,111 or 113, or its complementary sequence; (b) contain the polynucleotide of nucleotide sequence that coding comprises the polypeptide of following arbitrary aminoacid sequence: SEQ ID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114; (c) contain the polynucleotide of nucleotide sequence that coding and at least a portion of following arbitrary sequence have the polypeptide of at least 50% sequence similarity: SEQID NO:3,5,9,11,14,16,18,20,22,28,30,32,36,40,42,44,46,48,50,52,56,58,60,62,64,68,70,72,74,78,80,82,86,88,90,92,95,97,103,105,110,112 or 114, wherein said part contains at least 15 amino-acid residues that adjoin of this sequence; (d) contain at least under low preciseness condition polynucleotide with the nucleotide sequence of (a) and (b), (c) described sequence or its complementary sequence hybridization.